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Introduction 

Imroduccion 
Unheralded acute coronary syndromes are a common initial manifestation of 
coronary atherosclerosis, and most of these events arise from coronary lesions 
which are not flow limiting. Pathological studies have retrospectively proposed 
that plaque composition is a crucial determinant of the propensity of an ath-
erosclerotic lesion to rupture. A large study of victims of sudden cardiac death 
showed that 60% of acute coronary thrombi had as a substrate, a ruptured thin-
cap fibroatheromatous (TCFA) lesion. Furthermore, 70% of those patients had 
additional TCF As in their coronary tree that had not ruptured. A large necrotic 
core (avascular, hypocellular, lipid-rich area), a thin fibrous cap with inflamma-
tOry infiltration and pauciry of smooth muscle cells, and the presence of expansive 
(positive) remodelling have been identified as the major criteria to define TCFA 
lesions. In vivo early detection of these non-obstructive, lipid necrotic-rich, high-
risk plaques may have an important impact on the prevention of acute myocardial 
infarction and sudden death. 
For many years coronary angiography has been the gold standard to assess the 
morphology, and severity of atherosclerotic lesions in the coronary tree. Never-
theless, quantitative angiographic measurements can be deceptive because this 
technique only allows the assessment of the luminal silhouette. In contrast, ath-
erosclerosis is a disease of the vessel wall, and due to the compensatOry expansive 
remodelling effect, the lumen remains unaffected until final stage of the disease. 
Intravascular ultrasound (IVUS) is a safe catheter-based diagnostic tool that pro-
vides a real-time, high resolution, tomographic view of coronary arteries. Thereby 
it enables evaluation of the morphology, severity and extension of coronary 
plaque. In vivo plaque characterization through visual interpretation of grey-scale 
IVUS is suboptimal especially when assessing heterogeneous, lipid-rich plaques. 
The accuracy of grey-scale IVUS for discriminating lipid from fibrous tissue is 
limited, because in addition to the large amounts of extracellular lipid which have 
low echo-reflectance, the lipid core contains cholesterol crystals, necrotic debris 
and microcalcifications which are highly echo-reflective. On the contrary, spectral 
analysis of IVUS radio frequency (RF) data [IVUS-Virtual Histology (VH)] has 
emerged as a tool able to provide an objective and accurate assessment of coronary 
plaque composition. Four tissue components [calcified (white), fibrous (green), 
fibro-fatty (greenish-yellow) and necrotic core (red)] are identified using autore-
gressive classification systems. IVUS-RF data analysis may follow the progression 
of the disease not only with regards to its volume, but also to its composition. In 
addition, this novel IVUS application may potentially expand rowards natural 
history studies. 
In this thesis, it has been explored the in vivo accuracy and precision of 
IVUS-RF data analysis for the assessment of plaque composition. To achieve this, 
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we have investigated both the classification accuracy of the technique (chapter 
2.1) and its reproducibility (chapter 2.2). In addition, we have carried out an 
extensive program to define its potential clinical value. With this in mind we 
have compared our results to previous histo-pathological, and clinical studies as 
an indirect validation of the technique. IVUS-RF was therefore used to describe 
the extent, distribution, morphology and composition of coronary atherosclerosis 
in non-intervened coronary arteries. The association between flow dynamics and 
plaque composition is explored in chapter 3, whilst the correlation between plaque 
composition and demographical data is evaluated in chapter 4. 
This thesis would not be complete without exploring IVUS-VH as a tool to 
detect the two major components of plaque vulnerability (i.e. necrotic core and 
remodelling). In chapter 5 we discuss the global characteristics of plaque rupture; 
the relationship between coronary remodelling and plaque composition; and the 
prevalence and distribution of an in vivo histological surrogate ofTCFA. 
We also discuss the treatment of coronary atherosclerosis, in two modalities, 
applied locally (chapter 6) or systemically (chapter 7). 
Complementary to greyscale IVUS, tissue characterization by IVUS-RF 
analysis has the potential to add valuable information on the pathogenesis of stent 
thrombosis by providing information on plaque composition, specifically on the 
amount of necrotic core and its location (superficial or deep). Chapter 8.1. We 
also explore the potential usefulness of IVUS-RF to assess edge-stem restenosis 
(chapter 8.2) and its capabilities to evaluate serial changes in plaque type and 
composition in patients treated with bioabsorbable stenrs (chapter 8.3). 
A very important piece of the thesis is part II, where the effects of medication 
such as statins, ACE inhibitors and anti-diabetic drugs on coronary atherosclerosis 
are explored. 
Part III focuses on optical coherence tomography. This imaging technique has 
helped to improve our understanding of high-risk plaque, and also the delicate 
relationship between focal treatment (i.e. steming) and vessel walL 
To conclude, the aim of this thesis was fourfold: (I) to explore in vivo the size, 
morphology, distribution and composition of coronary atherosclerosis, and its 
relationship with established cardiovascular risk factors; (2) to explore potential 
IVUS RF and optical coherence tomography surrogates of plaque vulnerability 
as well as to help find a role for these techniques in the clinical setting; (3) to 
asses in vivo the effect of conventional medical interventions on plaque size and 
composition and (4) to evaluate the interaction of stems and the vessel wall. 
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CHAPTER 1.1 
Novel intravascular imaging technologies. 
Garcia-Garcia HM, Gonzalo N, Barlis P, Serruys PW 
In: Imaging in Clinical Management. Co-Editors: Dr Stephen Nicholls and Professor 
Srephen Wonhley. Jones and Bartlerr Publishers, Inc. 2009 
Chapter 1.1 
ABSTRACT 
Recently, several novel imaging coronary techniques have emerged aimed at 
describing mainly vulnerable plaques. Thin capped fibroatheroma has been postu-
lated as the precursor of plaque rupture. Detection of these vulnerable plaques in 
vivo is essential to assess their natural history and to evaluate potential treatment 
modalities which may ultimately impact on the prevention of acute coronary 
syndromes and death. Currently, conventional grayscale intravascular ultrasound 
(NUS), IVUS virtual histology (VH) and palpography are all acquired using the 
same catheter and pullback. Combining this catheter with either thermography 
or additional imaging capabilities with optical coherence tomography (OCT) or 
spectroscopy would herald an exciting era of invasive diagnostic imaging. Other 
modalities like intravascular magnetic resonance imaging also have tremendous 
potential in the detection of atherosclerotic plaque components. To date however, 
none of the techniques described above have been sufficiendy validated and, more 
importantly, they have not demonstrated a sound ability to predict future adverse 
cardiac events. Very rigorous and well-designed studies are compelling to help 
define the role of each diagnostic modality. 
Key words: Atherosclerosis, plaque rupture, thin-capped fibroatheroma, acute 
coronary syndromes. 
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INTRODUCTION 
The ability to detect vulnerable plaques in vivo is essential to study their natural 
history and to evaluate potential therapeutic interventions that may ultimately 
fuvorably impact on acute coronary syndrome (ACS) and death. Coronary angiog-
raphy offers valuable information on the long-term behavior of complex coronary 
lesions but does have several limitations. Goldstein et al(1) reported that patients 
with ST-segmem elevation myocardial infarction (STEM!) and multiple complex 
lesions had an increased incidence of recurrent ACS during the year following 
STEM! compared to patients with a single complex lesion (19.0% vs. 2.6%, p 
<0.001, respectively). Taking this into consideration however, angiography only 
permits a 2-dimensional view of the arteries and is unable to give precise detail 
about the vessel wall. As a result, a number of invasive imaging modalities are be-
ing tested or used, specifically geared toward the evaluation of vulnerable plaque 
(2). These techniques are capable of providing unique detail on the vessel wall, 
lumen, plaque tissue composition and the status of inflammation and therefore 
circumvent many of the limitations of coronary angiography. This chapter will 
provide a contemporary review of these technologies with particular reference to 
their use in the assessment of vulnerable plaque and coronary stems. 
1. HISTOPATHOLOGICAL VUlNERABlE PlAQUE DEFINITIONS 
The "classical", most described phenotype of vulnerable plaque is a thin capped 
fibroatheroma (TCFA) (3), characterized by a large necrotic core with an overly-
ing thin cap infiltrated by macrophages. Smooth muscle cells within the cap are 
absent or few. The thickness of the fibrous cap near the rupture site measures 23 
± 19 flm, with 95% of caps measuring <65 flm(4,5). Rupture of a TCFA with ex-
posure of the thrombogenic necrotic core to circulating platelets is thought to be 
responsible for 60% of all acute coronary syndromes (5). Macrophage infiltration 
of the thin cap with release of matrix metalloproteinases and local inflammation 
can cause extracellular matrix degradation and subsequent plaque rupture (6,7). 
Excessive mechanical strain, particularly at the junction of the TCFA and the 
normal vessel wall is another factor predisposing to rupture (8,9). 
Chevuru et al. (10) reported new pathological evidence on TCFA characteriza-
tion. The prevalence ofTCFA and rupture is low (0.46±0.95 and 0.38±0.70 per 
heart, respectively), focal in nature and located in the proximal segments of coro-
nary arteries. In earlier studies, up to 3 TCFA were found per heart(ll). Necrotic 
core size was relatively small for both, TCFA (1.6±1.8mm2' length 2.7±2.0mm) 
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and ruptured plaques (2.2±1.9mm2; length 1.9±3.6mm). In previous studies, the 
size of necrotic core in TCFAs was 1.7±1.1mm2 with a length of 8mm (range 
2-17mm), and in ruptured plaques 3.8±5.5mm2, with a length of 9mm (range 
2.5-22mm) (12). 
The second recognized phenotype of vulnerable plaque, accounting for ap-
proximately 40% of coronary thromboses in pathology series is plaque erosion 
in lesions consisting of either pathological intimal thickening or thick-capped 
fibroatheroma (13). These lesions typically have a high smooth muscle cell 
content and are rich in proteoglycans and are more common in young women 
and smokers, but are not associated with other conventional risk factors such as 
hypercholesterolemia (14, 15). 
Thirdly, there are calcified nodules, which may protrude into the vessel lumen 
and comprise up to 5% of lesions in pathological series. These lesions are char-
acterized by an absence of endothelial and inflammatory cells (15). In addition, 
intra-plaque hemorrhage secondary to leakage from the vasa vasorum may also a 
pathological role (16). 
2. IMAGING OF VULNERABLE PlAQUES 
Angioscopy 
Coronary angioscopy (CAS) is a well-established technique that allows direct visu-
alization of the plaque surface and intra-luminal structures. It enables assessment 
of the plaque color (white, red, yellow), and can illuminate plaque complications 
such as rupture, intimal tears and thrombosis with a higher sensitivity compared 
to angiography (17-20). On angioscopy, normal artery segments appear as glis-
tening white, whereas atherosclerotic plaques can be categorized based on their 
angioscopic color as yellow. Platelet-rich thrombus at the site of plaque rupture is 
characterized as white granular material, and fibrin/erythrocyte-rich thrombus as 
an irregular, red structure protruding into the lumen. Yellow plaques are associated 
with ACS (21) and thrombosis (22). They have also been correlated with other 
features of vulnerability such as positive remodeling and increased distensibility 
(23). Quantitative colorimetric angioscopic analysis provides objective and highly 
reproducible measurements of angioscopic color. This technique can correct for 
important chromatic distortions present in modern angioscopic systems. It can 
also help overcome current limitations in angioscopy research and clinical use 
imposed by the reliance on visual perception of color (24). 
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The major limitation of angioscopy is that it is a rather specialized technique 
that requires a blood-free field during image acquisition, which can be obtained 
either by complete vessel occlusion or by continuous saline Bushing distal to the 
angioscope. Presently, coronary angioscopy (Vecmova", Clinical Supply Co., Gifu, 
Japan) can be performed while blood is cleared from the field of view by injection 
of 5-l 0 ml normal saline. Nevertheless, angioscope only allows limited assessment 
of the coronary tree (i.e. vessels > 2 mm diameter) and assessment of stenotic le-
sions may prove technically difficult. Furthermore, imaging is only of the luminal 
surface and, although changes in the vessel wall are reflected on the surface, this 
might not be sufficiently sensitive to detect subtle alterations in plaque composi-
tion or plaque burden in the presence of positive remodeling (25). 
Kubo et a! (20) recently used CAS, optical coherence tomography (OCT) 
and IVUS to assess culprit lesion morphology in acute myocardial infarction 
(AMI). The incidence of plaque rupture observed by OCT was 73%,47% by CAS 
(p~0.035) and by IVUS 40%, (p~0.009). Furthermore, OCT (23%) was superior 
to CAS (3%, p~0.022) and IVUS (Oo/o, p~0.005) in the detection of fibrous cap 
erosion. The intra-coronary thrombus was observed in all cases by OCT and CAS, 
but was identified in 33% by IVUS (vs. OCT, p<O.OOl). 
Intravascular ultrasound radiofrequency analysis: Virtual histology 
Description of the technique 
Greyscale IVUS imaging is formed by the envelope (amplitude) of the radiofre-
quency signal, discarding a considerable amount of information lying beneath and 
between the peaks of the signal. The frequency and power of the signal commonly 
differ between tissues, regardless of similarities in the amplitude. IVUS-Virtual 
Histology (IVUS-VH, Volcano Corp., Rancho Cordoba, USA) involves spectral 
analysis of the data and evaluates different spectral parameters (Y-intercept, mini-
mum power, maximum power, mid-band power, frequency at minimum power, 
frequency at maximum power, slope, etc.) to construct tissue maps that classify 
plaque into four major components (fibrous, fibrolipidic, necrotic core and cal-
cium). Different plaque components are assigned different color codes: calcified 
(white), fibrous (green), fibrolipidic (greenish-yellow) and necrotic core (red) 
(26). Although this classification was initially evaluated in vitro, more recently 
IVUS-VH pre- and post-procedure have also been correlated with pathological 
atherectomy specimens showing good correlation for all 4 tissue types (27). As 
assessed by IVUS-VH, the sensitiviry and specificiry for fibrous tissue was 86% 
and 90.5%, fibro-f.my 79.3% and 100%, necrotic core 67.3% and 92.9% and 
dense calcium 50% and 98.9% respectively. More recently, these tissue-maps 
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have been validated using ex-vivo by comparison with histology via 899 selected 
regions (n=94 plaques) that comprised 471 fibrous tissue, 130 fibro-fatty, 132 
necrotic core and 156 dense calcium regions. The overall predictive accuracies 
were 93.5% for fibrous, 94.1 o/o for fibro-fatty, 95.8% for necrotic core and 96.7% 
for dense calcium with sensitivities and specificities ranging from 72 to 99o/o. The 
kappa statistic was calculated to be 0.845 indicating very high agreement with 
histology(28). 
IVUS-VH data is currently acquired using a commercially available 64-ele-
ment phased-array catheter (Eagle EyeTM 20 MHz catheter, Volcano Corporation, 
Rancho Cordova, USA). Using an automated pullback device, the transducer 
is withdrawn at a continuous speed of 0.5 mm/s up to the ostium. lVUS-VH 
acquisition is ECG-gated at the R-wave peaks using a dedicated console. 
IVUS B-mode images are reconstructed by customized software and contour 
detection is performed using cross-sectional views with semi-automatic contour 
detection software to provide quantitative geometrical and compositional mea-
surements. Due to the limitations of manual calibration (29), the radiofrequency 
data is normalized using a technique known as "Blind Deconvolution", an iterative 
algorithm that deconvolves the catheter transfer function from the backscatter, 
thus accounting for catheter-to-catheter variability (30,31). 
It has been our observation that in the near field, an excessive amount of 
necrotic core is present. The developers have accounted for this with a corrected 
version introduced in the latest release of the classification tree. 
Virtual histology and plaque characterization 
Lesion classification is based on static images obtained from autopsy specimens. 
In brie£ some believe that atherosclerotic lesion progression starts with pathologic 
intimal thickening in which lipid accumulates in areas rich in proteoglycans (lipid 
pools), but no trace of necrotic core. Others believe that the earliest change of ath-
erosclerosis is the fatty streak, also called as intimal xanthoma. The earliest lesion 
with a necrotic core is the fibroatheroma (FA), and this is the precursor lesion that 
may give rise to symptomatic heart disease. Thin-capped fibroatheroma (TCFA) 
is a lesion characterized by a large necrotic core containing numerous cholesterol 
clefts. The overlying cap is thin and rich in inflammatory cells, macrophages and 
T lymphocytes with few smooth muscle cells. Plaques prone to rupture are those 
with decrease cap thickness, large lipid-necrotic core and severe inflammatory 
infiltrate A study done by Burke et al(4). identified a cut-off value for cap thick-
ness of <65 microns for vulnerable coronary plaque definition. 
Virtual Histology can potentially identify detect thin-capped fibroatheromas 
(TCFAs). In addition, the progression of the disease can also be followed-up. 
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Table 1: VH-NUS Proposed Lesion Types 
Lesion Type 
Adaptative Intimal Thickening (AIT) 
Pathological intimal Thickening (PIT) 
Fibrotic Plaque (FT) 
Fibrocalcific Plaque (FC) 
Fibroatheroma (FA) 
Thin Cap Fibroatheroma (TCFA) 
Novel intravascular imaging technologies. 
Brief Description 
<600 !lm of intima thickness 
?:600 llm thickness for >20% of the circumference with FF 
>15%, and no confluent NC or DC 
Dominant FT and no confluent NC or DC 
Confluent DC with no confluent NC 
Confluent NC not at the lumen on three consecutive frames 
Confluent NC at the lumen on three consecutive frames 
FT- fibrous tissue; FF- fibro-fatty tissue; NC- necrotic core; and DC- dense calcium. 
Figure I. IVUS-VJ.I'tual histology proposed lesion types. AIT, adaptative intimal thickening; PIT, 
pathological intimal thickening; FT, fibrotic plaque; FC, fibrocalcific; FA, fibroatheroma;CaFA, 
calcified fibroatheroma; TCFA, thin-capped fibroatheroma. 
Table 1 outlines the virtual histology plaque and lesion rypes that are proposed 
based on the above pathologic data. (figure 1). 
Our group recently evaluated the incidence of IVUS-derived thin-cap fi-
broatheroma (IDTCFA) using IVUS-VH (32). Two independent IVUS analysts 
defined IDTCFA as a lesion fulfilling the following criteria in at least 3 con-
secutive cross-sectional areas: l) necrotic core ~10% without evident overlying 
fibrous tissue, 2) lumen obstruction ;,40 %. In this study, 62% of patients had 
at least one IDTCFA in the interrogated vessels. ACS patients had a significantly 
higher incidence of IDTCFA than stable patients [3.0 (interquarrile range 0.0, 
5.0) IDTCFA/coronary vs. 1.0 (interquartile range 0.0, 2.8) IDTCFA/coronary, 
p~ 0.018]. Finally, a clear clustering pattern was seen along the coronaries, with 
66.7 o/o of all IDTCFAs located in the first 20 mm whereas further along the 
vessels the incidence was significantly lower (33.3%, p~0.008). This distribution 
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ofiDTCFAs is consistent with previous ex vivo and clinical studies, with a clear 
clustering pattern from the ostium demonstrating a non-uniform distribution of 
vulnerable plaques along the coronary tree (33). Patients presenting with ACS 
had a significantly higher prevalence ofiDTCFA even in non-culprit vessels, sup-
porting the concept of a multi-focal process (34). Of note, the lesion percent area 
stenosis and the mean necrotic core areas of the IDTCFAs detected by IVUS-VH 
were also similar to previously reported histopathological data (55.9 o/o vs. 59.6 o/o 
and 19 o/o vs. 23 o/o respectively) (12). 
It is worth mentioning that, although the most accepted threshold to define a 
cap as "thin" has previously been set at <65 flm, this was based on post mortem 
studies that studied ruptured plaques (35). Extrapolation of such criteria to in 
vivo studies therefore requires caution. It is well established that tissue shrinkage 
occurs during tissue fixation (36). Shrinkage (particularly of collagen, the main 
component of fibrous caps) of up to 60 o/o, 15 o/o and 80% can occur during 
critical-point-drying, free-drying, and air-drying respectively (37). Furthermore, 
post-mortem contraction of arteries is an additional confouncling factor (38,39). 
Since the axial resolution of!VUS-VH is 246 flm, we assumed that the absence of 
visible fibrous tissue overlying a necrotic core suggested a cap thickness of below 
246 flill and used the absence of such tissue to define a thin fibrous cap (40). 
We have recently developed software to quantifY the amount of necrotic core 
in contact with the lumen, enabling refinement of our analysis. Our current defi-
nition of an IVUS-derived TCFA (IDTCFA) is a lesion fulfilling the following 
criteria in at least 3 consecutive cross-sectional areas (CSAs): 1) plaque burden 
2: 40%; 2) confluent necrotic core 2: 10% in direct contact with the lumen (i.e. 
no visible overlying tissue) in the investigated CSA; all consecutive CSAs having 
the same morphologic characteristics are considered as part of the same IDTCFA 
lesion (41). In a recent study, using this refined definition ofTCFA as assessed by 
IVUS-VH, in patients with ACS underwent IVUS of all three epicardial coronar-
ies, on average, there were 2 IVUS-derived thin cap fibroatheroma (IDTCFA) per 
patient with half of them showing outward remodeling(41). 
The potential value of IVUS-VH in the precliction of adverse coronary events 
is currently under evaluation in t\Vo international multicentre prospective studies 
(PROSPECT and IBIS 2 trials). 
Virtual histology and coronary embolization 
Identification of subclinical high-risk plaques is potentially important because 
they may have greater likelihood of rupture and subsequent thrombosis. In 55 
patients, a nonculprit vessel with < 50o/o diameter stenosis was studied with 
IVUS-VH. Mean necrotic core percentage was significantly larger in patients with 
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acute coronary syndrome when compared with stable patients (12.26% +I- 7.0% 
vs 7.40% +1- 5.5%, P = .006). In addition, stable patients showed more fibrotic 
vessels (70.97% +1- 9.3% vs 63.96% +1- 9.1 %, P = .007)(42). However, not only 
the amount of necrotic is larger in patients with ACS, but it appears that NC is 
also unevenly distributed. In 51 consecutive patients, a non-culprit vessel was 
investigated through IVUS-Virtual Histology. The overall length of the region of 
interest, subsequently divided into 10 mm segments, was 41.5+1-13 mm long. 
No significant change was observed in terms of relative plaque composition along 
the vessel with respect to fibrous, fibro-fatty, and calcified tissue, whereas the 
percentage of necrotic core resulted to be increased in the first (median: 8.75%: 
IQR: 5.7-18) vs. the third (median: 6.1 %; IQR: 3.2-12) (P=0.036) and fourth 
(median: 4.5%; IQR: 2.4-7.9) (P=0.006) segment. At multivariable regression 
analysis, distance from the ostium resulted to be an independent predictor of rela-
tive necrotic content [beta=-0.28 (95%CI: -0.15, -0.41)], together with older age, 
unstable presentation, no use of statin, and presence of diabetes mellitus(43). 
Recently, two studies evaluated the usefulness of IVUS-VH plaque composi-
tion to predict the risk of embolization during steming (44,45). In one of them, 
71 patients with STEM! that underwent primary PC! within 12 hours of the 
beginning of the symptoms were included. After crossing the lesion with a guide-
wire and performing thrombectomy with an aspiration catheter, VH-IVUS of the 
infarct-related vessel was performed. The stem was then deployed without embolic 
protection. ST segment re-elevation was used as a marker of distal embolization 
during stenting. Eleven patients presented with ST segment re-elevation after 
stenting. Total plaque volume was similar in both groups, but the NC volume 
was significantly higher in the group of patients with ST segment re-elevation 
(32.9 ± 14.1 mm3 vs. 20.4 ± 19.1 mm', p < 0.05). On receiver-operating char-
acteristic curves, NC volume was the best predictor of ST re-elevation after stent 
deployment as compared with fibrous, fibro-lipid, dense calcium, and total plaque 
volumes. The cut-off point for NC volume that was best predictive for ST re-
elevation was 33.4 mm', with a sensitivity of 81.7% and a specificity of 63.6%. 
The second study included 44 patients who underwent elective coronary steming. 
Plaque composition was assessed with VH-IVUS, and small embolic particles 
liberated during steming were detected as high-intensity transient signals (HITS) 
with a Doppler guidewire. Patients were divided into the tertiles according to the 
HITS counts. Dense calcium and NC area were significantly larger in the highest 
tertile. In the multivariate logistic regression analysis, only necrotic core area was 
an independent predictor of high HITS counts (odds ratio 4.41, p = 0.045). 
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Intravascular Ultrasound Radiofrequency analysis: Palpography 
This technique allows the assessment of local mechanical tissue properties. For a 
defined pressure difference, soft tissue (e.g. lipid-rich) components will deform 
more than hard tissue components (e.g. fibrous, calcified) (46,47). Radiofrequency 
data obtained at different pressure levels are compared to determine the local 
tissue deformation. 
Each palpogram represents the strain information for a certain cross section 
over the full cardiac cycle. The longitudinal resolution of the acquisitions depend 
on heart rate and pullback speed. With a heart rate of 60 bpm and a pullback speed 
Figure 2. NUS-palpography. In the upper left side the palpography strain map is opened up. The 
local strain is calculated from the gated tadiofrequency traces using cross-correlation analysis and 
displayed, color-coded, from blue (for Oo/o strain) to red to yellow (for 2o/ostrain). Plaque strain 
values are assigned a Rotterdam Classification (ROC) score ranging from I to IV (ROC I= 0-<0.6 
o/o; ROC II= 0.6- <0.9 o/o; ROC III= 0.9-<1.2 o/o; ROC IV= >1.2 o/o). At the bottom, in the same 
cross-sectional area a high-strain spot (ROC III) is shown (left); in the virtual histology (VH) image 
(right) a confluent necrotic core area in contact with the lumen is seen, suggesting an IVUS-derived 
thin capped fibroatheroma. The IVUS-VH color-code is fibrous tissue (green), fibro-futty tissue (light 
green), necrotic core (red) and dense calcium (white). 
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of 1.0 mm/ s, the longitudinal resolution is 1.0 mm. Palpograms are acquired using 
a 20-MHz phased array IVUS catheter (Eagle Eye™ 20 MHz catheter, Volcano 
Therapeutics, Rancho Cordova, USA). Digital radiofrequency data are acquired 
using a custom-designed workstation. 
The local strain is calculated from the gated radiofrequency traces using cross-
correlation analysis and displayed, color-coded, from blue (for 0% strain) to red to 
yellow (for 2%strain) (48). Plaque strain values are assigned a Rotterdam Classifi-
cation (ROC) score ranging from I to IV (ROC I= 0-<0.6 %; ROC II= 0.6- <0.9 
%; ROC III= 0.9-<1.2 %; ROC IV= >1.2 %) (49) (figure 2). Our group has 
demonstrated that palpography has a high sensitivity (88%) and specificity (89%) 
to detect vulnerable plaques in vitro (46). Postmortem coronary arteries were 
investigated with intravascular elastography and subsequently processed for histol-
ogy. There was a positive correlation between the presence of high strain and the 
degree of macrophage infiltration (P<0.006) and an inverse relation between the 
amount of smooth muscle cells and strain (P<O.OOOl). Vulnerable plaques identi-
fied by palpography had a thinner cap than non-vulnerable plaques (P<O.OOOJ). 
In a subsequent study, 55 patients with either stable or unstable angina, or 
acute MI were analyzed. Among patients with stable angina, the prevalence of 
deformable plaques was significantly lower per vessel (0.6+1-0.6) than in patients 
presenting with unstable angina (1.6+1-0.7, p=0.0019) or with acute MI (2.0+/-
0.7, p<O.OOOJ). In the IBIS I study, on palpography, both the absolute number 
of high-strain spots (grade III/IV) in the ROI (p=0.009) and their density per em 
(p=O.O 12) decreased significantly between baseline and follow-up. This decrease 
in the overall population was largely driven by changes in the subgroup of patients 
with STEM!; this group had both the highest number of high-strain spots at 
baseline and the most marked relative decrease during follow-up compared to 
patients with other clinical presentations. At 6-month follow-up, the density of 
high-strain spots (1.2±1.4/cm) was comparable among clinical subgroups (50). 
The potential value of!VUS-palpography is currently under evaluation in two 
international multicentre prospective studies, PROSPECT and IBIS 2 trials. These 
two studies have also obtained IVUS-virtual histology during the same IVUS 
pullback, allowing for the assessment of both morphological and biomechanical 
properties of a particular plaque. Assessing several characteristics of a given plaque 
could potentially enhance invasive risk stratification by identifying very high-risk 
plaques, thereby lowering the number of vulnerable plaques that deserve to be 
serially followed and ultimately treated (figure 2). 
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Optical coherence tomography 
Optical coherence tomography (OCT) is an optical analogue of ultrasound, how-
ever it uses light instead of sound to create an image (51,52). For OCT imaging, 
low coherence, near infrared light with a wavelength around 1300 nm is used 
since it minimizes the energy absorption in the light beam caused by protein, 
water, hemoglobin, and lipid. The light waves are reflected by the internal micro-
structures within biological tissues as a result of their differing optical indices. 
This technique provides a resolution of 1 0-20f1m in vivo (53); this level of 
detail is well beyond the level of resolution of IVUS (100-150rm) (54). OCT 
has been demonstrated to be highly sensitive and specific for characterizing ath-
erosclerotic plaques in vitro when compared with histological analysis (55-57) 
with a sensitivity and specificity of 71-79% and 97-98% for fibrous plaques, 
95-96% and 97% for fibrocalcific plaques, and 90-94% and 90%-92% for lipid-
rich plaques, respectively. In addition, the inter- and intra-observer reliabilities 
of OCT assessment were high (kappa values of 0.88 and 0.91, respectively) (57). 
In vitro comparison of OCT with IVUS have demonstrated superior delineation 
by OCT of structural details such as thin caps, lipid pools or tissue proliferation 
(58). An in vitro comparison of OCT, integrated backscatter IVUS (similar meth-
odology to IVUS-VH) and conventional IVUS found that OCT had the best 
potential for tissue characterization of coronary plaques, with higher sensitivity 
and specificity compared to the other imaging modalities (59). However, a recent 
study comparing OCT to histopathology reported a lower sensitivity for plaque 
components. Misclassification occurred in 41 o/o of lesions, predominantly due 
to a combination of incomplete penetration depth into the vessel wall and the 
inability to distinguish calcium deposits from lipid pools (60). 
In a pilot clinical study, our group performed in vivo OCT analysis of the 
coronary arterial wall in patients who were undergoing percutaneous coronary in-
tervention. Imaging was possible in all patients and the entire vessel circumference 
was visualized at all times. A wide spectrum of different plaque morphologies was 
observed. OCT allowed for differentiation of the normal artery wall and inhomo-
geneous, mixed plaques, as well as thin cap fibroatheromas with inhomogeneous, 
low-reflecting necrotic cores, covered by highly-reflecting thin fibrous caps (54). 
As a result of its high axial resolution, there is no doubt that OCT is the in 
vivo gold standard for identifying and measuring the thickness of the fibrous cap 
(figure 3); an in vivo study found a significant difference in minimal cap thickness 
between acute MI and stable angina patients, with median (interquartile range) 
values of 47.0 (25.3-184.3) rm and 102.6 (22.0-291.1) rm respectively (p= 0.02) 
(61). On top of its reliability as a tool to measure the thickness of the cap in 
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Figure 3. The optical coherence tomography image shows thin cap fibrous atheroma (TCFA). 
The cross-section demonstrates a region of low reflectivity with diffuse borders between the 3 and 5 
o'clock position consistent with a lipid-rich plaque. This is covered by a thin, highly reflective fibrous 
cap (TCFA) which measured between 10-30 microns in thickness 
vivo, recent post-mortem and in vivo studies have shown that OCT is capable of 
evaluating the macrophage content of infiltrated fibrous caps (62,63). 
Kubo er a!. (20) evaluated the ability of intracoronary OCT to assess culprit 
lesions during primary PCI in patients with acute MI. The thickness of the rem-
nants of the fibrous cap after symptomatic rupture measured was 49±21 rm. The 
main limitation of OCT is the shallow tissue penetration depth (1.5-2mm) which 
hampers imaging of the entire vessel wall in large vessels and light absorbance 
by blood thar currently needs to be overcome by saline infusion and balloon 
occlusion, thereby precluding interrogation of long and proximal segments of 
the coronary tree. This has recently been parrly overcome with the use of non-
occlusive techniques whereby contrast is flushed through the guiding catheter 
during simultaneous image acquisition at 3.0mm/seconds (M3, LightLab Imag-
ing Inc., Westford, MA, USA). Furthermore, even more encouraging is the use 
of optical frequency domain imaging (OFDI) that enables even faster pullback 
speeds without compromise of image quality and resolution. 
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Thermography 
Atherosclerosis is accompanied by inflammation, and vulnerable plaques have 
been associated with increased macrophage activity, metabolism and inflammation 
( 64). Activated macro phages produce thermal energy, which might be detected 
on the surface of these atherosclerotic lesions using specially-designed catheters 
equipped with thermistor sensors at the distal tip (65). A rise in temperature 
can be found in atherosclerotic plaques as compared to disease-free coronary 
segments. Temperature differences between an atherosclerotic plaque and normal 
vessel wall increase progressively from patients with stable angina to patients with 
acute MI with a maximum temperature difference to the background temperature 
of 1.5±0.7"C (66). In a prospective study, Stefanadis et al reported an association 
between temperature heterogeneity and the incidence of adverse events at follow-
up in patients with coronary artery disease undergoing successful PCI ( 67). In 
addition, treatment with statins seemed to affect the thermographic results: in 
non-culprit lesions the temperature difference was lower in the group treated with 
statins compared with the untreated group (0.06 ± 0.05oC vs. 0.11 ± 0.10°C; p 
= 0.05) (68). 
More recently, a correlation between morphologic and functional characteris-
tics of culprit lesions (CL) in patients with acute coronary syndromes and chronic 
stable angina (CSA) has been reported(69). In 81 consecutive patients (48 with 
ACS and 33 with CSA), remodeling index (Ri) by IVUS and temperature differ-
ence (Delta T) by angioscopy between the CL and the proximal vessel wall were 
measured. Patients with ACS had greater remodeling index than patients with 
CSA (l.l5±0.18 vs. 0.90±0.12; p < 0.01), as well as increased DeltaT (0.08±0.03 
degrees C vs. 0.04±0.02 degrees C; p < 0.01). Patients with positive Ri had higher 
Del taT than patients with negative Ri (0.07±0.03 degrees C vs. 0.04±0.02 degrees 
C; p < 0.001). Patients with rupture plaque had increased DeltaT compared with 
patients without rupture plaques (0.09±0.03 degrees C vs. 0.05± 0.02 degrees C; 
p < 0.01). Multivariate analysis showed that Delta Twas independently correlated 
with the presence of rupture plaque, positive Ri, and ACS. 
However, there are several different aspects that deserve further investigation. 
The prevalence and distribution of inflammatory cells in stable and unstable ath-
erosclerotic plaque is unclear, and the predictive value of 'warm' lesions remains 
elusive. Furthermore, the impact of different coronary flow conditions on plaque 
temperature ('cooling effect') is still not completely understood (70,71). Simula-
tions have revealed that the correct interpretation of intravascular thermographic 
measurements requires data on the flow and on the morphologic characteristics of 
the atherosclerotic plaque (72). 
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There are a few limitations to the routine use of thermography in the cath-
eterization laboratory: (i) most of the catheters used still comprise over-the-wire 
systems; (ii) accurate temperature assessment requires direct contact of the 
thermistors wirh the vessel wall, with the associated potential risk of endothelial 
damage (73) and (iii) as the temperature wirhin the vessel changes rapidly with 
fluid application, any intracoronary injection of contrast, flush or medication has 
to be avoided before and during measurements(74). 
Intravascular Magnetic Resonance 
Magnetic resonance (MR) is a non-ionizing diagnostic tool exploiting the spins 
of the nuclear protons in a strong magnetic field. For intravascular diagnosis, two 
different approaches have been introduced. 
The first, conventional approach visualizes the anatomical structure by using 
a coil placed in a catheter or wire in combination with an external magnet (MR 
imaging). While this approach has previously been shown to be able to provide 
detailed information on structure and composition of the arterial wall and plaque, 
(75) the procedure has to be performed in a MR room, not in a cardiac catheteriza-
tion laboratory. The accuracy for MRI differentiation of plaque components has 
been validated in vitro and feasibility demonstrated in vivo (76). The 0.030-inch 
IVMRI coil had a sensitivity and specificity of73% and 85% respectively for lipid, 
83% and 81 o/o respectively for fibrous tissue and 100% and 97% respectively for 
calcification. Subsequendy, the same system was applied in human iliac arteries 
in vivo using a L5T magnet with a resolution of 312rm. Complete vessel wall 
analysis was possible in all25 patients and required 20 minutes for an arterial seg-
ment of 20mm length. Compared to IVUS, mean lumen diameters were similar, 
but the outer wall area was overestimated by IVMRI (mean 116.4±4.7mm2 vs. 
86.6±5.8mm2 , p=0.0001). However, inter-observer agreements for IVMRI were 
much higher (kappa 0.68-0.79) than for IVUS (kappa 0.21). 
The other, novel approach analyses the chemical composition by placing both, 
the coils and miniaturized magnets on the tip of a catheter, without the need of 
external magnets (MR spectroscopy) and can be performed in the cardiac cath-
eterization laboratory (77). 
MR spectroscopy can identifjr fibrous and lipid-rich tissue by measuring dif-
ferential water diffusion in a field of view. Acquired data is displayed as color-code 
sectors based on the lipid fraction index (LFI) for each zone of the FOV Blue indi-
cates no lipid, gray correspond to intermediate lipid content and yellow indicates 
high-lipid content (figure 4). Clinical feasibility of catheter-based, self-contained 
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- soft plaque, echogcnicity <the surrounding adventitia. 
fibrous plaque , intermediate echogenicity between soft and calcified 
calcified plaque, echogcnicity >the adventitia with shadowing. 
mh::ed plaques. when they contain more than one acoustical subtype. 
necrotic core. remnants of foam cells and lymphocytes. cholesterol clefts and Ca-t 
fibrous tissue • densely packed bundles of collagen fibers with no lipid 
fibrofatty tissue. loosely packed collagen fibers and cells with high lipid content. 
dense calcium. identifies focal areas of calcification in pathology 
- lipid-rich plaque. low reflectivity. homogenous and diffuse margins 
- fibrous plaque, high reflectivity. homogenous and finely textured 
- calcified plaque. low reflectivity. inhomogeneous and sharp margins 
lipid plaque 
no substantial lipid deposition 
intermediate lipid deposition 
artefact. usually seen in calcified plaqur. .. 'S 
Figure 4. Multi-imaging in the coronary arteries. The same coronary segment (represented by one 
frame) has been imaged by 4 different imaging techniques. In the greyscale IVUS (panel A), IVUS-
virtual histology (panel B), optical coherence tomography (panel C) and intravascular magnetic 
resonance spectroscopy (IVl'vfR) the results of the same frame across different techniques are shown. 
Of note, in the upper left quadrant of the plaque a calcified area is seen in three imaging modalities, 
but in IVl'vfR where an artifact is observed. On the right hand side, the different plaque and tissues 
types across the coronary imaging techniques is shown. 
IV MR spectroscopy has been recently demonstrated in patients scheduled for 
coronary catheterization(78). 
Preclinical trials employing this technology demonstrated its capaciry to differ-
entiate plaque components of human aortas, coronary and carotid arteries in vitro: 
IVMR spectroscopy was able to accurately detect different components (fibrous 
cap, smooth muscle cells, organizing thrombus. fresh thrombus, edema, lipid and 
calcium) with sensitivities and specificities ranging from 84-100%. Agreement 
with histology for grading the extent of intra-plaque lipid accumulation was 74% 
and 80% for grading intimal thickness. Further analysis revealed high correlation 
to histological analysis of a wide spectrum of plaque types in 15 of 16 (94%) 
aortic lesions and 16 of 18 (89%) coronary lesions (sensitivity 100%, specific-
iry 89%), including one plaque rupture, three TFCAs. seven thick-cap fibrous 
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atheroma, four fibrocalcific plaques, rvvo intimal xanthomas, and one adaptive 
intimal thickening (79). 
Current limitations include the limited field of view, the size of the catheter, 
the need for direct vessel wall contact and the time required for acquisition. In 
the past, the use of an auto-perfusion balloon during data acquisition has been 
proposed to limit ischemia(80). 
Clearly IVMR diagnostics remain an exciting area still under development. 
Catheter-based system will further increase the user friendliness, their sample vol-
ume and allow for scanning of longer arterial segments. Upcoming developments 
include the improvement MR plaque differentiation by the use of contrast agents, 
such as paramagnetic gadolinium-based contrast(Sl) or supraparamagnetic con-
trast agents (iron oxide nanoparticles), that can accumulate in macrophages (82). 
There are still a few unanswered questions, including the effect of the thermal 
energy generated on small arteries and on coronary artery stents, although con-
ventional MRI appears safe in this setting(83). 
Recently in our center, a study has been started to explore a multi-modality 
imaging approach of atherosclerotic plaque in-vivo. The same coronary segment 
is assessed by greyscale IVUS, IVUS-VH and OCT and IVMR (figure 4). This 
has been a challenging process, since we are dealing with the different imaging 
resolutions and the lack of common nomenclature and classification across these 
imaging techniques. 
Raman and near infrared spectroscopy 
A number of spectroscopic intravascular imaging techniques have been developed 
recently and are still under investigation (84). Spectroscopy can provide qualitative 
and quantitative information about chemical plaque composition. The Raman ef-
fect is created when incident laser light (typically 750-850nm wavelength) excites 
molecules in a tissue sample, which scatter light at a different wavelength. This 
change in wavelength, called the "Raman effect" is dependent on the chemical 
components of the tissue sample (85,86) and can therefore provide quantitative 
information about molecular composition (87-89). Raman spectroscopy has 
shown acceptable correlation compared with histology (r = 0.68 for cholesterol 
and r = 0.71 calcification) (89) and with IVUS in vitro (88). 
Raman spectroscopy technology collect scattered light with optical fibers and 
route the collected signal to spectrometer systems for analysis. Previously optical 
fiber probes utilized a region of the Raman spectrum called the "fingerprint" (FP) 
region ( < ~ 1800 em·' shifted light) to conduct remote assays, bur due to technical 
problems with this approach, it has been recently replaced by using another region 
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of the Raman spectrum, called high wavenumber (HW) Raman shifted light (> 
-2500 em·' shifted light). This allows us to collect Raman spectra via a single 
optical fiber, simplifYing the size and complexity of the catheter and making it 
clinically feasible (Eurointervention 2008, in press). Thus, the optical catheter 
system (OCS) (vPredict~) has been introduced as a tool for measuring the chemi-
cal composition of coronary vessels in-vivo using Raman spectroscopy and the 
subsequent mapping and quantification of the vessel and plaque components 
for evaluating plaque progression. In a xenograft model, lipid-laden plaque were 
identified with the collected Raman spectra by utilizing the overall cholesterol 
content, i.e. the sum of the free cholesterol and cholesterol esters contents, and 
setting a decision threshold at 12 o/o, as determined in previous studies. As ex-
pected, the lipid laden plaques exhibit an increased content of free cholesterol and 
cholesterol esters, while the non-atherosclerotic samples are mainly protein and 
triglycerides. Table 2. 
The vPredict OCS delivers infrared light to the vessel wall through optical 
fibers contained within a small flexible catheter and captures a portion of the 
reflected light for spectral analysis. This analysis provides information about the 
composition of the underlying tissue. Figure 5. 
Alternatively, near inftared (NIR) molecular vibrational transitions can be 
measured in the NIR region (750-2500 nm) (90) and laser spectroscopy using 
wavelengths of360-510 nmhas been evaluated in vitro (91). 
Near-infrared spectroscopy observes how different substances absorb and scatter 
NIR light to different degrees at various wavelengths. A NIR spectrometer emits 
light into a sample and measures the proportion of light that is returned over a 
wide range of optical wavelengths. The return signal is then plotted as a graph of 
absorbance (y-axis) at different wavelengths (x-axis) called a spectrum. 
Table 2. Plaque/vessel components detectable by Raman spectroscopy. 
Demonstrated: 
Possible: 
36 
Collagen, 
Elastin, 
Myosin, 
Triglycerides, 
Beta-carotene, 
Foam cells, 
Cholesterol! esters, 
Hemoglobin, 
Fibrin 
Metalloproteinases, 
Low density lipoprotein {LDL), Oxidized LDL, 
Proteoglycans, Glycosaminoglycans, 
Plasmin, 
Nucleic acids, 
Nitrotyrosine 
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Figure 5. vPredict,. optical catheter system (OCS). This cacheter has 8 optical fibers chat deliver 
infrared light to the vessel wall and captures a portion of the reflected light for spectral analysis. 
Image counesy of Prescient Medical, Inc 
In aortic and coronary artery autopsy specimens, the ability of the technique to 
identify lipid-rich TCFA through blood has been confirmed (92). A catheter-based 
system has been developed to address the challenges- of access to the coronary 
artery, blood, motion, and the need to scan-that must be overcome for use in 
patients. Initial clinical experience in six patients with stable angina demonstrates 
that high-quality NIR spectra can be safely obtained (93). Additional studies are 
planned to validate the ability of the technique to identify lipid-rich coronary 
artery plaques and ultimately link chemical characterization with subsequent oc-
currence of an ACS (94,95). 
3.1MAGING OF CORONARY STENTS 
Intravascular Ultrasound radiofrequency analysis: Virtual Histology 
Intravascular ultrasound- virtual histology classifies stent struts as "dense cal-
cium" (DC) and "necrotic core" (NC). We applied this property to follow-up 
the degradation of a bioabsorbable stent by measuring the temporal changes in 
IVUS-VH characteristics. 27 consecutive patients treated with a single bioab-
sorbable everolimus-eluring stem (BVS, Abbott Laboratories, IL USA) in simple 
lesions were imaged with IVUS-VH after predilation (pre-stenting cohort of 13 
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Figure 6.IVUS-virtual histology in stented segments. In the left: hand side, a coronary angiogram 
of the left coronary system shows on the distal segment of the left circumflex artery an eccentric 
lesion. A pre-stenting vin:ual histology (VH) frame showed a fibrotic type of plaque (location ofVH 
frame is indicated by a black line). On the right hand side, the post-stenting VH frame is depicted. 
Of note, at the lumen and surrounding areas an increase in the amount of'"'dense calcium" and 
"necrotic core" is observed. This is due to the presence of stent struts that are misclassified by VH. 
PCI, percutaneous coronary intervention. 
pts), post-stenting and again following 6 months. There was an increase in abso-
lute "dense calcium" and "necrotic core" by 297% and 256% respectively from 
pre- to post-stenting. Overall, patients (n=27) with post-stenting and follow-up 
VH showed a significant decrease in "dense calcium" (28.3% vs. 20.9, p<O.OOI). 
Individually, in 21 out of 27 patients, there was a regression in the "calcified" 
pattern. J\..lthough not significantly, "necrotic core" content also decreased (22.4o/o 
vs. 20.3, p=0.227). In turn, both fibro-fatty and fibrous tissue increased (5.0% 
vs. 7.4, p=0.024 and 44.3% vs. 51.4%, p=0.006 respectively). In conclusion, the 
quantitative assessment of the IVUS-VH changes at 6 months suggests a reduc-
tion of the DC compatible with early struts alteration of the BVS. (figure 6). 
Optical coherence tomography 
OCT permits the detailed assessment of stems and their relation to the vessel wall, 
both immediately following implantation and, at follow-up. Furthermore, OCT 
also allows the quantification of neointimal tissue surrounding each individual 
stem strut. Unlike bare metal stems (BMS), which develop circumferential cover-
age with an average thickness of 500p.m or more, well visualized with IVUS and 
angiography, (96) drug-eluting stems (DES) delay and prevent this hyperplastic 
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Figure 7. OCT and stent. Panel A; Demonstrates the optical coherence tomography (OCT) 
imaging of a bare metal stent 4 months following implantation. The circumferential tissue struts are 
visible with shadowing induced by the metal. The neointimal tissue measured between 140 and 220 
microns in thickness. Panel B: OCT imaging of a drug-eluting stent (DES) at 4 months follow-up 
showing the circumferential struts with a very thin neoimimallayer (1 0-40 microns thlck). The 
arrow indicates a strut with no visible tissue coverage 
response so that the average late lumen loss can be as low as 0.1 or 0.2mm, (97,98) 
which means the amount of intimal tissue will not be detectable with IVUS. 
(96) 
Several small studies have recently been published highlighting the application 
of OCT in the detection of stem tissue coverage at follow-up. Matsumoto et a! 
(99) studied 34 patients following sirolimus-eluting stem (SES) implantation. 
The mean neointima thickness was 52.5 microns, and the prevalence of struts 
covered by thin neoimima undetectable by IVUS was 64%. The average rate of 
neoimima-covered struts in an individual SES was 89%. Nine SES (16%) showed 
full coverage by neointima, whereas the remaining stents had partially uncovered 
struts.(99) Similarly, Takano et a! (100) studied 21 patients (4,516 struts) 3 
months following SES implantation. Rates of exposed struts and exposed struts 
with malapposition were 15% and 6%, respectively. These were more frequent in 
patients with ACS than in those with non-ACS (18% vs 13%, p <0.0001; 8% vs 
5%, p <0.005, respectively). The ability of OCT to image at high resolution is 
the major advantage over IVUS and it also affords the potential to quantifY the 
amount of neointimal tissue formed over struts, an application which remains 
elusive for a technique like angioscopy. OCT is now also being incorporated in 
more and more clinical stent trials with the goal of assessing neointimal tissue 
coverage, an important potential surrogate marker for late thrombosis. (101,102) 
(figure 7) 
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CONCLUSION 
Several invasive imaging techniques are currently under development to detect 
vulnerable coronary plaques in human coronary arteries in vivo. To date however, 
none of the techniques described above have been sufficiently validated and, more 
importantly, they have not demonstrated a sound and reproducible ability to pre-
dict future adverse cardiac events. Intravascular palpography and virtual histology, 
based on conventional IVUS catheters, appear to be very promising and their 
predictive role is presently under investigation in a large international trial. 
Very rigorous and well-designed studies are compelling for defining the role of 
each imaging modality. Non-invasive techniques and the assessment of humoral 
and genetic factors comprise complementary and important tools in this direc-
tion. 
At present, the main purpose of all these evolving techniques is to improve 
our understanding of atherosclerotic disease and to define its natural history. 
Ultimately, the aim is to identifY patients at high risk for future cardiovascular 
events and to evaluate the benefits from either local or systemic therapeutic inter-
ventions. 
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Abstract 
This documer.t suggests standards for the acquisition, measurement, and repo1t1ng of radiofrequency data 
analysis (virtL:al histology- VH) intravascL:iar ultrasound (IVUS) studies. Readers shouid view this documen: 
as :ne authors' best attempt in an area of rapidly evolving investigation, an area where rigorous evidence is 
:lOt yet available or wideiy accepted. Nevertheless, this document is based on know:l pathologic da::a as 
well as prev:ous'.y reported ir.1aging data; where practical, this data is sur.1marised in the curre:~t document, 
a document whici", wil: also inc:ude recommendations for fut~;re evolutior: of ~he :echnology. 
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Introduction 
There is increasirg attention in ~he possibilty tha~ recognitor and 
treatment of high-risk plac;ues wouiC improve the progress made 
agai:-1st coronary artery d'sease. To add:ess the ~ormer issue, 
innova:ions i:-1 invasive imaging tech:-~iques -i.e. intravascular 
radiofrequency da;a ana:ys's fo: tissue composi:ion (Virtual 
Histoiogy™)- may help to bette: understand coronary atherosclerosis. 
indeed, Virtual Histology (VH) can potentia!ly detect thin-capped 
fibroatheromas CTCFAs). In addi~ion, the progression of the disease 
can aiso be foiiOVIIed-up. The technique has been validated in vivo and 
ex vivo anc! its reproduclbili':y tesLed in pat:er:ts WiLh encouraging 
resui':S. Therefore, several S:ud'es in different cor:texts have beer 
already reported in the literature. Furthermore, ~arge natural h:story 
studies and randomised controlled trials are ongoing in which the 
technique is being used. Thus, there is a need to establish standards 
01 acq;.~isition guidelir:es, analysis, definitions and reporting. 
Description of the technique 
VH-IVUS is a :echnique that allows tissue characte:isacion of 
vascular lesions. It is based upon the spectral analys's of the raw 
'.:lacKscattered ultrasound data that has been correlated wi:h 
vascular tissue types determ:ned from his~ology. Once the spectral 
signature of four tissue types (fibrous tissue, fibro-:atty tissue, 
necrotic core [NC], and dense ca:cium) a:e determined, these 
signatures a:e programmed into sottware, ei~her on the lVUS console 
or stand-a1'one sofuNare pacl<.ages, for the ana:ysis of patient data. 
independent studies have demonstrated in vivo a re1ativeiy hig:1 
!eve: o7 accuracy and reproducibii:ty of IVUS-VH ir. hu1;1an arteries. 
The technique has Oeen vaiidated in vivo, util:sing di~ectional 
coronary atherectomy speci1;1ens1, yielding predictive accuracies of 
up to 95% :n nan-ACS patents. Recent ex vivo studies2 ~haL 
validated VH :mages direct:y with the histopathology sect:ons gave 
accuracies of :.Jp ~a 97%. 
The oepraducibility of ~he technology using same and different 
cat\ieters has been s~udied using ex vivo IVUS pu!!bacl\s through 
excised human coronary arteries and in vivo frorr. randomly 
selected patients undergoing e!ective percutaneous coronary 
interJentlon (PCil. No statistical d:fferences were found between the 
pullbacks from the ex vivo or in vivo s:udies irrespecLive o: whether 
the same or a different catheter was used3. VH ;san IVUS based 
technology and as such is subject to the !imitations of iVUS. The 
axia: resolutior: of IVUS is apprax 100f.l:Tl and the lateral resolution is 
250 f.Jm. In addition, VH analyses data in blocks of 250 ~m. 
Therefore, for example, de~ect:on of thin fibrous caps <65 fjm in 
thickness, is below the resolution of the ~echnology. 
Screening and image acquisition 
VH~!VUS is a technique that is specific to equipme:-~t a'ld (as o7 this 
writing) solid-state IVUS catheters manufactured '.:ly Volcano 
(Rancho Cordova, CA, USA). VH-IVUS image acq:.Jisition requires 
ECG gating, a'ld although the ECG is not recorded along w'th the 
VH-lVUS da:a, it is important to ensure that the ECG signal is 
generating an:y one frame per cardiac cyc:e ("R taps"). If there is no 
ECG recording (at ~his moment arty detectable when acquired 
together with palpograpr.y), then ~he study should not be ana!ysed. 
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Step by ste[l} tJrocedme 
In the past. Virtual Histology was acquired using ~he In-Vision Gold 
console and a 20 MHz Eagle EyeTM Gold catheter. Currently, the 
Volcano s5 lmagi:~g System is ;.~sed for ~he qualitative and 
q~,;antitative eva:uatio:-~ of vascular :-norphology in the coronary 
arteries and vessels of the peripheral vasculatu~e. One of its 
components, the Vir':ual Histology System, is intended to perform 
spectra! analysis of RF u:trasound signa:s of vascula~ feat~.:res 
dur:ng routine diagnostic ultraso~.:nd imaging exarr.inations. 
Although two types of catheters can be used with this system, 
a 20 MHz electronic catheter or a 45 MHz mechanical catheter, the 
VH-IVUS for the 45 MHz is under develop:~~ent. 
System description 
The Volcano s5 system offers two options for IVUS acquis:tion: the 
s5 tower and the s5i (integrated) system. 
The s5 tower- The hardware system consists of the syste1;1 console 
that :ncludes monitor a keyboard, and the patient interface module 
(PIMJ. The cabling co:~ nectar at the PIM end allows fo~ the PlM ~o 
be discon:~ected and rep1aced. 
The sSi system - This system can be integrated into any of the 
availab:e angiographic systems. The CPU is the heart of t'le s5i 
p:atfarr:l. The CPU can be located in different locations, such as in 
the control room, the patient exam roo1;1 or in ar: equipment closet. 
The sSi control panel with a slide ou;: keyboard can be mounted on 
a support bracket from a patient ':able DIN rai!. It can also be placed 
on a table in ~he control room. A separa~e joystick option or a touch 
panel is availab!e for the physician at the bedside if desired which 
wil! provide basic systems functions from the bedside. 
Guidetines for acquisition 
It is worth mentio:-~ing that before IV US is performed, admin:Strat:on 
of between 100 and 300 \.Jg of i:-1tracoronary nitroglycerin is highty 
desirable in order to avoid spasm of tr,e vessel and mi:~imise 
ischaemia. Cor:sider patient's b:ood p-ess;.~re before ni::oglyceri:l 's 
administered. 
The detai1ed acquisition process is described in Table 1. 
Because image acquisition is EGG-gated, while the puiiOack speed 
is constant, the number of frameslmm will vary with the heart rate. 
The higher the heart rate, the more data (number of frames pe:-
mrr:} _<s collected: the pullback speed shouid, ideally, be 
0.5 mm/sec. At th1::. pullback speed and depending on the heart 
rate, three to six image s:ices will be acquired per 1.5 mm segment. 
Studies must be acquired usirg motor:sed catheter pu!lback. 
Mar:ual pullback is unacceptable and shouid not be done when 
acquiring VH-IVUS data. Volcaro man:.Jfactures two matorised 
pullback devices: TrackBack II 2nd R-100. The TrackBack II device 
:s not t~e most recommended for VH-IVUS image acquisition 
becaL:se of ~he absence of steady grasp of the catheter (related, in 
?art, to the l;.~bricious nature of ~he catheter shaft itself) and the 
weakness of ro!!er maverr:ent causing the ca~heter to be withdrawn 
unevenly. The R-100 device is the best pullback device currently 
available for the so!id-s:ate IVUS catheter. When imaging single 
stents of known length, 80-85% of ste:lts measured using the R-
100 device were withi:l 20% of known length compared to only 65-
70% of stent measL:red using the TrackBack I! device4. Third party 
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Tabte 1. Step-by-step acquisition procedure 
You must perform the following before you begin using the s5 system 
for imaging: 
- Ensure that the Patient Interface Module (PIM) is attached 
-Prepare the catheter in the same manner as for standard IVUS 
acquisition 
- Have a DVD-R ready 
VERY IMPORTANT: The ECG cable must be connected and capturing the 
R wave. The amplitude of the R wave must be at least 2X the amplitude 
of the T wave in order to ensure appropriate capture of data (the larger 
the "R'' wave, the better). 
-A red heart is visible on the upper right of the screen. It must be 
flushing at the speed of the patiertt's heart rate irtdicatirtg the trigger 
to acquire the RF data. It is importartt to confirm this function in order 
to ensure the acquisition. 
-The IVUS pullback can be performed viewing the grey scale IVUS modus. 
After the pullback, it is useful to switch to the virtual histology {VH) 
modus to confirm the quality of the datl.. VH is generated in real time and 
therefore it is immediately visible using preliminalY automatic borders. 
Step by step 
1. Check the settings: Date, time, language, archive (what information 
you want included with save frames and recorded loops, e.g. 
measurements, annotations, graticules). VH-IVUS, click VH ON by 
default. Adjust the default opadty levels for each VH parameter. This 
allows you to customise the type of tissue colour to be displayed. For 
example, you may be most interested in necrotic (red) tissue. This last 
option is especially useful for clinical decision-makers who ore colour 
blinded. Gain refers to the intensity of the ultrasound echoes. fl.s Gain 
is increased, the echoes become more intense and the image becomes 
brighter. To change the Gain: 1. Open the Adjust Image dialog box. 
For IVUS Eagle Eye Gold catheter the range is 1-68 and the default 
gairt is 50. Changes in the default gain settings will not affect tissue 
characterisation in VH. 
2. Enter patient information, press the Patient tab on the menu bar. 
The patient information dialogue box displays. 
motorised puiiback dev'1ces recuire validation before being used for 
VH-IVUS acquisition. Currently, the Globai VH Registry inciudes 
a combination of TrackBack II and R-100 acquired cases; IBIS-2 
and PROSPECT studies usee' only the R-100 Cev\ce. lr. general, 
pullbacks of the solid-state iVUS catheter appear to be iess unifocn 
in tortuot;S vessels, the left circumflex coronary artery, and i:-1 
s~ented and calcified segments; therefore, considera':.ion s·nou:c be 
given to exc:udir.g to1uows or heavily calcified vessels. 
During pulibacK, the catheter can stall or "stick" during image 
acquisition. In addition, typ:cally when imaging very !eng leClgths of 
the coro:1ary artery, VH-IVUS data nust be acquired in two 
overlapping segments because the !ength o~ the artery is greater 
~han t.'le capacity of ~he pullbac;.; device. Non-continuous or 
overlapping pullback sections should be deleted from the file, and 
~he two residual ends stitched together electronically durir.g image 
analysis. However, the cut-and-paste technique shouid be used 
only if there is one long segment of the ;:lUll back t~at is continuous 
(i.e. >10 mmJ that contains clearly identifiable landmarks; no more 
3. Select the IVUS tab on the interface user. 
4. Plug the catheter into the PIM at the patient's bedside. 
5. Place the catheter in the ostium of the vessel is going to be imaged. 
6. Press the Ringdown button to eliminate rirtgdown artefact when 
used with an Eagle Eye catheter. Manual rirtgdown from the sSi 
Controller can be done for peripheral catheters. It is often desirable to 
perform Ring Down because phase array IVUS transducers produce an 
area of noise around the catheter. This noise is caused by transducer 
resonance after an ultrasound pulse. The Ring Dowrt process normalises 
the trartsducer noise. 
5. Position the catheter distal to the lesion of interest and implement 
the pullback device if desired. This last is recommended when 
volumetric measurements are required. 
6. Press the Record buttort on user irtterface unit to begin recordirtg. 
The default mode for the Eagle Eye Gold catheter is ifH Ort" if the ECG 
trigger is available. VH 'Nill be visible in real time once the VH mode is 
selected. During the pullback the borders are defined on the 
Longitudinal view and, depending on the conFigure uration of the 
settings, the VH analysis appears automatically. 
The collection of VH data is interrupted/terminated once the ECG 
trigger stops and a message is displayed indicating the recording 
stopped due to a loss of the ECG trigger 
7. During the pullback and at any time after, the Bookmark button can 
be used to mark locatiorts of interest if desired. 
8. Press the Stop button on user interface to end Recording. 
9. Choose a pullback speed (1.0mm/sec, O.Smmjsec or Manual). 
10. Press Play to review the current Recording, or select from the 
Playback List buttort. 
11, longitudinal view for the sS system displays a sagittal view of the 
blood vessel that offers additional information for lesiort diagnosis, 
Longitudinal measurements, and other diagnostic and treatment 
options. 
than '::wo segmen;s can be joined together, and the cut-and-paste 
technique shou:d not be used to extend the ler.gth of the analysis 
segment if there is a good, continuously imaged, 40 mm long 
segnent that can be analysed. If the cut-and-paste technique is 
used, it is very impo1ant that tr.e same (identical) landmarks 
(fiduciary points) at both ends of the reconstructed analysis 
segment be identified and used in the baseline and foliow-wp 
s~udies. It is equal:y important that the segment that is to be 
removed have its own identifiable proxirr.al and distal fio·ucial)' 
points. 'tt is possibie that the distribution of atherosclerosis will be 
skewed by tr.e use of the cut-and-paste technique; therefore, this 
techniqt_;e should not be used if the numbec of patients in the study 
is small. 17 CCJttir.g and pasting has ta"..:en ;Jiaced during the process, 
this shot;ld be described in the methodology. 
ECS or zoom settfr.g ~Jrob~ems 
Beca~.:se VH-IVUS reouires ECG-gating with one inage slice per 
caroiac cyde, it is recommended that the software be modi~ed so 
tr,at at ~he time of :ecording and analysis, the ECG signal is cieariy 
visible. It is essential ~hat the ECG leads be connected to the patient 
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Figure 1. This patient was imaged in the same region with two 
different catheters during the same procedure. The graphs show all the 
frames acquired (x axis) and in they axis the distance bet\Neen them 
is given. Small variations in the intervals were observed. 
such that a good ECG ~racing is obtained and output to the IVUS 
system (figure 2). The R wave must be at least 2X the ampli~ude of 
the T wave in order to ensure app~opriate captt.:re of data (the large• 
t:1e "R" wave, t~e better). 
The zoom factor shot.:id NOT be changed during pullback. To 
ensL:re ':hat the en:ire circumference of t~e artery :s imaged 
2·~~--=-~~~s..._-t=:...~t~ ........ ~ 
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Figure 2. This figure shows the heart beats recorded during VH-JVUS 
acquisition (in this case palpagraphy was also recorded simultaneously). 
In black, the EGG signal; in purple the "R" top marker; in green and red 
the acquired VH-IVU$ frames. The blue line indicates the segmentation 
per heart beats based on the blood pressure signal (blood pressure curve 
not shown). In panel A, a quasi-normal EGG-gating acquisition is seen, 
the VH-/VUS frames (green markers) were constantly acquired 
throughout the pullback. Only few extra VH-/VUS non-"R"-top related 
were acquired (red markers). In panel B, due to a bad EGG signal the 
EGG gating was poor. This graph has been created by Frits Mastik at 
Erasmus Medical Center. 
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throughout its length, the proximal part o7 the vessel shou\d be 
imaged wh!\e inserting the catheter i:-1 order to set the zoom factor. 
Gain settings do not influence VH-IVUS o'ata and ana~sis and can 
be adjusted dur:ng pullbacl<. Eventually, segments with an 
inadequate ECG, incorrec;: triggering, or with the media "ouL of the 
image" are unreliable and should not l.:le analysed. 
Seg~ent ~en~hs 
There is no upper limit to the !ength of artery that can be assessed 
using VH-IVUS. It is limited only by the memory (or :1ard disk space) 
of the instrument and the capacity of the pullback device. 
Scramt1lng o-f lmage s~ices 
Scrambiing of the image slices occurs because of antegrade I retrograde 
motion of the transduce: during systole and diastole. In sheath-
based, mechanical IYUS catheters, :his averages 1.5 mm (range 
0.5 to 5.5 mml~. For this reason (as we!: as because of pullback 
issues), the following is recommended. 
Up to three consecutive scramble slices should be deleted from the 
file {"ignored frame"), a:1d the two residua\ er.ds stitched together 
electronically during image analysis. To this end, clear anatomical 
landmarks, st.:ch as side-branches, must be taken into account to 
recognise the scramble frames. 
Vesse1-specif[c 1im[ta~ions 
It is often dificult to image the very proximal segment of the RCA 
because the guiding catheter is in Lhe ostium. Even the conus 
branch is freq~.;ent:y covered by :he gt.:iding catheter. One option is 
to disengage the guiding cathete:, tak:ng care not to introduce too 
no.uch tension into the coaxial system. Another option is :o use a 
dista1 side-branch as the primary, fiduciary lanc!mark. The priority 
for the fiduciary point when imaging the RCA should be the aorta-
ostia: junction, the:~ the conus branch or a proxim<ll atria! branch, 
and finally a distal side branch. 
A similar probiern exists when imaging the left main (LM). However, 
it :s easier to disengage the guid'ng catheter from the LM while 
mai:~taining catheter stability. It S recommended that the LAD or 
LCX be imaged first and t~en the gL:iding catheter disengaged to 
image the LM. The carina is the most recommended fiduciary point. 
Contours 
There are on\y two reproducible borders {contours) in non-stented 
arter.ies: the extema! e!astic membrane (EEM) and the lumen. Once 
the bo:ders are traced, there will be a VH-IVUS classification of all 
structures within t:1is region of interest. Therefore, accurate contou: 
detection is critical. While there is a "flare" (ring down a:tefact) 
around the catheter, the lumen contour must be draw:~ away irorn 
this fiare (Figure 3). 
On the current YH-IVUS d!splay, the grey contour representing the 
media can occupy up to 40% of the plaque area, althoL:gh this area 
can be subtracted to obtain only ~he VH-IVUS plaque and its four 
tissue types: it was built into the display as a :and mark denoted the 
outer edge of :he vessel. Histologically, Lhe "normal" media is 250 
mic:-ons thick, bu: it is frequently destroyed during var:ous 
pathologic processes including athe~oscierosis. Media thickness 
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Figure 3. Panels A and A' show that the lumen border was drawn halfway into the flare (ring down artefacV of the catheter (yellow circle), in the 
VH frame this was misclassified as dense calcium. Panels 8 and 8' show the recommended approach to draw the lumen border, away from the 
flare of the catheter. Panels C and D show the proposed method to draw the contours at side-branches. Lumina! contour (yet/ow fine) should be 
drawn just beyond the vessel contour, so that in the VH-IVUS this appears as an empty space. $8, side-branch. 
cannot be measured using either greyscaie or VH-IVUS imaging. 
Because 1) media thickness is variabie, 2) the contours for 
greyscale IVUS, VH-IVUS, and other derived techniques such as 
palpography should be the same, and 3) :he pia que cross-sectiona'1 
area measured by greyscale IVUS, VH-IVUS, and other derived 
technolog.es shOuld also be the same. New software modifications 
will allow the display witr. or without the grey contour for media. 
Sid·e branc~es 
Cross-sectional image slices containing a side-branch should not be 
ignored or deleted from the VH-IVUS analysis (un!ess the side-branch 
OCJening is > 90 degrees). Neverthe:ess, because side-branch 
contahing cross-sect:ons do not d:s;Jiay the artery as a "circle," some 
ru:es are necessary fo~ de7ining the contours of the EEM and lumen 
ll The EEM co;:tour shou!d be in;erpolated as to follow the ;Jre- and 
post-side branch frames EEM morphology. 2) The lur.1en cor:tour 
should be drawn just beyond the EEM contour to avoid computa~ion 
of tissue 1ypes and to create in the VH-IVUS images an empiy area 
indicat;ng the position of the side-branch (F;,gure3). 
rr:romJus 
Current:y, there is no VH-IVUS class:fication for thrombL<S. It is not 
clear when or if SL.:ch a classifica~ion will err.erge because thrombi 
evolve a~d develop over time so that a single classi~ication for 
thrombus r.1ay never be possible. Work is ongoing for identification 
of fresh thrombus; however, identification of iate thrombws appears 
to be mo:e difficult With higher frequency greyscale IVUS, the real-
time, co:Jtinuously changing appearance of a clot during imaging is 
a usefui cr:terion for the presence of a thrombus. However, even 
wi~h 40/45 MHz transdJcers, the sensitivi1y/specifici1y of detecting 
thrombus is low<'; and with 20 MHz and ECG gating used for VH-
IVUS, terr.poral resolution is lost along with many of the sL.:bjective 
criteria of thrombus. Thrombus is :nisclassified as frbrous or 
fibrofatty by VH-IVUS7• However, it is advisable tr.at the luminal 
border should be drawn to include the thrombus as part of the 
piaque for :he following reasons (Figve 4): 1) there is no consistent 
border between thrombus ana· plaque that would clearly separate 
Figure 4. Two consecutive frames showing a ruptured plaque in 
a patient with an acute coronary syndrome. The luminal contour (not 
shown to allow visualisation of the discontinuity area of plaque surface) 
should be drawn including the cavity(white arrow) in the analysis. 
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thrombus from plaque and a!iow quantification of just the plaque. 
2) Thrombus is a moving target, changing with age. 3} Mural and 
intrarr.L:ra\ Lhrombus is even more difficult to detect than 
intraluMinal thrombus and impossible to quantify. 4) Lumen 
d!me:~sions (and, therefore, stenosis severity) are affected by the 
presence of thrombus. 5) Whenftf a classification for thrombus is 
developed, it will only be necessary to reprocess the images, not to 
red:aw the lumen contours. However, it is recommended that 
lesions suspected of containing thrombus be flagged for future 
study and reanalysis. 
Pathological plaque characteristics 
Based on post-mortem studies, there are three main causes o7 
thrombosis in atherosclerotic coronaries. The most frequent cause of 
th:-oMbos:s is plaque rupture, which in the coronary arteries accounts 
for 65 w 70% of cases dying suddenly, plaque erosion accounts for 
30 to 35% of cases and calcified nodule for another 2 to 5%. 
The rupture of a thin fibrous cap over a necrotic core is the most 
corr;mon underlying mechanism of atherothrombosis8. Although 
pathologic features that predict plaque rupture are elusive, 
increasing size of the necrotic core, decre.::sing thickness of the 
cap, int;ap\aque haemorrhage, and concentration of macrophages 
within the cap are associated with plaque instability. As the p!aque 
:-up~ures, the exposure of the tissue factor to fiowing blood results in 
activation of the coagulation cascade w:th formation of a platelet-
rich thrombus (Figure 5). 
Figure 5. Coronary plaque rupture with overlying luminal thrombus. 
A shows the area of the thrombus and rupture site (arrow) and 8 shows 
the site of rupture (arrow) with the overlying thrombus at higher 
magnification. 
In smaller calibre arteries such as the coronaries, the plaque 
rupture results in lumina: thrombus but the necrotic core contents 
tend not to emboiize distally; the core contents (free cholesterol 
crystals, ce!lular debris) intermingle with red cells, fibrin and 
platelets. The platelet thrombus is seen to embolize downstream in 
40% of cases dying suddenly. However, post-mortem data implies 
that in large arteries, such as the aorta and carotid, excavation of 
be necrotic cere underlying the ruptu~e site is frequent, with 
creation of a deep filling defect or u:cer crater with superficial 
organization of thrombus (figure 6). Because of high fiow 
conditions in the carotid, the contents of the necrotic core along 
with platelet rich thrombus embo!ize. Using grey scale IVUS, the 
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Figure 6. Ulcerated plaque, carotid artery. A. Haematoxy/in eosin stain. 
B. Movat pentachrome stain showing the ulcerated plaque (arrow) and 
the various plaque components. C. Macrophage staining (C068) 
showing macrophages (brown) close to the area of the ulceration and 
the underlying core. D. There is abundant fibrin within the ulcerated 
necrotic core. 
site of the plaque r:..~pture with disrupted fibrotic cap may appear as 
an empty cavity due to the space !eft ~rom the emboiised necrotic 
core and flow within the crater or the deep ulcer (F:gure 6}. 
The greyscale IVUS defini~ion of a p:aque rupture is a cavity wi~hin the 
plaque Lhat communicates with the lumen with or without an overlying 
fibrous cap fragmen~'\10 . HD1Never, not ail plaque ruptures are detected 
by greyscaie iVUS because the cavity is often filled with thrombus and 
b'ood. lnformatio:~ from greyscale lVUS should be used to define t'1e 
residual plaque end exclude the cavity from VH-IVUSanalysis, whe:~/if 
this is empty. When a p!aque :-up':ure is present on greyscale IVUS, this 
should be noted to imply previous p;esence of a thin capped 
fibroatheroma (TCFA) even though the NC may no longer be in contact 
with the lumen on VH-IVUS because of overlying thrombt.~s. 
Ca~cificat~on 
Focal calcification of atherosclerotic plaques is a near:y universal 
finding in advanced plaques and in elder:y patients. Because 
several components of the plaque can calcify, there is significant 
heterogeneity of the morphology of ca!cium deposits within 
atherosclerotic lesions. This heterogeneity precluCes general 
statements associated with plaque calcif;cation and p!aque 
sta bi lity/insta bil ity 
It is believed that calcification is an act:ve cellular process. Intima! 
smooth muscle cells ca!cify by the formation of me:nbrane vesicles 
(so-caiied "mat:"ix vesicles") which pinch off from the cell, calcify, 
and form a nidus for surrour.d:ng collagen calcification. This 
mechanism of calcification has been studied in vitro using cultures 
of vascular smooth musc!e cells that have the ?rDpensity for 
caldication under certain conditions of the grmvth medium and in 
conditions of cell death (apoptosis). Other patterns of plaque 
calcification have not been stud.ied in detail due to a lack of in vitro 
models. Matrix calcification, especially in lipid-rich poo!s (?athologic 
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Figure 7. Stable plaque, coronary artery A shows focal calcification 
(dark purple areas). 8 shows an area of sheet calcification (double 
arrow) of a collagen rich plaque where as the single arrow points to an 
area of necrotic core calcification. C illustrates as area of speckled 
calcification along a necrotic core. Dis the area from C underneath the 
arrow at higher magnification showing single cell calcification. 
Figure 8. Coronary arteries showing patterns of calcification. Left: 
A. Pathologic intimal thickening. B. Calcium stain demonstrating 
microscopic calcifications (von Kassa). Middle: A. Fibrocalcific plaque, 
non-occlusive. B. Speckled calcification within an early necrotic core 
(Movat stain). C. Shows fibrous plaque calcification. Right: A. 
"Pipestem" calcification circumferentially around the vessel, with 
apparent stabilisation of the plaque. 
Intimal thickening) has been observed morphologically. 
Proteog:ycans, especially O:ecorin, may play a ro!e in binding of 
phosoholipids initiating extracellular calcif1catlon.ln the absence of 
sigr.ificant :nflammation, calcif:cation may have a ~stabilising" effect 
as dense collageno'.Js calcified plates radiographically seen as 
"blocks" of ca!cium. However, macrophages may also form a nidus 
for caic'lficatiOn, resuaing in "speckled" caicium that is associated 
w;th plaque instability and plaque rupture. Calcification of nec;otic 
cores is often partial and "speckled" radiographically. Necrotic 
cores, along with surrounding co:!age:'l a:~d block of calcium, are 
more often seen in stabie plaques (so-called fibrocaicific piaques, 
which are considered stable) (F:gure 7 to 10). In plaque rupture 
calcification is most often seen as speckled or fragments of 
caicification which involve either necrotic core or fibrous t;.ssue and 
calcification is observed in 80% of plaques that rupture. Finally, 
there is a form of ca!cificatior. associa'ced w:th caic'1fied nodules with 
Figure 9. Unstable calcification. A. Macrophage marker {CD 68) 
demonstrating macrophage infiltration of an early necrotic core. B. 
Higher magnification of spicule of calcification (arrow) within an area 
of necrotic core. 
Figure 10. Coronary plaque showing healing plaque rupture. A and B 
at higher magnification show the site of previous plaque rupture where 
the fibrous cap is disturbed (arrow) and overlying healing thrombus. 
The rupture is almost fully healed towards the lumen. 
Figure 11. Nodular calcification in a coronary plaque. Note the calcification 
{A) some of which is nodular in nature in the area close to lumen. B is 
area underneath arrow in A at higher power showing nodular 
calcification with fibrin (dull red) in between nodules (bright red). 
overlying p:atelet thrombus which has been termed "nodL>Iar 
calcificatio!l" (Figure 11). This form o~ calcification is most often 
assodated with deposition of fibrin and even bone formation. 
Nodular calcification is an L:ncommon cause of !urninal th:ombosis 
in the coronary arteries. However, in the caro~id arteries, nodular 
calcification is :no:e common occ~,;rring in 5-10% of cases of 
thrombosis by histology. 
There is an ongoing controversy whether VH-IVUS can see ber.ind 
calcium. I~ there is a so!id "rock" o~ calcium, then VH-IVUS cannot 
see behind the ca!ciu:n. Solid "rocks" of calcium can be superfiCial 
(near ~he lumen) or a·eep (near ~he adventitia). Conversely, if :he 
calcil..im is non-confluent w'rt:h ga;Js of approximately 100 microns 
(ty;Jicai with speckled calcium that is present in a !lecrotic core). 
then some signal is present even if it is attenuated. On VH-IVUS 
imagi:'lg large confluent ca!cium deposits can be solid "rocks" of 
caidum or represent mui~iple, nearby, calcium deposits. It is also 
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unclear how often there Is a defi:~abie signal and how often there is 
mostly noise; Lhe current hardvvare and soft.Nare do not make this 
distinction. Therefore, in some cases, the signal behind calcium is 
mostiy noise while in other cases it contains useful data. Studies are 
currently underway to determine when there is e:~ough signal to 
accu;ate:y assess plaque composition behind calcium and when 
there is mostly noise and the signal ambiguous. 
Nevertheless, in the case of both solid and speckled (or multifocail 
calcium, shadowing caused by the presence of calcifications 
necessitates extrapolation of the EEM contours. Extrapolation can 
be assisted by longitudinal reconstruction of the cross-sectional 
images. T.1e following are suggested guidelines. Extrapolation can 
be performed 1) if the arc of calcium is ~90 degrees or 2) if the arc 
of calcium is 90-180 degrees. <5mm in length, and the 
"continuation" of the EEM evident using iongitudina! views. 
Extrapolation should not be performed if the arc of calcium is 
>180 degrees and/or >5 mm in length. However, these are just 
guidelines, and the location of the transducer relative to the calcium 
also influence the validity of extrapolation. The presence and 
qualitative assessment of calcification may be prognostically 
important, even though quantification of its thickness anc! of the 
tissue behind the calcium are difficult. 
Pathologic p~aque pmgression 
Pathology of lesion classification is based on autopsy observations 
which are based on static images. Although the natural history of 
coronary atherosclerosis is unknown, some believe that 
atherosclerotic lesion progression starts with pathologic intimal 
thickening in which lipid accumulates in areas rich in proteoglycans 
(lipid pools), but :n absence of necrotic core. Others believe that the 
earliest change of atherosclerosis is the fatty streak, a:so cal!ed as 
intimal xanthoma. 
The earliest lesion with a necrotic core is the fibroatheroma (FA), 
and this is the precursor lesion that may give rise to symptomatic 
heart disease. It is believed that ~upture of an atherosclerotic plaque 
is the u:~deriying cause of 70% of symptomatic disease. It has been 
shown in patients dying suddenly without prior symptomatic heart 
disease that at least 60% of cases will show prior rupture site or 
"healed plaque rup~ure" (Figure 10) suggesting that ruptu~e of an 
atheroscle~otic plaque may occur in the absence of symptoms. On 
the other hand, only 11% of ruptured plaques in patients dying 
sudden have a virgin rupture !.e., the first time that a plaque had 
ruptured. In the majority of cases, piaque rupture is silent, hea:s 
and leads to plaque progression through repetition of this cycle. 
Pathological intimal thickening (PJn 
The pathological intimal thickening (Figure 12 and 13) is a poorly 
defined entity sor;~etimes referred in the literature as "intermediate 
lesior.". This type of plaque does not encroach the lumen and 
consists of intimal thickenir.g cor;~posed of fibrous plaque with 
extracellular lipid and proteoglycans. True necrosis is no~ evident. 
The area overlying the lipid is rich in smooth musc:e cells and may 
contain a variab!e number of macrophages and T lymphocytes. It 
has been demonstrated that in tl"ce coronaries the majority of 
erosions occu~ over areas of pathological intimal thickening giving 
rise :o a clinically significant role for these lesion types. 
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Figure 12. AHA plaque classification. (Stary HC. The histological 
classification of atherosclerotic lesions in human coronary arteries. In: 
Fuster V, Ross R, Topol £, eds. Atherosclerosis and Coronary Artery 
Disease.). fc: fibrous cap; nc: necrotic core 
Fibrous cap atheroma (fibroatheroma} 
This type of lesion is constituted by a large lipid-necrotic core (Figure 
12 and 13) comprising large amounts of extra cellular !ipid, 
cholesterol crys'":.als, and necrotic debris, surrounded by a fibrous 
cap consisting principally of smooth muscle cells in a coilagenoL:s-
proteoglycan matrix, with varying degrees of infiltration by 
macrophages and T lymphocytes, and a variable number of 
surrounding in~lammatory ceHs surrounded also the lipid-:~ecrotic 
core. This !esio:~, according to the AHA classification which 
distinguishes between lesion types IV and V on the basis of the 
development of complicating features, may progress and became 
highly calcified or develop complications such as mural haemorrhage. 
Thin capped fibroatheroma (TCFA) 
This lesion is characterised by a large necrotic core containing 
nL:merous d"wlesterol clets (F;gure 12 and 13). The overlying cap 
is thin and rich in inflammatory cells, macrophages and T 
lymphocytes with few smooth muscle cells. Plaques prone to 
rupture are those with decrease cap thickness, large lipid-necrotic 
core and severe inflammatory infiltrate A study done by Burke et 
al1' has identified a cut-off va!ue for cap thickness of <65 microns 
for vulnerable coronary plaque definition. 
Healed lesions 
Healed ruptures are characterised by a disrupted fibrous cap filled 
in by smooth muscle ce!is, proteoglycans, and collagen (Figure 12 
a:1d 13). Healed ruptures are best identified by picrosirius red 
staining, whereby new!y synthesised type Ill collagen is seen 
over!ying a ruptured fibro~s cap consisting prirrari\y of :ype I 
collagen. The matrix within the healed fbrous cap defec': may 
consist of a proteoglycan-rich mass or a coliagen-rich scar 
depending on the phase of healing. Lesions with healed ruptu-es 
~ay exhibit mul:i-layering of iipid and necrotic core, suggestive of 
previous episodes of thrombosis. 
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Figure 13. Modified AHA classification. Virmani eta/, ATVB 2000; 20:1262~75. EL: extracellular lipid; nc: necrotic core; fc: fibrous cap; th: thrombus 
Fibrocalcific lesions 
F:bro::c plaques with e:Censive accumulations of calciur:1 are called 
fibrocalcific ;Jiaques (Figure 12 and 13). 
VH-IVUS lesion type or classification 
Tabie 2 outlines the plaque and lesion types tr.at are proposed 
based on the above pa~hologic data. 
Confluence is impor-.ant to minimise over reporting isolated islets or 
individual pixels of VH-IVUS detected necrotic core which can be 
artefacts. The term confluent is defined as a substantial area of 
necrotic core or dense calc'lum that is present in the Vrl~IVUS image 
as ar. aggregate indicative of the p!aque type not just image 'noise.' 
This was determined based on observations from numerous VH-
Table 2- VH-IVUS proposed Lesion types.. 
IVUS images and co~responCing histology '1mages, such t~at 
a 'confiuent area' is equivaient to ar, area of approximately 10% of 
necrotic core. Two other impor<--ant concepts are 1) the size of t~e 
major confluent necrotic core (area, volume, leng'"Jl, and arc) and 2) 
size of the major necrotic core in contact with the iumen (length and 
arc). iVUS derived TCFAs (VH-TCFAJ or fibroatheromas can also be 
subclassified according to 1l the number of necrotic cores or the 
presence of multiple layers of necrotic core; 2} presence or absence 
of calcification and number of focal or layered calcific deposits 
(presumed evidence of previous rupture); and 3) plaque burden (or 
lumen compromise). Given any two-dimensional (20) VH~IVUS 
image, the following text ou~ines a possible algorithm for lesior: 
analysis. 
Leslon type Brief description 
Intimal Medial Thickening (IMT) <600 1-1m crf intima thickness 
Pathological Intimal Thickening (PIT) <:600 )Jm thickness for >20% of the circumference with FF >15%, and no confluent NC or DC 
Fibrotic Plaque Dominant Ff and no confluent NC or DC 
Fibrocalcific Plaque >10% Confl.uent DC with no confluent NC 
Fibroatheroma (FA) >10% Cor~fluent NC on three consecutive frames 
Virtual Histology Thin Cap Fibroatheroma (VH-TCFA) >10% Confluent NC on three consecutive frames and arc of NC in contact with the lumen for 
36 degrees along lumen circumferer~ce 
Ff: fibrous tissue; FF: fibro-futty tissue; ND: necrotic core; DC: dense calcium 
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The plaque thickness is first checked to determi:~e '7 the VH-IVUS 
'mage represents intima-medial thickeni:~g (iMT) or a lesion. For this 
criterion to be satisfied, the p1.aque has to be greater than 360 IJm 
thick for over 20% of the circumference cove~ea by the piaque. For 
VH-IVUS images, this distance is ca!cuiated beyond the grey-
coloured media area that is considered to be 250-350 urn, 
represe:1ting healthy media. Hence, the total cLJt-off d;stance is 
approximately 600 IJffi. Next, an area of confluent necrotic core or 
de:~se calcium is searched fo: i'l the image. Confluent necrotic core 
or cod!uent dense calcium can also be present together wi:h their co-
existe:lce resulting in the formation of calcified fibroatheroma and 
calcified thin cap fibroatheroma categories. If a codlue:~t necrotic 
core is found, its proximi'0' ;o the lumen is determined to define 
whethe~ the lesion is a FA or a VH-TCFA. The term confluent at the 
lumen is defi1ed as a confluent necrotic core that is consistently 
presen~ for at least 36 degrees along the circumference of the iLJmen. 
If the confluent necrotic core ;s not at the lumen, ~he plaque is s:mply 
a fibroatherorra The addition of attached confluent-dense-calcium 
lends to the presence of either Ca fibroatheroma orCa VH-TCFA 
dependent on the iumen confluency condition. If conf!uent necrotic 
cere is absent but confluent dense calcium :s present, the plaque is 
fibrocalcific. 1:1 absence of both confluent necrotic core and confluent 
dense calcium, the rer:1aining categories are either PIT or fibrous 
plaque. Presence of >15% fibre-fatty component indicates PIT and 
<15% frbro-fatty component indicates fibrous p:aque. 
A plaque becomes a lesion when the plaque burden (plaqueJEEMl 
exceeds 40% over three co:~secutive frames. Lesions separated by 
5'11n; !engths of artery with a plaque burden <40% should be 
considered separate lesions. Lesions Should be classified according 
to t~e wcrs:-case scena~io or highest risk lesion. We hypotl"':esise 
that an "evolutionary~ lesion c!assifica:ion wiil be, i:~ order, IMT, PIT, 
F:bro:ic plaqL:e, Fibroatheroma, VH-TCFA, and (fina!!yl Fibrocalcific 
(Figure 14). We also hypothesise that a classificatlo:~ in term of 
vulnerabil'ty wi\1 be different with VH-TCFA being highest risk 
plaque: IMT, PIT, Fibrotic, Fibroatheroma, and VH-TCFA. ThLJs, 
there shou!d be different approaches for pharmacclog'cal versus 
prognostic versus interventiona: studies. The interventior;a! 
cardiologist may be more concerned with plaque morpho!ogy that 
influences the procedure (le. calcification, necrotic core-rich 
plaque), lesion preparation pre-interver;tion, acute complications 
post-:nterven"tion (piaque shifting, stent thrombosis), and fir;a! 
results. Pharmacologic or other natural history studies may be more 
interested in serial changes in plaque compositio:~, lesion 
classification, and lesion vulnerability. 
Stents 
CJrrently, VH-IVUS has not been validated for meta: stents, for 
intimal hyperplasia, for tissL:e surrounding a:~d behind stent struts 
in general, and for the chronic effect of drug-eluting stent polymers. 
Metallic stent struts appear white surrounded by a red halo; thus, 
stent metal is artefactLJal\y included i:~ t~e calculation of both 
ca!cium and necro:ic core. However, from a quantitative point it 
would be interesting to develop a third (ster;t) contour with 
va:idation of stent metai and peri-s~ent tissue. This should be 
feasible because stent struts are small and the gaps between stent 
struts are !arge. For example, in the TAXUS-11 study12, there was a 
chronic increase in EEM dimensions; it would be interesting to know 
what type of tissue cor;tributed to t~is process. It is recommended 
that frames containing stents being n;arked as containing a stent 
and that these frar:~es be assessed visually, but not inc!Jded !:1 the 
VH-IVUS calcu!ations similar to the approach recomr:~ended for 
heavy calcification (above). 
However, a distinction should be n;ade for bioabsorbaOle sten:S. 
Recently, the feasibility and safety of a bioabsorbable everolimus~ 
Figure 14. Examples of VH-IVUS images classified by a two-dimensional lesion analysis. (IMTJ intimal medial thickening; (PIT) pathological intimal 
thickening; (FT) fibrotic plaque; (FC) fibroca!cific plaque; (FA) fibroatheroma and (caFA) calcified fibroatheroma; (VH-TCFAJ Virtual Histology-thin 
cap fibroatheroma and (VH-caTCFA) Virtual Histology-calcified thin cap fibroatheroma. 
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eluting stent {BVS) was assessed. In a prospective, open-label 
stuc'y, 30 patients with a single de novo lesion that vvas suitable for 
treatment with a single BVS, were enrol:ed. Stent struts are 
class·~ied as "dense calcium" (DC) and "necrotic core" (NCJ by 
IVUS-VH. From pre- :o post-stenting, in 13 patients imaged with VH 
(n=13J, ~here vvas an increase in mean "DC" (9.8 vs. 25.4%, 
p=D.0002) and "NC" (15.5 vs. 30.5%, P=0.0002J. Comparing 
post-s~ent:ng with six mo:1:hs foliow-up {n=27J, VH showed 
a decrease in "DC" {29.7% vs. 21.1%, P=O.OOOll. "NC" also 
decreased (26.9 vs. 21.5%, P=0.0027). 
The q~.:antitative assessment of ~he IVUS-VH changes at six months 
swggests ear!y st;ut alteration of the SVS stent with reduction of 
radiofrequency backscat:ering. Thus, virtual histology helps in 
assessing the bioabsorption rate of such stents1~. 
Core tabs, analysis software, and their 
validation 
Based on current experience with programs develoP2d by individual 
laboratories, the following should be incorpo:ated into an ideal 
software package. 
1. Optimised automatic contoL:rdetection 
2. Quantitative output of data along the longitudinal axis of the 
segment to include "Greysca:e" parameters such as EEM, rumen, 
and p',aque-c-media areas and remodeiing 
3. Absolute and relative VH-IVUS plaque components (in which ~he 
total of the four components equals the absoiute "greyscale" 
plaque areal 
4. Presence of "norrr:al" or non-diseased cross-sections 
5. Volumetric analyses 
6. Automatec targeted lesion classification sof2Nare 
7. Manual annotation -for example, lesior. ciassif:cation, evidence 
of plaque rupture on greyscale imaging, presence of a stent, 
;Jresence of multi pie necrotic cores, artefacts, presence of a non-
diseased cross-section, etc. 
8. Manual selection of reference segments for calculation of 
remodelling 
Only or.e ana·lysis sotware package should be used in a given 
study; unfortunately, this may result :.n not !:le'1ng able ~o SINi~ch to 
:he latest, most efficie~t software when it becomes available. 
Either phantoms or a standard set of cases be developed for 
validation of :lew software and new core laboratories. Inter and ir.tra-
observer reproducibility should include all sources of variation from 
image acquisition ~o core lab analysis: general precision/accuracy of 
the technique, P1 vs zo pui'i":Jack, r'· vs 2nd catheter, one type of 
cathete vs another, lc·1 vs 2"d observer, and r· vs 2nd core lab, 1~: vs 
2-.d set of contours, and lesion classification. 
Study-design related recommendations 
Single point-in-time studies (transversal or observational studies) 
Each artery shouid be divided into segments defined by proximai 
anc' distal fiduciary branches. most often side-bra:lches. The 
shortest segmen~ that should be analysed at one point in time is 
1.5 mm within a >10 mm continuously imaged vessel segment and 
near to one or more definable fiduciary points tr.at can be used for 
interpoiatior. The rationale fer this recommendation :s 1} a 1.5 mm 
segment will contain at least ~hree consecutive frames at a puiiback 
speed of 0.5 mm/sec (when heart rate is 60 bpm); 2) this is the 
average antegrade/retrograde catheter motion during systole/ 
diastole; and 3) tr:e Medis quantitativeaflgiogra;Jhic analysis system 
reports coro:lary artery iengths as short as 1.5 mm. Therefore, VH-
IVUS can be referenced to the coronary angiog;arn L:Sing nearby 
sidebranches that can be identified on both studies. It is highiy 
recommended that a picture of the angiogram be ;Jrov:ded for 
comparative purposes. PROSPECT '.s analys~ng the three maJor 
epicardial arte ·es in 1.5 mm segments. 
Serial studies (longitudinal or natural history studies) 
The shortest segment that shouid be analysed on serial studies is 
10 mm. It is also recommended that the zoom settir.g be tr.e 
same for each of the serial studies. Because the number of 
frarr.es/mm will vary with heart rate and because the heart rate 
may differ between two VH-!VUS studies, ser~al studies shol.'ld 
use both a proximal and distal :a:ldmark ~o define the analysis 
segment; and the VH-IVUS data should be averaged en a per 
segment bas:s or reported as a normalised volwme. (Ti"' .. ls is 
s:milar to wha~ has been done for greyscale IVUS analysis of 
p rogressi on/regression. J 
Vulnerable plaque studies 
Because of angiograpi"'.ic studies documen~ing the dis~ribution of 
acwte coronary occlusions and because o~ greyscaie IVUS studies 
documenting the location of ruptured plaques, it is recommended 
that long-term prognostic studies include VH-IVUS analysis of the 
proximai 40 mm of the LAD and LCX and the RCA down to ~he 
crux' ..... 18. However, this may not always be possible or practical. 
Therefore, at the very least, the most prcxirr.al30 mm of each offne 
three major epicardial arteries shOuld be imaged. The US FDA 
recommends imaging 1) at least a 30 rnm :ong non-stented 
segment of an 'Jntreated artery or 2) a 30 mm long non-stented 
segmen~ of a treated a;tery that is at least lOmm removed from tl"',e 
ster.t ec'ge. The minimum length of LM that should be imaged is 
5mm or 50% of LM length. However, natural history studies :n 
which the origin and morphology of vuinerab!e plaques were 
prospectively identified have not been comp:etec·. In the 
PROSPECT study the left mair1 coronary artery and the proximal 5-
8 em of the th~ee major epicardial coronary arteries have been 
imaged in >600 patients, with follow-up ongoing. 
Reporting 
VH-IVUS data can be reported per !esion, per segment, pe~ vessel, 
and per patient (Table 3). On one hand, a study geared to providing 
prognostic information should aim a: the most complete 
assessment of the coror.ary tree possible. The minimai segment to 
be analysed shoJid be 1.5 mm. It is unclear whether such short 
segments of coronary tree are independent of eacr, other in terms of 
VH classification. However, we assume that there is some degree of 
:nterdepenc'ence. Thus, there maybe a va!ue in analysing the entire 
length of the coronary tree for S'"catistical power. On the other hand, 
a study gea;ed to assessing coronary 'rntervention should focus in 
the lesion, itself. 
Whenever possible, all VH-IVUS continuous data shouid be 
reported as cor.tinuous variables. 
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Table 3. VH-IVUS variables for reporting. 
VH-IVUS 
Lesion tevel 
1. Lesion length 
2.. Lesion loe<~tion 
3. CASS segment (hee<~use a lesion e<~n cover more than one CASS segment, the 
lesion should always be assigned to the more proimal CASS segment where the 
lesion is initiated) 
4. Conventional greyscale IVUS par<lmeters [external elastic membr<lne (EEM), 
lumen, plaque&media, plaque burden, eccentricity, and remodelling] at specified 
loe<~tions (i.e. the site of the minimum lumen area) as well as aver<lged over the 
entire lesion 
5. Absolute and reliltive Virtwl rlistology (VH)-NUS par<lmeters [fibro-fatty (FF), 
fbrotic, necrotic core (NC), and dense e<~lcium) at spetifed loe<~tions, aver<lged 
over the entlre lesion, and reported as mean areas and/or as volumes 
6. Lesion type and full description of necrotic core and calcification 
7. Presence of bifure<~tion 
S. Presence of stent 
Segment level 
1. Proximal and distal fiduciary br<lnches 
2.. Segment length 
3. Segment location 
4. Absollrte and relative VH-IVLJS par<lmeters (FF, fibrotic, NC, anC dense e<Jlcium) 
aver<lged over the entire segment and repor'.:ed as mean areas anc!jor as 
volumes 
5. The 10 mm long worst section withir. this segnent e<~n also be repartee! 
separately 
6. Lesions and their classification 
7. Plaque free length 
Vessel level 
1. Proximal and distal fiduciary branch 
2.. Vessel length 
3. Vessel loe<~tlon 
4. Absollrte and reliltive VH-IVUS parameters (FF, fibrotic, NC, and calcium) 
averaged over the entire vessel anc! reported as mean areas and/or as volumes 
5. Lesions and their classification 
6. Plaque free length 
Patient Level 
1. Absolute and relative VH-NLJS par<lmeters (FF, fibrotic, NC, and calcium} 
aver<lged over the entire vessel and reported as mean areas and/or as volumes 
2. Lesions and their dassifie<~tion 
3. Pldque free length 
Greysc:ale IVUS 
Greyscale and VH-IVUS data shou!d be integrated. I~ addition to 
VH-IVUS, a co~plete report shou!d also ir.cl~.:de fuil greyscale 
quantification: EEM, lumen, and plaque&media area; plaque 
buro'en (plaque&~edia divided by EEM); remodelling (lesion EEM 
compared to a pre-determined reference EEM); eccemrici:y (based 
on maximum and m:nimun; p!aque&media Lhickness); and calcium 
(arc, iength, and location). 
When assessing remodelling, the EEM CSA o7 a single, pre-specified 
iesion site cross-section should be compared to a pre-defined 
reference. For non-bifurcation lesions, it is recommended that the 
reference segment be the single frame (or three consecutive frames) 
wrth least plaque burden within the same segment as the lesion. If 
the !esion extends over more than one segment, then the sing!e, pre-
specified lesion site cross-section should be compared to the pre-
defined reference within the same segment. 
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In the case of a b:f-urcation lesion, if the image slice with the 
minimum lumen area is proximal to the carina, the:~ a proxitT.al 
reference should be ~.:sed to calculate remodelling. If the image 
s~ice with the minimum lumen area is distal to the carina, tner. 
a dista! reference should be used to ca1culate remodelling. 
Remodelling should be reported as a conti:~uous p!ot over the 
length of the coronary segment based on the reference segfflents 
that are selected. 
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CHAPTER 2.1 
Combined optical coherence tomography and intravascular 
ultrasound radio frequency data analysis for plaque 
characterization: Classification accuracy of human coronary 
plaques in vitro related to image artifacts. 
Goderie TPM, van Soest G, Garcia-Garcia HM, Gonzalo-Lopez N, Koljenovic S, 
van Leenders A, Regar E, Serruys P"W, van der Steen AFW 
Submitted 
Chapter 2.1 
ABSTRACT 
Aims: The purpose of this study was to characterize coronary plaque types, with 
special interest in misclassification in both optical coherence tomography (OCT) 
and in intravascular ultrasound (IVUS) radiofrequency (RF) data analysis, and to 
investigate the possibility of error reduction by combining both techniques. 
Methods and results: Regions of interest were selected and imaged with OCT in 
50 cross-sections and IVUS in 36 cross-sections, from 14 human coronary arter-
ies, sectioned from 14 hearts at autopsy. Plaques were classified based on IVUS 
RF data analysis (VH-IVUS~), OCT and the combination of those. Histology 
was the benchmark. OCT was able to correctly classified 32 out of 50 cross-
sections; VH-IVUS correctly classified 26 out of 36 cross-sections. VH-IVUS 
and OCT combined were able to correctly classify 28 out of 36 cross-sections. 
Systematic misclassifications in OCT were intimal thickening (IT) classified as 
fibre-atheroma (FA) in 7 cross-sections and IT classified as thin-cap fibre-atheroma 
(TCFA) in 3 cross-sections. Misclassifications in VH-IVUS were IT as FA in 3 
cross-sections and IT as calcified fibre-atheroma in 3 cross-sections. 
Conclusions: Typical image artifacts, both new ones and previously identified, 
were found to affect the interpretation of OCT data. Adding VH-IVUS to OCT 
reduced the error rate. 
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BACKGROUND 
Pathology studies have demonstrated that most of acute coronary syndromes 
originate from vulnerable plaques. 1·5 These plaques have a mechanically weak cap, 
consisting of a thin fibrotic layer that is infiltrated by macrophages, overlying 
a lipid-rich necrotic core.2'6-9 The current challenge is to specifically identify in 
vivo plaques that exhibit these characteristics and thus are likely to cause acute 
coronary syndrome10• Clinical diagnosis may benefit from complementary infor-
mation gathered by different imaging technologies, as they may be sensitive to 
specific aspects of the anatomy.6.Jl-J6 
Grayscale Intravascular Ultrasound (IVUS) has since long been a standard 
diagnostic tool in cath labs worldwide, and intravascular Optical Coherence To-
mography (OCT) looks set to rapidly become one as well. 14 ·17•20 Radio frequency 
(RF) data analysis adds plaque composition information to grayscale IVUS, which 
may help to distinguish high-risk lipid-rich necrotic plaques from other rypes of 
plaques.21 •23 IVUS RF data analysis (commercially available as VH-IVUS'"; Vol-
cano, Rancho Cordova, CA) aims to provide quantitative information on plaque 
composition classifying plaque as fibrotic, fibro-fatty, necrotic core or dense 
calcium, based on spectral analysis of the RF signal." Although criteria have been 
formulated for VH-IVUS to detect TCFA, as a standalone technique it is not able 
to recognize this rype of lesion because of its limited resolution (> 250 )1m). 16•24·26 
In this article, we will refer to IVUS RF data analysis as VH-IVUS, since we used 
that technology specifically. 
Optical coherence tomography (OCT) generates real time tomographic im-
ages from backscattered infrared light with a high resolution (I 0-15 )lm axial). 14•27 
Its resolution allows direct imaging of a thin fibrotic cap, in principle. Main 
disadvantages are the limited depth of penetration (approximately 1.5 mm) and 
the need to flush blood from the imaged artery. 14 This latter issue is relieved by the 
advent of high-speed intracoronary imaging systems that allow full imaging of a 
coronary artery with only short flush. 17 
The relatively small penetration depth of OCT limits the reliability of dif-
ferentiation of heterogeneous plaques.28 Misinterpretations of calcified tissue as 
lipid in OCT have been reported, leading to misdassified OCT-derived TCFA. 16 
The cause of misclassification of a lesion may be an interpretation error by the 
image reader, or image artifacts inherent to the technique. As confounders are 
likely to be specific to a certain technique, studies using the combined strengths 
of multiple modalities, for instance OCT and VH-IVUS, could lead to a better 
classification of plaques than interpretation of the techniques' imagery separately. 
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The aim of this study was to compare the ability of OCT and VH-IVUS to 
classifY plaque and to assess the performance of a combination of the two mo-
dalities to identifY different plaque types. While a few in-vivo studies have been 
published, 16•29 in this work we present the first comparison between VH-IVUS 
and OCT, using histology as a benchmark. 
METHODS 
Study population 
Between June 2007 and January 2008, 14 coronary arteries have been collected 
from 14 human hearts acquired during autopsy (57% men, 12 left anterior de-
scending arteries, 2 right coronary arteries, mean age 64) at the Department of 
Pathology of the Erasmus MC. All patients died of non-coronary causes. Permis-
sion to use autopsy material for scientific study was obtained from the relatives. 
This study was approved by the local institutional review board. 
Tissue preparation and data acquisition 
Atherosclerotic human coronary artery segments were excised from the heart and 
imaged within 36 hours postmortem. During the excision all side branches were 
closed with sutures. The arteries were mounted benveen 2 sheaths in a water tank 
filled with physiological saline. A water column system, also containing physi-
ological saline solution, was connected to the proximal sheath, to pressure-load 
the vessel. The vessels were pressurized to I 00 mmHg to close up remaining leak-
ages. 
The vessels were imaged with OCT (M2-CV and Image Wire 2 catheters; 
Lightlab Imaging, Westford, MA) and IVUS (In-vision Gold; Eagle-Eye™ 20 
MHz catheters; Volcano, Rancho Cordova, CA). Regions of interest (ROis) were 
selected based on the presence of plaque and plaque size. ROis were marked with 
a needle. 12 After imaging the needle was replaced by a suture. 
ROis were first imaged with the IVUS-system, followed by OCT. The vessels 
were pressurized to 100 mmHg for imaging. For IVUS, the vessels were kept at 
room temperature 20 ±zoe; OCT was performed at 37'C.3031 
After imaging, the artery sections were pressure fixed at 100 mmHg in form-
aldehyde for 24h at room temperature, and subsequently stored in formaldehyde 
at 4°C for further processing. Vessels were partially decalcified for 24 hours in 
formic acid.32 After fixation and decalcification, sutures marking the imaged 
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cross-sections were replaced by ink dots. The tissue was embedded in paraffin and 
serially sectioned for histological staining. Each imaged cross-section was stained 
with Hematoxylin-Eosin (H&E), Picrosirius red, Elastic van Gieson (EvG) and 
immunohistochemical stain CD68. 
DATA CLASSIFICATION 
Plaques were characterized in the images acquired with the two modalities, as 
well as in histology. As histological tissue slices are much thinner (5 flm) than the 
thickness sampled by OCT (25 flm) or IVUS (-200 flm) 333' there is an unavoid-
able sampling error. Imaged cross-sections that were obviously mismatched with 
histology, based on anatomical features, were removed from the data set before 
analysis. 
VH-IVUS 
VH-IVUS constructs tissue maps that classify plaque into four major components 
(fibrous- green, fibrofatty-light green, NC- red, and dense calcium- white) 35 
Data were acquired, and B-mode images were reconstructed from the RF data by 
customized software (pcVH 2.2, Volcano Corporation), which allows a semiau-
tomatic detection of the lumen and the media-adventitia borders and provides 
the compositional parameters. VH cross-sections were quantitatively measured 
and were classified as one of the categories described in table I by an experienced 
analyst that was blind for pathological and OCT findings. 36·38 
OCT 
Classification of OCT was based on characteristics as mentioned in table I by an 
experienced OCT reader. 143637•39 Because of the limited depth of imaging and the 
limited penetration in OCT, tissue types could not be expressed as percentages of 
the intima like in VH-IVUS, but had to be based on the visible part of the OCT 
image. In cross-sections with no visible cap, defined by a transition of signal from 
homogeneous signal rich to othenvise, the cross-section was classified as intimal 
thickening. In presence of a cap the dominant tissue type behind the cap was used 
to assess lesion type. 
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Combined OCT and VH 
After independent analysis of each technique, side-by-side visual assessment of 
VH-IVUS and OCT cross-sections allowed us to evaluate the plaque types in a 
combined fashion. The criteria in Table 1 were applied for both techniques. If 
the classifications diverged between VH-IVUS and OCT, signal rich regions in 
OCT overruled VH-IVUS tissue characterization. In signal poor regions in OCT, 
VH-IVUS overruled OCT. This choice was made because a loss of OCT signal 
can occur due to artifacts, whereas artifacts are unlikely to cause a gain in image 
intensity. 
Table 1. Criteria for plaque characterization; NC =necrotic core, DC= dense calcium, FA= fibre-
atheroma, CaFA =calcified fibro-atheroma, TCFA =thin-cap fibro-atheroma, CaTCFA =calcified 
TCFA. 
lesion type Brief description in VH 1~18 Brief description in OCT ''.1437J~ 
Intimal 
thickening 
Plaque with <1 0% of NC and <1 0% of calcified tissue Homogeneous signal-rich region 
Fibrocalcific 
plaque 
> 10% of confluent DC with <1 0% of confluent NC Homogeneous sharply delineated signal poor regions 
Fibre-atheroma plaque with > 10% of confluent NC 
Calcified FA FA containing> 10% of confluent DC 
TCFA > 10% Confluent NC in contact with the lumen 
CaTCFA TCFA containing > 10% of confluent DC 
Histology 
Heterogeneous signal poor regions poorly delineated 
Areas of heterogeneous signal poor regions mixed 
with sharply defined signal poor regions 
FA with a cap <6S11m measured at the thinnest point 
Same as CaFA but the NC is covered by a cap <65 11m 
Histological cross-sections were characterized by two observers blinded for the 
VH-IVUS and OCT results. Characterization was done by making a map of 
all the cross-sections, with color coding for different types of tissue, separating 
fibrotic tissue, lipid pool, necrotic core and dense calcium. In case of disagreement 
between the two pathologists, pathologist 1 and pathologist 2 re-evaluated the 
slides and reached a consensus diagnosis. Classification of cross-sections was done 
using the modified American Heart Association (AHA) classification. 37 
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RESUlTS 
Comparison of histology and optical coherence tomography 
OCT imaging, with positively matched histology, succeeded in 50 cross-sections 
of 14 vessels. By histology, 33 cross-sections were classified as intimal thickening of 
which OCT correctly classified 21. There were two cross-sections misclassified as 
IT by OCT. There were four fibrocalcific plaques in histology, two were correctly 
classified by OCT. Further, OCT misclassified three cross-sections as fibrocalcific 
plaque. Our of the six fibroatheromas by histology, OCT correctly classified three. 
Of note, OCT misclassified another seven. In histology, there were seven calcified 
fibroarheromas, six correctly classified by OCT. In addition, OCT misclassified six 
more plaques, two as calcified fibroarheroma, three as thin capped fibroarheroma 
and one as calcified thin capped fibroarheroma. These results are summarized in 
Table 2. 
Table 2. Classification and misdassification by OCT in 50 cross-sections. IT= intimal 
thickening, FC = fibrocalcific, FA= fibre-atheroma. CaFA =calcified fibroatheroma. TCFA = 
thin-cap fibro=atheroma, CaTCFA =calcified thin-cap fibre-atheroma, OCT= optical coherence 
tomography. 
OG+ oa- Histology 
IT+ 21 12 33 
IT- 2 15 17 
FC+ 2 2 4 
FC- 3 43 46 
FA+ 3 6 
FA- 7 37 44 
CaFA+ 6 7 
CaFA- 2 41 43 
TCFA+ 0 0 
TCFA- 3 47 so 
CaTCFA+ 0 0 0 
CaTCFA- 49 so 
Virtual histology findings 
Our of 50 cross-sections, 36 cross-sections in 9 vessels also had VI-I-IVUS data. 
By histology, 29 cross-sections were classified as intimal thickening of which 
VH-IVUS correctly classified 25. There were six cross-sections misclassified as 
IT by VH-IVUS. There was only one fibrocalcific plaque in histology, which 
was not correctly classified by VH-IVUS. Further, VH-IVUS misclassified one 
cross-section as fibrocalci.fic plaque. Our of the six necrotic core-rich plaques 
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Table 3. Classification and misclassification by OCT, VH-IV1..TS and OCT!VH-IVUS combined, 
using histology as a benchmark, in 36 cross-sections. IT= intimal thickening, FC = fibrocalcific_, FA 
= fibro-atheroma, CaP A= calcified fibroatheroma, TCFA =thin-cap fibro=atheroma, CaTCFA = 
calcified thin-cap fibro-atheroma, OCT= optical coherence tomography, VH = VH-IVUS. 
OCT+ OCT· VH+ VH- OCTNH+ OCTNH- Histology 
IT+ 19 10 25 4 26 29 
IT· 2 5 6 5 2 7 
FC+ 0 0 0 1 1 
FC- 34 1 34 34 35 
FA+ 0 2 0 2 2 
FA- 5 29 31 1 33 34 
CaFA+ 1 3 2 2 4 
CaFA- 31 0 32 0 32 32 
TCFA+ 0 0 0 0 0 
TCFA- 33 0 36 35 36 
CaTCFA+ 0 0 0 0 0 0 
CaTCFA- 0 36 0 36 36 36 
VH 
Figure 1. Chart of misdassifications. Only misclassifications occurring ~2 are included in the 
figure. Misclassifications are derived from 36 cross-sections in VH-IVUS and OCT and VH-IVUS 
combined, misdassi:fications in OCT are derived from 50 cross-sections. Yellow = histology, green = 
VH-IVUS. orange= OCT OCT!VH-IVUS =red. IT= intimal thickening, FC = fibrocalcific, FA 
= fibro-atheroma. CaFA =calcified fibroatheroma, TCFA =thin-cap fibro-atheroma. For example: 
of the lesions that were identified as IT in histology. 7 were classified as FA in OCT, 3 as FA in VH-
IVUS, and 2 as FA in OCT and VH-IVUS combined. 
classifed by histology, VH-IVUS classified only one correctly, that was a calcified 
fibroatheroma. Unlike OCT, VH-IVUS did not misclassify any plaque as thin 
capped fibroatheroma. 
Table 3 lists the results of the comparison between histology and OCT for 50 
cross-sections. Figure 1 shows misclassifications and directions of misclassifica-
tions. Only repetitive misclassifications are included. 
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DISCUSSION 
The results in Tables 2 and 3 demonstrate that the classifications by both OCT 
and VH-IVUS agree with histology in most cases. Figure 2 illustrates a representa-
tive example, where both OCT and VH detect a calcified fibre-atheroma, which 
is in accordance with the histological classification. 
Manfrini et al. were the first to apply the American Heart Association criteria 
to lesion classification with OCT 23 Classification was done in four groups using 
the AHA criteria of 1995.36 In this study we used a modified version of the AHA 
criteria, including the extra categories, calcified fibre-atheroma, TCFA and calci-
fied TCFA.37 1he study of Manfrini showed a sensitivity of 45% for FA, 68% for 
calcified lesions and 86% for fibrotic lesions. Similar results in our study were seen 
in the detection ofF A (3/6 correctly classified). Our study used three categories for 
calcified plaque FC, CaFA, and CaTCFA, having the following results; 2/4, 617 
and 0/0 classified correctly, respectively. Subclassification of calcified plaque did 
not affect the results, compared to the Manfrini study. Fibrotic plaque, categorised 
in our study as intimal thickening, showed slightly different results compared to 
the Manfrini study (21133 correctly classified). 
The sample size in our study was sufficient to detect repetitive misclassifica-
tions and provide an explanation of those misclassifications based on the image 
data. These systematic misinterpretations of the data also suggest future possibili-
ties how combining intravascular imaging techniques could help reduce errors in 
classification. The limited size of our study did not permit reliable calculation of 
sensitivities and specificities, however. 
Recent studies in OCT showed difficulties detecting TCFA in OCT and in 
characterizing plaques with OCT. 16·23 Misclassifications were reported as a result 
oflimired penetration depth, problems in distinguishing lipid pool from calcifica-
A 
Figure 2. (A) Histology of a calcified fibroarheroma (hemato:>..ylin-eosin stain). (B) Corresponding 
VH-IVDS classified as calcified fibroatheroma. (C) Corresponding OCT classified as calcified 
fibroarheroma. The needle used to mark rhe site can be seen in rhe bright feature at 6 o' dock in 
OCT, as well as in rhe appearance of dense calcium in rhat location in VH-IVUS. 
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Figure 3 (A) CD68 stained cross-section. The intima consisting of a collagen/glycoprotein matrix 
is densely infiltrated by macrophages. (B) Magnification of selected region in A (C) Corresponding 
OCT image. The region infiltrated by macrophages appears as a thin-cap fibre-atheroma. The bar 
indicates 1 mm. 
tions and vice versa, or heterogeneity of necrotic cores, consisting of necrotic 
debris and calcifications. 14- 16·28•29 
In our data we have encountered the same confounders. In addition, we ob-
served the following features, compromising the classification of lesions based 
on OCT. Dense infiltration of macrophages in the intima or the outer layers of 
a fibrotic plaque led to high scattering of OCT signal, causing the underlying 
collagen/glycoprotein matrix to appear as a (thin-cap) FA. Figure 3 shows an 
example. In such sections, signal-poor regions were seen, with poorly delineated 
borders, which is the exact definition oflipid pool. 14•39 The possibility of detecting 
macrophages with OCT has been reported earlier, but their potential to confound 
lesion classification was not noted at that time.40A 1 In four cross-sections, scat-
tering caused by dense macrophage infiltration led to misclassification in which 
two times an IT in pathology was called a FA in OCT and in rwo times an IT in 
pathology was called a TCFA in OCT. 
Catheter position may also interfere with image features and definition. The 
published image classification schemes are based on features that are routinely ob-
served with a catheter that is well centered in the lumen. Light from an eccentric 
catheter, or one that is even touching the vessel wall, may be incident on the tissue 
under a glancing angle. The light path through tissue to a certain radial depth 
in the vessel wall is longer in such an imaging geometry than in one where the 
imaging beam strikes the interface perpendicularly. The limited penetration depth 
or large attenuation occurring over a limited radial distance, leads to fibrotic areas 
misinterpreted as FA or TCFA. This situation is illustrated in Figure 4. 
Finally, we observed that the efficiency of the optical catheter to emit or receive 
the imaging light beam may vary with rotation scan angle in some catheter speci-
mens. This leads to darker sectors in the image, and these regions can appear as 
signal poor regions like FAs, see Figure 5. A possible cause for this observation is 
optical impurities sticking to the outside of the catheter. These can be picked up 
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Figure 4. (A) H&E stained cross-section. (B) Intimal thickening is misinterpreted as thin-cap 
fibre-atheroma (TCFA) in optical coherence tomtography (OCT). The large arrow points at the 
spot interpreted as a thin-cap. The four small arrows indicate the OCT beams and are all of the same 
length. The loss of signal due to tissue penetration is similar for each arrow. Because of eccentric 
catheter position this cross-section, classified as intimal thickening in histology, appears as a thin-cap 
fibre-atheroma (TCF A) in OCT. The bar indicates 1 mm. 
Figure 5- (A) H&E stained cross-section with (B) the corresponding optical coherence tomography 
(OCT). The arrow indicates a collagenous region in histology mistaken for a lipid region in OCT. 
Reduced optical efficiency of the catheter in this image section creates a dark sector, making mild 
intimal thickening appear as a fibre-atheroma. The bar indicates 1 mm. 
on insertion of the catheter, for example. While the in vitro setting, in absence of 
flow, may aggravate this problem compared to clinical use, it is difficult to ascertain 
intra-procedurally that the image quality is constant across the rotation. 
In VH-IVUS incorrect drawing of lumen and media borders may have led 
to misclassification in 3 cross-sections. Incorrect drawing of borders was seen in 
two typical situations: lumen borders at sites where the catheter was against the 
lumen wall, and media borders at sires where the adventitia was invisible due to 
75 
Chapter 2.1 
acoustic shadowing. Drawing borders with knowledge of histology retrospectively 
corrected the misclassifications in 2 out of 3 cross-sections. 
Cross-sections were imaged in a static situation, not performing a pullback. 
In this situation a plaque can not be seen in the context of its surrounding which 
complicates identification of correct borders. Also, excised specimens do not 
always have sufficient adventitia to help differentiate the media border from its 
surroundings. 
Qualification of plaques in VH-IVUS is straight-forward and the lesion type 
could often easily be assessed by the bare eye. Plaques with confluent NC or Ca 
around 10% might fall in one or the other classification group, and hence may be 
sensitive to misclassification. 
In VH-IVUS, classification is an automatic process, giving less inter-observer 
variability, but also giving no explanation of errors in VH-IVUS compared to 
histology. Misclassification that could not be explained was seen in five cross-
sections. In three cross-sections it involved classification as FA while there was 
in histology little NC (2x) or no NC (lx) at all. In rwo cross-sections it involved 
histological FA classified as IT in VH-IVUS. 
Overall, VH-IVUS classified plaque correctly 26 out of 36 cross-sections. 
Detection of IT (25/29 correctly identified) corresponds to the sensitivity as 
reported by Dietrich et al (89%).38 However, detection ofF A (sensitivity~ 54,1% 
by Diethrich et al) did not correspond to our data (0/2 correctly identified)." Our 
sample size is to small to draw definitive conclusions out of these numbers how-
ever our results are in line with previous findings of Granada who reported lower 
sensitivities and specificities. 1235.42-'3 Misclassification in VH-IVUS alone typically 
also led to misclassification in OCT and VH-IVUS combined. VH-IVUS could 
positively influence OCT in cases where OCT misclassified plaques as FA, that 
were IT according to histology. The artifacts mentioned above led to a high false-
positive number ofF As in OCT. FA orTCFA in OCT, which was classified as IT 
in VH-IVUS, meant in 6 out of 7 times it was indeed an IT in histology. In three 
out of six it involved plaques classified as TCFAs by OCT. 
A recent study describes the low incidence of histology-derived TCFA and FA 
(1.5% and 10.5% of advanced lesions, respectively).44 Our data show a relatively 
high false-positive rate for TCFA or FA: IT in histology was classified in OCT 
as TCFA or FA in 10 cross-sections.37 Given the incidence of FA and especially 
ofTCFA, the positive predictive value of OCT, an important parameter in rare 
incidence, could be small for these clinically significant plaque types. Since the 
group of non-TCFAs appears to be 98.5% in advanced lesions, the finding of 
a TCFA in OCT must be regarded with caution, and corroborated with other 
evidence if possible. An in vivo study by Sawada et al. combined VH-IVUS and 
76 
Combined optical coherence tomography and intravascular ultrasound radio frequency data analysis 
OCT for detection ofTCFA. Only lesions classified as TCFA both in OCT and 
in VH-IVUS were considered real TCFAs. 16 This definition is indeed a sensible 
one, as the resolution ofVH-IVUS is insufficient per se to identifY thin caps, and 
OCT is seen to suffer from many false positives. 
In conclusion, adding VH-IVUS to OCT could help reduce misclassification 
by OCT of FAs and TCFAs. In vitro studies with larger sample sizes are needed 
to assess the full potential of the added value of OCT and VH-IVUS combined. 
Criteria for classifYing VH-IVUS combined with OCT have not been optimally 
validated and could possibly be improved using larger datasets. 
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Abstract 
Objectives: The purpose of this study was to assess in vivo the reproducibility of tissue characterization 
using spectral analysis of intravascular ultrasound (IVUS) radiofrequency data (IVGS-VH). Back-
ground: Despite the need for reproducibility data to design longitudinal studies. such information remains 
unexplored. Methods and results: IVUS-VH (Volcano Corp .. Rancho Cordova. USA) was performed in 
patients referred for elective percutaneous intervention and in whom a non-intervened vessel was judged 
suitable for a safe IVUS interrogation. The IVUS catheters used were commercially available catheters 
(20 MHz. Volcano Corp., Rancho Cordova, USA). Following IVUS-VH acquisition. and after the dis-
engagement and re-engagement of the guiding catheter, an additional acquisition was performed using a 
new IVUS catheter. Fifteen patients vvith 16 non-significant lesions were assessed by 2 independent 
observers. The relative inter-catheter differences regarding geometrical measurements were negligible for 
both observers. The inter-catheter relative difference in plaque cross-sectional area (CSA) was 3.2% for 
observer I and 0.5% for observer 2. The limits of agreement for (observer 1 measurements) lumen. vessel, 
plaque and plaque burden measurements were 0.82. -1.10 mm2: 0.80, -0.66 mm2: 1.08, -0.66 rnm2: and 
5.83, -3.89%; respectively. Limits of agreement for calcium. fibrous. fibrolipidic and necrotic core CSA 
measurements were 0.22, -0.25 mm2: 1.02. -0.71 mm2: 0.61, -0.65 mm2; and 0.43, -0.38 mm2 respectively. 
Regarding the inter-observer agreement, the limits of agreement for lumen. vessel, plaque and plaque 
burden measurements were 2.6L -2.09 mro2; 2.20-3.03 mm2: 1.70, -3.04 mm2: and 9.16, -16.41%: 
respectively, and for calcium. fibrous, fibrolipidic and necrotic core measurements of0.08, -0.09 mm2: 0.89, 
-1.28 mm2: 0.74, -1.06 mm2: and 0.16, -0.20 mm2: respectively. Conclusions: The present study demon-
strates that the geometrical and compositional output of IVUS-VH is acceptably reproducible. 
Introduction 
Intravascular ultrasound (IVUS) imaging has been 
shown to provide safe. accurate, real-time, tomo-
graphic measurements of coronary vessels in vivo 
[1-4]. Over the past decade. IVUS has been used to 
describe the extent, severity, distribution. and 
morphology of coronary atherosclerosis [5-7]. 
Furthermore, several studies have evaluated the 
temporal effect of conventional and novel medical 
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therapies on plaque progression by means of IVUS 
[8-10]. 
Since the fate of coronary atherosclerotic plaques 
has been related to their histological composition 
[11], precise in-vivo tissue characterization could 
provide important additional information and be-
come a target for future drug therapy studies. 
In-vitro studies have shown that visual inter-
pretation of IVUS gray-scale images for plaque 
characterization is imprecise, in particular when 
assessing heterogeneous, lipid-rich plaques [12]. 
This has lead investigators to explore the radio-
frequency data analysis, a potential source for 
in-vivo tissue characterization. Indeed, a recent 
ex-vivo study on explanted coronary segments 
showed that plaque characterization using spectral 
analysis of !VUS radio frequency data (IVUS-VH) 
was feasible and provided a high predictive accu-
racy to estimate the composition of atherosclerotic 
plaques [13]. Several in-vivo studies have been 
conducted thereafter using this approach [14-17]. 
Nevertheless. although prior knowledge about the 
reproducibility of measurements are essential for 
the internal validity of any study using this tech-
nique, to date, only indirect evidence on the 
reproducibility of the technique is available [18]. 
Accordingly, we sought to study the inter-observer 
and inter-catheter agreement of IVUS-VH mea-
surements at a single time-point. 
Methods 
Patient population 
This was a single-center prospective, investigators-
driven study that sought to explore in vivo the 
reproducibility of spectral analysis of IVUS ra-
diofrequency data (IVUS-VH. Volcano Corp .. 
Rancho Cordova, USA). The study population 
consisted of consecutive patients that were referred 
for elective percutaneous intervention and in 
whom a non-intervened vessel was judged suitable 
for a safe IVUS interrogation of a vessel segment 
of at least 30 nun. 
Exclusion criteria included the presence of severe 
calcification, vessel tortuosity, and haemodynamic 
instability. The study protocol was approved by the 
86 
institutional ethics committee and a written in-
formed consent was obtained from all patients. 
IVUS-VH 
IVUS-VH evaluates different spectral parameters 
of the radio frequency data (Y -intercept, minimum 
power, maximum power, mid-band power, fre-
quency at minimum power. frequency at maxi-
mum power, slope, etc.) to construct tissue maps 
that classify plaque into four major components. 
In preliminary in vitro studies, four histological 
plaque components (fibrous, fibrolipidic, necrotic 
core and calcium) were correlated with a specific 
spectrum of the radiofrequency signal [13]. These 
different plaque components were assigned color 
codes. Calcified, fibrous, fibrolipidic and necrotic 
core regions were labeled white. green, greenish-
yellow and red respectively. 
IVUS- VH acquisition 
The IVUS catheters used were commercially 
available phased array catheters (Eagle Eye 
Gold™ 2.9 F 20 MHz. Volcano Corp .. Rancho 
Cordova, USA). The catheter probe was advanced 
at least 10 mm distal to a clearly visible side-branch 
and angiographic cine runs. before and during 
contrast injection, were performed to define the 
position of the IVUS catheter before the pullback 
was started. Using an automated pullback device, 
the transducer was withdrawn at a continuous 
speed of 0.5 mmjs. IVUS-VH acquisition was 
ECG-gated and acquired using a dedicated console 
(Volcano Corporation. Rancho Cordova, GSA). 
IVUS-VH data was acquired after intra-coronary 
administration of isosorbide dinitrate and data was 
stored on DVD. Subsequently, and after the dis-
engagement and re-engagement of the guiding 
catheter, the same procedure was performed using 
a new catheter (Eagle Eye Gold™ 2.9 F 20 MHz, 
Volcano Corp., Rancho Cordova. USA) and with 
the same side-branches as landmarks. 
IVUS- VH analysis 
IVUS-VH analysis was performed by an indepen-
dent core laboratory (Cardialysis BV, Rotterdam. 
Reproducibility of intravascular ultrasound radiofrequency data analysis 
The Netherlands) using a semi-automatic contour 
detection software (IVUSLab 4.4, Volcano Corp., 
Rancho Cordova. USA). A region of interest 
(ROI) was identified using the inner side of two 
clear side-branches as reference and avoiding the 
presence of large side-branches \\-ithin the ROL 
Subsequently, the same ROI was identified in the 
other catheter's acquisition using side-by-side 
longitudinal and cross-sectional, contour-free 
views. 
Contour detection of the lumen and the media-
adventitia interface was performed by 2 indepen-
dent experienced IVUS analysts, The same 2 IVUS 
analysts re-analyzed the same cases, leading to the 
possibility of multiple comparisons: 2 sets (observ-
ers 1 and 2) ofintra-catheter agreement, and 1 set of 
inter-observer agreement [observer 1 (catheters 1 
and 2) vs. observer 2 (catheters 1 and 2)]. 
The contours of the external elastic membrane 
(EEM) and the lumen-intima interface enclosed 
an area that was defined as the coronary plaque 
plus media area. Geometrical and compositional 
data were obtained for each cross-sectional area 
(CSA) and an average was calculated for each 
ROI. Plaque burden was calculated as [(EEMarea 
- Lumenarea/EEMarea) X 1 00]. The lumen and 
vessel eccentricity indexes were calculated dividing 
the minimum (lumen and vesseL respectively) 
diameter by the maximum diameter. whereas the 
plaque eccentricity index was calculated dividing 
the minimum plaque thickness by the maximum 
plaque thickness. 
Statistical analysis 
Discrete variables are presented as counts and 
percentages. Continuous variables are presented as 
means ± SD. The inter-observer and inter-cathe-
ter agreement were assessed using Bland-Altman 
plots (19]- This method plots the mean against the 
difference in measurements. Limits of agreement 
were determined by adding two standard devia-
tions to the mean difference for the upper limit and 
by substracting two standard deviations from the 
mean difference for the lower limit. A two-sided 
p value of less than 0.05 indicated statistical 
significance. 
Results 
Fifteen consecutive patients with 16 non-signifi-
cant lesions were included in the study. Baseline 
characteristics of the patients included are depicted 
in Table 1. The study vessel was the left anterior 
descending in 9 patients (60.0%), the left circum-
flex in 5 (33.3%), and the right coronary artery in 1 
patient (6.7%). There were no peri-procedural 
complications. 
Inter-catheter agreement 
The studied length determined by landmarks was 
19.71 ± 10.5 mm for catheter 1 and 21.01 ± lU 
mm for catheter 2 (p = 032). Geometrical and 
compositional data of matched ROis interrogated 
v.rith IVUS-VH using 2 subsequent 20 MHz cath-
eters are extensively depicted in Tables 2 and 3. 
The relative inter-catheter differences regarding 
geometrical measurements were negligible for both 
observers. Of note, the inter-catheter relative dif-
ference in plaque CSA was 3.2% for observer 1 
and 0.5% for observer 2. Only other less common 
indirect measurements such as plaque eccentricity 
and plaque minimal thickness showed relative 
differences > 5%. Compositional measurements 
showed higher relative differences, although not 
Table J. Study population (n= 15). 
Age (years±SD) 
Male sex 
Diabetes 
Hypertension 
Current smoking 
Previous smoking 
Hypercholesterolemia 
Family history of coronary disease 
Lipid lowering agents 
Clinical presentation 
Stable angina 
Unstable angina 
Study vessel 
Left anterior descending 
Left circumflex 
Right coronary artery 
n (%) 
63.1±8.6 
8 (53.3) 
2 (13.3) 
II (73.3) 
l (6.7) 
5 (33.3) 
8 (53.3) 
9 (60.0) 
11 (73.3) 
14 (93.3) 
l (6.7) 
9 (60.0) 
5 (33.3) 
l (6.7) 
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Table 2. Mean CSA geometrical measurements of matched ROI with two subsequent 20 MHz IVUS imaglng catheters (n:16). 
Catheter 1 Catheter 2 Absolute 6. Relative !:. (%) 
Observer 1 
Lumen CSA (mm1) 11.08 ± 3.5 10.94±3.5 0.14±0.5 1.3 
Lumen rna."\. diameter (mm) 4.03±0.7 4.01 ~0.6 0.02±0.1 0.4 
Lumen min. diameter (mm) 3.37 ± 0.6 3.34±0.6 0.03±0.1 0.9 
Lumen mean diameter (mm) 3.69±0.6 3.67 :t: 0.6 0.02±0.1 0.6 
Lumen eccentricity 0.84±0.0 0.83±0.0 O.OO:cO.O 0.5 
Vessel CSA (mm:) 17.40±4.0 17.46±4.0 0.07 ± 0.4 0.4 
Vessel rna."\. diameter (rom) 4.92±0.6 4.93±0.6 O.Ql ±0.1 0.3 
Vessel min. diameter (mm) 4.36±0.6 4.37 ± 0.6 0.01 ±0.1 0.2 
Vessel mean diameter (mm) 4.63±0.6 4.64±0.6 0.01 ±0.0 0.2 
V es.sel eccentricity 0.89~0.0 0.89::!::0.0 0.00±0.0 0.1 
Plaque CSA (mrn:-:) 6.32±2.0 6.53±2.1 0.21 ±0.4 ' ' 
, __ 
Plaque max. thickness (rnm) 1.01 :c0.2 1.02 == 0.2 0.01±0.1 0.7 
Plaque min. thickness (mm) 0.09±0.1 0.09±0.1 0.01 :i:O.O 8.2 
Plo.que eccentricity (rum) 0.09±0.1 0.10±0.1 0.01 ±0.0 10.0 
Plaque burden(%) 36.80±9.9 37.77:'::::9.9 0.97±2.4 2.6 
Observer 2 
Lumen CSA (mm1) 10.66:c3.8 10.67±3.8 0.01 ±0.4 0.1 
Lumen max. diameter (mm) 3.90±0.7 3.91 ± 0.7 0.01 ±0.1 0.2 
Lumen min. diameter (nun) 3.34±0.6 3.33±0.6 0.01±0.1 0.3 
Lumen mean diameter (mm) 3.61 ±0.6 3.61 ±0.7 0.00±0.1 0.0 
Lumen eccentricitY 0.86±0.0 0.85±0.0 0.01 :::o.o 0.6 
Vessel CSA (mm1) 17.76±4.0 17.80:t.4.0 0.05 ± 0.4 0.3 
Vessel max. diameter (rnm) 4.95::::::0.6 4.96±0.6 0.01 :t.0.1 0.3 
V cssel min. diameter (mm) 4.41±0.6 4.42±0.6 0.01±0.1 0.1 
Vessel mean diameter (mm) 4.68:t.0.6 4.69::r::0.6 O.Ql ±0.0 0.1 
Vessel eccentricity 0.89±0.0 0.89:!: 0.0 0.00 :t: 0.0 0.1 
Plaque CSA (mm1) 7.10±2.1 7.13±2.2 0.03 ± 0.4 0.5 
Plaque max. thickncs..o;; (nun) 1.05±0.2 1.04:t.0.3 0.00±0.1 0.2 
Plaque min. thickness (mm) 0.16±0.1 0.16±0.1 0.01 :t.O.O 4.7 
Plaque eccentricity (mm) 0.16±0.1 0.17±0.1 0.01 ±0.0 6.7 
Plo.que burden(%) 40.75± 10.7 40.93 ± 11.2 0.19±1.8 0.5 
LCSA. VCSA and PCSA refer to lumen, vessel and plaque CSA.s. Plaque burden was calculated as [(EEMLlrcu - Lumenarca/ 
EEMure~•) X 100]. 
exceeding 10%, except from calcium (11%) for 
observer 1 and fibrolipidic tissue (13%) for 
observer 2 (Table 3). Indeed. Bland-Altman plots 
showed a good inter-catheter agreement for 
geometrical (Figure 1) and compositional (Fig-
ure 2) measurements. The limits of agreement for 
(observer 1 measurements) lumen, vessel, plaque 
and plaque burden measurements were 0.82, 
-!.10 mm': 0.80. -0.66 mm2: LOS. -0.66 mm': 
and 5.83, -3.89%; respectively. Limits of agree-
ment for calcium. fibrous. fibrolipidic and necrotic 
core CSA measurements were 0.22. -0.25 mm2; 
1.02. -0.71 mm2: 0.61. -0.65 mm': and 0.43. 
-0.38 mm2 respectively. 
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lnter~observer agreement 
For the assessment of the inter-observer agree-
ment, a comparison between the same matched 
cross-sections (653 frames for catheter 1 and 663 
frames for catheter 2) were analyzed by 2 inde-
pendent observers. These 2 datasets were merged 
resulting in a paired inter-observer agreement 
evaluation of 1316 frames. 
Inter-observer differences were larger than the 
inter-catheter measurements (performed by the 
same observer). This was particularly noticed in 
indirect measurements such as plaque CSA (1 0% ). 
plaque minimal thickness (53%) and plaque 
Reproducibility of intravascular ultrasound radiofrequency data analysis 
Table 3. :'vlean CSA compositional measurements of matched ROI with two subsequent 20 :\1Hz IVCS imaging catheters (n:16). 
Catheter 1 
Observer l 
Calcium CSA (mnr') 0.17±0.3 
Calcium(%) 4.27±5.2 
Fibrous CSA (mm~) 1.96:::::1.0 
Fibrous(%) 60.37±9.2 
Fibrolipidic CSA (nun~) 0.66:::0.4 
Fibrolipidic (%) 21.10±9.8 
Necrotic core CSA (mm~) 0.40±0.4 
:"J"ecrotic core(%) 11.27 ± 6.8 
Observer 2 
Calcium CSA (mm~) 0.17:::::0.3 
Calcium(%) 4.08±5.0 
Fibrous CSA (mm2) 2.21::: 1.l 
Fibrous(%) 58.12± 10.5 
Fibrolipidic CSA (mm~) 0.88±0.6 
Fibrolipidic (%) 22.97± 11.7 
Kccrotic core CSA (nun~) 0.42±0.4 
Necrotic core(%) 10.75:::6.9 
LCSA. VCSA and PCSA refer to lumen. vessel and plaque 
EEMarcu) X lOOJ. 
1; ~ 
11············································· 
+ ... 0,51 0 -l::-=-::-=-=c::o:s~•c-::-:::,.=-=.~1~o.,.=-=~-~-"1s~-~.".~--==-=2-o 
·0,5 • 
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·1,8 
Mean Plaque CSA (mm2) 
Catheter 2 Absolute .1. Relative .1. (%) 
0.16±0.2 0.01 ~0.1 8.0 
3.82±3.8 0.45±2.6 11.l 
2.11:::1.1 0.16:::0.4 7.7 
62.15±8.7 1. 78 ± 10.0 2.9 
0.63 ::1:0.3 0.02±0.3 3.5 
19.58±7.0 1.53 ± 8.3 7.5 
0.43 ± 0.4 0.02±0.2 5.7 
10.87±6.6 0.40 = 5.4 3.6 
0.16::i:0.2 0.01:::0.1 8.7 
3.74±3.4 0.34±2.4 8.7 
2.28::~: 1.2 0.07 .:t: 0.4 3.1 
60.63±7.9 2.51 ± 10.1 4.2 
0.77±0.4 0.11±0.4 13.1 
20.95± 10.8 2.01:::9.6 9.2 
0.45±0.5 0.03±0.2 6.1 
11.02 ::i: 6.5 0.26 :I: 5.5 2.4 
CSAs. Plaque burden was calculated as [(EEMurcu - Lumenureu/ 
1.: }l 
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Figure!. Bland-Aitman plots depicting: the (observer 1) agreement between catheters for geometrical measurements (n= 16). 
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Figure 2. Bland-Altman plots depicting the (observer 1) agreement between catheters for compositional measurements (n= 16). 
eccentricity (54%). The largest relative difference 
was found in fibrolipidic measurements (Table 4). 
Narrow limits of agreement and few outliers 
(Figures 3 and 4) were found between observers 
both for geometrical (limits of agreement for lu-
men, vessel, plaque and plaque burden measure-
ments of 2.61, -2.09 mm2; 2.20-3.03 mm2; 1.70, 
-3.04 mm2; and 9.16, -16.4!%; respectively) and 
compositional (limits of agreement for calcium, 
fibrous, fibrolipidic and necrotic core measure-
ments of 0.08, -0.09 mm2: 0.89, -1.28 mm2; 0.74, 
-1.06 mm2; and 0.16. -0.20 mm2; respectively) 
measurements. It is noteworthy that the fibrous 
and fibrolipidic CSA measurements were highly 
accurate when assessing cross-sections with small 
fibrous or fibrolipidic content (Figure 4). 
Discussion 
Over the past few years. IVUS has been employed as 
a tool to assess the temporal effect of conventional 
90 
and novel drug therapies on coronary plaque size in 
longitudinal studies [8, 20]. More recently, the dis-
cordance between the beneficial clinical effects of 
secondary prevention strategies and their effect on 
plaque volume had lead investigators to explore a 
potential significant effect on plaque composition 
[21]. 
Tissue characterization by means of IVUS ra-
diofrequency (RF) data analysis is a potential tool 
to enable an accurate evaluation of the composition 
of coronary plaques [13}. Several investigators have 
explored the potential of RF data analysis in vivo 
and reported promising findings [15-17. 22, 23). 
This technique has the potential to detect temporal 
changes in plaque composition and therefore stud-
ies have been conducted to assess the effect of con-
ventional drug therapies on the phenotype of 
coronary atherosclerosis [18. 22. 23]. In addition. 
there are currently several large trials being con-
ducted with the aim to assess the natural history of 
high-risk plaques by means of this technique. 
Reproducibility of intravascular ultrasound radiofrequency data analysis 
Table 4. Geometrical and compositional measurements of matched CSAs between different observers (n:l316). 
Observer I Observer 2 Absolute .1. Relative Ll (%) 
Geometrical data 
Lumen CSA (mm::!) 10.83±3.8 10.51 ±4.0 0.26± 1.2 2.5 
Lumen max. diameter (mm) 3.96:t:0.7 3.86±0.8 0.08 ± 0.4 2.1 
Lumen min. diameter (mm) 3.34±0.6 3.31 ±0.7 0.01 ±0.3 0.2 
Lumen mean diameter (mm) 3.65 :i:: 0. 7 3.58:~::0.7 0.04±0.3 Ll 
Lumen eccentricity 0.84±0.1 0.86±0.1 0.02±0.1 ' ' 
-·' Vessel CSA (mm::!) 16.90 ±4.2 17.22:::4.3 0.41 :1: 1.3 2.4 
V esse! max. diameter (mm) 4.84±0.6 4.87±0.6 0.06±0.4 Ll 
Vessel min. diameter (nun) 4.30±0.6 4.35±0.6 o.os,;,o.3 1.7 
Vessel mean diameter (mm) 4.56±0.6 4.61 ±0.6 0.07±0.3 1.5 
Vessel eccentricity 0.89±0.1 0.89±0.1 0.01 ±0.1 I.l 
Plaque CSA (nun:!) 6.07::::2.3 6.72:::2.3 0.67± L2 10.3 
Plaque rna-.;.. thickness (mm) 0.96±0.3 1.01 ±0.3 0.03±0.2 3.4 
Plaque min. thickness (mm) 0.09±0.1 0.16:::0.1 0.07::::0.1 53.3 
Plaque eccentricity (mm) 0.09±0.1 0.16±0.1 0.07±0.1 53.6 
Plaque burden (%) 36.62± 12.2 40.07 ± 12.5 3.6h6.4 9.5 
Compositional data 
Calcium CSA (mm::!) 0.12±0.2 0.12±0.2 0.00±0.0 2.9 
Calcium(%) 3.66 = 6.4 3.51:::6.0 0.13±2.4 3.7 
Fibrous CSA (mm::!) 1.86± 1.3 2.05±1.3 0.20±0.5 10.2 
Fibrous(%) 61.48± 18.2 60.05± 18.2 1.10:::14.3 l.S 
Fibrolipidic CSA (nun:!) 0.60±0.5 0.75±0.7 0.16±0.5 23.5 
Fibro!ipidic (%) 22.34± 14.0 22.09± 15.3 1.86 ± 11.8 S.S 
Necrotic core CSA (mm::!) 0.35:1:0.4 0.37±0.4 0.02±0.1 6.3 
Necrotic core (%) 10.45±10.1 10.22±9.8 0.17±5.7 1.6 
LCSA, VCSA and PCSA refer to lumen. vessel and plaque CSAs. Plaque burden was calculated as [(EEYfnrcn - Lumen""'" /EEM"'~J x 
100]. 
As the impact of drug therapies on the athero-
sclerotic plaque burden and composition over time 
is relatively small, highly reproducible IVUS-VH 
measurements are essential. Despite such pivotal 
need for reproducibility data to address the sta-
bility of the technique. such studies are lacking. 
Only indirect evidence of reproducibility has been 
reported such as a study conducted by our group 
to assess the 6-month change in plaque composi-
tion with no controlled therapeutic intervention 
[18], and the study conducted by Kawasaki et al. 
who reported the intra and inter-observer vari-
ability of measurements performed using the same 
pullback [22]. 
The present study has a unique characteristic 
since we used two catheters of the same kind at the 
same time-point, thus simulating the scenario of a 
longitudinal study. 
The main finding of the present study was that 
IVCS-VH measurements had an acceptable 
reproducibility. As expected, compositional mea-
surements were more variable than geometrical 
measurements. Nevertheless. it is noteworthy that 
inter-catheter differences were predominantly 
lower than 10%, highly correlated and showed a 
good agreement. Of note, necrotic core measure-
ments, probably the most relevant component of 
coronary plaques and currently subject of intense 
research, showed an excellent inter-catheter and 
inter-observer agreement. This has a major 
importance since the temporal change of such 
component could potentially become an imaging 
endpoint of longitudinal studies. Similarly, cal-
cium measurements, another important compo-
nent of atherosclerotic plaques, showed good 
inter-catheter and inter-observer agreement. The 
relatively high inter-observer variability of some 
IVCS-VH variables raises some caution and 
should be taken into consideration when 
performing longitudinal studies analyzed by 
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Figure 3. Bland-Altman plots showing the inter-observer agreement for geometrical measurements (n = 1316). 
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Reproducibility of intravascular ultrasound radiofrequency data analysis 
core laboratories. OveralL the inter-catheter and 
inter-observer differences shown might provide 
boundaries over which changes are statistically 
significant. 
It is evident yet worth mentioning that precise 
contour detection probably has an essential role in 
the reproducibility of IVGS-VH measurements. 
The inter-observer relative difference in plaque 
CSA measurements was 10%, the commonly ac-
cepted threshold. This gives an additive value to 
our study, since it provides a ''real-world" scenario 
that can aid investigators to perform precise power 
calculations for longitudinal studies. 
Finally, although we aimed at studying non-
tortuous and non-severely calcified vessels, 
phased-array IVUS imaging catheters are devoid 
from a covering sheath and pullbacks are therefore 
occasionally prone to be non-uniform. This clearly 
has an impact on determination of the size and 
composicon of atherosclerotic plaques and needs 
to be taken into consideration for the design of 
longitudinal studies (Figure 5). 
Uniform pullback 
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Figure 5. Sequential plotting of a matched ROI interrogated with two catheters. The mean CSA (y axis) of each plaque component is 
colour~codcd (calcium: white, fibrous: green. fibrolipidic: grcenish~ycllow and necrotic core: red). This figure shows an example of the 
impact of non~ uniform pullbacks on geometrical and compositional measurements. 
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Limitations 
The studied population was relatively small. Nev-
ertheless. the conductance of large in vivo studies 
of this nature is complicated due to obvious ethical 
issues. The selection of a population of patients 
with non-tortuous and non-severely calcified ves-
sels was driven by the aim to study the reproduc-
ibility of the technique itself. not of the pullback 
device. Nevertheless, as shown in Figure 5. the 
impact of non-uniform pullback speed was not 
negligible potentially influencing the results. 
Conclusions 
The present study demonstrates that the geomet-
rical and compositional output of IVUS-VH is 
acceptably reproducible. In addition, by providing 
a --real-world"' scenario, this study can aid inves-
tigators to perform precise power calculations for 
longitudinal studies. 
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CHAPTER 3.1 
Relation of plaque size to necrotic core in the three major 
coronary arteries in patients with acute coronary syndrome 
as determined by intravascular ultrasonic imaging 
radiofrequency. 
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Intravascular Ultrasonic Imaging Radiofrequency 
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According to pathologic studies, the content of a necrotic core increases in a "linear fashion" as 
plaque enlarges. In addition, these 2 plaque characteristics have been associated \Vith plaque 
vulnerability. This study assessed the relation between plaque cross-sectional area (CSA) and 
content of necrotic core (NC). Twenty-five patients (75 arteries) with acute coronary syndrome 
were studied. In total, 7.834 CSAs were analyzed. An analysis of plaque CSA in percentiles was 
performed (median 5.5 mm2, interquartile range 3.7 to 7.8); subsequently. plaque CSA values 
were categorized as small (::53.7 mm2). medium (>3.7 to ::57.8 mm2). and large (>7.8 mm2). 
There was a difference in content of the NC between arteries within each plaque CSA category. 
This observation was con.finned in a multivariate analysis in which only 2 variables remained 
statistically significant. plaque CSA (estimate 134, SE 0.05, p <0.0001) and studied artery (left 
anterior descending coronary artery. estimate 0.29, SE 0.08. p ::; 0.0003~ left circumflex 
coronary artery, estimate 0.23. SE 0.07, p ::; 0.0014: and these vs the right coronary artery). In 
conclusion.. the NC and plaque increase in patients with acute coronary S)Tidromes. © 2007 
Elsevier Inc. AU rights reserved. (Am J Cardiol2007;99:790-792) 
The mechanisms of how atherosclerotic plaques grow are not 
fully understood. Two main mechanisms of plaque progression 
have been postulated~ the first describes a continuous and 
progressive lipid accumulation and collagen synthcsis.1 
whereas current evidence favors a stepwise process resulting 
from progressive accumulation of a necrotic core (NC). thin-
ning of the fibrous cap and its rupture vvith consequent healing 
leading to an increase in luminal narrowing. 1::. or intraplaque 
hemorrhage that abruptly increases the plaque.3 In any case. 
according to pathologic studies, it seems that the content of a 
NC increases in a "linear fashion·· as plaque enlarges:1..5 In 
addition, these 2 plaque characteristics have been associated 
with plaque vulnerability.6 Pathology offers detailed and ac-
curate information on these atherosclerotic plaques. How-
ever. pathologists can only analy~::e retrOspectively and 
somewhat incompletely because they study the coronary 
vessel every 3 to 5 mm.5·7 Conversely. the sampling rate of 
in vivo imaging techniques such as intravascular ultrasound 
(IVUS) can be set up every 0.25. 0.5. or 1 mm.N although 
the resolution is lower. IVUS allows tomographic assess-
ment of the vessel wall that has been recently comple-
mented with backscatter radiofrequency data analysis. also 
called IVUS virtual histology (IVUS-VH: Volcano Thera-
peutics. Rancho Cordova, California). To date. no in vivo 
study has assessed the relation between plaque cross-sec-
tional area (CSA) and content of the NC. 
Methods and Results 
This prospective investigator-driven study included patients 
with an acute coronary syndrome (ACS). namely. unstable 
"Thoraxcenter. Erasmus MC; and bC.:rrdi::~lysis BY. Rotterdam, The 
Netherlands. Manu~cript received August !I. 2006; revised m::muscript 
received and accepted October 9. 2006. 
''Corresponding uuthor: Tel: 31-10-463-5260; fu:c 31-10-436-9154. 
E-mail address: p.w.j.c.scrruys@erasmusmc.nl (P.W. Serruys). 
0002-9149/07/$- sec front mutter 6 2007 Elsevier Inc. All rights reserved. 
doi: 10.1 0 16/j .:unjc.:rrd.2006.1 0.037 
angina pectoris according to tl1e Braunwald classification. 
non-ST-segment elevation myocardial infarction. and ST-
segment elevation myocardial infarction. in which all 3 coro-
nary arteries were interrogated using rvus racliofrequency 
data analysis. IVUS-VH was performed with 20-:MHz cathe-
ters (Eagle Eye. Volcano Therapeutics). and contour detection 
was determined using a previously reported methodology .9 
This racliofrequency data analysis allows tissue characteriza-
tion. JO.IJ Specifically. it can identify 4 different tissues (NC. 
red: dense calcium. white; fibrofatty tissue. greenish: and fi-
brotic tissue. green). Informed consent was obtained from all 
patienl". Data acquisition was electrocardiographically gated 
and recorded during automated withdrawal of the catheter 
using a mechanical pull-back device (Volcano Therapeutics) at 
a pull-back speed of 0.5 mm/s. Cine runs before and during 
contrast injection were performed to define the position of the 
rvus catheter before pullback was started. 
The IVUS-VH sampling rate during pullback is gated to 
the peak R wave and is therefore dependent on heart rate. 
For instance. during a constant heart rate of 60 beats/min. 
data will be collected every 0.5 mm. 
Discrete variables are presented as counts and percent-
ages. Continuous variables are presented as means :!: SDs. 
A 2-sided p value <0.05 indicated statistical significance. 
Assumptions for normality were checked after transforma-
tion based on a p value >0.20 when using the Kolmogorov-
Smimov test and on visual assessment of Q-Q plots of 
residuals. Accordingly, log transfonnation was petformed 
on variables with skewed distribution. 
All CSAs were assessed as a function of the distance 
from the ostium of the artery. Coronary artery length was 
divided into 3 segments: the proximal segment comprised 
the first 3 em. the midsegment the second 3 em. and the 
distal segment the following 3 em. C sing a general mixed 
model and allowing an autoregressive correlation structure 
with content of the NC (square millimeters) as a dependent 
wv:w.AJConline.org 
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Table 1 
Composition::U :md geometric :mnlysis (n = 25 patients. 75 arteries) 
Calcified (mm~) 
Cnlcili.ed ('7<:>) 
Fibrous (mm~) 
Fibrous(%) 
Fibrolipid (mm~) 
Fibrolipid (%) 
NC(mm::) 
~c (%J 
Vessel CSA (mm~) 
Lumen CSA (mm::) 
Plague CSA (mm::) 
Plague eccentricity (min/mn..") 
Plague burden (%)* 
Values arc means ::: SDs. 
0.17::!: 0.36 
3.6::!: 5.7 
2.1 = 1.8 
64.6 = 13.2 
0.65::!: 0.76 
19.6 ± 13.4 
0.48:: 0.69 
12.2 ± 10.8 
17.2±7.5 
10.5 = 5.3 
6.7 ± 3.6 
0.14 3: 0.15 
39.0 ± 12.6 
*Defined US EE:\IIareo - lumen,.,..,JEEM.,."" X 100. where EE.\11 is 
cxtem:il e]n..~tic membrane, mux = maximum; min = minimum. 
A~OVA zol- p=0.009- - p<O.OOI-
I 
,J 
- p<O.OOl-
Smull PCSA Medium PCSA Large PCSA 
VESSEL 
0 ~D 
E! LCX 
0 RCA 
Figure 1. Bur graph shows plaque CSA (PCSA) categorized into 3 groups 
according to pluque size (x n.."Us) :md rel::ttive amount of the ~C (y n.."Us) in 
the left anterior descending coronary artery (blue bars), left circumflex 
coronary urtery (green bars). und right coronary anery (yellow bars). 
ANOV A = analysis of vuriunce. 
variable and the artery. the culprit vesseL location of CSAs 
(i.e .. proximaL mid. and distal), plaque CSA. lumen CSA. 
and interaction between plaque CSA and location and be-
tween artery and location as independent covariates, the 
hypothesis was tested. 
Twenty-five patients (75 arteries) were studied. Patients' 
mean age was 53 ± 11 years. Most were men (84%). and 
12% were diabetic. Forty-eight percent presented with ST-
segmem elevation myocardial infarction. In total. 7.834 
CSAs were studied. The overall compositional and geomet-
ric analysis is presented in Table 1. Analysis of plaque CSA 
100 
in percentiles was performed (median 5.5 mm1 , interquartile 
range 3.7 to 7.8): subsequently plaque CSA values were 
eateRorized as ~mall (::::::3.7 mm1), medium (>3.7 to ::::::7.8 
mm-). and large (>7.8 mm1). Figure 1 shows percent dif-
ferences in content of NC between vessels within each 
plaque CSA category. This observation was confirmed in 
multivariate analysis. where only 2 variables remained sta-
tistically significant, namely. plaque CSA (estimate 1.34. 
SE 0.05. p <0.0001) and studied vessel (left anterior de-
scending coronary artery, estimate 0.29. SE 0.08. p = 
0.0003: left circumflex coronary artery. estimate 0.23. SE 
0.07. p = 0.0014: these vs right coronary artery). 
OveralL the Pearson correlation coefficient was 0.62 
(p <0.001) between plaque CSA and ~C. In particular. the 
Pearson correlation coefficient was 0.68 (p <0.001) in the 
left anterior descending coronary artery compared with 0.50 
(p <0.001) and 0.64 (p <0.001) in the left circumflex and 
right coronary arteries (Figure 2). 
Plaque CSA in patients with unstable angina/non-ST-
segment elevation myocardial infarction was 5.4 ± 2.8 
versus 7.1 :±: 4.2 mm1 in patients with ST -segment elevation 
myocardial infarction (p <0.001): content of the NC in pa-
tients with unstable angina!non-ST-segment elevation myo-
cardial infarction!ST -segment elevation myocardial infarction 
was 0.30 :±: 0.43 mm1 ; in patients with ST -segment elevation 
myocardial infarction. the content of NC was 0.58 ± 0.82 
mm1 (p <0.001). Pearson's correlation coefficients between 
plaque CSA and 1\C were 0.54 (p <0.001) and 0.65 
(p <0.001) in patients with unstable angina/non-ST-seg-
ment elevation myocardial infarction and in patients with 
ST-segment elevation myocardial infarction, respectively. 
Discussion 
Regarding instability of plaque. the size of the NC is of 
critical importance. In thin cap fibroatheromas. there are 
different degrees of disease. Not all of these plaques will 
actually rupture. Those that do rupture arc significantly more 
obstructive and contain a larger NC, macrophage infiltration. 
calcium. fewer smooth muscles cells. and more positive re-
modeling than nonruptured thin cap fibroatheromas.0 
Although the increment in plaque size is followed by an 
increase in the :KC. it seems that this occurs to a slightly 
different degree in each vesseL In this study, the CSAs with 
the same plaque size in the left anterior descending artery 
compared with the left circumflex and right coronary arter-
ies had a significantly larger NC. This finding is in line with 
what has been reported in many clinical studies in which the 
left anterior descending coronary artery is the most common 
culprit vesseL Further. although in this CSA-based analysis. 
simple correlations do not properly assess the relation of 
plaque CSA and the NC mainly due to a lack of indepen-
dency. the slope of the regression line is steeper in the left 
anterior descending than in the left circumflex coronary 
artery and similar to the right coronary artery. Subsequently, 
multivariate analysis was performed to take into account the 
serial correlation (consecutiveness of CSAs along the ves-
sel) and dependency of the variables. and plaque CSA and 
vessel were found to be the only predictors of NC. 
Interestingly. in patients with ST-segment elevation 
myocardial infarction. plaque CSA was larger than in pa-
Relation of plaque size to necrotic core in the three major coronary arteries 
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Figure 2. Scauerplots ~how ~imple correlation. between plaque CSA and the :-JC in the (A) left anterior descending coronary artery (LAD), (B) left circumflex 
coronary artery (LCX). and (C) right coronu.ry artery (RCA). Abbreviation as in Figure 1. 
tients with unstable anginalnon-ST -segment elevation myo-
cardial infarction. as was the content of the NC This finding 
is in line with previous studies in which different markers of 
vulnerability were found to be different between these 2 
populations. 12 
Thus. plaque size could be a surrogate of NC size in the 
coronary tree of patients presenting with ACS. This obser-
vation extends the concept of "act local. act global'' by 
Libby, 13 which incorporates the need to further assess the 
coronary tree beyond the culprit lesion; apart from the 
culprit lesion. in the same vessel or in the other 2 main 
coronary vessels. other NC-rich atherosclerotic plaques 
might be encountered. more likely those with a large plaque 
burden. This concept from a clinical point of view. seems 
logical and simple but has a tremendous effect on midterm 
follow-up in this specific population. Goldstein et aJ1 4 re-
ported that patients with ST-segment elevation myocardial 
infarction and multiple complex lesions during the year after 
ST -segment elevation myocardial infarction had an increased 
incidence of recurrent ACS compared with patients with single 
complex lesions (19.0% vs 2.6%. p <0.001. respectively) and 
repeated angioplasty. particularly of noninfarct-related lesions 
(32.0% VS 12.4%, p <0.001). 
Caution should be used with these results. because this is 
a highly selective population in terms of clinical presenta-
tion. i.e .. all patients had an ACS. A previous report by our 
group 15 found that patients with ACS had a significantly 
larger percent mean NC compared with stable patients 
(12.26 ± 7.0% vs 7.40:!:: 5.50%. p = 0.006). Therefore. the 
relation between plaque CSA :1nd the NC might differ in 
patients with stable angina. 
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Plaque Composition in the left 
Main Stem Mimics the Distal But Not the 
Proximal Tract of the left Coronary Artery 
Influence of Clinical Presentation, Length of the Left 
Main Trunk, Lipid Profile, and Systemic Levels of C-Reactive Protein 
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Objectives 
Background 
Methods 
Results 
Conclusions 
We sought to investigate whether plaques Joc.~ted In the left m<Jin stem (LMS) differ In terms of necrotic core 
content from those sited In the proximal tract of the left coronary artery. 
Plaque composition, favoring propensity to vulnerablllty, might be nonunlformly distributed along the vessel, 
which might explain the greater Hkelihood for plaque erosion or rupture to occur In the proximal but not in the 
distal tracts of the coronary artery or In LMS. 
A tot<JI of 72 patients were Included prospectively; 48 (32 men; me<Jn age 57 = ll years; 25 with st<Jble angina 
<Jnd 23 affected by acute coronary syndromes) underwent a satisfactory noncu!prlt vessel Investigation through 
spectral analysis of lntrav<Jscular ultrasound radlofrequency datil (IVUS..VIrtual Histology, Volcano Corp., Rancho 
Cordova, California). The region of Interest was subsequently divided Into LMS and LMS carina, followed by 6 
consecutive nonoverlapplng 6-mm segments in left anterior descending artery In 34 patients or In circumflex 
artery in :1.4 patients. 
Necrotic core content(%): l.) was minimal in LMS (median [interqu<Jrtlle range]: 4.6 [2 to 7]), peaked in the first 
6-mm coronary segment (1.1..8[8 to :1.6]; p < 0.01.), and then progressively decreased dlstaHy; 2) was overall 
greilter In patients with acute coronary syndromes (1.1..4 [5.5 to :1.9.8]) than stable angina (7.3 [3.2 to 1.2.9]; p < 
0.001.); 3) was largely Independent from plaque size; and 4) did not correlate to systemic levels of C-reactlve 
protein or lipid profile. 
Plaques loc<~ted In the LMS carry minimal necrotic content, Thus, they mimic the distal but not the proximal 
tract of the left coronary artery, where plaque rupture or vessel occlusion occurs more frequently. 
(JAm Coli Cardlol 2007;49:23-31.) © 2007 by the American College of Cardiology Foundation 
The distribution of ruptured or prone-to-rupture plaques is 
knov.rn to be nonuniform throughout the coronary tree 
(1-5). Pathological studies have suggested the so called 
"thin-cap atheromas" -necrotic-rich core plaques at high 
risk for rupture---are infrequent in the left main stem 
(LMS) and in the distal tracts of the coronary vessels, 
whereas they group together with ruptured and healed 
plaques in the proximal segments of the 3 main coronary 
arteries (1). 
Similarly, 1) angiographic studies in patients with ST-
segment elevation myocardial infarction recently have 
shown that sites of occlusion are clustered vvithin the 
proximal third of each of the vessels (2,3), and 2) intravas-
cular ultrasound (IVUS) analyses have observed that plaque 
rupture rarely occurs in the L:MS or the distal part of the 
coronary arteries, whereas it is far more common in the 
proximal part of the coronary vessels (4), especially in the 
left anterior descending (LAD) artery (5). 
From the Er:1smu, Medical Center, Thoraxcenter. Rotter<krn, the Netherland,. 
Dr. Rodriguc:-.:~Gr-~nillo h~' receivcd "- tc>"'o.rch punt from Volcano Corp. 
Mo.nu><:ript received December 1, 2005; rC\~oed mo.nu>Cript received Fcbn.wy 28, 
2006, acc9tcd March 7, 2006. 
The reasons why vulnerable or ruptured plaques tend to 
spare the LMS and distal segments of the left coronary 
vessels remain poorly understood. Plaque composition, fa-
voring propensity to vulnerability (6-S), might also be 
nonuniformly distributed along the coronary arteries. 
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ACS = acute coronaey 
syndrome 
CFX = circumflex arteey 
CRP = C-reactlve protein 
CSA = cross-sectional aroa 
EEM =external elastic 
membrane 
HDL = high-density 
llpoproteln 
IQR = lnterquartllc range 
IVUS "' lntravasculllT 
ultrll5ound 
LAD = lett 11nterlor 
descending arteey 
LOL = low-density 
lipoprotein 
LMS = lett mllln stem 
VH = virtual histology 
We sought to investigate 
whether the plaques located in 
the LMS, which are knovvn to be 
at low probability of rupture, dif-
fer in terms of composition from 
those sited in the proximal tract 
of LAD or circumfie.x artery 
(CFX), where rupture or occlu-
sion occurs more frequently. This 
may contribute establishing in 
vivo the role of plaque composi-
tion as kev determinant of vul-
nerability. in humans. In this 
conte."\.'1:, the role of clinical pre-
sentation, length of LMS, lipid 
profile, and systemic level of 
C-reactive protein (CRP) also 
were investigated. 
Methods 
Srody protocol and patient 
enrollment. This was a single-
center, investigator-driven, observational study aimed at 
evaluating the distribution of plaque composition along the 
left coronary artery in consecutive patients referred to our 
institution for elective or urgent percutaneous coronary 
intervention in whom the nonculprit, nontreated vessel was 
judged suitable for a safe IVUS 35-mm pullback or more, 
based on angiographic (absence of the following: >SOo/o 
stenotic diqease, e;...1:ensive calcification, severe vessel tortu-
osity) and clinical (hemodynamic stability) findings. 
According to the protocol, not more than one vessel per 
patient could be evaluated, and the region of interest was 
subsequently divided into the following coronary segments: 
LMS and LMS carina, based on anatomical landmarks, 
followed by 6 consecutive nonoverlapping 6-mm segments, 
with the first one to be started at the coronary ostium of 
either the LAD or CFX arteries. The length chosen for 
those coronary segments located distally to the LMS carina 
was based on the median length of LMS in the study 
population. 
To ensure that the ostial-proximal part of the LMS was 
included in the IVUS pullback and to rule out the occur-
rence of deep intubation by the guiding catheter, the last 
part of the pullback was :6Jmed and each angiogram carefully 
inspected before patient inclusion. An analyzable interro-
gated vessel length of at least 35 mm beyond LMS carina, 
starting from coronary ostium, was the main selection 
criterion, once the patient was included in the study. This 
protocol was approved by the hospital ethics committee and 
is in accordance with the Declaration of Helsinki. Written 
informed consent was obtained from every patient. 
Intravascular ultrasound-virtual histology (VH) acquisi-
tion and analysis. Details regarding the validation of the 
technique, on explanted human coronary segments, have 
106 
previously been reported (9). Briefly, IVUS radiofrequency 
data (IVUS-Vlttual Histology, Volcano Corp., Rancho 
Cordova, California) uses spectral analysis of IVUS radio-
frequency data to construct tissue maps that classifY plaque 
into 4 major components. In preliminary in vitro studies, 4 
histological plaque components (fibrous, fibre-lipid, ne-
crotic core, and calcium) were correlated with a specific 
spectrum of the radiofrequency signal (9). These dilfcrent 
plaque components were a.<;...:;igned color codes. Calcified. 
fibrous, fibrolipidic, and necrotic core regions were labeled 
white, green, greenish-yellow, and red, respectively (10). 
IVUS-VH data were acquired after intracoronary admin-
istration of nitrates using a continuous pullback (0.5 mm/s) 
with commercially available mechanical sector scanners 
(Ultracross 30-:MHz catheter, Boston Scientific, Santa 
Clara, California or Eagle Eye 20-.MHz catheter, Volcano 
Corp.), by a dedicated IVUS-VH console (Volcano Corp.). 
The IVUS-VH data were stored on a CD-ROJ\1/DVD and 
sent to the imaging core lab for offiine analysis (Cardialysis). 
IVUS B-mode images were reconstructed from the RF data 
by customized so:ftvvare and contour detection was per-
formed using cross-sectional views with a semi-automatic 
contour detection software to provide geometrical and 
compositional output (IvusLab 3.0 for 30 :v.IHz acquisitions 
and IvusLab 4.4 for 20-MHz acquisitions, respectively; 
Volcano Corp.) (10). 
The contours of the e.\.1:ernal elastic membrane (EEM) 
and the lumen-intima interface enclosed an area that \Vas 
defined as the coronary plaque plus media area. Plaque burden 
"""' colcuhred as ([EEM=" - Lum-~/EE~J X 100). 
Plaque eccentricity was defined as minimum plaque thick-
ness divided by ma:cimum plaque thickness. Geometrical 
and compositional data were obtained for each cross-
sectional area (CSA), and an average was calculated for e:~.ch 
coronary and for the total coronary tree. RF data were 
normalized using a technique knovvn as "blind deconvolu-
tion," an iterative algorithm that deconvolves the catheter 
transfer function from the backscatter, thus accounting for 
catheter-to-catheter variability (11,12). 
Biochemical measures. Antecubital venous blood was col-
lected from all patients at entry, left in ice for 45 min, 
centrifuged at 1,700 gat 4oC for 15 min and serum obtained 
finally stored at -S0°C. High-sensitivity CRP was mea-
sured in serum using a commercially available kit (N High 
Sensitivity CRP, Dade Behring, :Marburg, Germany). 
Plasma concentrations of total cholesterol, high-density 
lipoprotein (HDL) cholesterol, and triglycerides were mea-
sured in the local laboratory. The F ricdewald formula was 
used to derive low-density lipoprotein (LDL) cholesterol 
levels. 
Statistical analysis. The sample size \VaS calculated on the 
assumption that plaques located in the most proximal 6-mm 
segment of the LAD or CFX would display a mean necrotic 
core content of approximately 10% and a standard deviation 
of 10%, based on previous findings (13), with a relative 
necrotic core content of around 5% in plaques located in the 
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LMS. To detect this effect size with SO% power and a type 
I error (alpha) of 0.05, at least 46 patients were required 
(modcl1). Model2 also was created to explore whether in 
patients with LMS length beyond median value (long L.L\I.IS 
cohort) plaque composition differs in the proximal com-
pared to the distal tract of the LMS. 1'\o formal sample size 
was calculated for modcl2 as it was meant to be a hypothesis 
generating analysis. 
Values are C)..-pressed as mean :!: SD and median and 
interquartile range (IQR) whenever appropriate. Because :ill 
cross-sectional areas, provided by rvus analysis, were 
shown to have a non-normal distribution at Kolmogorov-
Smirnov goodness-of-fit test, they were log-transformed 
before analysis. Similarly, to all percentages relative to 
stenosis rate and plaque composition an arcsin transforma-
tion was applied (14). Assumptions for normality were 
checked after transformation based on a p value >0 .20 at 
Kolmogorov-Smirnov test and on visual assessment of Q:Q 
plots of residuals. 
Comparisons between the 2 groups were performed \vith 
the Student t test. The Fisher exact test was used for 
categorical variables. Comparisons among coronary seg-
ments were accomplished through a general linear mi.xed 
model and post-hoc comparisons by T ukey honest signifi-
cance difference test (15). Spearman's correlation coeffi-
cients were used to detect any association between variables. 
Study Population 
., 
Variable {n = 48) 
Age {yrs) 57::o;U 
Males, n (%) 32(67) 
Weight (kg) 82:<:12 
Height {em) 174:':9 
BMI(kVm~) 27:':3 
Dlobetes, n (%) U(23) 
Hyportonslon. n (%) 37(77) 
Current smokors, n (%) :1.9(40) 
Provlous smoker, n (%) :1.6(33) 
C-moctlvc protein (mg/1) 29 ;<: 48 
Low-density llpoprcteln (mmol/1) 3.09 :': 1..22 
HDL(mmol/1) 1..22 ;<: 0.5 
Cholesteroi/HOL ratJo 4..26:': 1..49 
Medlcol history, n (%) 
"'"' 
2(4) 
''" 
.1.:1.(23) 
Acuta coronary syndrome :1.8{37) 
MedJcol treatment, n (%) 
Aspirin 48(:1.00) 
Clopldogrol 48(100) 
Stotln 42 (88) 
ACE Inhibitor 40(83) 
Beto-blod<cr 42(88) 
Plus-minus voluos ore mc~n ::SO. 
Probability was significant at a level of <0.05. Statistical 
analysis was performed using Statistica 6.1 Software (Stat-
soft Inc., Tulsa, Oklahoma) and R-language (R Founda-
tion, Free Software Foundation, Boston, Massachusetts). 
Results 
From December 11, 2003, to July 27, 2005, 72 patients were 
prospectively included in the protocol. Twenty-four patients 
were subsequently e.xcluded from the final analysis because 
of short ( <36 mm) IVUS pullback in 16, uncertainty 
regarding the true interface lumen-vessel wall based on 
IVUS grey-scale in 4 and occurrence of angiographic:illy 
confirmed deep intubation of the guiding catheter during 
the pullback in 4 patients. Thus, 48 patients (32 men), ages 
30 to 75 years (mean age, 57 :!: 11 years) constituted the 
final patient population. Their baseline characteristics are 
provided in Table 1. 
The study vessel was the L\1S and the LAD artery in 34 
(71%) patients and LMS and CFXin 14 (29%). The overall 
LMS length was 7.49 :!: 4 mm (median [IQR], 6 [4.8 to 
9.3]; range, 3.4 to 20) in the SA group versus 7.8 :!: 5 mm 
in the acute coronary syndromes (ACS) group (p = 0.64). 
Lumen and vessel CSAs decreased significantly, starting 
fi-om the first 6-mm segment of the coronary aner;r as 
compared with LMS (Table 2). Plaque CSA in the LMS 
Patients 
SA Group ACS Group 
{n = 25) {n = 23) p Value 
ss::o;u 57 :':12 0.8:1. 
:1.6(64) :1.6 (65) >0.99 
gj.;':1.2 84:':12 036 
:1.73=8 :1.76:<: :tO 0.28 
27:': 4 27 :':2 0.81 
S(20) 6(26) Q.75 
20(80) :1.7(74) >0.99 
8{32) U(48) 0.32 
9 (36) 7(30) 0.50 
12.7 :': :1.5 38:':58 Oi9 
3.26 = 1..3 2.9 :': 1..3 M4 
1..30 :': 0.6 :L:l.4:!; 0.4 039 
4.26 :':1..5 4.25 = .1..2 0.99 
2(6) 0(0) 029 
8(32) 3 (1.3) 0.'2 
:1.0(40) 8(35) >0.99 
25(:1.00) 23 (100) >0.99 
25{:1.00) 23(100) >0.99 
23(92) 19(83) O.M 
25 (:1.00) :l.5{65) 039 
23(92) :1.9(83} 0.84 
ACE ~ Yn~lo!enoln.convortlng enzyme; ACS ~ nouto oomnor)l syndrome; I)MI ~ body m~>;;s Index; CA.BG • coronary ortory bypo.,. ~roftln!!; HDL ~ 
hlg!>.<jnnslty lipoprotein; PCI ~ ~rout1>n001J~ coronory lntorvontlorr. SA ~ !>table ongiM. 
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Quantit<Jtive Vessel Analysis at IVUS Stratified Into Coro111ary Segme111ts 
Cross Sectional Areas ( mm2) Plaque Plaque 
Eccentricity Burden 
Lumen Vessel Plaque Index (%) 
Model:!. (n = 48) 
c->ronary segments 
'"' 
15.2 (12~17) 24.5 (19~26) 8(6-9) 0.:11 (0.05-0.18) 34.3 (29-38) 
LMS carina 12.2 (:11~15) 20.4 (16-24) 6.7 (6-8) 0.03 (0.01~0.06)* 33.8 (31-39) 
1" (0-6mm) 9.9 (7~11)~ 16.2 (14-18)* 6.4(5-7) 0.09 (0.07-0.14) 38.6 (36-46) 
2" (6-12mm) 9.1 (7~10)* 16 (14-18)* 6.8 (5-8) 0.:11 (0.06-0.16) 40 (39-45) 
3" (12~18 mm) 8.6 (7~10)• 15 (13~17)* 6.9 (5-8) 0.10 (0.08-0.15) 41(40-46) 
4 • (18-24 mm) 8..2 (7-10)* 14(:1.3~:1.6)* 6.3 (5-7) 0.:1.3 (0.06-0.17) 4:1.(37-51) 
s· (24-30 mm} 7.5 (6-9)* 13.2 (12~15)* 5.6(5-6) 0.16 (0.10-0.20) 40{38-54) 
6" (30-36 mm} 7.2 (6-8)* 12.3 (:11~14}* 4.9 (4-6)• 0.12 (0.08-0.21) 42 (36-47) 
P ~ai~Ie <0.0001 <0.0001 0.0006 0.0001 0.16 
Model 2 (n = 24) 
Coronary o;egments 
Proximal LMS 16.1 (:1.3-19) 23.4 (21-27) 7.5 (5-9) 0.:11 (0.07-0.15) 32 (29·39) 
Olstal LMS :1.4.6 (12-:1.7) 25.8 (20-27) .. $.9 (7-10) 0.:11 (0.07-0.25} 38(33-43) 
LMS cmlno :1.3.1 (:11-15)* 21.2 (18-25)* 7.7 (7-8) 0.05 (0.02-0.08) 37 (31-43) 
1" (0-6 mm) 9.9 (8-1.1}* 16.3 (15-19)* 7.1(6-8) 0.:1.3 (0.09-0.14) 43{37-48) 
2" (6-12mm) 9.1 (7-:11)'• 16.6(:1.4-19)* 7.7 (6-9) 0.15 (0.08-0.17) 47 (45-SO)t 
3" (12·18 mm) 8.6 (7-10)• 15.7 {14-18)* 7.4(6-8) 0.:11 (0.09-0.21) 50(4S-S3)t 
4" (18-24 mm) 8..2(7-10)'• 14.5 (:1.3-16)"" 7.0 (5-8) 0.14 (0.09-0.17) 48 (38-S:I.Jt 
s• (24-30 mm) 8.2 (6-10}* 14.0(12-17)* 5.7 (5-7) 0.19 (:1.3-24) 45(34-54) 
6" (30-36 mm) 7.0{6-8)* 12.0 (:11-14)* 5.1 (4-7Jt 0.19 (0.:11-0.30) 45 (39-51) 
p value <0.001 <0.000:1. 0.002 0.019 0.0093 
pvoluos rolorto rosults lor the whole model otgonorallln<>or onot)rsls. *p <:: 0.01; tP <:: 0.05 ntodju~tod post-hoe com~~""" os e<>mPorod with loft moln stom (LMS) In modol1ond to proximal LMS In 
model 2. Results oro ~lvon as median (lntorquortllo ron~o). 
IVUS ~ lntrovasculor ulrosound. 
was significantly increased only compared vvith the most 
distal 6-mm segment. The degree of plaque eccentricity was 
relatively constant throughout the vessel e..xcept in the LMS 
carina, where it resulted to be higher compared vvith both 
the LMS and the coronary segments distal to the first one. 
Plaque burden did not change along the vessel in model 1, 
despite a trend being progressively increased from proximal 
to distaL 
Mode12 (Table 2), in which LMS has been stratified 
into the proximal and distal segment after selection of 
those patients (n = 24) with long LMS (length >6 mm), 
mainly confirmed the trends observed along the vessels in 
model 1. 
Change in plaque composition along the study vessel. 
Fibrous tissue was the most prevalent component of plaque 
composition in each analy.t.:ed segment throughout the 2 
models, followed by fibrolipidic tissue, necrotic core and 
calcium (Table 3). No significant change was observed in 
terms of relative plaque composition throughout the study 
vessel with respect to fibrous and calcified tissue content. 
The percentage of fibrolipidic tissue decreased in the second 
and third 6-mm segment when contrasted to the LMS. 
VVhen compared to the sD.:th coronary segment, however, no 
di:ff'erence emerged among the vessel tracts in terms of 
fibrolipidic content at post-hoc analysis. 
The necrotic core increased significantly in the first, 
second, and third 6-mm segment compared with the LMS. 
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When the most distal segment of the study vessel was taken 
as reference, the necrotic core remained greater in both the 
:first and second 6-mm segment at post-hoc analysis. As 
shown in Figure 1, the necrotic core was the plaque 
component with the highest relative change along the 
vesseL Changes in terms of plaque composition in model 2 
are shown in Table 3. 
Change in plaque composition according to clinical 
presentation. ).Jo significant change in calcium, fibrous, 
and fibrolipidic content vvith respect to clinical presenta-
tion (stable vs. unstable) was observed when all 384 
coronary segments were pooled together (Fig. 2). Ne-
crotic core (%) was significantly increa..o:;ed in patients 
with (median [IQR]: 11.4 [5.5 to 19.8]) as compared 
with those (median [IQRJ: 7.3 [3.2 to 12.9]) without 
ACS (p < 0.001) (Fig. 2). After introducing ::matomical 
location stratified into 8 coronary segments in the model, 
the increase in necrotic core in patients with ACS was 
mainly confined to the LMS (6.9 [2.6 to 9.4] vs. 3.5 [1.4 
to 6.2] in stable patients; p = 0.02), in the first (14.9 [7.7 
to 19.6] vs. 11.5 [4.9 to 17.3] in stable patients; p = 
0.03), second (12.2 [5.5 to 16.1] vs. 9.4 [5.1 to 20.6] in 
stable patients; p = 0.03), and third 6-mm coronary 
segment (11.4 [5.4 to 15] vs. S [3.6 to 14.4] in stable 
patients; p = 0.04). However, the statistical interaction 
between necrotic core and the anatomical location of the 
segments did not reach the significance (p = 0.12). 
Plaque composition in the left main stem mimics the distal bm not the proximal tract 
Plaque Composition Along the Left 
• Coronary Artery Stratiffed Into Coronary Segments Plaque COmposition (%) 
Calcium Core Rbrous Core Rbrellpldlc Core Necrotic Core 
Modcl.1 (n ~ 48) 
Coronary segments. 
CMS 0.65 (0..2-1.7) 63.5 (57 -68) 24.9 (20-29) 4.6(2-7) 
LMS car1no l..1(0.3-l..6) 63.6(62-71) 23.0 (.15-28) 7.2(4-9) 
.1" (0-6mm) 2.1 (0.8-3..8} 61.6 (59-70) 19.8 (8-24) 11.8 (7 .8-16Jt 
2" (6-:1.2 mm) 2..2(U-3.3) 62.4 (59-68} l.5 (10-24) .. 10.8(7-:1.6)* 
3" (12-18 mm) l..9(1.0-3) 64.4(60-70) 1.7.4(1.0-2lY 9.5 (6.5-.1.3.3}* 
4" (18-24 mm) 1.6(1.-3) 61.7 (57-70) :1.7.6 (1.:1.-23) 8.7 (6-1.0) 
5" (24-30 mm} 1.2 (.1-3) 63.4(58-66) 18.7 (13-26) 7(4-1.:1.) 
6" (30-36 mm) 1.4 (0.6-2.4) 61.5(57-67) 18.4 (1:1.-25} 6.1(3-9) 
pvolue ,,, o.ss 0.0:1. 0.000.1 
Model2 (n ~ 24} 
Cc>ronory SClgments. 
Proximal LMS 0.85 (0.08-1.5) 62.8 (55-.69) 24.6 (20-30) 3.8 (2.3-6.8) 
Dlstol LMS 1.0 (0.3-2.1.) 64 . .1(59-69) 25(22-28) 6.5 { 4.5-8.8) 
LMS cnrlno 1.3 (0.3-1.6) 64(6.1-71.) 28.8 (20-29) 7.3(4.2-8) 
.1" (0-6mm) 2.3(.1-3.4) 62.9 (60-7.1) 20.9 (l.3.l.-25) 11.3 (8-.16)t 
2" (6-:1.2 mm) 2.3 (1.2-5.0} 62.6 (55-69) 18.8 (.13-27) 9.1.(7-1.3)" 
3" (:1.2-18mm) 2..2 (0.98-4.3) 64.2 (60-70) 20(.16-23) 8.7 (6.7-1.3.3)* 
4" (18-24 mm) 1.2(0.9-4.5) 64.4(57-71) 1.9.5 (1..1-26) 8.9 (8-.10)* 
5" (24-30 mm) .1.3 (0.3-4-..S} 63.4 (58-68) 22.5 (.13-27) 4,9 (4-8} 
6" (30-36 mm) 1.2 (0.6-4) 59.9 (52-66) 22.2 (13-29) 3.5(1.8-6} 
p vulue ,,. 0.89 0-'.9 <0.0001. 
p v~IU<t> refarto result!> for tho whole mGdel <>t gono.,lllnoor on<~lysls. •p < 0.05; tP < 0.01 at odjustod post ..floc comporloon ~o compored with 
laft main ~tom (LMSJ In modcl1 and to pro<lmol LMS In modol2. R<t>ult.. ""' gjvcn os median {lntorq""rtllo rongo). 
Length of LMS as a predictor of plaque composition 
along the study vessel. Patients were stratified into 2 
groups based on median LMS length (short LMS :=£6 
mm and long LMS >6 mm). These 2 groups did not 
differ in terms of baseline and procedural characteristics. 
VVhen each coronary segment was separately analyzed, no 
difference emerged between the 2 groups for IVUS-
derived quantitative vessel analysis. The same held true 
if all 384 coronary segments were cumulatively consid-
ered independently from their anatomical location. Cal-
cium, fibrous, and fibrolipid content did not differ be-
rween the 2 groups (data not shown). The pattern of 
necrotic distribution in relation to LMS length is shown 
in Figure 3. 
Correlations. In a segment-based analysis, necrotic core 
\v:J.S largely independent from plaque area (r = 0.17; p = 
0.06; R2 = 0.09) (Fig. 4). Similarly, we failed to find an 
association between necrotic core content and CRP levels 
(c ~ 0.09, p ~ 0.8), levelofLDL cholescewl (p ~ 0.11, p ~ 
0.23), or HDL cholesterol (r = -0.2, p = 0.4) at entry. 
However, there was a significant, although weak, direct 
correlation between necrotic core and cholesterol!HDL 
rntio (c ~ 0.18, p ~ 0.01; R2 ~ 0.1). 
Discussion 
There is increasing evidence that the distribution of rup-
tured or prone-to-rupture plaques is not uniform along the 
coronary vessel: they cluster in the proximal tract of the 3 
major coronary vessels whereas they tend to spare both the 
LMS and distal segments of coronary arteries (4,16). 
These findings have been recently confirmed by mapping 
the distribution of angiographic sites of occlusive or non-
occlusive culprit lesions along the coronary arteries in 
patients with ST-segrnent elevation ACS (2,3). 
The reason why vulnerable plaques show a tendency to 
cluster in partially predictable hor spots located within 
the proximal tracts of coronary vessel is largely unknown. 
Atherosclerotic plaques also cluster within the proximal 
portions of the 3 major coronaries (17-20). Thus, rhe risk 
to undergo rupture may be identical for each coronary 
plaque independently from its anatomical location, being 
rupture simply more likely ro occur where atherosclerotic 
plaques are more frequently clustered (21). This may 
easily e.xplain the nonuniform distribution of ruptured or 
prone-to-rupture plaques without calling into quesrion 
the idea that plaque rupture is partially a site-specific 
phenomenon. 
Alternatively, plaques located within the proximal 
third of each coronary may harbor some specific hallmark 
of vulnerability which makes them individually more 
likely to undergo rupture. To gain some insights into this 
topic of debate, we hypothesized that plaque necrotic 
core content, which is a well-known determinant of 
vulnerability (7,8,22), may differ along the coronary 
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~ Change in Plaque Composition Along the Lett Coron:Jry Artery 
I 
P:aquc compos;tlon in terms Of median necrotic, fibrollpid, fibrous, and calcium core content a:onc tho left coronory ve%01 (A). In panel B. tho pomontage of each 
plaque component i& rtoportod with rcspoct to loft main coronary artery (LMCA) taken as rclorenco. All analyses oro based on model 1. 
vessel, being greater at the spots where plaque rupture is 
known to be more frequent. 
Our main findings can be summarized as follows: 
1. The plaque necrotic content was minim:ll in the LMS, 
particularly in the most proximal tract, whereas it 
peaked in the first 6-mm segments after the ostium of 
the 2 major left coronaries, progressively decreasing 
toward the more distal segments. 
2. The plaque CSA was largely unrelated to necrotic core 
content throughout the left coronary vessel. This state-
ment is supported by the absence of correlation between 
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necrotic content in plaques and plaque CSA at the 
segment-based analysis and by the observation that 
plaque CSA showed a progressive increase in the 
distal-proximal direction along the vessel whereas 
plaque necrotic content did not. 
3. The necrotic core was greater in patients with clinical 
instability presenting with ACS compared to those 
affected by stable atherosclerotic disease. 
4. The necrotic core content was not related to systemic 
inflammatory stams, as measured by a well-recogni7...ed 
prognostic marker of infu.mmation such as CRP nor 
Plaque composition in the left main stem mimics the distal but not the proximal tract 
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LDL or HDL alone, whereas it showed a significant 
although weak correlation to cholesterol!HDL ratio. 
5. The length of left main trunk was shown to affect the 
distribution of necrotic core along the vesseL In patients 
\vith long LMS, necrotic core content peaked immedi-
ately in the first coronary segment after LMS and 
rapidly decreased distally. Conversely, the necrotic core 
content peaked in the second 6-mm segment in patients 
with shon LMS and it resulted to be increased in the 2 
most distally analyzed segments compared to the long 
L::."vi:S group. 
It is tempting to speculate that the observed clustering of 
ruptured or prone-to rupture plaques in the proximal 
segment of each coronary artery is not just a simple 
reflection of the nonuniform distribution of atherosclerosis 
along the coronary vessel. The necrotic content of those 
plaques located in these proximal segments, independent of 
their size, was greater, both compared \vith the LMS and 
with those segments that are more distally located. The 
plaques located \vithin the proximal segments of the left 
coronary artery, being relatively richer in necrotic content, 
may undergo rupture more easily than those located in the 
L.\1S or in the distal tracts of the vessel. 
Some preliminary unpublished :findings by our group 
suggest that plaque necrotic core content, as assessed 
through IVUS-"VH, may be the only independent predictor 
for mechanically deformable regions (high-strain spots) (23) 
throughout the coronary aneries in humans. Thus, when 
our :findings are put in perspective of current evidence, they 
suppon the idea that vulnerability may cluster in necrolipid-
rich regions throughout the vessel 
Necrotic core content in the present study was greater in 
patients with ACS, suggesting again that plaque composi-
tion in itself may play a pivotal role in detenrllning vulner-
ability. Interestingly, it was recently reponed that when 
rupture of coronary plaques occurs in the LMS, the distal 
half ofLMS is more likely to be involved (24). Our findings 
that the distal LMS tends to harbor a greater necrotic core 
content compared with proximal haJf, together with the 
well-established role of shear stress in bifurcated lesions 
(25), may contribute to explain the nonuniform distribution 
of plaque rupture even within the LMS. 
The reasons why the plaque necrotic core seems to e.xceed 
in the proximal as compared with the dist::U tracts of the 
coronary vessel or the L"v:IS remain speculative at the 
present time. Low-oscillatory shear stress is known to 
induce a loss of the physiological flow-oriented alignment of 
the endothelial cells, an enhancement of the e.xpression of 
adhesion molecules, and a weakening of cell junctions, 
ultimately leading to an increase in permeability to lipids 
and macrophages (25). The segments located in the .first few 
centimeters of the coronary arteries, because of flow turbu-
lence generated by high-velocity blood impacting against 
anatomical flow dividers (26), may be more exposed to 
low-oscillatory shear stress compared with the most proxi-
mal (i.e., LMS) or more distal coronary segments, thus 
possibly e.·-..:plai.ning our present :findings (27). Concomitant 
quantitative measurement of shear stress and plaque com-
position along coronary vessels in vivo would be pivotal in 
corroborating this working hypothesis. 
Study limitations. On the basis of previous :findings and 
the well-known role of necrotic core content in determining 
vulnerability (6-8,22), our investigation was primarily fo-
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cused on the distribution of necrotic core content along the 
left coronary artery. To assess relatively minor changes in 
plaque composition along the longimdinal artery a.-xis, such 
as that observed for fibrous tissue, a larger, properly powered 
sample size is clearly needed. In keeping with previous 
considerations, all other analyses and comparisons per-
formed in the current report should be regarded as e.\."Plor-
o.tory and hypothesis-generating because we cannot rule out 
the possibility that inflation of type I error due to multiple 
comparisons may have confounded our results. 
In our study, the operators were left free to wire the most 
suitable vessel for the IVUS pullback, provided it was 
supplying a major left ventricle territory, which resulted in 
the predominance of LAD as a region of interest, whereas 
the CFX artery was mainly investigated in those patients 
presenting with small or tortuous LAD. The distribution of 
necrotic core along the vessel did not differ in LAD as 
compared with CFX. The same held true for other studied 
plaque components. However, the applied selection process 
may have biased this comparison. Thus, whether the distri-
bution of plaque composition may cl.i[er in relation to the 
studied vessel remains to be tested. Similarly, to ma.ximize 
patients' safety and avoid potential IVUS-related complica-
tions, individuals -.,.vith severe angiographic calcification were 
e.xcluded. Despite the fact this decision may have clearly 
contributed to generate some selection bias, the distribution 
of calcium along the coronary vessel intriguingly mirrored 
the one observed for the necrotic core. Further studies are 
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needed to investigate the specific role of calcium content in 
determining pbque vulnerability. 
Patients with proximal occlusions have bigger myocardial 
ischemia and, thus, they are more likely to present to 
hospital and be referred for angioplasty. Similarly, myocar-
dial infarction with LMS as culprit artery often may result 
in immediate death. Thus, it may be argued that a selection 
bias might have artificially increased the prevalence of 
patients with culprit lesions located in the proximal com-
pared to distal tracts of coronaries or L.MS. This is obviously 
theoretical possible. However, for the follo'-ving reasons, we 
believe that this possibility is relatively unlikely: 
1. The necrotic core in our series clustered in the same 
coronary spots in which previous studies, based on 
postmortem e."{amination, found a greater prevalence of 
ruptured or healed plaques. 
2. Our results are based on the investigation of the 
nonculprit vessel. Thus, they are potentially le::;s prone 
to suffer from clinical selection due to the location of the 
culprit lesion in the culprit vessel. 
3. Although it seems to be e.'\.-acerbated in patients present-
ing with clinical instability, the nonuniform distribution 
of plaque composition along the vessel also has been 
observed in patients with stable coronary disease, in 
whom the selection bias due to the importance of the 
culprit lesion is less obvious, at least for the comparison 
LMS versus proximal tracts of LAD or CFX. 
Plaque composition in the left main stem mimics the distal but not the proximal tract 
Thus, based on these considerations, we think that our 
findings, especially when put in the context of previous 
evidence (1-5), may help reinforcing the notion that there 
may be some hot spots along the coronary vessel which are 
per se more prone to develop vulnerable plaque and as such 
undergo plaque rupmre. 
Summary and conclusions. Plaque composition was found 
to be not uniformly distributed along the left coronary artery 
with a progressive increase in necrotic core starting from the 
proximal half of the LMS to the most proximal segments of 
the LAD or CFX, followed by a steady decline toward those 
segments which are more distally located along the vessel. 
The necrotic core appeared to be increased in patients with 
ACS, especially in the LMS and in the 3 proximal coronary 
segments of LAD or CFX, whereas it did not correlate with 
the CRP or lipid profile. The relatively site-specificity of 
necrotic core content toward the proximal segment of the 
left coronary artery is in keeping with the increasing 
evidence that a clear clustering of ruptured or prone to 
rupture plaques occurs in humans within this region (23,5). 
Our :findings 1) reinforce the notion the plaque composition 
may be a major determinant for and subsequently a potential 
t:trget of plaque vulnerability in humans and 2) call for 
prospective evaluation of the independent role of plaque 
composition on long-term outcome in patients with estab-
lished coronary artery disease. 
Reprint request$ and con:e,-pondcncc: Pro£ Patrick W. Serruys, 
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Aims Relative plaque composition, more than its morphology alone, is thought to play a pivotal role 
in determining propensity to vulnerability. Thus, we investigated in vivo whether the distance from 
coronary ostium to plaque location independentlY affects plaque composition in humans. This may 
help explaining the recently reported non-uniform distribution of culprit lesions along the vessel in 
acute coronary syndromes. 
Methods and results In 51 consecutive patients (45 men}. aged 38-76 years (mean age: 58± 10), a non-
culprit vessel was investigated through spectral analysis of IVUS radiofrequency data (IVUS-Virtual His-
tology™). The study vessel was the left anterior descending artery in 23 (45%) patients; the circumflex 
artery in nine (18%}, and right coronary artery in 19 (37",\). The overall length of the region of interest, 
subsequently divided into 10 mm segments, was 41.5 :t 13 mm long (range: 30.2-78.4}. No significant 
change was observed in terms of relative plaque composition along the vessel with respect to 
fibrous, fibrolipidic, and calcified tissue, whereas the percentage of lipid core resulted to be increased 
in the first (median: 8.75%; JQR: 5.7-18} vs. the third (median: 6.1%; IQR: 3.2-12} (P= 0.036} and fourth 
(median: 4.5%: JQR; 2.4-7.9) (P = 0.006) segment. At multivariable regression analysis, distance from 
the ostium resulted to be an independent predictor of relative lipid content LB = -0.28 (95%CI: 
-0.15, -0.41)], together with older age, unstable presentation, no use of statin, and presence of 
diabetes mellitus. 
Conclusion Plaque distance from the coronary ostium. as an independent determinant of relative lipid 
content, is potentially associated to plaque vulnerability in humans. 
Coronary plaque rupture or erosion, by triggering local 
thrombosis is thought to play a pivotal role in the genesis 
of acute coronary syndromes (ACS) and sudden death.u. 
A series of landmark angiographic studies in the mid-1980s 
demonstrated that nearly two-thirds of all myocardial 
infarction originate from non-flow limiting atherosclerotic 
lesions and prior angiographic studies focusing on plaque 
morphOLogy alone failed to identify quiescent plaques 
prone to rapidly progress or rupture. 3·7 
Consequently, the mechanical and biological properties of 
coronary plaques, which overall reflect plaque composition, 
along with systemic inflammation has mainly been targeted 
for the diagnosis and treatment of plaque instability.8 
Epidemiological studies in patients with ST-segment 
elevation myocardial infarction (STEM!) report that sites of 
occlusion are not uniformly distributed throughout each of 
* Corre5pondinS uuthor. Tel: -31 10 4635260: fax: +31 10 4369154. 
E-mail addre-ss: p.w.J.c.serruys@crasmusmc.nl 
the major epicardial coronary arteries but tended to 
cluster within the proximal third of each of the vessels.9·10 
Accordingly, despite the recognition that several factors 
involved in the pathogenesis of plaque vulnerability are 
widespread, 11 - 14 local trigger(s} should be also targeted to 
explain the presence of high-risk coronary spots. 15 
Plaque composition, favouring propensity to vulnerability, 
might also be non-uniformly distributed along each coronary 
vessel. This might explain the higher likelihood for plaque 
erosion or rupture to occur proximally in the coronary tree. 
To investigate this hypothesis, the non-culprit, non-
treated vessel containing angiographically non-obstructive 
(<50%) lesions was systematically investigated to assess 
plaque composition through spectral analysis of !VUS radio-
frequency data [IVUS-Virtual Histology™ (IVUS-VH)] in 
consecutive patients referred to our institution for percuta-
neous coronary intervention (PCI}. 
Our findings support for the first time to the best of our 
knowtedge in vivo the hypothesis that plaque composition 
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in humans may differ in relation to plaque localization along 
the coronary tree. 
Methods 
Study protocol and patients enrolment 
This was a single-center; investigators-driven, observational pro· 
spective study aimed to evaluate the distribution of plaque 
composition along the coronary vessel in consecutive patients 
referred to our institution for elective or urgent PCI, in whom the 
non-culprit, non-treated vessel was judged suitable for a safe 
IVUS 30 mm-pullback or more, based on angiographic (absence of 
the following: >50% stenotic disease, extensive calcification. 
severe vessel tortuosity) and clinical (haemodynamic stability) 
findings. According to the protocol. not more than one vessel-per 
patient could be evaluated and the region of interest (ROI), sub· 
sequently divided into 10 mm segments, had to start from the 
coronary ostium. Thus, an analysable interrogated vessel length of 
at least 30 mm. starting from coronary ostium, was the main 
selection criterion, once the patient was included in the study. 
In the group of patients presenting with an ACS, the culprit lesion 
has been categorized as complex or non-complex, based on anglo· 
graphic findings as previously described. 12 
This protocol was approved by the Hospital Ethics Committee and 
is in accordance with the declaration of Helsinki. Written informed 
consent was obtained from every patient. 
lVUSNH acquisition and analysis 
Details regarding the validation of the technique, on explanted 
human coronary segments. have previously been reported. 16 
Briefly, IVUS-VH uses spectral analysis of IVUS radiofrequency data 
to construct tissue maps that classify plaque into four major com· 
ponents. In preliminary in vitro studies, four histological plaque 
components (fibrous, fibro-lipid, lipid core, and calcium) were cor-
related with a spedfic spectrum of the radiofrequency signa\.16 
These different plaque components were assigned colour codes. 
Caldfied, fibrous, fibrolipidic, and Lipid-necrotic regions were 
labelled white, green, greenish-yellow, and red, respectively.17 
IVUS-VH data was acquired after intracoronary administration of 
nitrates using a continuous pullback (0.5 mm/s) with a commerdally 
available mechanical sector scanner (Ultracross™ 2. 9F 30 MHz cath· 
eter, Boston Scientific. Santa Clara. CA), by a dedicated IVUS-VH 
console (Volcano Therapeutics, Rancho Cordova, CA). The IVUS-VH 
data were stored on a CD·ROM and sent to the imaging core lab 
for offline analysis. IVUS B-mode images were reconstructed from 
the RF data by customized software (IVUSLab, Volcano Thera-
peutics, Rancho Cordova, CA).'7 Manual contour detection of both 
the lumen and the media-adventitia interface was performed and 
the RF data was normalized using a technique known as 'Blind 
Deconvolution', an iterative algorithm that deconvolves the 
catheter transfer function from the backscatter, thus accounting 
for catheter-to-catheter variability. 18• 1 ~ 
Statistical analysis 
The sample size was calculated on the assumption that plaques 
located in the proximal segment of the coronary artery, defined as 
the first 10 mm coronary segment, would display a mean lipid 
content of around 40%, with a sigma of around 35% based on previous 
findings, 20 with a lipid content of 10% in the distal plaques, defined as 
those located beyond the first 20 mm from the coronary ostium. To 
detect this effect size with 80% power and a type-I error (alpha) of 
0.05, 48 patients were required. Four main models were constructed 
based on the number of 10 mm segments that were included. 
Model1 comprised three 10 mm segments available in all patients 
included. 
Model 2 comprised four 10mm segments available in 43 patients. 
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Models 3 and 4, composed of five and six 10 mm segments in 20 and 
11 patients, respectively, were considered as exploratory analysis 
because of limited sample size. 
Values are expressed as mean :t SD and median and inter-quartile 
range (IQR) as appropriate. 
As al\ cross-sectional areas (CSA) provided by IVUS analysis, were 
shown to have a non-normal distribution at Kolmogorov-Smirnov 
goodness-of-fit test, they were log-transformed before analysis. 
Similarly, to all percentages relative to stenosis rate and plaque 
composition were applied an arcsin transformation.21 Comparisons 
between the two groups were performed with the Student's t-test. 
Fisher's exact test was used for categorical variables. Comparisons 
among 10 mm segments were accomplished through a general 
linear mixed model with a compound symmetry correlation struc-
ture and the intercept as only random effect. Maximum llkelihood 
method was adopted to estimate parameters in the models. Linear 
contrasts were applied to evaluate effects of distance, analysed as 
dummy variable, on the studied parameters. Post hoc comparisons 
were systematically performed by Turkey honest significance 
difference test. 22 
Because of limited statistical power in models 3 and 4, the multi-
variable analysis regarding both clinical presentation and plaque 
location along the vessel, along with the interaction between the 
two was restricted to models 1 and 2. 
In order to establish the determinants of lipid relative content in 
the plaques in our model and confirm distance from the coronary 
ostium as an independent predictor of relative lipid content, a uni-
variate (including age, sex, history of hypertension, hypercholester-
olaemia, cardiovascular disorders in the family, diabetes mellitus, 
levels of LDL HDL and triglycerides, use of statin, coronary 
vessel analysed, clinical presentation, and distance for the ostium 
stratified into 10 mm segments) and multivarlable (with all variables 
showing a P-value of _:sO. 1 at univariate analysis) linear mixed model 
using percentage of Lipid content in all1 0 mm segments, analysed as 
outcome variable, was also applied. 
All statistical tests were two-tailed. Probability was significant at 
a level of <0.05. Statistical analysis was performed using Statistica 
6.1 Software (Statsoft Inc.) and R-language (R Foundation). 
Results 
From 16 April2003 to 10 September 2004, 67 patients were 
prospectively included in the protocol. Sixteen patients 
were subsequently excluded from the final analysis 
because of short (<30 mm) lVUS pullback in 10, poor \VUS 
quality in two and lack of coronary plaque at \VUS investi-
gation in four patients. Thus, 51 patients (45 men), aged 
38-76 years {mean age: 58± 10) constituted the final 
patient population. Their baseline characteristics are pro-
vided in Table 1. Overall, 33 patients were affected by 
stable angina (SA), whereas the remaining 18 patients 
were admitted to hospital because of a non-ST-elevation 
ACS. In the SA group, the mean cardiovascular canadian 
Score was 2 :': 1, whereas the TIMI risk score, the percen-
tage of patients with troponin T above upper limit of 
normal (0.02 11-g/l) and the delay from symptoms onset to 
PCI were 4 ::i: 2, 56% and 4±3 days in the ACS group. 
respectively. \n the ACS group, the culprit lesion was 
located in the proximal coronary segments in 13 (72%) 
patients, including 6 (33%) in the left anterior descending 
artery (LAD), four (22%) in the circumflex artery (CFX), 
and three (17%) in the right coronary artery (RCA), while 
in the remaining five (28%) patients the culprit lesion was 
located in the mid or distal segment of the coronary 
vessels. Overalt, 11 out of 18 identified culprit lesions in 
the ACS group satisfied the criteria for complex lesions 
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Table 1 Study population 
Variables 
Age (years) 
Males, no. (%) 
Weight (kg) 
Height {em) 
BMI (kg/m2) 
Diabetes, no. (%) 
Hypertension, no. (%) 
Current smokers. no. (%) 
Previous smoker, no. (%) 
Medical history, no. (%) 
CABG 
PC! 
ACS 
Medical treatment at entry, no. (%) 3 
Aspirin 
Clopidogrel 
Statin 
ACE-inhibitor 
13-Blocker 
Patients 
All 
(n"" 51) 
58± 10 
45 (88) 
80 ± 9 
174± 7 
27 :t 4 
12 (23} 
20 (39) 
19 {37) 
16 (31) 
3 (6) 
11 (22) 
23 {45) 
51 (100) 
51 (100) 
38 (75) 
40 (78) 
48 (94) 
SA Group ACS Group 
(n~33) {n= 18) 
56± 12 59± 9 
28 (85) 16 (94) 
80::::8 81 ± 9 
174 ± 7 175 :;1: 8 
27 ± 3 28 ± 5 
8 (24) 4 (22} 
14 (42) 6 (33) 
13 (39) 6 (33) 
9 {27) 7 (39) 
2 (6) 1 (6) 
8 (24) 3 (17) 
18 (54) 5 (28) 
33 (100) 18 {100) 
51 (100) 18 (100) 
25 (76) 13 (72) 
30 (91) 10 (56) 
32 (97) 16 (89) 
Plus-mlnus v.:.lucs are means::':: SD. BMI, Body mass mdex; CABG, coronal)' artel)' bypass grafting; 
ACE. angiotensin converting enzyme. 
The SA group was well matched (P-value >0.3) With the ACS group With respect to all variables 
reported e.:.rlier. 
'For this analysis we considered all medications administered in the previous 4 or more days. At dis· 
charge all patients C>Xcept one were taking st.:.tlns. 
based on angiographic findings. The study vessel was the LAD 
artery in 23 (45%} patients, the CFX in nine {18%), and RCA in 
19 (37%). The overall length of the RO! was 41.5.:: 13 mm 
Long [{range: 30.2-78.4) {41 ± 13 in SA group vs. 42 ± 13 
in ACS group, P= 0.6}]. The results regarding quantitative 
coronary IVUS analysis in the whole population, stratified 
into 10 mm vessel length (paired-segment analysis), are 
reported in Table 2. Lumen CSA significantly decreased 
every 10 mm in model 1 , whereas this happened starting 
from the third segment, as compared with first coronary 
tract, in model 2. 
As compared with ostial 10 mm segment, vessel CSA 
resulted to be decreased in the third and fourth segment 
in models 1 and 2, respectively, whereas plaque CSA reduc-
tion reached statistical significance only in the fourth 
segment of model 2. Distance from the coronary ostium 
did not affect the percentage of stenosis. The third and 
fourth models, restricted to a progressively Lower number 
of patients but based on a longer vessel Length, mainly 
confirmed the trends observed in the first two models. 
Change in plaque composition along 
the study vessel 
The results regarding quantitative coronary plaque compo-
sition analysis are reported in Table 3. 
Fibrous tissue was the most prevalent component of 
plaque composition in each 10 mm segment throughout the 
four models considered, followed by fibrolipidic tissue, 
Lipidic core, and calcium. 
No significant change was observed in terms of relative 
plaque composition passing from the most proximal to 
those progressively more distally located segments along 
the vessel with respect to fibrous, fibrolipidic, and calcified 
tissue. Conversely, the percentage of lipid core resulted to 
be increased in the first [(mean: 13%; 95%CI: 10, 16), 
(median: 8.75%: IQR: 5.7, 18)] with respect to the third 
segment [{mean: 8.7%; 95%Cl: 6.5, 11), (median: 6.2%; 
IQR: 2.6, 12.1 )J in model 1 (P < 0.05; primary endpoint) 
and to third [(mean: 8.4%; 95%CI: 6, 11), (median: 6.1%; 
IQR: 3.2-12)] (P < 0.05) and fourth [(mean: 6.8%; 95%CI: 
4, 9.6), {median: 4.5%; IQR: 2.4-7.9)] (P< 0.01} segment 
in model 2 (Figure 3). A similar shift in relative plaque 
composition along the vessel was observed in models 3 and 
4. Interestingly, ACS patients presenting with the culprit 
lesion located in the proximal segment of the coronary 
artery did not differ in terms of relative plaque distribution 
along the vessel with respect to those with culprit lesion 
sited in the mid of distal tract. 
Clinical presentation and change in plaque 
composition along the study vessel 
No significant change in calcium content with respect to 
clinical presentation (stable vs. unstable) was observed 
(data not shown). In model 1, fibrous plaque content was 
overall significantly increased in stable (68%) [95%CI: 65J~, 
71%] vs. unstable (63%) [95%CI: 59%, 64.7%] group, 
whereas a decrease in stable {17%) [95%CI: 16%, 19%] vs. 
unstable {22%) [95%CI: 20%, 2490] patients was observed for 
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Table 2 Quantitative vessel analysis at IVUS 
Coronary segments Mean cross-sectional areas (mm2) Stenosis(%) 
lumen Vessel Plaque 
Model1: n =51 
, (0-10 mm) 9.4 :::': 3.6 
2- (10-20 mm) 7.8 ± 2.9t 
3' (20-30 mm) 7.1 ± 2.8+ 
P-value 0.002 
Model2; n = 43 
, (0-10 mm) 9.3 :t 3.6 
2 (10-20 mm) 7.7 ± 2.7 
3 (20-30 mm) 7-'- 2.6· 
4 (30-40 mm) 6.4 ± 2.7r 
P-value 0.0002 
Model 3; n co- 20 
, (0-10 mm) 10.4 ± 4.3 
2 (10-20 mm) 8.8 ± 2.8 
3 {20-30 mm) 8 ±2.9 
4 (30-40mm) 7.3 ± 3.2 
5 {40-50 mm) 7 ± 2.9 
P-value 0.07 
Model4; n-,-, 11 
, (0-10mm) 10.7 ± 2.8 
2 (10-20 mm) 9.3 ± 3.7 
3 (20-30mm) 8.6 :t 2.3 
4 (30-40 mm) 8.3 ± 2.2 
5 (40-50 mm) 7.5 ::': 2.5 
6 (50-60 mm) 6.7 ± 2.6t 
P-valuc- 0.023 
17.1 :::': 8.1 
15.7 ± 7.8 
14.2 ± 3+ 
0.01 
17.4 ± 8.6 
15.9 ± 8.2 
14.5::::8.7 
13.5 ± 9.7T 
0.001 
20.5 ± 11.5 
19 ± 11 
17.4 :::': 12 
16.5 ± 13.3 
16.2 ± 15 
0.12 
19.3 ± 2.7 
18 ± 4 
16.8:t4.6 
17.1 ± 5 
15.3_::4.9 
13 ± 4 
0.06 
7.3 ± 3.7 
7.2:::: 3.4 
6.2 ± 2.7 
0.12 
7.6 ± 3.9 
7.3 ± 3.5 
6.3 ± 2.8 
6:::: 3.4~ 
0.02 
9 ± 5.2 
8.2 ± 4.7 
6.9 ± 3 
6.8 ± 4.2 
5.7 ± 2.3 
0.054 
8.6 ±2.1 
8.6 ± 2.4 
8.2 ± 2.4 
8.8 :t 2.8 
7.8 ± 2.6 
6.2 _:::2 
0.063 
41.4 ± 10.5 
46 ± 12 
45 ± 11 
0.08 
42 :t 11 
46 ± 12 
45 ::': 11.2 
45.3 ± 12.4 
0.4 
39.8 :::': 10.5 
41.7 ± 12 
42 ± 10 
42 :!:: 12 
41 ± 11.4 
0.98 
45 ± 7.8 
49 ± 10 
48 ± 8.3 
51 ± 5.7 
51.3 _:::': 4.8 
48.2 ± 9.7 
0.4 
•p < 0.01; "P < 0.05; lp < 0.001 <JS compared wtth xgment 1 <:~t post hoc analysis. 
Re!;u\t5 arc given as mc-<:~n ='= SD. 
fibrolipid content when all 227 segments were pooled 
together (P = 0.03 and P = 0.006, respectively). However, 
when distance from the ostium, stratified into 10 mm 
segments, was also inserted into the model, only trends 
towards increase in fibrous and decrease in fibrolipidic 
content in stable vs. unstable patients were observed, 
which did not reach statistical significance. This was 
confirmed in model 2. In contrary, even when analysed 
simultaneously, both plaque location along the vessel 
(P = 0.044 and P = 0.002 for models 1 and 2, respectively) 
and clinical presentation (stable vs. unstable) (P = 0.01 
and P = 0.004 for models 1 and 2, respectively) resulted to 
be independent predictors of lipid content (Fisures 18 
and 28) after adjustment for age, sex, diabetic status, 
type of coronary artel)l analysed, and use of statin. 
Finally, in order to evaluate whether the shift in lipid 
content along the vessel was influenced by clinical presen-
tation, the interplay between these two main determinants 
of lipid content was investigated. but no statistical 
interaction emerged between plaque location and lipid 
core content (P = 0.8 and P = 0.49 for models 1 and 2, 
respectively). 
Distance from the ostium as an independent 
predictor of lipid content 
In Table 4 the variables found to be associated to the rela-
tive lipid content along the vessel are shown. The lipid 
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core in the most distatly located coronal)' segment 
(segment 3) in model 1 was significantly lower compared 
with segment 1, taken as a reference, lndependentty from 
all other identified predictors. When all 227 segments 
were included in the model, distance from the ostium, stra· 
tified into 10 mm segments, resulted to be an independent 
predictor of relative lipid content along vessel watt, 
together with older age, unstable presentation. no use of 
statin, and the presence of diabetes mellitus. In keeping 
with the results obtained at the post hoc analysis, after 
adjusting for clinical presentation, relative lipid content in 
segment 1 did not differ from segment 2 [/3 -0.08 (95%CI: 
-0.28, 0.116)], while it did so starting from segment 3 [/3 
-0.22 (95%CI: f3 0.39. f3 0.05)]. with a progressively lower 
{3-value for segment 4 [/3 -0.34 (95%CI: -0.39. -0.05)] 
and 5 [/3 -0.38 (95%CJ: -0.55, -0.21)]. 
Discussion 
Several lines of research in the last decades have dearly 
pointed out how factors involved in pathogenesis and pro-
gression of atherosclerotic lesions are widespread through-
out the circulatory bed. 3' 11 ' 12•14•2u 4 
As a corolla!)' to this, evidence that a single pharmaco-
logical or mechanical treatment, when applied locally, is 
able to affect progression of coronal)' atherosclerosis is 
weak and not conclusive.25 On the other hand, systemic 
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Table 3 Plaque composition stratified into 10 mm segments 
Coronary segments Plaque composition(%) 
Calcium Fibrous Fibrolipidk lipid core 
Model1;n~51 
1· {0-10mm) 0.69 {0.26-1.98) 67.1 (60-74.4) 16.86 (11.2-24) 8.8 (5.7-18) 
2 (10-20mm) 0.67 (0.3-1.58) 68.3 (60-77) 18.1 (12.7-23.1) 9.6 (4.3-15.1) 
3 {20-30 mm) 0.79 (0.37-1.82) 69 (64-78) 18.7 {13.4-25.3) 6.2 (2.6-12.1)" 
P-value 0.67 OAO 0.84 0.039 
Model 2; n = 43 
1 (0-10 mm) 0.76 (0.28-2.3) 64.7 (59.3-74) 17.7 (13.4-24.5) 8.01 (5.7-18) 
2 (10-20 mm) 0.70 (0.4-1.58) 66.9 {57.9-77} 18.6 (14-24.4) 10 (4.2-16.7) 
(20-30mm) 0.75 (0.37-1.82) 69 (63.9-77.8) 19.8 (14.3-25.4) 6.1 (3.5-12r 
4 (30-40 mm) 0.48 (0.09-1.5) 68.7 (60.8-75) 21.1 (17-28.2) 4.5 (2.4-8)t 
P-value 0.36 0.55 0.63 0.0058 
Model 3; n co.· 20 
1 (0-10mm) 0.77 (0.5-2.6) 71.4 (49.7-76.4) 17.3 (13.4-23.7) 8 {6-25) 
2 (10-20mm) 0.49 (0.18-1.15) n.3 (57.9-79.59) 17.2 (100-22.7) 9.3 (4.1-14.6) 
3 (20-30 mm) 0.87 (0.1-2.4) 69.3 (61.1-79.6) 17.4 (13.1-25.3) 6.8 (4.1-12) 
4 (30-40 mm) 0.9 {0.2-2.6) 67.8 (57.1-77.6) 19.1 (17.4-30) 6.1 (3-8.3) 
5 (40-50mm) 0.65 (0-1) 75.3 (60.6-81.4) 16.4 (14.5-32.6) 3.5 (0.7-5.8)* 
P-value 0.14 0.8 0.71 0.039 
Model4;n=o-11 
1 (0-10 mm) 0.3(0.2-1.6) 74.1 {61-79) 20.8 {16-28) 5. 97 (2.25-12) 
2 (10-20mm) 0.8 {0.4-1) 74 (64-79) 20.5 (18-22) 5.7 (3-13} 
(20-30 mm) 0.54 (0.13-1.6) 75.1 (70-80) 18.5 (16.8-22) 5 (2.8-6.5) 
4 (30-40 mm) 0.63 (0.1-1.8) 75.7 (66-77) 21 {20-27) 3.4 {92.4-5.7) 
5 (40-50mm) 0.38 (0.1-1.3) 73.1 (67-81) 21.2 (15-27) 3.2 (2.7-5.3) 
6 (50-60 mm) 0.37 (0-0.8) 77.3 (66-79) 24 (19-28) 2.7 (1-4.3)" 
P-value 0.65 0.78 0.98 0.036 
• P < 0.05; rp < 0.01 as comp<:~recJ with 5egment 1 at post hoc analysis. 
Re-sults arc- given as mec!i<ln (IQR). 
therapy, such as an intensive lipid-lowering treatment, has 
been convincingly shown to be able to stop atherosclerotic 
disease progression and even induce coronary lesions 
regression in some studies.26- 30 The same paradigm is 
thought to be true for factors involved in atherosclerotic 
lesions vulnerability, albeit probably in a more elusive 
way.zs 
These findings should be combined, however, with the evi-
dence provided by recent epidemiological studies, which 
corroborate the hypothesis according to which sites of 
occlusions are not uniformly distributed throughout the 
coronary tree, rather they show a tendency to cluster in 
partially predictable hot spots located within the proximal 
third of each coronary vessels. 9 ·10 
Thus, the interplay among systemic and local factors able 
to promote progression and vulnerability of atherosclerotic 
coronary lesions should be probably both targeted in the 
attempt to control the chronic and acute consequences of 
coronary atherosclerosis.15 
Among local factors known to affect genesis and pro-
gression of coronary atherosclerotic lesions, shear stress 
(5$) has been extensively investigated. 
Fluid SS, acting on genes 'sensitive' to local haemo· 
dynamic forces, is known to elicit a large number of 
humoural, metabolic, and structural responses in endo· 
thelial cells {EC).31 Low SS on ECs partially explains the 
local arterial susceptibility to atherosclerosis, as low SS 
enhances the oxidation of lipids and their accumulation in 
the intima.31 •32 
Moreover, fluid turbulence in itself is able to directly 
activate platelets, thus possibly playing a pivotal role in 
thrombogenesis as well. 33 
It is tempting to speculate that other local factors 
could play additional roles in modulating progression 
and instabllity of atherosclerotic lesions in coronary 
arteries. Among them, pathological studies have 
suggested that the distribution of thin-cap atheromas, 
which are Lipid rich core plaques known to be at particu-
Larly high-risk for rupture, are not uniformly distributed 
along the coronary vessels in post-mortem examin-
ations. 34 Rather, they cluster in the proximal segments 
of the three main coronary arteries, which is in keeping 
with the longitudinal distribution of both ruptured and 
healed plaques. 34 
This non-uniform distribution of vulnerable plaques in 
humans could partially explain the clustering of occlusive 
culprit lesion in the proximal or middle tract of coronary 
arteries. In this regard, we hypothesized that plaque compo-
sition was also not uniformly distributed in vivo in humans in 
patients with symptomatic coronary disease. Thanks to a 
recently developed technology based on spectral analysis 
of IVUS radiofrequency data (lVUS-VH), 16•17 we prospec-
tively evaluated whether plaque composition is indepen-
dently affected by the distance from coronary ostium in a 
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Figure 1 Relative change in plaque composition with respect to segment 1. Stt~rtlng from :;<,>gmcnt 3, rcl<.~twc lipid content showed a progressive decrease with 
respect to ostial scgmt,>nt (segment 1) taken as a reference. Relative changes in segments 2 and 3 were calcutJtcd using m00el1, where a"> for the relative change 
ln segments 4, 5, and 6, models 2, 3, ond 4 were employed, respectively. All relatwe changes are expressed as mean value and standnrd deviation. 
consecutive series of patients. Our findings support the 
concept that coronary ptaques located in the proximal 
tract (~20 mm) of coronary vessets are relatively richer in 
lipid content with respect to those more distally located, 
independently from clinical presentation. In this regard, 
the magnitude of lipid content appeared to be relatively 
higher in patients presenting with clinical instability but 
no interaction emerged in our model between clinical pres· 
entation and lipid content, suggesting that the relative 
change in plaque composition along the vessel is a well-
preserved phenotype in both groups of patients. Moreover, 
distance from the coronary ostium resulted to be an inde-
pendent predictor of relative lipid content along the 
vessel wall in our regression model, together with age, 
unstable presentation, presence of diabetes mellitus, and 
no use of statin. 
Our current findings should be regarded as an attempt to 
extend the pathophysiological knowledge on plaque vulner-
ability, mainly because of the well-known linkage between 
plaque composition and risk of plaque rupture or 
erosion.34· 3& Thus, this might contribute to explain the 
higher likelihood for plaque erosion or rupture to occur 
proximally in the coronary tree. Moreover. the finding 
that coronary plaques show a relatively higher lipid 
content if proximally located along the longitudinal axis 
of the vessel with respect to those more distally Located 
mfght elicit new methodological issues in future inves-
tigations. In particular, hypothesizing that plaque 
progression/regression studies accomplished through 
aggressive lipid-Lowering regimen would mainly affect the 
Lipid content in the plaque, it seems reasonable to 
believe that the relative effect of the tested medication 
observed at lVUS investigation in terms of overall plaque 
CSA, could differ in relation to the localization of ROI 
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with respect to the coronary ostium. This could bear 
special hazard particularly in those studies having Limited 
R0llength.37 
An interesting finding of our study was that the percen-
tage of stenosis did not differ in relation to the distance 
from the ostium, whereas plaque area was progressively 
smaller moving form proximal to distal segments. This 
might be explained by the interplay between the physio-
logical proximal-distal tapering of the coronary vessel 
and the higher propensity of the proximal segments to 
undergo positive remodelling with respect to those 
located more distally. This seems to be in keeping with 
our recent findings that positive remodelling is indeed 
more pronounced in lipid-rich coronary segments.38 
Limitations of the study 
As exploratory-pilot investigation, our current findings 
should be regarded as provisional. ln particular, to assess 
relatively minor changes in plaque composition along longi· 
tudinal vessel axis, such as that observed for fibrous tissue, 
or for highly dispersed data such as for relative calcium 
content, a bigger, properly powered, sample size is clearly 
needed. Similarly, the observed insignificant trends for 
fibrous tissue to be increased and fibrotipidic content to be 
decreased in stable vs. unstable patients may reflect a 
type- I! error. Our results mainly apply to the first 40 mm of 
the three main coronary arteries, whereas the Longitudinal 
pattern of shift in coronary plaque composition in coronary 
segments more distally located or in left main coronary 
artery should be evaluated in studies specifically designed 
for such an aim. ln particular, in keeping with our primary 
endpoint, the only comparison for which this study was 
properly powered for is the one between the first and the 
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Figure 2 Per-segment distribution of relative lipid content in the study 
popul<J.tfon. Per-S<'gment distribution of relative lipid contents both in the 
whole popul<J.tion and stable vs. unst.:tble patients m modell (A) and 2 (8). 
BMs indicate meaian values In the whole population. As shown in Table 3. 
rel<.itive lipid content significantly dC"Crea:;ed In the whole population in 
segment 3 in model 1 OJnd in segments 3 and 4 In model 2 With respC'ct to 
segment 1 at post hac anOJlysfs. 
third segment in model 1. All other analyses, including the 
tests for four models and all post hoc comparisons should 
be regarded as exploratory. Despite careful examination of 
all angiograms, we cannot completely rule out the 
possibility that patients with a higher number of IVUS inter-
rogated 10 mm segments had a more favourable coronary 
anatomy as compared with those in whom a tong pull-back 
could not been obtained. 
Relevant to this point, it is the fact that: (i) plaque com-
position in the first three coronary segments did not differ in 
patients with 30 mm pull back length as compared with 
those in whom a longer IVUS pull back was obtained; and 
(ii) the change in plaque composition along the study 
vessel was remarkably consistent in all the four models 
analysed. 
We failed to find sex-related differences in the proximal-
distal pattern of plaque composition. However, the great 
majority (88%) of patients enrolled were males, which 
Table 4 Predictors of plaque lipid content at uni- and multi-
variate analysis in model 1 
Variables 
Univariate analysis 
Age (years) 
Sex (M vs. F) 
Smoking status 
Previous history of 
Hypertension 
CVD in the family 
Hypercholesterolaemia 
Diabetes mellitus 
ACS 
Coronary 
revascularization 
Coronary vessel'' 
ACS at presentation 
LDL (mg/dL) 
HDL (mg/dL) 
Triglyccrides (mg/dl} 
Use of statin 
Distance from ostiumb 
Multivariable analysisc 
Distance from ostiumb 
Age (years) 
ACS at presentation 
Use of statio 
Diabetes mellitus 
Coronary 
revascularization 
HDL (mg/dL) 
Beta-values (95% Cl} P-values 
-0.12 
0.029 
0.022 
0.048 
-0.038 
0.08 
0.14 
0,044 
-0.15 
0.038 
0.25 
0.09 
-0.12 
0,04 
-0.25 
-0.32 
-0.28 
-0.26 
0.16 
-0.18 
0.21 
-0.07 
-0.02 
-0.25, 0.008 
-0.101,0.16 
-0.108,0.15 
-0.08, 0.16 
-0.16, 0.082 
-0.032, 0.197 
0.023, 0.257 
-0.086,0.174 
-0.2, -0.028 
0.069 
0.66 
0.7 
0.4S 
0.56 
0.21 
0.041 
0.50 
0.02 
-1.93, 2.008 0.5 
0.11, 0.39 0.0032 
-0.04. 0.22 0.42 
-0.25, 0.01 0.067 
-0.09, 0.17 0.78 
-0.37, -0.12 0.0001 
-0.45, -0.30 <0.0001 
-0.15, -41 
-0.12, -40 
0.03, 0.29 
-0.36, 0.004 
0.07' 0.34 
-0.02, 0.12 
-0.05, 0.21 
<0.0001 
0.0004 
0.005 
0.057 
0.003 
0.46 
0,84 
CVD, cardiovascular disease·. LDL. low-den~Jty lipoprotein; HDL, high-
density lipoprotein. 
0AnalysC'd as left anterior descending vs. circumflex vs. right coronary 
artery 
bAnalysed as segment 1 taken as a reference vs. segment 3. 
0Adjustea R2 ~ 0.36 for the model. 
Figure 3 IVUS-VH C5A along a coronary v=cl. IVUS-VH cro:;s·sectiona.l areOJs 
in a representative patient shoWing the change In pl<.ique composition 
(C<!lcium: white; fibrous: green; fibrolipidic: greenish-yellow; and lipid 
core: red) along the longitudinal ax1s of the vessel. U/i, left main coronary 
artery; CFX, drcumflex artery: lAD, left anterior descending artery. The dis-
tance between the cross--:;oxtlonal area OJnd the ostium of the ve5sel is 
reportC'd in millimetres (mm). 
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calls for future studies with more balanced sex-distribution 
to properly address this gender issue. 
Finally, it should not undergo unnoticed that the 
proportion of lipid core content predicted by our multi-
variable regression model, despite highly significant, was 
far from being optimaL This means that future investi-
gations should probably aim to increase the capability to 
predict relative lipid content in coronary plaques taking 
a broader set of possible independent predictors into 
account. 
Conclusion 
Our study provides proof of concept for a non-uniform 
longitudinal distribution of plaque composition mainly in 
terms of Lipid core content along the main coronary arteries 
in vivo in humans. The clinical and pathophysiological 
meaning of this observation and whether it could help 
explaining the non-uniform distribution of vulnerable 
plaques along the coronary vessel remains unclear. Future 
studies are needed to extend and possibly confirm our 
current findings. 
Conflict of interest: none declared. 
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Plaque Composition and its Relationship With 
Acknowledged Shear Stress Patterns in Coronary Arteries 
To the Editor: Sevenl. studies in coronary and peripheral arteries 
h::1ve demonstrated that atherosclerosis has a tendency to arise 
more frequently in low-oscillatory shear stress (LOSS) regions 
such as in inner curvature of nonbranching segments and opposite 
to the flow divider (FD) at bifurcations (1-3). In p:rrticular, 
::1therosclerotic disease has certain predilection for the outer wall of 
the left m:Un coronary artery bifurcation, sparing the FD (2). 
Intravascular ultrasound (lVUS) has been used to describe the 
CA'tent, distribution, and profile of plaques in the proximal left 
anterior descending coronary artery (LAD) (2). :Jevertheless, in 
vivo dat::l regarding tissue composition of this region remain 
unknown. Furthermore, to date, no study has e;.,_-pl.ored the char-
acteristics of plaques located in the proximal LAD compared to the 
left main coronary artery (LMCA). In the present study, we sought 
to ex-plore the morphologic and compositional characteristics of 
plaque located at an acknowledged LOSS area (outer wall of the 
ostial LAD [OLAD]) and compare them to the chancteristics of 
plaque located at an :weragc shear mess region (distal LMCA 
[DU1CA]). 
This prospective investigators-driven study included patients 
where the LAD was interrogated before :my intervention using 
IVUS radiofrequencydata (RFD) analysis (IVUS-'VH: Volcano 
Therapeutics, Rancho Cordova, California). The IVUS-'VH 
uses spectral analysis of IVUS RFD to construct tissue maps 
that were correlated with a specific spectrum of the RFD and 
assigned color codes (Fig. 1) (4). The IVUS-'VH W::lS performed 
with 30-MHz (Ultra cross; Boston Scientific, Santa Clara, 
California) and 20-MHz (Eagle Eye; Volcano Therapeutics) 
catherers, and contour detection was determined using previ-
ously reported methodology (5). Informed consent was obtained 
from all patients. Plaque eccentricity was defined ::lS the ratio of 
ma..-cimal to minimal plaque thickness (1). Plaque burden was 
defined as ([EEMarc~ - lumen.._,.,.J!EEM.._,.,j X 100. The 
carina of the bifurcation was identified as the frame immediately 
distal to the t:Lke-o.ff of the circumftc.-.:. 
The ma.-cimn.l plaque thickness (MPT) was calculated at this 
level and spatially located according to ::1 circumference ranging 
from 0" to 360", being the inner and opposite part of the carina at 
0" and 180", respectively. Lesions were therefore prospectively 
divided into two groups, according to their localization in the outer 
(from 91" to 271 ") or inner (from 270" to 90") hemisphere of the 
carina. 
Two regions were prospectively identified and their morphology 
and composition compared. The OLAD was defined as the carina 
and the immediate 3-mm distal segment, because the flow in this 
area is still influenced by the bifurcation (6). Simihrly, the 
DLMCA was identified as the 3-mm segment immediately 
Figure 1. Intravascular ultrJ.Sound cross-section images from the =ina of the left anterior descending coronary artery and of the left ma1n coronary a..."tery. 
The left side shows the reconstnlcted grays<.:alc, and the right side shows the color-<.:odcd data (green =fibrous; ycllow-gn:en = fibrolipidi.<.:; .:ed = necrotic 
core; white = calcium) provided by the IVUS-VI-I unit (Vo1Cll10 Therapeutics, Rancho Cordova. C:ilifomU). LCx =left circumflex artery; .:.YIPT = 
ma:cimal pbque thickness. 
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Table 1. Volumetrical and Compositional Comparative Results 
Between the Ostial Left Anterior Descending Coronary Artery 
(OLA.D) and the Distal Left Main Coronary Artery (DLMCA) 
OLAD DLMCA p Value 
Plnque burden (%) 45.5::!: 10.2 36.4::!: 10.8 <0.0001 
Pb.que eccentricity 14.5 ± 11.6 10.4 = 7.6 0.05 
Max. plaque thickness {mm) 1.24 ::':: 0.4 1.04::!: 0.3 0.002 
-='iecrotic core (%) 12.4 ± 9.2 7.9:!: 8.6 <0.0001 
Calcium(%) 4.1:!: 5.1 1.3 ± 2.0 <0.0001 
Fibrou~ (%) 64.5::!: 13.6 64.9 :!: 13.3 0.82 
Fibrolipidic (%) 18.4 ± 11.8 24.9::!: 12.8 0.005 
Values urc presented"" mean :o: SD. Plaque ecccntricityw:J.-; defined us the mtio of 
ma:illmJ to minimal p)llque thickneo,;. Plaque burden wru; defined""' ([£EM.....,, -
lumen,,..]/£EM""'J X 100. 
proximal to the bifurcation. Compositional and geometrical data 
were expres..~ed :J.S mean percentages. 
Discrete variables are presented as counts and percentages. 
Continuous variables are presented as mean ::!:: SD. Differences in 
means among groups were analyLCd by two-sample t test. A p clue 
of <0.05 (two-sided) was considered to indicate st:J.tistical signif-
icance. 
Forty-four patients were fin:illy included in the analysis. The 
clinical presentation was stable angina in 23 patients (523%), 
unstable angina in 10 patients (22.7%) and acute myocardial 
infarction in 11 patients (5%); the mean age of the patients was 
53.3 = 11.5 years, and 33 patients (75%) were male. Geometric 
and compositional comparative results between the OLAD and 
the DLMCA arc depicted in Table 1. Plaque burden was larger in 
the OLAD than in theDLMCA (45.5 ± 10.2%vs. 36.4 ± 10.3%; 
p < 0.0001). OLAD plaques presented more calcified (4.13 = 
5.1% vs. 1.23 ::: 2.0%; p < 0.0001) and necrotic (12.36 ::: 9.2% vs. 
7.90 = 3.6%, p < 0.0001) core content. 
The MPT was located in the outer hemisphere of the carina in 
77.3% (n = 34) of the cases and the mean angle was 170.7::::: 60.6". 
Only one ose presented the MPT at 0 degrees. Necrotic core 
content was hrger in outer than in inner lesions (14.4::: 10.0% vs. 
6.3 ::: 6.9%; p = 0.02). 
The current investigation extends earlier findings on atheroma 
distribution in the LAD by comparing in vivo plaque burden and 
composition in acknowledged areas oflow and average shear stress. 
It h:J.S been previously established that an inverse relationship exists 
between LOSS and thickness of the vessel wall (3). The patho-
physiology of such phenomena can briefly be explained by the fact 
that LOSS induces a loss of the physiologic :flow-oriented align-
ment of the endothelial cells, thus causing an enhancement of the 
e.\:pression of adhesion molecules and a weakening of cell junc-
tions, ultimately leading to an incre:J.Se in permeability to lipids and 
macrophages (3.7-9). The results of the present study are in line 
with histopathologic data, showing higher concentrations of ne-
crotic core and czlicium in an acknowledged area subject to LOSS. 
Such difference may be driven by the lipid leakage present in these 
areas (3). The high lipid load in addition to the eccentric 
characteristics of the atheroma would potentially render these 
plaques more susceptible to rupture (10). Conversely, the more 
stable phenotype observed in DLMCA lesions supports the low 
incidence of atherothrombotic events at this level (11). Finally, 
these results may provide another potential explnn.ation for the 
higher risk of restenosis after percutaneous coronary intervention 
of bifurcation lesions. 
130 
In summary, we found that OLJ\D atherosclerotic plaques 
present larger plaque burden, eccentricity, and MPT than 
DLMCA plaques. In addition, a larger calcified and necrotic core 
content was found distal to the circum:Be.x take-off. Lesions were 
predominantly located in the outer wall of the carina, and such 
location was associated with larger necrotic core content. 
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ABSTRACT 
Objective: We assessed compositional characteristics of atherosclerotic plaque in 
coronary artery bifurcations with intravascular ultrasound radio frequency data 
analysis. 
Background: Coronary artery bifurcations are prone to develop atherosclerotic 
plaque accumulation. 
Methods: As global virtual histology registry (N=990), we analyzed the geometri-
cal and compositional characteristics of plaque at the 3 segments at the sites of 
the major bifurcations, 5 mm proximal and distal segments to the bifurcation at 
different bifurcation sites. (N=258, lefr main (LM)-lefr anterior descending artery 
(LAD)=41, LM-left circumflex artery (LCX)=2, LAD-diagonal= 128, LCX-obruse 
marginal artery (OM)=34, right coronary artery (RCA)-acute marginal artery 
(AM)=53). 
Results: The percent (%) necrotic core including media in just and distal segments 
ofLM-LAD bifurcations was significantly greater than proximal segments (6.75 ± 
5.07%, 7.36 ± 6.01 o/o vs. 4.89 ± 4.78%, all p<0.05). In contrast, the% necrotic 
core in proximal segments of non-LM bifurcations was significantly greater than 
just and distal segments of bifurcations (8.08 ± 6.21% vs. 6.47 ± 5.11 %, 6.28 
± 5.05%, all p<0.001). The o/o necrotic core in proximal and distal segments of 
LM-LAD bifurcations were significantly correlated with plaque+media (P+M) 
burden (r=0.45, p=0.003, r=0.42, p=0.006, respectively). The% necrotic core in 
each segment of non-LM bifurcations showed a significant positive correlation 
with P+M burden and negative correlation with lumen cross sectional area (CSA) 
(0.51:5r$0.64, all p<0.001 and -0.35$r$-0.31, all p<0.001, respectively). 
Conclusions: The current study demonstrates that the bifurcation sites of LM-
LAD had greater necrotic core at just and distal segments of the bifurcation, while 
non-LM showed greater necrotic core in proximal segment of bifurcation. The 
results may suggest a heterogeneous distribution of the atherosclerosis plaques in 
bifurcation lesions and may support a strategy of an imaging guided therapeutic 
for complex coronary plaques such as bifurcation lesions. 
Key words: atherosclerosis; bifurcation; intracoronary ultrasound, virtual histol-
ogy 
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CONDENSED ABSTRACT 
We assessed geometrical and compositional characteristics of major coronary 
bifurcations with intravascular ultrasound radiofrequency data analysis. The % 
necrotic core including media at just and distal segments of left main-left ante-
rior descending bifurcations were significantly greater than proximal segments, 
however, the o/o necrotic core including media in proximal segments of non-left 
main bifurcations were significantly greater than at just and distal segments of 
bifurcations. These results might support the strategy of imaging guided therapy 
for coronary artery disease in humans. 
ABBREVIATIONS 
IVUS, intravascular ultrasound 
LM, left main coronary artery 
LAD, left anterior descending coronary artery 
LCX, left circumflex coronary artery 
RCA, right coronary artery 
OM, obtuse marginal coronary artery 
AM, acute marginal coronary artery 
P+M, plaque+ media 
RFD, radiofrequency data 
VH, virtual histology, spectral analysis plaque characterization methodology 
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INTRODUCTION 
Atherosclerotic plaques of the coronary artery are prone to develop at specific 
locations such as bifurcation and ostial locations [1-2]. Percutaneous coronary 
intervention of bifurcation lesions still remain a challenging lesion subset [3]. 
The differential lesion characteristics, different tissue composition and adaptive 
arterial remodeling at bifurcation sites may be derived from different geometric 
variation and additional factors such as shear stress, and vessel Structure [4-6]. 
The abiliry to visualize and quantifY the different components of atherosclerosis 
provides important information not only on the mechanism of coronary artery 
disease, but also on potential future therapeutic interventions to alter the disease 
process and optimize interventional outcome. A new spectral analysis of the intra-
vascular ultrasound (IVUS) radiofrequency data (RFD) may be a useful tool [7,8] 
because it allows detailed assessment of plaque composition, witb a high predic-
tive accuracy of 93.1% to 96.7% in fibrous tissue, fibro-fatty, dense calcium, and 
necrotic core regions with sensitivities and specificities ranging from 72o/o to 99°/o 
[9]. In addition, rcecent studies demonstrated that in-vivo tissue characteristics of 
patients with coronary artery disease can be available and it is useful imaging tool 
in understanding the pathophysiology of the disease process [10-12]. 
Until now, the compositional characteristics at the bifurcation sites and 
proximal and distal segments of major bifurcation sites are not well investigated 
and not evaluated according to their coronary artery locations. Thus, the current 
study was designed to evaluate the geometrical and compositional characteristics 
of atherosclerotic lesions at the bifurcation sites among proximal, at the site and 
distal segments of bifurcations and their differential characteristics according to 
their anatomical locations. 
METHODS 
Study Subjects 
To evaluate the compositional characteristics of atherosclerotic plaque in the 
coronary atherosclerosis, subjects who underwent IVUS-RFD analysis, virtual 
histology (VH) were prospectively enrolled to multicenter, international, global 
VH registry (N=990). To evaluate tbe geometrical and compositional character-
istics of atherosclerotic plaque in coronary artery bifurcations, we analyzed tbe 
IVUS-RFD of major bifurcation sites (tbe diameter of side branch more tban 
2mm by IVUS) from this registry. The exclusion criteria of the present study 
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included the presence of intervening other major side branch and previous history 
of percutaneous coronary intervention within 10 mm of index bifurcation sires. 
Intravascular Ultrasound Virtual Histology Examination 
The methods of the IVUS-RFD analysis were described previously [8-13]. The 
IVUS-RFD analysis was performed with a dedicated IVUS-VH console (Volcano 
Therapeutics, Rancho Cordova, California) during the routine coronary angiogra-
phy afi:er intracoronary administration of 1 00 to 200 p.g nitroglycerin. A 20-MHz, 
2.9F monorail, electronic Eagle Eye Gold IVUS catheter (Volcano Therapeutics, 
Rancho Cordova, California) was advanced into the distal to the index sires, and 
automatic pullback at 0.5 mm/s was done to an proximal to the index sites. The 
IVUS-RFD image was recorded on a DVD-ROM and sent to the imaging core 
lab for offline analysis later. 
Spectral Analysis of Intravascular Ultrasound Radiofrequency Data 
These offline analyses were done with personal computer (PC) VH program soft-
ware (Volcano Therapeutics, Rancho Cordova, California) by an examiner who 
was unaware of the clinical characteristics of the subjects. For both the lumen and 
the media-adventitia interface, semiautomatic contour detection was done for all 
the frames of the whole examined coronary segments. Then, the borders were 
manually corrected in all the frames [1 0-12]. For each frame, compositional tissue 
characteristics were expressed in colors, as previously described (green for fibrous 
tissue, green-yellow for fibro-fatty, white for dense calcium, and red for necrotic 
core area) [8]. We analyzed geometrical and compositional characteristics of the 
5mm-proximal, just bifurcation and 5mm-distal segments at bifurcation sires, the 
number of frames correspond to their length were analyzed (Fig. 1.). 
To evaluate the reference vessel we examined the single frame with the largest 
lumen and smallest plaque+ media (P+M) burden % within 1 Omm proximal and 
distal to just bifurcation segments. Mean vessel cross sectional area (CSA), lumen 
CSA, P+M CSA, P+M burden%, remodeling index were calculated. P+M CSA 
was calculated as (vessel CSA - lumen CSA). o/o P+M burden was calculated as: 
(P+M CSA/vessel CSA) x 100. Proximal and distal remodeling index were calcu-
lated as (vessel CSA with most P+M burden %/average vessel CSA of proximal and 
distal reference vessel). In addition, compositional parameters such as mean dense 
calcium CSA (mm2) and o/o (including media), fibrous tissue CSA (mm2) and o/o, 
fibro-fatty CSA (mm2) and%, necrotic core CSA (mm2) and o/o were calculated. 
The definition of bifurcation lesion was P+M burden % on the frame which had 
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Fig. 1. The schematic definition of proximal, just bifurcation and distal segments of bifurcations 
(upper panel). Gray IVL~S (middle panel) and VH-IVUS (lower panel) of each frame were analyzed. 
The proximal segment and distal segment of the bifurcation sites were analyzed in the 5 mm 
proximal and distal to bifurcation sites. The just bifurcation segment were analyzed in each segment 
length. The proximal and distal reference sites were analyzed in the frame which showed the least 
P+M% within 10 mm of the bifurcation site. 
the largest P+M burden o/o had more than 75% of the vessel CSA. The types of 
bifurcation lesions were defined as proximal or distal type of bifurcation lesion if 
bifurcation lesion existed in the proximal or distal segments of bifurcations. 
Statistical Analysis 
All analyses were done using SPSS (version 12.0; SPSS Inc, Chicago, Illinois). 
Discrete variables are presented as counts and percentages. Continuous variables 
were summarized as mean ± SD. Pearson's chi-square or Fisher exact test, Student 
t test, and Wilcoxon rank-sum tests were performed, as indicated. The one-way re-
peated measures AN OVA was used to compare the geometrical and compositional 
characteristics of plaque among proximal, just bifurcation and distal segments of 
bifurcation sites. Mauchly's test of sphericity was done. If the sphericity assump-
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tion was not met, sphericity assumption was corrected by Greenhouse-Geisser 
method. Post-hoc tests were performed by multiple comparisons for the means 
of all paired combinations of the three repeated measures condition, which were 
adjusted using Bonferroni method. The Spearman's correlation coefficient was 
used to assess associations between measured parameters. Statistical significance 
was accepted asp less than 0.05. 
RESULTS 
Baseline Characteristics of Subjects 
239 subjects, 258 major bifurcation sites (lefr main (LM) and lefr anterior de-
scending artery (LAD)~41, LM and lefr circumflex artery (LCX)~2, LAD and 
diagonal artery~I28, LCX and obtuse marginal artery (OM)~34, right coronary 
artery (RCA) and acure marginal artery (AM)~53) which meet the inclusion and 
exclusion criteria of rhis srudy from global VH registry were analyzed. 
Table 1. Baseline Characteristics of the Study Population 
Variables 
Age, yrs 
Male,% 
Diabetes,% 
Hypertension,% 
Smoking 
Current 
Ex 
Noo 
Hypercholesteronemia 
Clinical Presentation 
Stable angina 
Acute coronary syndrome 
Bifurcation site 
LMto LAO 
LM to LCX 
LAD and Diagonal 
LCXand OM 
RCA and AM 
Bifurcation Lesion 
(P+M burden % > 75} 
Data are expressed as number(%). 
N=239 
61.1±11.3 
184 (77.0) 
49 (205%} 
144(603%) 
72 (30.1%} 
55 (23.0%} 
112(%.9%) 
141 (59.0%) 
146 (61.1%} 
93 (38.9%} 
N=258 
41 {15.9%) 
2(0.8%) 
128(49.6%) 
34(13.2%) 
53 (20.5%) 
37(143%) 
LM: left main coronary artery, LAD: left anterior descending artery, LCX: left circumflex artery, 
OM: obtuse marginal artery, 
AM: acute marginal artery, P+M: plaque+media 
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The baseline characteristics of the study subjects are shown in table 1. The 
mean age of study subjects was 60.8 ± 11.0 and male subjects were 75.7%. 
The study subjects were presented as stable angina (61.2%) and acute coronary 
syndrome (38.8%). 
The Baseline Characterization of left main bifurcations and non-left main 
bifurcations 
In Table 2 is shown the baseline characteristics of subjects with LM-lAD bifur-
cations (N~41) and non-LM bifurcations (N~204). The subjects in LM-lAD 
bifurcation sites had a tendency to have diabetes (p~O.OS) and significantly high 
Table. 2. The Baseline Characteristics of Subjects Between Left Main and Non-Left Main 
Bifurcation Sites 
Variables Subjects Subjects 
(LM-LAD Bifurcation, N=41) (Non-LM Bifurcation, N=204) 
Age, yrs 62.7±12.1 60.8± 11.0 
Male,% 34 (82.9) 154 (75.5} 
Diabetes,% 13 (31.7) 39 (19.1) 
Hypertension,% 28 (68.3) 121 (59.3) 
Smoking,% 
Non 19 (46.3) 95 {46.6) 
Ex 13 (31.7) 44 (21.5) 
Current 9(22.0) 65 (31.9) 
Clinical Presentation 
Stable angina 27 (65.9) 124 (60.8) 
Acute coronary syndrome 14(34.1) 80 (391) 
Total Cholesterol (mg/dL) 1721±57.4 183.7 ±45.0 
Triglyceride (mg/dl) 87.0±79.6 93.0 ±90.6 
HOL-Cholesterol (mg/dl) 44.9±172 47.9± 15.0 
LOL-Cholesterol {mg/dl) 99.4±42.1 1093 ±37.7 
Medication 
Aspirin 35 (85.4) 181 (88.7) 
Beta blocker 31 (75.6) 118(57.8) 
RAS blockade 14(34.1) 89 (44.3) 
Calcium channel antagonist 3{73) 39 (19.1) 
Statin 27 (65.9) 136 l66.n 
Bifurcation Lesion 4(9.8) 35 (163) 
(P+M burden%> 75%) 
Bifurcation Lesion type 
Proximal type 1 (2.4) 12 (5.6) 
Distal type 3(73) 9(42) 
Data are expressed as number (o/o) or means± SD. 
RA.S: rennin anigiotensin aldosteron system, P+M: plaque+ media 
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proportion of taking beta-blockers (p=0.03). There were no significant differences 
in the proportion of bifurcation lesion and their types between two groups. 
The Geometrical and Compositional Characteristics of LM-LAD and non-LM 
Bifurcation Sites 
Table 3 and 4 showed differential geometrical and compositional characteristics 
among proximal, at the bifurcation and distal segments ofLM-LAD and non-LM 
bifurcation sites. As expected, in LM-LAD bifurcations, the vessel CSA, lumen 
CSA, P+M CSA and o/o P+M burden of proximal were greater that those of distal 
bifurcation segment (all p<0.05). The o/o fibro-fatty of proximal and just bifurca-
tion segment were significantly greater that that of distal segment in LM-LAD 
bifurcation sites (13.81 ± 8.66o/o, 14.60 ± 7.87o/o vs. 9.94 ± 6.83o/o, all p<0.05). 
Of interest, o/o necrotic core and dense calcium of at the bifurcation site and distal 
segments were greater than that of proximal bifurcation segment in LM-LAD 
bifurcation sites (6.75 ± 5.09o/o, 7.36 ± 6.01 o/o vs. 4.89 ± 4.78o/o and 3.31 ± 2.9o/o, 
3.73 ± 3.28o/o vs. 1.89 ± 2.1o/o, all p<0.05, Table 3, Fig. 2.). 
Table 3. Geometrical and Compositional Characteristics in Left Main-LAD Bifurcation Sites 
(N=41) 
Variables Proximal (P) Just Bifurcation (B) Distal (D) AN OVA 
Geometrical parameters P/B P/D B/D 
Vessel CSA {mm2) 26.83 ± 5.44 25.65 ±6.44 18.51 ±430 <0.001 NS <0.001 <0.001 
Lumen CSA {mm2) 16.05 ±4.55 1537 ±5.73 9.85 ± 3.03 <0.001 NS <0.001 <0.001 
P+M CSA (mm2) 10.78±3.64 10.28± 3.00 8.66±3.20 <0.001 NS <0.001 <0.001 
Plaque CSA (mm2) 5.98±3.66 6.14±2.86 4.75 ±3.07 0.001 NS 0.019 <0.001 
P+M Burden (%) 40.40 ± 11.76 41.15±11.01 46.55 ± 12.08 <0.001 NS 0.002 0.001 
Remodeling Index 1.19±0.18 0.85±0.14 <0.001 
Compositional parameters P/B P/D B/D 
DCCSA (mm2) 0.22±0.26 037::::036 036±036 0.007 0.004 0.076 NS 
DC{%) 1.89±2.10 331 ± 2:07 3.73 ± 3.28 <0.001 <0.001 0.002 NS 
FTCSA (mm2) 3.52±2.18 3.43 ± 1.63 2.71±1.78 0.006 NS 0.023 0.003 
FT(%) 29.88± 10.66 31.81 ±8.87 28.58± 10.91 NS 
FFCSA{mm2} 0.89 ±0.80 1,07±0.81 0.64±0.58 <0.001 0.055 0.003 <0.001 
FF(%) 13.81 ±8.66 14.60±7.87 9,94:t6.83 <0.001 NS 0.004 <0.001 
NCCSA(mm2) 0.61 ±0.77 0.76±0.70 0.70±0.64 NS 
NC(%} 4.89 ±4.78 6.75 + 5.09 7.36 ±6.01 0.006 0.001 0.026 NS 
Data are expressed as means± SD. The proportions of compositional characteristics were derived 
from plaque area including media. 
P/B=Proximal segmentvs Bifurcation segment, P/D=<Proximal segment vs distal segment, BID= 
Bifurcation segment vs distal segment, CSA=<Cross sectional area, P+M=<Plaque+media,DC"'Dense 
calcium, FT "'Fibrous tissue, FF=Fibrous-fatty, NC=Necrotic core, NS=not significant. 
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Fig. 2. The comparison of necrotic core o/o among the proximal, just bifurcation and distal segments 
ofLM-LAD, non-LM (LAD-diagonal, LCX-OM, RCA-A..\1) bifurcations. Values are mean± SEM. 
'P<0.05. +P<O.Ol. tP<O.OOI 
In non-LM bifurcation sites (Table 4.), vessel CSA of the proximal and at 
the bifurcation segments were significantly greater than that of distal segments 
(all P<0.001). The o/o P+M burden of proximal segment was significantly greater 
than rhose of just at rhe bifurcation and distal bifurcation segments (all p<0.05). 
Remodeling index of proximal segment in non-LM bifurcations was significantly 
greater than that of distal segment (p<0.001). The o/o necrotic core and dense 
calcium of proximal segment were significantly greater than those of just bifurca-
tion and distal bifurcation segments (8.08 ± 6.21 vs. 6.47 ± 5.11, 6.28 ± 5.05 and 
4.57 ± 4.67 vs. 3.38 ± 3.44, 3.55 ± 3.74, all p<0.05, Table 4, Fig. 2.). 
Table 5. showed geometrical and compositional characteristics of each coronary 
artery in non-LM bifurcations. Of interest, o/o necrotic core of proximal segment 
of LAD-diagonal, LCX-OM, RCA-AM bifurcation sites were significantly greater 
than those of at the bifurcation or distal segments of bifurcations (all p<0.05, 
Fig. 2.). 
The Comparative Analysis of Compositional Characteristics Between LM-LAD and 
non-LM Bifurcation Sites 
Table 6 showed rhe comparison of compositional characteristics between LM-
LAD and non-LM bifurcation sites. LM-LAD bifurcation sites had significant 
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Table 4. Geometrical and Compositional Characteristics in Non-Left Main Bifurcation Sites 
CN·215) 
Variables Proximal (P) Just Bifurcation (B) Distal {0) AN OVA 
Geometrical parameters P/B P/D B/D 
Vessel CSA (mm2) 17.82±4.68 17.85±4.63 13.75 ±4.05 <0.001 NS <0,001 <0.001 
Lumen CSA (mm2) 9.12±3.65 9.86±3.72 731 ±2.70 <0.001 <0.001 <0.001 <0.001 
P+M CSA (mm2) 8.71 ±2.89 7.99 ±2.64 6.44±2.42 <0.001 <0.001 <0.001 <0.001 
PtM Burden% 49.41 ± 12.12 4534± 1111 46.80±10.68 <0.001 <0.001 0.009 NS 
Remodeling Index 1.15±0.18 0.90±0.15 <0.001 
Compositional P/B P/D B/D 
parameters 
DCCSA(mm2) 0.42± 0.46 0.30 ±0.34 0.25 ±0.29 <0.001 <0.001 <0.001 NS 
DC(%) 457±4.67 338± 3.44 3.55± 3.74 <0.001 <0.001 0.006 NS 
FTCSA(mm2) 2.91±1.73 2.61 ±1.47 1.89 ± 1.30 <0.001 0.004 <0.001 <0.001 
Ff(%) 31.07±10.20 30.46±9.74 26.25±1094 <0.001 NS <0.001 <0,001 
FFCSA(mm2) 0.91 :t 0.78 1.03±0.85 0.65±0.64 <0.001 0.029 <0.001 <0.001 
FF(%) 9.83 ± 6.93 12.02±7.44 8.22::!: 6.47 <0.001 <0.001 <0.001 <0.001 
NCCSA(mm2) 0.77±0.74 0.57 ±055 0.45±0.45 <0.001 <0.001 <0.001 0.002 
NC(%) 8.08±6.21 6.47:t5.11 6.28±5.05 <0.001 <0.001 <0.001 NS 
Data are expressed as means ± SD. The proportions of compositional characteristics were derived 
from plaque area including media. 
P/B:::Proximal segment vs Bifurcation segment, P/D==Proximal segment vs distal segment, B/D::: 
Bifurcation segment vs distal segment, CSA=Cross sectional area, P+M=Plaque+media,DC=Dense 
calcium, FT =Fibrous tissue, FF=Fibrous-fatty, NC=Necrotic core, NS=not significant. 
lesser 0/o dense calcium and necrotic core compare to non-LM bifurcation sites in 
the proximal bifurcation sites (1.89 ± 2.10% vs. 4.57 ± 4.67% and 4.89 ± 4.78% 
vs. 8.08 ± 6.20%, all p<0.001). The LM-LAD bifurcation sites had significant 
greater% fibro-fatty compare to non-LM bifurcation sites in just bifurcation seg-
ment (14.60 ± 7.87 vs. 12.02 ± 7.44, p=0.045). 
The Correlation Between %Necrotic Core and Geometrical Parameters in LM-LAD 
and non-LM Bifurcation Sites 
The % necrotic core of the proximal and distal segments in LM-LAD bifurcation 
sires significantly correlated with% P+M burden (r=0.45, p=0.003, and r=0.42, 
p=0.006, respectively, Fig. 3a.). There were no significant correlation bervveen 
necrotic core % and lumen CSA in each segment of LM-LAD bifurcations (Fig. 
3b.). The necrotic core o/o of each segment in non-LM bifurcation sites showed 
significant positive correlation with P+M burden o/o (proximal segments; r=0.5 L 
p<O.OOl, just bifurcation segments; r=0.55, p<O.OOl, distal segments; r=0.64, 
p<0.001, Fig. 4a.) and negative correlation with lumen CSA (proximal segments; 
r•-0.35, p<O.OOl, just bifurcation segments; r=-0.35, p<0.001, distal segments; 
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Table 5. Geometrical and Compositional Characteristics in Each Non-Left main Bifurcation 
Variables 
LAD-Diagonal (N=128} 
Geometrical parameters 
Vessel CSA {mm2) 
Lumen CSA {mm2) 
P+M CSA {mm2) 
P+M Burden% 
Remodeling Index 
Compositional parameters 
DCCSA{mm2) 
DC(%) 
FTCSA{mm2) 
FT{%) 
FFCSA{mm2) 
FF(%) 
NCCSA{mm2) 
NC{%) 
LO-OM {N=34) 
Geometrical parameters 
Vessel CSA (mm2) 
Lumen CSA {mm2) 
P+M CSA {mm2) 
P+MBurden% 
Remodeling Index 
Compositional parameters 
DCCSA{mm2) 
DC{%) 
FTCSA (mm2) 
FT{%) 
FFCSA{mm2) 
FF(%) 
NCCSA(mm2) 
NC{%) 
RCA-AM (N=53) 
Geometrical parameters 
Vessel CSA (mm2) 
Lumen CSA (mm2) 
P+M CSA {mm2) 
P+M Burden% 
Remodeling Index 
Compositional parameters 
DCCSA{mm2) 
DC(%) 
FTCSA(mm2) 
FT(%) 
FFCSA(mm2) 
FF(%} 
NCCSA (mm2) 
NC(%) 
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Proximal 
Segment(P} 
17.68±4.64 
8.91 ±3.54 
8.76± 2.99 
50.06 ± 1230 
1.19±0.17 
0.46±0.51 
4.86±4.94 
2.89 ± 1.73 
30.59 ± 10.42 
0.94± 0.82 
10.00±7.57 
0.78 ±0.73 
8.15±6.01 
18.83±450 
10.05 ±3.95 
8.78 ±2.40 
47.68±11.90 
1.12±0.19 
037±034 
4.04± 3.62 
2.98 ± 1.54 
32.01 ±1121 
0.82± 0.55 
9.28±5.55 
0.83 ± 0.83 
855::!: 6.99 
17.53±4.89 
9.01 ±3.70 
8.53 :t 2.97 
4929±11.94 
1.07±0.18 
038±0.43 
4.20±4.61 
2.90±1.84 
31.63 ± 9.05 
0.89 ± 0.80 
9.77±6.17 
0.69± 0.71 
7.60±6.22 
Just Bifurcation Distal Segment {D} AN OVA 
(B) 
17.74::!:457 
9.67 ± 3.59 
8.Q7 ±2.78 
45.89 ± 11.67 
0.36± 0.38 
3.97 ± 3.67 
259 ± 1.49 
29.80 ±9.86 
1.05 ± 0.93 
11.98±7.96 
0.62±0.55 
7.05 ± 5.18 
18.38±4.33 
10.62± 3.98 
7.76± 1.92 
4331 ±10.06 
017±032 
3.24±3.60 
2.50± 1.11 
30.82±9.14 
0.89 ±0.51 
11.19±5.48 
0.54:::0.50 
6.32 ±4.87 
17.77 ± 5.01 
9.82± 3.84 
7.94±2.72 
45.31 ± 10.82 
0.17± 0.20 
2.05 ± 221 
2.72 ± 1.64 
31.82±9.84 
1.07 ± 0.81 
12.66±7.28 
0.46± 0.57 
5.14±4.90 
13.52 ±3.78 
6.99±234 
6.52± 2.47 
47.88± 10.59 
0.91 ±0.16 
030 ± 0.33 
4.09 ±4.02 
1.91 ± 1.26 
26.45 ::'.:: 10.66 
0.62±0.70 
8.22± 6.81 
0.50 = 0.44 
6.98 ±5.20 
13.25 ± 3.40 
7.25 ± 270 
5.99 ± 2.13 
45.60±1244 
0.89±0.16 
0.21 ±0.22 
3.44± 3.84 
1.67 = 1.32 
24.23 ± 1235 
0.51 ± 0.46 
7.40::'.::5.44 
0.40 ±0.38 
6.02±4.99 
14.62±4.91 
8.10±332 
6.52 ±2.50 
44.95±9.49 
0.90 ± 0.13 
0.16±020 
234±2.56 
1.97±1.40 
27.07±10.72 
0.64± 0.58 
8.75 ± 617 
035±0.48 
4.74±4.41 
<0.001 
<0.001 
<0.001 
0.001 
<0.001 
<0.001 
0.055 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
0.029 
<0.001 
<0.001 
<0.001 
NS 
<0.001 
0.021 
NS 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
0.044 
<0.001 
<0.001 
<0.001 
0.002 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
PIB 
NS 
0.004 
0.002 
<0.001 
P/B 
0.023 
0.038 
NS 
NS 
0.001 
0.006 
0.028 
PIB 
NS 
NS 
0.014 
PID BID 
<0.001 <0.001 
<0.001 <0.001 
<0.001 <0.001 
NS 0.085 
PID B/0 
0.001 NS 
<0.001 <0.001 
0.001 <0.001 
<0.001 <0.001 
0.007 <0.001 
<0.001 0.040 
NS NS 
P/0 S/0 
<0.001 <0.001 
<0.001 <0.001 
<0.001 <0.001 
PIS P/0 B/0 
NS 0.067 NS 
NS <0.001 0.002 
NS 0.009 0.006 
NS 0.003 <0.001 
0.025 NS <0.001 
0.007 0.015 NS 
0.007 NS NS 
P/B 
NS 
0.012 
NS 
0.007 
P/B 
<0.001 
<0.001 
NS 
NS 
0.055 
<0.001 
0.001 
<0.001 
P/D BID 
<0.001 <0.001 
0.032 <0.001 
<0.001 <0.001 
0.007 NS 
PID B/0 
0.001 NS 
0.006 NS 
<0.001 <0.001 
0.004 <0.001 
0.003 <0.001 
NS <0.001 
0.001 NS 
0.001 NS 
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Data are expressed as means ± SD. The proponions of compositional characteristics were derived 
from plaque area including media. 
LAD: left anterior descending artery, CSA: cross sectional area, P+M: plaque+ media, P/B=Proximal 
segment vs Bifurcation segment, P /D=Proximal segment vs distal segment, 
BID= Bifurcation segment vs distal segment, DC=Dense calcium, FT =Fibrous tissue. FF=Fibrous-
fatty, NC=Necrotic core, NS=not significant. 
LCX: left circumflex artery, OM : obtuse marginal artery, RCA: right coronary artery, AM: acute 
marginal artery 
NS=nor significant. 
Table 6. The Comparison of Compositional Characteristics Between IM-LAD and Non-LM: 
Bifurcation Sites 
LM-LAD 
Bifurcation 
(N=41) 
Proximal Segment 
DC(%) 1.89±2.10 
Ff(%) 29.88±10.66 
Ff(%) 13.81 ± 8.67 
NC(%) 4.89±4.78 
Just Bifurcation Segment 
DC(%) 3.31 ±2.87 
FT(%) 31.81 ±8.87 
FF(%) 14.60±7.87 
NC(%) 6.75 ±5.09 
Distal Segment 
DC(%) 3.73 ±3.28 
FT(%) 2858± 10.91 
FF(%) 9.94±6.83 
NC(%) 736±6.01 
Non-LM 
Bifurcation 
(N=215) 
4.57±4.67 
31.07±1020 
9.83 ±6.93 
8.08±620 
3.38±3.44 
30.46±9.74 
1202 ± 7.44 
6.47±5.11 
3.55±3.74 
2615:!:: 10.94 
8.22± 6.47 
6.28 ±5.05 
p 
<0.001 
050 
0.008 
<0.001 
0.90 
0.41 
0.045 
0.75 
0.78 
021 
0.12 
0.22 
Data are expressed as means± SD. The proportions of compositional characteristics were derived 
from plaque area including media. 
LM: left main artery, LAD: left anterior descending artery, DC= Dense calcium, FT =Fibrous tissue, 
FF=Fibrous-fatty, NC=Necrotic core 
r=-0.31, p<0.001, Fig. 4b.). There were no significant correlation between % 
necrotic core and the remodeling index in LM -LAD (proximal segment: r=0.05, 
p=NS, distal segment: r=-0.0], p=NS) and non-LM bifurcation sites (proximal 
segment: r=0.14, p=0.06, distal segment: r=0.05, p=NS). 
DISCUSSION 
The current study demonstrates for the first rime the geometrical and composi-
tional characteristics of coronary atherosclerotic plaques at bifurcations sires in 
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Fig. 3b. The correlations between necrotic core o/o and lumen CSA in each segment ofLM-LAD 
bifurcations. 
humans and demonstrated that bifurcation sites ofLM-LAD have greater necrotic 
core at the site and distal segments of the bifurcation compared to proximal seg-
ments. In contrast, bifurcation sites of non-LM coronary arteries showed greater 
necrotic core in proximal segment of bifurcation. Secondly, there were significant 
positive correlations between °/o necrotic core and P+M burden in each segment 
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of coronary bifurcation sires, which might be derived by differential anatomical 
locations and additional factors such as shear stress, vessel structure of bifurcation 
sites. The current study suggests that there is a heterogenous mechanism and 
distribution of atherosclerotic plaques between bifurcation sires. 
It is well known rhar vulnerable plaques and ruptured or prone to ruptured 
plaques are non-uniformly distributed along the coronary arteries [10, 14-17]. 
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However, to our knowledge, there is no previous in vivo data regarding composi-
tional tissue characteristics of atherosclerosis in the coronary bifurcations accord-
ing to their anatomical locations. Thus, the current study may have implications 
on the imaging guided approach for the treatment of coronary artery disease. 
left Main-LAD Bifurcations 
The previous histological and intravascular ultrasound studies of the LM coronary 
artery bifurcation have demonstrated that atherosclerotic plaques are localized 
exclusively on the non-flow dividing walls (opposite to carina) of the left anterior 
descending and left circumflex coronary artery [4,6,18]. Valgimigli et al. [19] re-
cently reported that the amount of necrotic core increases significantly in the first, 
second, and third 6mm segment ofLM-LAD, LM-LCX when compared with the 
LM trunk by IVUS-VH study. In addition, Rodriguez-Granillo et al. [20] recently 
reported that ostial LAD atherosclerotic plaques present larger plaque burden, 
eccentriciry, and plaque thickness than distal LM coronary plaques. In this study, 
a larger calcified and necrotic core content by IVUS-RFD analysis was found 
distal to the LCX take-off in ostial LAD. 
In the current study, the segments at the site of the bifurcation and distal to 
the bifurcations of the LM-LAD has greater% necrotic core and dense calcium 
compared to proximal segment of bifurcations. In addition, % P+M burden of 
distal segment in LM-LAD bifurcations was significantly greater than those of 
proximal and just bifurcation segments in LM-LAD bifurcations. Of interest, 
the necrotic core of proximal and distal segments in LM-LAD bifurcation sites 
correlated significantly with o/o P+M burden. These results indicated that distal 
segments ofLM-LAD bifurcations have structurally larger atheroma burden and 
functionally also greater necrotic core in these segments. Our study extends previ-
ous observations and demonstrates the differential distribution of the component 
of the plaque in LM-LAD bifurcation sites. 
Non-left Main Bifurcations 
Regarding Non-LM bifurcations, Badak et al. [21] reported the results of 
IVUS analysis in the LAD-diagonal and LCX-OM bifurcations. Volumetric 
analysis showed that vessel CSA, lumen CSA and P + M CSA were larger in the 
proximal segment of bifurcations than in the distal segment, where 0/o P+M 
burden was similar between these segments. The data from the current study, 
is consistent with this previous observation study also reports the tissue char-
acterization of these lesion. Moreover, in the current study we reported that 
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the o/o necrotic core and dense calcium in the proximal segment of non-LM 
bifurcations were greater than those of just bifurcation and distal segments. 
In the current study, the degree of necrotic core in each segment of non-LM bi-
furcation sites had significant positive correlation with P+M burden and negative 
correlation with lumen CSA. These observations support the role of the necrotic 
core in the lesion development and its contribution to remodeling process [22]. 
Clinical Implications 
Large body of evidence have demonstrated a significant relationship benveen 
early atheroma development and low or oscillatory shear forces resulting from 
bifurcations of vessel [2, 20, 23-25]. These data suggest that differential anatomi-
cal location, shear forces at the bifurcationsires between LM-LAD and non-LM 
bifurcations might lead to the formation of atheroma at different predilection sites 
among proximal, just bifurcation and distal segments of bifurcations. 
Post mortem data suggests also that plaque composition itself plays a pivotal 
role in determining plaque vulnerability [26]. Our results, which show differential 
geometrical and compositional characteristics benveen LM-LAD bifurcations and 
non-LM bifurcations, suggest a differential likelihood for plaque rupture to occur 
at LM and non-LM bifurcations. 
Bifurcation coronary lesions remain a challenging lesion subset for interven-
tional procedures even during drug eluting stent era [3]. It has been reported 
that the baseline plaque accumulation is related to the long-term outcome of 
interventional procedures [27]. Finn et al. suggested that a tendency for lesions 
with penetration of necrotic core by drug eluting stent struts to be associated with 
late stent thrombosis by their unpublished pathologic data [28]. The importance 
to characterized the plaque components is underscored by recent studies which 
demonstrated that, necrotic core rich lesion assessed by IVUS-RFD analysis was 
an important predictor of the risk of distal embolization after stem deployment 
in patients with myocardial infarction and in patents with elective percutaneous 
intervention [29, 30]. 
In the current study, necrotic core rich segment was observed in coronary 
bifurcations sites, this may suggest at least in part the less favorite outcome of 
intervention for bifurcation lesions as compared to non-bifurcation lesions. Fur-
thermore, our results suggest that more effective treatment strategy of intervention, 
such as imaging guided or more specific drugs will be needed for the treatment of 
coronary bifurcations. 
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In addition, our results suggest that the main therapeutic target in the LM-LAD 
bifurcation should be just bifurcation and distal segment of the bifurcation and in 
the non-LM bifurcation should be the proximal segment of the bifurcation. 
Study Limitations 
Our study has some limitations. We did not evaluate the effects of side branch 
locations in terms of the orientation of side branch toward the myocardial or 
epicardial surface and the obliquity of the side branch take-off. In addition, we 
did not analyze the characteristic of flow divider and non-flow divider sides of 
bifurcation site. 
In conclusions, the current study demonstrates that there is a heterogeneous 
distribution of atherosclerotic plaques and its components between different 
bifurcation sites. The bifurcation sites of LM-LAD had greater necrotic core at 
the bifurcation and distal segments of bifurcation opposite to bifurcation sites of 
non-LM. These results might be derived from differential morphology, anatomical 
locations (possible angle dependency) and additional factors such as shear stress 
and vessel structure (elastic vs. muscular) of bifurcation sites. 
The current study supports the development of an imaging guided interven-
tion for complex coronary artery disease such as bifurcation lesion. 
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Synergistic Effect of Cardiovascular Risk Factors and 
Clinical Presentation on Necrotic Core in Coronary Arteries: 
A Report From the Global Intravascular Radiofrequency 
Data Analysis Registry. 
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ABBREVIATIONS LIST 
ACS- Acute coronary syndrome 
IVUS- Intravascular ultrasound 
NC- Necrotic core 
RFD - Radiofrequency data analysis 
ABSTRACT 
Objectives: We explored whether an individual or a cluster of risk factors affects 
the extent of necrotic core (NC) assessed by IVUS-radiofrequency data (RFD) 
analysis. 
Background: Several systemic diseases contribute to the development of coronary 
artery disease. 
Methods: Volcano Registry was a prospective, multi-center and non-randomized 
study that enrolled 990 patients with coronary artery disease in whom one major 
coronary artery was imaged by IVUS-RFD. For the multivariable analysis, the 
population was divided into 4 classes: young females, young males (both :S62 yrs), 
old females, and old males (>62 yrs). Mean NC area was categorized as 1: top 
quartile (;, 0.62 mm2) or as 0: lower three quartiles. 
Results: Young patients had 0.40±0.36mm2 of NC vs. 0.50±0.46mm2 in old 
patients, p=0.0007. Non-diabetics had 0.43±0.41mm2 ofNC vs. 0.51±0.44mm2 
in diabetics, p=0.02. NC area measured 0.40±0.36mm2 in normotensives vs. 
0.48±0.44mm2 in hypertensives, p=0.02. All significantly-associated variables in 
the bivariate analysis (age, hypertension, diabetes, and prior CABG) were intro-
duced in the logistic regression model; but only age [OR 1.023 (1.009, 1.037), 
p=0.001] and diabetes [OR 1.636 (1.174, 2.279), p=0.004] remained statistically 
significant. In a per-class logistic regression analyses including only diabetes as 
covariate, in young females the OR was 2.1 (95%CI 0.77, 6.0), p=0.14; in young 
males the OR was 1.6 (95%CI 0.90, 2.7), p=O.ll; in old females the OR was 
2.3 (95%CI 1.09, 4.9), p=0.03; and in old males the OR was 1.6 (95%CI 0.96, 
2.7), p=0.07. Further, when only patients with diabetes and hypertension were 
included, in young females the OR was 2.4 (95%CI 0.69, 8.6) p=0.17; in young 
males the OR was 2.0 (95%CI 1.03, 3.8) p=0.041; in old females the OR was 
3.04 (95%CI 1.029.1) p=0.046; and in old males the OR was 2.2 (95%CI 1.1, 
4.2) p=0.025. 
Conclusion: Individually and collectively, age and diabetes mellitus are associated 
with an increase in necrotic core. 
Coronary risk factors and necrotic core 
Key words: Cardiovascular Risk factors, Clinical presentation, Intravascular ultra-
sound, Plaque composition. 
INTRODUCTION 
Several systemic diseases contribute to the development of coronary artery dis-
ease (CAD). For example, in a very large international registry of patients with 
established CAD, 38.3% were diabetics, 80.3% were hypertensive, 77.0% were 
hypercholesterolemic, 45.4% were obese, and 13% were current smokers (1). 
These well-known cardiovascular risk factors not only modifY coronary plaque 
composition (2), but also predispose patients to coronary plaque rupture or acute 
coronary thrombosis (3). Two of the chief modifiers of plaque morphology are age 
and gender (4). 
A postmortem study showed that the necrotic core (NC) size and plaque burden 
are larger in diabetics compared to non-diabetics(2). Furthermore, the simultane-
ous presence of both diabetes mellitus and dyslipidemia was associated with an 
increase in necrotic core size when compared to patients with only diabetes(2). 
The purpose of the current analysis was to assess whether the extent of necrotic 
core in coronary arteries, as measured by intravascular ultrasound-radiofrequency 
data analysis (IVUS-RFD) analysis, is influenced by the presence of one or more 
cardiovascular risk factors in a worldwide registry of patients. 
METHODS 
Patient selection 
The Volcano Global Registry is a prospective, multi-center (42 centers), non-
randomized study of CAD patients admitted for coronary catheterization and 
undergoing analysis by IVUS-RFD; it started enrolment in March 2004, and the 
current analysis includes the first 990 patients enrolled. Patients, irrespective of 
their clinical presentation, older than 18 years old were eligible if at least one of 
their coronary vessels containing an atherosclerotic lesion by visual assessment was 
suitable for IVUS interrogation (absence of extensive calcification and/or severe 
vessel tortuosiry). The selection of the investigated artery was left to the opera-
tor's decision; in the case report form the investigator reported the target lesion 
diameter stenosis by visual assessment and/or quantitative coronary angiography 
(QCA). Acute coronary syndrome (ACS) encompassed unstable angina (UA) 
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according to the Braunwald classification, non-ST-segment elevation myocardial 
infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI). 
All the local ethical committees of the participant centers approved the protocol, 
and informed written consent was obtained from all patients. 
Clinical definitions used in this study 
Diabetes mellitus was defined if the patient had a fasting glucose ;, 1.26 giL, if this 
risk factor was documented in the medical record, or if the patient was receiving 
diet, oral drug, or insulin treatment. 
Hypercholesterolemia was defined if the patient had a total cholesterol more 
than 200 mg/ dl, if this risk factor was documented in the medical record, or if the 
patient was receiving any lipid-lowering treatment such as diet or pharmacologi-
cal. 
Arterial Hypertension was defined if systolic blood pressure was ;, 140 mmHg or 
diastolic blood pressure was ;,90 mmHg, if this risk factor was documented in the 
medical record, or if the patient was receiving antihypertensive treatment. 
IVUS-RFD Acquisition and Analysis 
Image acquisition was performed during diagnostic coronary angiography, pre-
intervention, post-balloon dilation, or post-stenting; however, the treated segment 
and 5mm of adjacent reference was not included in the analysis. 
Details regarding the validation of the technique have been reported(5,6). 
Briefly, IVUS-RFD uses spectral analysis of IVUS radiofrequency data to build 
tissue maps that are correlated with a specific spectrum of the radiofrequency 
signal and assigned colour codes [fibrous (labelled green), fibrofatty (labelled 
greenish-yellow), necrotic core (labelled red) and calcium (labelled white)](5). 
IVUS-RFD data was acquired using continuous catheter pullback (Eagle-Eye™ 
20 MHz Volcano Therapeutics, Rancho Cordova, CA) and a dedicated IVUS-RFD 
console (Volcano Therapeutics, Rancho Cordova, CA). The IVUS-RFD data were 
stored on DVD and sent to the Corelab (Cardiovascular Research Foundation, NY, 
US; Erasmus Medical Center/Cardialysis, Rotterdam, The Netherlands, or Toyo-
hashi Heart Center, Japan) for offline analysis. Data acquisition was ECG-gated 
and recorded during the automated withdrawal of the catheter using a mechanical 
pullback device (TrakBack II or R-1 00 Volcano Therapeutics, Rancho Cordova, 
CA) at a pullback speed of 0.5 mm/s. The IVUS-RFD sampling during pullback 
is gated to the peak R-wave and is therefore dependent on heart rate. For instance, 
during constant heart rate of 60 bpm, samples will be collected every 0.5 mm. 
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NUS images were reconstructed from the RF data by customized software 
(pcVH 2.2, Volcano Therapeutics, Rancho Cordova, CA). Longitudinal and 
cross-sectional views were used to determine the contours. Manual contour 
detection of both the lumen and the media-adventitia interface was performed; 
and the radiofrequency data was normalized using a technique known as "Blind 
Deconvolution"(?), an iterative algorithm that deconvolves the catheter transfer 
function from the backscatter, rhus accounting for catheter-to-catheter variability. 
Geometrical and compositional data were obtained for every slice. Plaque burden 
was calculated as EEM -Lumen /EEM X 100, where EEM refers to the 
area arc:~ area 
external elastic membrane. For rhis study, rhe mean cross-sectional area (CSA) of 
necrotic core of rhe entire vessel pullback per patient was analyzed. 
Statistical analysis 
The distribution of the amount of necrotic core, expressed as the mean area in mm2, 
was right skewed. Accordingly, non-parametric statistics were used ro calculate p 
values for the comparison between groups. Bivariate analysis and multivariable 
logistic regression analyses were performed to identifY predictors of necrotic core. 
To this aim, rhe study population was divided into two: i. patients (n~732) with a 
mean necrotic core area corresponding to the three lower quarriles (NC <0.62mm2) 
of the overall NC disrriburion (coded as 0); and ii. patients (n=250) with a mean 
necrotic area corresponding to the upper quartile of the mean necrotic core area 
(NC ~0.62mm2), coded as L All variables significantly (p <0.1 0) associated with 
mean MC area on bivariate analysis were entered into subsequent models. Next, a 
logistic regression analysis with rhe enter method was performed for all pertinent 
covariates. The only two variables that remained statistically significant were age 
and diabetes. The Hosmer and Lemeshow Goodness-of-Fit rest statistic was 0.14. 
This means thar the model explains rhe variance in rhe dependent variable to a 
significant degree. 
In a second approach the population was divided into four classes according to 
the age (the median age was 62 years; age therefore was stratified into two classes: 
:062 vs >62 years of age) and gender: i. young females (n=90), ii. young males 
(n=406), iii. old females (n=l53), and iv. old males (n~333). Then, for each class a 
logistic regression analysis was performed including diabetes as a covariate because 
diabetes was the only variable thar was statistically significant in rhe previous 
multivariable analysis. Afterwards, for each class a new logistic regression analysis 
was performed including a variable that identified rhe simultaneous presence of 
diabetes and hypertension (coded as 1) or their absence in a patient (coded 0). 
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Results of logistic regression analyses are reported as odds ratios with 95% 
confidence intervals and p values. All analyses were performed with SPSS version 
12 statistical software (SPSS Inc., Chicago, Illinois). 
RESULTS 
This analysis includes the first 990 patients (990 vessels) enrolled in this global 
registry. The baseline characteristics are depicted in table 1. The studied vessel 
was the left anterior descending in 484 (49.3%) cases, the left circumflex in 171 
(17.4%) patients, or the right coronary artery in 289 (29.4%) cases; in 38 (3.8%) 
patients other vessels were imaged, but 8 patients with imaging of a saphenous 
vein graft were excluded from the analysis. Image acquisition was performed dur-
ing 425 diagnostic coronary angiography procedures; the others were acquired 
pre-intervention (n;355), after balloon dilation (n;62), or after stenting (n;126). 
The rest were acquired post-thrombectomy. The worst lesion diameter stenosis 
was 61.4±27.3% (visual assessment) or 63.2±20.3% (QCA). 
Patient age was 62.1± 11.4 years, and most patients were male (75.3%). 
Pullback length was 48.7±21.5mm. The mean EEM CSA was 15.6±4.8mm2 , the 
mean lumen CSA was 8.7±3.0mm2 , the mean plaque+media CSA (EEM minus 
lumen) was 6.8±2.7mm2 , and the mean plaque burden was 43.5±9.2%. Overall in 
this population, the mean CSA of the necrotic core was 0.45±0.41mm2 (12.3%), 
the mean CSA of calcified tissue was 0.31±0.38mm2 (8.5%), the mean CSA of 
fibrotic tissue was 2.2± 1.4mm2 ( 60.1 o/o ), and the mean CSA of fibrofatry tissue 
was 0.70±0.58mm2 (19.1 %). ACS comprised 40.9% of the total population; 
these patients had nearly the same amount of necrotic core (0.46±0.42mm2) as 
non-ACS patients (0.44±0.41mm2 , p;Q.74). 
Cardiovascular risk factors and coronary plaque composition 
Gender. male patients had a non-significant trend towards more necrotic core 
(0.46±0.43mm2) than female patients (0.42±0.38mm2, p;0.20). Table 2. 
Age: necrotic core content increased with age; patients ~62 years had mean NC 
CSA of0.40±0.36mm2 vs. 0.50±0.46mm2 in patients >62 years, p;0.0007. 
Diabetes Mellitus: non-diabetic patients had on average a mean NC CSA of 
0.43±0.41mm2 vs. 0.51±0.44mm2 in diabetic patients, p;0.02. Of note, insulin-
requiring diabetic patients had an even larger mean NC area (0.57±0.47mm', 
p;0.04) than the non-insulin-requiring diabetic population. 
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Table I. Demographics and baseline characteristics, n:::982 
Age (years+5D) 
Male 
Prior cardiac history 
Hypertension 
Diabetes 
Insulin user 
Lipid disorder 
PriorMI 
PriorCABG 
Family history of CAD 
Current smoker 
Previous smoker 
Clinical presentation 
Non-ACS 
ACS 
Vessel imaged 
LAD 
LCX 
RCA 
Other 
Medication 
Statin 
Aspirin 
Beta-blocker 
Ace Inhibitor 
Calcium channel blocker 
Bloodtest 
Total cholesterol (mg/dl) 
LDL cholesterol (mg/d~ 
HDLcholesterol {mg/dl) 
Triglycerides (mg/df) 
CK(U/U 
CK·MB ("9/U 
CRP (mg/dl} 
Coronary risk factors and necrotic core 
n{o/o) 
62.1 (11.4) 
739 (753) 
585 (59.8) 
625 (63.9) 
240 (24.6) 
61 (253) 
639 (65.1) 
269 (27.9) 
53 (5.4) 
425 (47 2) 
255 (25.8) 
253 (25.7) 
581 (59.1) 
4{)1 (40.9) 
484 (49.3) 
171 (17.4) 
289 {29.4) 
38 (3.8) 
670 (682) 
857 (87.6) 
600{615) 
405 (41.2) 
185 (19.0) 
179.8 {45.4) 
105.7 (36.7) 
47.4{14.8) 
97.8 (98.3) 
221.8(4025) 
20.1 (493) 
35.8 {93.8) 
SD, standard deviation; MI, myocardial infarction; CABG, coronary artery bypass graft; CAD, 
coronary artery disease; NSTEMI, non ST segment elevation myocardial infarction; STEMI, ST 
segment elevation acute myocardial infarction; ACS, acute coronary syndrome; UD, left anterior 
descending; LCX, left circumfle.x; RCA. right coronary artery; SVG, saphenous vein graft; CK, 
creatine kinase;CRP, C-reactive protein. 
Hypercholesterolemia: there was no difference berween patients with this hyper-
cholesterolemia than those without hypercholesterolemia. 
Hypertension: mean NC CSA was 0.40±0.36mm2 in normotensive patients vs. 
0.48±0.44mm2 in hypertensive patients, p=0.02. 
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Table 2. Content of necrotic core per cross-sectional area according to clinical presentation and 
cardiovascular risk factor status 
Mean so pvalue 
Gender 020 
Female 0.42 038 
Male 0.46 0.43 
Age 0.0007 
Younger than 62 years 0.40 0.36 
Older than 62 years 050 0.46 
Clinical presentation 0.74 
Non-AG 0.44 0.41 
ACS 0.46 0.42 
Diabetes 0.02 
.-Yes 051 0.44 
.-No 0.43 0.41 
lipid disorder 0.92 
.-Yes 0.45 0.42 
.-No 0.45 0.41 
Hypertension 0.002 
.-Yes 0.48 0.44 
.-No 0.40 036 
Prior cardiac history 0.0007 
.-Yes 0.48 0.42 
.-No 0.41 0.40 
Prior Ml 0.04 
.-Yes 0.49 0.44 
.-No 0.43 0.41 
Prior CABG 0.04 
.-Yes 0.61 0.65 
.-No 0.44 039 
Medication 
Ace Inhibitor 0.03 
.-Yes 0.42 0.43 
.-No 0.47 0.46 
Calcium channel blocker 0.01 
.-Yes 050 0.41 
.-No 0.44 0.42 
Bloodtest 
Total cholesterol 0.98 
>200 mg/dl 0.42 033 
<=200 mg/dl 0.45 0.42 
LDL cholesterol 0.83 
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Mean so pvalue 
>100 mg/dl 0.44 039 
<=lOOmg/dl 0.44 0.40 
HDL cholesterol 0.0001 
<50 mg/dl 0.48 0.41 
>=50 mg/dl 0.38 0.35 
Triglycerides 0.30 
>150mg/dl 0.42 0.36 
<=150 mg/dl 0.45 0.38 
CRP 0.07 
>3 mg/dl 0.43 0.40 
<=3 mg/dl 039 0.40 
ACS, acute coronary syndrome;.MI, myocardial infarction; CABG, coronary artery bypass grafting; 
CK, creatine kinase;CRP, C-reactive protein; 
Prior cardiac history or an MI or CABG: patients with a history of cardiovascular 
disease had a larger mean NC CSA than their counterparts. 
Smoking: neither previous smokers nor non-current smokers had a statistically 
significant larger mean NC CSA than non-smokers, p=0.23 and p=0.37 respec-
tively. 
Univariab/e and multivariable analysis of necrotic core area. 
All significantly associated variables in the bivariate analysis (age, hypertension, dia-
betes, and prior CABG) were introduced in the logistic regression model; but only 
age [OR 1.023 (1.009, 1.037), p=O.OO 1] and diabetes [OR 1.636 (l.l7 4,2.279), 
p=0.004] remained statistically significant. 
In a per class logistic regression analyses including only diabetes as covariate, 
in young females the OR was 2.1 (95%Cl 0.77,6.0), p=0.14; in young males the 
OR was 1.6 (95%Cl 0.90,2.7), p=0.11; in old females the OR was 2.3 (95%Cl 
1.09,4.9), p=0.03; and in old males the OR was 1.6 (95%Cl 0.96,2.7), p=0.07. 
Further, when only a variable that identified patients with diabetes and hyperten-
sion was included, in young females the OR was 2.4 (95o/oCI 0.69,8.6), p=0.17; in 
young males the OR was 2.0 (95o/oCI 1.03,3.8), p=0.041; in old females the OR 
was 3.04 (95o/oCI 1.02,9.1) p=0.046; and in old males the OR was 2.2 (95o/oCI 
l.l,4.2), p=0.025. (Table3 and 4). 
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Table 3. Logistic regression predictors for the top quartile measure of necrotic core area 
Parameter Beta coefficient Wald OR 95% CJ 
Age,yrs 0.023 10.4 1.023 1.009 1.037 
Hypertension (Y/N} 0.180 1.1 1.197 0.862 1.662 
DiabetesMe!litus(Y/N} 0.492 85 1.636 1.174 2179 
PriorCABG (Y/N} 0.494 2.7 1.638 0.911 2.945 
Constant ~2.8 
Y, yes; N, no; CABG, coronary artery bypass graft. 
Table 4. Logistic regression analysis 
Model1: Patients with diabetes 
Model2: Patients with diabetes and 
hypertension 
DISCUSSION 
Young females (S62 
yrs}, n=90 
OR2.1 
(95%(1 0.77,6.0} 
p=0.14 
OR2.4 
(95%0 0.69,8.6} 
p=0.17 
-0.081 
Young males (S62 
yrs}, n=406 
OR1.6 
{95%(1 0.90,2.7) 
p=0.11 
OR2.0 
(95%01.03,3.8) 
p=0.041 
-Q.012 
Old females (>62 
yrs}, n=153 
OR23 
(95%(11.09,4.9} 
P= 0,03 
OR3.04 
(95%CI1.02,9. 1 I 
p = 0.046 
pvalue 
0.001 
028 
0.004 
0.09 
0.007 
Old males (>62 
yrs}, n=333 
OR1.6 
(95%0 0.96,2.7) 
p= 0.07 
OR21 
(95%01.1 ,41) 
p=0.025 
The main findings of this paper are the following: 1). The relative amounr of 
necrotic core found in this in vivo study resembles that previously reported in 
pathological srudies(8,9). 2). The presence of some individual cardiovascular risk 
factors is related to an increase in necrotic core. 3). In a per class logistic regression 
analysis it appears that some cardiovascular risk factors assert a synergistic effect 
on the amount of necrotic core in coronary atherosclerotic plaques. 
The relevance of studying necrotic core lies in its role in rhe instability of 
atherosclerotic plaque. Rupture of TCFAs accounts for more than 60% of 
acute coronary events (4). Ruptured plaques are significantly more obstructive 
and contain larger necrotic cores, more macrophage infiltration, more calcium, 
fewer smooth muscles cells, and more positive remodeling than intact thin-cap 
fibroatheromas (TFCA) (10). 
The individual and collective impact of many cardiovascular risk factors in 
terms of cardiac morbidity and mortality has been described. Individually, these 
risk factors can either affect the overall plaque composition or specifically the 
necrotic core (figure 1). Similarly, the synergistic effect of two or more cardiovas-
cular risk factors can either affect the overall plaque composition or specifically the 
necrotic core; this more accurately reflects reality since a patient usually is diabetic 
and hypercholesterolemic, diabetic and hypertensive, ere. Consider a patient of 
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0 Calcium 
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Figure 1. Top: Cross~sectional areas of the same coronary atherosclerotic plaque, on the left 
hand side a greyscale image and on the right hand side the corresponding NUS radiofrequency 
data image. Bottom: Cardiovascular risk factors (CRF) act alone or in combination (biological 
interaction) to assert their effect on overall plaque composition. Note that the impact of these CRFs 
varies (thickness of the arrow). Their effect could exclusively be on overall plaque composition or 
simultaneously affect necrotic core, once again, individually or collectively. 
any age, gender, and diabetes status (figure 2). When this patient is analyzed as 
a part of a given patient population, cardiovascular risk factor ''A" could have no 
effect because the impact of rhis cardiovascular risk factor depends on the class to 
which rhe patient belongs even if this population is split by age, gender, or any 
orher cardiovascular risk factor. How can this be tested statistically? One option 
is to introduce interaction terms in the multivariable analysis in order to assess 
the biological interaction among variables that compound the interaction term. 
However, this requires a complex statistical analyses that is difficult to put into 
perspective in clinical practice. Instead, we categorized the current population 
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DM 
Non-
DM 
Female 
<62 yrs >62 yrs 
CRFA 
... 
CRFA 
" 
Male 
<62 yrs >62 yrs 
CRFA 
... 
CRFA 
... 
Figure 2. The population has been divided by age, gender and diabetes, resulting in eight categories. 
The same cardiovascular risk factor (CRF) "A" is assessed in each of them in terms of change in 
necrotic core. This CRF "A" can have not effect (horizontal arrow), increase (upward arrow) or 
decrease (dovmward arrow) the amount of necrotic core. W'hen a population based analysis is 
conducted, either by age, gender or clinical presentation no effect can be found, although there is a 
significant change in some of the categories. DM, diabetes mellitus. 
into four classes considering two variables that are intrinsic and not modifiable: 
age and gender. Eventually we had four groups - young females, young males, 
old females, and old males - in whom we assessed the effect of diabetes that was 
the only independent predictor of necrotic core area in the overall population. 
Diabetes was associated with an increase in necrotic core area in old females, and 
a strong trend was observed in old males. When a variable that identified patients 
with both diabetes and hypertension was entered into the logistic regression analy-
sis per group, being diabetic and hypertensive was associated with an increase in 
necrotic core not only in old patients, but also in young males. Of note, in this 
second model all of the odds ratios were larger than in the first model where only 
diabetes was tested. Thus, the combined presence of diabetes and hypertension 
exerted a synergistic and differential effect across age/ gender groups. 
In post-mortem studies smoking was associated with acute thrombosis (OR 
3.6, p=0.004) and low serum HDL cholesterol was associated with plaque rupture 
(p=0.008)(3). In our study the necrotic core was larger among patients with low 
HDL cholesterol levels, but this variable failed to be an independent predictor 
in the multivariable analysis. The rest of the cardiovascular risk factors correlated 
only mildly with the size of the necrotic core. The same group of pathologists later 
reported the plaque composition among diabetic patients(2). Type II diabetic 
patients had larger necrotic cores, more calcium, and more inflammation than 
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non-diabetics. Patients who were diabetic and hypercholesterolemic had larger 
necrotic cores compared to patients who were only diabetics while patients with 
diabetes and hypercholesterolemia had a larger macrophage infiltrate compared 
to patients with normal cholesterol and no diabetes mellitus. Although some of 
our results were in line with this pathological study, we refrained from a direct 
comparison berween pathology and our in vivo study because these pathological 
studies defined cardiovascular risk factors based on clinical history and postmortem 
blood and sera analysis as well as by histology and IVUS-RFD is not pathology 
even though the predictive accuracy of necrotic core detection is reported to be 
95.8%(6). 
This study has many potential clinical implications. First, necrotic core is a 
pathological marker of atherosclerotic plaque instability. In future prospective 
studies aiming to describe the relation of necrotic core rich plaques to clinical 
events, an enrichment of the study population can be performed by increasing the 
number of hypertensive and diabetic males and older diabetic and hypertensive 
females, variables that were strongly associated with larger NC areas in this cur-
rent study. Second, we are entering in a new NUS era where not only size, but 
also qualitative plaque composition, specifically necrotic core, matters. In classical 
IVUS plaque regression studies not all patients in the treated arm were regressors, 
and some of them were even progressors(ll). In vivo tissue characterization could 
help to evaluate the temporal changes of the plaque composition in addition 
to overall progression/ regression. Third, previous epidemiological studies have 
studied only clinical, angiographic, tomographic, and biomarkers in relation to 
patient mortality and morbidity; IVUS-RFD allows assessment of actual plaque 
composition in relationship to patient outcomes. Fourth, the synergistic and ad-
ditive presence of "traditional" cardiovascular risk factors on plaque composition 
can be prospectively analyzed with IVUS-RFD to understand the dynamic nature 
of the atherosclerosis disease. 
Limitations 
This study has several limitations. The most important is that external validity is 
limited because the studied population is still small and some of the cardiovascular 
risk factors, such as female gender and diabetes, are not extensively represented. 
Furthermore, we used analyses that were optimized based on the dataset, that is, 
we used the top quartile of necrotic core measures and age cutpoints (i.e. :562 
years). The use of"optimized" analyses has the potential to be less generalizable to 
validated analyses. 
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Other metabolic, chemical, mechanical, and rheological factors that influ-
ence the behavior of a diseased coronary vessel wall were not measured; these are 
independent from plaque composition and are not investigated concurrently in 
this study. 
Conclusions 
Overall plaque composition as analyzed by IVUS-RFD is similar to pathology. 
Individually and collectively, specific cardiovascular risk factors are associated 
with an increase in necrotic core. 
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ABSTRACT 
Background. Few post-mortem studies compared plaque composition with avail-
able patient characteristics and no comprehensive correlations between these vari· 
ables have been undertaken in vivo. Therefore, we explored the impact of patient 
demographics, anthropometric measures, CV risk factors, and soluble biomarkers 
on plaque composition and its overall size in patients with coronary heart disease 
(CHD). 
Methods and Results. The Integrated Biomarkers and Imaging Study-2 trial 
enrolled patients with CHD (n=309). Baseline patient variables were entered 
in univariable and multivariable regression procedures along with necrotic core 
(NC) area and total plaque area, as measured by IVUS-RF. The set of variables 
with a p-value of :50.15 were used for the multivariable regression analyses. A 
bac1.-ward selection approach was used; the stay criterion was set to 0.1. In the 
multivariable analysis, age, male gender, waist circumference and systolic blood 
pressure were positive, whereas urinary TxB2 negative, independent predictors 
of NC area; while only age and waist circumference were positively and urinary 
TxB2 were negatively associated with an increase in overall plaque size. 
Conclusions. In non-culprit vessels, patient demographics (age, male gender), 
anthropometric measures (waist circumference), clinical risk factors (systolic 
blood pressure) are related plaque composition (larger necrotic core area) after 
multivariate adjustment. Accordingly, necrotic core, as assessed by IVUS-RF, 
could be viewed as a novel in situ/in vivo biomarker, potentially reflecting the 
long-term impact of cardiovascular risk on plaque phenotype. 
Key words: Atherosclerosis, necrotic core, IVUS backscarrering radiofre-
quency data analysis 
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INTRODUCTION 
Cardiovascular (CV) disease remains the principal cause of death worldwide, 
with three-fourths of CV deaths attributed to atherosclerosis. Pathological studies 
in patients who died from coronary heart disease (CHD) showed an extensive 
coronary atherosclerosis.1 The current paradigm asserts that the main cause of 
cardiac death is primarily due to rupture of an advanced atherosclerotic lesion. 2 
Ruptured plaques contain the largest amount of necrotic core (NC) among the 
atherosclerotic lesions, suggesting a link between the amount of NC and their 
predisposition to rupture. 3 
The anthropometric measures and conventional cardiovascular (CV) risk fac-
tors relate to the risk of subsequent CV events as demonstrated by the original 
Framingham cohort and more recently the INTERHEART multiethnic study of 
the predictors of the first myocardial infarction.45 Notwithstanding these observa-
tions, accurate prediction of major coronary events on the individual patient level, 
as opposed to population based studies, remains challenging. Therefore, there is 
an interest in additional markers of patient vulnerability that would enhance pre-
cision of risk estimation beyond that afforded by Framingham risk score or other 
conventional risk engines. The ability to quantifY NC in vivo by the intravascular 
ultrasound radiofrequency (IVUS-RF) data analysis offers the opportunity to 
provide unique information about plaque rype to enhance precision of clinical 
and laboratory variables used to assess CV risk. Although the ultimate validity of 
this measurement will require very large and long-term natural history studies, 
the first step is to examine the relationship between patient derived variables and 
NC. Accordingly, we sought to explore in vivo the relationship between patient 
demographics, anthropometric measures, CV risk factors, soluble biomarkers and 
plaque composition (NC area) or its overall size (plaque area). 
METHODS 
Study Design 
The Integrated Biomarkers and Imaging Study-2 trial has been published else-
where. 6 Briefly, it was an international, multicenter, randomized, double blind, 
placebo-controlled study in patients with confirmed CHD. Institutional review 
boards at each center approved the protocol, and patients provided written 
informed consent. From the original cohort of IBIS-2 patients, 309 patients 
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with complete information regarding baseline clinical characteristics, laboratory 
measurements and imaging data were selected for this study. 
Patient Population 
Patients 18 years of age or older undergoing carcliac catheterization for acute 
coronary syndrome (ACS - NSTEMI or STEMI) or non-ACS (eg, chronic stable 
angina or troponin-negative resting chest pain) were eligible. The protocol speci-
fied 50% of randomized patients to have troponin-positive ACS. The randomiza-
tion was stratified according to ACS status and center. Key exclusion criteria were 
planned surgical revascularization, stroke in the past 6 months, chronic hepatic 
disorder or abnormal ALT, bilirubin (ALT >2.5 or bilirubin > 1.5 upper limit of 
normal), serum creatinine >2.0 mg/dL, blood pressure >1601100 mm Hg, poorly 
controlled diabetes mellitus (HbA1, > 10%), severe heart failure or left ventricular 
ejection fraction <30o/o, and current life-threatening condition. Patients were 
ineligible if angiography demonstrated left main coronary stenosis >50% or 
coronary anatomy was inappropriate for IVUS. 
IVUS Imaging 
The ECG-gated IVUS-RF acquisition was performed using EagleEye catheter (20 
MHz) at pullback speed of 0.5 mm/sec as described-' The quantitative IVUS 
analysis was performed by the Core Imaging Laboratory (Cardialysis, Rotterdam, 
The Netherlands) using customized software (pcVH 2.1, Volcano Therapeutics). 
The analyst selected the region of interest flanked by the presence of easily identifi-
able anatomical landmarks. Vessel and lumen areas data were obtained for every 
cross-section throughout the region of interest by semiautomatic planimetry of 
the leading edges of the luminal and external elastic membrane borders. The com-
position of coronary atheroma was assessed using spectral analysis of backscatter 
RF signals. Necrotic core was identified with autoregressive classification system 
that showed sensitivity and specificity of 92% and 97% for detection of necrotic 
core, respectively.7'8 To assess intra- and interobserver variability of necrotic core 
measurements, 20 patients from the current study (2465 frames) were analyzed 
twice by two different analysts. The mean absolute difference for necrotic core area 
was 0.01 mm2 (SD 0.06) for the intraobserver and 0.02 mm2 (SD 0.08) for the 
interobserver variability, respectively. 
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Study End Point Definitions (IVUS-RF) 
Plaque area contains both atherosclerotic plaque and media. This was obtained 
after planimetry was completed at the lumen/plaque boundary and at the medial 
adventitia boundary in each cross-section forming the region of interest. Plaque 
area was reported in mm2. 
The necrotic core area was automatically obtained in each cross-section forming 
the region of interest using dedicated software (pcVH 2.1, Volcano Therapeutics). 
Necrotic core values were expressed in mm2. 
Biomarkers 
Plasma hsCRP was measured as described previously.? Plasma Lp-PLA, activ-
ity was measured by a colorimetric method.? Other biomarkers (IL-6, MPO, 
ICAM-1, and MMP-9 activity) were assayed using commercially available kits. 
Oxidized phospholipid content per particle of apoB (oxPL/apoB) was measured 
using murine monoclonal antibody E06 as described.' Platelet biomarkers were 
measured in plasma (P-selectin, CD40L) and urine (11-dehydro thromboxane 
B2 normalized by urine creatine concentration [11-dehydro-TxB/mmol Cr]) as 
described.? 
Statistical Analysis 
Continuous variables were reported as mean±SD. Based on the plots of the residuals 
against the predicted values it was decided to log transform the necrotic core area 
and those continuous variables, from which the maximum z-score superseded the 
value 4. (The z-score was calculated for each continuous variable as the number of 
standard deviations change from its mean). All class variables except gender were 
coded [0,1] with 0 for absence or 1 for presence. Gender was coded 0 for females 
and 1 for males. In total 41 variables were entered into the univariable regression 
procedure. The set of thirteen variables with a p-value of <=0.15 were used for 
the multivariable regression procedure. A back"Vifard selection procedure was used, 
both rhe entry criterion for the forward and the stay criterion for the backward 
procedure were set to 0.1. 
To further understand relationship between age and antropometric variables 
and imaging parameters, the population was categorized into classes according to 
the distribution of age in tertiles. First tertile ranged from 33 to 52 years, second 
rertile from 53 to 63 years and in the third tertile from 64 to 82 years. Further, 
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waist circumference was also categorized as follows: first terrile from 68 to 93 em; 
second terrile from 94 to 101.5 and third terrile 102 to 131 em. 
Statistical analyses were performed with use of SAS V8.02. 
RESULTS 
Between November 16'\ 2005 and August 16'\ 2006,330 patients were enrolled 
with 309 patients included in this analysis. The reasons for not including 21 
patients (6%) included missing imaging data or suboptimal quality (6 patients 
did not undergo imaging, 14 had non-interpreatable IVUS images, and the image 
data of 1 patient was lost in the archiving/saving procedure). In Table 1, the 
Table 1. Basdine Characteristics 
Clinical characteristics 
Age(y) 
Males(n, %) 
Waist circumference (em) 
Body-mass index (kgfml) 
Diabetes mellitus (n, %) 
Hypertension (n, %) 
Hypercholesterolemia (n, %) 
Current smoker (n, %) 
Metabolic syndrome (n, %) 
Prior medical history (n, %) 
Prior myocardial infarction 
Prior coronary revascularization 
Prior srroke 
tndexhospltallzation (n, %) 
AC5 
Stable 
Cardiovascular medications at randomization (n, %) 
Statins 
Laboratory values 
Cholesterol (mg!dL) 
Total 
LDL 
HDL 
Triglycerides (mgldL) 
Median 
IQR 
hsC-reactive protein (mg/L) 
Bfood pressure 
Systolic-mmHg 
Diastolic- mm Hg 
172 
(n=309) 
58.6±10.0 
254(822) 
97.6±11.0 
27.7±3.9 
42(13.6) 
188 (60.8) 
181 (605) 
117 (37.9) 
71 (23) 
94 (30.4) 
95 (30.8) 
8(2.6) 
154 (49.8) 
155 (502) 
100 (33.7) 
184,6±463 
105.6±40.1 
475±11.9 
1363 
(95.6. 196.5) 
9.4±24.7 
127.1±16.4 
75.4±9.7 
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baseline characteristics of patients with complete information regarding clinical 
and imaging data are shown. The mean age was 58.6±10.0, mostly men were 
included (82.2%). By design, 155 (50.2%) had stable CHD and 154 (49.8%) 
had troponin-positive acute coronary syndrome. The mean waist circumference 
was 97.6 em and the mean systolic and diastolic blood pressure values were 127.1 
and 75.4 mmHg, respectively. Overall, the mean LDL-cholesterol was 105.6 mg/ 
dL and the mean HDL-cholesterol was 47.5 mg/dL. 
Mean length of the IVUS pullbacks was 50.3±16.8mm. In total, 37,617 
cross-sectional areas (CSAs) were included in this subsrudy. Our of these, 28620 
(76.1 o/o) were CSAs with necrotic core. Overall, the mean percent atheroma 
plaque was 40.2 o/o. 
Univariab/e association between baseline characteristics with necrotic core and 
plaque area 
The following variables were strongly associated with necrotic core (p50.05): 
male gender, age, waist circumference, weight, height, body mass index, current 
smoker, systolic blood pressure, creatinine, HgA1 C, urine 11-Dehydro TXB2 and 
o/o diameter stenosis by QCA; and the following with plaque size: male gender, age, 
Table 2. List of variables (only with a p value< 0.15) and their univariable association with necrotic 
core area and plaque area 
In Necrotic core area Plaque area 
Estimate 95%CI pvalue Estimate 95%(1 pvalue 
Waist circumference {em) 0.026 0.013 0.039 0.0001 0.007 0.003 0.012 0.0019 
Weight{kg) 0.020 0.009 0.030 0.0003 0.006 0.003 O.D10 0.0007 
Diameter stenosis byQCA (%) 0.024 0.010 0.037 0.0005 0.007 0.002 0.011 0.0049 
Systolic blood pressure (mmHg) 0.014 0.006 0.023 0.0012 0.004 0.001 0.007 0.0080 
Body Mass Index 0.059 0.022 0.096 0.0018 0.017 0.004 0.029 0.0127 
Current smoker ·0.410 -0]04 -0.116 0.0064 -0.118 -0.221 -0.014 0.0256 
Age in years 0.018 0.004 0.031 0,0124 0.008 0.003 0.013 0.0009 
Male gender 0.477 0.104 0.850 0,0124 0.145 0.014 0276 0,0304 
Creatinine 0.010 0.002 0.018 0.0161 0.003 0.001 0.006 0.0690 
Height(cm) 0.017 0.001 0.035 0.0500 0.006 0.001 0.012 0.0513 
Urine 11-Dehydro TX82 -0.232 -0.467 0.003 0.0541 -0.087 -0.169 -0.005 0,0373 
G/ycosy/ated Hemoglobin A IC 1.196 -0.019 2.411 0.0546 0.417 -0.009 0.843 0.0560 
Glucose 0.572 -0.031 1.175 0.0639 0.170 -0.041 0382 0.1159 
Oxidised Phospha/ipids/Apolipoprotein 8700 ratio 0.163 -0,013 0340 0.0701 0.057 ·0.005 0.119 0.0714 
BaselineeGFR value- m//min/1.73 td -0507 -1.113 0.099 0.1023 
Hypertension 0.241 -0.053 0.535 0.1079 0.103 0.001 0205 0.0502 
Oiasto/icb/aod pressure (mmHg) 0.012 ·0.003 0.027 0.1128 0.005 0.001 0.010 0.0662 
Previous PC/ or CABG 0.082 -0.027 0.191 0.1409 
Mean lumen diameter (mm) 0.293 0.202 0384 0.0001 
173 
Chapter 4.2 
waist circumference, weight, height, body mass index, current smoker, hyperten-
sion, systolic blood pressure, HgAlC, urine 11-Dehydro TXB2 and o/o diameter 
stenosis and mean lumen diameter by QCA (Table 2). 
Other tested variables that failed to be statistically significant were: clinical 
presentation (acute coronary syndrome), diabetes, LDL-c, HOL-e and hs CRP. 
A complete table that included all tested variables is published online. (APPEN-
DIXA) 
Multivariab/e association between baseline characteristics with necrotic core and 
plaque area 
In the multivariable analysis, age, male gender, waist circumference and systolic 
blood pressure were independent positive predictors of NC; while only age and 
waist circumference were positively associated with (increase in) plaque size. The 
urine ll-Dehydro TXB2 was an independent negative predictor for both necrotic 
core and plaque size. Table 3. 
To further understand relationship between age, antropometric variables and 
imaging parameters, the population was categorized by age and waist circumfer-
ence in tertiles. 
Within the first and second age tertiles, the mean necrotic core area and mean 
plaque area were not different across different waist circumference groups. In 
contrast, in older patients (the third age tertile: >64 years), the mean necrotic core 
area and the mean plaque area were significantly higher with increasing degree of 
abdominal obesity tertiles (Figure 1). 
Table 3. List of variables and their multivariable association with ln(Necrotic core area) and plaque 
area 
A. NC predictors Parameter Estimate 95% Confidence Limits Pvalue 
Intercept -5.25 ·733 -3.16 <.0001 
Urine 11-Dehydro TXB2 ·0233 ..0.471 0.006 0.056 
Systolic blood pressure 0.011 0.0009 0.021 0.033 
Age O.D18 0.003 0.033 0.022 
Waist circumference 0.021 0.007 0.034 0.003 
Male gender 0.446 0.047 0.845 0.029 
B. Plaque predictors Parameter Estimate 95% Confidence Limits Pvalue 
Intercept 0.944 0287 1599 0.005 
Previous CABG and PC/ 0.083 ·0.031 0.196 0.154 
Age 0.009 0.004 0.014 0.001 
Waist circumference 0.007 0.0024 0.012 0.003 
Urine 11-Dehydro TXB2 -0.094 -0.178 -0.009 0.030 
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P= 0.01 
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Figure 1. Stratification of mean plaque area and necrotic core area according to both age and waist 
circumference tertiles. 
DISCUSSION 
Our findings indicate that age, waist circumference, systolic blood pressure 
and urine 11-Dehydro TxB2 are independent predictors of necrotic core in the 
multivariable analysis, with fewer variables predictive of overall plaque size. This 
raises the possibility that the measurements of necrotic core may offer additional 
prognostic information in risk assessment of individual patients. 
Necrotic Core and Cardiovascular Risk Factors in Pathological Studies 
Prior attempts to correlate patients characteristics with plaque morphology 
assessed during post-mortem examination are limited by selection bias (only 
patients with fatal events due to coronary or no coronary causes are included) 
and often post-mortem ascertainment of laboratory values. History of smoking 
was associated with evidence of acute coronary thrombosis (OR 3.6, p=0.004) 
and low HDL-cholesterollevels were associated with plaque rupture (odds ratio 
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for each additional milligram per deciliter, 1.01).9 Diabetes was shown to be as-
sociated with larger necrotic core and increased macrophage content consistent 
with clinically observed increased of CV events in these patients. 10 The differences 
with the current study may stem from the fact that our observations focused on 
non-culprit vessels. In addition, current algorithm for spectral analysis of IVUS-
RF is unable to detect thrombus and lacks precision to detect inflammatory cell 
content. Post-mortem measurement of HDL-cholesterol is also fraught with 
potential confounding factors. 
Plaque size by intravascular imaging and its relationship with CV risk factors 
Several CV risk factors such as male gender, BMI, diabetes and prior coronary 
revascularization have been found strong predictors of atheroma volume measured 
by conventional IVUS. 11 As shown by Nicholls eta!., atheroma volume in women 
is smaller even in the presence of more risk factors in secondary prevention trials. 12 
Our study extends these observations showing independent impact of male gender 
on the size of necrotic core. We were unable to detect relationship berv.reen dia-
betes or prior coronary revascularization and IVUS measurements. These findings 
were unexpected and possibly related to too few diabetics enrolled in the current 
study (14%). It is noteworthy, however, that continuous measurements reflecting 
cardiometabolic risk (waist circumference, blood pressure, HgAI C), demonstrated 
stronger relationship with the size of necrotic core in either univariate or multi-
variate analysis in our dataset. Obesity is an important but complex contributor 
to CV morbidity and mortality. 13 Waist circumference, simple measure of visceral 
(abdominal) obesity, has a superior predictive value for the presence CHD or the 
risk of MI to that of BMJ.l4 Large multiethnic INTERHEART study showed 
significant relationship betv.reen waist circumference or waist-to-hip ratio and risk 
of first MI even afrer full adjustment for other risk factors.' Furthermore, patients 
with low BMI but increased waist circumference have increased 1-year mortality. 15 
In our study, increasing waist circumference was not only predictor of plaque size 
but more importantly an independent predictor of necrotic core area. 
Despite favourable effects of cholesterol-lowering therapy with statins in 
primary and secondary prevention, single measurement of serum lipids did not 
correlate with IVUS measurements of atheroma size or necrotic core in univariate 
or multivariate analysis. These findings are consistent with those reported by oth-
ers regarding conventional IVUS measures and do not contradict halting plaque 
progression or even its regression with intensive LDL cholesterol lowering. 16,17 In 
contrast to lipid measurements, systolic blood pressure was specifically related to 
larger necrotic core size. It is noteworthy that systolic blood pressure is an inde-
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pendent predictor of plaque progression by IVUS and therapeutic intervention(s) 
lowering blood pressure below current guideline mandated thresholds may retard 
progression of atherosclerosis and reduce CV events. 18 
Study Limitations 
This study is a cross-sectional analysis that has number oflimitations. First, sample 
size was small thus possibly limiting full exploration of categorical variables (e.g., 
diabetes). Second, the measurements of biomarkers that entered into the model 
do not reflect chronic circulating levels as 50% of patients presented with ACS, 
which transiently alters inflammatory biomarkers. In addition, our data indicate 
that ACS status does not affect necrotic core size when assessed in non-culprit 
vessels. Although pan-coronary inflammation was reported in ACS patients, 
IVUS methodology is not well suited to measure such endpoints. Third, some of 
the measurements are confounded by concomitant treatments. For example, 99o/o 
of patients were receiving aspirin, thus the inverse relationship between urinary 
TxB2 and necrotic core or plaque size is clearly confounded by the impact of this 
therapy. Fourth, we wish to emphasize that all IVUS studies are limited to the 
analysis of a relatively short segment of coronary arterial tree that does not fully 
reflect disease characteristics elsewhere. 
Conclusions 
In non-culprit vessels, patient demographics, anthropometric measures, clinical 
CV risk factors are related not only to increase in plaque size but also its composi-
tion (increase in necrotic core) size after multivariate adjustment. Accordingly, 
necrotic core, as assessed by IVUS-RF, should be viewed as a novel in situ/in vivo 
biomarker, potentially reflecting the long-term impact of cardiovascular risk on 
plaque phenotype. Longitudinal studies with hard clinical endpoints are needed 
to fully assess clinical value of this measurement. 
APPENDIX 
Core Laboratories: Imaging (Cardialysis, Rotterdam, The Netherlands). 
Participating Centers (number of patients enrolled): Austria: Hanusch Kranken-
haus, Georg Gaul (6). Belgium: Centre Hospitalier Universitaire Sart-Tilman, 
Victor Legrand (10); ZNA Campus Middelheim, Stefan Verheye (25); Cardio-
vascular Center, Aalst, William Wijns (14). Czech Republic: VSeobecni Fakultni 
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Nemocnice, Michael Aschermann (23). Denmark: Skejby Universiry Hospital, 
Hans Erik B0tker (18). Germany: West German Heart Center, Raimund Erbel 
(7); KerckhoifKlinik, Christian Hamm (7); Universitatsklinikum Heidelberg, Ste-
fan Hardt, Helmut Kiicherer (1); Universitatsklinikum Miinchen, Volker Klauss 
(14), Universitatsklinikum Ulm, Wolfgang Koenig (9); Segeberger Kliniken, Gert 
Richardt (3). The Netherlands: Medisch Spectrum Twente, Clemens von Birgelen 
(14); Medisch Centrum Leeuwarden, Adrianus Johannes van Boven (12); Catha-
rina Hospital and Catherine R&D, Herman Rolf Michels (14), Erasmus Medical 
Center, Patrick Serruys (20); Medisch Centrum Rijnmond Zuid, Pieter Smits 
(11). Norway: Haukeland Sykehus, Oyvind Bleie (20). Poland: Upper Silesian 
Heart Center, Pawel Buszman (40); Szpital Uniwersytecki, Dariusz Dudek (19). 
Spain: Hospital Marques de Valdecilla, Thierry Colman (9); Hospital Clinico San 
Carlos, Carlos Macaya (9). Switzerland: Kantonsspital Luzern, Paul Erne (25). 
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Abstract 
Background: Virtual histology (VH) uses intravascular ultrasound (IVUS) radiofrequency spectral analysis to 
locally identify the morphology and composition of atherosclerotic plaques. We sought to explore in vivo the 
relation between IVUS-derived thin cap fibre-atheroma (IDTCFA) and remodelling index in patients with 
acute coronary syndromes using IVUS-VH. 
Methods and results: Twenty-one patients (63 vessels) were enrolled. When compared to cross sectional 
areas (CSAs) without necrotic core in contact with the lumen (NCCL), CSAs with NCCL had a iarger plaque 
burden 42.8±11.5% vs. 32.8±11.5%, p<0.001; higher overall necrotic core content [13.8±10.7% vs. 
2.3±7.9% (p<0.001)J and calcified tissue [4.7±6.5 vs. 0.66±2.1% (p<O.OOl)]. On average there were 
2 IVUS-derived thin cap fibre-atheroma (IDTCFAl per patient. Nearly half of the IDTCFAs had positive 
remodelling. 
Conclusions: CSAs with NCCL had worse morphological profiles than those with no NCCL. The simultane-
ous and more detailed assessment of IDTCFA and remodelling index identifies a reduced number of 
allegedly high-risk plaques. The findings of this study may have impor'"..ant clinical implications, s\nce they 
shed light into a possible method of identiying potentially high-risk plaques suitable for pharmacological 
and/or local treatment. 
" Corresponding author: Thoraxcenter, Bd583a, Dr.Molewaterplein 40, 3015-GD Rotterdam, The Netherlands 
E-mai!:p. w.j. c.serruys@erasmusmc. nl 
~J Europa EditiOn 2006. All rights reseNed. 
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Abbreviations and acronyms 
ACS: Acute coronary syndrome 
CSA: Cross sectional area 
EEM: External elastic membrane 
IDTCFA: IVUS-derived thin cap fibre-atheroma 
iVUS: Intravascular ultrasound 
NC: Necrotic core 
NCCL: Necrotic core in contact with the lumen 
NSTEMI: Non-ST segment elevation myocardial infarction 
PB: Plaque burden 
Rl: Remodelling index 
STEM I: ST segment elevation myocardial infarction 
UA: Unstable angina 
VH: VIrtual Histology 
Introduction 
For the most part, acute coronary syndromes (ACS) are the conse-
quence of the rupture of particular atherosclerotic plaques called 
thin-cap fibre-atheromas (TCFAsl. These TCFAs have a thin fibrous 
cap, oauclty of smooth muscle cel!s, heavy inflammatory infil'.:ration of 
the cap, large necrotic core, positive remodelling and high strain'-6. 
Coronary plaque rupture is a frequent and unpredictable event that 
impacts the global burden of cardiovascular disease7. Indeed, coro-
nary heart disease is expected to be the leading cause of disability-
adjusted life-years in 2021J8. Accordingly, many cutting-edge imaging 
techniques have recently been developed to help us bet::er under-
stand the atherosclerotic process. The first in vivo studies using such 
techniques were performed against the background of previous 
histopathological knowledge about morphological and compositional 
features related to plaques prone to rupture. so seve;al studies have 
been published recent!ythat mimic previous pathological findings9·1:. 
Spectral analysis of the IVUS radiofrequency data (IVUS-VH) is 
emerging as a tool to assess plaque morphology and composi-
tion12·:3. This combined assessment of remodelling and plaque 
characterisation might allow a more accurate and complete charac-
terisation in vivo for allegedly high-risl; plaques. 
We thus sought to further explore in vivo the relation between com-
positional features of coronary atherosclerotic plaques, specifically 
IVUS-derived thin cap fibre-atheroma and remodelling index. in 
patients with acute coronary syndromes. 
Methods 
Patient se~ection 
From January to May 2005, all patients with acute coronary syn-
dromes admitted for coronary catheterisation and subsequent 
intervention were eligible if all three coronary vessels were suitable 
for IVUS interrogation (absence of extensive angiographic calcifica-
tion and/or severe vessel tortuosity}. Acute coronary syndrome 
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encompasses unstable angina (UA) according to the Braunwald 
classification, non-ST-segment elevation myocardial infarction 
(NSTEMI) and ST-segment elevation myocardial infarction 
(STEM I). The three-vessel IVUS-VH acquisition timing was as fo> 
lows: in patients with UA/NSTEMI, acquisition was performed just 
after the interventional treatment; in patients suffering from STEM I 
it was done when the patient was symptom-free, without ECG 
changes and haemodynamically stable (defined as systolic blood 
pressure >90 mmHg without vasopressor or inotropic support, and 
with a heart rate of between 60 and 100 bpm). Informed written 
consent was obtained from all patients. Our local Ethics Committee 
approved the protocol. 
1\IUS-Vll acquisition and analysis 
Details regarding the validation of the technique on explanted 
human coronary segments and in vivo post-atherectomy have pre-
viously been reported 12·13. Briefly, lVUS-VH uses spectral analysis of 
IVUS radiofrequency data to construct tissue maps that are corre-
lated with a specific spectrum of the radiofrequency signal and 
assigned colour codes (fibrous [labelled green], fibre-lipidic 
[labelled greenish-yellow], necrotic core [labelled red] and calcium 
[:a belled white])12. 
The IVUS-VH sampling rate during pull-back is gated to peak R-wave 
and is therefore dependent on heart rate. For instance, during con-
stant heart rate of 60 bpm, then data wiil be collected every 0.5 mm. 
IVUS 8-mode images were reconstructed from the RF data by cus-
tomised software (lVUSLab Version 4.4, Volcano Therapeutics, 
Rancho Cordova, CA, USA). Semi-automated contour detection of 
both lumen and the media-adventitia interface was performed, and 
the RF data was normalised using a technique known as "Blind 
DeconvolutionH, an iterative algorithm that deconvolves the 
catheter transfer function from the backscatter, thus accounting for 
catheter-to-catheter variability14·'5• Compositional data was 
obtained for every slice and expressed as mean percent for each 
component. 
Quantification of the necrotic core in contact with the lumen 
(NCCL) and its angle was performed using MATLAB® (MathWorks, 
Natick, MA, USA). 
Definitions used in t(Jis study 
Necrotic core tissue in contact with the lumen, is defined as the 
presence of necrotic core tissue in direct contact with the luminal 
space and with no detectable overlying fibrous tissue; this is report-
ed as (i) a continuous variable in mm2, (ii) as a percent of the total 
plaque composition and (iii} as a percent out of the total necrotic 
core, (iv) as a binary variable considering the presence or absence 
of NCCL In addition, the major confluent pool of NCCL was selec· 
tively quantified in terms of area in mm2 and as a percentage of 
both the total plaque composition and the total necrotic core. The 
angle (measured from the gravity centre of the lumen) occupied by 
the entire NCCL was measured as well as the specific angle occu-
pied by the major confluent NCCL. (Figure 1} 
Plaque burden (PB), is defined as EEM,,_,-Lumen""jEEM""'" X 100, 
where EEM refers to external elastic membrane. 
Virtual histology and remodeling index allow in vivo identification of high risk coronary plaques 
Figure 1. An example of selective quantification of the necrotic core in contact with the lumen. (a) The originai/VUS-VH cross-sectional area; 
(b) Modification using the VH tool to selectively quantify the major confluent necrotic core that is in direct contact with the lumen. 
(c) Measurement of the angle occupied by the entire necrotic core in contact with the lumen (white and red lines) and specifically the angle 
occupied by the major confluent necrotic core in contact with the lumen (red fines). 
Remodelling was assessed by means of the remodelling index 
(RI), expressed as the EEM CSA at the site of minimum luminal 
area divided by the reference EEM CSA as previously 
described ::.16•17• 
The reference site wasSlO mm proximal to the selected lesion 18. There 
were no major side branches between the MLA and reference sites. We 
defined positive remodelling as Rl ~ 1.05 and negative remodelling as 
Rl s0.95. Values in between were considered neutral (no remcdt:Jiing). 
IVUS-derived TCFA (IDTCFA)s, is defined as a iesion fulfilling the fol-
lowing criteria in at least 3 consecutive CSAs: 1) plaque burden 
~40%; 2) confluent necrotic core~ 10%19 in direct contact with 
the lumen in the investigated CSA (Figure 2). All consecutive CSAs 
having the same morphologic characteristics were considered as 
part of the same IDTCFA lesion. 
proximal--!~ distal 
MLA, 5.77 mm2 
PB, 44.6% 
VCSA 1 0.39 mm2 
MLA, 3.94 mm2 
PB, 66.4% 
Remodelling index 
1.13 --vcsA 11.75 mm2 
MLA, 3.81 mm2 
PB, 49.3% 
VCSA 7.51 mm2 
Figure 2. The figure shows the IVUS grey scale and the corresponding IVUS-VH frames of an IVUS derived thin cap fibro-atheroma (four central 
frames) and the proximal and distal reference segment in which the remodeffing index was calculated. MLA, minimum luminal area; PB, plaque 
burden; VC$A, vessel cross sectional area. 
185 
Chapter 5.1 
Statistical analys;s 
Discrete variables are presented as counts and percentages. 
Continuous variables are presented as means ±SO. A tvvo-sided 
p value of less than 0.05 indicated statistical significance. 
Assumptions for normality were checked after transformation based 
on a p.value >0.20 at Kolmogorov-Smirnov test and by visual 
assessment of Q.Q plots of residuals. Accordingly, log transforma-
tion was performed on the variables with skewed distribution. 
To compare CSAs with and without NCCL, in a General Estimating 
Equations model, with binomial distribution and a logit link function, 
cases were regarded as a random factor (as we had multiple obser-
vations for each patient); we also a!lowed for an autoregressive cor-
relation structure and the vessel was a fixed factor in the model. 
Statistical analyses were performed with use of SPSS software ver-
sion 11.5. 
Results 
Twenty-one (63 vessels) consecutive patients were included in this 
study. The baseline characteristics of the patient population are 
depicted in Table 1. The mean age was 52.9±7.8 years, most being 
male patients (71.4%). Sixty-six percent of the patients presented 
with acute myocardial infarction. The culprit vessel was the left 
anterior descending (l.P.Dl in 47.6%, the left circumflex (LCXJ in 
23.8% and the right coronary artery (RCA) in 28.6% of the patients. 
The mean length of the IVUS pull-back was 45.7 ±22.9 mm. 
IVUS-\IH lindings 
A total of 6,351 CSAs were analysed with IVUS-VH. Necrotic core in 
contact with the lumen was found in 71.7% (4556/6351) of CSAs. 
These CSAs had a mean area of necrotic core in contact with the 
lumen of 0.59±0.72 mm2 which corresponds to 13.8±10.7% of 
Table 1. Baseline characteristics, n•21 
Age, yrs (mean±SD) 
Male% 
Body mass index, kg/m2 (mean±SD) 
Diabetes mellitus % 
Hypertension % 
Family history of CHD% 
Current smoking% 
Hypercholesterolaemia % 
Previous Ar:5 % 
Previous PO % 
Clinical presentation % 
Unstable angina/Non-Sf-segment elevation MI 
ST-elevation MI 
Culprit vessel %, n•2l 
Left anterior descending 
Left circumflex 
Right coronary artery 
52.9±7.8 
71.4 
27.3±4.2 
33.3 
33.3 
42.9 
71.4 
33.3 
14.3 
28.6 
33.3 
66.7 
47.6 
23.8 
28.6 
SD, standard deviation; CHD, cardiovascular heart disease; ACS, acute coronary 
syndrome; PCI, percutaneous coronary intervention; MI, myocardial infurction, 
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the total plaque area; on average 53.8±35.2% of the total amount 
of necrotic core present in a CSA was in contact with the lumen and 
the angle occupied by the necrotic core in the luminal circumfer-
ence was 30.3±34.8°. Nearly all the geometrical and composition-
al parameters of the CSA with NCCL were significantly different 
compared with CSAs without necrotic core in contact with the 
lumen (Table 2). Specifically, CSAs with NCCL had a higher plaque 
burden compared to CSAs without NCCL, 42.8±11.5% vs. 
32.8±11.5%, p<0.001 and more necrotic core and calcified tissue 
compared to the ones without NC in contact with the lumen, 
13.8±10.7% vs. 2.3±7.9% (p<0.001) and 4.6±6.4 vs. 0.59±2.1% 
(p<0.001) respectively. 
Table 2. Compositional and geometrical analysis of CSAs with 
necrotic core in contact with the Lumen. 
Calcifiai mm1 
Calcifiai"!c 
Fibrous mm1 
Fibrous% 
Fibrolipid mm1 
Fibrolipid % 
Necrotic core mm' 
Necrotic core % 
Vessel CSA mm1 
Lumen CSA mm1 
Plaque CSA mm1 
Plaque eccentricity 
Plaque burden % 
NC No contact 
(1795 CSAs) 
Mean SD 
0.02 0.05 
0.59 2.1 
1.5 1.7 
65.3 17.4 
0.58 0.85 
30.7 18.0 
0.04 0.12 
2.27 7.9 
16.7 5.5 
11.2: 4.1 
5.5 1.9 
0.11 0.12: 
32,5 11.2 
NC, necrotic core; CSA, cross sectional area. 
NC COrita'ct' -
(4556 CSAs) 
Mean so 
0.2:1 0.38 
4.5 5.4 
1.5 1.8 
62.7 12.0 
0.84 0.86 
18.9 11.5 
0.59 0.72 
13.8 10.7 
18.0 5.5 
10.3 4.5 
7.5 3.4 
0.18 0.15 
42.8 11.5 
p value 
0.03 
<0.001 
0.01 
0.03 
0.86 
0.50 
0.005 
<0,001 
0.24 
0.29 
0.006 
0.65 
<0.001 
Overall, there were 805 (12.7%) CSAs with confluent NCCL >10%; 
among these only 430 CSAs had a PB >40% (Table 3). 
Table 3. Number of CSAs according to the amount of confluent 
necrotic core in contact with the lumen and plaque burden >40%. 
Over.lll. 'CSAs-With PB >4o%; 
_ n•6351 n .. 2_886 
Confluent NCCL >10% 805(12.7%) 430(14.9%) 
Confluent NCCL >15% 385(6.1%) 198(6.9%) 
Confluent NCCL >2ff'/o 218(3.4%) 105(3.6%) 
Confluent NCCL >25% 125(2%) 44(1.5%) 
Confluent NCCL >30% 73(1.1%) 23(0.8%) 
NCCL necrotic core in contact with the Lumen; CSA, cross-sectional area; 
PB, plaque burden 
IVIJS-derived thin cap libro-alheroma 
A total of 42 IDTCFAs were detected in the 21 patients. However, 
13 patients had at least one IDTCFA in their coronaTY :ree (38.1% 
of the population did not have any IOTCFA). Thus, on average there 
were 2 IDTCFAs per patient. Seventeen IDTCFAs were found in the 
LP.D, 12 in the LCX and 13 in the RCA. In 7 patients at least one 
Virtual histology and remodeling index allow in vivo identification of high risk coronary plaques 
other IDTCFA was found in a different vessel and in 13 vessels more 
than one IDTCFA was found in the same vessel {Table 4). 
Table 4. Description of the multifocal aspect of IDTCFA. 
No. patients with: 
Oce 
Two 
Three 
Four or more 
No. of vessels with: 
Oce 
Two 
Three 
Four or more 
No. of patients with one IDTCFA in at least 
one other vessel 
IDTCFA n•42 
13 
8 
5 
23 
13 
7 
CSA, cross-sectional area: IOTCFA, IVUS-derived thin cap fibr<ratheroma 
The mean IOTCFA lesion length was 4.8±2.8 mm (Range: 0.95-
13.5 mm) and the remodelling index was 1.09±0.21. In three 
IDTCFAs it was not possible to measure the remodelling index due 
to lack of reference segment: two of them were located in the prox-
imal LAD, so the only segment without disease proximal to the 
lesion was the !eft main artery. Five (11.9%) IDTCFAs had negative 
remodelling, 14 (33.3%) no remodelling and 20 (47.6%) had pos-
itive remodelling. The IDTCFAs were divided into three different cat-
egories according to the largest confluent necrotic core in contact 
with the lumen, largest confluent NCCL < 20%, NCCL between 20-
30% and NCCL >30%. Subsequently, the remodelling index was 
plotted against these three categories (F1gure 3). The overall mean 
necrotic core was 26.5±9.7%, and the major area of confluent NC 
that was in contact with the lumen was 12.2±8.0% which repre-
Remodelling index 
Figure 3. Bar graph shows the number of IVUS-derived thin cap fibre-
atheroma according to the largest confluent necrotic core in contact 
with the lumen (NCCL) and the remodelling index. It seems that 
among the !DTCFAs there are different degrees of disease, possibly 
with different likelihoods of rupture. 
sented 44.9±21.2% of the total amount of NC present in the CSA. 
The circumference occupied by the confluent NCCL was 
27.6±17.SO. The mean plaque burden was 50.3±8.5, whilst the 
vessel CSA and lumen CSA were15.4±6.2 mm2 and 7.6±3.3 mm2 
respectively (Table 5). 
Table 5. Characteristics of IVUS-derived thin cap fibro-atheroma. 
IDTCFA.._ n .. 42 
Mean SD 
Calcified mm2 0.35 0.38 
Calcified% 7.6 7.0 
Fibrous mm 2 2.5 1.7 
Fibrous% 54.4 10.6 
Fibrolipid mm~ 0.56 0.65 
Fibrolipid% 11.5 8.5 
Necrotic core mm 2 1.2 0.81 
Necrotic core % 26.5 9.7 
Major confluent NC in contact with the lumen 
-Area mm 2 0.68 0.58 
-% out of the total NC 45.0 21.2 
-% out of the total PCSA 12.2 8.0 
-Angle of the NC (degrees) 27.6 17.5 
Vessel CSA mm< 15.4 6.2 
Lumen CSA mm2 7.6 3.3 
Plaque CSA mm~ 7.8 3.4 
Plaque eccentricity 0.21 0.16 
Plaque burden % 50.3 8.5 
Length (mm) 4.8 2.8 
Remodelling index 1.1 0.21 
NC, necrotic core; CSA, cross sectional area; PCSA, plaque CSA; SD, standard 
deviation. 
Discussion 
The main findings of this study that included 21 patients (63 ves-
sels) with acute coronary syndrome are: 1) on average there were 
2 IDTCFAs per patient; 2) after treatment of the culprit lesion, 
38.1% of the population did not have any IDTCFA; 3) CSAs with NC 
in contact with the lumen were more obstructive and with larger 
vessel CSA than their counterparts without NC in contact with the 
lumen; 4) CSAs with NC in contact with the iumen had also larger 
necrotic core and calcified tissue compared to the ones without NC 
in contact with the lumen; 5) Nearly half of the IDTCFAs had posi-
tive remodelling. 
To date, there is no single isolated marker of vulnerability that can 
accurately and precisely identify atherosclerotic plaques at risk of 
rupture. On the contrary, it seems that the in vivo simultaneous 
assessment of acknowledged high-risk atherosclerotic plaque char-
acteristics may improve the accuracy to reliably identify vulnerable 
plaques. For the first time IDTCFA and remodelling index are 
assessed in an in vivo three vessei IVUS-VH based study in patients 
with acute coronary syndrome. 
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Trying to understand the atherosclerosis process has continued for 
more than a century, and while many paradigrr.s have lost irr.por-
tance, others still remain. Specifically, although vast information 
with respect to the pathophysiology of acute coronary syndromes 
has been published, only a few concepts are today generally 
accepted. First, the former belief that acute coronary syndromes 
originate exclusively from flow-limiting stenoses has shifted to well-
defined histological plaque phenotypes. These plaques have partic-
ular characteristics, such as large necrotic core, thin fibrous cap, 
inf:ammation within the cap and positive remodellingU2.20·22. 
Nevertheless, to date, the natural history of lesions with these char-
acteristics remains unknown and the limited knowledge about their 
eventual prognosis is provided by retrospective histopathological 
studies7•23 • Second, inflammation plays an important part in the 
development and growth of such plaques, and most importantly in 
triggering unpredictable rupturing events2~. Third, the multifocal 
distribution of vulnerable plaques has been proven by means of 
pathology:, angiographf-5, angioscopf-0• IVUS26, palpography27 and 
lately IVUS-VH9. This latter concept is once again demonstrated in 
this study, where in 33.3% (7/21) of the patients IOTCFAs were 
present in at least two vessels. Moreover, in 31.7% of the vessels, 
tv-lo or more IOTCFAs were detected. 
Spectral analysis of IVUS radiofrequency data has been used as a 
tool to assess plaque composition and remodelling11·12, since they 
are acquired in one single pull-back, simultaneous and comple-
mentary information can be retrieved. The previous manuscript 
from our group reporting the incidence of lOTCFA is essentially sim-
ilar from the methodological point of view, but dramatically different 
from the quanti!:ative point of view. So in the first report by 
Rodriguez-Granillo et al9 , one of the criteria was the presence of 
NC>10% in a GSA with some NC in contact with the lumen. with-
out considering its distribution along the luminal circumference 
(spotty or confluent). Thus, the main difference with the approach 
used in this report is the fact that the CSAs were included only if the 
necrotic core was confluent and this pool of NC represented more 
than 10% of the tissue present in the CSA and was in direct contacL 
with the lumen. This different methodology may impact on the 
reported incidence of vulnerable plaque, but it offers a definition 
which is closer to the pathological one. Nevertheless. the inability to 
precisely measure the thickness of the fibrous cap makes our 
observations a surrogate of the pathological TCFA. 
Positive remodelling has been associated with an unstable clinical 
presentation17•28 and with characteristic pathologicalo and IVUS-VH:1 
lesion types. In line with these previous reports, the remodelling 
index found in this study shows the out-Nard growth of these types of 
plaques. Some lipid lowering trials using conventional IVUS have 
suggested that there is a change in "composition" after a period of 
treatment29 , whilst another with a similar design reported a change 
in the remodelling index:8 . IVUS-VH offers the opportunity to follow-
up these lesions and to correlate longitudinally and simultaneously 
the composition and the change in the remodelling index. 
It seems that among IDTCFAs there is different degree of disease. 
Not ail of them have positive remodelling. The only opportunity to 
know if there is a different degree of risk among the same type of 
lesion is to look back into the pathological studies to learn which 
188 
TCFAs have been undergone rupture. It is clear that ruptured 
plaque have more necrotic core, macrophage infiltration, ca!cifica-
tion. less smooth muscles cells and more positive remodelling than 
TCFAs30. We can then conclude that those IDTCFAs having abun-
dant necrotic core with positive remodelling have a higher risk, and 
it turns out that in this study these are few in number. 
The clinica! implications of these findings are manifold. Firs~. the 
capability of simultaneously assessing more than one of the differ-
ent acknowledged features of "high-risk" plaques could potential~ 
iy enhance the prognostic value of the invasive detection of vulner-
able plaque. Second, this combined assessment can potentially 
identify very high-risk plaques, thereby lowering the number of vul-
nerable plaques that deserve to be fol!owed and ultimately treated. 
Limitations 
Although we have included all consecutive patients with three vessel 
IVUS assessment in a defined period of time, the sample size is small. 
In general, the more severely diseased part of the vessel was stent-
ed before IVUS acquisition eliminating the analysis of potentially the 
most pathological region of interest. 
The inferior axial resolution of IVUS-VH in comparison to histology 
remains a major handicap, but is partially compensated by the 
higher samp!ing rate of the u!trasonic approach when compared to 
the pathologic. 
Conclusions 
Cross sectional areas with necrotic core in contact with the lumen 
had a worse morphological profile than the ones without NC in con-
tact with the lumen. The simultaneous assessment of IOTCFA and 
remodelling index identifies a reduced number of high-risk plaques. 
The findings of this study have potentia!ly important clinical impli-
cations, since for the first time it sheds light into the possibility to fol-
low these plaques after pharmacological treatment and/or to treat 
them locally. 
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OBJECTIVES 
BACKGROUND 
METHODS 
The purpose of this study was to assess the prev::tlence of intmvascular ultrasound (IVUS)-
derived thin-cap fibroatheroma (IDTCF A) and its relationship with the clinical presentation 
using spectral an:llysis ofiVUS radiofrequency data (IVUS-Virtual Histology [IVUS-VH]). 
Thin-cap fibroatheroma lesions are the most prevalent substrate of plaque ruprure, 
In 55 patients. a non-culprit, non-obstructive (<500,6) lesion was inve::.-tigated with IVUS-VH. 
We classified IDTCF A lesions as foc::tl, necrotic core-rich (2::10% of the cross-sectional area) 
plaques being in contact with the lumen; IDTCF A definition required a percent atheroma 
volume (PA V) 2::40%. 
RESULtS Acute coronary syndrome (ACS) (n = 23) patients presented a significantly higher prev:tlencc 
ofiDTCFA than stable (n = 32) patients (3.0 (interquartile range (IQR) 0.0 to 5.0] vs. 1.0 
[IQR 0.0 to 2.8], p = 0.018). No rdation was found between patient's charncteristics such as 
gender (p = 0.917), diabetes (p = 0.217), smoking (p = 0.904), hypercholesterolemia (p = 
0.663), hypertension (p = 0.251), or family history of coronary heart disease (p = 0.136) and 
the presence ofiDTCF A A clear clustering pattern was seen :llong the coronaries, with 35 
(35.4%), 31 (31.3%), 19 (19.2%), and 14 (14.1%) IDTCFAs in the first 10 mm.ll to 20 mm, 
21 to 30 rom, and 2::31 nun segments, respectively, p = 0.008. Finally, we compared the 
severity (mean PAV 56.9 ± 7.4 vs. 54.8 ::: 6.0, p = 0.343) and the composition (mean 
percent necrotic core 19.7::!: 4.1 vs. 18.1::!: 3.0, p = 0.205) ofiDTCFAs between stable and 
ACS patients, and no significant differences were found. 
CONCWSIONS In this in vivo study, IVUS-VH identified IDTCFA as a more prevalent finding in ACS than 
in stable angina patients. GAm Coli Cardiol2005;46:2038-42) © 2005 by the Americ:m 
College of Cardiology Foundation 
Sudden cardiac death or unheralded acute coronary syn-
dromes (ACS) are common initial manifestations of coro-
nary atherosclerosis, and most such events occur at sites of 
non-flow limiting coronary atherosclerosis (1,2). Autopsy 
data suggest that plaque composition is a key determinant of 
the propensity of atherosclerotic lesions to provoke clinical 
events. Thin-cap fibroathcroma (TCF A) plaques with large 
avascular, hypoeellular lipid cores seem particularly prone to 
rupture and result in epicardial occlusion (3-5). 
Careful systematic evaluation, in a large series of victims 
of sudden cardiac death, suggested that ruptured TCF A was 
the precipitating factor for 60% of acute coronary thrombi. 
Furthermore, 70% of those patients had other TCF As that 
had not ruptured (5). 
Intravascular ultrasound (IVUS) is the gold standard for 
evaluation of coronary plaque, lumen, and vessel dimensions 
(6,7). However, although visual interpretation of gray-scale 
IVUS can identify calcification within plaques, it cannot 
reliably differentiate lipid-rich from fibrous plaque (7). 
Recently, spectral analysis of IVUS radiofrequency data 
(IVUS-Vrrtual Histology [IVUS-VH]) has demonstrated 
potential to provide detailed quantitative information on 
From the Er-o~smu" :Medico.! Center, Thoraxccnter, Rotterdam, t:hc Netherland,. 
Manu=1pt rccc',ved May 25, 20{)5; revi,ed man<.L,cript ree<'ived June 24, 2005, 
accepted july 25, 2005. 
plaque composition and morphology and has been validated 
in studies of CA"Planted human coronary segments (S). 
In the present study, we evaluated the prevalence of 
IVUS-derived TCF A (IDTCF A) in coronary artery seg-
ments with non-significant lesions on angiography using 
IVUS-VH. 
MElliODS 
In 55 patients, a non-culprit, de novo, angiographically 
non-obstructive (<50%) lesion was investigated with 
IVUS-VH. Written informed consent was obtained from 
:ill patients. 
IVUS-VH acquisition and analysis. Details regarding the 
validation of the technique on C."q>lanted human coronary 
segments have previously been reported (S). Briefly, 
IVUS-VH uses spectral analysis of IVUS rndio:frequency 
data to construct tissue maps that classity plaque into four 
major components (fibrous [labeled green], fibrolipidic [la-
beled greenish-yellow], necrotic core [labeled red], and 
calcium [labeled white]) which were correlated with a 
specific spectrum of the radio:frequency signal and assigned 
color codes (S). 
Intravascular Ultrasound-V rrtual Histology data were 
acquired after intracoronary administration of nitrates using 
a continuous pullback (Ultracross 2.9-F 30-MHz catheter, 
Boston Scientific, Santa Clara, California), by a dedicated 
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Abbreviations and Acronyms 
ACS "" acute coronary ~-yndrome 
IDTCFA ::::: intravascular ul=ound-derivcd thin-cap 
fibroatheroma 
IQR "" intcrqu:mile =ge 
IVUS "" intrnvnscuhr ultr':Uiound 
IVUS-VH"" lntravnscuhr Ultro.sound-Vlrtllal Histology 
LAD = left anterior de~cending coronary artery 
LCX = left circumfk.x artery 
PAY 
RCA 
ROI 
TCFA 
"" percent atheroma 
= right coronary artery 
= region of interest 
= thin-cap fibroatheroma 
lVUS-\IH console (Volcano Therapeutics, Rancho Cor-
dova, California). The IVUS-\IH data were stored on a 
CD-ROM and sent to the imaging core lab for o:ffi.inc 
analysis. Intravascular ultrasound B-mode images were re-
constructed from the radiofrequency data by customized 
software (IVUSLab, Volcano Therapeutics, Rancho Cor-
dova, California). Manual contour detection of both the 
lumt..'"Il and the media-adventitia interface was performed, 
and the radiofrequency data were normalized using a tech-
nique known as "blind deconvolution," an iterative algo-
rithm that deconvolves the catheter transfer function from 
the backscatter, thus accounting for catheter-to-catheter 
variability (9). Geometric and compositional data were 
obtained for every slice and expressed as mean percent for 
each component. The plaque eccentricity index (EI) was 
calculated by dividing the minimum plaque thickness by the 
ma.ximum plaque thickness. Percent atheroma volume 
(PA V) was defined as: EEM,u~a ~ lumen""',_/EEM,""" X 
100, where EEM refers to C..\.1:emal elastic membrane. 
Subsequently, we evaluated the presence of IDTCF A 
lesions along the interrogated vessels, and their incidence 
and characteristics were determined. Finally, the spatial 
distribution ofiDTCF A along the coronaries was evaluated 
starting from the ostium and dividing the vessel in 10-mm 
segments, evaluating a minimal length of 30 mm. 
Definition of IDTCF A. Two experienced, independent 
IVUS analysts defined IDTCF A as a lesion ful£lling the 
following criteria in at least three consecutive frames: 1) 
necrotic core 2:10% without evident overlying fibrous tissue 
(Fig.!); md 2) PAV "'40%. 
We selected this cutoff value because TCF A lesions are 
very unlikely present in segments with <40% occlusion 
(10). Cross sections with non-uniform rotational distortion 
artifact were excluded from the analysis. 
Statistical analysis. Discrete variables are presented as 
counts and percentages. Continuous variables arc presented 
as medians (25th, 75th percentile) or mean values :!: SD 
when indicated. Pearson's chi-square or Fisher exact test, 
Student t test, and WJ.lcoxon rank-sum tests were per-
formed, as indicated. A two-sided p value of <0.05 indi-
cated statistical significance. Logistic regression analysis was 
performed to identifY potential predictors of the presence of 
IDTCF A. Statistical analyses were performed with usc of 
11.5 SPSS software (SPSS Inc., Chicago, Illinois). 
RESULTS 
The baseline characteristics of the patients (n = 55) we 
studied are presented in Table 1. Thirty-four (61.8o/o) 
patients had at least one IDTCF A in the region of interest 
(ROI). 
The population was prospectively divided into two 
groups, stable patients and patients presenting with ACS 
(defined as unstable angina, non-ST -segment elevation 
myocardial infarction, or ST -segment elevation myocardial 
infarction). 
IDTCFA incidence and predictors. Acute coronary syn-
drome patients had a signi£cantly higher incidence of 
IDTCFA than stable patients (3.0 [interquartile range 
(IQR) 0.0 to 5.0] vs. 1.0 [IQR 0.0 to 2.8], p = 0.018). 
\Nhen corrected for the length of the ROI, the density of 
F"~g~~re 1. Lef:: anterior descending artery depicted by Intrav:1scuhr Ultrn..;ound-Vll"tU:Il Histology, where calcified, fibrous, fibrolipidic, nnd necrotic core 
regiom are bbeled white, green, greenish-yellow. and red, re~pectively. Panel A show.; :m inmvnscuhr ultrn.wund cro~s-t<ectional area recon~tructed from 
bnekscattered signals. Panel B ~hovvs the corresponding tissue map depicting a necrotic core-rich pbque w:ith necrotic core tisoue in contact with the lumen. 
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Table 1. Baseline Characteristics (n "" 55) 
Age (VI'S::':: SD} 
M:t!e gender 
Diabetes 
Hyperten~ion 
Current smoking 
Previous smolcing 
Hypercholesterolemia 
Family history of coron:uy di.5e::u;e 
Vessel 
Right coron;uy artery 
Left anterior descending 
Left circumflex 
Clinical present:Ltion 
St:~.ble 
Acute eoron:uy syndrome 
n(%) 
57.6 :±:: 9.5 
44 (80.0) 
5 (9.1) 
20 (36.4) 
15 {27.3) 
14 {25.5) 
46 (83.6) 
30 (54.5) 
22 {40.0) 
23 (41.8) 
10 (18.2) 
32 (58.2} 
23 (41.8) 
IDTCFA remained statistically significant (0.7 [IQR 0.0 to 
1.3] !DTCFNcm vs. 0.2 [IQR 0.0 to 0.7] !DTCFNcm, p 
~ 0.031) (Table 2). 
:--Jo relation was found between patient's ch:l!acteristics 
such as gender (p = 0.917), diabetes (p = 0.217), smoking 
(p = 0.904), hypercholesterolemia (p = 0.663), hyperten-
sion (p = 0.251), or family history of coronary heart disease 
(p = 0.136) and the presence ofiDTCFA. 
Characteristics and location. We compared the severity 
(mean PAV 56.9 ± 7.4% vs. 54.8 ± 6.0%, p = 0.343) and 
the composition (mean percent necrotic core 19.7 ± 4.1% 
vs. 18.1 :!: 3.0%, p = 0205) ofiDTCFAs between ACS 
and stable patients, and no significant differences were 
found. Although not significantly, the left anterior descend-
ing coronary artery (LAD) (73.9% of the LADs, n = 23) 
was the most frequent location, followed by the left circum-
flex artery (LCX) (60.0% of the LCXs, n = 10) and the 
right coronary artery (RCA) (50.0% of the RCAs, n = 22, 
p ~ 0.254). 
Four patients were e:xcluded from the spatial distribution 
subanalysis, three because the IVUS assessment of the ROI 
was shorter than 30 mm and the last one because the 
pullback did not reach the ostium. A total of 99 IDTCF A 
were present in vessels that met the aforementioned criteria. 
A clear clustering pattern was seen along the coronaries, 
with 35 (35.4%), 31 (31.3%), 19 (19.2%), and 14 (14.1%) 
IDTCFAs in the first 10 mm, 11 to 20 mm, 21 to 30 mm, 
and ;::::;31 mm segments, respectively, p = 0.008 (Fig. 2). 
The results showed a clear clustering pattern of the lesions 
:Uong the coronaries, with 66 (66.7%) IDTCFA located in 
0-10 11-20 21-30 ~31 
Distance from the ostium (mm) 
Figure 2. Bar gmphs illustr:lting the frequency ofintr:~va:;cuhr ultm.~ound­
derivcd thin-cap fibroatheror= (IDTFCA) starting from the ostium. 
the first 20 mm, whereas further along the vessels the 
incidence was significantly lower (33, 33.3%, p = 0.008). 
DISCUSSION 
Post-mortem observations have documented several char-
acteristic histologic:U patterns that are substrates for sudden 
death related to epicardial coronary occlusion, of which the 
most common is TCFA (5,11,12). The same srudies have 
demonstrated that plaque rupture at TCF As may also occur 
without clinic:U consequences. The ability to identify TCF A 
in patients would both help clari.:fjr the natural history of 
TCF A and provide the means to assess the effects of 
pharmacological, or other, intervention. 
Until recently, no technique could identify TCF A in vivo. 
However, spectral analysis of IVUS radiofrequency (IVUS-VH) 
data has demonstrated potential to provide detailed quan-
titative information both on overall plaque composition and 
on the anatomic relation of specific plaque components to 
the lumen of the vessel, and it has been validated in studies 
of e: .. 'planted human coronary segments (8). 
IDTCF A definition. It is well established that tissue 
shrinkage occurs during tissue fixation (13). Shrinkage of up 
to 60%, 15%, and 80% can occur during critical-point 
drying, free drying, and air drying, respectively (14). Fur-
thermore, postmortem contraction of arteries is an addi-
tional confounding factor (15). 
.Although the most accepted threshold to define a cap as 
"thin" has been set at 65 f.Lm (16), a number of important 
Table 2. Incidence and Characteristics of IDTCFA Lesions in Stable and ACS Patients 
Length of ROI IDTCFA IDTCFNcm %PAV %~C EI 
St:Lble (n - 32) 35.41 '::':: 11.6 1.0 (0.0, 2.8) 0.2 (0.0, 0.7} 54.8 ± 6.0 18.1 ± 3.0 0.23 ::':: 0.1 
ACS (n = 23) 33.90 '::':: 15.0 3.0 (0.0, 5.0) 0.7 (0.0, 1.3) 56.8 :±: 7.4 19.7 :±: 4.1 0.27 :±: 0.2 
p value 0.684 0.018 0.031 0.343 0.205 0.35 
Cor~tinuou~ V:lriabb P.r<: pr~sc:r>ted U.' mccli:ms (25th, 75th percentile) or m= values :::: SD when indirnted. 
ACS = acute coror>ary >-yndrome; EI = plaque eccentricity index {defir>ed"" minimum plaque thiclm""' divided by maximum plaque thickne;;); IDTCFA = intr:J.v:t.<culru" 
ultrasound-derived thin-rnp fibroatherom~;% PAV"' percent atheroma volume (ddlned"" EEM:.~,- lumen.,..jEEM..,., X 100, where EEM refer. to external clu.,tic 
memb,.,ne); ROI "' region ofintere~t;% NC "" percent neaoti~ core of d1e croo,-«ecrional urea. 
195 
Chapter 5.2 
ex vivo studies have used higher (> 200 ~-tm) thresholds 
(4,17,18). Indeed, one of these studies identified a mean cap 
thickness of 260 and 360 ~-tm for "vulnerable" and "non-
vulnerable" plaques, respectively (18). Because the axial 
resolution of IVUS-'VH is between 100 to 150 JMD, we 
assumed that the absence of visible fibrous tissue overlying a 
necrotic core suggested a cap thickness ofbelow 100 to 150 J.Lffi 
and used the absence of such tissue to define a thin fibrous 
cap (19). Figure 1 depicts a typical e.xample of!DTCFA. 
Incidence, characteristics, and distribution ofiDTCFA The 
major findings of our study were first that IVUS-VH 
findings, compatible with IDTCF A, were common in 
non-culprit lesions of patients undergoing percutaneous 
intervention in another vessel. Second, the prevalence of 
IDTCF A was significantly higher in patients who presented 
with ACS compared to stable patients. In addition, the 
distribution of IDTCF A lesions along the coronary vessels 
was clearly clustered. Finally, we found no signilicant 
correlation between the presence of conventional risk factors 
and the occurrence of IDTCF A. 
In vivo studies established that a multifocal instability 
process is present in ACS (20,21). Rioufol et al. (20) found 
at least one plaque rupture remote from the culprit lesion in 
80% of patients and from the culprit artery in 71% of 
patients (20). The significantly higher prevalence of 
IDTCFA in non-culprit coronaries of patients presenting 
with an ACS supports the theory that holds ACS as 
multifocal processes. 
The distribution of the IDTCF A in the coronaries was in 
line with previous e.\: vivo and clinical studies, with a clear 
clustering pattern from the ostium, thus supporting the 
non-uniform distribution of vulnerable plaques along the 
coronary tree (22,23). Of note, the mean PAV and the mean 
necrotic core percentage of the IDTCF As detected by 
IVUS-VH were also similar to previously reported his-
topathological data (55.9% vs. 59.6% and 19% vs. 23%, 
respectively) (10). 
The large number of high-risk plaques found throughout 
the coronary tree by means of angiography, angioscopy, 
IVUS, and palpography, in addition to the unpredictability 
of the natural history of such lesions and the uncertainty 
about whether vulnerable plaque characteristics will subse-
quently lead to fatal or non-fatal ischemic events, suggests 
that potenti::U local preventive strategies could not be cost-
effective (12,20,21,24,25). On the contrary, a systemic 
"phque stabilization" approach including statins and 
angiotensin-converting enzyme inhibitors could be capable 
of "cooling-down"' the inflammatory burden. 
To our knowledge, this is the :first study to detect in vivo 
the presence of an IVUS surrogate of TCF A. This novel 
intravascular diagnostic tool could potentially aid the assess-
ment of the effect of antiathcrosclerotic drugs, and allow a 
more comprehensive pathophysiologic approach towards 
natural history studies. 
Study limitations. The present was an observational study 
where we evaluated only one coronary artery per patient. 
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The inferior a.....ial resolution ofiVUS-'VH in comparison to 
histology could influence our results. This study does not 
directly assess the incremental value of IVUS-VH over 
visu::U identification of plaque characterization. The main 
finding of the study (IDTCF A) is only a surrogate of a 
histopathological finding. Besides, the lack of a direct 
comparison between IVUS-VH and histopathology renders 
our observation to some extent only exploratory. Accord-
ingly, interpretation of our findings must be cautious. 
Prospective studies are needed in order to evaluate the 
prognostic value and natural history of such finding. The 
seemingly high prevalence ofiDTCFA in comparison with 
histopathological studies is mainly driven by the sampling 
limitation of such studies and has previously been acknowl-
edged (26). 
Conclusions. In this in vivo study, IVUS-'VH identified 
IDTCF A as a more prevalent finding in ACS than in stable 
angina patients. Prospective studies are needed in order to 
evaluate the prognostic value of such finding in natural 
history studies. 
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Aims To compare the global characteristics of patients with and without evidence of plaque rupture (PRJ 
in their coronary tree and to evaluate the phenotype of ruptured plaques using intravascular ultrasound 
(lVUS) radiofrequency data analysis (IVUS-VH). 
Vulnerable plaque 
Methods and results Forty patients underwent three-vessel IVUS·VH interrogation. Twenty-eight PRs 
were diagnosed in 26 vessels (25.7% of the vessels studied) of 20 patients (50% of the population). 
Ruptures located in the left anterior descending were clustered in the proximal part of the vessel, 
whereas ruptures located in the right coronaty artery were more distally located (P = 0.02). Patients 
with at least one PR presented Larger body mass index (BMI) (28.4 = 3.7 vs. 25.8::: 2.6 kg/m2 , 
P= 0.01) and plaque burden (40.7 ± 7.6 vs. 33.7 ± 8.4%, P= 0.01) than patients without rupture, 
despite showing similar lumen cross-sectional area (9.6 ± 3.3 vs. 9.2 ± 2.3 mm2 , P"" 0.60). Among 
current smokers, 66.7% presented a PR in their coronary tree. Finally, PR sites showed a higher 
content of necrotic core compared wlth minimum lumen area sites {17.48 ± 10.8 vs. 13.10 ± 6.5%, 
P = 0.03) and a trend towards higher calcified component. 
Conclusion Patients with at least one PR in their coronary tree presented larger BMI and worse IVUS-
derived characteristics compared with patients without PR. 
Introduction 
!t has been established that coronary plaque rupture (PR) is 
the cause of death in a large proportion of sudden coronary 
death patients. 1 Despite its pre-conceived dire prognosis, 
retrospective studies have determined that PR is a 
common finding in both coronary and non-coronary sudden 
death patients. 1•2 !n addition, clinically silent PR has been 
identified as a cause of plaque progression.3 •4 The fate of 
a given atherosclerotic plaque is thus tinked not only to its 
severity but also to its histological composition, and the 
presence of a rich necrotic core has been consistently 
related to plaque fissuring.5•6 
Intravascular ultrasound (!VUS) has been largely demon-
strated to be an accurate diagnostic tool able to provide a 
high resolution, real ·time, tomographic view of the coronary 
arteries. As such, several studies have portrayed the preva-
lence of PR in living patients by means of IVUS.7 •8 IVUS has, 
though, a suboptimal predictive value to estimate the com-
position of coronary arteries, particularly of tipid deposits. 9 
• Corresponding: author. Tel: +31 10 4635260; fax: +31 10 4369154. 
E·ma/1 address: p.w.j.c.scrruys@erasmusmc.nl 
In turn, spectral analysis of IVUS radiofrequency data has 
demonstrated improved accuracy for tissue characteriz-
ation.10 Besides, to date, no study has reported the global 
burden of the disease and its relationship with PR by 
means of IVUS. 
The purpose of our study was two-fold: first, to compare 
the global characteristics of patients with and without evi-
dence of PR in their coronary tree, and secondly, to evaluate 
the phenotype of ruptured against non-ruptured plaques 
using !VUS radiofrequency data analysis (IVUS-VH). 
Methods 
Patients 
In this single-centre, investigators-driven, observational, prospec-
tive study, patients referred to our institution for elective or 
urgent PC! with the absence of extensive caldfica.tion, severe 
vessel tortuosity and haemodynamic instability and with suitable 
anatomy underwent IVUS interrogation of the three main epicardial 
coronal)' arteries. The patients included in this study, are part of 
published (1815·1)11 and unpublished (LICO, BETAXJ mono-centre 
studies conducted at our centre. 
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Patients with stable angina, unstable angina, and acute myocar-
dial infarction (MI) were included. Ml was diagnosed by an increase 
in the creatine kinase MB Level to more than two-fold the norma\ 
limit. Acute coronary syndrome (ACS) patients encompassed 
patients presenting With unstable angina, non-ST·segment elevation 
Ml, or ST-segment elevation MI. The institution's Ethics Committee 
approved the study protocol, which complies with the Declaration 
of Helsinki, and written informed consent was obtained from all 
patients. 
Intravascular ultrasound 
IVUS acquisition 
The IVUS catheters used were commercially available mechanical 
and electronical catheters (Ultracross™ 30 MHz catheter, Boston 
Scientific, Santa Clara, USA; Eagle Eye™ 20 MHz catheter, Volcano 
Corporation, Rancho Cordova, USA). After administration of intra· 
coronary nitrates, the IVUS catheter was introduced up to the 
distal coronary bed of the three coronary vessels. IVUS was aimed 
to be performed prior to any intervention. Using an automated pull· 
back device, the transducer was withdrawn at a continuous speed of 
0.5 mm/s until the ostium was seen. Cine runs, before and during 
contrast injection, were performed to define the position of the 
\VUS catheter before the pullback was started. \VUS-VH (Volcano 
Corporation) acquisition was ECG-gated using a dedicated console 
(Volcano Corporation). \VUS-VH data were stored on CD-ROM/DVD 
and sent to the imaglng core lab for offline analysis. 
IVUS~VH analysis 
\VUS B-mode images were reconstructed from the RF data by 
customized software, and contour detection was performed using 
cross-sectional views with a semi-automatic contour detection soft-
ware to provide geometrical and compositional output (lvusLab 3.0 
for 30 MHz acquisitions and lvusLab 4.4 for 20 MHz acquisitions, 
respectively; Volcano Corporation). The RF data were normalized 
using a technique known as 'Blind Deconvolution', an iterative 
algorithm that deconvolves the catheter transfer function from the 
backscatter, thus accounting for catheter-to-catheter variablity.11 
Details regarding the validation of IVUS-VH on explanted human 
coronary segments have previously been reported.10 Briefly, 
IVUS-VH uses spectral analysis of IVUS radiofrequency data to con-
struct tissue maps that classify plaque into four major components. 
In preliminary in vitro studies, four histological plaque components 
(fibrous, fibrolipidic, necrotic core, and calcium) were correlated 
with a specific spectrum of the radiofrequency signat.10 These 
different plaque components were assigned colour codes. 
Calcified, fibrous, fibrolipidic, and necrotic core regions were 
labelled white, green, greenish-yellow, and red, respectively. 
The contours of the external elastic membrane (EEM) and the 
lumen~intima interface enclosed an area that was defined as the 
coronary plaque plus media area. Plaque burden was calculated as 
[(EEMarca -lumenorca/EEM:,,"a) x 100]. Following a previously 
reported classification, PR was defined as a ruptured capsule with 
an underlying cavity (Figure 1) or plaque excavation by atheroma-
tous extrusion with no visible capsu\e.7.8 Rupture sites separated 
by at least 5 mm length of rupture-free vessel were considered as 
different ruptures. Screening for diagnosis of a PR required the inde-
pendent review and agreement between two experienced \VUS 
observers (G.A.R.·G. and H.M.G.-G.), who had no knowledge 
about demographical data of the patients. Disagreement was 
solved by consensus between the observers. lumen contour detec-
tion at the rupture site was performed following the intima-lumen 
interface, excluding the rupture cavity from the plaque cross· 
sectional area (CSA) calculation. Absolute geometrical data and 
absolute and relative compositional data were obtained for each 
CSA and an average was calculated for each coronary and for the 
total coronary tree. Finally, measurements were calculated in 
CSAs meeting criteria of PR and at the site of the minimum lumen 
area (MlA). 
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Figure 1 Thr(.'('·vesscl imaging using IVUS-VH (where caldfied tl:osue is 
labelled as white, fibrous as grC<.'n, fibrolipidlc tl:osue as grC<.'nish-yellow, 
and necrotic core as red) in a 57-year-old male presenting with unstable 
angina. PR in the ostiill LAD (lAD a). The underlying substrate of the cavity 
is rich in necrotic-core (red) ilnd caldum (white), whereas the thrombus 
has migrated distally (LAD c, asterisk). 
As pre-spedfied subanalysis, we compared the different geo-
metrical and compositional characteristics of the three main epicar-
dial coronaries. In addition, the difference between culprit/target 
and non-culprit/non-target vessels was assessed. 
Statistical analysis 
Discrete variables are presented as counts and percentages. 
Continuous variables are presented as means ± SO or medians 
(25th, 75th percentile) when indicated. On the basis of previous his-
topathological findings showing that ruptured plaques presented 34% 
of necrotic core, 10% more than non-ruptured plaques, 1 we calcu-
lated a sample size of 36 subjects to achieve a power of 80% to 
detect a true difference in population means, considering a type I 
error of O.OS (two-sided) and a within group standard deviation of 15. 
Comparisons between groups were performed using paired and 
independent Student's t-test, or ;1 tests as indicated. For variables 
with a non-normal distribution, we used Kruskal-Wallis or Wilcoxon 
signed ranks tests as indicated. A two-sided P-vatue of less than 
0.05 indicated statistical significance. Statistical analyses were per· 
formedwiththeuseofSPSSsoftware, version 13.0 (Chicago, ll, USA). 
Results 
Patients 
Forty-six patients were included in the study protocol. 
Subsequentty, six patients were excluded from the final 
analysis due to the absence of coronary plaque outside the 
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stented segment in one patient, and bad quality acquisition 
owed to non-continuous putlback in five patients. 
Accordingly, 40 non-consecutive patients were prospectively 
included in the study. JVUS interrogation of the three main 
coronaries was attempted in atl patients. Two-vessel JVUS 
interrogation was achieved in all patients and three-vessel 
IVUS imaging was achieved in 31 (77.5%) cases. Five 
vessels were excluded from the analysis due to the tack of 
a diseased non-stented segment. Patient characteristics 
are provided in Table 1. The mean age was 55.7 ± 11.0 
years. Twenty-nine {72.5%) patients were male. There was 
a low prevalence (10.0%) of diabetes. Thirteen (32.5%) 
patients presented with stable angina (SA), 12 {30.0%) 
with unstable angina, and 15 (37.5%) with AM!. The global 
geometrical and compositional characteristics of the coro-
nary tree are presented in Table 1. 
PR: prevalence and location 
Twenty-eight PRs were diagnosed in 26 vessels (25.7% of the 
vessels studied) of 20 patients (50% of the population). 
Sixteen (59.3%) ACS patients presented at least one PR in 
Table 1 Baseline characteristics and average IVUS parameters 
(n ""40) 
Age (years ± SO) 
Male sex 
Diabetes 
Hypertension 
Current smoking 
Previous smoking 
Hypercholesterolaemla 
Family history of coronary disease 
Height {em± SO) 
Weight (kg± SO) 
BMI (kg/m~ ±SO) 
LOL (mmol/L ±SO) 
HOL (mmol/L ±SO) 
Clinical presentation 
SA 
Unstable angina 
AcuteMI 
IVUS-VH measurements 
Analysed length (mm)~ 
Geometrical parameters 
Lumen CSA (mm2 ±SO) 
Vessel CSA (mrrf ± SO) 
Plaque CSA (mm2 ± SO) 
Plaque max. thickness (mm :':SO) 
Plaque burden (% ± SO) 
Compositional parameters 
Calcium CSA (mm2 ± SO) 
Calcium (%±SO) 
Fibrous CSA (mm2 ± SO} 
Fibrous (% ± SO) 
FibroUpidic CSA (mm2 ± SO) 
Fibrolipidic (% ± SO) 
Necrotic core C5A (mm2 ±SO) 
Necrotic core(%± SO) 
n (%) 
55.7±11.0 
29 {n.5J 
4 (10.0) 
17 (42.5) 
15 (37.5) 
6 (15.0) 
20 (50.0) 
19 (47.5) 
174.5 ± 9.2 
82.8 ± 14.0 
27.1 ± 3.4 
2.70 ± 0.7 
1.20 ± 0.5 
13 (32.5) 
12 (30.0) 
15 (37.5) 
46.9 (33.9-59.8) 
9.4 ± 2.8 
15.1 ±4.8 
5.8 ± 2.7 
0.9 ± 0.2 
37.2±8.7 
0.07 (0.03-0.14) 
2.50 (1.45-3.53) 
1.53 (0.81-2.11) 
57.84 (52.3-64.5) 
o.48 (0.26-0.n) 
17.96 (13.9-21.9) 
0.26 (0.15-0.42) 
10.13 (6.2-12.6) 
Discr~tc variables arc prc-..cntcd t~s counts and percentages. Continuous 
variables ar~ presented as means± SO or medians (25th, 75th percentile) 
when fndtc..ted. 
"The average analysed l~ngth per <:oronary. 
their coronary tree, whereas such finding was observed in 
four (30.8%) stable patients. The tear was located in the 
shoulder of the plaque in 18 (64.3%) cases and in the 
centre of the plaque in 10 (35.7%) cases. 
Ruptures were located in the left anterior descending 
(LAD) artery in 13 cases (34.2%), in the left circumflex 
(LCx) in seven cases (21.2%), and in the right coronary 
artery (RCA) in eight cases (24.2%). Ruptures located in 
the LAD were ctustered in the proximal part of the vessel 
[median mm from the ostium (interquartile range, IQR): 
14.16 (8.5-26.5)], ruptures located in the LCx were widely 
distributed [median (IQR): 21.9 (5.7-35.5)], and ruptures 
in the RCA were more distally located [median (IQR): 38.8 
(28.8-60.0)]. PRs were located at the MLA in six cases 
(21.4%), proximal to the MLA in nine cases (32.1%) and 
distal to the MLA in 11 cases (39.3%). The MLA could not 
be identified accurately in two (7 .1 %) cases due to the pre-
sence of diffuse disease. Six (28.6%) of the culprit vessels of 
ACS contained aPR, whereas such finding was present in 16 
{31.4%) of non-culprit vessels. 
Multiple PR was present in six ACS patients (22% of all ACS 
patients). No multiple PR was identified in stable patients. 
Two patients presented two different ruptures in the same 
vessel. 
PR: demographical and IVUS-derived 
characteristics 
Table 2 depicts the demographical characteristics and the 
IVUS-VH measurements of patients with and without the 
presence of PR in their coronary tree. Body mass index 
(BM!) was significantly higher in patients with rupture 
(28.4 ± 3.7 vs. 25.8 ± 2.6 kg/m2, P = 0.01 ). Of note, 
66.7% of current smokers presented a ruptured plaque in 
their coronary tree. 
Patients with ruptured plaques in their coronary tree had 
globally more severe disease (plaque burden 40.7 ± 7.6 vs. 
33.7 ± 8.4%, P=0.01) (Table 2). 
Finally, PR sites showed a higher relative content of 
necrotic core compared with MLA sites (16.7, 7.9-26.5 vs. 
11.8, 8.4-17 .1%, P = 0.03) {Table 3). 
Differences between coronaries and culprit vs. 
non-culprit lesions 
The LAD presented more severe plaques (plaque burden; LAD 
42.2 ± 9.9 vs. LCx 33.17 ± 9.2% vs. RCA 33.96 ± 10.3), more 
calcified plaques (LAD 3.15; 1.74-4.91 vs. LCx 2.10; 
1.17-3.79 vs. RCA 1.49; 0.39-2.53%), and showed larger 
necrotic core content (lAD 11.68; 5.3-15.8 vs. LCx 7.71; 
4.15-13.6 vs. RCA 9.18; 3.87-13.3%) of plaques compared 
with the LCx and the RCA, respectively (Table 4). 
There were no significant differences in IVUS~VH measure-
ments between SA (n = 13) and ACS (n = 27) patients. 
IVUS-VH parameters other than mean plaque burden 
(40.62 :=:: 10.7% vs. 35.26 ± 10.2 %, P= 0.02) did not differ 
significantly between culprit/target and non-culprit/non-
target vessels. Furthermore, in ACS patients, geometrical 
and compositional characteristics did not differ significantly 
between culprit and non-culprit vessels, only showing trends 
for larger plaque burden {39.39 ± 10.0 vs. 34.60 ± 10.0%, 
P = 0.07) and relative necrotic core content (12.16; 
5.4-16.6 vs. 9.66; 5.2-13.8%, P= 0.17) in culprit vessels. 
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Table 2 Demographica\ characteristics and !VUS·derived of patients with and without the presence of PR 
Rupture {n "" 20) No rupture (n = 20) P-value 
Age {years ± SO) 53.0 ± 11.4 58.5±10.1 0.12 
BMI (kg/m2 ±SO) 28.4 ± 3.7 25.8 ± 2.6 0.01 
se, 
Male (% v.rithin RF) 17 (58.6) 12 (41.4) 0.08 
Female (% within RF) 3 (27.3) 8 (72.7) 
Diabetes (% within RF) 2 (50.0) 2 (50.0) 0.99 
Hypertension (%within RF) 10 (58.8) 7 (41.2) 0.34 
Current smoking (%within RF) 10 (66.7} 5 (33.3) 0.09 
Hypercholesterolemia (% within RF) 11 (55.0) 9 (45.0) 0.53 
Family history of coronary disease 8 (42.1) 11 (57.9) 0.34 
(% within RF) 
LDL (mmol/L ±SO) 2.72 ± 0.5 2.69 ± 0.9 0.92 
HDL (mmol/l ± SO) 1.19 ± 0.6 1.21 ± 0.3 0.91 
Clinical presentation 
SA 4 (30.8) 9 (69.2) 0.09~ 
ACS 16 (59.3) 11 (40.7) 
IVUS·VH measurements 
Geometrical parameters 
Lumen CSA (mm2) 9.6 ± 3.3 9.2 ± 2.3 0.60 
Vessel CSA (mm2) 16.5 ± 6.0 13.8 ± 2.7 0.08 
Plaque CSA (mm2) 6.9 ± 3.3 4.6 ± 1.4 0.01 
Plaque max. thickness (mm) 1.0 ± 0.2 0.8 ± 0.2 0.02 
Plaque burden (%) 40.7± 7.6 33.7 ± 8.4 0.01 
Compositional parameters 
Calcium CSA (mm2) 0.09 (0.06-0.16) 0.04 (0.02-0.11) 0.01 
Calcium(%) 2.53 (2.09-3.53) 2.06 (0.67-3.58) 0.14 
Fibrous CSA (mm2) 1. 94 (1.31-3.49) 1.00 (0.70-1.68) 0.003 
Fibrous(%) 62.3 (55. 9-64.8) 54.2 (47.0-63.8) 0.04 
Fibrolipidic CSA (mm2) 0.58 (0.34-1.08) 0.34 (0.22-0.55) 0.03 
Fibrolipidic (%) 17.8 (15.0-22.5) 18.9 (12.8-21.9) 0.95 
Necrotic core CSA (mm2) 0.30 (0.22-0.51) 0.22 (0.06-0.37) 0.02 
Necrotic core (%) 10.74 (7.7-12.5) 9.22 (4.1-13.02) 0.26 
Values arc expressed as means ± SO. 
"Across groups. CompariSons between groups were performed using independent Student's t-tcst,l or Kruskall-Wallis test 
as1nd1catcd. 
Table 3 Focal characteristics of ruptured plaques and MlA controls (n = 28) 
Rupture site MlAsite P·value 
Geometrical parameters 
Lumen CSA (mm2) 9.47 ± 6.3 6.76 ± 4.2 <0.001 
Vessel CSA (mm2) 19.09 ± 9.3 19.15 ± 9.8 0.95 
Plaque CSA (mm2) 9.63 ± 4.2 12.38 ± 6.9 0.01 
Plaque max. thickness (mm) 1.38 ± 0.3 1.71 ± 0.5 0.002 
Plaque burden (%) 51.32 ± 10.6 64.06 ± 10.1 <0.001 
Compositional parametersn 
Calcium CSA (mm2) 0.25 (0.05-0.55) 0.27 (0.05-0.49) 0.50 
Calcium (%) 4.75 (1.22-7.83) 2.97 (0.87-7.18) 0.14 
Fibrous CSA (mm2) 3.65 (1.67-5.67) 4.09 (3. 18-6.89) 0.008 
Fibrous(%) 60.3 (50.1-67.9) 58.3 {55. 6-66.2) 0.53 
Fibrolipidic CSA (mm2) 0.94 (0.40-1.82) 1.40 (0.93-3.25) 0.001 
Fibrolipidic (%) 15.4 (10.9-22.6) 20.5 (13.5-28.6) 0.005 
Necrotic core CSA (mm2) 0.83 (0.41-1.52) 0.92 (0.54-1.64) 0.35 
Necrotic core {%) 16.7 (7.9-26.5) 11.8 {8.4--17.1) 0.03 
"Values arc expressed il'l means ::r: SD or mcd1an (IQR) as indicated. Comparisons between groups were 
performed using paired Student's t·tcst and Wilcoxon signed ranks test. 
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Table 4 Differences between the coronaries {n"" 101) 
LAD {n"" 37) LCx (n= 32) RCA {n =32) 
Analysed length (mm ± SD) 42.37 ± 17.7 48.85 ± 20.9 51.76 ± 16.6 
Geometrical parameters 
Lumen CSA (mm2) 8.53 ± 2.6 9.26 ± 3.2 11.07:::4.6 
Vessel CSA (mm2) 14.94 ± 4.6 14.18 ::': 5.6 16.81 ± 6.8 
Plaque CSA (mm2) 6.43 ± 2.8 4.92 ± 3.3 5.74 ± 3.0 
Plaque max. thickness (mm) 1.05 ± 0.3 0.84 ± 0.3 0.85 ± 0.3 
Plaque burden (%) 42.2::9.9 33.17 ± 9.2 33.96 ± 10.3 
Compositional parameters 
Calcium CSA (mm2) 0.11 (0.04-0.22) 0.05 (0.02-0.14) 0.04 (0.01-0.09) 
Calcium(%) 3.15(1.74-4.91) 2.10 (1.17-3.79) 1.49 (0.39-2.53) 
Fibrous CSA {mm2 ) 1.82 (1.12-3.13) 0.90 (0.59-1.55) 1.12 (0.68-2.52) 
Fibrous(%) 62.1 (54.0-68.2) 56.5 (42.5-66.0) 59.5 (52.2-68.0) 
Fibrolipidic CSA (mm2) 0.52 (0.30-1.01) 0.31 (0.16-0.49) 0.34 (0.18-0.83) 
Fibrolipidic (%) 17.6 (12.8-23.0) 15.2 (12.7-21.0) 18.6 (13.5-23.6) 
Necrotic core C5A (mm2) 0.28 (0.19-0.57) 0.14 (0.07-0.30) 0.21 (0.05-0.38) 
Necrotic core (%) 11.68 (5.3-15.8) 7.71 (4.15-13.6) 9.18 (3.87-13.3) 
Values are expressed in means ± SD or median {IQR) as indicated. 
Discussion 
Several histopathological and, more recently, IVUS studies 
have described the distinctive morphological features 
present in PR sites. Nevertheless, none has prospectively 
compared the clinical and IVUS·derived characteristics of 
patients with and without the presence of PR in their coro· 
nary tree. 
In the present prospective three-vessel IVUS study, 
patients with at least one PR in their coronary tree 
presented larger BMI and overall worse IVUS·derived (geo· 
metrical and compositional) characteristics compared with 
patients without evidence of PR. In addition, PR sites had 
a worse phenotype than the MLA sites of the same vessels. 
Coronary PR is the ultimate consequence of the progressive 
accumulation of lipid· rich atheroma and fibrous cap thinning, 
commonty involving haemodynamically non-significant 
lesions. 13 For decades, the corollary of such event has been 
deemed an acute occlusion of the corresponding artery with 
the subsequent ACS and its inherent dire prognosis. Ex vivo 
studies have challenged such concept by providing evidence 
that subclinical rupture is not rare in sudden death patients. 2•4 
Furthermore, recent IVUS studies have reported a prevalence 
of PRof 20-30% in SA patients.7· 12•14 In agreement with such 
previous reports, we identified PR in 30.8% of SA patients, 
whereas 59.3% of the ACS patients presented PR. 
Patients with at least one PR in their coronary tree (50% of 
the population) showed a larger BMI and were more likely 
current smokers. These findings have a physiopathological 
basis because both high body weight15 and smoking16 are 
associated with an increase in the expression of matrix· 
metalloproteinases, enzymes involved in the collagen break· 
down of fibrous caps. 17 Patients with PR also showed more 
severe burden of the disease and larger calcium, fibrous, 
and necrotic content of plaques than patients without 
rupture. 
Several studies showed increased inflammatory marker 
levels, larger lipid cores, and pronounced medial thinning 
in positive remodelled vessels. 18- 20 
Our study extends those earlier findings and establishes a 
link between PR and coronary remodelling. Despite larger 
mean plaque CSAs, patients with the presence of at least 
one PR in their coronary tree showed simitar lumen CSAs. 
The lack of lumen encroachment despite a significant 
increase in plaque burden was probably driven by a positive 
remodelling phenomenon, dearly shown as a significant 
increase in vessel CSA. 
At site-specific locations, ruptured sites showed an overall 
worse phenotype than MLA sites. In particular, ruptured sites 
showed a higher necrotic core content (16.7; 7.9-26.5 vs. 
11.8; 8.4-17.1%, P = 0.03). These results were in line with 
histopathological findings supporting the rote of the athero· 
matous core as the most thrombogenic component of ather· 
osclerotic plaques.21 Of interest, and in agreement with 
Farb et alY who frequently found calcium in ruptured 
plaques, ruptured sites showed a larger calcium content 
than the MLA sites and the overall population. 
It is noteworthy yet confirmatory of a previous ex vivo 
studf3 that there was no significant difference in plaque 
composition between culprit and non-culprit vessels, sup-
porting the validity of the interrogation of a single vessel 
to estimate the global burden of the disease.24 
Nevertheless, several differences were detected between 
the three major epicardial arteries. Interestingly, the LAD 
showed more severe lesions and a worse phenotype than 
the LCx and RCA. Jn addition, ruptures located in the LAD 
were clustered in the proximal part of the vessel, ruptures 
located in the RCA were more distally located, and ruptures 
in the LCx showed no apparent site specificity. A recent IVUS 
study found a similar distribution throughout the coronary 
tree.25 Overall, these findings might potentially explain 
the higher re·stenosis rates seen in the LAD, particularly in 
the proximal LAD, compared with the LCx and RCA, 
respectively. 26 
Clinical and ex vivo studies have conclusively established 
that there is commonly a delay between the rupture of a 
plaque and its clinical consequence, if any. 14•27•28 Indeed, 
Rittersma et al. 28 have recently studied thrombectomy 
material of STEM! patients and found that 51% of the 
patients had day·to-week·old thrombotic material. 
Thrombotic occlusion of a vessel seems to be an episodic 
event4 and the underlying prevailing composition of the 
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cavity (Figure 1) might potentially have a prognostic value in 
identifying plaques at higher risk of occlusion. Large pro· 
spective studies using IVUS·VH might shed light into this 
question. 
Limitations 
All analyses and comparisons performed in the present 
manuscript beyond the assessment of the necrotic core 
content in ruptured vs. non-ruptured plaques should be 
regarded as exploratory and hypothesis-generating because 
we cannot rule out the possibility that inflation of type 1 
error due to multiple comparisons may have confounded 
our results. The relatively small population included may 
limit this study. Small ruptures, ruptures masked by over· 
tying thrombus and the lack of assessment of minor branches 
may lead to an underestimation of the prevalence of such 
finding. Finally, prioritizing patient's safety, the decision 
to perform pre-intervention and three-vessel IVUS was 
at the discretion of the operator, potentially inducing a 
selection bias. 
Conclusions 
The present study extends earlier findings about the preva-
lence, distribution, and morphology of PR in the coronary 
tree. In this prospective three-vessel !VUS study, patients 
with at least one PR in their coronary tree had larger BMI 
and overall worse !VUS-derived characteristics compared 
with patients without evidence of PR. In addition, PR sites 
had a worse phenotype than the MLA sites of the same 
vessels. 
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A 42-year-old man with chronic 
heart failure and permanent 
atrial fibrillation was referred to 
our cardiology institute for diag-
nostic assessment and therapy. 
The patient denied any known 
family history of heart disease. 
No clinical/echocardiographic sign 
of heart disease was detected 
among living first-degree rela· 
tives. Atrial fibrillation and 
progressively worsening effort 
dyspnoea had started at age 25. 
Physical examination showed 
moderate bilateral leg oedema, 
marked hepatomegaly, and raised 
jugular venous pressure and 
gallop rhythm. ECG showed atrial 
fibrillation with right bundle 
branch block and Left anterior 
hemiblock. Cardiomegaly and 
chronic interstitial lung oedema 
were apparent on chest X-ray. 
Echocardiography revealed a 
normally sized, mildly hypokinetic 
left ventricle (ejection fraction= 
45%) and an enlarged, mildly 
hypokinetic ri~t ventricle, 
accompanied by massive right 
and left atrial enlargement and 
severe tricuspid regurgitation. 
The apical portions of both ventricles had a coarsely trabeculated, spongy ap~arance suggestive of non-compaction (Panel A). 
E-wave deceleration time was abnormally shortened in the echo-Doppler profile at transmitral Level (Panel B). Coronary arteries 
were normal at angiography. At the right heart catheterization, restrictive physiology was evident (Panel C). Pulmonary artery pressures 
were 40/20/22 mmHg; mean pulmonary capillary wedge and right atrial pressures were 22 and 15 mmHg, respectively; cardiac index 
was 2.1 L/min/m2. The patient was submitted to heart transplantation, which was successfully performed. The explanted heart 
(Panel D) provided definitive confirmation of biventricular non-compaction and restrictive cardiomyopathy (without signs of infiltrating 
myocardial diseases or desmin accumulation). Ventricular non-compaction has been shown to occur in the context of congenital 
anomalies, otherwise normal hearts or, most often, dilated cardiomyopathy, To our knowledge, the present case provides the first 
documentation of (bi)ventricular non-compaction in the context of a restrictive cardiomyopathy. This obse!Vation is in line with the 
concept that isolated ventricular non-compaction is more likely to be a morphological trait that can be found within different types 
of cardiomyopathy rather than a distinct cardiomyopathy. 
Panel A. Two-dimensional echocardiography in four-chamber view shows huge biatrial dilation, a normally sized left ventricle, and a 
moderately enlarged right ventricle. The apical portions of both ventricles have a coarsely trabeculated, spongy appearance, suggestive 
of ventricular non-compaction. 
Panel B. Transmitral echo-Doppler profile indicates very short deceleration time, suggesting restrictive physiology. 
Panel C. Right ventricular catheterization trace (bottom) shows 'square-root' morphology in the diastolic portion of the cuf\le 
accompanied by protodiastolic pressure above zero, confirming restrictive physiology. 
Panel D. Macroscopic longitudinal section of the explanted heart (lacking the upper portion of the atrial cuff) dearly shows biven-
tricular non-compaction with coarse apical trabeculation and deep inter-trabecular recesses. The non-compacted portions of both ven-
tricles are predominant, drastically limiting cavity volumes, The histological detail (inset) after Mallory's trichrome staining additionally 
shows mild fibrotic endocardial thickening and moderate interstitial fibrosis. 
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Coronary artery remodelling is related to plaque composition. 
Coronary artery remodelling IS related to plaque 
composition 
G A Rodriguez-Granillo, P W Serruys, H M Garcia-Garcia, J Aoki, M Valgimigli, 
C A G van Mieghem, E McFadden, P P T de Jaegere, P de Feyter 
Heart 2006;92:388-391. doi: 1 0.1136/hrt.2004.05781 0 
Objective: To assess the potential relation between plaque composition and vascular remodelling by using 
spectral analysis of intravascular ultrasound (!VUS) rodiofrequency data. 
Methods and results: 41 coronary vessels with non-significant (<50% diameter stenosis by 
angiography), .;; 20 mm, non-ostial lesions located in non-culprit vessels unde!'W"ent IVUS interrogation. 
!VUS radiofrequency data obtained with a 30 MHz catheter, were analysed with IVUS virtual histology 
software. A remodelling index (RI) was calculated and divided into three groups. Lesions with R1 :;:,- 1.05 
were considered to have positive remodelling and lesions with Rl ,:;; 0.95 were considered to have 
negative remodelling. Lesions with Rl :;:,- 1.05 hod a significantly larger lipid core than lesions with Rl 
0.96-1.04 and Rl ,::;; 0.95 (22.1 (6.3) v 15.1 (7.6) v 6.6 (6.9), p < 0.0001). A positive correlation 
between lipid core and Rl (r = 0.83, p < 0.0001) and on inverse correlaf1on between fibrous tissue and 
Rl (r = -0 . .45, p "" 0.003) were also significant. All of the positively remodelled lesions were thin cop 
fibroatheroma or fibroatheromotous lesions, whereas negatively remodelled lesions hod a more stable 
phenotype, with 64% having pathological intimal thickening, 29% being fibrocolcific lesions, and only 7% 
fibrootheromatous lesions (p < 0.0001 ). 
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17 June 2005 Conclusions: In this study, in vivo plaque composition and morphology assessed by spectral analysis of 
IVUS radiofrequency data were related to coronary artery remodelling. 
Glagov ct af' described vascul.:rr remodelling as a compensJ..tory enlargement of the coron.:uy .:~.rteries in response to an increase in pl.:~.que area. This concept 
has further evolved into a dynamic theory whereby vessels 
may also shrink in response to plaque growth.' This 
remodelling modality has been related to a more stable 
phenotype .:~.nd clinic.:~.! presentation,,_., whereas several 
studies showed J1l increase in iniTammatory marker con-
centrations, larger lipid cores, and pronounced mediJl 
thinning in positively remodelled vessels." ' 7 
Recently, retrospective pathological studies have identified 
morphological and compositional features ch.lracteristic of 
plaque rupture."" This has led to a new classification of 
coronary lesions that more comprehensively illustmtcs 
plaque progression.'' 
Grey scale intrawscubr ultrasound ( IVUS) is of limited 
value for identification of specific plaque components.' 0 
However, spectral analysis of IVUS radiofrequency data 
(I\fl,"S virtual histology (YH)) has the potential to provide 
detailed quJlltitativc information on pl.:tque composition Jlld 
has been vJ.lidated in explanted hum • .m coronary segments." 
In this study, we sought to evaluate in vivo the relation 
between plaque composition and coron.:uy artery remodelling 
by using ultr.:tsound r.:~.diofrcquency d.:tta anJ.lysis. In addi-
tion, we classified lesions with respect to their morphology 
,:md evalu.:tted the potential rel.:ition between lesion type and 
coromry remodelling." 
METHODS 
Patients 
Forty one consecutive pJ.tients were retrospectively selected 
after screening a 54 patient database where non-culprit, 
angiographiCJUy non-obstructive (<50%), ,:;; 20 mm, non-
ostiJ.l lesions were investigated with IVUS. Patients were 
excluded if they had diffusely diseased vessels or !Jd(ed .1 
lesion occluding ;:, 40% of the cross sectionJ.l area (CSA). 
Lesions located in proximal and mid segments of a coronary 
artery were included in the study. 
Major exclusion criteria were coronary Jllatomy that 
precluded s.:tfe IVl:;S examination of a suitable region of 
interest. Informed, written consent was obtained fro~ all the 
patients. 
IVUS~VH acquisition and analysis 
Details regarding the vJ.Lidation of the technique on 
explanted human coronary segment.~ have previously been 
reported.'' Briefly, IVUS-YH uses spectral Jllalysis of IVUS 
radiofrcquency data to construct tissue m.:~.ps that classify 
pl.:tque into four major components. In preliminary in vitro 
studies, four histologic.:tl plaque components (fibrous, fibro-
lipidic, lipid core, and calcified) were correlated with a 
specific spectrum of the radiofrequency signJ.l. '' These plaque 
components were assigned colour codes. Calcified, fibrous, 
fibrolipidic, and lipid core regions were labelled white, green, 
greenish yellow, and red, respectively. 
IVUS-YH data were acquired after intracoron.:uy adminis-
tration of nitrates by meJllS of a continuous pullb.;ck 
(0.5 mm/s) with a commerci.:tlly available mechanical sector 
scanner (L'ltracross 2.9 French. 30 MHZ catheter; Boston 
Scientific, Santa Clara, CJ.lifornlJ.., USA) by a dcdiCJted NUS-
VB console (Volcano Therapeutics, R.:tncho Cordova, 
California, USA). The IVUS-YH data were stored on a CD 
ROM and sent to the imaging core laboratory for ofiTine 
anJ.lysis. IVUS B mode images were reconstructed from the 
r.:~diofrequency d.:tta by customised software (IVUSL:lb, 
Volcano Therapeutics). Subsequently, contours of both the 
lumen .:tnd the media-adventitia interface were detected 
Abbreviations: CSA, cross sectional aroo; IVUS, intravascular 
ultrasound; MIA, minimum lumen area; Rl, remodelling index; VH, 
virtual histology 
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m<:~nually. To J.ccount for catheter to c.:ttheter v.:triJ.bility the 
J.cquircd radiofrcqucnc.y dat.:t were norm.:iliscd by .:1 technique 
known as "blind deconvolution". Blind deconvolution is an 
iterative algorithm th.:n dcconvolvcs the catheter transfer 
function from the backsc.:mcr, thus {."!lilbling <JutomJ.tcd datJ. 
normalis<ltion.'"" CompositionJ:l dJtJ of the minimum 
lumen J.IC<l (MLA) were expressed as percentage of the 
plaque CSA corresponding to c.Jch plaque component. 
The MLA site <1nd <l reference site ,.; 10 rnm proximal to 
the lesion were selected. There were no m.:~jor side branches 
between the MLA <1nd reference sites. 
Remodelling was <1sscsscd by means of the remodelling 
index (RI), expressed .:IS the external clastic mcmbr<tnc CSA 
(MLA site) divided by the reference external d<~stic mem-
brane CSA as previously described.'',.". 
We defined positive remodelling as RI ~ 1.05 and negative 
remodelling as RI < 0.95. Values in between were considered 
ncutr.:tl (no remodelling). PercentJge stenosis of the MLA site 
was defined as: 
vcssclareaMLA - lumenur~.,MWvesscl~,NMLA X 100. 
In JccordJnce with previously reponed datJ, we classified 
lesions Js pJthologicJl intimJl thickening (malnly fibrotic-
fibrolipidic tissue, with the lipid core constituting 0% to 
,:;:; = 3% of the CSA), fibroc.:tlcific lesions (featuring m.1lnly 
fibrotic plaques, with some C<llcific<ltion md J lipid core 
occupying between 3-10% of the CSA), fibrous cap atheroma 
(lipid rich (> IO% CSA) plJques with overlying fibrous 
tissue), and thin cap fibroatheroma (lipid-rich(> 10% CSA) 
plaques with no overlying fibrous tissue). Figure 1 depicts 
cxJmplcs of this clo.ssification. To classify lesions, these 
critcriJ hJd to be met in the MLA site plus the immediate 
distal md proxlmo.l cross sections. Since the Jxio.l resolution 
of this technique is between 100--150 ).llTI, we assumed that 
the absence of fibrous tissue overlying a lipid core suggested J. 
cap thickness of below 100-150 ).llTI.'" 
Statistical analysis 
Discrete variables Jre presented <1S counts Jnd percentJges. 
Continuous vJriJbles are presented as meJn {SD). We looked 
for corrclJtions between the RI o.nd both plJ.quc components 
and percentage stenosis MLA by using Pearson corrclJ.tion 
coefficients. Differences in mcms between groups were 
.Jnalysed by a two sided t test or by one way malysis of 
V.Jriance. We compmcd frequencies by means of the x= test. 
A probability value of p < 0.05 indicJted significmce. Do.ta 
were statisticJlly o.n.:tlysed with SPSS software version 11.5 
(SPSS Inc, Chicago, Illinois, USA). 
RESULTS 
TJ.ble 1 shows patientchJ.Iacteristics. Mem age was 55.9 ( 10.9). 
Most patients were men (83%) with o. low prev.:tlence of 
diJ.betes (7.3% ). The study vessel was the right coronary artery 
in 19 patients (46.3%), the left anterior descending in 16 
patients (39.0%), md the left circumflex in six po.tients ( 14.6%). 
Lesions with positive remodelling had significantly larger 
lipid core percentages tho.n lesions with no remodelling or 
negative remodelling (22.1 (6.3)% v 15.1 (7.6)% v 6.6 (6.9)%, 
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Table 1 Baseline characteristics (n=41) 
Ago()'<Xll">) 
Moo 
Diabotos 
Hyportonsion* 
c~!'l'\lnt smoking 
Provio~s smoking 
Hyporcholcstcralaomict 
Family history of ooronory disoo:.c 
ProviQI.Is myoeordiol infarction 
55.9 (10.9) 
19(83%) 
3(7.3%) 
12 (29.3%) 
a (19 . .5%1 
15 (36.6%) 
32(78%) 
19(46.3%) 
6 {14.6%) 
-~ Riaht coronary 
Loft ontcrior dos.::cndina 
Loft cirwmAox 
Clinicol pro!-Cntotion 
No angino:j: 
Stobie ongino 
Umtoblo ongii"KI 
Myocordial infarction 
19 (46.3%) 
16 (39%) 
6 (14.6%) 
11 (26.8%) 
14 (34.1%) 
6(14.6%) 
10 (24.4%) 
Doto oro moon (SO) or numbor (%). 
·e.lood pr<r..s~ro ;,160/95 mm Hg or traalmtlnt far 
hyportonsion; ttotol cholc:storol >5.57 mmol!l or trootmoot 
far hyparcholostcrolcmio; tthosc potients wore studied ot 
scheduled follow up ongiogrophy. 
Table 2 Geometri<:al ond compositionol dolo of the 
minimum lumen oreo (MlA) site 
Remodelling index 
~0.95 0.96--1.04 ;:-1.05 pValoo 
Number 29 (70.7%) 3 (7.3%) 9(22%) 
Ster.osis (%) 63.1 (7.5) 69.1 (8.6) 59.9 (9.9) 0.24 
1.67(1.6) 0.88 
58.1 (12.9) 0.13 
18.1 (12.6) 0.39 
22.1 (6.3) <0.0001 
Cold~c CSA (%) 1.38 (2.7) 2.07 (3.2) 
fibrous CSA (%) 68.6 (13.7) 62.9 (9.5) 
fibralipidic CSA (%) 23.5 (9.9) 19.9 (6.9) 
UpidooroCSA(%) 6.6(6.9) 15.1 (7.6) 
Dota oro moon (SO). 
Percentage stenosis of tho MLA site is coleulatod os vessci""""""'LA -
lullltln0 ..,MWve=I""""""'LA xlOO. Remodelling index {RI) isdoflnod os 
MLA of tho external dos~c mom bronc (EEM) er~s :.cctionol oreo {CSA)/ 
roforence EEM CSA. 
respectively, p < 0.0001). Negative remodelling lesions 
tended to ho.ve larger fibrous tissue percentages than lesions 
with no remodelling .:md positive remodelling (68.6 { 13.7)% v 
62.9 (9.5)% v 58.1 (12.9)%, p = 0.13). TJblc 2 shows these 
results. 
Table 3 presents Pearson corrdo.tion coefficients between 
the RI and both pl;:Jque components and percentage stenosis 
MLA. The positive co.rebtion between the lipid core and the 
RI was significant{"" = 0.83, p < 0.0001) (fig 2). Moreover, 
fibrous tissue WJ.S inversely corrcl;:Jted with the RI 
{r = -0.45, p = 0.003) (fig 3). Lastly, the percentage 
stenosis of the MLA .:lnd the RI were non-significantly 
inversely rd;:Jted (r = -0.27, p = 0.09). 
With regard to lesion type, thin co.p fibroathcroma Jnd 
fibroJ.theromatous lesions comprised 100% of the positively 
Figure 1 Minimum lumen orca (MLA) 
sites depicting the progression of 
othcrosdcrotic disease. The plaque 
components were assigned colour 
code:.. ColciBod, Bbrous, Bbrolipidic, 
and lipid core regions wore labelled 
white, green, greenish ~llow, and rod, 
respectively. MLA siros feature 
(A) pathologicol intimal thickening and 
(B) tibrocalcific, (Q fibroothoromatous, 
ond (D) thin cop Bbroatheromotous 
lesions. 
Coronary artery remodelling is related to plaque composition. 
Table 3 Relations between remodelling index 
{RI), percentage stenosis of the MLA, and plaque 
composifion of the MLA site 
Rl p VolOJO 
Lipid core CSA (%) 
F1bro~s CSA (%) 
PercontogQ ~tonosis MIA 
Colcilic CSA (%) 
Fibrolipidic CSA (%) 
0.83 
-0.45 
-0.27 
0.12 
-0.17 
Doto oro Poorson eorrdo~on coofficients. 
<0.0001 
0.003 
0.09 
0.47 
0.28 
remodelled lesions, whereas nej}:ltive remodelling lesions hJ.d 
a more stable phenotype: 64% h<~d pathological intim<~l 
thickening, 29% were fibroc<~lcific, .:md only 7% were 
fibroJ.therom<~tous lesions (p < 0.0001) (fig 4}. 
DISCUSSION 
Recently, the relation between vasculJ.r remodelling and 
plJ.que composition WJ.S J.ssesscd by IVUS. 11~0 This CJ.theter 
bJ.sed diagnostic tool provides J.n J.Ccurate tomogr.Jphic view 
of the coromry J.rteries .:md in vitro validation studies have 
shown a high correlation with hlstological samples.,,_, 
Nevertheless, accurate plaque characterisation with visuJ.l 
interpretJ.tion of grey scale IWS, particularly of lipid rich 
plaques, rem.:1ins unresolved." On the contr.:try, spectral 
analysis of IVUS r.:tdiofrequency data (IVUS-VH} has the 
potential to provide detJ.iled qu.:mtitative infonnJ.tion on 
plaque composition and hJ.s been validated in studies of 
explJ.ntcd human coron<try segments.'' 
The results of the present study confirm in vivo the relation 
between plaque composition and coron.:1ry remodelling. Lipid 
core size was significantly larger in positively remodelled 
coronary lesions th.:m in those with vessel shrinkage. 
Funhennore, the fibrotic burden of the plaque was sig-
nificantly and inversely correlated with the RI. 
Lastly, positively remodelled lesions hJ.d a higher risk 
phenotype, with 56% of them being classified as thin cap 
fibroatheroma, the lesion type most likely to rupture.>• On the 
contrary, neg.:1tivc remodelling was associJ.ted with a more 
st<~ble phenotype: 64% hild pathological intimal thickening 
and no evidence of thin C<lp fibroJ.theroma. Fibrocalcific 
lesions, a potential hJ.llmark of the end stage of .Jtheroma-
tou5 plaque rupture or erosion with healing and calcifimtion, 
were found in 29% of negatively remodelled lesions.'' 
Overall, these fmdings support the impOrt.Jncc of the 
histological composition of atherosclerotic plaque as a major 
contributor to its fate J.S described by Davies et at: who 
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Figure 2 Uncor rcgrossion plot showing positive corrolotion betwoon 
lipid ooro and remo<lelling. CSA, cross sectional area. Remodelling 
index is do~nod as MLA of tho external clastic membrane (EEM) CSA/ 
roforoncc EEM CSA 
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Figure 3 Uncor regression plot showing on irwerso relation betwoon 
~brous tissue and romodolling. 
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Figure 4 Bar graphs illustrating tho lesion type frequencies according 
to remodelling modality. All of tho high risk Plaques had positive 
remodelling (56% wore thin cap Rbroothcroma and 44% 
fibrootheromatous lesions). Negatively remodelled lesions hod a more 
stable phonotypo, with 93% being low risk lesions and only 7% 
Rbroothcromataus lesions. 
showed thJ.t plaques vvith a large lipid core ha.rbour .J. higher 
risk of rupture and subsequent thrombosis. The lipid core is a 
source of metalloproteinases, a group of proteolytic enzymes 
that have J.Il importJ.nt function in VJ.Scular remodelling 
mechJ.nism$ .:md whose most common locations arc foam 
cell accumulation .:trNS and shoulder regions.'',,, 
Conversely, ncgJ.tively remodelled vessels consisted pre-
dominJ.ntly of fibrotic plaques. In addition, in line with 
previou$ly reported data, negatively remodelled lesions had a 
hlgher degree of stenosis.' " '" The findings of this ~tudy arc 
consistent with previous pathological findings in patients 
after sudden death.' However, such postmortem studies do 
not hi.!ve implic.Jtions in the natur.:1l hlstory of high risk 
plaques J.nd thus in the clinical outcome of patients. On the 
contrary, we strongly believe that the identification of these 
high risk plaques in vivo may provide more insights into the 
prognosis and naturill history of such lesions and into the 
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effect of conventional ;md emerging anti-atherosclerotic 
pharmacological interventions. 
Limitations 
Since this was a cross scctionJ.l study and atherosclerosis is 
usually a diffuse disease, fmding a fully non-diseased 
reference site is not guaranteed. Therefore, we c.nm.ot rule 
out the c;rrly presence of remodelling in the reference site. In 
addition, this was a pilot study that needs further confrrma-
tion in a l:rrgcr population. Moreover, classifying lesion types 
by this teclmiquc lacks the Jccur<:~cy of histopathological 
cl<.tssific.:ttion, since resolution is inferior. ::\'cvcnhclcss, a 
signiJic.mt relation was found by using this <trbitrary 
cl.:tssification. Although histopathological classification 
remains the ideal, spectral analysis of NUS radiofrcqucncy 
data has the potcnti.:tl to provide real time accuro.te 
information regarding tissue char<tcterisJ.tion <tnd plaque 
morphology. 
Conclusions 
In thls sm<tll dlnical study, ln vivo plaque composition <md 
morphology assessed by spectr.ll J.nalysis of IVDS radio-
frequency data were related to coron<try <trtery remodelling, 
supporting the role of plaque composition in the mechilllisms 
of vessel remodelling. Lipid core size wJ.s significantly Lll'ger 
in positively remodelled coromrylcsions th<tn in those with 
vessel shrinkage. Furthermore, the fibrotic burden of the 
plaque was significantly and inversely correlated with the RI. 
The findings of thls study J.Ie consistent with previous 
pathological findings. However, postmortem studies do not 
have the potential to provide prospective inform<ttion about 
the natur<tl history of high risk plaques. On the contrary, we 
strongly believe that the identification of these high risk 
plaques in vivo may provide more insights into the prognosis 
and natural history of such lesions and into the effect of 
conventional and emerging anti-atherosclerotic pharmacolo-
gical interventlom. 
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CHAPTER 6.1 
Diagnosis and treatment of coronary vulnerable plaques. 
Garcia-Garcia HM, Gonzalo N, Granada JF, Regar E, Serruys PW. 
Expert Rev Cardiovasc Ther. 2008;6:209-22. 

EXPERT I I REVIEWS 
Hector M 
Garda-Garda, 
Nieves Gonzalo, 
Juan F Granada, 
Evelyn Regar and 
Patrick W Serruys t 
t Author for correspondence 
Thoraxcenter, Ba~583, 
Erasmus MC, Dr. 
Mofewaterplein 40, 307 5 GO 
Rotterdam, The Netherlands 
Tel.: +37 704 635 260 
Fax:+31104369154 
p.w.].c.serruys@ 
erasmusmc.nl 
Di3.::,onosis and trearmem of coronary vulnerable plaques. 
Diagnosis and treatment of 
coronary vulnerable plaques 
Expert Rev. Cardiovasc. Ther. 6 {1), 209-222 (2008) 
Thin~capped fibroatheroma is the morphology that most resembles plaque rupture. Detection 
of these vulnerable plaques in vivo is essential to being able to study their natural history and 
evaluate potential treatment modalities and, therefore, may ultimately have an important 
impact on the prevention of acute myocardial infarction and death. Currently, conventional 
grayscale intravascular ultrasound, virtual histology and palpography data are being collected 
with the same catheter during the same pullback. A combination of this catheter with e'1ther 
thermography capability or additional imaging, such as optical coherence tomography or 
spectroscopy, would be an exciting development. Intravascular magnetic resonance imaging 
also holds much promise. To date, none of the techniques described above have been 
sufficiently validated and, most importantly, their predictive value for adverse cardiac events 
remains elusive. Very rigorous and well-designed studies are compelling for defining the role of 
each diagnostic modality. Until we are able to detect in vivo vulnerable plaques accurately, no 
specific treatment is warranted. 
KEYWORDS: acute coronary syndrome • atherosclerosis • plaque rupture • thin-capped fibroatheroma 
Unheralded acute coronary syndromes (ACS) 
are common initial manifestations of coronary 
atherosclerosis and are frequencly caused by 
plaque ruptures [1]. Histopathological studies 
h:tve identified sever:.U plaque morphologies 
associated with ACS and sudden cardiac death, 
such as calcified nodule, plaque erosion and 
chin-ca.pped fibroatheroma (TCFA). The 
plaques th:tt are at increased risk of thrombosis 
:md rapid progression of lumen encroachment 
arc referred to as high-risk or vulnerable lesions 
[2]. However, the natural history of these lesions 
remains unknown and the limited knowledge 
about their eventual prognosis is provided by 
retrospective histopa.thological studies !3]. 
Detection of these vulnerable pbques in vivo is 
essential to study their natural history and to 
evaluate potential treatment modalities and, 
therefore, may ultimately ha.ve an importlnt 
impact on the prevention of acute myocardial 
infurcrion (A..\1I) and death. Coronary :mgio-
graphy offers valuable information on the long-
term behavior of the complex lesions. Goldstein 
et aL reported that patients with ST-segment 
elevation myocardial infarction (STEMI) and 
multiple complex lesions during the year after 
STEMI had an increased incidence of recurrent 
ACS compared with pa.tients with single com-
plex lesions (19.0 vs 2.6%; p < 0.001. re..~pec~ 
tivcly) and repeated :mgiopla.sty, particularly of 
noninfurct-rcl:.ued lesions (32.0 vs 12.4%; 
p < 0.001) [4]. However, angiography is limited 
to fully eva.lu.1.te the vessel wall, Therefore, there 
a.re currendy sever:.U diagnostic invasive imaging 
techniques aiming at specifically evaluating indi-
c::ttors of plaque vulnerability [5]. These tech-
niques Cl1l provide inform:ttion on the vessel, 
lumen and wall size, tissue composition. and the 
status of infu.mmation. This article aims to 
review the current histopa.thological definitions, 
state-of-the-art of inY:tSive imaging techniques 
and treatment of coronary vulnerable pbqucs. 
with focus on TCFAs. 
Histopathological vulnerable 
plaque definitions 
The 'classical', most described phenotype of a. vul-
nerable pbque is a TCFA (6], which has a large 
necrotic core with an overlying thin cap infiltrated 
by m:tcrophagcs. Smooth muscle cell~ in the ctp 
arc absent or few. The thickness of the fibrous ctp 
near the ruprure site measures 23 ± 19 )lffi• with 
95% of the ca.ps measuring less than 65 J.lffi [l.i]. 
Rupture of a. TCFA with exposure of ilie throm-
bogenic necrotic core to circulating platelets could 
be responsible for 60o/o of :ill ACS [t:. Macro-
phage infrltr:ttion of the thin ca.p with release of 
matrix met:tlloprotein:L')es and local inflamm:t-
tion can cause extracellular matrix degradation 
Reproduced from Expert Rev. Cardiovasc. Ther. 6 (1), 209-222 (2008) with permission of Expert Reviews Ltd. 
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and subsequent plaque rupture [8.9]. E.xcessivc mechanical strain, 
pa.rcicularly at the junction of the TCFA and ilie normal vessel wall 
is another fucror contributing to rupture :to,t t;. 
Chevuru et aL reported new pathological evidence on TCFA 
chat:lcterizacion 112:. The prevalence of TCFA and ruptured 
TCFA is low (0.46 ± 0.95 and 0.38 ± 0.70 per heart, respec~ 
tivdy), foca1 and located in the proximal segments of the coronar~ 
ics. In =lier studies, up to three TCFA were found per heart [13], 
~ccrocic core size was relatively small for both, TCFA (1.6 ± 1.8 
mm2: length: 2.7 ± 2.0 mm) and ruptured plaques (2.2 ± 
1.9 mm2: length: 1.9 ± 3.6 mm). In previous studies. the size of 
necrotic core in TCFAs was 1.7 ± 1.1 mm2 with a length of 
8 mm (range: 2-17 mm), and in ruptured plaques 3.8 ± 
5.5 mm2, with a length of9 mm (r.:tnge: 2.5-22 mm) [14]. 
The second recogni7.ed phenotype of vulner:~.ble plaque, 
accounting for approximately 40% of coronary thromboses in 
pathology series, is pb.que erosion in lesions consisting of either 
parhologic:U intimal thickening or thick-capped fibroatheroma ;15]. 
These lesions rypica.lly have a high smooch muscle cell content, are 
rich in proteoglycans and are more common in young women and 
smokers, but are not :JSsociated with other conventional risk 
factors, such :J..S hypercholesrerolemia [1.16]. 
Third, there are calcified nodules, which may protrude into 
the vessel lumen and comprise up to 5% oflesions in patholog-
ic.'ll series. These lesions are characterized by an absence of 
endothelium and inflammatory cells [1]. In addition, intn-
plaque hemorrhage secondary to leakage from the vasa vasorum 
may also play a role [17:. 
Imaging of vulnerable plaques 
Coronary angiography 
Angioscopy 
lntr.1coronary angioscopy (CAS) is a well-established technique 
that allows direct visunli7..ation of the plaque surface and intralumi-
nal structures. It enables assessment of the plaque color (white, red 
or yellow), and can illuminate plaque complic:ttions, such as rup-
rure. intimal tears and thrombosis with a higher sensitivity than 
angiognphy [21-24]. Angioscopically, normal artery segments 
appear X> glistening white, where:J.S atherosclerotic pbques can be 
categorized based on their mgioscopic color X> yellow or white. 
Platelet-rich thrombus at the site of plaque rupture is ch:tr:lcterizcd 
:JS white granular materi.'ll and fibrin/erythrocyte-rich thrombus as 
an irregular, red suucrure protruding into the lumen. Yellow 
plaques are associated w:ith ACS and thrombosis :2s.26]. They have 
also been correlated with other fearures of vulner::tbility, such X> 
positive remodding and increased distensibility [27]. 
The major limitation of angioscopy is that it requires a blood-
free field during image acquisition, which can be obtained either 
by complete vcsscl occlusion or by continuous saline flushing in 
front of the angioscope. Specific:tlly, nowadays. CAS (Vccmova®, 
Clinical Supply Co .. Gifu, Japm) can be made while blood is 
cleared aw:1y from viC\V by the injection of 5-10 ml saline. Further-
more, only a limited p:ut of the coronary tree can be investigated 
(i.e., vessels > 2 mm in diameter) md assessment of stenotic lesions 
may prove difficult. Finally, angioscopy only images the luminal 
surf.tce and, although chmge.~ in the vessd wall arc reflected on the 
sur&ce, this might not be ~ufficiently sensitive to detect subtle 
alterations in plaque composition or plaque burden in the presence 
of positive remodeling [::s:. 
Although coronary angiography repre-
sents the standard modality for visualiza-
tion of the coronary attery disease, there 
is a cle:1r discrepancy between the 
appearance of the opacified vascular 
lumen and the accual extent of athero-
sclerosis (FIGt:RE 1). Additionally, the per-
cemage diameter stenosis of a lesion does 
not provide reliable information con-
cerning the risk for myocardial infarc-
tion and death [l8.1<J;. Large r::tndomized 
lipid-lowering trials using both angie-
graphic and clinical assessment have 
shown minimal or no improvement of 
angiographic lumen diameter but a 
much more impressive reduction in clin-
ical endpoints, including myocardial inf-
arccion [20]. In face, the 'luminogram' is 
unable to provide information on the 
composition of the anery wall and is 
therefore unable to distinguish between 
stable and high-risk, vulnerable plaques. 
Figure 1. (A. B & 0 show three consecutive intravascular ultrasound images of the 
proximal left anterior descending (D), which is disease-free angiographically. Note that 
the intravascular ultrasound images show a plaque burden of 50%. 
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Kubo a aL reported the ability of optic:tl coherence tomography 
{OCJ! for a;."Se;Sment of the culprit lesion morphology in A\11 in 
comparison with intravascular uitr:lSOund (IVUS) and CAS [21o]. 
The incidence of phque rupture observed by OCT was 73%, 47% 
by CAS (p"' 0.035) and 40% by NUS, (p"' 0.009). Furthermore. 
OCT {23%) was superior ro CAS (3%: p" 0.022) and IVGS (Oo/o: 
p " 0.005) in the detection of fibrous ca.p erosion. The intr.:tcoro-
nary thrombus was observed in all cases by OCT and CAS, but it 
was identified in 33% by rvus (vs ocr: p < 0.001). 
Intravascular ultrasound 
Currently. the gold standard for inm.coronary im:tging is 
IVUS. Positive vessel remodeling can readily be evaluated with 
IVUS :z9-31J, In addition to the lumen and vessel borders, IVUS 
examination can provide real-rime, high-resolution images of the 
plaque (FIC:IJRE 2). Visu:ll assessment of phque echogenicity pro-
vides semiquantitative tissue ch::uacteriza.tion :32;. Calcification 
can be identified with a sensitivity and specificity of approxi-
mately 90%, as bright echo signals with acoustic sh:tdowing 133;. 
Lipid deposits, visuali7..ed as echolucent zones, can be detected 
with high sensitiviry (78-95%), but low specificity (30%) [3-1.35]. 
Moreover. the a:dal resolution of NUS is in the range of 
100-150 flm. whereas the fibrous cap of a TCFA is thinner th:m 
65 fliTl md, therefore, cannot be visualized by IVUS. Despite 
these limitations, large eccencric plaques containing an echo-
lucent zone by IVUS were associated with the development of 
ACS in a prospective study :36]. Microbubble contrast-
enhanced IVUS can measure activity and inflammation within 
atherosclerotic plaques by imaging vasa v::tSOtum density, which 
is increasingly considered as a strong marker for plaque vulnera-
bility [37]. A few limitations ofiVUS can be improved by analyz-
ing the backscattered ultrasound signal using more sophisticated 
techniques for tissue characterization [38]. 
Intravascular ultrasound radiofrequency analysis: 
virtual histology 
IVUS gray-scale imaging is formed by the envelope (amplitude) 
of the radiofrequency signal, discarding a considerable amount 
of information lying beneath and between the peaks of the sig-
nal. The frequency and power of the signal commonly differ 
between tissues, regardless of similarities in the amplitude. 
IVUS~virtu.1.l histology (NUS-YH, Volcano Corp., Rancho 
Cordoba, USA) involves spectral analysis of the data and evalu-
ates different spectral parameters (e.g .. Y-intercept, minimum 
power, maximum power, mid-band power, frequency at mini-
mum power, frequency at rnxcimum power. slope) to conscrucr 
Figure 2.1VUS plaque types. These IVUS images, taken from distal to proximal in the same vessel (A-F), represent different IVUS gray 
scale plaque types. (A) shows a soft plaque, large plaque burden and positive remodeling. On the contrary, (B) shows a fibrotic plaque 
(similar echogenicity to adventitia). (C) Depicts a superficial calcified plaque (see shadowing). (D-F). a plaque rupture is illustrated; a 
large empty cavity (red oval, [D)) with the remnant of fibrous cap is overhanging the lumen {arrow, [E]). 
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tissue maps th:lt cla...<>Sify plaque into four major components 
(fibrous. fibrolipidic. necrotic core :tnd calcium). Different 
phquc components are assigned different color codes: c:Jcificd 
(white). fibrous (green), fibrolipidic (greenish-yellow) and 
necrotic core (red) [39] • .Although this cbssifiotion W:J.S initially 
ev:lill:lted in vitro, more recently IVUS-VH pre- and post-pro-
cedure has also been correlated with pathological specimens 
obt:llncd by atherecromy with good correlation for :ill four tis-
sue types [~o:. A~ assessed by IVUS-VH, the sensitivity and spe-
cificity for fibrous tissue was 86 o.nd 90.5%. fibrofutty 79.3 :md 
100%, necrotic core 67.3 and 92.9%. and dense c::Jcium 50 
and 98.9%. respecrively. 
lVUS-VH data are currently acquired using a commercially 
:tvaibble 64-element phascd-:1rray c:uheter (Eagle Eye™ 
20 MHz catheter. Volcano Corporation, Rancho Cordova, 
lJSA). Vsing :lll :mtomated pullback device, the tr:lllsducer is 
withdrawn at a continuous speed of 0.5 mmls up to the 
ostium. IV1JS-VH acquisition is ECG-gated at the R-wave 
peaks using a dedicated console. 
IVUS B-mode images are reconstructed by customized soft-
ware :llld contour detection is performed using cross-sectional 
views with semi-automatic contour detection software to pro-
vide quantitative geometrical and compositional measure-
ments, Due to the unreliability of m:111ual calibration, the 
radiofrequency data is normalized using a technique known as 
'blind deconvolution', an iterative algorithm that deconvolves 
the catheter transfer function from the backscatter, thu..~ 
accounting for catheter-to-catheter variability [41--43]. 
It has been our obscrv::ttion that in the near field :lll excessive 
amount of necrotic core was present. The developers have 
accounted for this :llld a proper correction was introduced in 
the current version of classification tree. 
Our group recently evaluated the incidence ofiVUS-derived 
TCFA (IDTCFA) using IV1JS-VH [4{. Two independent 
IVUS :lllalysts defined IDTCFA as a lesion fulfilling the fol-
lowing criteria in at least three consecutive cross-sectional areas 
(CSAs): necrotic core of 10% or more without evident over-
lying fibrous tissue. :llld lumen obstruction greater th:lll or 
equal to 40%. In this srudy, 62% of patients had at least one 
IDTCFA in the interrogated vessels. ACS patients had a signif-
icancly higher incidence of IDTCFA th:lll stable patients (3.0 
Unterqua.rtile range: 0.0-5.0] IDTCFA!coronaryvs 1.0 [inter-
quartile r:lllge: 0.0-2.8] IDTCFA!corona.ry: p"' 0.018) 
Finally, a cl~ clu..~tering pattern was seen along the coronaries, 
with 66.7% of all IDTCF.A.s located in the first 20 mm, 
whereas further along the vessels the incidence was signifi-
cantly lower (33.3%; p "' 0.008). This distribution of IDTC-
FAs is consistent with previous ex vivo and clinical studies, 
with a clear clustering pattern from the ostium demonstrating 
a nonuniform distribution of vulnerable plaques along the cor-
onary tree [45]. Patients presenting with ACS had a signifi-
c.1.Ilcly higher prevalence of IDTCFA even in nonculprit ves-
sels, supporting the concept of a multifocal process [46]. Of 
note, the lesion percent o.rea stenosis and the mean necrotic 
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core areas of the lDTCFAs detected by NUS-VH were also 
similar to previously reported histopathological data (55.9 vs 
59.6% and 19 vs 23%, respectively) [lfJ]. 
It is worth mentioning that, although the most accepted 
threshold to define a cap as 'thin' h::~s previously been set at less 
than 65 )lm. this was based on postmortem studies that looked 
at ruptured plaques [7]. Extrapolation of such criteria to in vivo 
studies requites caution. It is well established that tissue shrink-
age occurs during tissue fixation [1,7]. Shrinkage (particularly of 
collagen tissue, the main component of fibrou..~ caps) of up to 60, 
15 and 80% can occur during critical~point-drying, free-drying 
and air-drying, respectively ;-ts]. Furthermore, postmortem con-
traction of arteries is :lll additional confounding factor [49.50:. 
Since the axial resolution ofiVUS-VH is 246 pm. we assumed 
that the absence of visible fibrous tissue overlying a necrotic 
core suggested a cap thickness of below 246 pm and U.."Cd the 
absence of such tissue to defme a thin fibrous cap :51]. 
We have recencly developed softvva.re to quantifY the amount 
of necrotic core in conoct with the lumen, enabling refinement 
of our analysis. Our current definition of an IVUS-derived 
TCFA (IDTCFA) is a lesion fulfilling the following criteria in 
at least three consecutive CS.A.s: 
Plaque burden greater than or equal to 400;U; 
Confluent necrotic core oflO% or more in direct contact with the 
lwnen (Le., no visible overlying tissue) in the inve;cigated CSA; 
AJl consecutive CSA~ h.·wing the same morphologic characteristics 
are considered as part of the same IDTCFA lesion :5~]. 
In a recent study, using this refined definition of TCFA as 
as .. "Cssed by IVUS-VH, in patients with ACS underwent IVUS 
of all three epicardial coronaries. on average, there were two 
IDTCFA per patient with half of them showing outward 
remodeling :52] (FlcURE3). 
The potencial value of IVUS-VH in the prediction of adverse 
coronary events is currently under evaluation in two international 
multicenter prospective studies (the PROSPECT study :llld the 
Integrated Biomarker and Imaging Study [IBIS] II trial). 
Intravascular ultrasound radiofrequency 
analysis: pa/pography 
This technique allows the assessment of local mechanical tissue 
properties. For a defined pressure difference, soft tissue (e.g .. 
lipid-rich) components will deform more than hard tissue com-
ponents (e.g .. fibrous, calcified) [53.5~]. R:1.diofrequency data. 
obta..ined at different pressure leveL~ are compared to determine 
the local tissue deformation. 
Each pa.lpogram represents the strain information for a cer-
tain cross section over the full c.'U'diac cycle. The longitudinal 
resolution of the acquisitions depends on heart rate :llld pull-
back speed. With a heart rate of 60 bpm and a pullback speed 
of 1.0 mm/s, the longitudinal resolution is 1.0 rom. Palpo-
grams are acquired using a 20-MHz phased array IVUS cathe-
ter (Eagle Eye). Digital radiofrequency data are acquired using a 
custom-designed workstation. 
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Figure 3. Intravascular ultrasound (IVUS) gray~scale frames and their corresponding virtual histology frames of an 
IVUS-derived thin~cap fibroatheroma (four central frames) and the proximal and distal reference segment in which the 
remodeling index was calculated. 
MLA: Minimum luminal area; PB: Plaque burden; VCSA: Vessel cross-sectional area. 
Virtual histology color code: green is fibrous, greenish is fibrofatty, red is necrotic core and white is dense calcium. 
The local strain is calculated from the gated radiofrequency 
traces using cross-correlation analysis and displayed, color~ 
coded, from blue (for 0% strain) to red to yellow (for 20/o 
stro.in) [55]. Plaque strain values are assigned a Rotterdam classi· 
ficacion (ROC) score ranging from I-IV (ROC I = 0 co <0.6%; 
ROC II= 0.6 to <0.9%: ROC III= 0.9 to <1.2%: ROC IV> 
1.2%) (F!GURE ~l [)6]. A region is defined as a high~stn..in spot 
when it has a ROC III-IV that spans an arc of at least 12° at 
the surface of a plaque (identified on the IVUS recording) adja-
cent to low~str:lln regions (<0.5%). Our group has demon· 
mated that palpography has a high sensitivity (88%) and spe~ 
cificity (89%) to detect vulnerable pl.1.ques in vitro [5J:. 
Postmonem coronary aneries were investigated with intra-
vascular dastography and subsequently processed for histology. 
There was a positive correlation berween the presence of high 
strain and the amount of macrophages (p < 0.006) and an 
inverse relation berween the amount of smooth muscle cells 
and strain (p < 0,0001). Vulnerable plaques identified by pal-
pography had a thinner cap than nonvulnerable plaques 
(p < 0.0001). In a subsequent study. 55 patients with stable 
angina, unstable angina or A..\1I were analyzed. Among patients 
with stable angina. the prevalence of deformable plaques per 
vessel was significantly fewer (0.6 ± 0.6) than in unstable 
angina patients (1.6 ± 0.7: p = 0.0019) or Al\IH patients (2.0 ± 
0.7; p < 0.0001), In IBIS I study, on palpography, both the 
absolute number of high-strain spots (grade 3/4) in the ROI (p 
= 0.009) :md their density per centimeter (p = 0.012) decreased 
significantly berween baseline and follow~up. This decrease in 
the overall popul."l.tion was largely driven by changes in the sub~ 
group of patients with STEMI; this group had both the highest 
number of high-strain spots at baseline and tl1e most marked 
relative decrease during follow~up, compared with patients 
with other clinical presentations. At 6-month follow-up. the 
density of high-strain spots (1.2 ± 1.4/cm) was comparable 
among clinical subgroups :s?J. 
Optical coherence tomography 
Optical coherence tomography (OCf) is an optical analogue of 
ultrasound; however, it uses light instead of sound to create an 
image [58.59:. For OCT imaging, low coherence, near infrared 
(NIR) light with a wavelength around 1300 run is used since it 
minimizes the energy absorption in the light beam caused by 
protein, water, hemoglobin and lipids. The light waves are 
reflected by the internal microstructures within biological tis~ 
sues as a result of their differing optical indices. 
This technique provides a resolution of I 0-20!J-ffi in viv(!'. 
this level of detail is well beyond the level of resolution of IVUS 
(100-150 !J-ffi) [60.61]. ocr has been demonstrated to be highly 
sensitive and specific for characterizing atherosclerotic plaques 
in vitro when compared with histological analysis ;6::-6~] with a 
sensitivity and specificity of71-79% and 97-98% for fibrous 
plaques, 95-96% and 97% for fibrocalcific plaques, and 
90-94% and 90-92o/o for lipid~rich plaques, respectively. In 
addition, the interobservcr and inuaobservcr reliabi!iries of 
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I I 
/v; a result of irs high axial resolution, 
there is no doubt that OCT is the in vivo 
gold standard for identifYing md mea.sur~ 
ing the thickness of the fibrous cap 
(F:tcuJm5J: m in vivo study found a signifi~ 
cant difference in minimal cap thickness 
between AMI md stable :l.Ilgina patients, 
with medim (interqua.rtile rmge) values of 
47.0 Jlm (25.3-184.30) md 102.6 Jl1Il 
(22.0-291.1), respectively (p"' 0.02) [<is:. 
On top ofits reliabiliry as a tool ro measure 
the thickness of the cap in vivo, recent 
postmortem :md in vivo studies have 
ROtterdam Classification (ROC) 
shown that OCT is opable of evaluating 
the macrophage content of inflltrated 
fibrous caps :69.70]. 
Grades (ROC) 
IV 
Strain(%) Kubo et al. evaluated the abiliry of 
intracoronary OCT to assess culprit 
lesions during primary PCI in patients 
with AMI. The thickness of the rem~ 
nmts of the fibrous cap after sympto~ 
marie rupture measured in vivo was 49 ± 
>1.2 
Ill 0.9-1.2 
0.6-0.9 
(}-(}.6 
21 Jlffi [2.j], 
The main limitation of OCT is the 
Figure 4. IVUS palpography. The local strain is calculated from the gated 
radiofrequency traces using cross·correlation analysis and displayed, color-coded, from 
blue (for 0% strain) to red to yellow (for 2% strain). 
shallow penetration depth (2 mm) into 
the tissue, which hampers imaging of the 
en tire vessel wall in large vessels and 
light absorbance by blood that currently 
needs to be overcome by saline infusion 
Plaque strain values are assigned a Rotterdam Classification (ROC) score ranging from 
1 to 4 (ROC I= 0 to <0.6%; ROC II= 0.6 to <0.9%; ROC Ill= 0.9 to <1.2%; ROC IV 
>1.2%). 
and balloon occlusion, thereby preclud~ 
ing interrogation of long and proximal 
OCT assessment were high (K values of 0.88 and 0.91, respec~ 
tivcly) [6'1:. In vitro comparison of OCT with IVC'S demon~ 
strated superior delineation by OCT of structural details such 
as thin caps, lipid pools or tissue proliferation ~65], .A.n in vitro 
comparison of OCT, integrated backscatter IVUS (similar 
methodology to NUS~VH) and conventional IVVS found that 
OCT had the best potential for tissue characterization of coro~ 
nary plaques, with higher sensitivity and specificity compared 
with the other imaging modalities [66::. However, a recent study 
comparing OCT with histopathology reported a lower sensiriv~ 
ity for plaque components. Miscb.ssification occurred in 41% 
of lesions, predomina.ndy due to a combination of incomplete 
penetration depth into the vessel wall and the inability to 
distinguish calcium deposits from lipid pooL~ :67]. 
In a pilot clinical study, our group performed in vivo OCT 
analysis of the coronary arterial wall in patients who were 
undergoing percutaneous coronary interventions. Imaging was 
possible in all patients and the entire vessel circumference was 
visualized at all times. A wide spectrum of different plaque 
morphologies was observed. OCT allowed for differentiation of 
the normal artery wall and inhomogeneous, mixed plaques, as 
well as TCFAs with inhomogeneous, low~reflecting necrotic 
cores, covered by highly reflecting thin fibrous e1ps [61]. 
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segments of the coronary tree, which may limit the clinic.'tl 
applications of this technique. 
Thermography 
Atherosclerosis is accompanied by inflammation, and vulnerable 
plaques have been associated with increased macrophage activity, 
metabolism md inflammation 71]. Activated macrophage..~ pro-
duce thermal energy, which might be detected on the surfuce of 
these atherosclerotic lesions using specially designed catheters 
equipped with thermistor sensors at the dist::tl tip (72]. A rise in tern~ 
pet:lture can be found in atherosclerotic plaques compared with 
disease~.&ee coronary segments. Temperature differences between 
m atherosclerotic plaque and normal ve..<;;.<;el wall increase progres~ 
sively .&om pa-tients with stable angina to patients withA.\11 with a 
maximum tempct:lture difference to the background tempet:lture 
of 1.5 ± 0.7°C 73]. In a prospective study, the same investigators 
reported m association between tempet:lture heterogeneiry and the 
incidence of adverse events at follow~up in patients with coronary 
artery disease undergoing a successful percutaneous intervention 
[74], In addition, t=tmentwith sta.tins seems to affect the therrno-
gnphic results: in nonculprit lesions the temperature difference 
was lower in the group treated with srmins compared with the 
untreated group (0.06 ± 0.05°C vs 0.11 ± 0,10°C; p"' 0.05) [75], 
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field. For intravascul:ll" diagnosis, two dif-
ferent approaches have been introduced. 
The firsr. conventional approach visual-
izes the anawmic:tl structure by using a 
coil placed in a catheter or wire in combi-
nation with an external magnet (MR 
imaging [MRIJ), While this approach has 
been (10 years ago) [SO] principally shown 
to be able to provide detailed information 
on structure and composition of the :ll"te-
rial wall and plaque, the procedure h:is yet 
to be performed in a MR magnet, not in a 
cardiac catheterization laboratory. The 
accuracy for MRI differentiation of 
plaque components has been validated in 
vitro and feasibility demonstrated in vivo 
[Sil. The 0.030-inch intravascul:ll" (IV)-
MRI coil had a sensitiviry and specificity 
of 73 and 85%, respectively, for lipid, 83 
and 81%. respectively. for fibrous tissue 
and 100 and 97%, respectively, for calcifi-
cation, Subsequently, the same ~ystem 
was applied in human iliac :ll"teries in vivo 
using a 1.5-T magnet with a resolution of 
312 iJlll· Complete vessel wall analysis 
was possible in all 25 patients and 
required 20 min for an arterial segment of 
20 mm length. Compared to IVCS, mean 
Figure 5. ocr and standard coronary angiography correlation. Angiography 
shows a complex lesion in the mid left anterior descending. The optical coherence 
tomography image shows a ruptured plaque with thrombus at that site (white arrow). 
Proximally and distally to the culprit lesion, thin-capped fibroatheroma lesions are 
present ([B] and [A] respectively). lumen diameters were similar, but the 
outer wall :ll"e:t was overestimated by IVMRI (mean 116.4 ± 4.7 
mm2 vs 86.6 ± 5.8 mm2; p = 0.0001). However, interobserver 
agreements for IVMRI were much higher (K: 0.68-0.79) than 
for IVUS {K: 0.21). 
However, there are several different aspects that deserve fur-
ther investigation. The prevalence and distribution of inflam-
matory cells in stable and unstable atherosclerotic plaque is 
uncle:ll", and the predictive value of'w~rm' lesions remains elu-
sive. Furthermore, the impact of different coronary flow condi-
tions on pbque temperature ('cooling effect') is still not com-
pletely understood :7G,;;]. Simulations have revealed that the 
correct interpretation of intravascular thermographic measure-
ments requires cbra on the flow and on the morphologic 
characteristics of the atherosclerotic plaque )'S]. 
There are a few limitations to the routine use of thermography 
in the catheterization laboratory: 
• Most of the Cltheters used still comprise over-the-wire $)'Stems; 
• Accurate temperature assessment requires direct contact of 
the thermistors with the vessel wall, with the associated 
potential risk of endothelial damage; 
Since the temperature within the vessel changes rapidly with 
fluid application, any intracoronary injection of contrast dye, 
flush or medication has to be avoided before and during 
measurements [79]. 
Intravascular magnetic resonance 
Magnetic resonance (MR) is a nonionizing diagnostic tool 
exploiting the spins of the nuclear protons in a strong magnetic 
The other, novel approach analyses the chemical composition 
by placing both, the coils and miniaturized magnets on the rip 
of a catheter, without the need of external magnets (MR spec-
troscopy) and can be performed in the cardiac catheterization 
hborarory [s::>.;. 
MR spectroscopy can identify fibrous and lipid-rich tissue by 
measuring differential water diffusion in a field of view. 
Acquired data are displayed as color-code sectors based on the 
lipid fraction index for each zone of the field of view. Blue indi-
cates no lipid, gray corresponds to intermediate lipid content 
and yellow indicates high lipid content (FrcuR£ GJ. Clinical fesi-
bility of cather-based. self-contained IV MR spectroscopy has 
been demonstrated recently in patients scheduled for coronary 
catheterization [SJ]. 
Preclinical trials employing this technology demonstr~ted 
its capability to differentiate plaque composition of human 
aortas. coronary and carotid arteries in vitra. IVMR spectros-
copy could accurately detect different components (fibrous 
cap, smooth muscle cells, organizing thrombus, fresh throm-
bus, edema, lipid and calcium) with sensitivities and specifici-
ties r~nging from 84 to I 00%. Agreement with histology for 
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grading the extent of intraplaque lipid accumulation was 74% 
for grading of intimal thickness 80%. Funher :malysis revealed 
high correlation to histological :m:Uysis of a wide spectrum of 
plaque types in 15 of 16 (94%) aortic lesions and 16 of 18 
(89%) coronary lesions (sensitiviry: 100%; specificity: 89%), 
including one plaque rupture, three TCFAs, seven thick cap 
fibrous atheromas, four fibroc:Ucific plaques. two intimal 
xmthomas :md one adaptive intimal thickening [8~]. 
Current limitations include the limited field of view, the size 
of the catheter, the need for direct vessel wall contact and the 
time required for acquisition. In the past, the use of an auto-
perfusion balloon during data acquisition has been proposed to 
limit ischemia [85]. 
Clearly, IVMR diagnostics remain an exciting area still under 
development. Catheter-based systems will funher increase the 
user friendliness, their sample volume and allow for scanning of 
longer arterial segments. Upcoming developments include the 
improvement MR plaque differentiation by the use of contrast 
agents, such as paramagnetic gadolinium-based contrast or 
supraparamagncric contrast agents (iron oxide nanoparticles), 
that can accumulate in macrophages [86.87]. There are still a few 
unanswered questions, including the effect of the thermal 
energy generated on small arteries md on coronary artery 
stents, although conventional MRI appears safe in this setting 
188). In addition, the presence of a permanent pacemaker is a 
contra-indiCJ.tion for any MRI imaging 
due to reports of arrhythmiJ.S and death. 
In near-infrared spectroscopy, it is observed how different sub-
stances absorb and scatter NIR light to different degrees at vari-
ous "Wavelengths. An NIR spectrometer emits light into a sam-
ple and measures the proportion of light that is returned over a 
wide range of optic:li wa.velengrhs. The return signal is then 
plotted as a graph of absorbance (y-axis) at different wave-
lengths (x-axis) called a spectrum. 
In aortic and coronary artery autopsy. specimens have 
confirmed the abiliry of the technique to identify lipid-rich 
TCFA.s through blood [97]. A catheter-based system has been 
developed to address the challenges of access to the coronary 
artery, blood, motion and the need to scan, which must be 
overcome for use in patients. Initial clinical experience in six 
patients with stable angina demonstrates that high-quality 
NIR spectra can be safely obtained 189]. Additional studies 
are planned to validate the abiliry of the technique to iden-
tifY lipid-rich coronary artery plaques and ultimately link 
chemical characterization with subsequent occurrence of an 
ACS (FIGURI'. 7) [98,99]. 
Treatment 
Treatment of asymptomatic. nonob;;tructive coronary lesions may 
be a desirable pursuit, but the pre-emptive strike may be a risky. 
time-consuming and expensive proposition. Assumptions include: 
Raman & near-infrared spectroscopy 
A number of spectroscopic intravascular 
imaging techniques have been developed 
recently and are still under investigation 
[891, Spectroscopy can provide qualitative 
and quantitative information about 
chemical pbque composition, The 
Raman effect is created when incident 
laser light (rypically 750-850 nm wave-
length) excites molecules in a tissue sam-
ple, which scatter light at a different 
wavelength. This change in wavelength, 
called the R.:un:m effect is dependent on 
the chemical components of the tissue 
sample [9Q.9C and can therefore provide 
quantitative information about molecu-
lar composition [92-9·\]. Raman spectros-
copy has shown acceptable correlation 
compared with histology (r = 0.68 for 
cholesterol and r = 0.71 calcification) 
and with IVUS in vhro [9~.951. 
Alternatively, NIR molecular vibrational 
transitions can be mc:~surcd in the 1\:IR 
region (750-2500 nm) and hser spectro-
scopy using "Wavelengths of 360-510 nm 
has been evaluated in vitro [95.96]. 
Figure 6. Intravascular magnetic resonance. The magnetic fields generated by the 
probe located at the tip of the catheter, create a FOV with a sector shape, looking 
sideways into the artery wall. The FOV has a lateral resolution of 60°, a longitudinal 
length of 2 mm and a depth of 200 ~m. It makes the analysis for the area comprised 
between 50 and 200 ].Jm from the lumen. 
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Acquired data is displayed as color-code sectors based of the lipid fraction index for each 
zone of the FOV. Blue indicates no lipid, gray correspond to intermediate lipid content 
and yellow indicates high lipid content. 
FOV: Field of view. 
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• Accepting that the specific pathology can be defined in living 
subjects 
• Presuming that this particular pathology is responsible for 
future dinica.l events 
• The 'fingerprint' of this pathology can be reliably detected 
• These findings are predictive of future adverse dinica.l events [3] 
Based on these assumptions, initial risk stra.tificttion of 
asymptomatic patients drawn from the general population will 
be required, probably using an early screening method able co 
detect nonobstructive suspicious lesions. Then, patients will 
have to be further stratified based on noninvasive/invasive 
imaging {'regional stratification cool'). Once a suspect lesion is 
identified, focal treatment will be based on a prediction model 
co prove both safety and efficacy, assuming the endovascul:u 
detection modality was correct. Among symptomatic patients 
(non--obstructive, non-culprit lesion in the setting of an ACS), 
a regional str:~_tification strategy may be sufficient to justify 
ther:1py in the fucure. The main question still remains as if the 
rher:1py should focus on the entire segment containing the 
lesion or the 'foca.l' area in which the TCFA is identified. 
Segmental therapy 
Treating all three m:1jor coronary arteries or their proximal p:ucs 
requires a technology cap:1ble of delivering the therapeutic effect 
across long segments with our the need for multiple interventions 
or guicltnce to :1 particular lesion. Current scenting technology is 
simply not up to the task to consider so-called 'full-metal-jacket' 
stenring of an entire vessel [too]. Until further improvements in 
vascular prosthesis :ue made, the industry is seeking methods for 
passiV:lting at-risk vessels through therapeutic :1pplications of 
drugs and energy. The merge between t:ugetcd nanop:ucicles and 
local drug delivery :ue of special interest as potential therapeutic 
alternatives capable of tre:lcing large vascular territories [101]. 
Sonotherapy direcrs energy in the form of ultt:lSonic vibr:1tions 
to the lesion and vessel wall and has been shown to decrease cell 
prolifer:J.tion :md smooth muscle cell migration in vitro, but very 
little clinical experience exists. Cryotherapy involves the thera-
peutic :1pplicarion of heat removal or 
Focal therapy 
Myocardial infurctions :ue typically the result of focal complex or 
vulner:J.ble lesions, :md it is quite reasonable that many interven-
tionalists have suggested treating high-risk plaques with the same 
tools currendy employed for these symptomatic lesions (bare 
metal stents or drug-eluting scents). Balloon-expandable metallic 
scaffoldings provide substantial r::tdial forces for dilating hard, 
obstructive plaques le:1ding to the una.voi<lable and uncontrollable 
disruption of the vascular structures intended tO trC:lt. Restenosis 
after treating a lesion with a b:ue metal stent has been curbed by 
slow-release antiproliferative drug coatings :1pplicd directly to the 
stem. Unfortunately. recent clinical evidence points to increased 
risk of late thrombosis as a result of the drug :md its :illect on 
endothelial cell functioning and vascular healing, especially in the 
setting of ACS :105] Based on these risk~. these devices, in their cur-
rent form. do not :1ppear to be :1 proper :1pproach co pre-emptive 
treatment of vulnera.ble or at-risk pla.ques. 
It is dear that current practices and :1Vailable teChnologies in 
focal treatment are primarily focused on improving luminal 
diameter in occlusive pbques and are not well suited for treat-
ment of vulnera.ble pl:1ques. More focus is needed on :J.chieving 
the main objectives of focal ther:1py: mechanical stabilization, 
promotion of vascular healing :md reduction of inflamm:1tion. If 
mechanical stabilization is the objective, the proposed device 
must find :1 point of equilibrium its intrinsic expansive force 
r.uii;ll force and its c::Lp:lbility to induce excessive vascular injury. 
Computational finite element and fluid structure interaction 
models are critical in the development of these devices. Recendy, 
it has been shown that geometrical changes in the shape of the 
lumen may affect unf.tvorably or fuvorably the distribution of 
local stress. either leading to plaque rupture or reinforcing of the 
thin fibrous cap [106,107]. Preliminary data using sclf-expanda.ble 
nitinol-bascd devices designed with the objective of inducing 
reinforcement of the c::Lp and necrotic core compression but not 
cap rupture have been published [108,109]. Conceptu::Llly, these 
devices must reinforce the fibrous cap, resha.pe the necrotic core 
and meeh:mically ~1:abiliz.c the lesion at risk of disruption. Another 
important aspect of device development is the possibility of in situ 
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hyperthermia. in :1 segment to induce a pas-
siV:ltion effect on the intim::t to halt disease 
progression [10:!,103]. Photodynamic ther-
:lPY utilizes ph:um:1ceutical compounds, 
which :ue :lctivated locally to reduce d:un-
age outside of the treatment zone ll04]. A 
more selective :1pproach to photo-:lngi-
ophsty is a cell targeting technique known 
as selective photothermoly.sis, which targets 
pan:icul:u cells (e.g., macrophages) for 
apoptosis using nanom:ukets, limiting 
damage to nearby structures. The other 
directed energy techniques ;:u-e still in early 
stage research and there are not available 
data on their safety and efficacy. 
Figure 7. Near infra-red spectroscopy. Demonstration of spectrai findings in the left 
anterior descending coronary artery of an autopsy specimen (unpublished data, on file 
lnfraReDx, Inc., Burlington, Massachusetts). The panel sho\NS the results of the scan, 
with distance along the lumen on the x-axis and arc of rotation on the y-ax"1s. As 
indicated by the yellow signal, the scan successfully detected lipid necrotic core rich areas. 
Image courtesy of James E Muller. 
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rures. TCFA is the morphology that 
most resembles plaque rupture. How-
r~~~~~ R;es;h~a~p~e~lo~m~eoito~ces~to;c;e~h;e;m;o~d:y~oa"m""lcs~l I inforc  fibrous ap I Mechanical vessel wall reconstruction I Retract and retain necrotic coral {increasing resistance to rupture) I Recover endothelium functionality I 
ever, the narur:J. history of these high-
risk or vulne~ble lesions remains 
unknown and the limited knowledge 
about their eventual prognosis is pro-
vided by retrospective histopathologic:J 
studies. Detection of these vulnerable 
plaques in vivo is essenti::tl to study their 
natural history :md to cv:Uu:J.te potential 
treatment mochlities :md, therefore, mn.y 
ultimately h:1ve :m important impact on 
I Remodelling of the vessel I 
Reassessment beyond 
the coronary ostia 
Vulnerable vascular bed, myocardium, 
blood and patient 
Figure 8. Treatment of coronary vulnerable plaques. 
promoting tissue regeneration. Specifically, the regeneration of 
the endothelium and recovery of its functionality by means of 
passive or active endothelial cell attraction is also under devel-
opment :no]. Ideally, drug elution specifically targeting the 
inflammatory components of the plaque must be required to 
mitigate inflammation with the use of these devices. Although 
still early for human application, several technologies specifi-
cilly designed to passivate vulnerable plaques are under valida-
tion phases in animal models. Their potential :JS therapeutic 
alternatives will probably depend on the development of accu-
rate risk stratification str:uegies and the validation of device 
safety in the appropriate clinical setting. 
Conclusion 
Several invasive imaging techniques are currently under devel-
opment to detect vulnerable coronary plaques in humm coro-
nary arteries in vivo. To date, none of the techniques described 
previously have been sufficiently validated and, most impor-
tantly, their predictive value for adverse cardiac events remains 
elusive. Intravascular palpography md virtual histology, based 
on conventional IVU$ catheters, appear tO be very promising 
and their predictive role is presently under invescigacion in a 
large international trial. 
Very rigorous and well-designed studies are compelling for 
defining the role of each imaging modality. Noninvasive tech-
niques and the assessment of humoral md genetic Sctors com-
prise complementary and important tools in this direction. 
At present, the rmin purpose of all these evolving techniques is 
to improve our understanding of n.therosclerocic disea.<>e and tO 
define its mrural history. V1cimately, the aims are to identifY 
patients at high risk for future cudiovascular events and tO evaluate 
the benefit from either local or systemic therapeutic interventions. 
Expert commentary & five~year view 
Unheralded ACS are common initial manifestations of coro-
nary atherosclerosis and are frequently caused by pbque rup-
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the prevention of A ..iV1I and death. Sev-
eral invasive imaging techniques :ue cur-
rently under development to detect vul-
nerable coronary plaques in human coronary arteries in vivo. 
The optimal device for imaging vulnerable plaque would 
combine several techniques, overcoming the deficiencies of 
each and providing information on different aspects of vul-
nerability. Currently, conventional grayscale IVUS. IVUS-VH 
and palpography are imaged with the same catheter during 
the same pullback. A combination of this catheter with either 
thermography capability or alternative imaging such as OCT 
or spectroscopy would be an exciting development. IVMRI 
also holds much promise. To date, none of the techniques 
described previously have been sufficiently validated and, 
most importantly, their predictive value for adverse cardiac 
events remains elusive. Very rigorous and well-designed stud-
ies are compelling for defining the role of each imaging 
modality. Koninvasive techniques and the assessment of bio-
humoral and genetic f.:tctors comprise complementary and 
important tools in this direction. 
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Key issues 
• The natural history of the so-called vulnerable plaque 
is unknown. 
• There is not a single imaging technique able to fully 
characterize vulnerable plaques. 
• Combination of some of these techniques may improve 
accuracy on vulnerable plaque detection. 
• Ongoing studies using these techniques would provide better 
understanding of this intrincate process. 
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Treatment 
What IfDiogenes Would Have 
Found What He Was Looking For?* 
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Evelyn Regar, MD, PHD 
Rotterdam, the Netherlands 
In this issue of the journal, Kubo et al. (1) and Cheruvu 
et aL (2) provide essential anatomical information about 
plaques that cause acute coronary thrombotic occlusion and 
their postulated precursors, thin-capped :fibroatheromas 
(TCF As). Histopathological assessment (Cheruvu et a1. [2]) 
of the epicardial vascul:J.r tree revealed that the incidence of 
TCF As and ruptured plaques is low and their spatial 
distribution is focal. An in vivo investigation of patients 
'With acute myocardial infarction (Kubo et al. [1]) confirmed 
that, indeed, ruptured TCFA is the predominant morpho-
logic substrate. Linking these observations together can cast 
light on possible options for treatment of such coronary 
lesions. 
See pages 933 and 940 
From Postmortem Observations 
to the In Vivo "Hot Plaque .. Characterization 
The current paradigm postulates a particular morphology 
for so-called vulnerable plaques, including a thin :fibrous cap 
overlying a necrotic-rich core. However, it is difficult to 
translate postmortem :findings into a prospective, prognos-
tically relevant concept for patients. 
•Editoriub publi<hed in the journal o/ thr /Jmm'r:an Callrgc o/ Cardiolopy ref!ecr the 
viev.o; of the autho"' and do not nece>orrtily represent the vi<:W>. of j/JCC or the 
Amcri01!1 College of Curdiology. 
From the Thoraxcentcr, Rotterdam, the Netherbncb. 
\Nhen is a :fibrous cap considered thin? Pioneering 
pathology studies applied various criteria regarding study 
population, region of interest, and cap definition, .Y.Iann and 
Davies (3) reported on 160 coronary plaques obtained from 
31 subjects who died of sudden cardiac death. Mean cap 
thickness was 250 !J-m (range 20 to 1,140 f.Lm) in types N 
and V plaques. Burke et al. (4) sectioned coronaries at 
3-mm intervals. Only cross sections '-'lith more than 50% 
lumen narrowing were analy-ad. In ruptured plaques, fi-
brous cap thickness was 23 :!:: 19 ).J..m, and in 95% of these 
plaques cap thickness was <65 J.UU. This value of cap 
thickness of ruptured plaques has been used-maybe inap-
propriately-for the definition of nonruptured TCF A (5), 
despite the fact that TCF As have less necrotic core, less 
cholesterol clefts, and less macrophage infiltration compared 
'With ruptured plaque. 
The present reports use the <65-J.tm criterion to define 
TCFA. However, there is no consensus among clinicians 
and pathologists regarding the critical threshold for cap 
thickness that would reliably predict imminent plaque 
rupture. The criticism of clinicians stems from the fact that 
application of absolute histomorphometric values can be 
misleading due to anisotropic tissue shrinkage and to the 
lack of longitudinal data. In addition, the absence of a 
technique able to provide an accurate cap assessment in vivo 
has resulted in a lack of knowledge on the natural history of 
such plaques. 
Optical coherence tomography (OCT), the optical ana-
logue to pulse-echo ultrasound imaging, can directly visu-
alize a thin :fibrous cap. Currently, intracoronary OCT 
systems work with a resolution of 10 to 15 ).J..m. Cilingiroglu 
et al, (6) demonstrated that OCT is able to accuratelv 
visualize thin :fibrous caps in vivo (7). Optical coherenc~ 
tomography can evaluate the macrophage content (7-9) and 
the collagen composition of a :fibrous cap (7). In the current 
issue, Kubo et al. (1) evaluated the ability of intracoronary 
OCT to assess culprit lesions during primary percutaneous 
coronary intervention in patients '-'lith acute myocardial 
infarction. Optical coherence tomography was superior in 
detecting plaque rupture and erosion as compared '-'lith 
intravascular ultrasound (IVUS) and angioscopy. The study 
is remarkable in several respects. Obviously, it demonstrates 
the feasibility of a complex imaging protocol including 
IVUS, angioscopy, and OCT in the acute setting. Secondly, 
it confirms the pathology-driven hypothesis of the promi-
nent role of TCF A rupture in acute coronary thrombotic 
occlusion. Third, it allows for the first time in vivo estima-
tion of critical cap thickness in patients, The thickness of 
the remnants of the fibrous cap after symptomatic rupture 
measured in vivo was 49 ± 21 p.m. These observations 
represent a very encouraging step toward a prospective, 
in-vivo evaluation of "hot" plaques at high risk for acute 
coronary events. However, the results should be interpreted 
'-'lith caution. The incidence of plaque rupture cannot be 
generalized, as there was considerable selection bias in the 
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study cohort. Optical coherence tomography differentiation 
of necrotic-rich core from calcified plaque by visual assess-
ment of the gray scale image can be difficult (10). Therefore, 
it would important to know the actual intra- and interob-
scrvervariability ofKubo et al. (1) to assess the accurateness 
of their results. 
When Distribution and Frequency Matters 
As atherosclerosis is a systemic disease, plaque rupture is 
considered a ubiquitous process that may be clinically silent 
or symptomatic in different regions of the vascular system. 
In patients with acute coronary syndrome (ACS), Rioufol 
et al. (11) reported at least 1 plaque rupture remote from the 
culprit lesion in 80% and remote from the culprit artery in 
71% of their patients. A meta-analysis described that more 
than 20% of ACS patients have more than 1 ruptured 
plaque (12). Likewise, a high prevalence of rupture-prone 
lesions throughout the coronary tree has been reported by 
angiography (13), angioscopy (14), and polpogcaphy (15). 
The report of Cheruvu et al. (2) is at variance "With 
previous reported data. First, the prevalence of TCF A and 
ruprured plaques is low (0.46 ± 0.95 and 0.38 ± 0.70 per 
heart, respectively), focal, and located in the proximal seg-
ments of the coronaries. In earlier studies, up to 3 TCF A 
were found per heart (16). E::,.'planations for this might be 
demographic differences in studied population and in meth-
ods, namely longitudinal instead of cross-sectional cutting of 
the coronaries. Second, necrotic core size was relatively small 
for both, TCFA (1.6 ± 1.8 mm2; length2.7 ± 2.0 mm) and 
ruprured plaques (2.2 ± 1.9 mm2; length 1.9 ± 3.6 mm). In 
previous studies, the size of necrotic core in TCF As was 
1.7 ± 1.1 mm2 "With a length of8 mm (range 2 to 17 mm), 
and in ruprured plaques 3.8 ± 5.5 mm2, "With a length of9 
mm (range 2.5 to 22 mm) (5). The difference in length is 
striking. Therefore, we may wonder whether the intrinsic 
risk varies among the type oflesions that arc labeled by the 
same morphologic term "TCFA." 
The Cheruvu et al. (2) findings have potentially impor-
tant clinical implications, since maybe only TCF A that are 
proximally located, "With large necrotic core and ounvard 
remodeling, should be considered for local treatment, Un-
fortunately, remodeling index is not reported, likely due to 
the methodology Oongitudinal cut in 4 quadrants). 
To date, there is no single marker that can accurately 
identif)r the risk of rupture for an individual plaque. But it 
has been suggested that assessment of several plaque char-
acteristics (morphologic, biochemical, and mechanical) may 
improve the ability to correctly diagnose vulnerable plaques. 
Radiofrequency IVUS data analysis (e.g., virtual histology, 
palpography) has emerged as a tool to potentially detect 
TCFAs in vivo. In a recent study, patients with ACS 
underwent IVUS-VH analysis of all 3 epicardial coronaries. 
On average, there were 2 IVUS-derived TCF A per patient 
with half of them showing outward remodeling (17). Inter-
estingly, the si7..e of the necrotic core (1.2 ± 0.8 mm2) is in 
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line "With the Cheruvu et al. (2) histopathological data. 
Another interesting approach is the combination ofVH and 
palpography. Both datasets can be simultaneously acquired 
during one single rvus pullback, allo-wing for the assess-
ment of both morphologic and biomechanical properties of 
a particular plaque. Assessing several characteristics of a 
given plaque could potentially enhance invasive risk strati-
fication by identi:f)ring very high-risk plaques, thereby low-
ering the number of vulnerable plaques that deserve to be 
followed over time and ultimately treated. 
What If Diogenes Would Have 
Found What He Was Looking For? 
The cynic Greek philosopher Diogenes walked through 
Athens in broad daylight carrying a lighted lamp, looking 
for an honest man. Needless to say, he never found one. 
\i'i/hat if we ever became able to identify in vivo the 
uncommon TCF As on the verge of imminent ruprure? 
Vessel wall reinforcement should be considered mandatory. 
Ideally, lesion coverage and cap reinforcement by a dedi-
cated shield with thin and dense struts (permanent or 
preferably absorbable) strong enough to progressively 
change the geometry of the lumen by self-e."q'ansion "With-
out rupturing the cap would be appealing. Computational 
finite element and fluid dynamics taught us that geometrical 
changes in lumen shape can aifect local mechanics unfavorably 
or favorably, either leading to plaque rupture or to reinforce-
ment of the thin fibrous cap (18,19). Fmally, having acutely 
constrained the necrotic core, it should subsequently be re-
duced by a pharmacologic agent or mechanically. Furthermore, 
regeneration of the endothelium and recovery of its function-
ality, possibly by passive or active endothelial cell attraction, 
would heal the endothelial lining, while drugs specifically 
targeting the necrotic core could be released abluminally. Such 
nC'Nly designed absorbable stents are currently contemplated as 
future focal treatment for vulnerable plaque. 
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Paul Erne. MD. PhD: Stefan Verheye. MD. PhD; Michael Aschermann. MD; 
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Clemens von Birgelen, MD, PhD: Don D'Amico. MA: Tammy Hutchinson, MSc: 
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D. Geoffrey Vince. PhD: Peter Ganz. MD; Christian W. Hamm. MD; 
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for the Integrated Biomarker and Imaging Study-2 Investigators 
Background-Lipoprotein-associated phospholipase A::. (Lp-PLA::) is expressed abundantly in the necrotic core of 
coronary lesions. and products of its enzymatic activity may contribute to inflammation and cell death, rendering plaque 
vulnerable to rupture. 
Methods and Results-This study compared the effects of 12 months of treatment with darapladib (an oral Lp-PLA~ 
inhibitor, 160 mg daily) or placebo on coronary atheroma dcfonnability (intravascular ultrasound palpography) and 
plasma high-sensitivity C-reactive protein in 330 patients with angiographically documented coronary disease. 
Secondary end points included changes in necrotic core size (intravascular ultrasound radiofrequency), atheroma size 
(intravascular ultrasound gray scale). and blood biomarkers. Background therapy was comparable between groups. with 
no difference in low-density lipoprotein cholesterol at 12 months (placebo. 88:±:34 mg/dL; darapladib. 84:±:31 mg/dL; 
P=--0.37). In contrast. Lp-PLA~ activity was inhibited by 59% with darapladib (P<O.OOl versus placebo). After 12 
months. there were no significant differences between groups in pl::Lque defonnability (P=--0.22) or plasma high-
sensitivity C-reactive protein (?=0.35). In the placebo-treated group. however. necrotic core volume increased 
significantly (4.5::!:17.9 mm3 ; P=--0.009). whereas darapladib halted this increase (-0.5::!:13.9 mm3; P=--0.71). resulting 
in a significant treatment difference of -5.2 mm3 (?=0.012). These intraplaque compositional changes occurred 
without a significant treatment difference in total atheroma volume (?=0.95). 
Conclusions-Despite adherence to a high level of standard-of-care treatment, the necrotic core continued to expand 
among patients receiving placebo. In contrast, Lp-PLA~ inhibition with darapladib prevented necrotic core expansion. 
a key determinant of plaque vulnerability. These findings suggest that Lp~PLA1 inhibition may represent a novel 
therapeutic approach. (Circulation. 2008;118:1172~1182.) 
Key Words: atherosclerosis • drugs m imaging • lipoprotein-associated phospholipase A2 
D espite intensive_ managerr:ent of conven.tional risk fac-tors. many pat:J.ents contmue to expenence recurrent 
coronary events. 1 Most acute coronary events arise from 
Received Febru-ary 8, 2008: accepted Ylay 23. 2008. 
initially non-flow-limiting stenoses that often arc underesti-
mated by angiography.~.3 The salient features of culprit 
lesions resulting in fatal myocardial infarction include the 
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disruption of a thin fibrous cap, the presence of a large 
lipid-rich necrotic core, and an extensive inflammatory cell 
infiltrate.4 Recent intravascular ultrasound (IVUS)-based 
regression trials could not address these important lesion 
characteristics because of inherent limit::ttions in IVUS tech-
nology, although they have demonstrated a relationship 
between changes in the overall plaque volume and pl:lsma 
low-density lipoprotein cholesterol (LDL-C) levels. 5·t> Be-
cause the current standard of care for high-risk cardiovascular 
patients already mandates intensive LDL-C lowering. intra-
vascular imaging that could ::t.'>sess changes in plaque biomc-
chanical or compositional ch::tracteristics may be p::rrticularly 
helpful in evaluating the mechanisms of future events or the 
efficacy of new pharmacological agents that act via novel 
meehanisms.7 
Editorial p 1120 
Clinical Perspective p 1182 
Lipoprotein-associated phospholipase Ac. (Lp-PLA2) is a 
circulating enzyme produced and secreted by inflammatory 
cells centrally involved in atherosclerosis, ~- 11 bound predom-
inantly to apolipoprotein B-containing lipoproteins, and 
highly expressed in the necrotic core of atherosclerotic 
lesions, 12•13 Although this enzyme was first described as the 
platelet-activating factor aeetylhydrolasc, it has much broader 
substrate specificity. 14 Lp-PLA~ rapidly degrades oxidatively 
modified phospholipids in LDL-C. leading to formation of 
proinflammatory and cytotoxic produets.~· 15 • 16 Because en-
h:mced cell death :md impaired clearance of apoptotic bodies 
arc thought to be key mechanisms for necrotic core exp:m-
sion.17 Lp-PLA~ inhibition may favorably affect rupture-
prone lesions. 
The objective of this study was to explore the effects of 
treatment with a direct Lp-PLA: inhibitor (darapladib) on 
coronary plaque deformability. composition. and size. In 
addition. the effects ofLp-PLA: inhibition on several biomar-
kers and clinical safety par::uneters were assessed. 
Methods 
Study Design 
The Integrated Biomarkers ::md Imaging Study-2 trial W:lS an 
internationaL multicenter. randomized, double-blind, placebo-
controlled study of patients with angiographically confirmed coro-
nary heart disease. The trial was designed by the Steering Committee 
(Appcndi:<) in collaboration with the sponsor. Institutional review 
boards at each center approved the protocol. and patients provided 
written informed consent. 
Patient Population 
Patients <"::18 years of age undergoing carcliac catheterization for 
acute coronary syndrome (ACS: ST-segment elevation myocardial 
infarction or non-ST-segment elevation myocardial infarction) or 
non-ACS (eg. chronic stable angina or troponin-negativc resting 
chest pain) were eligible. The protocol specified 50% of randomized 
patients to have troponin-positive ACS. Key exclusion criteria were 
planned surgical rcvasculari7..ation, stroke in the past 6 months. 
chronic hepatic disorder or abnormal alanine aminotransferase. 
bilirubin (alanine aminotransferase >2.5 or bilirubin > 1.5 times the 
upper limit of normal), serum creatinine >2.0 mg/dL, blood pressure 
> 160/100 mm Hg, poorly controlled diabetes mellitus (HbAk > 10%). 
severe heart failure or left ventricular ejection fraction <30%. and 
current life-threatening condition. Patients were ineligible if angiog-
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raphy demonstrated left main coronary stenosis >50% or their 
coronary anatomy was inappropriate for IVUS. Within I 0 days of 
qualifying cardiac catheteri7..ation. eligible patients were randomized 
to oral doses of darapladib 160 mg (GlaxoSmithKline, King of 
Prussi:l. Pa) or placebo once daily (1:1 ratio) for the 12-month 
treatment. The !"'..tndomization W:l." stratified accon:ling to ACS status 
and center. 
IVUS Imaging 
After intracoronary nitroglycerin administration. the vessel was 
imaged with a 20-MHz IVUS catheter (Eagle-Eye, Volcano Thera-
peutics. Rancho Cordov:1, Calif) during a 0.5-mm/s continuous 
motorized pullback (R-100 pullback device). The nonintervened 
studied segment had to be at least 40 mm long and exhibit <50% 
stenosis by angiography. All imaging data were stored digitally in a 
dedicated console (In-Vision Gold. Volcano Therapeutics, Rancho 
Cordova, Calif). Patient.~ who received at least 1 dose of the 
investigational agent were scheduled to undergo IVt:S of the same 
study vessel at 12 months. Patients who required urgent cardiac 
catheterization <12 months but >6 months after randomization had 
their imaging data included in the analysis. Details regarding 
imaging methodologies are provided in the online Datu Supplement 
and are illustrated schematically in Figure 1. 
IVUS~Based End~Point Delmitions 
IVUS~Based Palpography 
The density of high strain per 10 mm (the coprimary end point) W:l." 
defined as the number of cross sections with strain values 2.:0.9% 
divided by the number of all analy7..able cross sections in the region 
of interest and normalized for 10 mm.7 
JVUS-Based Radiofrequency Analysis 
The necrotic core volume was calculated by multiplying the mean 
necrotic core area of the region of interest by its length. Necrotic core 
values were expressed in cubic millimeters or as the percent of total 
radiofrequency (RF)-dcrived plaque volume. Other components of 
the plaque (dense calcium, fibrofatty tissue, and fibrous tissue) were 
calculated in the same manner. 
IVUS Gray Scale 
Total atheroma volume and percent atheroma volume were calcu-
lated. The latter was derived by dividing the total atheroma volume 
by the total vessel volume and multiplying by I 00. Of note, total 
atheroma volume derived from IVUS gray scale contains both 
atherosclerotic plaque and media. 
Biomarkers 
Blood samples were collected at baseline and after randomization. 
Pl:l."ma high-sensitivity C-rc:J.ctive protein (hsCRP: coprimary end 
point) was measured as described previously.'x Ph-;ma Lp-PLAc 
activity was measured by a colorimetric method with an intra-assay 
precision of 1.7% and interassay precision of 4.8%. 11 • 1x Details 
regarding other biomarkers are provided in the online Data 
Supplement. 
Clinical Safety 
Patient safety was assessed through adverse event reporting, physical 
examinations, ECG monitoring. and clinical laboratory tests. After 
l"' •.tndomi7..ation. patients visited the study centers at 1 and 3 months 
::md every 3 months thereafter. 
To detect any potential signal of harm. the Independent Data 
Monitoring Committee met every 3 months, by teleconference or in 
person, to review the unblindcd safety data. The Independent Data 
Monitoring Committee deliberations took place entirely separately 
and independently of the Steering Committee or the sponsor 
(Appendh:). 
Statistical Analysis 
Continuous variables for imaging end points were reported :l." 
mean±SD. Within-treatment-group changes from baseline were 
The Effects of the Direct Lipoprotein-associated Phospholipase A2 Inhibitor Darapladib 
Only the amplitude {echo intensity) 
is used to construct the IVUS-greyscale image 
c 
Frequency {beneath the amplitude) 
of echo signal can vary, 
depending on tissue content 
E 
i )(\\...__ 
'_d ___ ~~ 
G - IVUS at high BP ~ 
- IVUS at low BP 
l l 
Classification tree Time delay estimation 
Figure 1. A, The ultrasound signal is generated in a piezoelectric crystal (*}that transmits and receives sound waves. B, Ultrasound 
reflected by the tissue deforms crystal, generating RF signal. C, Gray~scale JVUS is derived from the amplitude of RF signal, discarding 
information beneath the peaks of the signal. D, Changes in the electric field of the piezoelectric crystal caused by ultrasound reflection 
are used to generate a gray~tone image. E, IVUS RF analysis uses several additional spectral parameters to identify 4 plaque campo~ 
nents. F, Plaque components that are identified are dense calcium (white}, fibrous (green}, fibrofatty (greenish~yellow), and necrotic core 
(red}. G, IVUS palpography takes advantage of RF signals generated by the artery being deformed by blood pressure (BP). Using analy~ 
sis of RF signals at "lowH and "high" BP, the strain (deformation} in the inner layer of atheroma is determined. H. This strain is quanti~ 
fied and superimposed on the IVUS image at the lumerVvessel wall boundary. Note that high strain (yellow} is found at the shoulders of 
the eccentric plaque. 
evaluated by paired t tests. and treatment compari:;ons of change:; 
from ba..o.;clinc in IVUS were analyzed with ANCOVA adjusted for 
ACS st:J.tus, pooled country, baseline value. and segment length. 
Treatment differences were expressed as the adjusted mean. 95% CI. 
and probability value. Biomarkers were log transformed and ana~ 
lyzed with last·observation--carried~forward AN CO VA and repeated~ 
meu..-;ures mixed modeling adjusted for ACS status. pooled country. 
visit, and interaction between visit and treatment. Treatment differ~ 
enccs were expressed a.-; adjusted perecnt::lge change, 95% CI, and 
probability value. l'\o multiplicity adjustments were applied; all 
probability vulucs arc presented 2 sided. 
The sample size was determined with an estimation approach 
because the effects of an Lp-.PLA, inhibitor on novel imaging 
parameters were unknown. The SDs of changes for high-str:Jin 
density (IVUS p:Upography) and hsCRP in a similar patient popu· 
lation were used, with additional eonsidemtion given to the expected 
number of noncvaluablc IVUS imagings.7 With this approach, by 
recruiting -300 patients. the study could estimate the treatment 
effects on the reduction of plaque dcfonnability or hsCRP with good 
precision; reductions of ""'20% were anticipated to reach st::ltistical 
significance. 
The authors had full access to and t:J.kc full responsibility for the 
integrity of the data. All authors have read and agree to the 
manuscript a._-; written. 
Results 
Between November 16, 2005. and August 16. 2006. we 
randomized 330 patients. We assigned 155 patients to pla~ 
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451 Screened 
I 330 Randoml;;:ed I 
I I 
155 Placebo 
4 did not receive study drug 
175 Dar.tpladlb 160 mg 
3 did not receive study drug 
I I 
Figure 2.. Patient disposition flow chart. 
Completed treatment refers to patients who 
received 2:11 months of treatment. 
21 discontinued study drug 
11 adverse event 
20 discontinued study drug 
7 adverse event 
5 withdrew cor~sent 
3 lost to follow up 
11 withdrew consent 
1 lost to follow up 
1 non-compliance 0 non-compliance 
1 other 1 other 
I I 
f 130 ComplotodTrcatment 1 
(86%) 
152 Completed Treatment 
(88%) 
cebo and 175 patients to darapladib (Figure 2). As shown in 
Table I. both groups were well matched except for a higher 
prevalence of hypertension among those receiving darap~ 
ladib. At randontization. there was a high level of adherence 
to guideline~mandated treatments. including statin usc in 
""-'90% of patients. 
Imaging Efficacy Results 
Of randomized patients who received at least I dose of 
placebo or darapladib. those with analyzable baseline and 
follow-up IVUS after a minimum of 6 months of treatment 
constituted the imaging population. The median time to 
follow-up IVUS was 364 days in the placebo and 364 days in 
the d::rrapladib group, with repeat IVUS at ~ 11 months after 
randomir..ation in 97% and 96% patients, respectively. 
IVUS Palpograpby 
At baseline. the density of high strain per 10 mm was 
comparable between placebo-treated (n= 115) and darapladib-
trcated (n=131) patients (0.44:±:0.64 versus 0.43::::0.63, re-
spectively). At follow-up, the between-group comparison of 
the change from baseline in density of high strain (coprima.ry 
end point) was not statistically significant ( -0.08; 95% CI. 
-0.21 to 0.05: P=0.22). Details regarding prespecified 
sensitivity analysis. including only vessels with high strain at 
baseline, arc provided in the online Data Supplement. 
In the lO~mm subsegments with the highest baseline 
density of high strain per 10 mm (placebo, 1.22±1.56: 
darapladib, 1.21 :±: 1.62), both groups showed significant re-
ductions after 12 months (placebo. 35%, ?=0.001; darap-
ladib, 33%. P=0.002). but the difference between groups was 
not significant (?=0.87). 
IVUS RF Analysis 
At baseline, necrotic core volume measurements were com· 
p:rrable between treatment groups in the entire region of 
interest and in the worst 10-mm subsegment (Table 2). 
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In the entire region of interest, necrotic core volume 
increased significantly during the study period among those 
receiving pl:lcebo (4.5±17.9 mm3: P=0.009) but remained 
unchanged in the darapladib group (-0.5:!::13.9 mm\ 
?=0.71 for within-group comparison). 'When the change 
from baseline was compared between groups, there was a 
significant treatment effect in favor of d:rrapladib ( -5.2 mm3; 
95% CI. -9.2 to -1.1: ?=0.012). The nominal changes in 
necrotic core expressed as percent of RF-derived atheroma 
volume showed consistent treatment effects (Table 2). 
In the lO·mm subsegment containing the largest necrotic 
core volume. there also was a significant treatment effect in 
favor of darapladib (-2.2 mm3: 95% CI. -3.6 to -0.8: 
P=0.003: Table 2). 
Figure 3 illustrates the high degree of consistency in 
treatment effect of darapladib compared with placebo in 
several important clinical subgroups. 
'When the individual plaque components were analyzed as 
a percent of IVUS RF-derived atheroma, an increase in 
necrotic core was paralleled by a decrease in fibrous tissue. In 
a comparison of the 2 groups. the differences in necrotic core 
(P=0.047) were accompanied by the reciprocal changes in 
fibrous tissue (P=0.021) (Figure 4). These findings suggest 
that in the placebo group a larger amount of fibrous tissue 
was converted into necrotic core, whereas in the darapladib 
group this process was significantly attenuated. The Table 
in the online Data Supplement provides data for all plaque 
components. 
Gray-Scale IVUS 
At baseline, total atheroma volume was comparable between 
the placebo-treated (n=ll8) and darapladib·trcated (n=143) 
groups (placebo, 313::::149 mm3: darapladib, 327±189 mm3: 
P=0.51). At 12 months. atheroma volume decreased by 
-4.9±32.7 mm3 in the placebo group (P=O.lO) and 
-5.0±28.0 mm3 in the darapladib group (P=0.033). 
The Effects of the Direct Lipoprotein-associated Phospholipase A.2 Inhibitor Darapladib 
Table 1. Baseline Characteristics 
Placebo Darapladib 
(n""151} (n=-172) 
Clinical characteristics 
Age. y 57.3::!::10.9 59.4::!::9.8 
Men, n (%) 126 (83) 140 (81) 
Body mass Index, kg/m2 27.8::!::3.8 27.5::!::4.0 
Diabetes mellitus, n flo) 22 (15) 22 (13) 
Hypertension, n (%) 89 (59) 115 (67) 
Low HOL cholesterol (<40 mg/dL), n (%) 40 (26) 45 (26) 
Hypercholesterolemia, n (%) 95 (63) 108 (63) 
Current smoker, n (%) 57 {38) 6413n 
Pr10r medical history, n (%) 
Prior myocardial Infarction 49(32) 51 (29) 
Prior coronary revascularlzation 47(31) 50 (29) 
Peripheral artery disease 7 (5) 17 (10) 
Prior stroke 3 (2) 4{2) 
Index hospitalization, n (%) 
ACS 74(49) 87 {51) 
STEM I 35 {23) 40(23) 
Non-STEMI 39(2~ 47 {27) 
PCI during Index hospitalization 122 {81) 130 (76) 
Cardiovascular medications at randomization, n {%) 
Aspirin 138{91) 149 {87) 
Clopldogrel or ticlopld!ne 122{81) 136 {79) 
Any antiplatelet medication 150 {>99} 170{99) 
ACE Inhibitors or ARBs 88 {58) 101 {59) 
13-Biockers 119 (79) 138 (80) 
Statins 134 (89) 157 (91} 
Laboratory values 
Cholesterol, mg/dL 
Total 187.3:::47.6 182.3:::43.2 
LDL 108.2:::41.4 103.6:::37.4 
HDL 46.8:::11.2 48.0::::12.4 
Trlglycerldes, mg/dl 
Median 141 136 
lOR 97-202 96-193 
hsCRP, mgll 
Geometric mean 2.4 2.4 
95% a 1.9, 3.1 1.9,3.0 
Lp-PLA! activity, ,u.mol • min-1 • L _, 
Geometric mean 159 160 
95% Cl 152,167 153,167 
Blood pressure, mm Hg 
Systolic 125.7:!:16.9 128.0:::16.1 
Diastolic 75.2:!:10.1 75.6:!:9.9 
Study vessel• 
LAO, n (%) 44(36) 56 (39) 
LCx, n {%) 32 (26) 37 (26) 
RCA, n {%) 45 l'n 51 (35) 
Diameter stenosis, %t 28.0 (10.5) 26.6 (10.3) 
Mean lumen diameter, mmt 2.9:!:0.5 3.0±.0.6 
HDL Indicates high-density lipoprotein; STEM!, ST-segment-elevatkln myocardial infarctjon; PCI, percutane-
ous coronary lntmvention: Ar:J:., angiotensin-converting enzyme: ARB. angiotensin receptor blocker; lOR, 
lnterquart!le range: L.AD, left anterior descending artery; LCx. left circumflex artery, and RCA, light coronary artery. 
Values are presented as mean:::SD unless otheiWise specified. To convert to mmoi/L, multiply values of 
cholesterol by 0.02586 and triglycetides by 0.0113. 
•Jmaglng evaluable populatlon: placebo, 121 patlents; darapladlb, 146 patients. 
tOuantltatlve coronary angiography: placebo, 121 patients; darapladib, 144 patlents. 
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Table 2. Necrotic Core Measurements Based on IVUS 
RF Analysis 
Placebo Darapladlb 
(n=110) (n=129) 
Region of interest, mm 48::::16 49::::16 
Necrotic core volume, mm~· 
Baseline 
Mean::::SD 21.5z:21.9 22.8z:24.5 
Median 14.8 13.6 
lnterquartile range 6.1 to28.2 7.3to32.4 
Follow-up 
Meanz:SD 26.0::::25.3 22.4±25.8 
Median 15.7 16.3 
lnterquartile range 8.1 to36.4 5.6to27.1 
Change from baseline 
Mean::::SD 4.5±17.9 -0.5:!:13.9 
Pt 0.009 0.71 
Least-squares mean -5.2 (-9.2to -1.1) 
(95% Cl}! 
Necrotic core of total plaque,%" 
Baseline 
Mean±SO 13.1±7.6 13.4:::6.5 
Median 12.6 12.5 
lnterquartlle range 6.8 to 16.8 9.1 to 17.5 
Follow-up 
Mean:::so 15.7:::8.8 13.9±7.7 
Median 14.7 12.6 
lnterquartile range 8.5 to 22.1 7.8 to 18.7 
Change from baseline 
Mean±SD 2.5:!:9.6 0.5z:7 .6 
Pt 0.006 0.453 
Least-squares mean -2.0 (-3.9to -0.0} 
(95% Cl) :j: 
Necrotic core in the worst 
10 mm, mm~ 
Baseline 
Mean:::SD 9.2:!:8.1 9.1:::7.6 
Median 7.2 6.8 
lnterquartile range 3.5 to 11.8 3.2to 12.7 
Follow-up 
Mean:::SD 10.1 ±9.2 7.9:::6.7 
Median 7.3 5.7 
lnterquartile range 3.3to 16.0 2.7to 11.2 
Change from baseline 
Mean±SD 0.9±6.6 -1.2::::4.9 
Pt 0.162 0.008 
Least-squares mean -2.2 (-3.6 to -0.8) 
(95% Cl}:j: 
"Values denote measurements In the entire region of Interest. 
tPaired ttest (within-group comparison}. 
p 
0.012 
0.047 
0.003 
:j:ANCOVA adjusted for ACS, pooled country, baseline value, and matched 
segment length (between-group comparison). 
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The between-group comparison of change from baseline 
was not significant (?=0.95). The percent atheroma volume 
also was similar between groups (placebo, 42.2::!.:10.0%; 
darapladib, 40.7::!.:10.1%: ?=0.24) at baseline. The within-
group changes and between-group differences were not sig-
nificant (?=0.90). Likewise. atheroma volwne showed no 
treatment effect in the worst 10-mm subsegment (data not 
shown). 
Biomarkers and Other Laboratory Assessments 
At 12 months. hsCRP was 1.0 mg/L (95% CI. 0.8 to 1.2) 
among those receiving placebo (n=140) and 0.9 mg/L (95% 
CI. 0.8 to I.l) in the darapladib group (n=l62). Nonsignif-
icant reductions in hsCRP were observed with repeated-
measures analysis (~15%: 95% CI. ~36 to 11: ?=0.22). 
These results were consistent with the last-observation-
carried-forward analysis and observed data at 12 months 
(hsCRP was lower in the darapladib group by - 12% (95% 
CI. -32 to 15: P=0.35] and -22% [95% CI. -41 to 3: 
?=0.08]. respectively). A significantly higher percentage of 
patients. however. achieved very low levels of hsCRP (<1 
mg/L) on darapladib (62%) than did those on placebo (45%) 
(odds ratio, 1.99~ 95% CI. 1.22 to 3.24: ?<0.008). 
Plasma Lp-PLA: activity was significantly reduced by 
darapladib at all time points. At 12 months. Lp-PLA1 activity 
was 153 ,umol · min- 1 • L- 1 (95% CI. 147 to 159) in the 
placebo and 62 ,umol · min- 1 • V 1 (95% CI. 58 to 65) in the 
darap1adib group. This corresponds to ~59% (95% CI. -62 
to ~56: P<O.OOI) inhibition of Lp-PLA1 activity compared 
with placebo (repeated-measures analysis and l::ist-
observation-carried-forward analysis). The concentrations of 
other biomarkers (interleukin-6. mye1operoxidase, intracellu-
lar adhesion molccule-1, oxidized phospholipid/apolipopro-
tein B. and matrix metalloproteinase-9 activity) did not 
change significantly. 
Approximately 94% patients continued stltins at the end 
of the treatment period. The 12-month LDL-C was 88:±:34 
mg/dL in the placebo group and 84::::31 mg/dL in the 
dampladib group (?=0.37). Plasma high-density lipoprotein 
cholesterol also was unaffected by treatment ( 48 :±: 11 mg/dL 
in the placebo: 50± 13 mg/dL in the darap1adib group: 
P~O.!S}. 
Adverse Events, Clinical Safety, and Outcomes 
Table 3 summarizes adverse events in both treatment groups. 
A higher incidence of malodor (mainly feces or urine) was 
reported with darapladib (16%) compared with placebo (3%) 
but was an uncommon cause of withdrawal from the study 
(dampladib. 2%). 
Vital signs were similar except for the mean on-treatment 
systolic blood pressure, which was higher in the d::u-apladib 
group by 3.0 mm Hg (95% CI. 0.3 to 5.7: ?=0.031) when 
analyzed with the repeated-measures analysis adjusted for 
baseline values. After 12 months, systolic blood pressure was 
129.6±17.2 mm Hg in the placebo and 133.3:±:18.5 mm Hg 
in the darapladib group. A posthoc analysis of the intraaonic 
blood pressure at the time of follow-up cardiac catheteriza-
tion showed no differences between groups (placebo, 
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p vnluo 
-I for lntomctlon <65 yrs (n=172} 0.29 
<::65 yrs (n"'67) 
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Non-smokor (n:149) 
OM (n"33) 0.11 
non-OM (n=206) 
BP <140/90 mmHg (n=174) 0.79 
BP ;:,140/90 mmHg (n<:65) 
oGFR <60 ml/mlnl1.73rn2 (n"'19) 0.20 
-
oGFR ::60 mlfmln (n:::217) 
Prior stntin thoropy (n=70) 0.89 
No prior stotln thompy (n:160) 
ACS (ne118) 0.64 
non-ACS (n:121) 
LDL <70 mgldl. (n"67) 0.95 
LDL <::70 mgldL (n"169) 
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Figure 3. Treatment differences in necrotic core volume across clinical subgroups. The results are displayed as adjusted mean treat~ 
ment difference and 95% Cl. LDL~C and high~density lipoprotein (HDL) cholesterol values refer to on-treatment levels. DM Indicates 
diabetes mellitus; eGFR, estimated glomerular filtration rate. 
124.1::!::23.8 mm Hg; darapladib. 121.8::!::23.0 mm Hg; 
P~0.19). 
There was no evidence of significant differences in 
platelet biomarkers (P~selcctin. sCD40L. and urinary 
11 ~dehydro--thromboxane B2) measured at multiple time 
points (3, 6. and 12 months) except for higher levels of 
CD40L at 12 months (placebo. 181 pg/mL [95% CI. 150 to 
217]; darapb.dib, 258 pg/mL [95% CI. 208 to 320]: 
?=0.024). No imbalance in clinical events related to in~ 
creased platelet activity was observed (Table 3). 
Discussion 
The main finding of this study was that darapladib, a direct 
Lp-PLA2 inhibitor. prevented necrotic core expansion. 
whereas patients receiving placebo showed significant pro-
gression despite standard-of-care treatment, with average 
LDL-C levels <90 mg/dL. The results suggest that human 
coronary atherosclerosis is a dynamic process with potential 
for replacement of fibrous tissue by necrotic core. Prolonged 
Lp-PLA2 inhibition halted this process. indicating a direct 
effect on human atheroma that is distinct from current 
phannacological therapies. 
Lp-PLAl and Necrotic Core Formation 
The mere presence of Lp~PLA2 in high~risk plaques does not 
necessarily establish its causal role in lesion propensity for 
rupture. However. Lp~PLA2 inhibition. with the subsequent 
reduction of its product. lysophosphatidylcholine. has re~ 
duced inflammation and cell death in studies in vitro. 1 :.t5.t~> 
Furthermore, darapladib decreased intraplaque lysophos~ 
phatidylcholine content. attenuated the expression of inflam~ 
matory genes. and reduced necrotic core in a porcine model 
of coronary atherosclerosis. 1 ~ In humans, treatment with 
darapladib not only inhibited intraplaque Lp-PLA2 activity 
but also reduced activity of the intracellular proteascs 
(caspase-3 and caspase~8) that are responsible for apoptotic 
cell death.2° Therefore. the finding from the present study, 
that darapladib interferes with necrotic core expansion. is 
consistent with the overall biological hypothesis and sup-
ports a proathcrogenic role for Lp-PLA2• 
Intravascular Imaging of Coronary Atherosclerosis 
Until recently, no intravascular imaging modality has been 
capable of assessing the composition of coronary atheroma in 
a precise manner. IVUS RF analysis has been validated in 
postmortem pressure~perfused human coronary arteries and 
in the specimens retrieved by coronary atherectomy and 
carotid endartcrectomy.21 - 24 The present study provides the 
first longitudinal observation of the atherosclerotic process 
among patients receiving standard~of~care treatment. We 
demonstrate continued necrotic core expansion in patients 
receiving placebo. whereas darapladib halted this process. 
with a consistent effect across several subgroups. Because 
atherosclerosis is a highly heterogeneous process. we also 
confirmed statistically significant regression of necrotic core 
volume in the worst 10-rnm subsegmcnts (Table 2). 
The IVLS palpography failed to detect a significant effect 
on biomechanical properties of coronary plaques during 
darapladib treatment. An unexpectedly high percentage of 
patients without high strain (37%) at baseline may have 
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Darapladib group Placebo group 
Differential redistribution of individual IVUS-RF pl::~que 
components in t~ overall population 
P""0.047 
Figure 4. Top, Representative examples of plaque composition in the darapladib- and placebo-treated groups. The gray-scale frames 
and corresponding IVUS RF frames are shown, The pie charts provide quantitative display of individual plaque components in the 
cross sections. Values are in millimeters squared {and percent of RF-derived atheroma area). In the darapladib-treated patient, a 
decrease in necrotic core is seen. In the placebo-treated patient, an increase in necrotic core is demonstrated. Bottom, Differential 
changes in plaque components from IVUS RF analysis in the overall placebo and darapladib groups. Results are expressed as mean 
change from baseline (BL), with individual components expressed as percent of RF-derived atheroma volume. FUP indicates follow-up. 
*Within-group change from baseline. 
reduced the statistical power needed to demonstrate signifi-
cant differences between treatment groups.7 Supporting this 
hypothesis is the prespecified sensitivity analysis demonstrat-
ing a significant reduction in high strain in the darapladib 
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group (?=0.009) when only patients with highly deformable 
plaque at baseline were analyzed. 
Despite the relatively short treatment duration. the changes 
in volumetric measurements using IVUS gray scale were 
The Effects of the Direct Lipoprotein-associated Phospholipase A2 Inhibitor Darapladib 
Table 3. Adverse Events, Clinical Outcomes, and Laboratory 
Abnormalities 
Placebo Darapladib 
Variable (n=o151) (n=172) 
Adverse events,~ n (%) 
Serious adverse event 46 (30) 49 (28) 
Any adverse event 109 (72) 121 (70) 
Any adverse event leading to wtthdrawai 11(7) 7(4) 
MACE event n (%) 
Composite of first MACE (DJ death, Ml, 29 (19) 29(1~ 
stroke, coronary revascularization) 
AJI components of MACE,t n (%) 
Death 0 
Myocardial Infarction 7(5) 4 (2) 
stroke 1(<1) 1(<1) 
Coronary revascularlzatlon 29 (19) 28 (16) 
Other ()J events,t n (%) 
Coronary restenosls 20 (13) 18(10) 
ln-stent thrombosis 2 (1) 1(<1) 
Hospitalization for myocardial ischemia 13 (9) 11 (6) 
Blood pressure-related events, n (%} 
Investigator-reported hypertensive 4{3) 3(2) 
adverse events 
Blood pressure ~140/90 mm Hg 95 {63) 117{68} 
Systolic blood pressure <.!140 mm Hg 89 {59) 112{65} 
Laboratory abnormalltles,:j: n (%) 
Alanine aminotransferase ~3 times ULN 1{<1} 2(1) 
Aspartate aminotransferase <.!3 times ULN 0 1(<1) 
Total bilirubin <.!1.5 times ULN 5(3) 1(<1) 
Alkaline phosphatase <.!2 times ULN 
MACE indicates major adverse cardiac events: CV, cardiovascular, Ml, 
myocardial infarction: and ULN, upper limit of normal. Adverse events were 
collected during treatment phase and up to 28 days after discontinuation of the 
study medication. 
"The safety population consisted of patients who received at least 1 close of 
placebo or darapladib. 
tpat'tents wlth >1 event are counteci more than once. 
:tAll counts refer to number of patients. 
comparable to those observed in other regression trials with 
similar on-treatment LDL-C values.zs IVUS gray scale has 
been recognized as an established method to assess regres-
sion/progression of atherosclerosis. but it relics exclusively 
on plaque volume measurements.5·t>.25 The present study 
demonstrates that IVUS RF analysis detects changes in 
atheroma composition in the absence of detectable overall 
plaque volume changes. We cannot exclude the possibility 
that a longer treatment duration (eg, > 12 months) may have 
allowed an even more pronounced effect on necrotic core and 
ultimately atheroma volume. 
Darapladib and Biomarker Response 
hsCRP. a broad marker of systemic inflammatory burden. 
showed only trends toward lower values in the darapladib 
group, similar to a recent report. 1 ~ The noxious effects of 
Lp-PLA2 depend on intraplaque concentrations of its sub-
strate (ie. oxidized phospholipid in modified LDL-C) and in 
situ Lp-PLA2 concentration. which may explain the predom-
inantly local effects of darapladib without a more profound 
systemic impact.:" A high adherence to sto.tin therapy also 
contributed to lowering hsCRP (and other inflammatory 
biomarkers). thus minimizing the opportunity for further 
reductions with darapladib. 
Clinical Safety 
Although the study was underpowered to address the effects 
of darapladib on cardiovascular outcomes, there was no 
imbalance in reported clinical outcomes. The higher sCD40L 
level in the darapladib group at 12 months is probably not of 
clinical relevance because only much higher values predict 
ischemic events.:7 Of note. other platelet biomarkers (P-
selcctin and 11-dehydro-thromboxane B2) did not differ 
between treatment groups. Importantly, there was no excess 
of clinical events associated with increased platelet reactivity. 
Higher systolic blood pressure in the darapladib group was 
not consistent with the results of a prior clinical study and 
requires careful attention in future studies.rx Additional com-
parison of the intraarterial blood pressure also revealed no 
differences between groups. 
Study Limitations 
This was an exploratory study that used novel imaging rvus 
modalities to assess plaque deformability. composition. and 
size. The clinical relevance of plaque compositional changes 
observed with sustained. long-term Lp-PLA: inhibition re-
quires confirmation in event-driven outcomes trials. 
Our observations focus on a small segment of the coronary 
arterial tree and might not fully represent disease progression 
elsewhere. Finally. the approach undert.:lken in this and other 
IVUS trials has not assessed changes in the precise plaque 
phenotype that may portend clinical risk (eg. thin-cap 
frbroatheroma). 
Conclusions 
This study demonstrated that necrotic core expansion occurs 
despite contemporary cardiovascular therapies. even in the 
absence of overall plaque size increase, This unabated ne-
crotic core expansion could be responsible. in part. for the 
recurrent cardiovascular events in high-risk patients. Lp-
PLA2 inhibition with darapladib halted this process and 
therefore may represent a new approach for the treatment of 
atherosclerosis if the benefit of this intervention is confmned 
by the results of future event-driven outcomes trials. 
Appendix 
Integrated Biomarker and Imaging Study-2 Steering Committee: 
Patrick W. Serruys (chairman: Rotterdam. the Netherlands), Gerrit-
Anne van Es (Rotterdam. the Ketherlands). Christian H::unm (Bad 
Nauheim, Germany). William Wijns (Aalst. Belgium), Andrew 
Zalewski (nonvoting member. King of Prussia.. Pa). and Andrew 
Zambanini (nonvoting member: Middlesex. UK). 
Independent Data Monitoring Committee: Peter G:mz (chairman: 
Boston. M::r..~s). Charles S. Abrams (Philadelphia.. Pa). Richard Cairns 
(Nottingham. UK), Barry R. Davis (ex officio: Houston. Tex). 
Marian Fisher (Madison. Wis), James Shepherd (Glasgow, Scot-
land). and Sidney Smith (Chapel Hill. NC). 
Core laboratories: im::rging (Cardialysis. Rotterdam, the Nether-
lands)~ clinical biochemistry/hematology (Que~t Diagnostics, Van 
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Nuys. Calif); biomarkers (Quest Diagnostics, Van i\uys. Calif; 
Boston Children's Hospital. Boston, Ma.-;s; Prognostix. Inc, Cleve-
land, Ohio: University of California at San Diego. Sun Diego). 
Participating center~ (number of patient~ enrolled): Austria: 
Hanusch Kr .. mkcnhaus. Georg Gaul (6). Belgium: Centre Hospit:ilier 
t:niversitairc Surt-Tilman. Victor Legrand (10): Z:"!A Campus Mid-
delheim, Stefan Vcrheye (25): Cardiova.~cular Center, Aulst, William 
Wijns (14). Czech Republic: VSeobecn:i Fukultni Nemocnice, 
Michael Aschermann (23). Denmark: Skejby University Hospital. 
Hans Erik B0tker (18). Germ:tny: West German Heart Center. 
Raimund Erbel (7): Kerckhoff Klinik. Christian Humm (7): Univer-
sitlitsklinikum Heidelberg. Stefan Hardt, Helmut Kticherer (l ): 
L'niversitlitsklinikum Mlinchen, Volker KJauss (14), Univer-
sitlitsklinikum Ulm. Wolfgang Koenig (9): Segeberger KJiniken, 
Gen Richardt (3). The Netherlands: Medisch Spectrum Twcnte, 
Clemens von Birgelen (14): Medisch Centrum Leeuwarden, Adria-
nus Johannes van Boven (12): Cathurina Hospital and Catherine 
R&D. Herman Rolf Michels (14). Erasmus Medical Center, Patrick 
Serruys (20): Medisch Centrum Rijnrnond Zuid. Pieter Smits (11). 
:r\orv,tay: Haukeland Sykehus. Oyvind Blcie (20). Poland: Upper 
Silesian Heart Center. Puwel Buszman (40): Szpital Uniwcrsytecki, 
Duriusz Dudek (19). Spain: Hospital Marques de Valdecillu. Thierry 
Colman (9): Hospital Clinico San Carlos, Carlos Macaya (9). 
Switzerland: Kantonsspital Luzern, Paul Erne (25). 
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CLINICAL PERSPECTIVE 
Despite intensive management of conventional risk factors, coronary events continue to recur at an unacceptably high rate. 
Thus, novel therapeutic options for treating coronary heart disease are needed. Inhibition of the enzyme lipoprotein-
associated phospholipase A: (Lp-PLAJ with darapladib has emerged as a potential approach to addressing residual risk of 
cardiovascular events by directly targeting high-risk coronary atheroma. This multicenter study used intravascular 
ultrasound-derived techniques to characterize coronary atheroma in patients receiving a standard~of-care treatment. The 
results demonstrate that the necrotic core. a key determinant of plaque vulnerability, continued to increase among patients 
receiving placebo despite a high level of adherence to recommended therapies. This result is consistent with a 
proatherogenic role for Lp-PLA: that is postulated to contribute to plaque vulnerability. In contrast. treatment with the 
direct Lp-PLAz inhibitor darapl.adib added to standard of care prevented necrotic core expansion. Pharmacological 
intervention with darapladib exerted favorable effects on coronary atheroma consistent with plaque stabilization. These 
findings suggest that direct Lp-PLA2 inhibition may represent a novel therapeutic approach to reducing residual risk in 
patients with coronary heart disease. 
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Phospholipase A2 Inhibitors. 
INTRODUCTION 
Atherosclerosis is the main cause of ischemic heart disease. At present, ischemic 
heart disease is the leading cause of death worldwide and it is predicted that 
it will continue to be the first in the world in 2030. 1 Although for long time 
atherosclerosis was regarded as a lipid-driven disease, it is now clear that it is 
an intricate process that involves also the simulta 1eous and combined effect of 
inflammatory and immunological factors2·4• A critical primary step is the accumu-
lation and oxidation of low-density lipoprotein (LDL) particles. Oxidized-LDL 
favors leukocyte recruitment and their activation, as well as cell death. This leads 
to generation of complex atherosclerotic plaques.5 1hese high-risk atherosclerotic 
plaques have a particular phenotype that is characterized by a high content of 
necrotic core, a thin inflamed fibrous cap (intense accumulation of macrophages) 
and scarce presence of smooth muscle cells. In the necrotic core underlying the 
thin fibrous cap are commonly found hemorrhage, calcification and intraplaque 
vasa vasorum. 6• 7 These lesions have been identified as vulnerable plaques, inferring 
to their association with cardiovascular clinical events. 
THE PHOSPHOLIPASE A, (PLA2 ) SUPERFAMILY 
This family of enzymes currently comprises 15 groups, a number of subgroups 
and five types of enzymes [i.e. the secreted PLA,s (sPLA), the cyrosolic PLA2s 
(cPLA.,), the Ca2' independent PLA.,s (iPLA.,), the platelet-activating factor 
" " " 
acetylhydrolases (PAF-AH), and the lysosomal PLA,s].3 Of these five, the secreted 
PLA2s and the platelet-activating factor acetylhydrolases (or lipoprotein-associated 
phospholipase A, - Lp-PIA,) have been associated with atherogenesis and its 
complications. Therefore, we focus our review on these two enzymes. 
Secreted phospholipase A, 
The secreted PLA2s hydrolyze the sn-2 position of glycerol-phospholipids to pro-
duce two biologically active lipids, namely arachidonic acid and lysophospholip-
ids. 8 Our of the ten different members of the sPLA, group IIA (sPLA,- IIA) is not 
" -
only found in atherosclerotic lesions, bur also is closely implicated with a number 
of atherosclerosis pathways. It has been linked to hydrolysis of LDL, therefore 
it is thought to be a contributor of atherogenesis. Specifically, modified LDL by 
sPLA, confers high affinity to proteoglycans, this results in accumulation ofLDL 
particles that are thereafter cleared by macrophages, thereby increasing foam cell 
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formation.' In addition, hydrolyzed LDL particles by sPLA2 caused spontaneous 
LDL aggregation which is proportional to the degree of LDL hydrolysis. Thus, 
sPLA2 may play an important role in atherogenesis by modifying LDL particles in 
the arterial wall, thereby enhancing their aggregation, retention, and macrophage 
uptake. 
In different clinical presentation settings, epidemiological studies have linked 
increased plasma levels of sPLA2 IIA and risk of cardiovascular events 10•13 • In the 
EPIC-Norfolk cohort13 , a total of 991 subjects that were followed during 6 years 
were compared to 1806 controls, matched by age and sex. Although the risk of 
incident coronary artery disease was associated with increasing quartiles of sPLA2 
activity (P<0.001), the combination of sPLA2 activity and CRP values was more 
useful to detect incident risk of CAD than either biomarker alone. Subjects in the 
highest quartiles of sPLA, activity and CRP had an adjusted odds ratio of 2.89 
(95% CI, 1.78 to 4.68; P<0.001) for CAD vs. those with the lowest quartiles of 
both markers. 
Lipoprotein-associated phospholipase A, 
Lipoprotein-associated phospholipase A, (Lp-PLA,) is produced and secreted by 
inflammatory cells involved in atherogenesis, 14-17 it is also bound predominantly 
to apoB-containing lipoproteins, and highly expressed in the necrotic core of 
atherosclerotic lesions. 18"20 Although this enzyme was first described as platelet ac-
tivating factor acetylhydrolase (or type VIIA PLA,), it has much broader substrate 
specificity.21 Lp-PLA, rapidly degrades oxidatively modified phospholipids in, for 
example, modified LDL leading to formation of proinflarnmatoty and cytotoxic 
products [i.e. lysophosphatidylcholine (LPC) and oxidized nonesterified fatty 
acids (oxNEFAs)].14• 22• 23 LPC promotes recruitment and activation of!eukocytes, 
initiation of apoptosis and impaired clearance of apoptotic bodies.18 A pathologi-
cal study showed that Lp-PLA, staining in pathologic intimal thickening plaques 
was nearly absent; while in complex lesions such as thin-cap fibroatheromas and 
ruptured plaques an intense Lp-PLA, expression within necrotic cores and sur-
rounding macrophages including those in the fibrous cap was shown. The degree 
of macrophage apoptosis was greater in thin-cap fibroatheroma and ruptured 
plaques compared with pathologic intimal thickening plaques. 19 This may imply 
that derived cytotoxic compounds from Lp-PLA, play an important role in plaque 
vulnerability. These observations, therefore, suggest that Lp-PLA, inhibition may 
favorably affect rupture-prone lesions. 
In epidemiological studies, increased concentrations ofLp-PLA., predict future 
cardiovascular events. In a study that included 466 patients with stable coronary 
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heart disease the prognostic value of Lp-PLA2 has been srudied.
24 Patients were 
followed-up for a median of 4.0 years. Higher Lp-PLA, levels were associated 
with a greater risk of events: the hazard ratio per SD was 1.28 (P=0.009), after 
adjusting for clinical and lipid variables and C-reactive protein. Koening eta!., 17 
reported the prognostic value of plasma concentrations and activity of Lp-PLA, 
in 1051 patients with coronary heart disease. In multivariable analyses, Lp-PLA, 
mass and activity were strongly associated with cardiovascular events after control-
ling for traditional risk factors, severity of CHD, statin treatment, cystatin C, and 
N -terminal proBNP. 
SELECTIVE PHOSPHOLIPASE A2 INHIBITORS 
Secretory phospholipase A2 inhibitors 
Initially, scientists from Lilly and Shionogi reported that substituted indoles and 
indolizines were the most potent sPLA2 inhibitors, such as the indolizine In-
doxam and the substituted indoles Me-Indoxam and 1 [LY315920 or varespladib 
sodium (sodium 2-(1-benzyl-2-ethyl-3-oxamoylindol-4-yl) oxyacetate;A-00 1). 
More recently, some other substituted in doles, 6,7 -benzoindoles, and indolizines 
derived from LY315920 have been tested. 25 
sPLA, potent inhibitors include: 1. varespladib methyl (1-H-indole-3-
glyoxamide;A-002) with selectivity towards sPLA2- IIA, sPLA2-V and sPLA2-X; 2. 
LY311727 (3-[1-benzyl-3-carbamoylmethyl)-2-ethyl-indol-5-yl]-oxypropylphos-
phonic acid; and 3. LY374388 ([3-aminnooxalyl-1-benzyl-2-ethyl-6-methyl-1H-
indol-4-yloxy]-acetic acid methyl ester). 
In the PLASMA srudy, varespladib methyl (1-H-indole-3-glyoxamide; A-002 
Anthera Pharmaceuticals, San Mateo, CA, USA) has been evaluated. This com-
pound has specificity towards sPLA2-IIA, sPLA2-V, and sPLA2-X enzymes. 26 1he 
PLASMA study was a phase II, randomized, double-blind, placebo controlled par-
allel arm dose-ranging study of four doses (50, 100, 250 or 500 mg) ofvarespladib 
methyl in 393 patients with stable coronary heart disease (NCT00455546). The 
primary objective was to examine the effects of A-002 on sPLA2 concentration 
and activity and on plasma lipoproteins and inflammatory biomarkers following 
8 weeks of treatment. 
More than 10% of the patients did not reached the primary endpoint, eventu-
ally 348 patients were studied (A-002 n=278, placebo n=70). Mean sPLA2-IIA 
concentration fell by 86-7%, (from 15·7 pmol!L to 2-1 pmol/L), in the treat-
ment group, vs. 4-8%, (from 15·7 pmol/L to 14-3 pmol/L), in the placebo group 
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(p<0-0001). The reductions in sPLA2-IIA concentration in the A-002 groups 
were dose dependent. In addition, oxidized LDL and C-reactive protein were 
reduced, as well as quantitative and qualitative lipoprotein changes were observed. 
Panicularly, in the A-002 treatment group, the mean difference from baseline 
in oxidized LDL was -3.8%±23.6 mU/L. The absolute reduction differed from 
placebo only for treatment doses of 100 and 250 mg. Mean C-reactive protein 
concentrations reduced from baseline significantly in the A-002 treated group 
(p<0.0001), however it was not different as compared to placebo (p=0.477). 
Interestingly, in 259 patients that were taking a statin, [the baseline LDL 
cholesterol was lower (range 1.9-2.0 mmol/L) than in the total study population 
(0.7-4.7 mmol/L)], the mean reduction in LDL cholesterol was similar to that 
seen in the total study population. This drug was in general well tolerated, in 
patients taking statins there was no evidence of hepatotoxicity. Only one patient 
had a serious adverse event (exacerbation of underlying chronic obstructive pul-
monary disease), in the 500 mg A-002 treatment group." 
The PLASMA II is a bio-equivalence study, double-blind, parallel assignment, 
placebo control and randomized (NCT00525954). This study examined the ef-
fects of 2 different doses (250 mg, 500 mg) of A-002 compared with placebo, on 
enzyme levels (sPLA, mass) and activity after 8 weeks of treatment. In addition, 
the effect of treatment on inflammatory markers of cardiovascular risk (C-reactive 
protein [CRP]), lipid levels and lipoprotein subclasses and other soluble biomark-
ers (e.g., ICAM-1, VCAM-1, TNF, MCP-1 etc) were assessed. As of this writing, 
although the study has been completed, no results have been posted so far. 
Another interesting context in which secretory phospholipase A, inhibitors 
may play an important role, it is in the setting of an acute myocardial infarction. 
The sPLA, has been found in the limits of the infarcted myocardium by immu-
nohistochemistry''. It has been shown that sPLA, products, specifically lysophos-
pholipids, are ligands for C-reactive protein. These are related to complement-
mediated tissue damage in acute myocardial infarction. 28 The FRANCIS-ACS 
Trial is currently enrolling patients with acute coronary syndromes to study the 
safety and efficacy of A-002. (NCT00743925). This is a double-blind randomized 
parallel group placebo controlled study. Subjects will be randomized to receive 
either, 1. A-002 500 mg once daily (QD) plus Atorvastatin (80 mg QD); 2. or 
placebo tablets in addition to 80 mg atorvastatin QD. 
The primary objective is the comparison of the mean percent changes in LDL 
hs-CRP, sPLA2 and other biomarkers between the two groups at 8 weeks. All 
enrolled subjects will remain on treatment until all subjects have been treated for 
a minimum of24 weeks or until the occurrence of a Major Adverse Cardiac Event 
(MACE). At that point, all active subjects (those who have not early withdrawn 
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or those that have nor already had a MACE) will be brought in for a final study 
visit. Subjects who complete the final study visit may be eligible to enroll in an 
open-label extension study for up to 2 years total study drug exposure. 
As of this writing, the varespladib (A-002) is also being tested in the context 
of percutaneous coronary intervention (PC!). The sPLA 2 Inhibition to Decrease 
Enzyme Release after PC! (SPIDER-PC! trial) is a also double blind (subject, 
caregiver, investigator, outcomes assessor), parallel assignment, placebo control, 
prevention, randomized, safery/ efficacy study. The primary endpoint is the in-
cidence of myocardial injury as evidenced by elevation of CK-MB or troponin 
I above the upper limit of normal at 8 hours and 18-24 hours posr-angioplasry. 
Patients in the active treatment group rake 250mg tablets BID beginning 3-5 days 
pre-angioplasry and for 5 days posr-angioplasry. 
Key exclusion criteria are: I. patients with ST elevation MI or any troponin 
elevation (non-STEM!) within preceding 1 Odays; and 2. elevation of CK-MB or 
troponin I at baseline. 
Selective lipoprotein-associated phospholipase A2 inhibitors 
In the past, there was considerable discussion over whether Lp-PLA, primarily had 
a pro-inflammatory (generation oflysophosphatidylcholine) or anti-inflammatory 
(degradation of PAF or PAF-like lipids) role in atherogenesis. With the advent 
of a selective and extremely potent and substrate-competitive inhibitors of this 
enzyme, it became clearer that Lp-PLA, had a predominantly pro-inflammatory 
role in atherogenesis. 14 Two inhibitors are being tested as therapeutical options, 
namely darapladib and rilapladib (GlaxoSmithKline, Philadelphia PA). 
In animal studies, selective lipoprotein-associated phospholipase A2 inhibitors 
(i.e. darapladib) have shown reduced development of advanced coronary athero-
sclerosis in diabetic and hypercholesterolemic swine.20 Specifically, darapladib 
treatment resulted in a considerable decrease in plaque area and necrotic core area, 
and reduced medial destruction, resulting in fewer lesions with an unstable phe-
notype. The mean plaque area (± s.e.m.) in the left anterior descending coronary 
artery was 0.178 ± 0.046 mm2 versus 0.636 ± 0.212 mm2 in the treated group 
compared to the control group. The mean necrotic core area (± s.e.m.) from the 
arterial section with the greatest plaque area was significantly reduced from 0.87 
± 0.33 mm2 ro 0.03 ± 0.003 mm2 (p =0.015) with treatment. Overall, the mean 
medial destruction score for control coronary vessels was 2.4 ± 0.027; whereas in 
the treatment group, the score was reduced (1.2 ± 0.24, p =0.003). 
More advanced coronary lesions (i.e. thin fibrous cap atheroma) were found in 
the control group as compared to treated group (41 vs. 10%, p=0.05) 
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The mean ratio of macrophages to total intimal and medial area was 1.78 ± 
0.44% in the control group, 0.71 ± 0.18% in the treated group (p = 0.036). 
In a multicenter, randomized, double-blind, placebo-controlled smdy in 959 
patients with coronary heart disease or CHD-risk equivalent subjects receiving 
atorvastatin 20 or 80 mg, the effects of 12-week darapladib treatment (40 mg, 80 
mg, and 160 mg oral) on Lp-PLA2 activity and mass, biomarkers and oxidized 
lipids was evaluated (NCT00269048) 29 Darapladib 40, 80, and 160 mg inhibited 
Lp-PLA, activity by approximately 43%, 55%, and 66% compared with placebo 
(p < 0.001 at week12), and mass by mass measured in a 9.6%, 12.9%, and 9.3% 
by darapladib 40, 80, and 160 mg, respectively, (p < 0.001 for all doses at week 12 
compared with placebo). Sustained dose-dependent inhibition was noted overall 
in both atorvastatin groups and at different baseline LDL-C (;2:70 vs. <70 mg/dl) 
and HDL-C (<40 vs. <:40 mg/dl). Interesting of note, at week 12, there was no 
significant interaction between atorvastatin and darapladib on change in Lp-PLA, 
activity (p = 0.60). Likewise, there was no interaction between baseline LDL-C 
(<70 mg/dl vs. <:70 mg/dl) or HDL-C (<40 mg/dl vs. 2:40 mg/dl) and the change 
in Lp-PLA, activity at 12 weeks for all darapladib doses (p = 0.12 and p = 0.13, 
respectively). 
Although hs-CRP at baseline was low due to intensive background atorvastatin 
therapy, treatment with darapladib 160 mg (n = 161) produced a 20.2% (p = 
0.003; within group comparison) and a 13.0% reduction with placebo (p = 0.15; 
between groups comparison). 
Patients treated with darapladib 160 mg (n = 150) had a 21.5% reduction 
in interleukin-6 (p < 0.001; within group comparison), it was also statistically 
significant compared with placebo (p = 0.028). 
The Integrated Biomarkers and Imaging Study-2 trial was an international, 
multicenter, randomized, double blind, placebo-controlled study in 330 patients 
with angiographically confirmed coronary heart disease (NCT00268996). 
30 At 12 months, there was no difference in LDL-cholesterol (placebo: 88±34 
and darapladib: 84±31 mg/dL, p=0.37). The primary endpoint was coronary 
atheroma deformability (IVUS-palpography) and plasma hs-CRP. Secondary end 
points included changes in necrotic core size (IVUS-radiofrequency), atheroma 
size (IVUS-greyscale), and blood biomarkers. The Lp-PLA, activity was inhibited 
by 59% with darapladib (p<0.001 versus placebo). After 12 months, there were 
no significant differences between groups in plaque deformability (p=0.22) or 
plasma hsCRP (p=0.35). hsCRP was 1.0 mg/L (95% CI, 0.8 to 1.2 mg/L) among 
those receiving placebo (n=140) and 0.9 mg/L (95% CI, 0.8 to 1.1 mg/L) in 
the darapladib group (n=162). However, a significantly higher percentage of 
patients, achieved very low levels ofhsCRP (<1 mg/L) on darapladib (62%) than 
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Figure 1. Temporal changes in necrotic core in a patient treated with placebo in the IBIS 2 
study 
Top: graph displayed the necrotic core (NC) areas in all consecutive cross-sections in this patient, the 
increase of necrotic core in placebo treated patient is apparent at several locations of the pullback, as 
highlighted by the arrows. In the entire analyzed region, there was increase in necrotic core volume 
of25.1 mm3 after one year, while in the worst 10 mm segment, an increase of 11 mm3 in NC was 
observed. 
Bottom: In these two sequential cross-sections from the same anatomical location, there is evidence 
of progression of necrotic core area (depicted in red) at the expense of :fibrous tissue (depicted in 
green). 
Overall, this graph illustrates changes in NUS virtual histologgy as typically seen in placebo-treated 
patients between baseline and follow-up. 
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Figure 2. Temporal changes in necrotic core in a patient treated with an Lp-PLA2 inhibitor 
(darapladib) in the IBIS 2 study 
Top: graph displayed the necrotic core (NC) areas in all consecutive cross-sections in this patient, a 
decrease of necrotic core in darapladib treated patient is apparent at several locations of the pullback, 
as highlighted by the arrows. In the entire analyzed region, there was increase in necrotic core volume 
of 19.1 mm3 after one year, while in the worst 10 mm segment, a decrease of8.7 mm3 in NC was 
observed. 
Bottom: In contrast to placebo, two cross-sections from the darapladib-treated patient demonstrate 
reduction in necrotic core area depicted in red. Of note, concomitant increase in :fibrous tissue (in 
green) is consistent with plaque stabilization effect. 
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did those on placebo (45%) (p<0.008). In the placebo-treated group, however, 
necrotic core volume increased significantly (4.5±17.9 mm3, p=0.009), whereas 
darapladib halted this increase (-0.5±13.9 mm3, p=0.71), resulting in a significant 
treatment difference of -5.2 mm3 (p=0.012). Figure 1 and 2. These intra-plaque 
compositional changes occurred without a significant treatment difference in total 
atheroma volume (p=0.95). 
The Stabilization of Atherosclerotic Plaque by Initiation ofDarapladib Therapy 
Trial (STABILITY, NCT00799903) is a clinical outcome study of darapladib 
versus placebo in patients with chronic coronary heart disease to compare the 
incidence of major adverse cardiovascular events (CV death [death due to a car-
diovasacular cause], non-fatal myocardial infarction, non-fatal stroke). Patients 
will remain in the study until a specified number of MACE events have occurred. 
It is anticipated that patients will be in the study about 3 years. This study is 
currendy recruiting participants. 
In conclusion, despite of standard of care treatment, patients with coronary 
artery disease continue to have recurrent cardiovascular events. Phospholipase A2 
inhibition may represent a new approach for the treatment of atherosclerosis if the 
benefit of this intervention is confirmed by the results of on-going event-driven 
outcomes trials. 
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Abstract 
Stent thrombosis is one of the major concerns after drug-eluting stent implantation. Multiple mechanical 
causes (i.e. stent under-expansion, edge dissection. geographic miss, resid•Jal stenosis, "mcornplete stent 
apposition and aneurysm) have been postulated. These features are easily identifiable by intravascular 
ultrasound. However, it is uncertain which of them are inextricably related to stent thrombosis, primarily 
due to the low number of such patients studied by IVUS in case control studies. 
Complementary to greyscale IVUS, tissue characterisation by JVUS radiofrequency data (RFDJ analysis has 
the potential to add valuable information on the pathogenesis of stent thrombosis by providing information 
on plaque composition, specifically on the amount of necrotic core and its iocation {superficial or deep). 
However. the clinical utility of IVUS-RFD analysis in this context has yet to be demonstrated. 
*Corresponding author: Thorax Center, ErasmusMC, 's-Gravendlj"kwa1230 3015 CE Rotterdam, The Netherlands 
E-maif:hgarciagarcia@erasmusmc.nl 
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Introduction 
In current practice, one of the most important concerns for the 
interventionalist is stent thrombosis, primarily of drug-eluting stents 
(0ESJ1·5. Among the multiple postulated causes, there is a large group 
encompassed in so-called mechanical causes (i.e. stent under-
expansion, edge dissection, geographic miss, residua! stenosis, 
incomplete stent apposition liSA] and aneurism [extreme ISA]). These 
were also formerly related to thrombosis of bare metal stents (BMS). In 
fact, for this stent type, it has been reported that in 78% of the patients 
with stent thrombosis at least one mechanical cause is present using 
greyscale intravascular ultrasound (IVUS)6• Furthermore, ISA at long-
term follow-up seems to be more frequent after sirolimus-elutingstent 
(SES) implantation than after BMS implantation7• Extreme posft:ive 
remodelling after DES implantation is one of the main processes 
involved in cases with late acquired ISA. More importantly, ISA has 
recently been linked to thrombotic coronary events4•8 • 
Complementary to greyscale IVUS, tissue characterisation by IVUS 
radiofrequency data (RFD) analysis has the potential to add valuable 
information on the pathogenesis of stent thrombosis by providing 
information on plaque composition, specifically on the amount of 
necrotic core (NC) and its location (superficial or deep). Although 
IVUS-RFD analysis is a new technique and there is a long way ahead 
to prove its clinical value in the context of stent thrombosis, in this 
report we describe pathological findings that have been related to 
stentthrombosis that are identifiable by IVUS-RFD. 
Findings on greyscale IVLIS during stent implantation 
associated with stent thrombosis 
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We also describe the current evidence that relates greyscale IVUS 
findings with stent thrombosis. 
Definitions of the mechanical causes of stent 
thrombosis (Figure ll 
Stem under-expansion index, defined as minimum stent cross-
sectional area (CSA) ..;.. mean of proximal and distal reference 
areas4•8. 
Significant residual reference segment stenosis, defined as the 
combination of a reference segment minimum lumen CSA <4 mm2 
plus a plaque burden >70%9• 
Geographical miss, defined as a mismatch of intended lesion and 
balloon-injured targets with subsequent stent deployment sites10. 
Unlike previous definition, geographical miss also refers to balloon-
injured areas ieft untreated. 
Incomplete stent apposition, defined as the lack of contact of at 
least one stent strut with the vessel wall. not encompassing a side 
branch. This can be detected immediately after stent implantation 
(acute or post-stenting ISA) or at foilow-up (six months and 
beyond- late acquired ISA). (Figure 2). 
Edge dissection, defined as the presence of a flap in close proximity 
to stent edges. 
Aneurysm, defined as an enlargement of both the external elastic 
membrane (EEMJ and lumen area >50% of the proximal reference 
segment1:. 
Findings on IVLIS-RFD during stent implantation potentially 
associated with stent thrombosis 
Figure 1. This illustration displays the potential use of greyscale IVUS and IVUS-radiofrequency data (RFDJ analysis across the different stages of 
the interventional procedure and imaging follow-up of the patients. Greyscale IVUS can categorise plaque types and the acute result of the 
intervention, as well as provide useful information on some characteristics that have been related to stent thrombosis such as incomplete stent 
apposition (!SA), edge dissection, residual stenosis, under-expansion and thrombus. IVUS-RFD could provide valuable information on the intact 
plaque, especially on necrotic core (NCJ amount and location. 
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Figure 2. Panel A shows a longitudinal view of an !VUS pullback. The 
arrow points to a proximal segment that is not apposed to the vessel 
wall. Panel 8 is the corresponding cross-sectional area (GSA). The 
arrow shows multiple stent struts that are not apposed. Panel C is a 
diagrammatic representation of the longitudinal view. Notice the tack 
of stent apposition signalled by the arrow. Panel 0 indicates the stent 
GSA throughout the segment. An important decrease in stent area is 
seen at the proximal part. 
G reyscale IVUS 
Incomplete stent apposition has been postulated to be one of the 
potential causes of stentthrombosis. Yet, is ISA truly highly prevalent 
in patients with stent thrombosis after DES implantation? Or is stent 
thrombosis a rare event among patients with ISA? This is not clear, 
the reported prevalence of ISA r;:ost~stenting among DES studies 
(sirolimus, paclitaxel ([PES]) and everolimus-eluting stents [EES)) 
varies from 2.4 to 34.4% 12•18• On the other hand, although late-
acquired ISA has, by deflnif1on, the same IVUS appearance as post-
stenting ISA, its postulated mechanisms are completely different 
including progressive expansion of the vessel wall, thrombus 
resolution and Jack of tissue growth around the stent struts17• In the 
literature, the incidence ranges from 0.0 to 16.7%;2·14.:&-2:. Possible 
explanatol)' reasons for the wide spread of occurrence au.oss all 
reported stent studies are the following: i) lesion-related (calcified, 
eccentric, chronic total occlusions or thrombusJl?: ii) procedure-
related (absence of postdilatation and IVUS-guidance); iii) device-
related (DES> BMSJ: and iv) corelab-related (inter-analyst and 
inter-coreiab variability). Of note, no clinical events related to ISA 
have been reported in these trials. 
The STLLR trial documented that geographical miss occurred in 
66.5% of implantations and was an additonal risk for late acute 
coronal)' events following drug-eluting stent impiantation 10. Thus, 
this suggests that angiographic-guided implantation of DES may be 
not satisfactol)'. In this regard, IVUS easily identifies incomplete 
lesion coverage, stent under expansion and ISA, yet remains 
infrequently used {approximately 7% of cases in the United 
Statesl22• Although IVUS-guided stenting could potentially improve 
stent implantation, the cost-effectiveness of routine IVUS use in this 
context has yet to be evaluated. More ;,mportantly, whether this 
approach would impact the incidence of late stent-related clinical 
events is unknown. However, we do not think all cases are suitable 
for IVUS-guided stenting. In this era of more liberal DES use, 
interventionalists frequently have to treat vessels with complex 
anatomy {e.g. severe tortuosity), in which even with IVUS~guided 
stenting, complete apposition may not be fully ensured. Thus, 
a careful analysis of the coronal)' anatomy prior to stent implantation 
may help operators to select cases in which IVUS imaging is safe and 
the information useful. 
Clinical studies of patients with stent 
thrombosis and intravascular ultrasound imaging 
Fujii et al9 compared 15 patients treated with SES who experienced 
early stentthrombosis with 45 patients who had no evidence of SES 
thrombosis. Incomplete stent apposition was found in 13% of 
patients with SES thrombosis vs. 16% of controls. The minimum 
stent CSA was 4.3±1.6 mm2 in patients with SES thrombosis 
compared with 6.2±1.9 mm2 in controls {p <0.001): the stent 
under-expansion index was smaller in SES thrombosis (0.65±0.18 
vs. 0.85±0.14; p<0.001), and the residual reference segment stenosis 
was 67% in theSES thrombosis group vs. 9% in the controls, p <0.001. 
In another case control study of 13 patients (14 DES with early 
thrombosis)23 , the min'1mum stent CSA was also smaller as 
compared to controls (4.6±1.1 vs. 5.6±1.7 mm2; p <0.05), with 11 
of 14 stents (79%) having a minimum stent CSAs ~ 5.0 mm2 
compared with 12 of30 (40%) in the contra! group (p=0.04). These 
authors also found larger residual reference segment stenosis in 
patients with thrombosis. 
Mintz et al2: reported the comparison of 15 cases of DES with early 
thrombosis with 45 cases of DES restenosis. In line with the above-
mentioned reports, the minimum stent CSA was smaller in DES 
thrombosis lesions (3.7±0.8 vs. 4.9±1.8 mm2: p""0.01). 
Independent predictors of stent thrombosis were diffuse stent 
under-expansion (odds ratio [ORJ, 1.5: P""0.03) and proximal 
location of the site of minimum stent CSA (OR, 12.7; p=0.04). 
Siquiera et a124 reported late-acquired incomplete stent apposition in 
10 out of 195 patients {seven with SES, three with PES} studied with 
IVUS at six months; two out of these 10 patients with late-acquired 
ISA had stent thrombosis at 331 (PESJ and 1,152 days (SES). 
A report of two cases with DES thrombosis {one SES and one PESJ 
revealed extensive positive remodelling (increase in vessel volume 
of 19.7 and 38.6%) leading to large areas of late-acquired 
incomplete stent apposition in both cases by means of serial 
angiography and IVUS2s_ 
More recently, Cook et al8 reported 11 patients with vel)' late DES 
thromboses and compared them with 198 controls that had 
undergone routine IVUS follow-up but did not develop stent 
thrombosis. Incomplete stent apposition was present at the time of 
thrombosis in 77% of patients with vel)' late DES thromboses vs. 
12% of controls imaged during routine follow~up; p <0.0001. The 
authors suggested that incomplete stent apposition may play a role 
in the pathogenesis of this adverse event. 
The latest report available in the literature is by Alfonso et al4 who 
reported 26 patients with DES thrombosis out of 1,974 patients 
treated with DES dur'mg the same period, resulting in a two-year 
stent thrombosis incidence of 1.3%. Only 12 were included in the 
IVUS substudy. Thrombotic occlusion was seen in all patients by 
IVUS. Severe stent under-expansion and significant residual 
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reference segment stenosis were again the common denominators 
in this series. Incomplete stent apposition was detected in 50% of 
the patients (three subacute, three iate thrombosis), and major side 
branches jailed by the stent were seen in 67% of the patients. 
According to the Multicentre Ultrasound Stenting in Coronaries 
Study (MUSIC} criteria26 , deployment of the stents was suboptimal in 
all patients with stent thrombosis. In contrast with other studies, the 
minimum stent area was not small (9±3 mm2). After re~interJention, 
residual thrombus was present in ai! patients (17±7% of stent 
volume post-interJention vs. 51±22% pre-intervention, p= 0.001). 
We can therefore conclude that incomplete stent apposition is 
high!y prevalent among patients with DES thrombosis that have 
been studied by IVUS. In addition, stent under-expansion and 
residual reference segment stenosis were also constantly associated 
with DES thrombosis. 
Tab!e 1 summarises the IVUS findings that have been reported 
among patients with stent thrombosis. 
Table 1. IVUS findings in patients with stent thrombosis. 
EEM CSA, mmz 28.6 Mean• 
Increase in EEM volume over time,% 19.7-38.6 Rangeb 
J5A,% 50-100 Range•bc 
Maximal J5A CSA, mm2 2.0-24 Range' 
Maximal J5A length, mm 6.3 Mear~" 
Calcium arc.. o 360 Mear~• 
Ster1t ur~derexpar~sion index 0.39-1.00 Range"' 
Stent asymmetry 0.77-0.90 Range' 
Minimum stent CSA, mmZ 3.7; 4.3; 4.6 Mear~<iof 
EEM: external elastic membrane; CSA: cross-sectional area; ISA: incomplete 
ster1t apposition; •Cook et at; b Feres et at; 'Alfonso et at; d Mintz et at; 
• Fujii et at; 1 Okabe et al 
IVUS Radiofrequency data analysis 
Our knowledge of the pathophysiology of iate DES thrombosis is 
derived from pathologic samp!es27•30• It has been demonstrated that 
DES cause substantial delayed healing (the most common cause of 
late DES thrombosis at autopsy) characterised by the lack of 
complete re-endothelialisation and persistence of fibrin when 
compared with BMS31• This cannot be assessed by any IVUS 
modality due to its limited axial resolution (100 ].Jm). 
Other proposed pathological mechanisms of coronary stent 
thrombosis are stenting of necrotic core-rich plaques with extensive 
tissue prolapse and plaque disruption in the proximity of the stented 
arterial segmenf'7•3:. (Figure 3). IVUS-RFD is able to characterise 
necrotic core with high sensitivity and specificity32. This technique 
also provides geometrical analysis of each frame, allowing us to 
have the combined assessment of necrotic core and plaque size; 
indeed this relationship has been tested in 25 patients with acute 
coronary syndromes in whom an increment in plaque size was 
followed by an increase in the NC33• Thus, pre-stenting imaging 
using IVUS-RFD can give us an insight not only into the extent of 
plaque but also on the extent of necrotic core within and beyond the 
intended stenting segment. This latter assessment is important 
since stenting has been lately performed, under conventional 
angiography guidance, from "normal to normal" arterial segments; 
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Figure 3. Greyscale /VUS frame and its corresponding IVUS-
radiofrequency data frames of an IV US derived thin cap fibro-atheroma 
(two upper frames). At the bottom, a stented necrotic core-rich plaque 
is shown. Notice the presence of stent struts at the lumen in the color 
picture as "dense calcium" on top of a confluent area of necrotic core. 
Virtual histology color code: green is fibrous, greenish is fibro-fatty, red 
is necrotic core and white is dense calcium. 
however, disruption of adjacent necrotic core-rich areas that are 
angiographically disease-free could be avoided by IVUS-RFD pre-
stenting investigation. In this context, we studied 24 patients in 
whom 26 stented segments (by angiography stenting was 
performed from "normal to normal" coronal)' segments) using 
IVUS-RFD were assessed. We observed that necrotic core rich 
areas were left unstented (5mm-proximal edge mean necrotic core 
17.0±13.5% and 5 mm-distal edge 18.5±16.5%); however, no 
stent thrombosis has been observed in this smali cohort of patients 
at six months follow-up. It has yet to be determined in a larger 
population whether incomplete coverage of necrotic core-rich 
coronal)' plaques or disruption of adjacent necrotic core areas by 
DES impact on long-term clinical events. 
Bifurcation lesions are the preferable location of TCFAs; in clinical 
studies this subset of lesions has been related to stent thrombosis-1; 
we therefore hypothesised that the evaluation of the location and 
amount of the necrotic core is crucial. Thus, not only may the 
bifurcation stenting technique change accordingly, mainly by 
avoiding overlapping segments on these NC-rich areas, but also the 
stent used to treat these lesions. The desirable objective is a device 
that offers: a) mechanical stabilisation, b) promotion of vascular 
healing and c) reduction of inflammation. Nevertheless, it is worth 
mentioning that although related to a different physiopathological 
process and other arterial segment - restenosis following carotid 
stenting -the dissection of a lipid-rich, inflammatory plaque has 
been recently associated with reduced risk of restenosis.34 
Theoretically, IVUS-RFD enables us to characterise in vivo TCFA-
IVUS..derived thin-capped fibre-atheroma (IDTCFA); these lesions 
Greyscale Intravascular Ultrasound and IVUS-Radiofrequency Tissue Characterization 
may pose a distinctive high risk of stent thrombosis, due to the fact 
that they contain large amount of necrotic core located superficially. 
We have recently developed software to quantify the amount of 
necrotic core in contact with the lumen, enabling refinement of our 
analysis. Our current definition of an IDTCFA is a lesion fulfilling the 
following criteria in at least three CSAs: 1) plaque burden ~40%; 
2) confluent necrotic core :::::;10% in direct contact with the lumen 
(i.e., no visible overlying tissue) in the investigated GSA: all 
consecutive CSAs having the same morphologic character"1stics are 
considered as part of the same IDTCFA lesion35. In a recent study, 
using this refined definition of TCFA as assessed by IVUS-RFD, in 
patients with ACS who underv.rent IVUS imaging of all three 
epicardial coronaries, on average, there were two IDTCFAs per 
patient, half of which showed outward remodeliing35 (Figure 3). 
Post-stenting analysis by IVUS radiofrequency data analysis is 
limited since this technique lacks proper validation in this respect 
An approach to get around this limitation could be to perform pre-
stenting and post-stenting IVUS-RFD to assess the acute changes 
in terms of composition and relate this to the follow-up findings. 
Thus an IVUS-RFD clinical study that investigates the relationship 
between plaque composition of the intended stent segment 
(including its 10 mm proximal and distal segments) and 
development of stent thrombosis is still to be scheduled. 
Conclusions 
Although there are several potential mechanical causes of stent 
thrombosis that can be detected during the index procedure by 
greyscaie IVUS as wei! as by repeated imaging at follow-up, it is 
uncertain which of them are inarguably related to stent thrombosis, 
primarily due to the low number of patients with stent thrombosis 
studied by IVUS in case control studies where causality is difficult to 
assess. A longitudinal and prospective study, adequately powered to 
demonstrate the mechanical factors potentially identifiable by IVUS 
and related to stentthrombosis is still awaited. 
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Characterization of Edge Effects With Paclitaxei-Eiuting Stents 
Using Serial Intravascular Ultrasound Radiofrequency Data 
Analysis: The BET AX (BEside TAXus) Study 
Hector M. Garcfa-Garcfa, Nieves Gonza!o, Shuzou Tanimoto, Emanuele Me!iga, Peter de Jaegere, 
and Patrick W. Serruys 
Thoraxcenter. Erasmus MC, Rotterdam, The Netherlands 
Introduction and objectives. At present, the effect of 
paclitaxel on tissue structure at the edges of Taxus® 
stents is unknown. The objective of this study was to 
investigate in vivo the temporal changes occurring at the 
edges of paclitaxel-eluting stents using intravascular 
ultrasound radiofrequency (IVUS-RF) data analysis. 
Methods. The study included 24 patients who had a 
total of 26 pac!itaxel-eluting stented segments. In all 
patients, IVUS-RF imaging was performed 5 mm 
proximally and 5 mm distally to the stent edges 6 months 
after stent implantation. For subsequent analysis. 
proximal and distal segments were divided into five 1-mm 
subsegments. 
Results. In the first 2 subsegments adjacent to the 
proximal edge of the stent, the vessel wall had grown to 
compensate for plaque growth without affecting the 
vessel lumen, while in the remaining three subsegments 
there was overcompensation ('ie, the vessel wall 
increased to greater than the plaque size). Consequently, 
the lumen had increased in size. At the distal edge of the 
stent, overcompensation was obseNed in all five 
subsegments and the lumen had increased in size. In 
general, proximal and distal growth was due to an 
increase in fibrolipid plaque (P<.001 and P<.001, 
respectively) along with a decrease in the necrotic core 
(P=-.014 and P<.001, respectively) and the presence of 
dense calcium (P<.001 and P<.001, respectively). 
Conclusions. Serial expansive vascular remodeling 
was obseNed at proximal and distal stent edges. 
Remodeling occurred in response to tissue growth, which 
was mainly due to increased fibrofatty tissue. 
Key words: Restenosis. Imaging. Drug-eluting stents. 
Coronary disease. 
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Caracterizaci6n de los efectos tisulares en los 
segmentos adyacentes a los stents liberadores 
de paclitaxel segUn el amilisis de datos de 
radiofrecuencia procedentes de ecocardiografia 
intravascular seriada: estudio BET AX (BEside 
TAXus) 
lntroducci6n y objetivos. En Ia actualidad se desco-
noce el efecto de paclitaxef en Ia composici6n tisular en 
los segmentos adyacentes (bordes) del stent Taxus®. El 
objetivo de este estudio fue investigar in vivo los cambios 
temporales que se producen en los bordes del stent Jibe-
radar de paclitaxel segCin un an<ilisis de los datos de ra-
diofrecuencia procedentes de ecografia intravascular 
(EIV). 
Metodos. En total participaron 24 pacientes (26 seg-
mentos con stents liberadores de paclitaxel). Se obtuvie-
ron im<igenes con EIV de los 5 mm proximales y los 5 
mm distales de los bordes del stent transcurridos 6 me-
ses del implante. Para realizar un an<ilisis posterior. los 
segmentos proximales y distales se fraccionaron en cinco 
subsegmentos de 1 mm cada uno. 
Resultados. En los primeros dos subsegmentos adya-
centes al stent del borde proximal. Ia pared del vasa cre-
ce para compensar el crecimiento de Ia placa sin que ella 
afecte a Ia luz, mientras en los siguientes 3 subsegmen-
tos se observ6 una sobrecompensaci6n (Ia pared del 
vasa aument6 mas que el tamafio de Ia placa). Par lo 
tanto. aument6 el tamafio luminal. En el borde distal, se 
obseN6 sobrecompensaci6n en todos los subsegmentos, 
seguida de un aumento del tamafio luminal. En general, 
el crecimiento proximal y distal se bas6 en un aumento 
de Ia placa fibrolipidica (p < 0,001 y p < 0,001 respectiva-
mente), con una disminuci6n del nCicleo necr6tico (p = 
0,014 y p < 0,001 respectivamente) y un contenido dense 
de calcic (p < 0,001 y p < 0,001 respectivamente). 
Conclusiones. Se obseN6 un remodelado vascular 
expansive y seriado en los bordes proximal y distal del 
stent. para acomodar un crecimiento tisular principal men-
te debido al aumento del tejido fibrolipfdico. 
Palabras clave: Reestenosis. Tecnicas de imagen. 
Stents farmacoactivos. Enfermedad coronaria. 
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ABREVIATIO:-IS 
CSA: cross-sectional area 
IVUS: intravascular ultrasound 
RFD: radiofrequency data 
INTRODUCTION 
Stent use has been one of the major break."throughs in 
the treatment of patients with coronary artery disease. 1 
Together with its many advantages some associated pitfalls 
are restenosis and stent thrombosis.M Regarding the 
vascular responses after stenting (ie. restenosis and 
remodeling). a response-to-injury pattern of wound 
healing occurs, mainly characterized by an increase in 
smooth muscle cells and extracellular matrix. 10 
In the Taxus II study a significant reduction in lumen 
size was observed at the proximal edge in both paclitaxel 
eluting stent and bare metal stent groups. while at the 
distal edge the reduction was only present in the bare 
metal stent group. This was mainly due to an augment 
in plaque size not fully compensated by vessel wall 
remodeling. 11 
Nowadays spectral analysis of the intravascular 
ultrasound (IVUS) radiofrequency data (RFD) analysis 1 ~· 13 
is emerging as a tool to assess tissue composition in the 
coronary arteries. Thus. not only serial geometrical 
changes can be analyzed. but also its composition. 
However. in stented vessels this can only be performed 
at the edges of the stent. because the actual stent area 
and its surroundings cannot be analyzed with IVUS-
RFD. due to: a) misclassification of the stent struts as 
'"dense calcium": b) lack of proper validation ofiVUS-
RFD in this context: and c) potential interference of the 
superficial stent struts on the backscattering of the tissue 
behind them. 
We hypothesized that the tissue involved in the increase 
of plaque at the edges of the stcnt. as assessed by IVUS-
RFD. is mainly fibro-fatty tissue. which has been described 
as loosely packed bundles of collagen fibers with regions 
of lipid deposit and extracellular matrix without necrotic 
areas. 14 
We thus sought in vivo the temporal geometrical and 
tissue composition changes at the edge of paclitaxel-
eluting stent as assessed by IVUS-RFD analysis. 
METHODS 
Patient Selection 
The BEside TAXus~>) (BETAX) study was a longitudinal 
and prospective cohort of non-consecutive patients who 
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had a clinical indication for coronary intervention and 
were treated with Tax us~] stcnt (Taxus0~ Express~TM: Boston 
Corporation. Natick. MA. USA) in at least one of their 
coronary arteries. Only patients who gave informed 
written consent were included in the study. Patients with 
stable angina and acute coronary syndromes were 
included. Acute coronary syndromes comprise unstable 
angina.. non-ST segment elevation myocardial infarction 
and ST-segment elevation myocardial infarction. IVUS-
RFD imaging was performed at post-stenting and at 6 
months. Our local Ethics Committee approved the 
protocol. 
IVUS-RFD Acquisition and Analysis 
Details regarding the validation of the technique, 
on explanted human coronary segments and in vivo 
post-atherectomy. have previously been reported. 12•14 
Briefly. IVUS-RFD uses spectral analysis of IVUS 
radiofrequency data to construct tissue maps that are 
correlated with a specific spectrum of the 
radiofrequcncy signal and assigned color codes (fibrous 
[labeled green], fibrofatty [labeled greenish-yellow]. 
necrotic core [labeled red], and dense calcium [labeled 
white]). 1 ~· 13 
IVC"S-RFD was acquired using a continuous pullback 
(Eagle-EyeT:\1 20 MHz Volcano Therapeutics. Rancho 
Cordova.. CA. USA) by a dedicated IVUS-RFD console 
(Volcano Therapeutics. Rancho Cordova, CA. USA). 
The IVUS-RFD recordings were stored on a DVD and 
sent to Corelab (Erasmus Medical Center/Cardialysis, 
Rotterdam. The Netherlands) for offline analysis. 
The 5-mm proximal (p) and 5-mm distal (d) segments 
adjacent to the stent were subsequently divided into 1-
mm 5 subsegments (ss) (Figure). 
The IVUS-RFD sampling rate during pullback is gated 
to peak R-wave and is therefore dependent on heart rate. 
For instance. during constant heart rate of 60 bpm, data 
will be collected every 0.5 mm. 
Compositional and geometrical data were obtained for 
every cross-section81 area (CSA) and expressed as mean 
areas and percent 1or each IVUS-RFD component. 
Statistical Analysis 
Discrete variables are presented as counts and 
percentages. Continuous variables arc presented as means 
(SD). A P value (2-sided) less than .05 was considered 
significant. Assumptions for normality were checked 
after transformation based on a P value >.20 at 
Kolmogorov-Smimov test and by visual assessment of 
Q-Q plots of residuals. Accordingly. log transformation 
was performed on the variables with skewed distribution. 
The comparison between baseline and follow-up was 
performed using paired Student t test. 
Statistical analyses were performed with use of SPSS 
software version 11.5. 
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Overall, 30 patients were included in this study, but 
only 24 (26 stented segments) patients were ultimately 
analyzed. Two patients refused angiographic follow-up 
and in other 4 patients the NUS image quality was poor 
(non-continuous pullback and presence of IVC"S 
artifacts). The baseline characteristics of the patient 
population are depicted in Table I. The mean age was 
57.6 (11.2) years. most being male patients (75%) and 
66% of the patients presented with stable angina. The 
studied vessel was the left anterior descending in 46.2 %. 
the left circumflex in 26.9 %. and the right coronary 
artery in 26.9% of the cases. The mean number of stent 
per patient was 1.5 (0.7). No stent thrombosis has been 
observed so far. 
111!1 Calcified GSA 
0 Fibrous GSA 
0 Fibro~Fatty GSA 
0 Necrotic Core GSA 
IVUS~RFD Findings. Changes From Baseline 
to Follow~up in Geometrical and 
Compositional Parameters Within 
and Between the Proximal and Distal 
Segments. 
At baseline. the mean vessel CSA (16.5 [4.9] vs 11.5 
[4.0] mm': P<.OOI). plaque CSA (7.7 [3.6] vs 5.3 [2.7] 
mm': ?<.001). and lumen CSA (8.8 [2.6] vs 6.2 [1.7] 
mm~: P<.001) of the entire 5wmm edge segment in the 
proximal edge were larger than their counterparts in the 
distal segment. The same holds at follow-up for the 
measurements of the mean vessel CSA (17.5 [5.9] vs 
12.8 [4.0] mm': P<.OOl). plaque CSA (8.2 [4.4] vs 5.1 
[2.6] mm': P<.001). and lumen CSA (9.3 [3.0] vs 7.7 
[4.0] mm': P<.001) (Table 2). 
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TABLE 1. Demographic, Medication, and Procedure 
Characterisitics (n=24)0 
Age, mean (SD). y 
BMI, mea11 (SO), kg/m< 
Male18 
Hyperte11sio11 
Diabetes mellitus 
Hypercholesterolemia 
Curre11t smoker 
Previous cardiac history 
Previous CABG 
Previous ACS 
Family history of CAD 
Cli11ical prese11tation 
Stable a11gina 
ACS 
Medicatiol1 
Aspirin 
Baseline 
6 Mo11ths follow-up 
Clopidogrel 
Baseli11e 
6 Mo11ths follow-up 
Beta-blockers 
Baseli11e 
6 Months follow-up 
ACE it1hibitor 
Baseline 
6 Months follow-up 
Calcium chan11el blocker 
Baseline 
6 Mo11ths follow-up 
Statins 
Baseli11e 
6 Mo11ths follow-up 
Studied vessel (n=26) 
LAD 
LCX 
RCA 
Procedure characteristics 
Stent length, mea11 (SD), mm 
Ste11t diameter, mea11 (SD), mm 
Balloon pre-dilatation 
Balloo11 length/stent le11gth ratio, mean (SD) 
Ste11t implantatiol1 pressure, mea11 (SD), atm 
57.6 (11.2) 
28.1 (3.8) 
(75) 
10 (41.7) 
6 (25) 
10 (41.7) 
4 (16.7) 
5 (20.8) 
0 
3 (12.5) 
11 (45.8) 
16 (66.6) 
9 (37.4) 
17 (70.8) 
24 (100) 
5 (20.8) 
24 (100) 
7 (29.2) 
19 (79.2) 
5 (20.8) 
12 (50) 
3 (12.5) 
1 (4.2) 
12 (50) 
21 (87.5) 
12 (46.2) 
7 (26.9) 
7 (26.9) 
16.6 (4.1) 
3 (0.41) 
11 (42.3) 
0.97 (0.27) 
19.6 (3.24) 
"ACS indicates acute coronary syndrome; BMI, body mass index; CABG, coronary 
artery bypass graft; CAD, coronary artery disease; LAD, left anterior descending: 
LCX, left circumflex; RCA, right coronary artery. 
Data are expressed as n (%)or median (SO). 
At the proximal and distal edges. a serial expansive 
vascular remodeling was observed at follow-up. with a 
significant increase in mean vessel CSA of the entire 
proximal (P=.031) and trend towards an increase in the 
distal segment (P=.06). 
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Tissue Characterization of the Edge Effects ofPaclitaxd-Eluting Stents 
Since plaque CSA hardly increases. this remodeling 
resulted in a significant increase in mean lumen CSA 
was observed (Table 2). 
In terms of tissue composition. at baseline, in the 
proximal segment as compared to the distal. the 
percentage of calcified tissue was not different (10.7% 
[11.5%] vs 11.0% [14.2%]: P=.80). the same was true 
for the necrotic core (17.0% [13.5%] vs 18.5% [16.5%]: 
P=.23); on the contrary significantly larger percentage 
of fibrous (57.9% [19.3%] vs 47.8% [29.2%]; ?<.001). 
and fibrofatty tissue (11.7% [11.9%] vs 7.0% [9.3%]; 
P<.OOI) were observed. 
At follow-up. all tissue types were larger in the proximal 
segment than in the distal. calcified (5.8% [8.2%] vs 
3.3% [6.3%]: P<.OOI). necrotic core (14.2% [13.8%] vs 
10.8% [12.6%]; P<.00l).fibrous (56.9% [18.4] vs53.0% 
[28.7%]; ?<.001). and fibrofatty tissue (18.7% [13.4%] 
vs 13.7% [13.1 %]; ?<.001) (Table 2). 
Overall. in the proximal and distal segments a 
significant increase of fibrofatty tissue was observed. 
whereas a decrease of calcified and necrotic core over 
the time was present. Fibrous tissue did not show 
significant temporal changes (Table 2). 
Subsegmental Analysis of Longitudinal 
Changes at 5-mm Edge Segment of Proximal 
and Distal Edges 
The mean absolute difference vessel CSA (follow-
up- baseline) was positive throughout the proximal 
and distal segments: this was accompanied by a positive 
mean absolute difference in lumen CSA: the most 
prominent increase in plaque CSA (although not 
significant) was documented in first three proximal 
subsegments. (Figure). In particular, at the proximal 
edge. in the first 2 millimeters the vessel wall grew to 
compensate for the plaque growth (1-mm pss. 8+0.52 
and 8+0.54 mm~: 2-mm pss. 8+0.65 and 8+0.58 mm~: 
vessel area change and plaque area change respectively) 
without affecting the lumen size (1-mm pss. 8-0.02 
mm~: 2-mm pss, 8+0.07 mm~ in lumen area change). 
while in the following 3 subsegments overcompensation 
was observed, that is the vessel wall grew more than 
the plaque (3-mm pss. 8+1.98 and 8+1.18 mm~; 
4-mm pss. 8+1.32 and 8+0.12 mm~; 5-mm pss. 8+0.54 
and 8+0.14 in vessel area change and plaque area 
change respectively). resulting in an increase in lumen 
size (3-mm pss. 8+0.81 mm~: 4-mm pss. fl.+l.21 mm~: 
and 5-mm pss. fl.+0.69 mm~). At the distal edge. 
overcompensation was observed in all5 subsegments. 
resulting in an increase in lumen size (1-mm dss . 
.6.+0.88:'1+0.23 and.6.+1.35 mm~: 2-mm dss. 8+0.67: 
8+0.04 and .6.+1.24 mm2: 3-mm dss. fl.+0.17: 8-0.63 
and .6.+1.72 mm~: 4-mm dss, .6.+0.51: .6.-0.36 and 
.6.+1.42 mm~~ 5-mm dss. 8+0.63: 8-0.10 and 
.6.+ 1.61mm~ in vesseL plaque and lumen area change 
respectively). 
At 6-month follow-up, the percentage of fibrofatty 
tissue increased in all subsegments. while fibrous tissue 
showed a more heterogeneous behavior. with calcified 
tissue and necrotic core being decreased throughout the 
ten subsegments analyzed. (Figure). 
DISCUSSION 
The main findings of this study were the following: 
a) at the proximal and distal edge. a serial expansive 
vascular remodeling was observed. with an increase 
in mean vessel area and mean lumen area of the entire 
edge from baseline to follow-up: b) in the first 3 
subsegments adjacent to the proximal part of the 
stent the most prominent increase in mean plaque 
area was observed. This is in line with the results of 
Taxus II and IV studies 11 •15 : and c) overall. in the 
proximal and distal segment a significant increase 
of fibrofatty tissue was observed. while a decrease 
of calcified tissue and necrotic core over time was 
present. 
The serial changes in tissue composition at the edges 
of the stent could vary depending on the location 
(proximal vs distal edge). the shear stress conditions. 16 
the morphological baseline characteristics (degree of 
obstruction) of the segment as well as the baseline tissue 
composition. Last but not least, the degree of vessel wall 
injury after dilatation plays a role. 17 In animal and human 
pathological studies the response-to-injury process after 
stenting has been extensively described. 10 Restenosis 
occurs secondary to accumulation of smooth muscle 
cells and extracellular matrix. which consists of 
proteoglycans. hyaluronan and collagen (Type I and ill). 
This extracellular matrix modulates neointimal growth 
and remodeling. 10 The IVUS-RFD tissue type that 
correlates with extracellular matrix is the fibro-fatty 
tissue. which happened to be the one that mostly increased 
in this study and. positive remodeling was also observed 
at both stent edges at 6 months. Serial remodeling has 
been proposed as the best approach to evaluate the 
geometrical vessel wall changes ll>_ In this regard other 
previous Taxus® stent studies have described this 
phenomenon at the edges. In particular, in TAXUS II' 1 
a positive remodeling was only observed at the distal 
edge in both slow and moderate release Taxus group due 
to an increase in plaque size and hardly not change in 
lumen size: while in TAXUS IV 15 almost no change was 
observed in vessel size at proximal edge and a trend 
towards negative remodeling was observed at the distal 
edge. It is difficult to put in perspective these three 
studies. since they all have different sample size. in 
TAXUS IV authors acknowledged potential selection 
bias. So, although this study has a small sample size. a 
more complete characterization of the serial changes 
has been achieved . 
In the present study. necrotic core rich areas were 
left unstented (proximal edge 17% [13.5%] and distal 
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edge 18.5% [16.5%]). however no stent thrombosis 
has been observed in this small cohort of patients. 
Proposed pathological mechanisms of stent thrombosis 
are stenting of necrotic core-rich plaques with extensive 
tissue prolapse and plaque disruption in the proximity 
of the stented arterial segment.l'l.20 IVUS-RFD is not 
only able to characterize necrotic core with high 
sensitivity and specificity. 14 it also provides geometrical 
analysis of each frame. allowing us to have the 
combined assessment of necrotic core and plaque size. 
Thus. pre-stenting imaging using IVUS-RFD can give 
us an insight into the extent of plaque and necrotic 
core within and beyond the intended stenting segment. 
This latter assessment is important since stenting has 
been lately performed from "normal to normal" arterial 
segments in angiography: however. disruption of 
adjacent necrotic core-rich areas that are 
angiographically disease-free should be avoided. 
Indeed. it has been reported that incomplete coverage 
of coronary atherosclerotic plaques with drug-eluting 
stents may impact on long-term clinical events, 
especially in necrotic-core rich plaques. 19 Nevertheless. 
in this study. a decrease in necrotic core was showed 
at both edges at follow-up. Whether this is related to 
the presence of stent or even more to the drug type 
eluted on the stent remains to be elucidated. 
The limitations of this study are various. firstly only 
a small cohort of patients has been included. since the 
study was considered mainly exploratory and without 
formal statistical hypothesis. Secondly. it would have 
been ideal to study completely the stent segment plus 
the edge effects. however as mentioned earlier. there is 
not validation of the tissue characterization behind the 
stent struts which may themselves interfere with the 
process of ultrasound backscattering of the tissue located 
behind the struts. Six-month follow-up may be a 
relatively short period of time to fully evaluate the tissue 
changes at the edges of the stent considering the fact 
that longer angiographic follow-up has been suggested 
to better evaluate the vascular responses at these 
locations. 
CONCLUSIONS 
Serial expansive vascular remodeling was observed at 
the proximal and distal edge of the stent to accommodate 
a tissue growth mainly due to an increase in fibrofatty 
tissue. 
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Abstract 
Aims: The main objective was to use IVUS..backscatter radiofrequency (IVUS-RF) to assess the degradation of 
a bioabsorbable stent by measuring serial changes in dense calcium (DC) and necrotic core (NCJ as assessed 
by intravascular ultrasound-Virtual Histology™ (IVUS-VHJ and in the strain as assessed by palpography. 
Methods and results: In the ABSORB trial, 27 patients treated with a single bioabsorbable everolimus-
eluting stent (BVS, Abbott Vascular, Santa Clara, CA, USA) were ail imaged with IVUS-RF post-stenting and 
at 6-month follow-up, and 13 and 12 patients were also investigated pre-stenting with IVUS-VH and 
palpography respectively. 
From pre- to post-stenting, with VH (n=13), there was an increase in mean "DC" (9.8 vs. 25.4%, 
p-=0.0002) and ~NC" (15.5 vs. 30.5%, p=0.0002). In palpography (n=12), the mean number of frames 
with Rotterdam Classification (ROC) III/IV per em decreased from 1.22±1.91 to 0.12±0.31 (p= 0.0781) 
and the mean cumulative strain values (ail frames with ROC I-IV scores) changed from 0.50±0.27 to 
0.20±0.10% (p= 0.0034). 
Comparing post-stenting with follow-up (n=27), VH showed a decrease in "DC" (29.7% vs. 21.1%, 
p=Cl.OOOl). "NC" also decreased (26.9 vs. 21.5%, p=0.0027). For palpography (n=25 patients), an 
increase in the mean number of frames with ROC III/IV per em was observed from 0.09±0.26 to 0.22±0.36 
(p=0.1563) while the mean cumulative strain values (all frames with ROC I-IV scores) changed from 
0.15±0.10 to 0.26±0.12% (p<O.OOOl). 
Conclusions: IVUS-VH changes at 6 months suggest alteration of the BVS with reduction of RF 
backscattering by polymeric struts. Strained plaques on the palpograms were almost abolished following 
stent implantation. However, strain values reappeared within 6 months suggesting an increase '1n 
endoluminal deformability of the stented vessel. 
• Corresponding author: Department of Cardiology, Erasmus Medical Center, Thoraxcenter, Ba583a, Erasmus MC, 's-Gravendijkwa! 230, 3015 CE 
Rotterdam, The Netherlands 
E-mail:p. w.j.c.serruys@erasmusmc.nf 
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Introduction 
Metal stent use has been one of the major breakthroughs in the 
treatment of patients with coronary artery disease.1 However, the many 
advantages are somewhat counterbalanced by associated pitfalls such 
as restenosis, the persistent metal presence that may preclude late 
surgica! revascularisation of the treated vessel, and jailing of side 
branches.2·9 The advent of a new bioabsorbable everolimus-eluting 
stent10 promises to overcome some of these disadvantages. The in vivo 
serial changes in its structural conformation (polymer degradation 
pro~le) were established in a porcine coronary artery model. Mass loss 
was approximately 30% at 12 months with a further reduction to 60% 
mass loss by 18 months after implantation'0. However, in human 
coronary arteries the bio-absorption process has never been explored. 
Hence in the ABSORB trial all clinically available and potentially useful 
invasive coronary imaging techniques to assess bio-absorption of 
polymeric struts were used (i.e. echogenicity, intravascular ultrasound 
[IVUSJ - radiofrequency IRFJ data analysis: Virtual Histology™ [VHJ 
and paipography and optical coherence tomography). Nevertheless, 
none of these techniques have been specifically designed to assess 
bio-absorption. Specifically, IVUS-VH11·12 is a tool developed to assess 
the tissue compositon of intact native coronary arteries. The analysis of 
the actual stent area and its surroundings by IVUS--VH identified the 
stent struts as "dense calcium" and "necrotic core" (white and red 
colour in the VH colour-code), which correspond to a specific 
backscattered radiofrequency of the polymeric strut structures (highly 
echogenic). Palpography is an IVUS-based technique that assesses 
the local mechanical deformation of the vessel wall by measuring the 
relative alteration of backscattered radiofrequency signals at ~o 
different blood pressure levels. For instance, lipid-rich vulnerable 
plaques ha ve greater deformation and higher strain values compared 
to calcific or fibrous plaques_l3 The main objective was twofold: i) to 
use IVUS-VH to follow-up the degradation of a bio-absorbable 
everolimus-eluting stent by measuring the temporal changes in IVUS-
VH characteristics at pre-, post-stenting and at 6 months; and ii) to 
evaluate the temporal changes in palpographic strain va!ues in the 
stented segment. 
Methods 
Study design 
The study design for the prospective, open label ABSORB trial has 
already been published elsewhere.lO Briefly, this was a single arm 
study that enrolled 30 patientsat4 participating sites between March 
and July 2006. Patients were older than 18 years, with a diagnosis of 
stable, unstable or silent ischaemia. All treated lesions were single, 
de novo in a native coronary artery of 3.0 mm, shorter than 8 mm for 
the 12 mm stentor .::;:14 mm for the 18 mm stent (only two patients 
received an 18 mm stent), with a % diameter stenosis 2:50% and 
<100% and a thrombolysis in myocardial infarction (TIMi)ilowgrade 
of 2:1. Major exclusion criteria were patients presenting with an acute 
myocardial infarction, unstable arrhythmias or patients who had left 
ventricular ejection fraction <30%, restenotic lesions, lesions located 
in the left main coronary artery, lesions involving a side branch 
>2 mm in diameter, and the presence of thrombus or another 
clinically significant stenosis in the target vessel. 
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The study was approved by the ethics committee at each participating 
institution and each patient gave written informed consent before 
inclusion. 
Study device 
The BVS stent has a polymer backbone of Poly-L (racemic)-lactic 
Acid (PLLA) coated with a Poly-D (racemic), L-!actic acid (PDLLA) 
polymer that contains and controls the release of the anti-
proliferative drug everolimus. Both PLLA and PDLLA are fuily 
absorbable. The absorption process occurs via hydro!ysis: the long 
chains of PLLAIPDLLA become shorter as bonds between the 
repeating units are hydrolysed, producing lactic acid which is 
metabolised via the Krebs cycle, and small particles <2 microns 
diameter that are phagocytosed by macrophages. The time for 
complete absorption of the polymer backbone is predicted from 
preclinical studies to be about 2-3 years whereas the polymer 
coating is absorbed in approximately 9 months. 
Stenting procedure 
Lesions were treated with routine interventional techniques that 
included mandatory pre-dilatation using a balloon shorter than the 
study device and 0.5 mm less in diameter. The BVS stent was implanted 
at a pressure not exceeding the rated burst pressure (16atm). Ail 
patients were pretreated with aspirin and a loading dose of at least 
300 mg of clopidogrel was administered according to local hospi~l 
practice. After the procedure, all patients were to receive aspirin 
2=75 mg daily for the study duration (5 years) and clopidogrel75 mg 
daily for a minimum of 6 months. Anticoagulation and glycoprotein 
II b/llla inhibitor use was according to local hospital practice. 
Imaging procedure 
Pre-stenting IVUS-VH (n=13) and pre-stenting palpography (n=12) 
imaging were obtained in a subgroup of patients treated at the 
Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands. The 
purpose of these analyses was to observe the acute changes after the 
implantation of the BVS stent Subsequently, in the entire population 
IVUS--RF was obtained post-stenting and at follow-up. Both imaging 
techniques were acquired simultaneously with a phased array 20 MHz 
intravascular ultrasound catheter (EagleEyeTM; Volcano Corporation, 
Rancho Cordova, CA, USA) using automated pullback at 0.5 mm per 
second. Four tissue components (necrotic core- red; dense calcium-
white; fibrous- green; and fibre-fatty- light green) were identified with 
autoregressive classification systems.11·14 Each individual tissue 
component was quantified and colour coded in al! IVUS cross sections 
as previously described. In a previous post-mortem validation study, 
RF analysis demonstrated sensitivity and specificity for detection of 
necrotic core of 92% and 97%, respectively.14 Ail IVUS- VH analyses 
were performed offline using pcVH 2.1 (Volcano Corporation, Rancho 
Cordova, CA, USA) by an independent clinical research organisation 
(Cardialysis, Rotterdam, The Netherlands). For each cross section, 
polymeric stent struts were detected as areas of apparent «dense 
calcium" and "necrotic core~. We used the change in quantitative 
analyses of these characteristics between implantation and follow-up 
as a surrogate assessment of the polymer bio-absorption process. 
IVUS-based palpography assesses deformability of the plaque. The 
underlying principle is that softer tissue is more readily deformed 
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compared with harder tissue when force (eg, pulsatile arterial 
pressure) is applied. 13 The deformability of coronary plaque is 
quantified using the analysis of radiofrequency signals at different 
diastolic pressure levels. The strain is normalised to a pressure 
difference of 2.5 mm Hg per frame. This allows the construction of 
a 'strain' image in which harder {low strain) and softer {high strain) 
regions of the coronary arteries can be identified, with radial strain 
values ranging between 0% and 2%. 13 In post-mortem coronary 
arteries that were investigated with histology and IVUS palpography, 
the sensitivity and specificity of palpography to detect high strain 
values were 88% and 89%, respectively.13 
Plaque strain values were assigned a Rotterdam Classification {ROC) 
score ranging from I to IV (ROC 1: 0% to 0.6%; ROC II: 0.6% to <0.9%; 
ROC Ill: 0.9% to <1.2%; ROC IV: >1.2%) as previously described.:s All 
IV US.. palpography analyses were performed by an independent clinical 
research organisation (Cardialysis, Rotterdam, The Netherlands). 
The clinical and geometrical analysis in the ABSORB study has 
already been reported.lO Thus, in this paper, we exclusively report 
changes in tissue composition and plaque deformability. 
Statistical analysis 
As stated in the main ABSORB Study, the sample size was not 
defined on the basis of an endpoint hypothesis but rather to provide 
information about device efficacy and safety. Therefore, the present 
substudy s~ould be seen as hypothesis-generating. 
Discrete variables are presented as counts and percentages. 
Continuous variables are presented as means ± SO, quartiles and 
ranges. A two-sided p-value of less than 0.05 indicated statistical 
significance. Due to the exploratory nature of these analyses, p values 
were unadjusted for multiple comparisons in this manuscript. 
The dens'1ty of h"1gh-strain spots per 10 mm was defined as the 
number of cross-sections with strain values ~.9% (i.e. ROC Iii or IV) 
divided by the number of all analysable cross sections in the region of 
interest and normalised for 10 mm. 
Paired comparisons between pre-procedure, post-procedure and 
follow-up were done by the Wiicoxon signed rank test. Statistical 
analyses were performed w·rtr. use of SAS 9.1. 
Results 
Overail, 30 patients were included ',n t\le ABSORB study. The mean 
age was 62±9 years, most being male patients (60.0%), while 70.0% 
of the patients presented with stable angina, 26.7% and 3.3% had 
unstable angina and silent ischaemia respectively. The studied vessel 
was the left anterior descending in 46.7%, the left circumflex in 
30.0% and the right coronary artery in 23.3% of the patients. 
Intravascular ultrasound Virtual Histologym 
Changes between pre- and pos!-stenting 
In 13 patients, IVUS-VH was performed pre- and post-stenting 
{Table 1 and Figure 1). The mean percentage of "dense calcium" 
increased from 9.8% to 25.4% (p=0.0002) and "necrotic core" went 
from 15.5% to 30.5% (p=0.0002). Fibrous tissue, the major 
component of the vessel wall when expressed as mean area did not 
demonstrate statistically significant changes post·stenting, however its 
Table 1. Acute changes in IVUS--VH in 13 patients. 
Pre stenting Post stenting_ p value 
Dense calcium (mm2) 0.0002 
Mean± SO (N) 0.42±0.44 (13) 1.23±0.68 (13) 
Median 0,27 1.12 
(Ql-Q3) (0.06, 0.89) (0.87, 1.51) 
Range (min, max) (0.01, 1.14) (0.39, 2.90) 
Dense Calcium (o/o) 0.0002 
Mean±SD (N) 9.83±9.64 (13) 25.42±11.27 (13) 
Median 6.19 27.09 
(Ql-Q3) (4.26, 15.06) (16.79, 31.78) 
Range (min, max) (0.25, 34.66) (9.91. 46.87) 
Fibrous (mm2) 0.1099 
Mean±SD (N) 2.52±1.37 (13) 2.12±1.17 (13) 
Median 2.43 2.37 
(Ql-Q3) (1.40, 3.62) (1.05, 2.88) 
Range (min, max) (0.17, 4.40) (0.32, 4.08) 
Fibrous(%) 0.0002 
Mean:tSD (N) 60.75±13.06 (13) 38.98±10.47 (13) 
Median 64.40 37.14 
(Ql-Q3) (52.32, 72.71) (31.73. 45.35} 
Range (min, max) (35.31, 76.90) (24.88, 58.28) 
Fibrofatty (mm2) 0.0034 
Mean±SD (N) 0.63±0,46 (13) 0.29±0.25 (13) 
Median 0.67 0.19 
(Ql-Q3) {0.32, 0.94) (Q.lO, 0.43) 
Range (min, max) (0.01, 1.50) (0.01, 0.81) 
Fibrofutty (%) 0.0002 
Mean±SD (N) 13.89±8.31 (13) 5.07±3.92 (13) 
Median 13.22 3.76 
(Ql-Ql) (8.76, 14.47) (2.45, 5.48) 
Range (min, max) (4.50, 34.16) (1.44, 14.31) 
Necrotic Core (mm 2) 0.0002 
Mean±SD (N) 0.74±0.62 (13) 1.66±0.86 (13) 
Median 0.60 1.70 
(Q1-Q3) (0.28, 1.24) (0.89, 2.28) 
Range (min, max) (0.03, 1.92) (0.29, 2.88) 
Necrotic Core(%) 0.0002 
Mean±SD (N) 1553±8.43 (13) 30.54±6.16 (13) 
Median 14.10 31.56 
(Ql-Ql) (9.86, 21.31) (28.39, 33.62) 
Range (min, max) (1.19, 33.01) (17.50, 41.82) 
Figure 1. Serial changes in the stent struts as assessed by /VUS Virtual 
HiStologyrM (VH). On the left hand side, greyscale !VUS images are 
shown at pre-, post-stenting and follow-up. In the central part, their 
corresponding colour code VH images are depicted. On the right hand 
side, per-cross section quantification in absolute and relative terms is 
shown. Of note. increases in "dense calcium" (white) and "necrotic 
core" (red) are noted after stenting. At follow-up, a change in the stent 
strut appearance in greyscale /VUS is noted and decreases in the 
"dense calcium" and ''necrotic core" contents in IVUS- VH are 
detected. Fibrous -green; and fibro-fatty - fight green. 
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relative contribution to the stented vessel wall decreased significantly 
(60.8% vs. 39.0%, P=().0002). In a similar fashion the percentage of 
fibro--fattytissue decreased (13.9% vs. 5.1 %, po:=0.0002). 
Changes !rom post-stenting to follow-up 
Overall, in patients (n=27) with post-stenting and follow-up VH, 
a significant decrease in ~dense calciumH (29.7% vs. 21.1%, 
p=0.0001) was shown. In 21 out of 27 patients, there was 
a regression in the "'calcified~ pattern (Table 2 and Figure 2). The 
content of "necrotic core" also decreased (26.9% vs. 21.5%, 
P-=0.0027). In turn, both fibro-fatty and fibrous tissue increased in 
terms of both mean areas and percentages (Table 2 and Figure 1). 
[ntravascular ultrasound paipography 
CHANGES FROM PRE- TO POST-STENTING 
In 12 patients, IVUS-palpography was performed pre- and post-
stenting (Figure 3 and 4). The mean number of frames with ROC 
III/IV per em decreased from 1.22±1.91 to 0.12±0.31 (p=0.0781}. 
The mean cumulative strain values in all frames with ROC I-IV 
scores changed from 0.50±0.27 to 0.20±0.10% (p= 0.0034). 
CHANGES FROM POST-STENTING TO FOLLOW-UP 
In ?atients (n=25} with post-stenting and follow-up paipography, 
a slight increase in the mean number frames with ROC 11!/IV per em 
from 0.09±0.26 to 0.22±0.36 (p=0.1563) was obseNed, while the 
mean cumulative strain values in all frames with ROC I-IV scores 
increased significantly from 0.15±0.10 to 0.26±0.12% (p<O.OOOl) 
(Figure 3 and 4}. 
Discussion 
In this substudy of the ABSORB clinical tria: the main findings in 
IVUS-VH were an important increase in "dense calcium" and 
"'necrotic core" immediately after stent implantation and a 
subsequent decrease of these tissue surrogates at 6 months follow-
up; this decrease potentially reflects echogenic alteration of the BVS 
stent struts. On the palpograms, the almost complete initial abolition 
of the high strain regions was decreased six months following stent 
implantation: presumably after partial stent absorption the mean 
strain values increased again. 
r,"' 
' ;:" 
~" 
PriMiolllln~ f'll>t..tolllln~ Foll......,p 
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P~ilonljrlg .PO>l .... llllrlg Fo~OW··~ 
1J.U.d.J ~4 1.2<1.1 
Figure 2. Temporal changes in virtual histology tissue types. From top to 
bottom, the mean percentage of "dense calcium", "necrotic core", fibrous 
tissue and fibrcrfatty tissue is reported. Thirteen patients were imaged at 
pre-, post-stenting and follow-up (red solid lines). A further 14 patients 
were only imaged at post-stenting and follow-up (black dotted lines). 
Figure 3. Sequential changes in high-strain values as assessed by fVUS-palpography. Panel A shows an intact plaque with a ROC !II spot at 4 
o'clock (white arrow). Panel 8 depicts abolition of this high strain spot following stenting (ROC 1). In panel C a slight increase in plaque 
deformability was documented (ROC!!). 
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P.....-.tnntln~ PO<Htnnt·n~ Fotiow·u~ 
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' Figure 4. Temporal changes in strain 11a!ues. The mean cumulati11e strain 
11afues in at/ frames with ROC !-tv scores are shown. Twellle patients were 
imaged at pre-, post-stenting and follow-up (red solid fines). Another 13 
patients were only imaged at post-stenting and follow-up (black dotted 
lines). After stenting, abolition of the strain 11atues was noted; howe11er a 
higher le11ef of plaque deformability was present at follow-up. 
Table 2. Changes from post ~procedure to 6-months. 
Post:stenting FoUow-up p value 
Dense Calcium {mml) 0.6065 
Mean±SD (N) 0.97±0.59 {27) 0.88±0.61 (27) 
Median 0.89 0.86 
(Ql-Q3) (0.49, 1.25) (0.31, 1.22) 
Range (min, max) (0.28, 2.90) (0.17, 2.82) 
Dense Calcium (%) 0.0001 
Mean±SD {N) 29.66±15.25 (27) 21.13±11.58 {27) 
Median 27.09 18.49 
(Ql-Q3) (18.22, 38.44) (10.86, 30.80) 
Range {min, max) (9.91, 72.10) (4.66, 44.91) 
Fibrous (mm2) <0.0001 
Mean±SD (N) 1.65±1.23 (27) 2.42±1.37 {27) 
Median 1.47 2.53 
(Ql-Q3) (0.69, 2.57) {1.19, 3.36) 
Range (min, max) (0.06, 4.08) (0.17, 4.93) 
Fibrous{%) <0.0001 
Mean±SD (N) 39.02±13.07 (27) 50.20±12.55 (27) 
Median 37.79 50.71 
(Ql-Q3) (30.70, 49.81) (40.26, 59.24) 
Range (min, max) {10.85, 63.69) (29.26, 68.95) 
Fibro-fatty (mm2) 0.0040 
Mean±SD (N) 0.21±0.23 (27) 0.38±0.42 (27) 
Median 0.11 0.22 
(Ql-Q3) (0.04, 0.33) (0.12, 0.48) 
Range {min, max) (0.00, 0.81) (0.01, 1.72) 
Fibro-fatty {%) 0.0096 
Mean±SD (N) 4.47±3.36 {27) 7 .22±6.12 {27) 
Me\Jian 3.32 4.72 
(Ql-Q3) (2.45, 5.65) (2.57, 11.16) 
Range (min, max) (0.54, 14.31) (1.21, 26.18) 
Necrotic core (mm 2) 0.4815 
Mean±SD {N) 1.14±0.86 (27) 1.01±0.73 (27) 
Median 0.89 0.90 
(Ql-Q3) (0.33, 1.77) (0.58, 1.23) 
Range (min, max) (0.10, 2.88) (0.13, 3.07) 
Necrotic core{%) 0.0027 
Mean±SD (N) 26.85±6.97 (27) 21.45±8.17 (27) 
Median 25.53 21.80 
(Ql-Q3) {21.85, 33.11) (13.61, 28.59) 
Range (min, max) (12.30, 41.82) {8.87, 39.70) 
In a previous study by Tamai et al, 16 PLLA stents analysed by 
greyscale IVUS at 6 months seemed to maintain their scaffolding 
properties and apparently did not exhibit changes in echogenicity as 
a sign of biodegradation. In the ABSORB trial, a reduction of the 
stent area was obseNed suggesting a mild recoil of the polymeric 
stent structures.10 Implantation of polymeric struts resulted in the 
appearance in the vessel wall of highly echogenic structures with 
radiofrequency backscattering similar to calcific structures 
(Figure ll. Indeed. 'in this study using IVUS-VH, an increase in 
absolute "dense calcium" (L-.0.82 mm2, p=0.0002J from pre- to 
post-stenting was observed. This dramatic and sudden change in 
"DC" may be attr'ibuted to the 'introduction of polymeric struts and 
might correspond to the VH fingerprint of the polymeric struts. 
Following BVS stent implantation, the mean fibrous tissue area 
showed a slight decrease that failed to reach statistical significance 
(from 2.5 to 2.1 mm2, p=O.l099). The mean fibro-fatty tissue area 
decreased significantly, although the change is numerically very 
small, and m'ight be an artefact. From the ultrasonic point of view, 
the introduction of these highly echogenic structures might affect 
ultrasound penetration and therefore the backscattering of other 
tissue components located behind the struts, since potentially less 
acoustic signals are reaching the tissue. 
Although we acknowledge that the classification tree of the IVUS 
radiofrequency analysis r.as not been validated for polymeric stent 
struts, the radiofrequency backscattering is expected to increase with 
the reduction in the echogenicity of the implanted stent. It is 
reasonable to assume that the hydrolysis of the polymer wh\ch affects 
its molecular weight and mass, will also alter its acoustic properties. 
The BVS stent is constituted of PLLA (backbone) and PDLLA 
(coating) which are both fully bio-absorbable. During bio-
absorption, the long chains of PLLA and PDLLA are progressively 
shortened and ultimately phagocytosed by macrophages. 10 At 
follow-up, these pseudo-dense calcific structures shrink by nearly 
30% (in absolute terms, an 8.6 % reduction in "de:lse calcium'' 
from 29.7% to 21.1 %), which is consistent with the reduction in 
mass of the BVS polymeric struts observed in animals. These 
observations are at variance with the previous report by Tamai et al 
where no signs of biodegradation were observedY' A possible 
explanation is that the speed of bioabsorption of a polylactic 
polymer is greatly influenced by its purity, crystallinity and relative 
composition of Land D isomers. 
The changes in the physical properties of an artery can be 
described in terms of stiffness, ability to distend and compliance. 
These characteristics are dependent on the composition of the 
vascular wallY Deployment of a stent against the vessel wall 
undoubtedly modifies the physical properties of the endoluminal 
surface. The near-abolition of the high strain values (ROC 111/IVJ 
immediately post-stenting reflects major changes in deformability of 
the plaque and the obseNed reductions in high strain values may 
be due to a real decrease in deformability of the scaffolded vessel 
walL Aiternatively, it may also reflect an ultrasonic artefact, namely 
the incapability of palpography to measure intrinsic changes in 
strain of the vessel due to the acoustic properties of the stent struts 
preventing a proper propagation of radiofrequency signai behind 
them. The loss of mass observed over time in the pordne model 
may cause the reappearance of high strain values on the 
endoluminal surface of the vessel wall. All these observations are 
indirect indicators of the mocmications in strut structure. Although 
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IVUS-VH and palpography have not been validated to detect 
change in the integrity of polymeric stents, they seem to change 
acL.:tely and chronically with the introduction and subsequent bio-
absorption of the polymeric struts. 
These new imaging techniques allow a better understanding of the 
effect of different therapeutic modalities. 
Among the many clinical implications of the use of a biobasorbable 
stent, the most relevant pertains to the possibility to avoid potentially 
deadly events such as late stent thrombosis, providing the stent is 
fully absorbed in a reasonable period of time. Ideally, bio-absorption 
must occur after neointimal growth has been modulated. Knowing 
that this occurs mainly during the first 6 months after stent 
implantation, we have assessed bio-absorption using IVUS 
radiofrequency data analysis over this period of time. The results of 
the present substudy are unique findings since the in vivo bio-
absorption rate in diseased human arteries is not known. 
Limitations 
In the context of stent studies, IVUS radiofrequency data analysis 
faces the following issues: il misclassification of the stent struts as 
"dense calcium" and unecrotic core" in VH; ii) with both techniques 
- VH and palpography -the lack of proper validation to assess 
polymeric stents and; iii) the potential interference of the superficial 
stent struts on the backscattering from the tissue behind them. 
However, these techniques have corroborated other observations of 
po!ymer alteration documented with light transmission. In other 
words, changes in optical coherence of the struts reported 
elsewhere confirm the ultrasonic modifications reported here. 
Conclusions 
The quantitative assessment of the IVUS-VH changes at 6 months 
suggests early strut alteration of the BVS stent with reduction of 
radiofrequency backscattering. High-strain plaques seen on the 
palpograms were almost abolished following stent implantation. 
However, strain values reappeared at 6 months in some patients 
also suggesting an increase in deformability on the luminal surface 
of the stented vessel. 
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Case 1 
A 58-year-old man was admitted to our coronary care with tropon"m 
negative uns~ble angina. His risk factors included, being an ex-
smoker for a year, treated hypertension and dyslipidaemia. 
Medication on admission was aspirin and a statin. ECG showed T-
wave inversion laterally. Nine years previously he had a bare metal 
stent implanted in his circumflex arteryfollowing a lateral infarction 
the preceding year. Angiography done during his acute presenta-
~ion revealed an in-stent restenosis in the previously treated cir-
cumflex artery and a diffusely diseased marginal branch. The left 
anterior decending coronary (lAO) was normal and the right coro-
nary artery (RCA) had a non-flow limiting lesion in the mid-vessel 
with a fractional flow reserve (FFRJ of 0.79. Intravascular ultra-
sound (IVUS) of the circumflex artery was performed using a 
20 MHZ Eagle eye IVUS catheter (Volcano Therapeutics, Rancho 
Cordova, CA, USA). The length of the stented segment was 30mm 
and had a minimal luminal area (MlAl 4.6 mm2• Nee-intimal for-
mation was visible throughout the stent (Figure 1). This gave a nee-
intimal hyperplasia (NIH) volume of 80.3 mm3• The NIH on virtual 
histology had a tissue composition of necrotic core (NCJ 13.6%, 
(0.08 mm 2, 2.4 mm3), calc:fied tissue 16.8%, (0.10 mm2, 
3.0 mm3), fibrofatty 5.8%, (0.03 mm2 , 1.04 mrn3), fibrotic tissue 
63.9%, (0.38 mm2, 11.5 mm3). Distal to the MLA at dis~ nee of 
18 mm IVUS revealed an eccentric soft nee-intimal ruptured 
plaque1.2 (Figure 1C) within the stent. The necrotic core was 22% 
with remnant plaque burden of 54% at the plaque rupture site 
{Figure 1 C'). Just distal to ruptured plaque the vessel wail was 
intact and the plaque burden was h"lgher 65% with no necrotic 
core in contact with the lumen (Figure 10"). 
This ruptured lesion was subsequently managed with a drug eluting 
stent (DES) that also covered the MLA. The histological findings of 
a similar plaque rupture are illustrated in Case 2. 
Figure 1. !VUS pullback. The top panel shows the longitudinal recon-
struction. The double-headed arrow indicates the location of the stent. 
The characters "a" through "d" indicate the position of the cross sec-
tional panels "A" through ''D"'. Pane! A: proximal part of the stent, 
arrows indicatestent rna/apposition. Panel 8 : minimal luminal area 
within the stent (Ml..A 4.6 mrri). Panel C: eccentric plaque rupture 
(arrowed}, Panel 0: directly distal, intact eccentric neo-intimaf plaque. 
Panel C" (magnified frame): /VUS VH of ruptured plaque within the 
neo-intima. Panel D" (magnified frame): immediately after the rup-
ture. Panels c·· and D" show a majority of fibrous tissue. Of note !VUS-
VH analysis included the stents' struts that were seen as spots of cal-
cium and necrotic core. F/, fibrotic tissue; FF; fibrofatty; DC, dense 
calcium; NC, necrotic core. 
~Corresponding author: Thoraxcenter, Bd 406, Dr Molewaterplein 40, 3015-GO Rotterdam, The Netherlands 
E-mail: p.w.j.c.serruys@erasmusmc.nl 
10 EuropCJ Ed1!10n 2007. All nghts reserved. 
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Case 2 
A 43-year-old obese male undervvent percutaneous coronary inter-
vention (PCI) with MINI-CROWN bare metal stent (BMS} implanta-
tion in 1999 for a severe lesion in the proximal left anterior descend-
ing coronary artery. He was a heavy smoker with a body mass index 
26.4 but no diabetes or hyperlipidaemia. His past history includes 
peripheral vascular disease with intermittent claudication. He was 
found dead at his friend's house following a party approximate!y 
seven years after stent implantation. At autopsy, the heart showed 
biventricular hypertrophy with a healed subendocardial infarction in 
anteroseptal and lateral left ventricle. The coronary system was left 
dominant and middle left circumflex coronary artery had a 95% 
luminal narrowing without evidence of plaque rupture. However, 
there was an occlusive platelet-rich thrombus at the site of the stent 
in the LAD that was implanted just proximal to origin of the first left 
diagonal branch. The histological examination revealed a large rup-
tured atherosclerotic plaque with an underlying occlusive platelet 
thrombus. This ruptured plaque was composed of a NC rich in cho-
lesterol cleft and an overlying fibrous cap was infiltrated by foamy 
macrophages (Figure 2). 
These images are the first reported examples of a plaque rup-
~ure within the nee-intima induced by a stent and illustrate pro-
gression in the pathological process of atherosc!erosis3 . 
Currently there are concerns about late stent thrombosis in DES 
due to delayed endothelialisation. However, these two cases of 
very late BMS thrombosis highlight that it can occur despite full 
stent coverage. 
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Online data supplement 
AVI File 1. IVUS pullback along the stent to reveal the ruptured 
plaque. 
AVl File 2. IVUS-VH superimposed on pullback along the stent to 
reveal the ruptured plaque. 
Figure 2. Histology of the case (Movat Pentachrome). A. B: Longitudinal section of the stent. The distal part of the stent shows site of plaque 
rupture and a superimposed platelet-rich adherent thrombus. C: X-ray of stented artery just above the bifurcation of LAD and left diagonal branch. 
D: High magnification image of the rupture site (*) and overlying platelet-rich thrombus is identified by the black arrow. £: The cross section of 
the proximal portion of the LAD stent. (corresponds to the black lines in panel A and B). Note the presence of a thin-cap fibroatheroma (vulner-
able plaque) within the stent site (*). F, G: The fibrous cap is extremely thin and infiltrated by foamy macrophages with an underlying necrotic 
core (NC). 
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Chapter 9.1 
RATIONALE FOR A CONSENSUS DOCUMENT 
Atherosclerotic cardiovascular disease is a leading cause of morbidity and mortality 
despite the widespread use of established medical therapies. This has prompted the 
search to identify new therapeutic approaches to achieve more effective prevention 
of cardiovascular events. Considerable interest has focused on the role of surrogate 
markers of therapeutic efficacy in the early evaluation of novel ami-atherosclerotic 
therapies. 
Monitoring changes in the extent of coronary atherosclerosis with intravascu-
lar ultrasound (IVUS) has been increasingly employed in clinical trials to assess 
progression and regression of atherosclerosis. This is based on the pivotal role 
that atherosclerotic plaque plays in the natural history of cardiovascular disease 
and the acceptance of validated arterial imaging approaches including coronary 
angiography and carotid intimal-medial thickness by regulatory authorities. The 
ability to generate high resolution imaging of the entire thickness of the coronary 
artery wall permits evaluation of the entire burden of atherosclerotic plaque. 
In order to understand the differences, similarities, limitations and pitfalls of 
the IVUS technique among different academic core laboratories, a number of 
meetings of representatives from these groups were convened in 2007 and 2008. 
This document is the result of those IVUS methodology meetings that assembled 
experts from core laboratories to discuss standards for image acquisition, defini-
tions, criteria, analyses, and primary and secondary endpoints. 
EQUIPMENT 
Early studies that employed coronary IVUS imaging typically involved the use 
of one imaging system in terms of both catheter and console. With technological 
advances a number of systems and catheters are now available that permit high 
resolution imaging within the coronary arteries. Given that studies often involve 
a large network of sites, there is likely to be marked heterogeneity in terms of 
imaging systems available among institutions and within each catheterization 
laboratory. As a result, there is now a much greater risk that an individual subject 
is imaged with different systems at different time points. It is critical that every 
possible effort is made to ensure that an individual is imaged with the same equip-
ment (catheters and consoles and pullback devices) for baseline and follow-up 
studies. 
It is the responsibility of the core laboratory to qualifY and specifY the systems, 
catheters, and pullback devices used in each study. While multivariate analysis 
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may be used to adjust for differences in cases where different systems are used 
within a single study, it remains to be determined whether this has any impact on 
the results. Regardless, every effort should be undertaken to include only imaging 
systems that have been demonstrated to produce high resolution imaging permit-
ting precise measurements to a standard deemed appropriate for use by the core 
lab. 
Consoks and catheters. Current rotating element IVUS catheters operate at 
frequencies between 30-45MHz (most commonly 40MHz); electronic phased 
array catheters operate at a center-frequency of approximately 20MHz. However, 
since the transducer manufacturing is difficult and performed under conditions of 
extremely high temperatures, the true center frequency of individual ultrasound 
elements may deviate from published specifications. It is unknown whether this 
has any impact on measurements. Given the higher resolution imaging that is 
generated with higher ultrasound frequency, rotational catheters are more often 
used in studies that evaluate the impact of medical therapies on progression of 
atheroma volume. 
The higher the frequency, the higher the resolution, bur the lower the pen-
etration1·2. However, recent improvements in transducer design have minimized 
the negative impact of higher frequencies on penetration. Improvement in the 
resolution of transducers is to be encouraged since it is expected that such im-
provements will decrease variability and improve reproducibility in the core lab 
analysis'. Manufacturers should report resolution, beam profile, bandwidth, and 
other technical data such as the variability between catheters and consoles and 
provide this data to the core laboratories. Manufacturers should also report the 
speed of sound used by the ultrasound consoles to produce the actual images. This 
speed of sound setting is important because it is the cornerstone of all dimensional 
measurements and is necessary to test phantoms and other standardizations. In 
the past speed of sound was used to develop an algorithm to correct for in vivo 
measurement inaccuracies using the 30MHz BostonScientific catheter connected 
ro a Clear View console.'. 
Measurements made with rotating vs. electronic array transducers or even with 
different rotating transducers made by the same or different manufacturers can 
vary significantly'. This is the reason that it is critical that the same equipment 
(catheters and consoles and pullback devices) be used for baseline and follow-up 
studies. Different clinical sires can use different systems as long as same equipment 
and settings are used for each individual patient. 
At the start of a study, the core laboratory or sponsor must contract with each 
of the IVUS companies to insure that an adequate supply of the same IVUS 
catheters be available for the duration of the study and that technical support for 
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existing consoles be maintained until tbe last patient has completed follow-up. 
In situations in which many patients have been imaged without standardizing 
baseline and follow-up equipment, a mathematical transformation of the data 
can be considered; however, this should be revealed in the methodology of the 
final report. Alternatively, subjects imaged witb different systems at baseline and 
follow-up can be considered major protocol deviators, a factor to be employed 
in subsequent per protocol analyses of data. Where sites have multiple imaging 
systems it should also be considered whetber the site is designated to use one 
specific system at the commencement of the study to facilitate consistency of im-
aging systems for patients at different time points. In addition, it is advisable that 
the same "major" machine settings - especially, the "zoom" and frame rate - be 
standardized for baseline and follow-up studies. Finally, it is ideal- but, of course, 
not practical - that the same technical personnel be involved in the baseline and 
follow-up studies. 
Experience has taught us that the performance of measurement software sys-
tems be evaluated in an objective and uniform manner. For example, quantitative 
coronary angiography (QCA) profoundly altered our approach to the assessment 
of percutaneous coronary interventions and strategies aimed to prevent recurrence 
and progression of stenoses. In one study 10 QCA systems at core laboratories in 
North America and Europe were validated. Cine films were made from phantom 
stenoses of known diameter (0.5 to 1.9mm) under 4 different experimental con-
ditions. The cine films were analyzed by each automated QCA system without 
observer interaction. Accuracy and precision were taken as tbe mean and SD of 
tbe signed differences between the phantom stenoses; and the measured minimal 
luminal diameters and tbe correlation coefficient (r), tbe SEE, the y intercept, 
and tbe slope were derived by tbeir linear regression. Performance of the 10 QCA 
systems ranged widely: accuracy, +0.07 to +0.31mm; precision, +i- 0.14 to +i-
0.24mm; correlation (r), .96 to .89; SEE, +1- 0.11 to +1- 0.16mm; intercept, 
+0.08 to +0.31mm; and slope, 0.86 to 0.646 
We do not have similar accuracy and precision data from various IVUS mea-
surement software, especially ones that use different edge detection algorithms. 
Power calculations and study design should be adjusted for tbe precision of tbe 
off-line IVUS analysis systems and reproducibility of measurements witbin the 
core laboratory in order to avoid tbe risk of failing to detect small differences 
in patient populations. Phantom studies for all new equipment - hardware and 
software - should be performed and reported before the equipment is used in 
clinical practice or in clinical trials. 
Pullback methodology for image acquisition. Automatic motorized pullback 
is mandatory usually at a rate of0.5 or 1mm/sec. Pullback accuracy is affected by 
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factors apart from the pullback devices themselves especially comparing sheath-
based versus non-sheath based catheters.' In case of non-sheath catheters, the pit-
falls of automatic pullback include presence of catheter slack outside the patient 
and friction in the coronary artery and guiding catheter during pullback affecting 
heterogeneity of pullback speed. Conversely, we believe that sheath-based, me-
chanical catheter systems allow smoother and more uniform pullbacks during 
image acquisition and are more precise in terms oflength measurement. However, 
this is counterbalanced by the appearance of NURD (non-uniform rotation dis-
tortion) that is unique to mechanical, rotating, sheath-based transducer catheters. 
NURD can occur for a number of reasons and can be difficult to recognize. To 
minimize or eliminate NURD, the following are recommended: (1) Straighten 
the IVUS catheter. (2) Make sure that the hemostatic valve is not too tight. (3) 
Make sure that the guiding catheter is not too small or has too tight of a radius 
curve. (4) Select the least tortuous coronary segment for interrogation. If these are 
not effective and NURD persists, then the IVUS catheter should be changed. 
The method of delivering power to an automatic pullback device potentially 
affects accuracy and consistency of the pullback speed. There are 3 different ways 
to deliver power and control the pullback device: battery, console that is not 
computer-controlled, and computer-controlled console. Tanaka K et al7 evaluated 
the accuracy of 4 IVUS pullback systems by studying 180 patients ( 45 in each 
group) who had been treated with a single stem of known length ranging from 8 
to 33mm. The correlations between known stem length and IVUS-measured stem 
length were 0.92 for CVIS, 0.83 for BostonSciemific Galaxy, 0.63 for Endosonics 
Track-Back, and 0.69 for Volcano Model R-100 research pullback device. At a 
pullback speed of0.5mm/s, the authors reported that a 10% error would cause a 
30mm length of artery to be measured as 27 to 33mm in length. It is important 
to make sure that batteries of a battery-powered pullback device are always at 
least 20% full to insure uniform pullback speed and to avoid having the pullback 
device fail in the middle of a run. Pullback devices should be tested from time to 
time either in a warerbed or a,aainst a single implanted stem of known length in a 
straight coronary segment. The pullback device is least accurate at the beginning of 
an imaging run (in the distal artery) and most accurate in the proximal artery. It is 
recommended that the pullback start at least 1 Omm distal to the distal anatomical 
landmark (fiduciary point) - the most distal side branch accessible for the IVUS 
probe. It is also recommended that slack be removed from the IVUS catheter 
before srarting automatic pullback. Ideally, the same pullback device should be 
used at baseline and follow-up 
Validation. Core laboratories should rake part in validation studies of new 
imaging systems to insure that the imaging consoles and catheters employed in 
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their studies generate high resolution imaging required for accurate measurement 
of disease burden. This is often performed with the use of a phantom model 
employing a range of lumen dimensions. This will enable accurate validation of 
new imaging systems for potential use in future studies. Validation data should be 
available for review by trial sponsors and regulatory agencies. 
IMAGE ACQUISITION 
Site Experience and Training. It is important to select experienced IVUS opera-
tors and sites with research experience, infrastructure, and demonstrated recruit-
ment and retention of patients during follow-up. The corelab should be involved 
in this selection process. Ideally, participating centers should have enrolled and 
followed up patients in other recent IVUS studies. The number of enrolled pa-
tients, quality of the recordings (ratio between enrolled patients and analyzable 
IVUS), and the follow-up rate should be considered in site selection. Equipment, 
imaging standards, and imaging protocols should be defined prior to the start of 
the study. It is advisable that each site perform test runs of their processes prior 
to patient enrollment. There should be meetings with the IVUS investigators to 
discuss these issues both before the start of the study (before any baseline studies 
are acquired) and again before the start of the round of follow-up IVUS studies; 
test cases should be discussed at such meetings. Training of the sites is crucial, 
especially for sites that are working with the core laboratory for the first time. 
While it is possible for the ultrasound companies to provide some support, it is 
essential that training be supervised and directed by the core laboratory to insure 
that the imaging details required for the study are provided to and followed by the 
sites. During the course of the study, feedback to the clinical sites and investiga-
tors is crucial and should not be delayed. An example of a feedback form is shown 
in Appendix A. 
Selection of patients. The natural history of coronary atherosclerosis involves 
progression with an increase in atheroma burden. To insure a cohort with dis-
ease progression, patients are selected for inclusion on the basis of established 
obstructive disease on a coronary angiogram performed for a clinical indication. 
Most groups typically require the presence of at least one lumen stenosis >20% 
by angiography. It has been established that such patients have diffuse coronary 
artery atherosclerosis that increases in severity over time. This enables assessment 
of therapies that might potentially slow disease progression. Patients with normal 
coronary angiograms are typically excluded as this will include some subjects with 
either no plaque or minimal disease. Patients with severe left main arterial disease 
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or significant lumen stenoses of all three major epicardial coronary arteries are 
typically excluded due the high likelihood that they will require intervention dur-
ing the course of the study and not be available for imaging at follow-up. 
Selection of Vessel for Imaging. The study vessel should be selected based 
on standard angiographic findings. As the imaging resolution of non-invasive 
techniques such as computed tomography continues to improve, it will likely 
become possible to select the target vessel for invasive imaging on the basis of non-
invasive findings. Some groups mandate that the vessel selected for IVUS imaging 
should include at least one diameter stenosis >20% by visual assessment of the 
angiogram and be the longest and least angulated vessel segment. Some groups 
require there to be a minimum plaque burden (atheroma area divided by external 
elastic membrane area) of 40% by IVUS. Other groups have not employed a 
minimal threshold of disease. However, from a practical standpoint, patients with 
no angiographic stenosis >20o/o are typically not randomized in these studies. 
Conversely, because the intent of the study is to evaluate the impact of medical 
therapies on the natural history of disease progression, vessels are usually excluded 
if they have undergone previous revascularization. 
Segment length. Given that there is an increase in variability when short seg-
ments are analyzed, a minimum threshold of 10-15mm is typically employed. 
However, all groups recommend the acquisition of at least 30mm of analyzable 
IVUS length, advising investigators to acquire a segment that is as long as possible. 
Increasing measured segment lengths has been one of the factors contributing to 
the reduction in measurement variability in more recent studies. In case of dys-
function of the equipment or poor acquisition due to technical difficulties (signal 
disappearing, spasm, ischemia, etc) the run should be repeated. Imaging should 
always continue until the aorta is visualized. The entire imaging run should be 
recorded onto digital media to send to the core laboratory. 
Measured pullback lengths of the same segment studied at baseline and follow-
up are not always the same. This is one of the major determinants of reproducibility. 
Reasons include not starting the catheter distal enough so that slack is removed 
prior to reaching the distal fiduciary point, too small of a guiding catheter or too 
tight of a hemostatic valve so that there is resistance to transducer withdrav.ral, 
anatomic considerations such as tortuosity or a bendpoint or a tight proximal 
stenosis, problems with the pullback device itself, wrong pullback speed, battery 
power being too low, etc. Some groups apply a pre-specified threshold difference 
between baseline and follow-up measured segment lengths that automatically 
excludes a specific patient in the study with a recommendation that a 15% dif-
ference in length between baseline and follow-up is the maximum acceptable. If 
the difference between baseline and follow-up length is <15%, volumes should be 
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calculated using the mean length from the two studies. In other groups algorithms 
are applied to normalize the ratio between image number and segment length. 
Regardless of the approach, it is imperative that any pullback that clearly indicates 
an erratic rate of pullback or catheter hangup that results in a gross discordance 
between the two studies should be excluded from analysis. Accordingly, every ef-
fort should be made by the imaging physician to meticulously observe the images 
during pullback to detect any concern that would jeopardize its use for analysis 
and to repeat the pullback if required. 
Use of Adjunct pharmacology. Today most diagnostic coronary angiograms 
are performed without anticoagulation. When performing IVUS imaging, it is 
important to give the patient an anticoagulant ( unfractionated or low molecular 
weight heparin, bivalrudin, etc.) before inserting the IVUS catheter into a coro-
nary anery. Otherwise, there is a risk of thrombosis. It is also advisable to give 
intracoronary nitroglycerine (1 00-200 micrograms) before imaging to avoid 
catheter-induced spasm and minimize ischemia; the dose should be limited only 
by the patient's blood pressure. 
Option for ECG gating. Motorized transducer pullback is critical for studies 
assessing progression and regression of atherosclerosis. However, all motorized 
pullback devices assume no cardiac motion. This is, of course, not correct; one 
previous study of 59 measurements in 31 patients showed that longitudinal cath-
eter motion between systole and diastole averaged 1.50 ± O.SOmm (range 0.5 to 
5.5 mm) 8• This could result in a non-anatomically correct order (or scrambling) of 
the image slices during pullback'- However, at end-diastole the ultrasound cath-
eter always returns to the same longitudinal location inside the coronary artery. 
ECG-gated image acquisition makes use of this periodic phenomenon. 
ECG-gated IVUS image acquisition10•11 or co-registration of the ECG and 
IVUS images to select near end-diastolic beats (Volcano method developed for 
VH-IVUS) can resolve motion-induced artefacts allowing analyses using so-called 
longitudinal views without the typical saw-tooth shaped vessel appearance that 
makes contour detection difficult or even impossible10·n. However, ECG-gated 
image acquisition never gained munch enthusiasm since a dedicated workstation 
and pullback device were necessary occupying valuable cath lab space and severely 
prolonging the IVUS examination possibly causing discomfort for the patient. 
Funhermore, there is a lack of convincing data to suggest that ECG gating results 
in more accurate assessment of atheroma burden. 
To overcome this problem an image-based, retrospective computer algorithm 
called the lntelligate" method' has been developed; it is capable of fully automatic 
selection of near end-diastolic frames from a non-gated continuous speed pull-
back IVUS. The algorithm has been validated against the hardware ECG-gated 
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IVUS image acquisition method and takes on average 20 minutes to complete a 
single processing'. This approach eliminates scrambled frames caused by catheter 
motion. saw-tooth shaped appearance of the vessel wall when longitudinally 
reconstructed, etc. The method has been and is applied successfully in several 
studies12- 15 •9• While there is little difference in mean values, contour detection is 
easier in the longitudinal view, and standard deviation of the measurements is 
improved_ However, there is no data that these improvements influence the final 
outcomes of large-scale studies; and most large-scale studies have not used this 
approach. 
Safety oftheiVUS Procedure. Hausman et al16 reported 2207 patients from 
28 centers (including 915 patients studied for diagnostic purposes)Y There were 
no complications in 2034 patients (92.2%). In 87 patients (3.9%), complications 
were judged to be unrelated to IVUS imaging. In 63 patients (2.9%) transient 
spasm occurred during imaging. In 9 patients (0.4%) complications were judged 
to have a "certain" relationship to IVUS (five acute occlusions, rvvo dissections, 
one embolism, and one dissection). In 14 patients (0.6%) complications were 
judged to have an "uncertain" relationship to IVUS (five acute occlusions, three 
dissections, and one arrhythmia). Major events (acute myocardial infarction 
or emergency bypass surgery) occurred in three of nine and five of 14 of these 
patients, respectively. The complication rate was higher in patients with unstable 
angina or acute myocardial infarction and in patients undergoing intervention (as 
apposed to just diagnostic imaging). 
Batkoff et alY reported 718 IVUS "examinations" performed at 12 centers. 
There were eight events ( 1.1 o/o), but no adverse clinical consequences; all occurred 
in patients with unstable angina undergoing percutaneous intervention_ There 
were four cases of transient vessel spasm, two cases of dissection, and two cases 
of wire entrapment. Gorge reported 7085 IVUS studies from 51 centers. 19 Spasm 
occurred in 3% of all studies. Major complications (dissection, thrombosis, ven-
tricular fibrillation, and refractory spasm) occurred in 10 (0.14%). There was only 
one major event. 
The long-term safety of IVUS has been reported by Ramassubu et al20 who 
studied transplant recipients imaged one or more times with IVUS and followed 
by coronary angiography at least one year after the last IVUS exam. Overall, 
548 coronary arteries in 226 patients were imaged by IVUS and compared to 
130 arteries that were not imaged by IVUS. Subsequent angiographic stenoses 
were observed in 19.5% (107/548) of imaged arteries vs 16.2% (211130) of non-
imaged arteries (p=0.4). The arterial diameters of non-imaged and imaged arteries 
were not significantly different (p=0.07) regardless of the number of IVUS exams 
and duration of follow-up. In a subgroup analysis of 31 patients, angiographic 
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lumen diameters were measured at baseline (within 8 weeks of transplantation) 
and at follow-up (after 2, 3, or 4 IVUS exams). There was a significant decrease in 
vessel lumen diameter over time in non-imaged as well as imaged arteries with no 
difference in the magnitude of the diameter decrease between the rwo groups 
Guedes et al. 21 used quantitative coronary angiographic analysis to compare 
IVUS-imaged and non-IVUS-imaged arteries in 525 patients at baseline and at 
18 to 24 months. The coronary change score (per-patient mean of minimum 
lumen diameter changes for all lesions measured) was -0.06 ± 0.23mm versus 
-0.05 ± 0.21 mm for IVUS-imaged and non-IVUS-imaged arteries, respectively 
(p=0.35). The increase in percent diameter stenosis from baseline to follow-up 
was 0.8 ± 6.7% and 1.2 ± 7.0% in tbe IVUS-imaged and non-IVUS-imaged 
arteries (p=0.29). New lesions occurred in 3.6% and 3.9% ofiVUS-imaged and 
non-IVUS-imaged arteries, respectively (p=0.84). When all coronary lesions were 
considered, the incidence of lesion progression was not significantly different be-
tween IVUS-imaged (1 1.6%) and non-IVUS-imaged (9.8%) arteries. Coronary 
spasm occurred in 1.9% of IVUS procedures, and there was one case of acute 
occlusion with no long-term sequelae. 
Thus, IVUS has been performed safely in a large number of subjects enrolled 
in research studies with no apparent increase in incidence of adverse effects. There 
is no evidence from studies that have employed serial imaging within the coro-
nary arteries that this approach has any influence in terms of accelerating disease 
progression. 
STORAGE AND TRANSFER OF IMAGES 
Storage of the full dataset is important, and back-up digital storage is advisable 
to ensure longevity of the information. Analogue videotape - the medium of the 
past - was standardized, bur is likely to be unavailable for use witb more modern 
imaging systems. Accordingly, every effort has been made to store data in a digital 
manner. The lack of full standardization of both CD-ROM and DICOM provide 
challenges for digital storage of images. 
Unfortunately, audio recording has become problematic with the advent of tbe 
CD-ROM. While DICOM allows for audio overlay that is already implemented 
in some of today's consoles, tbe IVUS community has been advised not to enable 
this feature because a DICOM file that includes audio overlay cannot be 'read' 
by all equipment and software analysis packages - especially, equipment and 
software used clinically. However, core laboratory view stations should be able to 
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read audio overlay. Audio archiving is currently supported in the BostonScientific 
DICOM- Basic Voice Audio Waveform Storage. 
It is also possible to install a DICOM reader on the individual CD-ROM 
disks as done by angiographic companies. The rvus manufacturers should be 
encouraged to implement this approach as long as the core laboratories are also 
able to override this feature as necessary. 
The full pullback should be stored on the digital medium. It is up to the corelab, 
not the clinical sites to select the segment of interest. Improvements in electronic 
transfer of digital information will allow for immediate submission of imaging 
directly from the site to the core laboratory. This already occurs in research studies 
that have employed other imaging modalities. While the file size of data to be 
transferred is substantial, there are likely to be ongoing developments in terms of 
uploading, transfer, and storing of digital data which will result in a more efficient 
transmission of images to the core laboratory. 
IMAGE ANALYSIS 
Paired analysis is highly recommended, preferably during the same session by the 
same analyst who is blinded to treatment assignment and where baseline vs follow-
up imaging have been de-identified. If the follow-up recording is not analyzable, it 
is recommendable that the baseline recording still be analyzed so that the patients 
are included in baseline population and demographics. 
Common language and dtifinitions. We recommend the nomenclature pro-
posed by the American College of Cardiology Clinical Expert Consensus Docu-
ment on Standards for Acquisition, Measurement and Reporting of Intravascular 
Ultrasound Studies (!VUS). 22 A report of the American College of Cardiology 
Task Force on Clinical Expert Consensus Documents: (1) external elastic mem-
brane (EEM), (2) lumen, (3) atheroma (or plaque&media) calculated as EEM 
minus lumen, and (4) % atheroma area (or plaque area) or atheroma burden 
(or plaque burden calculated as plaque&media divided by EEM). Atheroma (or 
plaque&media) thickness is also reported variably in some regression/progression 
studies. 
Corelab personnel qualifications. The corelab manager is responsible for 
training new employees and assessing his/her qualifications and competencies for 
corelab functions. After some tutorial sessions on the use of analysis software 
and understanding the anatomy and basic principles of the atherosclerosis disease 
process, new personnel can begin to analyze IVUS studies under supervision of a 
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senior analyst until the new analyst is considered to be able to perform indepen-
dently. 
Each corelab should maintain a library ofiVUS recordings that can be used to 
assess the performance of qualified personnel including reproducibility and inter 
and intraobserver variability. These known IVUS recordings should be given to 
the new analyst. The total, mean, and standard deviations of the vessel and lu-
men areas should be used for comparison. In addition, frame-level measurements 
that are >2 times the standard deviation for the entire reference group should be 
discussed. 
Corelab personnel peiformance and continuing education. To maintain the 
qualification of personnel, it is necessary to have systematic ongoing training. It 
is advisable that each corelab analyst measure known IVUS recordings twice each 
year. The region of interest should be the same for all analysts. Similarly, the total 
mean and standard deviations of the vessel and lumen areas should be used for 
comparison between qualified analysts. In some labs, the results of such quality 
control processes are provided for sponsors during the course of the study. Finally, 
it is recommended that there be monthly conferences in which interesting and 
difficult cases are discussed. 
Detection of Disease Borders. Cross-sectional measurements are fundamental 
to quantitative IVUS analysis. There are many computed-assisted methods that 
help with cross-sectional contour detection of the lumen and EEM. Software 
should be carefully assessed by each core laboratory before implementation. 
Given that each image needs to be reviewed by an analyst to confirm that the 
correct leading edges have been detected, it remains to be determined whether 
current automatic sofrvvare packages provide any benefit compared with manual 
planimetry by a trained analyst. 
Longitudinal image reconstruction and analysis can be incorporated into both 
semiautomatic, and user-defined contour detection can be used interactively with 
cross-sectional contour detection; however, every cross-section should still be 
checked. Antegrade-retrograde, side-to-side, and systolic-diastolic catheter motion 
(greater in the RCA and LCX than in the LAD) causes a saw-tooth appearance to 
the longitudinal images. Longitudinal contours can be drawn at the peak, middle, 
or valley "of the "saw-tooth'' and are analyst dependent; therefore, a standard-
ized protocol is necessary. It is suggested that longitudinal contour detection be 
performed after gating in order to get a smooth appearance of the boundaries. 
Selection of Anatomical landmarks and Segment for Analysis. The same 
proximal and distal fiduciary points must be used to identifY the analysis seg-
ment on baseline and follow-up studies such as clearly identifiable proximal and 
distal sidebranches at baseline and follow-up using the proximal part of the distal 
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sidebranch and rhe distal part of the proximal sidebranch. The priority for rhe 
fiduciaty point when imaging rhe RCA should be the aorta-ostial junction, chen 
the conus branch or a proximal atrial branch, and finally a distal side branch. For 
the left coronary system, rhe carina is the most recommended fiduciary point. 
However, every attempt should be made to continue to image while withdrawing 
the catheter into the aorta to permit imaging within the left main arterial segment. 
The analysis segment should be chosen using rhe two fiduciaty points that have 
rhe most similar lengths between the baseline and follow-up studies. 
Analysis segmen£ selection. Atherosclerosis is a diffuse disease. It is recom-
mended to analyze very long proximal segments compared to shorter distal seg-
ments because atherosclerosis is more proximally distributed and events occur 
in more proximal segments. Bifurcation segments are interesting for analysis. 
However, analyzing bifurcations produces its own challenges. Since sidebranch-
containing cross-sections do not display the artery as a "circle," some rules are 
necessaty for defining the contours of the EEM and lumen. (I) The EEM contour 
should be interpolated to follow rhe main vessel cross-sections just proximal 
and distal to the sidebranch. (2) The lumen contour should be drawn on top of 
rhe EEM contour at rhe mouth of the sidebranch. (3) Rules foe excluding the 
sidebranch-containing cross-sections should follow the rules for excluding cross-
sections containing calcium (see below). 
Imaging Artifacts. NURD is unique to mechanical catheter systems and re-
sults from mechanical binding of the drive cable rhar rotates the transducer'. Any 
cross-sections wirh a recognizable NURD that precludes accurate definition of the 
leading edge of rhe outer vessel wall border should be eliminated following rhe 
same rules as for calcium. The core laboratory must be also sensitive to any other 
artifacts such as side lobes. In rhe training ser of IVUS pullbacks, these artifacts 
should be included. Presence of EEM out of view, loss of image due to bubbles, 
or any orher artefact rhat prevents complete analysis of a single frame should be 
treated as calcium. 
Calcium. Calcium is a strong reflector of ultrasound, shadows deeper arterial 
structures including rhe EEM contour, and hampers visualization and analysis of 
rhe vessel wall. Ar rhe present time we do not know the relationship between IVUS 
calcium detection and NUS detectable progression and regression. The amount 
of calcium in an artery is influenced by the presence of a stenosis, the amount of 
plaque burden, and vessel size. On one hand, excluding calcified segments can 
make studies less applicable to a general patient population; on rhe orher hand, 
excluding calcified segments can provide results with more specific information. 
However, from a practical standpoint, patients studied in progression/ regression 
studies do not have severe stenoses and calcification; rherefore, (from experience) 
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while only approximately 2% of patients are voided because of calcium, this tends 
to be one of the leading reasons for exclusion of patients from studies. 
Therefore, we do not know whether calcium segments should or should not 
be included in the analysis. However, from a practical standpoint and in order to 
calculate changes in the plaque volume we are forced to deal with this confound-
ing factor. The issues are as follows. (I) How much calcium precludes accurate 
assessment ofEEM contours? (2) Which technique should be used to extrapolate 
contours behind calcium in either cross-sectional or longitudinal views? (3) When 
should individual cross-sections be excluded, and when should entire patients be 
excluded because of the extension of the calcium? 
Using the longitudinal approach, extrapolation is allowed if there is EEM 
shadowing <45' (cross-sectional analysis) or if there is EEM shadowing of 45-90', 
but <5mm in length. Using cross-sectional analysis, a single deposit with an arc 
of calcium >45' or multiple small arcs that add up to >180' voids an individual 
cross-section, but the length of calcium is not a consideration. When eliminating 
cross-sections, the same cross-sections should be eliminated at baseline and at 
follow-up. If after eliminating cross-sections, the "residual" length is less then 
I Omm, the entire case should be eliminated. It is advisable to document the num-
ber of frames and o/o of length eliminated due to the presence of calcium. 
STATISTICAL APPROACHES 
Selection of progression/regression endpoints. A number of endpoints are pos-
sible: (I) nominal change in Percent Atheroma Volume from baseline to follow-up, 
(2) nominal change in Total (absolute) Atheroma Volume from baseline to follow-
up, and (3) percent change in Total (absolute) Atheroma Volume from baseline 
to follow-up. These endpoints can be reported for the tool analysis segment and/ 
or for the most-diseased segment. It is recommended to report all three endpoints 
so that the totality of the data can be used to understand the results, but there is a 
preference to use the absolute change in Percent Atheroma Volume (from baseline 
to follow-up) as the primary endpoint, largely due to the smaller variability of this 
endpoint for analysis. Conversely, even though the most-diseased I Omm subseg-
ments contain the largest mean plaque burden, we do not recommend this as a 
primary endpoint because (I) the most-diseased subsegment lacks independent 
proximal and distal fiduciary points, (2) the minimum lumen area, the maximum 
plaque burden, and the most-diseased segment can shifr during follow-up, (3) 
the length of the worst segment at follow-up can vary considerably due to the 
heterogeneity of the pullback speed, and ( 4) the variability of measurements in-
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creases when the segment length is short. However, if analyzed, the most-diseased 
subsegment should contain at least one fiduciary point that is independent of 
lumen dimensions or plaque burden. 
Selection of remodeling endpoints. Remodeling is conventionally assessed 
by comparing lesion site EEM to reference segment EEM. However, for serial 
studies involving volumetric characterization within an arterial segment, such a 
static definition is not recommended. Instead, remodeling should be assessed as 
EEM at follow-up minus EEM at baseline where an increase in EEM is positive 
remodeling, no change in EEM is absence of remodeling, and a decrease in EEM 
is negative remodeling. Furthermore, vessel segments with positive remodeling 
should be subdivided as expansive (overcompensatory) where L'.EEM/ L'.atheroma 
>1 or incomplete where L'.EEM/L'.atheroma is between 0 and 1.0. 
Normalization for length. Normalization for segment length is very important 
for assessing total atheroma volume, but is less important for assessing percent 
atheroma volume (plaque burden). A common way of normalization is to multiply 
the mean atheroma area by the median or mean length for all patients completing 
the trial or by use of a fixed adjustment factor. This adjusts for differing segment 
lengths across patients, thereby providing equal weighting of each patient in the 
calculation of atheroma volume. 
EMERGING DEVELOPMENTS 
With improved pharmacology it is anticipated that quantitative changes in 
atheroma burden will become less and less. Therefore, it is also anticipated that 
qualitative changes in plaque morphology or lesion phenotype will become more 
important. Examples of technologies that have been developed to assess plaque 
composition include virtual histology (VH)-IVUS and integrated backscatter 
(IB)-IVUS. Finally, it is possible that in the future IVUS will be integrated with 
other modalities such as optical coherence tomography or spectroscopy that could 
also provide qualitative data. 
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APPENDIX A. CORELAB FEEDBACK LETTER 
To: 
Clinic 
From 
Subject : 
Dare 
Dear .... , 
We received your IVUS recording for ...... trial. 
Please find below our summary findings: 
0 IVUS pullbacks are of good quality 
The recordings are in agreement with the protocol requirements and acquisition 
guidelines. 
0 IVUS pullbacks needs some improvement. You are kindly requested to forward 
a new restrun/pullback. 
0 IVUS pullbacks are non analyzable 
The recordings are not in agreement with the protocol requirements and acquisi-
tion guidelines. 
For further details see next page. 
Yours sincerely, 
Corelab Director 
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Please tick when applicable: 
• All images were obtained using a motorized pullback system. 
• Pullback speed of 0. 5 m m/ sec 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Gain- and zoom-settings were carefully optimized before the pullback 
is started. 
The rvus procedure was preceded by the administration of 0.2 mg 
IC nitroglycerin (NTG) (check angiography views containing plates 
indicating NTG injection). 
Pullback started at least I em distal from the distal target segment and 
was performed up to lcm proximal of the proximal target segment. 
An angiographic film with AND without contrast injection must be 
performed to indicate the IVUS catheter position before pullback. 
If IVUS studies recorded on videotape, an audio commentary is re-
corded in the tape clearly describing the ongoing IVUS examination 
in English. The investigator should audio record the following: Posi-
tion of probe, i.e. coronary segment (LAD, LCX, or RCA); Pull-back 
speed; Start time of pull-back (time visible at IVUS screen); End of 
pullback time. 
The local time, displayed on the video screen should be filled our in 
the Technician's WorkSheet (not the video recorder time). 
If tape acquisition, the calibration grid was recorded . 
The pullback was continued until the transducer is in the guiding 
catheter. 
Is the EEM out of view in more than I /3 of the pullback 
Is the EEM out of view in more than 2/3 of the pullback 
The pullback is non continuous in more than 1/3 of the length of the 
pullback 
The pullback is non continuous in more than 2/3 of the length of the 
pullback 
Is the pullback too dark? 
Is the pullback too bright? 
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ABSTRACT 
Context: Rosiglitazone has several properties which may reduce the progression 
of atherosclerosis. 
Objective: To determine the effect of the thiazolidinedione rosiglitazone on 
coronary atherosclerosis as assessed by intravascular ultrasound compared to the 
sulfonylurea glipizide. 
Design: The APPROACH study was a randomized double-blind controlled study 
of rosiglitazone versus glipizide at a dose blindly titrated to achieve an A1 C ~ 7%. 
It was conducted between 2005 and 2008; mean follow-up was 16 months. 
Setting: 92 ambulatory sites located in academic and community settings in 19 
countries. 
Patients: 672 patients aged 30-80 years with established type 2 diabetes rreated 
by lifestyle, 1 oral agent or submaximal doses of 2 oral agents who had at least 
one atherosclerotic plaque with 10-50o/o luminal narrowing in a non-intervened 
coronary artery during a clinically indicated coronary angiography or percutane-
ous coronary intervention. 
Intervention: Up to 15 mg of glipizide and 8 mg of rosiglitazone was provided 
to participants. 
Main Outcome Measure: Change in percent atheroma volume (PAY) in the 
longest and least angulated non-intervened epicardial coronary artery. Secondary 
outcomes were the change in normalized total atheroma volume (TAV ,) and the 
change in total atheroma volume in the most diseased baseline 1 0-mm segment. 
Results: PAV did not significantly change in patients allocated to glipizide (0.43%, 
95% CI -0.22, 1.08; p=0.19) or rosiglitazone (-0.21 o/o, 95% CI -0.86, 0.44; 
p=0.53), and rosiglitazone did not significantly reduce PAV compared to glipizide 
(-0.64%, 95% CI -1.46, 0.17; p=0.12). TAVN did not significantly change on 
glipizide (1.2 mm3 , 95% CI -2.7, 5.1; p=0.54), but significantly decreased by 3.9 
mm3 (95% CI -7.8, -0.02; p=0.049) on rosiglitazone and rosiglitazone significantly 
reduced TAV,., by 5.1 mm3 (95% CI -10.0, -0.3; p=0.04) compared to glipizide. 
Atheroma volume within the 10 mm most diseased baseline segment decreased by 
3.6 mm3 (95% CI -5.3, -1.8; p<0.0001) on glipizide and by 5.3 mm3 (95% CI 
-7.0, -3.5; p<0.0001) on rosiglitazone; however rosiglitazone did not significantly 
reduce atheroma volume within the 10 mm most diseased baseline segment more 
than glipizide (-1.7 mm3, 95% CI -3.9, 0.5; p=0.13). 
Conclusions: Rosiglitazone did not significantly reduce progression of coronary 
atherosclerosis compared to glipizide in patients with type 2 diabetes and coronary 
atherosclerosis. 
Trial Registration: Clinicaltrials.gov NCTOO 116831 
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INTRODUCTION 
Type 2 diabetes (T2DM) is a strong independent risk factor for cardiovascular 
diseases' and epidemiologic studies have shown that this risk is progressively 
related to the degree of hyperglycemia as measured by the Al C 2• Whereas recent 
trials of more versus less intensive glucose-lowering with a menu of drugs did 
not detect a clear cardiovascular benefir'A the obst :vation of reduced myocardial 
infarction and all-cause mortality in metformin-treated obese subjects during 
active therapy in the United Kingdom Prospective Diabetes Study', and in all 
participants following a further 8.5 years of passive follow-up 6 suggests that spe-
cific glucose-lowering drugs may have cardiovascular benefits. Prior to completing 
long-term cardiovascular outcome studies, such an effect would be supported if 
these drugs reduced coronary atherosclerosis. 
Coronary atherosclerosis forms the substrate for vulnerable plaque which leads 
to clinical coronary events. Coronary atherosclerosis can be directly assessed us-
ing intravascular ultrasonography (IVUS), and progression of IVUS-determined 
atherosclerosis has been correlated with an increased risk of coronary events /·,s. 
Furthermore, reductions in IVUS-detected plaque volume have been demon-
strated in response to antihypertensive' and lipid-lowering therapies10· 13 that also 
reduce the incidence of coronary events. 
Thiazolidinediones (TZDs) have effects on cardiovascular risk factors, includ-
ing insulin sensitivity, 14;15 inflammatory biomarkers, 16 endothelial function, 17 
coagulabiliry, 16' 18' 19 plaque instabiliry, 16 and blood pressure," that may slow the 
progression of coronary atherosclerosis. Active-controlled trials of both thiazo-
lidinediones (rosiglitazone and pioglitazone) in patients with T2DM have sug-
gested a favorable effect of these agents on carotid atherosclerosis" and in-stem 
restenosis22, however, the applicability of these data to native vessel coronary 
disease is uncertain. Moreover, a recent large randomized trial of one TZD (pio-
glitazone) demonstrated that it reduced progression of coronary atherosclerosis in 
non-intervened arteries more than glimepiride23 . To date, comparable data using 
rosiglitazone have not been available. 
The Assessment on the Prevention of Progression by Rosiglitazone on Athero-
sclerosis in diabetes patients with Cardiovascular History (APPROACH) trial was 
designed to compare the effect of rosiglitazone and glipizide - agents that reduce 
glucose through different mechanisms - on progression of coronary atherosclero-
sis. Importantly, the trial was designed to provide comparable glycemic control 
between treatment arms and to evaluate the treatment effect on a background of 
optimized contemporary therapy for secondary prevention of coronary disease 
including statins, anti-platelet agents, and antihypertensive medications. 
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METHODS 
Study Design & Eligibility Criteria 
A detailed description of the APPROACH trial has been previously published24 
APPROACH was a prospective multicenter, double-blind, randomized, active-
controlled trial (Figure 1) of 672 patients from 92 centers in 19 countries, who 
were aged 30-80 years with established T2DM and who had clinically indicated 
coronary angiography or percutaneous coronary intervention (PCI) between 
February 2005 and January 2007. Patients were included if they had at least 
one atherosclerotic plaque with 10-50o/o luminal narrowing in a non-intervened 
coronary artery, and if their diabetes was treated with either lifestyle approaches 
alone (with an A1C >7% and,; 10%), or with oral agents comprising 1 oral 
agent at any dose, or 2 oral agents where each was prescribed at ::;50o/o of its 
I 1147 Screened 
475 Excluded 
n=376 Did not meet eligiblity criteria 
n=40 Withdrew consent 
n= 6 Adverse events 
n= 1 Protocol violation 
n=52 Other or information not available 
I 672 Randomized 
I 339 Glipizide I 1 333 Rosiglitazone I 
n=2 Did not receive blinded medication n=2 Did not receive blinded medication 
n= 6 Died before follow-up IVUS n=7 Died before follow-up IVUS 
n~ Baseline or follow-up IVUS unanalyzable n~ Baseline or follow-up !VUS unanalyzable 
n=31 Wrthd rew consent ~ H 
n=30 Wrthd rew consent 
"'8 Withdrew due to adverse event n=S Wrthdrew due to adverse event 
"'1 Protocol violation n= 6 Protocol violation 
n=10 Lostto follow-up n= 6 Lost to follow-up 
n= 3 Other n= 1 Other 
229 Evaluable baseline 223 Evaluable baseline 
I 
and follow-up IVUS and follow-up IVUS 
317 Final v~al status 316 Final vital status 
Figure I. Disposition of APPROACH participants 
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maximal dose (with an A!C >6.5% and,; 8.5%). Exclusion criteria were: ST-
segment elevation myocardial infarction in the prior 30 days; coronary artery 
bypass graft surgery; severe valvular heart disease; left ventricular ejection fraction 
<40%; any heart failure (New York Heart Association class I-IV); uncontrolled 
hypertension (systolic blood pressure > 170 mmHg or diastolic blood pressure 
>100 mmHg); renal insufficiency (serum creatinine <:1.5 mg/dL for men or <:1.4 
mg/dL for women); and active liver disease. Participant safety was monitored by 
an Independent Data Monitoring Committee who periodically reviewed rates of 
clinical outcomes according to unmasked therapy. The study protocol and consent 
forms were reviewed by the institutional review board at each site and all patients 
provided written informed consent. Study design, implementation, and analysis 
were performed under the supervision of the steering committee, which was 
composed of seven members from external, academic institutions and two from 
the sponsor. Data analysis was performed according to a prespecified plan that was 
developed with the approval of the steering committee. 
Management of Glycemia and Follow-up 
Patients were randomized in a 1: 1 ratio to receive masked rosiglitazone ( 4 mg/ 
day) or glipizide (5 mg/day) in one pill. At the time of randomization the doses of 
other oral antidiabetic drugs were reduced by 50% and were discontinued during 
a visit I month later. At that time and after 2 and 3 months, the dose of masked 
study drug was increased if tolerated and if the mean daily glucose level calculated 
from the patient's logbook of capillaty tests in the 3 days prior to the visit was <: 
126 mg/dl (7.0 mmol/1). If more than 1 titration was required, 2 pills per day were 
given. Titration doses of rosiglitazone at the 1 sr, znd and 3r<1 titration comprised 4 
mg/day (1 pill- unchanged dose), 8 mg/day (as 2 pills with active drug in the 
morning and placebo in the evening), and 4 mg bid respectively; glipizide dosing 
at these visits comprised 10 mg/day (1 pill), 10 mg in the morning and 5 mg in the 
evening (as 2 pills) and this same dose as the 3'd titration respectively. Open-label 
metformin (maximal total daily dose 2550 mg) and then once-daily basal insulin, 
or both was added after the first 3 months if needed to maintain a HbA1c ,; 7% 
using a glycemic titration algorithm designed to provide comparable glycemic 
control between treatment groups. Nonstudy drugs were reduced before study 
drugs in the event of hypoglycemia requiring dose reductions. Unless informed 
consent was formally withdrawn, all patients were followed until 18 months from 
randomization and clinical status ascertained regardless of whether they continued 
to take study medication. 
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Intravascular Ultrasound Examination and Image Analysis 
The longest and least angulated non-intervened epicardial coronary artery was se-
lected for IVUS examination. After intracoronary administration of nitroglycerin, 
an ultrasound catheter (2.5F Atlantis SR Pro Imaging 40 MHz) connected to a 
Gala>.-y G2 digital imaging console (Boston Scientific, Natick, MA) was advanced 
into the target vessel. The imaging transducer was positioned just distal to an iden-
tifiable side branch, and then motorized pullback of the transducer was performed 
at 0.5 mm/s. Follow-up IVUS examination was performed at study completion in 
all patients providing informed consent (irrespective of whether they continued to 
take study medication) with imaging of the same coronary artery segment identi-
fied at the baseline examination. If a participant required cardiac catheterization 
for a clinical indication between 9 and 18 months, follow-up IVUS examination 
could be performed at that time instead of at study completion. 
Intravascular Ultrasound Outcomes 
Core laboratory personnel (Cardialysis, Rotterdam, The Netherlands) who were 
blinded to treatment assignment analyzed all IVUS images using validated software 
(Curad, version 3.1, Wijk bij Duurstede, The Netherlands), that facilitates detec-
tion ofluminal and external elastic membrane (EEM) boundaries in reconstructed 
longitudinal planes. In order to obtain a smooth appearance of the vessel wall 
structures in the longitudinal views, the Intelligate'"M image-based gating method 
was applied 25'26 • The primary IVUS outcome is the change in percent atheroma 
volume (PAV) 9'27 calculated as PAV = (L[EEMCSA- LUMENcsJ I LEEMcsA) x 
100 where EEMcsA is the external elastic membrane cross-sectional area ( CSA) and 
LUMEN CSA is the luminal cross-sectional area. A secondary IVUS outcome is the 
change in normalized total atheroma volume (TAVN), calculated as the product of 
the mean atheroma area and the median segment lengrh in the entire population as 
follows: TAVN = (L[EEMcsA- LUMENcsJiN) x overall median segment length. 
This calculation adjusts for differing segment lengths across patients, thereby 
providing equal weighting of each patient in the calculation of atheroma volume. 
An additional secondary IVUS outcome is the change in total atheroma volume in 
the most diseased baseline 1 0-mm segment. This was calculated as the follow-up 
-baseline difference in the total atheroma volume within the 1 0-mm contiguous 
segment with the greatest atheroma volume at baseline. Intraobserver variability 
was assessed using IVUS recordings from 20 randomly selected patients. Baseline 
and follow-up IVUS examinations were each analyzed twice. The mean (SD) dif-
ferences were 0.09 (0.18) mm2 for vessel area, and -0.02 (0.23) mm2 for lumen 
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area. To evaluate variability between IVUS analysis methods, the same patients 
were analyzed twice longitudinally and twice cross-sectionallyl0 The mean (SD) 
differences (in mm2) were 0.10 (0.36) mm2 for vessel area and 0.001 (0.46) mm2 
for lumen area. Finally, to assess variability between core laboratories, the same 
patients were analyzed twice cross-sectionally at different core laboratories (Car-
dialysis, Rotterdam, The Netherlands and MedStar Research Institute, Division 
of Cardiology, Washington, DC). The mean (SD) differences (in mm2) were 0.53 
(0.37) mm2 for vessel area and -0.07 (0.45) mm2 for lumen area. 
Clinical Cardiovascular Outcomes 
Investigators submitted endpoint forms for any event which could potentially 
represent a myocardial ischemic event or heart failure. An independent endpoint 
committee blinded to treatment assignment prospectively adjudicated these car-
diovascular events, which included cardiovascular and noncardiovascular death, 
nonfatal myocardial infarction and stroke, coronary revascularization, hospitaliza-
tion for recurrent myocardial ischemia and heart failure. 
Statistical Methods 
Continuous variables are expressed as mean and standard deviation, or median 
and interquartile range if non-normally distributed, with categorical variables 
reported as percentage. IVUS outcomes were analyzed using analysis of covariance 
with terms for treatment group, baseline value, geographic region, gender, entry 
cardiac procedure (angiography or PC!), and prior oral antidiabetic medication. 
The change in PAV for each allocated group was calculated by estimating the 
model-adjusted mean change in PAV across the cohort. All p values are 2-sided 
and not adjusted for multiple testing, with p-values :5 0.05 considered significant. 
A worst-rank sensitivity analysis was performed as previously described to assess 
the potential influence on the primary endpoint of randomized patients who did 
not complete the follow-up IVUS examination due to a cardiovascular event'8• For 
this analysis, all patients with evaluable baseline and follow-up !VUS examinations 
were assigned a rank value based on their change in PAV (ordered from least to 
greatest). Patients without a follow-up IVUS as noted above were assigned a rank 
value that was worse than that of the patient with the greatest increase in PA V: The 
rank value for these patients was first assigned based on a pre-specified hierarchy 
determined by the Steering Committee accounting for both clinical severity and 
relationship of the event to coronary atherosclerosis as follows (lowest to highest 
rank): congestive heart failure, hospitalization for recurrent myocardial ischemia, 
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coronary revascularization, noncardiovascular death, nonfatal stroke, nonfatal 
myocardial infarction, and cardiovascular death. Within each event category, the 
final rank was determined by the time to event, with earlier events assigned a worse 
(higher) rank. The worst-rank analysis compared the distribution of rank values 
between treatment groups using a univariate Wilcoxon-Mann-Whitney test. 
Analysis of the primary IVUS outcome in pre-specified subgroups including 
region, angiography versus PCI, prior oral agent use (drug naive, sulfonylurea, 
metformin, dual therapy), age (:; 60 versus >60), gender, systolic blood pressure 
(:; 130 mm Hg versus > 130), statin use, body mass index, diabetes duration, 
and baseline high sensitiviry C-reactive protein (hsCRP), A1 C, HDL, LDL, tri-
glycerides and PAV (:; the median versus > the median value) was performed 
using ANCOVA with a test for treatment-by-subgroup interaction. The effect 
of treatment allocation on time to first occurrence of the various cardiovascular 
outcomes was estimated using a Cox proportional hazard model. 
Sample size calculations determined that 206 patients per group with evaluable 
baseline and follow-up IVUS examinations were required to provide 90% power 
using a 2-sided a of 0.05 to detect a treatment difference between the groups 
of 1.6%, assuming a 5.0% standard deviation for the primary IVUS outcome. 
These assumptions were based on prior IVUS studies of lipid-lowering therapies 
in patients with diabetes10 • Given prior noncompletion rates among patients with 
T2DM in contemporary IVUS studies ranging from 25-35% 9' 10'23'27 a total sample 
size of 634 randomized patients was required under the worst-case assumption of 
a 35% noncompletion rate. All analyses were performed using SAS version 9.1 
(SAS Institute, Cary, NC). Finally, to ensure the accuracy of the analyses, data 
for the primary and secondary endpoints were provided to an external biostatisti-
cian (Dr. Todd A. MacKenzie, Dartmouth Medical School) who independently 
repeated and confirmed all of the findings reported herein. 
RESULTS 
Participants 
Of 1147 people who were screened, 672 (68% men) of mean (SD) age 61 (9) 
years median diabetes duration of 4.8 years and mean A1 C of 7.2 (0.9) o/o were 
randomized to either glipizide CN=339) or rosiglitazone (N=333) from 92 sites in 
19 countries (Figure 1). Baseline characteristics by treatment group are noted in 
Table 1; by chance, patients allocated to rosiglitazone versus glipizide were slightly 
older and had a slightly higher serum creatinine and lower systolic blood pressure. 
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Table 1: Baseline Characteristics of Randomized Patients 
Glipizide Rosiglitazone Pvalue {N=339) {N=333) 
Age, mean (50), years 602(9.0) 61.8 {8.4) 0.03 
Male, number(%) 223 {65.8%) 233 (70.0%) 0.25 
Current smoker, number{%) 57 (16,8%) 55 {16.5%) 1.00 
Duration of diabetes, median [IQRJ, yrs 4,6 [1.7-8.9] 5.0 [2.2-7.9] 0.90 
Hypertension, number{%) 272{802%) 266 (79.9%) 0.92 
DysJipidemia, number(%) 227 (67.0%) 232 [70.0%) 0.46 
Prior myocardial infarction, number(%) 82 (24.2%) 81 {24.3%] 1.00 
Presenting condition, number{%) 
Acute coronary syndrome 130{383%) 128 (38.4%) 1.00 
Elective procedure 209 (61.7%) 205 {61.6%) 
Baseline procedure, number(%) 
Coronary angiography 171 (50.4%) 166{49.8%] 0.94 
Percutaneous coronary intervention 168(49.6%) 167(502%) 
Medication use, number(%) 
Aspirin 279{823%] 280 (84.1%) 0.61 
Other antiplatelet 195{57.5%] 196(58.9%] 0.75 
Beta-blocker 223(65.8%] 241 (72.4%) 0.07 
ACE inhibitor or ARB 238(701%) 237 012%] 0.80 
N'1trates 137 (40.4%) 125 (37.6%) 0.48 
5tatin 262073%] 248{74.5%) 0.42 
Fib rate or other lipid-lowering agent 24(7.1%) 34(10.2%) 0.17 
Weight, mean (50), kg 83.8 (18.5] 82DI19.1] 0.22 
Body mass index, mean (SO), kg/m2 29.8 (5.3] 29.3 (5.5) 0.14 
Blood Pressure, mean (SO), mmHg 
Systolic 131.0 (1 5.1) 127.9(16.1) 0.004 
Diastolic 763 (10.0) 752 (10.2) 0.16 
Serum creatinine, mean (SD), mg/dl 0.98 (022) 1.02 (025) 0.02 
A 1 C, mean (SO),% 72 (0.9) 7.1 (0.8] 0.08 
BNP'\ median [IQR], pg/ml 25 [12-53] 25 [11-58] 0.98 
Fasting insulin*, median [IQR], ~U/ml 13.0 [8.6-18.1] 13.0 [8.6-20.7] 0.49 
LDL cholesterol, mean (SD), mg/dl 912 (35.5) 89.6 (35.9) 0.63 
HDL cholesterol, mean (SO), mg/dl 42.7 (10.7] 42.4 (11.1) 0.77 
Triglycer'1des, median [IQR], mg/dl 1593 [122.1-204.9] 162.0 [122.1-2115] 0.93 
hsCRP, median [IQR], mg/l 5.4 [25-11.0] 4.9 [2.2-11.3] 0.54 
MMP-9, median [IQRJ, j.ig/l 86.9 [43.8-195.1] 88.6 [44.1-221.6] 0.44 
"'Performed in a subset of patients (BNP N=464; Fasting insulin N=435); Abbreviations: ACE, 
angiotensin-converting enzyme; BNP, B-natriuretic peptide; ARB, angiotensin II receptor blocker; 
BMI, body mass index, HbAlc, hemoglobin Ale; HDL. high-density lipoprotein; hsCRP, high-
sensitivity C-reactive protein; IQR, interquartile range; LDL, low-density lipoprotein; MMP-9, 
matri'\': metalloproteinase 9. SI conversion factors: to convert fasting plasma glucose to mmol/L, 
multiply by 0.0555, low-density lipoprotein and high-density lipoprotein cholesterol values to 
mmol/L, by 0.0259; triglyceride values to mmol/L, by 0.0113; serum creatinine to JliilOliL, by 88.4; 
fasting insulin to pmol/L, by 6.945; c-reactive protein to nmol/L by 9.524 
As randomization was stratified by the cardiac procedure, 50% of enrolled patients 
had diagnostic coronary angiography and 50% had a percutaneous coronary inter-
vention. A total of 38% presented with acute coronary syndrome, and 76% were 
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on statins. A total of229/339 patients (67.5%) allocated to glipizide and 233/333 
(70%) allocated to rosiglitazone had an evaluable baseline and follow-up IVUS. 
Compared to participants who did not have 2 evaluable IVUS exams, those who 
did had a slightly lower diastolic blood pressure (P=0.05), were more likely to be 
from South America (P=0.001), were less likely to be on 2 oral antidiabetic agents 
(P=0.004), and were more likely to have had a stem inserted (P=0.006). An assess-
ment of vital status at the 18 month final visit was available in 317 (93.5%) patients 
allocated to glipizide and 316 (94.9%) patients allocated to rosiglitazone. 
Patients were followed for a median of 18.6 months (IQR 18.2-18.9) and a 
mean (SD) of 16 (6) months; Patients allocated to glipizide were adherent (took 
~80% and ,;120% of their study medications) at 90.7% of visits and those al-
located to rosiglitazone were adherent at 92. 7o/o of visits. Adverse effects that were 
either of interest based on prior studies, that occurred in more than 5% of partici-
pants in either group, or that significantly differed in frequency between groups 
are noted in Table 2. Compared to patients in the glipizide group, those allocated 
to rosiglitazone had less hypoglycemia and more anemia. No between-group 
difference was noted in the rate of cardiovascular events (all adjudicated) which 
occurred infrequently during the trial (Table 3); 5 of the cardiovascular events in 
the rosiglitazone group (1 revascularization, 2 nonfatal myocardial infarctions, 1 
nonfatal stroke, and 1 cardiovascular death) occurred within 5 days of the baseline 
cardiac catheterization and were classified as procedure-related. 
Table 2: Major Adverse Events in .All Randomized Patients 
Patients with an Event, N (o/o) Glipizide Rosiglitazone Pvalue (N=339} IN=333} 
Events requiring change or stop in study medication 
Peripheral edema 1 (<1%) 2(<1%) 0,62 
Hypoglycemia 12(4%) 0(0%} 0.0004 
Peripheral edema 24(7%} 29(9%) 0.48 
Severe hypoglycemia {requk'mg external ass'1stance) 3(<1%) 0(0%} 0.25 
Hypoglycemia 96(28%) 27(8%) <0.0001 
Bone Fracture 2(<1%) 6{2%) 0.17 
Hemoglobin decrease> 3 g/dl from baseline 10(3%} 26(8%} 0.006 
Angina pectoris 35{10%) 31(9%} 0.69 
Chest Pain 17(5%} 12(4%} 0.45 
Cough 22(6%) 13(4%} 0,17 
Diarrhea 17(5%} 12(4%} 0.45 
Dizziness 18{5%) 17{5%) 1.00 
Fatigue 14(4%) 18{5%) 0.47 
Headache 23{7%) 15{5%) 0.24 
Hypertension 22(6%} 14(4%) 023 
Adverse events requiring changes in study drug, reported in;::: 5% of patients in either group, 
significantly differed bervveen groups, or were of interest based on other studies are listed. 
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Table 3: Adjudicated Clinical Cardiovascular Outcomes in All Randomized Patients 
Patients with an event, n {%) Glipizide Rosiglitazone Pvalue* 
IN=339) {N=333) 
Composite of all-cause death, nonfatal myocardial infarction, nonfatal stroke, 38 {11.2%) 39 (11.7%) 0.58 
coronary revascularization, or hospitalization for myocardial ischemia 
Composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal 
10{2.9%) 14(4.2%) 0.31 
stroke 
All-cause death 7{2.1%) 8 (2.4%} 0.72 
Cardiovascular death 3{0.9%) 4(1.2%) 0.50 
Myocardial infarction 
Nonfatal 6{1$%) 7~.1%) 0.71 
Fatal 1(03%) 1 (0.3%) 0.89 
Stroke 
Nonfatal 1(0.3%) 5(1.5%) 0.13 
Fatal 0(0%) 0(0%) 
Coronary revascularization 27(8.0%) 26 (7.8%) 0.82 
Hospitalization for myocardial ischemia 7(2.1%) 11(3.3%) 015 
Congestive heart failure 3(0.9%) 8 (2.4%} 0.14 
*All p-values calculated using Cox proportional hazard model using time to first event 
Blood Pressure Weight(kg) 
0 3.5 Diastolic 3.0 
-o.o5 3 2.5 
-Q.10 2.5 2.0 
-Q.15 2 
1.5 
-o.20 1.5 
-o.25 1 1.0 
-o.30 0.5 0.5 
.().3 
-Q.35 0 0 
7 HOL-e (mg/dL) LDL-c (mg/dl) 
6.2 4 2.8 
6 2 
5 0 -4 
4 P< 0.0001 -2 
..g 
3 -4 
2 -6 
·12 
1 -8 
-7.8 
-14.2 
0 -10 
-16 
Figure 2. Effect of rosiglitazone versus glipizide on mean change in Al C, blood pressure, weight, 
HDL, and LDL level and on median change in triglyceride level in patients with 2 evaluable 
intravascular ultrasound measures. P values refer to differences of the change between groups. Gray bars 
depict the change for the rosiglicazone group and black bars depict the change for the glipizide group. 
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Table 4: Post-randomization Values and Medication Use at Final Visit 
Patients with Evaluable IVUS 
Measurement 
Glipizide Rosiglitazone p 
IN=229l IN=2331 
Continuous Variables 
Mean A 1 C {95% Cl)% 6.9 {6.8, 7.0) 7.0 17.0, 7.1 I O.Dl 
Mean Blood Pressure {95% Cl), mmHg 
Systolic 131.1 {129.6, 132.6) 130.7{1293, 132.2) 0.71 
Diastolic 76.7 (75.8, 77.7) 75.4 (74.5, 76.4) 0.03 
Mean LDL (95% Cl), mg/dl 84.9 {80.7, 89. 1) 953(91.0, 99.6) 0.0001 
Mean HDL (95% Cl), mg/dl 455(44.3, 46.7) 48.7(47 5, 49.9) <0.0001 
Median Triglycerides (95% Cl), mg/dl 156.2(150.4, 164.6) 1465(138.9, 1513) 0.14 
Median hsCRP (95% Cl), mg!L 1.9(1.7,2.1) 0.9(0.8, 1.0) <0.0001 
Median MMP·9 (95% Cl), ug/L 56.8(54.2,61.0) 47.9 (44.4,50.8) <0.0001 
Mean weight (95% Cl), kg 83.6(83.1,84.1) 84.0 (835, 845) 0.22 
Final Visit Medication Use 
Aspirin 190 (83.0%) 199 (85.4%) 032 
Other antiplatelet 93 (40.6%) 82(352%) 0.25 
Beta-blocker 152 (66.4%) 158(67.8%) 0.77 
ACE inhibitor or ARB 166(725%) 176 {755%) 0.46 
Nitrates 78(34.1%) 76(32.6%) 0.77 
Statin 179 (78.2%) 190(815%) 0.42 
Fibrate or other lipid-lowering agent 27(11.8%) 35 (15.0%) 0.34 
Metformin 153 (66.8%) 152(652%) 0.77 
Any insulin 21 (9.2%) 14(6.0%) 012 
P values pertain to between-group differences in variables after randomization, and in medication use 
at the final visit. hsCRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; HDL, 
high-density lipoprotein, MMP-9, matrix metalloproteinase 9; ARB, angiotensin II receptOr blocker 
The mean (SD) dose of study drug for patients who had a baseline and follow-
up IVUS was I2.3 (4.3) mg for glipizide and 6.8 (1.8) mg for rosiglitazone. Of 
these patients, 220 (96. I o/o) of allocated to glipizide and 220 (94.4%) allocated to 
rosiglitazone had their follow-up IVUS done I7 or more months afrer the baseline 
IVUS. During the first 3 months of therapy when rosiglitazone or glipizide was 
substituted for other oral agents, HbAI c levels were higher on rosiglitazone. Sub-
sequently AI C levels were the same and the final AI C levels did not differ between 
groups however the fluctuations resulted in the average post-randomization Al C 
value on rosiglitazone being slightly higher on rosiglitazone versus glipizide (7.0% 
versus 6.9% respectively, p=O.OI). Figure 2 illustrates the change from baseline in 
AI C, blood pressure, lipids and weight for each group, and Table 4lists the post-
randomization mean or median values for these and other variables, as well the 
final use of concomitant medications by treatment group. Compared to patients 
on glipizide, those on rosiglitazone had a significantly lower post-randomization 
diastolic blood pressure, high sensitivity C-reactive protein, and matrix metal-
loproteinase 9 and significantly higher post-randomization AI C, LDL cholesterol 
and HDL cholesterol. 
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Effect on lntravoscular Ultrasound Endpoints 
Table 5 notes the effect of allocated therapy on the primary and secondary IVUS 
endpoints. During the course of the study, PAY (the primary outcome) did not 
significantly change from baseline in patients allocated to glipizide (0.43%, 95% 
CI -0.22, 1.08; p=0.19) or in patients allocated to rosiglitazone (-0.21 o/o, 95% CI 
-0.86, 0.44; p=0.53). Moreover, rosiglitazone did not significantly reduce PAY 
compared to glipizide (-0.64%, 95% CI -1.46, 0.17; p=0.12). Similar findings 
were noted: a) when the data were analyzed after adjusting for baseline differ-
ences in age, creatinine and systolic blood pressure (-0.60%, 95% CI -1.43, 0.23; 
p=0.15); and b) when the data were analyzed using a worst rank analysis compris-
ing 243 (72%) glipizide and 247 (74%) rosiglitazone patients, in which the 28 
patients (14 per group) who did not have 2 evaluable IVUS examinations due to a 
cardiovascular event were assigned a rank based on their event as described above 
(P =0 .20). The key secondary endpoint of total atheroma volume normalized for 
median segment length (TAYN) did not significantly change in patients allocated 
to glipizide (1.2 mm'. 95% CI -2.7, 5.1; p=0.54) and significantly decreased by 
3.9 mm3 (95o/o CI -7.8, -0.02; p=0.049) in patients allocated to rosiglitazone. 
Compared to glipizide, rosiglitazone significantly reduced TAYN by 5.1 mm3 
(95% CI -10.0, -0.3; p=0.04). Atheroma volume within the 10 mm most dis-
eased baseline segment was the other key secondary IVUS endpoint and decreased 
from baseline by 3.6 mm3 (95% CI -5.3, -1.8; p<0.0001) in patients allocated to 
Table 5: Intravascular Ultrasound Endpoints 
Mean Value of IVUS 
Glipizide Rosiglitazone Treatment 
Baseline Follow~up Changet Baseline Follow~up Change1 Difference Measurement (50) (95%CI) (95%CI) (95%CI) 
Mean (SDJ percent 
4D.6 (11.0) 41.0(112) 0.43 (·022, 4D.4 (11.8) 40.2 (11.4) ·021 (·0.86, ~0.64(-1.46, 
atheroma volume* 1.08) OM) 0.17)' 
Mean (SD) normalized 
232.8 2332 226.1 221.6 ·3.9 (-7.82, ~5.12 (~9.98, 
total atheroma volume (1152) (1165) 12 1·2.68, 5.08) (100.6) (100.7) -0.02)b ·0.26)' (mm1)~ 
Mean (SD) atheroma 
-3.6(-531, ~5.3 (-7.04, -1.7(~3.93, 
volume in the most 75.6 (32.6) 722(333) 
-1.8Q)d 71.0 (30.0) 66.0 (30J) 
-351)0 0.49) diseased 10 mm 
segment (mm1)1 
SD - Standard Deviation; CI - Confidence Interv::J.; "'Primary IVUS Outcome; !Key NUS 
secondary Outcomes; t change from baseline for each allocated group was estimated using analysis of 
covariance with terms for treatment group, baseline value, geographic region, gender, entry cardiac 
procedure (angiography or PCI), and prior oral antidiabetic medication. "P=0.12; bp=0.049; <P=0.04; 
dP<0.000l;eP=0.02;fP=0.01; *~similar P values were obtained for these outcomes when reanalyzed 
using a non-parametric test on rank-transformed data. 
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Figure 3. Effect of rosiglitazone versus glipizide on the primary outcome of change in percent 
atheroma volume according to predefined subgroups in patients with 2 evaluable intravascular 
ultrasound measures. P values reflect the test for an interaction between the subgroups and allocation 
to rosiglitazone versus glipizide. Median values are: BMI 28.9 kg/m2; Diabetes duration 4.9 years; 
HbA1c 7.1 %; HDL 42.5 mg/dl; LDL 87.0 mg/dl; T;iglyce;ides 165.0 mg/dl; hs CRP 5.2mgll; PAV 
41.3%. 
glipizide and by 5.3 mm3 (95% CI -7.0, -3.5; p<O.OOOI) in patients allocated to 
rosiglitazone; however the effect of rosiglitazone did not significantly differ from 
that of glipizide (-L7 mm', 95% CI -3.9, 0.5; p=0.13). 
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When analyzed according to prespecified subgroups (Figure 3), there was a clear 
interaction between treatment allocation and diabetes duration (P = 0.005) such 
that rosiglitazone reduced the PAV more than glipizide in patients with diabetes 
duration longer than the median duration of 4.9 years (i.e. a l.So/o decrease versus 
a 0.5% increase in those with a shorter diabetes duration). This analysis also sug-
gested a trend favoring a greater effect of rosiglitazone allocation on patients with 
a higher baseline hsCRP and those who had a stent inserted versus angiography 
alone (P = 0.05 and 0.07 respectively). 
DISCUSSION 
In this 1.5 year study of the effect of rosiglitazone versus glipizide on coronary 
atherosclerosis a significant difference in the primary IVUS endpoint of PAV was 
not achieved. The observation that the trend towards reduced PAV volume reached 
significance within the prespecified subgroups of longer diabetes duration suggests 
that rosiglitazone may have an anti-atherosclerotic effect in sicker patients with a 
longer history of exposure to hyperglycemia, but should be viewed as hypothesis 
generating due to the many subgroups tested. These findings, and the observations 
that rosiglitazone significantly reduced the TAV N more than glipizide support 
the hypothesis that rosiglitazone may reduce atherosclerotic plaque progression. 
\X'hether the rosiglitazone-mediated reduction in diastolic blood pressure, triglyc-
erides, hsCRP and MMP-9 and the increase in weight and LDL cholesterol were 
responsible for these findings remains unknown. 
These findings are consistent with those of a similar study in which another 
thiazolidinedione (pioglitazone) was compared to glimepiride23 • In that 18 month 
study PAV significantly increased by 0.73% on glimepiride and nonsignificantly 
decreased by 0.16% on pioglitazone, with a significant difference between groups 
(P=0.002). Pioglitazone also decreased the TAVN by 5.5 mm3 versus a nonsignifi-
cant decrease of 1.5 mm3 on glimepiride with no significant difference between 
groups (P=0.06). Indeed the effects of pioglitazone and rosiglitazone on IVUS 
indices and other metabolic and vascular markers were remarkably similar and 
are listed in Table 6. The absence of a statistically significant effect of rosiglitazone 
in this study may be due to the fact that the PAV in the glipizide control group 
only increased modestly whereas the increase in PAV in the glimepiride controls 
in the pioglitazone study was greater. These observations and reports of similar 
beneficial effects of these 2 drugs on carotid intima-media thickness 21 '29 and need 
for revascularization following percutaneous intervention30, as well as the adverse 
effect profile of these 2 drugs suggest that they have similar effects on atheroscle-
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Table 6o Comparison of APPROACH and PERJSCOPE 
Rosiglitazone (APPROACH} Pioglitazone (PERISCOPE} 
Measurement Baseline Change Baseline Change 
(SOoriQR} (95o/oCI} (SOoriQR} (95o/oCI} 
Mean {SO) percent atheroma volume 40.4 Ill B) -0.21 l-0.86, 0.44) 40.6 18.4) -0.16 (-Q57, 025) 
Mean (SO) normalized total atheroma 226.1 11 00.6) -3.9 1-7.82,-0.02) 207.5 183.8) -5.5 1-8.67,-238) 
volume (mm3) 
Mean (SD) atheroma volume in the 
71.0 130.0) -53 1-7.04, -3.51) 62.7 128.1) -2.0 l-333,-0.67) 
most diseased 10 mm segment {mm1) 
Mean HbA 1 c (SO),% 7.1 10.8) -0.3 {-0.4, -02) 7.411.0) -055 (-0.68,-D.42) 
Mean Systolic BP (SO), mm 127.6 116.9) 2.4 101, 4.6) 127.8{16.6) 0.1 (-1.4, 15) 
Mean Diastolic BP (SO), mm 74.7 (10.3) 0.1 (-12, 1.5) 75.7 110.7) -0.9 (-1.7, -O.Dl) 
Mean Weight (SO), kg 81.9 (17.9) 2.6 11.8, 3.4) 943 119.5) 3.6 {2.8, 4.4) 
Mean LDL (SO), mg/dl 905 136,6) 2.8 l-2.4, 8.0) 93.5 130.7) 2.1 (-15,5.8) 
Mean HDL (50), mg/dl 42.4 110.8) 62 (4.8, 7.6) 40.8111.5) 5.7 14.4, 7.0) 
Median TG* [IQR], mg/dl 162.8 [123.9-215.0] -141 1-23.0,-3.5) 139[104-198] -16.3 (-27.7,-11.0) 
Median Fasting insulin [IQR], IJU/ml 13.0 18.6-20.7) -2.6 l-3.5, -0.9) 21,0 [16.0-33.0) -5.0 1-7.0,-4.0) 
Median BNP [lQRJ, pg/ml 24[11-56] 5.0 (2.0, 11.0) 22.0 [11-52] 8.0 15.0, 1 0.5) 
Median hsCRP [IQR], mg/L 4.7 [22-1 0.5] -31 l-4.0, -24) 26 [11-6.5) -1.0 l-1.5, -0.8) 
SD- Standard Deviation; CI - Confidence Interval; IQR- Interquanile Range; BP -blood 
pressure; PERJSCOPE- Pioglitazone Effect on Regression oflntravascularSonographic Coronary 
Obstruction Prospective Evaluation 
rosis- However, whether they have similar or different effects on cardiovascular 
outcomes remains uncertain. 
Strengths of this study are the large sample size, the use of masked therapies, 
high adherence rates, achievement of similar levels of cardiovascular risk factors in 
both groups, and careful validated measurements ofiVUS indices. These findings 
are limited by the fact that 32.5% of patients allocated to glipizide and 30% of 
patients allocated to rosiglitazone did not have 2 evaluable IVUS measurements. 
Moreover, the observation that patients without 2 evaluable IVUS measurements 
were less likely to have had a stem inserted at baseline and were on fewer an-
tidiabetic agents than those who had the 2 IVUS measurements suggests that the 
patients who did have the 2 IVUS measurements were those with more advanced 
atherosclerosis at baseline. However, rhe findings of the worst rank analysis which 
include 490 of the 672 (73%) randomized participants who received at least 1 
dose of blinded medication, and which was similar to the analysis of patients with 
the 2 evaluable IVUS measurements suggests that it is unlikely that data from 
these individuals would have substantively altered the findings. These findings are 
also limited by the observation that rosiglitazone participants had a higher Al C 
level and that glipizide-treated patients had a lower LDL level afrer randomization 
despite blinded adjustment of medications designed to achieve similar levels of 
AlCandLDL 
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In summary, this study supports but does not prove the hypothesis that rosigli-
tazone has a greater anti-atherosclerotic effect than glipizide in patients with type 
2 diabetes, and suggests that that rosiglitazone may be more anti-atherosclerotic 
in patients with more advanced diabetes or higher risk for cardiovascular disease. 
Ongoing analyses will evaluate which factors relate to changes in atherosclerosis 
as measured by IVUS and will explore rosiglitazone's effects on atherosclerosis and 
plaque in more detail. 
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Meta-Analysis of the Studies Assessing Temporal Changes in 
Coronary Plaque Volume Using Intravascular Ultrasound 
Gast6n A. Rod.riguez-Granillo, MD. PhDa.c'*, Pierfrancesco Agostoni, MDct, 
Hector M. Garcia-Garcia, MD". Giuseppe G.L. Biondi-Zoccai. MD". Eugene Me Fadden. MD". 
Giovanni Amoroso. MD. PhDct, Peter de Jaegere. MD, PhDa, Nico Bruining. PhD3 , 
Pim de Feyter, MD. PhD", and Patrick W. Serruys. MD, PhD" 
To assess the temporal effect of statin therapy on coronary atherosclerotic plaque volume 
measured by intravascular ultrasound (IVUS), we searched PubMed for eligible studies 
published between 1990 and January 2006. Inclusion criteria for retrieved studies were 
(1) IVUS volume analysis at baseline and follow-up and (2) statin therapy in ~1 group of 
patients. All data of interest were abstracted in prespecified structured collection forms. 
Statistical analysis was performed with Review Manager 4.2. Random-effect weighted 
mean difference (WMD) was used as summary statistics for comparison of continuous 
variables. Nine studies of 985 patients (with 11 statin treatment arms) were selected. After 
a mean follow~up of 9.8 :::!::: 4.9 months. we found a significant decrease in coronary plaque 
volume (WMD -5.77 mm3• 95% confidence interval -10.36 to -1.17, p:::: 0.01), with no 
significant heterogeneity across studies (p = 0.47). Prespecified subgroup analyses showed 
similar trends. Studies in which the achieved low-density lipoprotein (LDL) cholesterol 
level was < 100 mg!dl showed a trend for plaque regression (WMD -7.88 mm3, 95% 
confidence interval -16.31 to 0.55, p :::: 0.07). whereas studies in which the achieved level 
of LDL cholesterol was :C:100 mg!dl, the trend was less evident (WMD -4.22 mm3 • 95% 
confidence interval -10.27 to 1.82, p :::: 0.17). Plaque volume remained essentially un-
changed in patients not treated with statins (\VMD 0.13 mm3, 95% confidence interval 
-4.42 to 4.68. p :::: 0.96). In conclusion, statio therapy, particularly when achieving the 
target LDL level, appears to promote a significant regression of coronary plaque volume as 
measured by IVUS. © 2007 Elsevier Inc. All rights reserved. (Am J Cardiol2007;99:5-10) 
We performed a meta-analysis of all clinical studies that as-
sessed intravascular ultrasound (IVUS)-based progression/ 
regression of coronary atherosclerosis to evaluate whether 
treatment with statins can promote coronary plaque regression 
over time. 
Methods 
Two trained investigators (GARG and PA) searched 
PubMed for eligible studies in peer-reviewed journals pub-
lished between January 1990 and January 2006. Search key 
words included "reduc*" or .. regres*" or "progress*" and 
"IVUS"' or "intravascular ultrasound.'' where * denotes a 
wildcard. which is a symbol used to search all words be-
ginning with the written root. PubMed was searched using 
the method described by Biondi-Zoccai et al. 1 No language 
uoepartrnent of Cardiology, Thoraxccnter. Erasmus Medical Center, 
Rotterdam: and bOnze Licve Vrouw Gasthuis, Amsterdam, The Nether-
lands: "Department of Cardiovascular Imaging, Otlmendi Hospital. Buenos 
Aires. Argentina: d Antwerp Cardiova.-;cular Cent<.'!' Middclheirn, Antwerp. 
Belgium: and "HJcmodyn.:unics and Cardiovascubr R:tdiology Service, Poli-
clinico San Donato. Nlilan, Italy. Manuscript received April 18. 2006: 
revised manuscript received and accepted July 13. 2006. 
*Corresponding author: Tel: 54-11-4964-8721: fax: 54-Il-4964-8721. 
E-mail address: grodriguezgranillo@gmail.com (G.A. Rodriguez· 
Granillo). 
restriction was used. Cross references were checked. and 
experts were contacted to identify other relevant trials. 
Citations initially selected by systematic search were first 
retrieved as title and/or abstract and screened independently 
by 2 reviewerS (GARG and PA). Potentially relevant reports 
were then retrieved as complete publications and assessed 
for compliance to inclusion and exclusion criteria. 
Inclusion criteria for retrieved studies were (I) NUS 
volume analysis in native coronary arteries at baseline and 
follow-up and (2) statin therapy in ==: 1 group of patients. 
Exclusion criteria were (1) no volumetric output (only 
cross-sectional area analysis) and (2) studies in vessels 
different from coronary arteries. 
All data of interest were abstracted in prespecified struc-
tured collection forms. Every study used the same IVUS 
imaging catheter at baseline and follow-up . .All rvus inves-
tigations were performed after intracoronary administration of 
nitrates. Cine runs. before and during contrast injection. were 
performed to define the position of the catheter distal to an 
identifiable side branch. Using an automated pull-back device. 
the transducer was withdrawn at a continuous speed of 0.5 
mm/s. and NUS data were stored on super-VHS for subse-
quent analysis. Our primary end point of interest was progres-
sion/regression of coronary atherosclerotic burden evaluated 
by NUS volumetric analysis. According to the different stud-
ies included in the analysis, plaque volume was calculated as 
ns.m=! (vessel=- lumenureJ X d. where n refers to number 
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Table 1 
Characteristics of studies included in the mcta·analysis 
Study Ye~ Design n (%)* Treatment Follow-up Age Moo LDL at Follow-up 
Mean(%) (yrs) (mg/dl) 
GAL"!~ I 2001 MC 48 {6) Atorvasmtin l2mos 61 85 86 :t:: 30 
ESTA.BLISH'0 2004 sc 24 (3) Atorv:t.~tatin 6 mos 61 86 70 = 25 
REVERSAL~ 2004 MC 253 (32) Atorv;u;tatin IS mos 56 71 79:!:: 30 
REVERSAL~' 2004 MC 249 (32) Pravastatin 18 mos 57 73 110:!: 26 
Petronio ct al." 2005 sc 36 (5) Simvastatin 12mos 63 72 94 ± 9 
Kawru;uki et al.~ 2005 sc 17 (2) Atorvastatin 6mos 66 71 95:!: 15 
Kawa..<;aki ct aF'· 2005 sc 18 (2) Pravastatin 6mos 67 72 102 ± 13 
~ishioka et ru.:.l 2005 sc 22(3) Statin 6mos 66 77 106:!: 20 
Jensen ct al.~ 2004 sc 40 (5) Simvastatin 12 mos 58 100 40:= 10 
Yokoyama et al.~ 2005 sc 29(4) Atorva.~tatin 6mos 62 90 87:!:: 29 
T:mi ct al." 2005 sc 52 (7) Pravastatin 6mos 63 75 104 = 20 
'" I'\umber of patients in treatment arm. 
MC = multicenter: SC = single center. 
of images. m to image, and d to distance between images. In 
case these data were not provided in the published report. the 
authors were contacted to obtain the.~ values. 
We compared baseline with follow-up plaque volume 
in patients receiving statins and control subjects (when 
present). In addition. as sensitivity analyses. we stratified 
the studies according to achieved low-density lipoprotein 
(LDL) cholesterol levels and time to follow-up. seeking an 
enlightenment of results. 
Statistical analysis was performed with Review Man-
ager 4.2.z Continuous variables are reported as mean :::: 
SD unless otherwise specified. Random-effect weighted 
mean difference (WMD) with 95% confidence intervals 
was used as summary statistics for comparison of con-
tinuous variables: this analysis is used when the unit of 
measurement of the variable under analysis remains con-
stant across different studies.3 The currently recom-
mended inverse variance-weighting method. according to 
Dersimonian and Laird. was used for random-effect com-
parison.:> Reported values were 2-tailed and results were 
considered statistically significant at p <0.05. Statistical 
heterogeneity (i.e .. between-study discrepancy in effect 
size estimates) was assessed with the Cochran Q test. 
This test strongly suggests underlying statistical hetero-
geneity for p values <0.10. even if other causes of 
heterogeneity. such as clinical differences between treat-
ments. follow-up duration. or patient population. are not 
dismissed. Appraisal of statistical heterogeneity is piv-
otal to meta-analysis because some authorities have ad-
vocated statistical pooling of different trials only in the 
presence of statistical homogeneity.3 To assess the risk of 
small-study bias (including publication bias). we built a 
funnel plot by graphically showing the relation between 
effect size and statistical weight for each study. A sym-
metric and funnel-shaped plot supports the lack of sig-
nificant small-study bias, whereas a strongly asymmetric 
plot suggests the underlying presence of small-study or 
publication bias (i.e .• where smaller studies reporting 
positive outcomes are more likely to be published than 
equally small studies reporting negative or nonsignificant 
results). Publication bias. if not recognized and acknowl-
edged. can lead to meta-analyses with biased and overly 
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optimistic findings and should thus be actively investi-
gated and appraised} 
Results 
PubMed queries permitted the retrieval of 977 citations. 
Most publications were excluded because they were edito-
rials. reviews. or studies addressing the role of IVUS as an 
adjunctive tool to percutaneous coronary interventions. 
Eighteen publications were assessed for compliance to in-
clusion and exclusion criteria. leading to further exclusion 
of 9 studies. One study was not included because only area 
measurements and not volume analyses were reported.4 One 
study did not include a treatment ann.5 Three other studies 
were excluded because they evaluated IVUS in femoral 
arteries and transplant-associated arteriosclerosis.<>~ll One 
study used antihypertensive agents and 3 others used lipid~ 
lowering therapies different from statins.9 - 1z Therefore, 9 
published studies were selected. to.t:-zo 
These 9 studies included 985 patients. Most studies were 
randomized comparisons of a statio versus placebo. aside from 
a study by Jensen et al.15 which was a single-ann observational 
study. In the randomized Reversal of Atherosclerosis with 
Aggressive Lipid Lowering (REVERSAL) trial. the 2 anns 
received statins. but different molecules: in a study by Ka~ 
wasaki et al. 19 2 groups received 2 different statins and 1 
received placebo. Thus. overall. 788 patients were allocated to 
statin treatment in 11 different groups (Table 1 ). 
All studies used absolute change in plaque volume in a 
matched region of interest evaluated at the longest available 
follow-up as an imaging end point apart from a study by 
Petronio et al.17 which reported change in plaque volume 
adjusted for analyzed vessel length. We contacted the au-
thors to obtain the absolute change in plaque volume. 
In the Gennan Atorvastatin Intravascular Ultrasound 
(G~') study. patients were allocated to atorvastatin in an 
increasing dose to achieve a LDL cholesterol level <100 
mg/dl or placebo.14 For the Early Statin Treatment in Patients 
With Acute Coronary Syndrome (ESTABUSH) study, 20 
mg/day of atorvastatin versus placebo was ad.ministrated. 13 In 
contrast the REVERSAL investigators compared an intensive 
with a moderated lipid~lowering therapy (80 mg/day of ator-
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Figure 1. \VMD with 95% confidence interval (CI) of difference in plaque volume between follow-up and baseline in the ~tatin arm of the included ~rudies. 
Table 2 
Stratification of change in plaque volume according to length of follow-up 
Study 
ESTABUSW" 
Ni~hioka et :J..l:!.' 
Follow-up 6 mo~ 
(n "" 158) 
Kawasaki ct :J..l1.o (atorvastatin) 
Kawa.'i!l.ki ct :J..l'" (prav:l.statin) 
Tani et 3.117 
Yokohama ct :J..l::.' 
Tot:J..l 
p V:J..luc 
CI = confidence intcrv:J..l. 
Table 3 
WMD (95% CI) 
-8.20 (-34.79 to 18.39) 
-4.60(-13.01 to3.81) 
-3.80(-24.84to 17.24) 
-1.60 (-23.18 to 19.98) 
-7.00 (-17.82 to 3.82) 
-3.90 (-21.18 to 13.38) 
-5.07 (-10.67 to 0.53) 
0.08 
Follow-up >6 mo~ 
(n = 626) 
Study 
GAIN" 
Jensen et :J..l"' 
REVERSAL'' (atorva.~tatin) 
REVERSAL" (pravn$tatin) 
Petronio ct :J..ll4 
Torn 
p V:J..lue 
WMD(95%CI) 
1.20 (-31.45 to 33.85) 
-3.70 (- 16.63 to 9.23) 
-0.50 (-20.07 to 19.07) 
5.10 (-14.85 to 25.05) 
-30.00 (-47.18 to -12.82) 
-6.67 (-19.62 to 6.28) 
0.31 
Stratitic:ltion of change in plaque volume according to low-density lipoprotein cholc~terol levels at follow-up 
Follow~up LDL Cholesterol Levels < 100 mgldl 
(n ~ 443) 
Study 
GAD/" 
ESTABUSH"" 
Jensen ct :J..l=::: 
REVERSAL" (atorva.~tatin) 
Kawa...aki ct al'" (atorvastatin) 
Petronio et aP' 
Yokohama et :J..l:!.' 
ToW 
p V:J..luc 
Abbreviation ns in Table 2. 
WMD (95% CI) 
1.20 (-31.45 to 33.85) 
-8.20 (-34.79 to 18.39) 
-3.70 (-16.63 to 9.23) 
-0.50 (-20.07 to 19.07) 
-3.80(-24.84to 17.24) 
-30.00 (-47.18 to -12.82) 
-3.90 (-21.!8 to 13.38) 
-7.88 (-16.31 to 0.55) 
0.07 
vastatin vs 40 mg/day of pravastati.n).21 Kawasaki et al 19 com-
pared 20 mg/day of atorvastati.n with 20 mg/day of pravastati.n 
with placebo. Petronio et al17 compared 20 mg/day of simva~ 
statin with placebo. Yokoyama et al 1N compared 10 mg/day of 
atorvastati.n with placebo control. Nishioka et al16 compared 
the administration of different stati.n regimens (10 mg/day of 
pravastatin, 10 mg/day of atorvastatin. 5 mg/day of simvasta~ 
tin. or 20 mg!day of fluvastatin) with placebo control. Tani et 
al20 compared 10 mg/day of pravastatin in patients whose LDL 
cholesterol level was <140 mg/dl with 20 mg/day in patients 
whose LDL cholestero1level was > 140 mg/dl versus controls. 
Follow-up LDL Cholesterol Levels ~100 mgldl 
(n = 341) 
Study 
:-lishioka ct a]::.' 
Kawa.<;aki ct :J..l'" (pravnstatin) 
REVERSAL'" (prava.~tatin) 
Tani et:J..l17 
Torn 
p Value 
WMD (95% CI) 
-4.60 (-13.01 to 3.81) 
-1.60 (-23.18 to 19.98) 
5.10 (-14.85 to 25.05) 
-7.00 (-17.82 to 3.82) 
-4.22 ( -10.27 to 1.82) 
0.17 
Patients in an observational study by Jensen et al 15 received 
increasing doses of simvastati.n to reach a LDL cholesterol 
level of <3.0 mmol!L. 
Except for 2 studies. 13•16 all investigations excluded pa-
tients presenting with an acute coronary syndrome. 
Figure 1 shows WMD in plaque volume between follow-up 
and baseline with respective 95% confidence intervals at a 
mean follow-up of 9.8 :±: 4.9 months. There was a significant 
decrease in coronary plaque volume over time (WMD -5.77 
mm3 , 95% confidence interval -1036 to -1.17. p = 0.01). 
with no significant heterogeneity between studies (p = 0.47). 
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Figure 2. \¥MD with 95% confidence interval of difference in lumen volume between follow-up and baseline in the statin rum of the included studies. 
Abbreviation as in Figure 1. 
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Figurt.: 3. \VMD with 95% confidenct.: interval of difference in vessel volume between follow-up and baseline in the sUtin arm of the included studies. 
Abbreviation as in Figure 1. 
.,. 
Figure 4. Funnel plot shows no asymmt.:try, so thcrt.: is no publication bias 
present in tht.: meta-analysis. 
According to prespecified subgroup analyses evaluating 
studies according to length of follow-up (Table 2). similar 
trends were noted in studies with a 6-month follow-up and 
in studies with longer follow-up. although significant plaque 
regression did not occur. possibly due to a smaller sample. 
No significant heterogeneity (p = 1.00) between studies was 
found for the former subgroup analysis. whereas a signifi-
cant heterogeneity between studies was present for the latter 
(p ~ 0.06). 
Studies in which the achieved LDL cholesterol level was 
<100 mg/dl showed a strong trend for plaque regression. 
Conversely. studies in which the achieved LDL cholesterol 
level was> 100 mg/dl showed that the trend toward plaque 
regression (Table 3) was less evident. Also. in these sub-
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group analyses. no significant heterogeneity between stud-
ies (p = 0.23 and 0.76. respectively) was noted. 
After a mean follow-up of 7.7 ± 2.9 months. plaque 
volume remained substantially unchanged when evaluating 
control groups not receiving statio therapy (7 groups. 206 
patients. WMD 0.13 mm3• 95% confidence interval -4.42 
to 4.68. p = 0.96). with no heterogeneity between studies 
(p ~ 0.83). 
Figures 2 and 3 show \VMD between follow-up and 
baseline in lumen and vessel volume. respectively. in pa-
tients receiving statin therapy. There was no significant 
change in coronary lumen volume or vessel volume over 
time. The funnel plot showed no evidence of publication 
bias (Figure 4). 
Discussion 
In the present systematic overview, statins were found to 
promote significant coronary plaque regression as assessed 
by IVUS. Nine studies and 11 statio arms were included in 
this meta-analysis in which. after a follow-up of approxi-
mately 10 months. a significant regression of coronary ath-
erosclerotic plaque volume was evident. Our data are further 
supported by the substantial statistical homogeneity across 
the included studies. 
Atherosclerotic plaque regression after onset of an 
intensive statin therapy strategy has been previously re-
ported in the peripheral circulation.22- 24 Mechanisms in-
volved in such a process are still not fully elucidated. 
having been ascribed thus far to changes in LDL and 
high-density lipoprotein cholesteroi. 1L22.2S It has been 
suggested that. by decreasing the lipid content of plaques 
Meta-analysis of the studies assessing temporal changes in coronary plaque volume 
and promoting a shift toward a more stable phenotype. 
statins may induce a "plaque stabilization" effect. Three 
studies included in the present meta-analysis found sig-
nificant differences in surrogates of plaque compOsition 
despite no significant changes in plaque volume. 14-H1.19 
Further. statins have been found to decrease the inflam-
matory burden of plaques and to improve endothelial 
function.::!G-::!x 
It is likely therefore that the antiatherosclerotic effect of 
statins is pleomorphic and effective against the 2 major 
mechanisms of atherosclerotic plaque progression. 
The results of our meta-analysis are indirectly further 
reinforced by a lack of regression in patients assigned to 
placebo. In these patients. no substantial modification of 
plaque volume was noted over time. 
Although NUS is a highly accurate tool to measure 
changes in the vessel wall. factors such as intra- and inter-
observer variabilities. severely calcified vessels. and artifacts 
can impair the reproducibility of serial measurements.::!".30 It is 
therefore important to establish new standards regarding the 
acquisition. analysis. and reporting of NUS clinical studies. 
This meta-analysis was not based on individual data. 
Further. only 1 vessel was interrogated with IVUS and 
thus may not be representative of the total burden of the 
entire coronary tree. Although no significant heterogene-
ity was present across studies. bias adjudicated to small 
trials cannot be fully disregarded. Moreover. minor dif-
ferences regarding rvus methodology might have influ-
enced our findings. 
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Long-Term Effect of Perindopril on Coronary Atherosclerosis 
Progression (from the PERindopril's Prospective Effect on 
Coronary aTherosclerosis by Angiography and IntraVascular 
Ultrasound Evaluation [PERSPECTIVE] Study) 
Gast6n A. Rodriguez-Granillo. MD. PhD". Jeroen Vos. MDc. Nico Bruining. PhD". 
Hector M. Garcia-Garcia. MD. MSc", Sebastiaan de Winter, BSca. Jurgen M.R. Ligthart, BSc". 
Jaap W. Deckers. MD. PhD". Michel Bertrand. MDd. Maarten L. Simoons. MD". 
Roberto Ferrari. MD". Kim M. Fox. MDr. Willem Remme. MDb. and Pim J. De Feyter. MD"·*. 
on behalf of the Investigators of the EUROPA Study 
The multicenter EUROPA trial of 12.218 patients showed that perindopril decreased adverse 
clinical events in patients with established coronary heart disease. The PERSPECTIVE study, 
a substudy of the EUROPA trial, evaluated the effect of perindopril on coronary plaque 
progression as assessed by quantitative coronary angiography and intravascular ultrasound 
(IVUS). In total 244 patients (mean age 57 years, 81% men) were included. Evaluable 
paired quantitative coronary angiograms were obtained from 96 patients randomized to 
perindopril and from 98 patients to placebo. Concomitant treatment at baseline consisted 
of aspirin (90%), lipid-lowering agents (70%), and ~ blockers (60%). The primary and 
secondary end point was the difference of minimum and mean lumen diameters (quanti-
tative coronary angiography) or mean plaque cross-sectional area (IVUS) measured at 
baseline and 3-year follow-up between the perindopril and placebo groups. After a median 
follow-up of 3.0 years (range 19 to 4.1), no differences in change in quantitative coronary 
angiographic or IVUS measurements were detected between the perindopril and placebo 
groups (minimum and mean luminal diameters -0.07 :!:: 0.4 vs -0.02 :!:: 0.4 mm, p = 0.34; 
mean luminal diameter -0.05 ::±: 0.2 vs -0.05 ::±: 0.3 mm, p = 0.89; mean plaque cross-
sectional area -0.18 ::±: 1.2 vs -0.02 :!: 1.2 mm2 , p = 0.48). In conclusion, we found no 
progression in coronary artery disease by quantitative coronary angiography and IVUS 
with long-term administration of perindopril or placebo, possibly because most patients 
were on concomitant treatment with a statin. (f) 2007 Elsevier Inc. All rights reserved. 
(Am J Cardiol 2007;100:159-163) 
Several preclinical and clinical studies have shown that 
angiotensin-converting enzyme (ACE) inhibitors exert an 
antiatherosclerotic cffect. 1- 6 Recent studies have shown that 
overall ACE inhibiton; decrease adverse cardiovascular 
eventsJ-1::! No data are available of the efficacy of ACE 
inhibitors on progression of coronary atherosclerosis. The 
purpose of the PERindopril's Prospective Effect on Coro-
nary aTherosclerosis by IntraVascular ultrasound Evalua~ 
tion (PERSPECTIVE). a substudy of the EUROPA trial. 
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Research Centre, Salvatore Maugeri Foundation. IRCCS, Gussago (Bres-
cia), Italy: and 'Cardiology Department. 1\'ational Heart and Lung Institute 
and Royal Brompton Hospital, London, United Kingdom. M.:tnuscript 
received December 12, 2006; revised manuscript received and accepted 
February 22, 2007. 
This ~rudy was supponcd by Servicr, France. Drs. Fox and Simoons 
were suppol1ed by Servier. Paris. France. 
*Corresponding author: Tel: 31-10-463-5071: fax: 31-10-463-2686. 
E-mail address: p.j.defeytcr@erasmusmc.nl (P.J. De Feyter). 
was to evaluate the effect of long~term administration of 
perindopril on coronary plaque size as assessed by quanti-
tative coronary angiography and intracoronary ultrasound 
(IVlJS). 
Methods 
The EUROPA trial evaluated the effect of ACE inhibitor 
perindopril on the prevention of cardiovascular events in 
12.218 patients with stable coronary artery disease. The 
methods of the EUROPA trial has been extensively de-
scribed elsewhere. 8 In the run-in period. enrolled patients 
received oral perindopril 4 mg/day for 2 weeks in addition 
to their normal medication. followed by 8 mg/day for 2 
weeks if the initial dose was tolerated. At the end of the 
run-in period. patients were randomly assigned to perindo-
pril 8 mg/day or placebo for :::::3 years. The efficacy out-
come was the combined end point of cardiovascular mor-
tality. nonfatal myocardial infarction. and cardiac arrest 
with successful resuscitation. 
Patients included in the main EUROPA trial in whom a 
coronary angiogram was indicated were eligible for the 
PERSPECTIVE study. In addition to EUROPA"s inclusion 
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I 1171)t:;wltl1medlalt101\S<dcclf~ I 16 pt:; nonsp•:o:lfio:<l <top ......-..on 
J ~ I 
I Perindopril, n=l.27 I I Placebo, n-u.7\ 
I I 
I I I I 
Matched QCA Matched IVUS Matched QCA Matched IVUS 
Baseline-FU, 11:5!§ Baseline-FU, 1EEZ5 Baseline-FU, JJ.=M Baseline-FU, ~ 
Death=2 ,.,.,., Death=l Death=l 
FU refusccl=17 FU refused=17 FU rdu$ed=8 FU refused=8 
Wlthdn:w consentc:6 Withdrew conscnt=6 Cancer=l le$1on not crossed=4 
Incomplete FU=6 Lesion not crossecl=3 Incomplete FU=9 cancer=l 
Technical failure=10 Technical fallure=16 
SuboptlmallVUS SuboptimallVtJS 
qualltv=14 qualityc18 
Figure 1. Flowchart of the PERSPECTIVE study. FU = follow-up: pl~ "" patient~; QCA = quantitative coronary angiogram. 
and exclusion criteria. vessels anatomically suitable for the 
quantitative coronary angiographic/IVUS substudy were re-
quired. 
Institutional ethics committees of all participating cen-
ters approved the study protocol and informed written con-
sent was obtained from all patients. 
Coronary angiograms were obtained at baseline before 
medication was started and at followwup after 2:3 years. At 
least 3 orthogonal projections of the region of interest were 
filmed at baseline. and the same projections were repeated at 
follow-up. Quantitative coronary angiographic analysis was 
performed by an independent core laboratory (Cardialysis 
BV. Rotterdam. The Netherlands) as previously described 
with a validated computer-based edge-detection system 
(CAAS II. Pie Medical. Maastricht. The Netherlands). 13 
The catheter tip was cleared of contrast for accurate cali-
bration. Interpolated reference diameter, minimal lumen di-
ameter. mean lumen diameter. and diameter stenosis were 
measured at the 2 time points using the "worst" view of an 
end-diastolic frame. 
A noninfarct-related or percutaneously treated vessel 
was selected for investigation. 
NUS was acquired using 20-. 30-. or 40-MHz imaging 
catheters after coronary angiography. The catheter was ad-
vanced distally to an anatomically identifiable landmark 
allow evaluation of a segment of 2:30 mm. Cine runs before 
and during contrast injection were performed to define the 
position of the IVUS catheter before pullback was started. 
Using an automated pullback device. the transducer was 
withdrawn at a continuous speed of 0.5 mm/s until the 
ostium. NUS data were acquired after intracoronary admin-
istration of nitroglycerin and stored on S-VHS videotape. At 
follow-up angiography. patients underwent repeat NUS 
examination of the same region of interest by using an 
identical NUS imaging catheter. 
Quantitative coronary ultrasound analysis was performed 
by an independent core laboratory (Cardialysis BV) using 
validated semiautomatic contour detection software (Curad 
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3.1. Wijk bij Duurstede. The Netherlands). The IntelliGate 
image-based gating method was applied to eliminate motion 
artifacts by retrospectively selecting end-diastolic frames. 14 
Cross-sectional areas of the lumen and vessel (defined as the 
external elastic membrane) were calculated for each cross-
sectional image. Contours of the vessel and lumen-intima 
interface enclosed an area that was defined as the coronary 
plaque-plus-media area. On the baseline IVUS study a re-
gion of interest was identified using landmarks such as side 
branches and the coronary ostium. At follow-up, the same 
region of interest was identified using the same landmarks. 
The primary end point was the difference in change of 
minimum and mean lumen diameters (quantitative coronary 
angiography) measured at baseline and 3-year follow-up 
between the perindopril and placebo groups. Prespecified 
secondary end points were the difference in change of mean 
plaque cross-sectional area (square millimeters) and of 
plaque volume (cubic millimeters) as measured by NUS at 
baseline and at follow-up between groups. Development of 
new lesions (2:20% decrease in minimum lumen diameter) 
was another prespecified secondary end point. 
Discrete variables were presented as counts and percent-
ages or as medians (interquartile ranges) when indicated. 
Continuous variables were presented as means :!: SDs. 
Based on a previous quantitative coronary angiographic 
progressionfregression trial. 15 we calculated a sample of 99 
paired subjects to achieve a power of 80%. considering a 
type I error probability of 0.05 (2-sided). a difference (be-
tween groups) in minimum lumen diameter of 0.08. and a 
within-group SD of 0.20. In this calculation a drop-out rate 
of 15% nonanalyzable patients was included. Differences 
between groups were assessed by paired and unpaired Stu-
dent's t test when applicable. For comparison between cat-
egorical variables, chi-square test was used. A 2-sided p 
value <0.05 was required for statistical significance. All 
analyses were performed using SAS 6.12 (SAS Institute. 
Cary. North Carolina). 
Long-term effect of perindopril on coronary atherosclerosis progression 
Table l 
Ba.<ielinc characteristics of population 
Pcrindopril 
(n ""96) 
Variables 
Age (yr:;) 57.5 :::: 9.3 
:vi en 77 (80) 
Diabetes mellitus 8 (8.3) 
Hypertension~' 19(20) 
Smoker 24(25) 
Hypercholesterolemi:t 75 (78) 
Peripheral va.~cular disea."«: 2 (2.1) 
Previous myocardial infarction 44(46) 
Previous percutaneous coronary intervention 83 (87) 
Previous coronary artery bypass graft~ I (1.0) 
Systolic blood pressure (rnm Hg) 133 :::: 16.0 
Dia."tolic blood pressure (mm Hg) 80.0 = 7.6 
Weight (kg) 79 = 12 
Heart rate 70::::. 11 
Anginal status (CCS cia.~) 
I 82 (86) 
rr 12 (13) 
m 2(2.1) 
IV 0 (0.0) 
Other medications 
Platelet inhibitors 92 (96) 
f3 Blockers 55 (58) 
~itrates 39 (31) 
Calcium channel blockers 52 (41) 
Lipid-lowering agent~ 93 (73) 
At follow-up 
Systolic blood pressure (rnm Hg) 131 = 18 
Change in systolic pressure (mm Hg) -1.9 :':: 18 
Dia.~tolic blood pressure (mm Hg) 76::!::. S.l 
Change in dia.~tolic pressure (mm Hg) -3.4:::: 9.2 
Values are means :':: SDs or numbers of patient~ (percentage~). 
* Blood pressure > 160/95 mm Hg or antihypertension treauncm. 
~Cholesterol level >6.5 mmol!L or lipid-lowering therapy. 
Placebo Difference 95% EUROPA (overall) 
(n = 98) CI (n = 12.218) 
56.1::::9.0 1.3 -1.3 to 3.9 60::::9 
80 (82) -1.4 -I3to9.6 10.439 (86) 
8 (8.2) 0.2 -7.6to7.9 1.502 (13) 
24(25) -4.7 -17to7.0 3.312 (27) 
22 (23) 26 -9.4 to 15 1.869 (16) 
79 (81) -2.5 -14to8.9 7.737 (63) 
4(4.1) -2.0 -6.8 to 2.9 883 (7.2) 
53 (54) -8.2 -23 to 5.8 7.910 (65) 
92 (94) -7.4 -I6to0.9 3.573 (30) 
r.o -I.Oto3.1 3.587 (30) 
13.1 :':: 14 15 -2.7 to5.8 137 (15) 
Sl::: 12 1.8 -0.3 to4.0 82(8) 
SI -2.6 -5.9 to 0.8 82 (12) 
67 :':: 7.8 3 0.4-5.8 68 (10) 
Sl (83) 2.8 -7.5 to 13 NA(Sl) 
IS (16) -2.8 -13 to 6.9 :-.rA (17) 
2(2.0) 0.0 -4.0 to4.0 l\"A(2) 
0 (0.0) 0.0 0.0-0.0 
96 (98) -2.1 -7.0to2.8 11.278 (93) 
62 (64) -6.0 20-7.8 7,535 (62) 
20 (17) 14.9 3.3-27 5.242 (43) 
41 (35) 6.9 -6.6to21 3.826 (32) 
86 (74) -5.7 -l8to6.5 7.033 (58) 
134::: 15 -2.7 -7.3to !.9 NA 
2.8 :':: 15 -4.7 -9.2 to 0.3 NA 
78 = 8.5 -1.9 -4.2to0.4 NA 
-0.3 :':: 9.2 -3.2 -5.7 to 0.6 ~A 
CI = confidence interval; CCS "" Canadian Cardiova.~cular Society: ~A = not available. 
Results 
Of 244 patients who were included in PERSPECTIVE and 
received randomized treatment, 194 had complete matched 
baseline and follow~up angiograms. Reasons for incomplete 
angiographic follow-up are presented in Figure 1. Baseline 
characteristics of the study population are presented in 
Table I . Coronary risk factors and baseline blood pressure 
were well balanced, showing no significant differences be-
tween groups. At baseline and during the study period, 
> 70% of patients received lipid-lowering treatment. >95% 
received platelet inhibitors, and -60% were on .8-blocker 
treatment. 
At a median follow-up of 3.4 years (range 1.5 to 4.3). the 
rate of cardiac death, myocardial infarction. and cardiac 
resuscitation was not statistically different between the per-
indopril and placebo groups (6, 6.2%, vs 7. 7.1%) and 
slightly lower than the event rate reported in the EUROPA 
trial (8.0% vs 9.9%) at 4.2 years of follow-up. Follow-up 
angiography was performed after a median of 3.0 years 
(range 1.9 to 4.1). No significant changes were apparent in 
reference diameter, minimal lumen diameter. or diameter 
stenosis (Table 2). Differences in minimum and mean lu-
men diameters between baseline and follow~up in the per-
indopril group did not differ from that observed in the 
placebo group. There was no difference in the occurrence of 
new lesions between groups. In total 144 matched evaluable 
IVUS images were available at follow-up. Thirty-two pa-
tients were excluded due to suboptimal rvus quality 
(caused by severely calcified vessels, severe image artifacts. 
or absence of clear anatomic landmarks). No significant 
differences were apparent over time in vessel area, plaque 
area, or plaque volume between groups (Table 3). 
Discussion 
Patients studied in the PERSPECTIVE substudy were sta-
ble. with a low adverse event rate of -2% per year. They 
received intensive background phannacologic treatment 
with aspirin and statins throughout the study to achieve a 
total cholesterol level of 4.8 mmolJL and a low-density 
lipoprotein cholesterol level of 2.8 mmol/L. They were 
normotensive, with mean systolic and diastolic blood pres-
sures of 132 ± 8 and 77 ± 88 mm Hg.. respectively. The 
PERSPECTIVE substudy demonstrated no beneficial effect 
on progression of atherosclerosis during 3.5 years of treat-
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Table 2 
Quantitative coronary angiographic results 
Variable Pcrindopril 
(n"" 96) 
Length (mm) 
Baseline 32:=: 17 
Follow-up 31 ::!: 16 
Nominal change -0.72::!: 3 
Referenc<:: diameter (mm) 
Baseline 3.09 ;:'.: 0.6 
Follow-up 3.04:!: 0.7 
}iominal change -0.05 ::!: 0.4 
Minimal lumen diameter (mm) 
Baseline 2.19 ± 0.5 
Follow-up 2.11::!: 0.6 
:-lominal change -om= OA 
Meun lumen diameter (mm) 
Baseline 2.92:!: 0.5 
Follow-up 2.87::!:: 0.5 
~aminal change -0.05 ::': 0.2 
Diameter stenosis(%) 
B::J.selinc 29 = 13 
Follow-up 29::!: 17 
1'\ominal ch:mge 0.42 = 12 
Development of new lesions(%)* 12 (12.5) 
-~ At least 20% decrea;;e in minimal lumen diameter. 
Table 3 
Intravascular ultra..<;eund results 
Meun Cross-Sectional 
Area (mm") 
Length (mm) 
Bn..~line 
Follow-up 
Vessel 
Bn..~eline 
Follow-up 
Nominal chunge 
Lumen 
Bn..~clinc 
Follow-up 
Nominal chunge 
Plaque 
Bn..~eline 
Follow-up 
Nominal chunge 
Plaque volume (mm3) 
Baseline 
Follow-up 
Nominal chunge 
Perindopril 
(n = 75) 
31 ± 14 
31:!: 14 
15.5 ± 4.5 
15.3 ± 4.4 
-0.2 ± 2.0 
9.1 ± 3.3 
9.1 ± 3.3 
0.1 ± 1.5 
6.4 ± 2.7 
6.2 ± 2.6 
-0.2 ± 1.6 
192 ± 115 
190 ± 114 
-2 ±55 
Placebo 
(n = 98) 
32::!: 15 
31::!: 14 
-0.36:!: 3 
2.96:!: 0.6 
2.93 ::!:: 0.6 
-0.03:!: 0.3 
2.14:!: 0.7 
2.13 :!: 0.6 
-0.02 ± 0.4 
2.88::!:: 0.6 
2.83 = 0.6 
-0.05 :!: 0.3 
28 ± 15 
27:!: 15 
-0.56 ± \3 
7 (7.1) 
Placebo 
(n"" 69) 
31 :!: 15 
31 ± 15 
15.8:!: 4.7 
15.9 ± 4.6 
0.1 ± 1.7 
9.6:!: 3.9 
9.8±4.1 
0.2 ± 1.7 
6.2:!: 2.3 
6.1 ± 2.5 
-0.1 ± 1.2 
190:!: 108 
186:!: 105 
-4 ±37 
ment with perindopril versus placebo as assessed with quan-
titative coronary angiography and intracoronary ultrasound. 
There are several reasons to explain the lack of effect of 
perindopril on coronary plaque size in our substudy. First. it 
is noteworthy that there was no progres..<:;ion of atheroscle-
rosis in the placebo and perindopril groups of whom >70% 
had received statio therapy before and during the study. This 
is in keeping with previous studies demonstrating no pro-
gression of coronary artery disease as assessed by quanti-
tative coronary angiography or intracoronary ultrasound in 
patients with intensive lipid-lowering treatment. 15- 17 Be-
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cause there was no progression of disease in the 2 groups. 
we could not demonstrate an effect of perindopril on plaque 
size because a potential effect would have become evident 
only if perindopril had induced regression of plaque size. 
Thus far. plaque regression has been shown to decrease only 
by aggressive lipid-lowering treatment after intensive treat-
ment with statins. 1 ~ Second. the number of patients studied 
in the PERSPECTNE substudy was lower than anticipated 
to demonstrate an effect of perindopril. We had calculated a 
sample of 99 paired subjects based on an SD of 0.2 mm in 
the quantitative coronary angiographic measurements. but 
the actual SD in the study was 0.5 mm. which would require 
an even larger sample to demonstrate an effect; in addition. 
a rather large proportion of patients was excluded from 
analysis due to poor image quality. 
Third. we cannot exclude the possibility that perindopril 
induced a change in the histologic composition of the 
plaque. which was not assessed in this study. However. it 
appears more likely that the beneficial clinical effect of 
perindopril found in the EUROPA study was related to an 
improvement in endothelial function and the effect that may 
have had on plaque stability rather than on absolute plaque 
size. This latter effect will be addressed in 2 separate sub-
studies of the EUROPA trial. 19-1° Fourth. another mecha-
nism may have played a role in which perindopril decreased 
cardiovascular events and could not be detected by IVUS. 
Fifth. it may be speculated that perindopril has no effect on 
coronary plaques compared with a beneficial effect of ACE 
inhibitors on carotid plaques shown in the Study to Evaluate 
Carotid Ultrasound Changes in Patients Treated With 
Ramipril and Vitamin E (SECURE) study. 11 However. 
other reasons may also explain difference in outcome be-
tween these 2 studies. In the PERSPECTIVE study. the 
follow-up period was shorter. the population was at lower 
risk (adverse events rate 6% vs 14%), and intensive lipid-
lowering medical therapy was more frequent than in the 
SECURE study. 
The present study has a number of limitations. A sub-
stantial number of patients was excluded from IVUS anal-
ysis due to suboptimal image quality and severe calcifica~ 
tion precluding accurate plaque size as..<;e..<;sment This 
resulted in a rather small study sample. Larger studies may 
be required, using IVUS as a primary end point, to conclu-
sively determine the efficacy of ACE inhibitors on progres-
sion of atherosclerosis. Different IVUS catheters with dif-
ferent specifications were used over a 3-year period. which 
may have induced small variations in measurements and 
thus may have obscured potential subtle changes in plaque 
measurements. although measurements obtained with the 
various 30-MHz catheters were adjusted according to a 
previously reported mathematical algorithm.21 
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Aims This study sought to evaluate the effect of perindopril in coronary remodelling. 
Progression: 
RemodC'llfng; 
Atherosclerosis: 
Regression; 
EUROPA 
Methods and results In this sub-study of a double-blind, multicentre trial, patients without clinical evi· 
dence of heart failure were randomized to perindopril 8 mg/day or placebo for at least 3 years and IVUS 
investigation was performed at both time-points. Positive and negative remodelling were defined as a 
relative increase (positive remodelling) or decrease (negative remodelling) of the mean vessel cross· 
sectional area (CSA) >2 SD of the mean intra-observer difference. A total of 118 matched evaluable 
IVUS (711 matched 5 mm segments) were available at follow-up. After a median follow-up of 3.0 
(inter-quartile range 1.9, 4.1) years, there was no significant difference in the chanee of plaque CSA 
between perindopril (360 segments) and placebo (351 segments) groups, P~ 0.27. Conversely, the 
change in vessel CSA was significantly different between groups (perindopril -0.18 ± 2.4 mm2 vs. 
placebo 0.19 ::= 2.4, P ~ 0.04). Negative remodellin£ occurred more frequently in the perindopril than 
in the placebo group (34 vs. 25%, P ~ 0.01). In addition, the placebo group showed a larger, although 
not significant, mean remodelling index (RI) than the perindopril group (1.03 ± 0.2 vs. 1.00 ± 0.2, 
P ~ 0.06). The temporal change in vessel dimensions assessed by the Rl was significantly correlated 
with the change in plaque dimensions (r = 0.48, P < 0.0001). 
Conclusion In this sub-analysis of a multicentre, controlled study, lonJZ·term administration of perindo-
pril was associated with a constrictive remodelling pattern without affecting the lumen. 
Introduction 
By preventing encroachment of the lumen and hence coron-
ary flow, outward (positive) remodelling of coronary vessels 
was initially regarded as beneficial. 1 Notwithstanding, 
several studies have shown increased tevel.s of inflammatory 
markers, larger lipid cores and pronounced medial thinning 
in positive remodelled vessels; being all factors related to 
the tendency of plaques to undergo rupture.z-s 
Angiotensin-converting enzyme (ACE) inhibitors have 
demonstrated their efficacy in reducing mortality in both 
high- and low-risk patients.6 •7 In parallel, ACE-inhibitors 
inhibit progressive left ventricular remodelling, a critical 
factor that determines life expentancy.8 •9 More recently, 
ACE-inhibitors have shown to be effective in reversing vas-
cular remodelling in the peripheral circulation.10•11 
Atherosclerosis is a highly dynamic and multifocal disease, 
and coronary remodelling occurs diffusely 'Nithin a vessel, 
even in seemingly healthy references. 12 Accordingly, 
"Corresponding author. Tel/fax: +54 11 49648n1. 
e-mail address: grodriguezgranillo@l!.)Tlail.com 
longitudinal studies have been recognized as the gold-
standard for remodelling assessment. 13 
Driven by the significant regression of coronary atherosclero-
sis induced by lipid-towering therapies, 14 the PERindopril 's Pro-
spective Effect on Coronary aTherosclerosis by IntraVascular 
ultrasound Evaluation (PERSPECTIVE) trial evaluated the 
effect of long-term administration of perindopril on coronary 
plaque progression as assessed by angiography and intravascu-
lar ultrasound (IVUS) and demonstrated that the clinical 
benefit of ACE-inhibitors cannot be attributed to their effect 
on plaque size.15 We performed a post hoc analysis of the 
PERSPECTIVE study to assess the effect of perindopril in cor· 
onary remodelling. In addition, we evaluated the effect of 
perindopril on a surrogate of plaque composition. 
Methods 
The EUROPA was a multicentre, randomized, double-blind, placebo· 
controlled study that evaluated the effect of perindoprilon prevention 
of cardiovascular events in patients with coronary artery disease on 
12 218 patients. PERSPECTIVE was a sub-study of the EUROPA trial 
that sought to explore the effect of perindopril on atherosclerosis 
progression/ regression using coronary angiography and IVUS. 
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The methodology of the EUROPA trial has been extensively 
described elsewhere.7 In brief, patients were eligible if they were 
aged ::18 years, without clinical evidence of heart failure and 
with evidence of coronary heart disease documented by previous 
myocardial infarction (>3 months before screening), percutaneous 
or surgical coronary revascutarization (>6 months before screen-
ing), or angiographic evidence of at least 70% narrowing of one or 
more major coronary arteries. 
In addition, for the IVUS sub-analysis patients required anatomi-
cally suitable vessels for the angiography/IVUS sub-study. 
In a run-in period, enrolled patients received 4 mg/day oral peri-
ndopril for 2 weeks in addition to their normal medication, followed 
by 8 mg/day for 2 weeks if the initial dose was tolerated. At the end 
of the run-in period, patients were randomly assigned to perindopril 
8 mg/day or placebo for 3 years. 
The institutional ethics committees of all participating centres 
approved the study protocol and informed written consent was 
obtained from all patients. 
Intravascular ultrasound acquisition 
IYUS was acquired using 20, 30, and 40 MHz imaging catheters fol-
lowing coronary angiography. The catheter was advanced distal to 
an anatomically identifiable landmark, allowing the evaluation of 
a segment of at least 30 mm. Cine runs, before and during contrast 
injection, were performed to define the position of the IVUS cath-
eter before the pullback was started. Using an automated pullback 
device, the transducer was withdrawn at a continuous speed of 
0.5 mm/s until the ostium. IVUS data were acquired after the intra· 
coronary administration of nitroglycerin and stored on 5-YHS video-
tape. The videotapes wc-:re digitized on a computer system, 
transformed into the DICOM medical image standard and stored on 
an IVUS Picture Archiving and Communications System (PACS). 
After a 3-year follow-up pc-:riod, patients underwent rc-:peat cathe-
terization and IYUS examination of the same region of interest 
{ROI) using an identical frequency IVUS imaging catheter. 
Intravascular ultrasound analysis 
Quantitative coronary ultrasound analysis was performed by 
an independent core laboratory (Cardialysis BY, Rotterdam, 
The Nethc-:rlands) using validated semi-automatic contour detection 
software (Curad, version 3.1, Wijk bij Duurstede, The Netherlands). 
The lntelliGate™ image-based gating method was applied to 
eliminate catheter-induced image artifacts, by retrospectively 
selecting end-diastolic frames. 16 
In order to avoid the significant impact of inter-observer variabil-
ity, 17 contour detection was performed by a single c-:xperienced IVUS 
analyst who was blinded for the randomization allocation and time-
point of the study. longitudinal and cross-sectional views were used 
to determine the contours. 
The contours of the c-:xternal elastic membrane (EEM) and the 
lumen-intima interface enclosed an area that was defined as the 
coronary plaque plus media area. Plaque burden (PB) was defined 
as [(EEM.,,..,~- lumenarrol/EE/1\,rca] x 100. Direct measurements 
[lumen and vessel cross-sectional area (CSA)] were also determined. 
In the baseline IVUS study, a ROI was identified using identifiable 
landmarks such as side-branches and the coronary ostium. At 
3-year follow-up, the same matched ROI was identified using the 
original anatomical landmarks to determine the lumen and vessel 
dimensional changes over time and consequently to calculate the 
impact on plaque changes. In order to assess more precisely the 
heterogeneous remodelling pattern within a vessel, the ROis were 
subsequently subdivided in matched 5 mm sub-segments indepen-
dently of the length of the pullback in the original IVUS study. 
Segments with a PB <10% were excluded. 
Coronary remodelling was assessed using continuous and categori-
cal variables. The remodelling index (Rl) was defined as EEM"'""' at 
follow-up divided by the EEMarcu at baseline. 
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Finally, we evaluated the number of segments presenting positive 
remodelling (defined as a relativc-: increase in vessel CSA >2 SD from 
the mean relative intra-observer difference) and negative remodel· 
ling (defined as a relative temporal decrease >2 SD from the mean 
relative intra-observer difference). 
IVUS tissue characterization 
We used a computer-aided, in-house developed gray-scale value 
analysis programme for plaque characterization.18 Using the mean 
gray level of the adventitia as a threshold, plaque was classified 
as more (hyperechogenic) or less (hypoechogenic) bright in relation 
to the adventitia. Upper and calcified tissue was defined as tissue 
that has a mean gray value higher than the mean adventitial inten· 
sity plus two times its standard deviation. The echogenicity soft-
ware calculated the distribution of the gray-values present in the 
adventitia layer. When this distribution was not normal (severely 
calcified vessels), the data were excluded for IVUS analysis since 
the acoustic shadowing obscures the media-adventitia interface 
thus introducing serious inaccuracy in the contour detection. 
Statistical analysis 
Discrc-:te variables arc-: presented as counts and percentages. 
Continuous variables are presented as means ± SD or medians 
(inter-quartile range) as indicated. Pearson correlation coeffid-
c-:nts were performed in order to estimate correlations between 
measurements. 
Differences between groups were assessed by paired and unpaired 
Student's t-test when applicable. Fisher's exact test was used for 
categorical variables. A two-sided ?-value <0.05 was required for 
statistical significance. All analyses were performed using SPSS 
version 13.0 software (Chicago, IL, USA). 
Results 
Study population 
A total of 118 patients who had completed lVUS investi· 
gation at baseline and follow-up were included in the study. 
Populations were well matched (Table 1). The mean age 
was 56.6 ± 8.9, 100 (83.3%) were mate, 11 (9.2%) had dia-
betes mellitus, 59 (49.2%) had history of prior myocardial 
infarction and 30 (25.0%) had hypertension. With regards 
to concomitant baseline medication, 115 (95.8%) were on 
aspirin, 67 (55.8%) were receiving beta-blockers, 32 (26.7%) 
were receiving nitrates, 46 (38.3%) were on calcium channel 
blocker therapy and 91 (75.8%) were on lipid-lowering 
therapy. Coronary risk factors and baseline blood pressure 
were well balanced between groups (Table 1). 
At a median follow-up of 3.0 (range 1.9, 4.1) years, the 
rate of adverse events was minimal. Coronary revascutariza-
tion [2 (3.3%) vs. 4 (6.9%), P= 0.38) and acute myocardial 
infarction [1 (1.7%) vs. 3 (5.2%), P= 0.30] rates were not 
statistically significant between perindopril and placebo 
groups. No deaths, strokes or admissions for heart failure 
were reported. 
IVUS intraMobserver variability 
Fifteen cases (678 frames) were re-analysed by the same 
observer yielding minor differences between the 2 measure-
ments. Relative differences for lumen, vessel, and plaque 
CSA were 1.43 ± 4.2%, 1.01 ± 3.4%, and 3.50 ± 8.5%, res-
pectively. In addition, lumen (?- = 0.99, P < 0.0001 ), 
vessel (?-=0.99, P<0.0001), and plaque (?-=0.87, P< 
0.0001) CSA measurements were highly correlated. 
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Table 1 Study population 
Perindopril Placebo P·vatue 
(n"" 60) (n"" 58) 
Baseline characteristics 
Age (years ± SO) 57.9::::9.2 55.2 ± 8.5 0.09 
Male sex 50 (83.3) 50 (86.2) 0.67 
Diabetes 4 (6.7) 7 (12.1) 0.32 
Hypertension 12 (20.0) 18(31.0) 0.17 
Smoking 15 (25.0) 11 (19.0) 0.43 
Hypercholesterolemia 51 (85.0) 47 (81.0) 0.57 
Family history of CHD 16 (26.7) 17 (29.3) 0.75 
Previous Ml 32 (53.3) 27 (46.6) 0.47 
Previous PTCA 53 (88.3) 57 (98.3) 0.03 
Previous CABG 1 (1.7) 0 (0.0) 0.33 
Systolic BP 130.6 ± 14.2 132.4 ± 13.6 0.48 
Diastolic BP 78.9 ± 6.9 79.2 ± 7.5 0.78 
BMI 26.5 ± 2.6 27.4 ± 3.1 0.91 
Heart rate 68.5 ± 10.1 65.7±7.1 0.09 
Anginal status 
CCS I 50 (83.3) 45 (77.6) 0.44 
ccs )I 8 (13.3) 12 (20.7) 0.29 
CCS Ill 2 (3.3) 1 (1.7) 0.58 
CCS IV 0 (0.0) 0 (0.0) NA 
Other medications 
Platelet inhibitors 58 (96.7) 57 (98.3) 0.58 
Beta-blockers 32 (53.3) 35 (60.3) 0.45 
Nitrates 20 (33.3) 12 (20.7) 0.13 
Ca·channel blockers 26 (43.3) 20 (34.5) 0.33 
Lipid lowering agents 46 (76.7) 45 (77.6) 0.91 
At 3-year follow-up 
Systolic BP 130.2 ± 16.5 131.1 ± 14.1 0.66 
Diastolic BP 76.5 ± 8.5 79.0 ± 8.4 0.12 
Other medications 
Platelet inhibitors 53 (88.3) 52 (89.7) 0.82 
Beta-blockers 37 (61.7) 36 (62.1) 0.97 
Nitrates 12 (20.0) 11 (19.0) 0.89 
Ca-channel blockers 20 (33.3) 21 (36.2) 0.75 
Lipid lowering agents 52 (86.7) 47 (81.0) 0.41 
Hypercholesterolemia defined as cholesterol >6,5 rnmolll or on 
lipid-lowering therapy. 
Blood pressure (BP) >160/95 mmHg or receiving antihypertensive 
treatment. 
CCS, Canad!;m Cardiovascular Society. 
Intravascular ultrasound measurements 
A total of 118 matched evaluable IVUS (711 matched 5 mm 
segments) were available at follow-up. Fifty-eight patients 
were excluded from the final analysis (29 from each group) 
due to sub-optimal IVUS quality (due to severely calcified 
vessels, severe artifacts or absence of clear anatomical 
landmarks). Quantitative IVUS results are shown in Table 2. 
In the perindopril group, the temporal change in mean 
plaque CSA compared with baseline was ~0.15 ± 1.7 mm2 
(P = 0.11 ). For the placebo group, the change was 
~0.01 ± 1.7mm2 (P=0.95), with a P-value of 0.27 
between groups. The temporal change in mean vessel CSA 
was ~0.18 ± 2.4 mm2 in the perindopril group and 0.19:;: 
2.4 mm2 in the placebo group, with a P-value of 0.04 
between groups. With regards to plaque hypoechogenicity, 
no significant difference was present between groups (peri· 
ndopril ~0.30±1.7mm2 vs. placebo ~0.11±1.7mm2 , 
P = 0.12). Both groups showed a highly hetero· 
geneous remodelling pattern along the coronary segments 
Table 2 Intravascular ultrasound quantitative analysis 
Mean Treatment Placebo P·value 
cross-sectional (n:::: 360) (n""' 351) 
area (mm2) 
Vessel 
Baseline 15.60 ± 5.0 15.82±5.1 0.57 
FoUow-up 15.42 ± 4.8 16.01 ±4.9 
Nominal change -0.18 ± 2.4 0.19 ±2.4 0.04 
Relative change -1.18 ± 17.0 1.20±15.7 
P-value 0.15 0.13 
compared 
with baseline 
Lumen 
Baseline 9.21 ± 3.9 9.76±4.1 0.07 
Follow-up 9.17±3.9 9.96±4.4 
Nominal change -0.04± 1.9 0.20 ± 2.4 0.14 
Relative change -0.42 ± 23.4 2.03 ± 26.6 
P·value 0.70 0.12 
compared 
with baseline 
Plaque 
Baseline 6.39 ± 2.8 6.06 ± 2.6 0.10 
Follow-up 6.25 ± 2.7 6.05 ± 2.8 
Nominal change -0.15::!: 1.7 -0.01 ± 1.7 0.27 
Relative change -2.28::!: 28.2 -0.09 ± 32.6 
P-value 0.11 0.95 
compared 
with baseline 
Plaque burden (%) 
Baseline 41.29 ± 13.1 39.01 ± 12.8 0.02 
Follow-up 40.81 ± 13.4 38.55::!: 14.3 
Nominal change -0.48 ± 8.1 -0.47::!: 9.5 0.98 
Relative change -1.16 ± 22.9 -1.20±29.9 
P·va\ue 0.26 0.36 
compared 
with baseline 
Hypaechogeniclty 
Baseline 5.87 ± 2.6 5.66 = 2.4 0.29 
Follow-up 5.56 ± 2.4 5.56 ± 2.5 
Nominal change -0.30 ± 1.7 -0.11 ±1.7 0.12 
Relative change -5.19 ± 32.2 -1.90±34.5 
P-va\ue 0.001 0.23 
compared 
with baseline 
(Fi3ure 1). Nevertheless, the placebo group showed a 
larger mean R! than the perindopril group (1.03::: 0.2 vs. 
1.00::: 0.2, P = 0.06). Of interest, negative remodelling 
was present in 124 (34.4%) segments in the perindopril 
group and in 86 {24.5%) segments in the placebo group. Con· 
versely, positive remodelling was observed in 102 (28.3%) 
segments in the perindopril group and in 110 (31.3%) seg· 
ments in the placebo group, with a significant (/) differ· 
ence between groups (P = 0.01 ). These changes are 
depicted in Table 3. 
Linear regression analysis 
The temporal change in vessel dimensions assessed by the R! 
was significantly correlated to the change in plaque dimen· 
sions (r = 0.48, P < 0.0001 ). The degree of such correlation 
was higher in the perindopril group than in the placebo 
group (r=0.58, P <0.0001 and r= 0.36, P< 0.0001, 
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Figure 1 Linear regression scatter plot between the wmodt>lling Index <:~nd 
the difference 1n plaque cross·sectional area. See online supplcmcntilry 
materi<ll for colour version of th!s figure. 
Table 3 Frequency of 5 mm segments with different remodelling 
patterns wlth perindopril and placebo, respectively 
Perindopril, n Placebo, n P·vatue (i 
(%) (n= 360) (%) (n-= 351) across group) 
Neutral 134 (37.2) 155 (44.2) 0.01 
Positive 102 (28.3) 110 (31.3) 
remodellingo 
Negative 124 (34.4) 86 (24.5) 
remodellingb 
"Defined as J rel<~tivc Increase 1n ve:;sct CSA >Z SD from the mean rcla· 
ttvc tntra·obscrvcr difference. 
bDeflned as a relative tcmporill decrease >2 SD from the mean relative 
intra-observer difference. 
respectively). As expected, the change in hypoechogenic 
content was highly related to the change in plaque 
(r = 0.95, P < 0.001) and vessel (r = 0.45, P < 0.001) CSA. 
A strong relationship was found between changes in 
plaque and changes in vessel size (perindopril r = 0.62, 
P < 0.0001 and placebo r= 0.35, P < 0.0001 ). Such relation 
became stronger with increasing levels of PB at baseline 
(Figure 2A). In parallel, the placebo group showed a signifi· 
cant inverse relationship between the change in plaque and 
lumen CSA that was stronger at earlier stages of the disease 
(Figure 26). 
Discussion 
The importance of coronary remodelling as a factor that has 
a major impact in the maintenance of lumen dimensions has 
been undoubtedly established. 1 Recently, several investi-
gators have linked this originally deemed protective com-
pensatory response of the vessel to the presence of a 
more unstable phenotype and plaque rupture.2· 5 ·19 Conver-
sely, a paradoxical negative remodelling pattern has been 
associated with a more stable clinical presentation and 
lesion phenotype. 2•20 To date, most studies have assessed 
coronary remodelling at a single time-point and focally 
within the vessel, using proximal and distal references as 
surrogates of vessel size before it becomes diseased. 
However, coronary atherosclerosis is commonty a diffuse 
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disease and finding a healthy reference is hard to attain. 
Moreover, such diffuse pattern implies a heterogeneous 
behaviour of atherosclerotic disease within a single vessel. 
Yet, although the assessment of coronary remodetling 
using serial determinations is highly required it has been 
scarcely exploited. 1 3·21 
The findings of the present longitudinal in vivo study offer 
several insights towards the better understanding of the 
long-term effect that ACE-inhibitors have on coronary 
atherosclerosis. 
Overall, no significant differences regarding the temporal 
changes in plaque and lumen size were present between 
patients assigned to perindopril and placebo. Nevertheless, 
there was a significant difference between groups regarding 
the change in vessel size. 
Negative remodelling occurred more frequently in the 
perindopril group than the placebo group. It is noteworthy 
though that, as a result of a parallel non-significant plaque 
regression effect, this slight constrictive effect had no 
impact on the lumen size. Similarly, the placebo group 
showed a larger mean Rl than the perindopril group and a 
trend towards an enlargement of the coronaries with no 
change in plaque size, resulting in a non-significant increase 
of the lumen area. 
The observed effect of perindopril on vessel remodelling 
might potentially be owed to the reduction in metalloprotei-
nase levels induced by ACE-inhibitors,22 since these enzymes 
have a central role in the pathophysiology of vessel remodel-
ling.12 Lipid lowering therapy with statins has recently 
shown to promote negative remodelling. The pathophysiol-
ogy of such finding might be attributed to the inhibition 
of matrix metalloproteinase production. 23 Statins and 
ACE-inhibitors thus have a common inflammatory target 
related to coronary remodelling and plaque stabilization. 
Contrasts with histopathology 
Coronary remodelling has been long believed a vessel 
response to accommodate increasing burden of plaque 
without affecting the lumen patency. 1 ln his study, Glagov 
made a static assessment of the correlation between 
plaque and vessel size in explanted left main coronary 
arteries. Our results are in line with the study of Glagov 
with respect to the fact that coronary remodelling is a 
phenomenon that occurs from very early stages of the 
disease and is mainly driven by the progressive accumulation 
of plaque within the vessel wall. Nevertheless, in our 
study, the strength of the relationship between changes in 
plaque CSA and changes in lumen CSA decreased with 
increasing levels of stenosis at baseline (Figure 1). Conver-
sely, Glagov established that the positive correlation 
between vessel size and plaque size was stronger in sections 
with stenoses ::::20% and that an abrupt drop in lumen area 
was evident only after the obstruction reached 30-40%. 1 In 
brief, our results contradict Gtagov's in the sense that 
control group patients showed higher remodelling capacity 
(and lumen manteinance) when the baseline severity of 
the disease was higher. lt is noteworthy, however, that 
Glagov's seminal investigation was performed in the left 
main coronary artery, a coronary segment with a more 
benign plaque composition,24 whereas it has previously 
been shown that the remodelling pattern of p\aques 
is highly related to the underlying composition of plaques.5 
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lt should be emphasized as well that statins, which have been 
shown to have a significant effect on plaque14 and vesset23 
size, are currently administrated in an almost unrestricted 
fashion to cardiovascular patients, whereas two decades 
ago they were limited to patients with hypercholesterolemia. 
Finally, it is worth mentioning that, although there was no sig-
nificant difference between groups regarding the change of 
hypoechogenic tissue, the administration of perindopril 
induced a significant beneficial shift in the echogenicity of 
plaques compared with baseline. 
The findings of the present study confirm that coronary 
atherosclerosis is a highly dynamic disease. Moreover, the 
constrictive, yet lumen-preserving, effect shown has pre-
viously been associated with a more stable phenotype of 
Lesions and better clinical presentation, suggesting that 
this pattern is associated with plaque stabilization. 
Study limitations 
A substantial number of vessels were excluded from the 
analysis due to sub-optimal image quality, principally due 
to the presence of severely calcified vessels. Nevertheless, 
we want to emphasize that this was essential to have a 
highly accurate assessment of the vessel contours. Only a 
single coronary artery was assessed by IVUS potentially 
being not representative of the entire coronary tree. More-
over, different IVUS catheters and consoles were used 
over a 3-year period, potentially influencing the results. 
Nevertheless, individual serial assessments were performed 
using identical IVUS catheters. To correct for any dimen-
sional discrepancies, the results of the 30 MHz catheter 
were adjusted using a previously reported mathematical 
algorithm.25 Larger studies in higher risk patients using 
IVUS as primary endpoint might conclusively determine the 
rote of ACE-inhibitors in atherosclerosis natural history. 
Conclusion 
Our findings convey the relationship between plaque pro-
gression and coronary remodelling. In this study, perindopril 
was associated with a constrictive remodelling pattern 
without affecting the lumen, suggesting that this pattern 
is associated with plaque stabilization. 
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SUMMARY 
Invasive coronary imaging techniques have improved our understanding of ath-
erosclerosis and have helped us to evaluate the effectiveness of new drugs and 
new intravascular devices. Rapidly, we have adopted them and integrated into our 
clinical-decision-making process in the catheterisation laboratory. Greyscale IVUS 
has been so far the most useful invasive imaging technique. Using greyscale JVUS, 
some lipid-lowering drugs showed to decrease plaque size, thereby these drugs 
have been widely included as part of standard of carel. 2 • Moreover, IVUS-guided 
stenting, following strict criteria of implantation, proved to decrease the resteno~ 
sis rate3 and more recently it has been published that this approach apparently 
decreases stent thrombosis4. The recent introduction of tissue characterization by 
means of radiofrequency data analysis (Virtual Histology'") offers a more detailed 
evaluation of the atherosclerotic plaque. This technique brings the possibility to 
go beyond plaque size evaluation to a more sophisticated approach which is to 
assess changes in tissue types. In IBIS 2 study', after 12 months and despite high 
adherence to standard-of-care treatment, the necrotic core continued to expand 
among patients receiving placebo, while Lp-PLA2 inhibition with darapladib 
prevented necrotic core expansion. 
However, the lack of high resolution of IVUS has hampered its broad clinical 
application. Therefore, new light-based imaging techniques have been introduced. 
Optical Coherence Tomography (OCT) and the new swept source OCT (55-0CT 
or frequency domain OCT) have gained sympathy among interventionalists due 
to the sharp and informative images especially at the luminal side of the vessel 
wall. During stenting, OCT offers the possibility to assess stent apposition in 
great detail and can identifY the presence of vessel injury due to stent implanta-
tion. At follow-up, the tissue coverage of individual struts can be imaged with 
OCT. This is of increasing interest in drug-eluting stents in which the neointimal 
proliferation is inhibited to such extent that might not be visualized with conven-
tional intracoronary imaging techniques such as IVUS. Regarding plaque type 
characterization by OCT, although less complete due to its lack of penetration, 
this technique holds promise due to its ability to provide very detailed informa-
tion about plaque composition, presence of macrophages and thickness of the 
fibrous cap. 
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INTRODUCTION 
So far, only significant lesions in the coronary angiogram have been treated either 
by percutaneous cornary intervention (PCI) or coronary bypass artery grafting 
(CABG); while normal-looking coronary segments in angiography have been 
regarded as "disease-free" and mild/moderate stenoses as "non-treatable" neither 
by PCI or CABG; from these non-significantly diseased areas may potentially rise 
acute coronary events. In response to this, many imaging coronary techniques 
have been developed to study these areas to better understand the pathophysiol-
ogy of atherosclerotic disease and to assess the performance of medical interven-
tions that may ultimately have an important impact on the prevention of acute 
myocardial infarction and death. This review aims at describing the usefulness 
of virtual histology (VH) to study intact plaques as well as the performance of 
coronary interventions. Likewise, a review on the applicabiliry of optical coher-
ence tomography (OCT) in coronary plaques and interventional procedures is 
here reported. 
INTRAVASCULAR ULTRASOUND RADIOFREQUENCY ANALYSIS: VIRTUAL 
HISTOLOGY 
7. Description of the technique 
Technologically speaking, the main difference between greyscale IVUS and Vir-
tual Histology is that greyscale IVUS imaging is only formed by the envelope 
(amplitude) of the radiofrequency (RF) signal. The frequency and power of the 
signal commonly differ benveen tissues, regardless of similarities in the amplitude. 
Figure 1. IVUS-Virtual Histology (IVUS-VH, Volcano Corp., Rancho Cordoba, 
USA) involves spectral analysis of this data to construct tissue maps that classifY 
plaque into four major components (fibrous - green, fibre-fatty - light green, 
necrotic core - red and dense calcium - white). 6 These tissue-maps have been 
validated ex-vivo by comparison with histology, the overall predictive accuracies 
were 93.5% for fibrous, 94.1% for fibro-fatry, 95.8% for necrotic core and 96.7% 
for dense calcium with sensitivities and specificities ranging from 72 to 99o/o. 7 
In the past, Virtual Histology was acquired using exclusively the In-Vision 
Gold console and a 20 MHz Eagle Eye- Gold catheter (Volcano Corporation, 
Rancho Cordova, USA). Currently, the Volcano s5 Imaging System is used, one 
of his components, the Virtual Histology System, is intended to perform spectral 
analysis of RF ultrasound signals of vascular features. Two types of catheters can 
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Figure 1: Schematic diagram of virtual histology (IVUS-VH) and optical coherence tomography 
(OCT). Left: The ultrasound signal is generated in a piez:oelectric crystal that transmits and receives 
sound waves. Ultrasound reflected by the tissue deforms crystal generating radiofrequency (RF) 
signal (a). Greyscale IVUS is derived from the amplitude (b) ofRF signal, discarding information 
beneath the peaks of the signal. IVUS-VH analysis uses several additional spectral parameters to 
identifY four plaque components (c). Plaque components that are identified are dense calcium 
(white), fibrous (green), fibro-fatty (greenish-yellow) and necrotic core (red) (d). 
Right: the electromagnetic spectrum encompasses the follovving regions: x-rays, microwaves and light 
(e). The visible part of the spectrum ranges from 0.4 to 0.77 p.m. The wavelengths used for OCT are 
indicated. Since the speed of light is much faster than that of sound, it is needed to use correlation or 
an interferometer to measure the backsca.ttered light. The interferometer splits the light source into 
two arms- a reference arm and a measurement arm- (/J. The measurement arm is directed into the 
tissue through the image wire and collects the backscattered light (g). The light coming back from 
both arms is recombined at a detector (h) in which the interferogram- the sum of the two signals 
- is generated. The optical properties of the tissue can be deduced by comparing the back-re:Hected 
optical intensity of the wo arms (i). Panel d and i correspond to the same anatomical region. Please 
note that the shape of the calcified regions is similar. 
be used with this system, the 20 MHz electronic catheter or a 45 MHz mechanic 
catheter. The VH classification tree for the 45 MHz is under development. An 
automated pullback device is used, usually the pullback speed is set at 0.5 mm/s. 
IVUS-VH acquisition is ECG-gated at the R-wave peaks. Table 1. 
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Table I. Technical specifications for virtual histology and optical coherence tomography 
Virtual Histology M3 M4 
Frame Rate, fps Heart rate 20 100 
# Lines/frame,n 256 240 450 
Pullback speed, mm/s 05·1.0 3,0 20 
Scan diameter, mm 10 6$• 8.3. 
Lateral resolution, f.im 346f.lm at 23mm 25-30 25-30 
Axial resolution, f.lm 138f.lm at 23mm 15·20 15-20 
Catheter profile, F 3,1 1.4 2.6 
Technology !VUS 1ime-domain OCT Swept-source OCT 
* In saline 
2. Study of intact plaques 
i. Virtual histology and necrotic core distribution 
Identification of subclinical high-risk plaques is potentially important because they 
may have greater likelihood of rupture and subsequent thrombosis. In 55 patients, 
the mean necrotic core percentage- in nonculprit vessels- was significantly larger 
in patients with acute coronary syndrome (ACS) when compared with stable 
patients (12.2±7.0% vs. 7.4±5.5%, p=0.006). In addition, stable patients showed 
more fibrotic vessels (70.9±9.3% vs. 63.9±9.1 %, p=0.007) 8• However, not only the 
amount of necrotic core content is larger in patients with ACS, but it appears that 
NC is also unevenly distributed. In 51 patients, the overall length of the studied 
vessels (i.e. non-culprit), subsequently divided into 10 mm segments, was 41.5± 13 
mm. The percentage of necrotic core resulted to be increased in the first (median: 
8.8%; IQR: 5.7-18) vs. the third (median: 6.1 %; IQR: 3.2-12) (p=0.036) and 
fourth (median: 4.5%; IQR: 2.4-7.9) (p=0.006) segment. At multivariable regres-
sion analysis, distance from the ostium resulted to be an independent predictor of 
relative necrotic content [beta=-0.28 (95o/oCI: -0.15, -0.41)], together with older 
age, unstable presentation, no use of statin, and presence of diabetes mellitus9• 
ii. Plaque characterization 
There is a continuous debate regarding how coronary atherosclerosis lesion pro-
gresses. Some believe that atherosclerotic lesion progression starts with pathologic 
intimal thickening (PIT) in which lipid accumulates in areas rich in proteoglycans 
(lipid pools), but no trace of necrotic core is seen. Others believe that the earli-
est change of atherosclerosis is the fatry streak, also called as intimal xanthoma. 
The earliest lesion with a necrotic core is the fibroatheroma (FA), and this is the 
precursor lesion that may give rise to symptomatic heart disease. Thin-capped 
fibroatheroma (TCFA) is a lesion characterized by a large necrotic core containing 
numerous cholesterol clefts. The overlying fibrous cap is thin and rich in inflarn-
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Figure 2: Plaque classification using OCT and IVUS-VH. OCT: optical coherence tomography; 
VH: virtual histology; NC: necrotic core; AIT: adaptive intimal thickening; PIT: pathological 
intimal thickening; FC: fibrocalcic; FT: fibrotic; CaP A: calcified fibroatheroma; FA: fibroatheroma; 
CaTCFA: calcified thin cap fibroatheroma; TCFA: thin cap fibroatheroma. 
matory cells, macrophages and T lymphocytes with few smooth muscle cells. A 
study done by Burke et al10• identified a cut-off value for cap thickness of <65 
microns for vulnerable coronary plaque definition. 
Virtual Histology can potentially identifY all above-mentioned plaque types 
including thin-capped fibroatheromas. The progression of the disease can also be 
followed-up. Figure 2 outlines the virtual histology plaque and lesion types that 
are proposed based on the above pathologic data. 
Our group evaluated the incidence of IVUS-derived thin-cap fibroatheroma 
(IDTCFA) using IVUS-VH 11 • IDTCFA was defined as a lesion fulfilling the 
following criteria in at least 3 consecutive frames: 1) necrotic core ;:::10°/o without 
evident overlying fibrous tissue, 2) plaque burden :,40%. In this study, 62% of 
patients had at least one IDTCFA in the interrogated vessels. ACS patients had 
a significantly higher incidence of IDTCFA than stable patients (p= 0.018). 
Finally, a clear clustering pattern was seen along the coronaries, with 66.7% 
of all IDTCFAs located in the first 20 mm. This distribution of IDTCFAs is 
consistent with previous clinical studies, with a clear clustering pattern from the 
ostium demonstrating a non-uniform distribution of vulnerable plaques along the 
coronary tree 12• Rioufol et a!., reported that patients presenting with ACS had 
370 
Virtual Histology and Optical Coherence Tomography: from Research to a Broad Clinical Application. 
Figure 3. IVUS-derived thin cap fibroatheroma by and virtual histology and its corresponding 
optical coherence tomography image (OCT). Right: Virtual histology image is color coded: red-
necrotic core, white- dense calcium, green- fibrous and greenish- fibro-fatty. There is an area of 
con:Huem necrotic core (NC) that is in direct contact with the lumen (CL). Left: OCT image shows 
an area with low reflectivity behind a thin cap. These characteristics have been correlated with a 
fibrous cap overlying a necrotic core rich area (arrow). 
a significantly higher prevalence of plaque ruptures even in non-culprit vessels, 
supporting the concept of a multi-focal process 13• Of note, the plaque burden 
and the mean necrotic core areas of the IDTCFAs detected by IVUS-VH were 
also similar to previously reported histopathological data (55.9% vs. 59.6% and 
19% vs. 23% respectively) 14• 
We have developed a software to quantifY the amount of necrotic core in 
contact with the lumen, enabling refinement of our analysis. Our current defini-
tion of an IVUS-derived TCFA is a lesion fulfilling the following criteria in at 
least 3 frames: 1) plaque burden ~ 40%; 2) confluent necrotic core ~ 10% in 
direct contact with the lumen (i.e. no visible overlying tissue) 15 • Using this refined 
definition of IVUS-derived TCFA, in patients with ACS who underwent IVUS 
of all three epicardial coronaries) on average, there were 2 IVUS-derived thin 
cap fibroatheroma per patient with half of them showing outward remodeling 15• 
Figure 3. 
The frequency and distribution of TCFA identified by virtual histology in-
travascular ultrasound in acute coronary syndrome (ACS = 105 pts) and stable 
angina pectoris (SAP =107 pts) in a 3-vessel IVUS-VH study have been recently 
published by Hong et al. 16 1here were 2.5 ± 1.5 in ACS and 1.7 ± 1.1 in SAP 
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TCFAs per patient, p <0.001). 76 patients with ACS and 58 with SAP had 
multiple ID-TCFA (p = 0.009). Presentation of ACS was the only independent 
predictor for multiple ID-TCFA (p = 0.011). Eighty-three percent of ID-TCFA 
were located within 40 mm of the coronary. 
The potential value of these VH IVUS-derived plaque types in the predic-
tion of adverse coronary events is currently under evaluation in an international 
multicentre prospective study (PROSPECT study). 
Important technical considerations about Virtual Histology 
Provides information of four tissue types: fibrous, fibro-fatry, necrotic core 
and dense calcium. 
Evaluation of the layout of these four different tissue types gives informa-
tion of different plaque types. 
As Virtual Histology is an IVUS derived technique, its axial resolution is 
limited. This precludes assessment of "thin" fibrous cap. 
Vinual Histology does not provide information on thrombus and inflam-
mation. 
iii. Virtual Histology and plaque rupture 
Our group described the ruptured plaque profile in 40 patients referred for cardiac 
catheterization 17• There were 13 with stable angina, 12 with unstable angina, and 
15 with acute myocardial infarction. Ruptured plaque was identified in 26 patients 
and, as expected, was more frequent in patients with acute myocardial infarction 
and unstable angina. Patients with ruptured plaques have larger body mass index 
when compared with those without plaque rupture and were more likely smokers 
and patients with ruptures had more diffuse calcification and necrotic core area. 
Of note, the location of plaque ruptures in this study mirrors the pathological 
findings 18• In our study, the proximal left anterior descen<:ing coronary artery was 
the most common site of plaque rupture. In a pathological series of 79 ruptures, 
Burke et al.18 have found 7 4% in the proximal left anterior descending. 
Similarly, in the report by Hong eta!., the frequency and distribution of rup-
tured plaques identified by IVUS-VH in acute coronary syndrome (ACS = 105 
pts) and stable angina pectoris (SAP =107 pts) in a 3-vessel IVUS-VH study were 
reported". There were 76 ruptured plaques (55 in ACS and 21 in SAP). Twelve 
patients withACS and 1 with SAP had multiple ruptured plaques (p <0.001). Pre-
sentation of ACS was also the only independent predictor for multiple ruptured 
plaques (p = 0.013). 
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iv. Coronary embolization 
Two studies have evaluated the usefulness of IVUS-VH plaque composition to 
predict the risk of embolization during stenting 19• 20 • In one of them, 71 patients 
with STEMI that underwent primary PCI within 12 hours of the beginning of 
the symptoms were included. After performing thrombectomy with an aspiration 
catheter, IVUS-VH of the infarct-related vessel was performed. The stem was 
then deployed without embolic protection. ST segment re-elevation was used as 
a marker of distal embolization during stenting. Eleven patients presented with 
ST segment re-elevation after stenting. Total plaque volume was similar in both 
groups, but the NC volume was significantly higher in the group of patients with 
ST segment re-elevation (32.9 ± 14.1 mm3 vs. 20.4 ± 19.1 mm3, p < 0.05). On 
receiver-operating characteristic curves, NC volume was the best predictor of ST 
re-elevation after stem deployment. The cut-off point for NC volume that was 
best predictive forST re-elevation was 33.4 mm3, with a sensitivity of 81.7% and 
a specificity of 63.6%. The second study included 44 patients who underwent 
elective coronary stenting. Small embolic particles liberated during stenting were 
detected as high-intensity transient signals (HITS) with a Doppler guidewire. Pa-
tients were divided into the tertiles according to the HITS counts. Dense calcium 
and NC area were significantly larger in the highest tertile. In the multivariate 
logistic regression analysis, only necrotic core area was an independent predictor 
of high HITS counts (odds ratio 4.41, p = 0.045). 
v. Virtual histology as imaging tool to assess temporal changes in coronary 
atherosclerotic plaques beyond plaque size 
Lipoprotein-associated phospholipase A, (Lp-PLA) is expressed abundantly 
in the necrotic core of coronary lesions and products of its enzymatic activity 
may contribute to inflammation and cell death, rendering plaque vulnerable to 
rupture. 
IBIS 2 study compared the effects of 12 months of treatment with darap-
ladib (oral Lp-PLA, inhibitor, 160 mg daily) or placebo on coronary atheroma 
deformability (IVUS-palpography) and plasma hs-CRP in 330 patients with 
angiographically documented coronary disease. Secondary end points included 
changes in necrotic core size (IVUS-VH), atheroma size (IVUS-greyscale), and 
blood biomarkers. Background therapy was comparable between groups, with 
no difference in LDL-cholesterol at 12 months (placebo: 88±34 and darapladib: 
84±31 mg/dL, p=0.37). In contrast, Lp-PLA, activity was inhibited by 59% with 
darapladib (p<O.OOl versus placebo). After 12 months, there were no significant 
differences between groups in plaque deformability (p=0.22) or plasma hsCRP 
(p=0.35). In the placebo-treated group, however, necrotic core volume increased 
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significantly, whereas darapladib halted this increase, resulting in a significant 
treatment difference of -5.2 mm3 {p=0.012). These intra-plaque compositional 
changes occurred without a significant treatment difference in total atheroma 
volume {p=0.95). 
Despite adherence to a high level of standard of care treatment, the necrotic 
core continued to expand among patients receiving placebo. In contrast, Lp-PL~ 
inhibition with darapladib prevented necrotic core expansion. 
3. Clinical findings in the stent studies 
Stent thrombosis is one of the major concerns after drug-eluting stent implanta-
tion. Multiple mechanical causes (i.e. stent underexpansion, edge dissection, geo-
graphic miss, residual stenosis, incomplete stent apposition and aneurism) have 
been postulated. These features are easily identifiable by greyscale intravascular 
ultrasound. However, it is uncertain which of them are inextricably related to 
stent thrombosis, primarily due to the low number of such patients studied by 
IVUS in case control studies. 
Our knowledge of the pathophysiology of late DES thrombosis is derived 
from pathologicsamples21"24 • It has been demonstrated that DES cause substantial 
delayed healing (the most common cause of late DES thrombosis at autopsy) 
characterized by the lack of complete reendothelialization and persistence of fibrin 
when compared with BMS25 • This cannot be assessed by any IVUS modality due 
to its limited axial resolution. 
Other proposed pathological mechanisms of coronary stent thrombosis are 
stenting of necrotic core-rich plaques with extensive tissue prolapse and plaque 
disruption in the proximity of the stented arterial segmenrlr. 25 
Complementary to greyscale IVUS, tissue characterization by IVUS-VH 
analysis has the potential to add valuable information on the pathogenesis of stent 
thrombosis by providing information on plaque composition, specifically on the 
amount of necrotic core and its location (superficial or deep )26 • However, the 
clinical utility ofiVUS-VH analysis in this context has yet to be demonstrated. 
i. Characterization of Edge Effects 
Virtual histology technique provides both geometrical and compositional analysis 
of each frame, allowing us to have the combined assessment of necrotic core and 
plaque size; we studied 24 patients in whom 26 stented segments (by angiogra-
phy stenting was performed from "normal to normal" coronary segments) using 
IVUS-VH were assessed. 27 1he objective of this study was to investigate in vivo 
the temporal changes occurring at the edges of paclitaxel-eluting stents using 
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IVUS-VH. Serial expansive vascular remodeling was observed at proximal and 
distal stem edges. Remodeling occurred in response to tissue growth, which was 
mainly due to increased fibrofatty tissue. 
We also observed that necrotic core rich areas were left unscented (5mm-prox-
imal edge mean necrotic core 17.0±13.5% and 5mm-distal edge 18.5±16.5%); 
however, no stent thrombosis has been observed in this small cohort of patients 
at 6 months follow-up. It has yet to be determined in a larger population whether 
incomplete coverage of necrotic core-rich coronary plaques or disruption of adja-
cent necrotic core areas by DES impact on long-term clinical events27. 
ii. Serial changes in patients stented with a fully absorbable stent 
We assessed the feasibility and safety of a bioasorbable everolimus-eluting stent 
(BVS). In a prospective, open-label study we enrolled 30 patients with a single 
de-novo lesion that was suitable for treatment with a single BVS. The serial as-
sessments of intravascular ultrasound assessments with virtual histology showed a 
significant decrease at 180 days in the dense calcium area, whereas we measured 
significant increases in fibro-fatty and fibrous areas. These tvvo observations sug-
gest on the one hand the first signs of the expected bioabsorption of struts, and on 
the other hand that the tissue growth documented at follow-up inside and outside 
the stem struts consists of fibrous and fibro-fatty tissues. 
Clinical usefulness ofVirtual Histology 
In the IBIS 2 study, the inhibition ofLp PLA,_ halted necrotic core progres-
sion. 
The potential value ofVH IVUS-derived plaque types in the prediction of 
adverse coronary events is currently under evaluation in an international 
multicentre prospective study (PROSPECT study). 
Necrotic core rich plaques have been related to distal embolization during 
percutaneous coronary interventions. 
OPTICAL COHERENCE TOMOGRAPHY 
7. Introduction 
Greyscale intravascular ultrasound allows evaluation of coronary atherosclerosis 
but its limited resolution (axial 150-200 flm, radial200-400 flm) precludes the 
visualization of certain microstructures (such as the thin fibrous cap or the fine 
strut coverage)28· 29 • Optical Coherence Tomography (OCT) is a light-based imag-
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ing modality can be used to study tissues in vivo witb near-histologic, ultrahigh 
resolution30 • This has provided new insights into tbe interaction between tbe stem 
and the vessel wall and has allowed a more precise characterization of atheroscle-
rotic plaques. 
2. Technical principles of OCT 
Current clinically available OCT systems use time-domain (TD) technology (M2 
and M3 OCT Imaging Systems - LightLab Imaging, Inc., Westford, MA, USA) 
while newer systems tbat are currently under development for clinical application, 
are based on frequency domain technology also called swept-source- SS; i.e. M4 
OCT LightLab Imaging). Time-domain OCT uses low-coherent near-infrared light. 
Figure 1. A wavelength around 1300 nm is selected because it minimizes tbe energy 
absorption in tbe light beam caused by protein, water, hemoglobin and lipids. 
While IVUS uses backscattered ultrasound, OCT uses reflected light to create 
high-resolution cross sectional images of the vessel. Since the speed of light is 
much faster than that of sound, an interferometer is required to measure the 
bad~scattered light. The interferometer splits the light source into two "arms" - a 
reference arm and a measurement arm, which is directed into the tissue. When the 
back-reflected optical intensity of the two arms (interference signal) is measured 
and compared, the optical properties of the tissue can be deduced. Figure 1. The 
intensity of the back-reflected light can be measured and quantified digitally in 
grayscale, enabling tbe creation of a digital image. The imaging deptb of TD-
OCT is approximately 1.5-2.0mm with an axial and lateral resolution of 15rm 
and 25)1m, respectively. Table 1. 
The M2 and M3 OCT Imaging Systems use identical console and PC-based 
operating system, however M3 permits imaging at a higher frame rate (20/sec 
vs. 15.6/sec for tbe M2) with a faster maximum pullback speed (3.0mm/sec vs. 
2.0mm/sec). Table 1. 
The new generation of OCT (SS-OCT or frequency domain OCT) uses a 
swept frequency laser as light source rather than using a broadband light source as 
in conventional TD-OCT. The echo-time delay and amplitude of light reflected 
from the tissue microstructure at different depths are determined by processing 
the interference between the tissue sample and a fixed reference mirror to create 
tbe OCT images31 · 32• These new technology allow a dramatically faster image 
acquisition (up to 40 mm/s), and an increased scan diameter. The latter permits 
imaging of larger arteries. 
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3. Techniques for image acquisition 
Red blood cells represent a non-transparent tissue causing multiple light scat-
tering and substantial signal attenuation. Figure 4a. Therefore, for an adequate 
OCT image acquisition blood must be removed from the vessel. In the past with 
the M2 system, this was achieved with proximal occlusion of the vessel with a 
low-pressure balloon and distal flush delivery (occlusive technique)". However, 
recently the increase in the pullback speed (i.e. with the use of M3) has made 
possible the OCT acquisition while the blood is removed by continuous contrast 
flush trough the guiding catheter without the need of occluding the vessel (non-
occlusive technique )54• 35 • The M2 and M3 systems use an imaging wire that has 
a maximum outer diameter of 0.019" (with a standard 0.014" radiopaque coiled 
tip) and contains an optical fiber core covered by a protective sheath (Image Wire'" 
LightLab Imaging Inc., Westford, MA, USA). In the new swept-source systems 
(i.e. M4 LightLab Imaging) the optical probe is integrated in a rapid-exchange 
Figure 4. Optical coherence tomography images of common stent findings. Panel a depicts 
a frame with insufficient blood clearance. Panel b shows a newly placed stent. Stent struts are 
recognized as bright structures that span 360 degrees with shadowing. Panel c illustrates an 
incomplete stent apposition site. Of note, stent struts are not apposed to the vessel wall (arrows). 
Panel d shows the relationship of a stent and the ostium of a sidebranch (arrowhead). Panel e depicts 
a frame with tissue prolapse. Dotted line denotes the space between two struts. A mass of tissue is 
protruding into the lumen (asterisk). Panel /illustrates a stent with neointimal hyperplasia which 
is the signal-rich area between the stent struts and the lumen (arrows). Panel g shows an overlapped 
segment. Two layers of stent can be seen along the circumference (arrowheads). Panel h illustrates an 
uncovered strut (no tissue is at the endoluminal side of the strut- arrow). In contrast, some other 
struts are covered by neointimal tissue (arrowheads). 
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catheter (crossing profile 2.6 F) that can be delivered in the coronary artery over 
any conventional 0.014"guidewire. 
Our current sertings for OCT acquisition using M3 Light Lab system are: 1. 
continuous contrast injection (usually Visipaque- at 37 degree Celsius) at a flush 
flow rate of3 mL/sec; 2. use of automatic injection (Medrad injection system); 3. 
pullback speed 3 mm/sec and 4. frame rate 20/sec. 
4. Safety of intravascular OCT 
The applied energies in intravascular OCT are relatively low (output power in the 
range of 5.0-8.0 m W) and are nor considered to cause functional or structural 
damage to the tissue. Safery concerns rhus seem mainly dependent on the need of 
blood clearance for image acquisition. One study evaluated the safety and feasibil-
ity of OCT in 76 patients using the occlusive technique. Vessel occlusion rime was 
48.3 ± 13.5 seconds. The most frequent complication was the presence of transient 
events, such as chest discomforr, brady- or tachycardia, and ST-T changes on 
electrocardiogram, all of which resolved immediately after the procedure. There 
were no major complications, including myocardial infarction, emergency revas-
cularization, or death. Furthermore, acute vessel occlusion, dissection, thrombus 
formation, embolism, or vasospasm along the procedure-related artery, were also 
not observed36. In our experience, the introduction in the clinical practice of the 
non-occlusive technique has led to an important reduction in the procedural time 
and in the rate of chest pain and ECG changes during image acquisition. This rare 
is expected to be even lower with the arrival of the new systems with high speed 
pullbacks that allow coronary imaging in few seconds. 
Optical coherence tomography allows examination of the vessel wall in a 
microscopic manner. 
Its excellent axial resolution (15-20 rm) permits precise measurement of 
the thickness of rhe fibrous cap. 
Some investigators have reported macrophage detection in the fibrous cap. 
Although very detailed information can be obtained, irs shallow penetra-
tion prevents from fully assessment of rhe coronary plaques. 
5. Clinical application 
i. Stent evaluation 
Mostly, srent struts can be identified in OCT as highly reflective surfaces with 
shadowing behind. Figure 4b. Due to irs high resolution OCT can be a very valu-
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able tool for the evaluation of rbe acute and long-term impact of catheter-based 
intervention on plaque structure and vessel architecture. This is of increasing 
interest in drug-eluting and new-generation coronary stents such as bioabsorbable 
stents. Drug-eluting stents (DES) have been shown to significantly limit neointi-
mal growth to such extent that the neointima tissue might consist of only a few 
cell layers that cannot be accurately visualised wirb IVUS37• The high resolution of 
OCT might offer the possibility to assess stem apposition and neoimima growrb 
patterns3s. 39. 
A. Stent apposition 
Classically in IVUS studies, incomplete stem apposition is defined as separation 
of at least one stem strut from the vessel wall wirb evidence of blood flow be-
hind the strut (Figure 4c) and not related with a bifurcation (Figure 4d). In the 
DES era, the assessment of stem apposition has become critical due to reported 
observations suggesting an association between incomplete stent apposition and 
thrombosis40 • OCT has demonstrated to be more accurate than IVUS for the 
detection of incomplete strut apposition to the vessel walL In a study in porcine 
coronary arteries in vivo, microanatomic relationships between stents and the 
vessel walls could be clearly identified only by OCT41 • Bouma et a!., imaged 39 
patients (42 stems) showing that incomplete stem apposition was more often ob-
served with OCT than wirb IVUS42 However, to avoid misclassification of struts 
as malapposed some considerations should be raken into account. Most DES are 
constituted by a metal body covered by a polymer. Since OCT can image only the 
endo-luminal surface of the strut due to limited penetration through the metal, 
strut and polymer thickness must be considered in assessing apposition for each 
type of DES design. Only if the distance from the endo-luminal surface of the 
strut to the vessel wall is longer than the sum of rbe metal and polymer rbickness, 
it can be considered that the strut is malapposed. The rbickness of the metal and 
polymer differs for each stem type. Therefore the cut-off point to establish malap-
position must take into account the type of stem. The strut rbickness for the most 
commonly used DES has been reported previously''. OCT has demonstrated its 
value to assess malapposition in the clinical practice. Tanigawa et al., reported that 
in overlapping segments in DES 40% of struts were malappposed despite high 
pressure dilatation with appropriate size balloons44 1he authors hyporbesized rbat 
this could be related wirb rbe delayed reported endothelization and increased risk 
of stem thrombosis in those segments. The same group evaluated the usefulness 
of OCT to assess the struts apposition in heavily calcified lesions showing malap-
position even after high pressure ballon dilatation and rotational atherectomy45 
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B. Stent expansion 
OCT can be useful for the in vivo assessment of acute stem recoil one of the 
features identified as a contributor to inadequate stent expansion. Our group 
reported OCT findings during stepwise post-dilatation of a Cypher stem showing 
a change in stem diameter from 3.5 at 22 arm to 2.94 at 5 atm46 This could be 
clinically relevant as final stem area is known to be an important predictor for 
restenosis and subsequent clinical events. Stent asymmetry, another of the features 
related with stem thrombosis, can be assessed with high precision with OCT. 
C. Identification of vessel injury after stenting 
Due to its higher resolution OCT can also identifY more often than IVUS acute 
complications after stent implantation such as edge dissection and tissue pro-
lapse42. Edge dissection appears in OCT as a disruption in the vessel continuity 
with a visible flap (Figure 5). High-pressure stenting techniques have proved to be 
useful for stent deployment optimization but this strategy can often create certain 
degree of vessel damage in the stem edges47• Although animal and post-mortem 
information correlated vessel injury and in-stent restenosis48' 49 , some IVUS stud-
ies have shown that non-Bow-limiting edge dissections may not be associated with 
an increase in acute or long-term events or the development of restenosis50' 51 • 
However some data suggested that imracoronary imaging may be helpful to assess 
which of these residual dissections could be more prone to acute vessel occlusion. 
Nishida et al., reported that the area stenosis by IVUS at the site of the dissection 
was predictor for the incidence of in-hospital major cardiac adverse events52 • 
Figure 5. Edge dissection. In this patient a drug duting stent was placed proximally in the left 
anterior descending. At the proximal edge of the stent a 4-mm dissection was noted in the optical 
coherence tomography images (a through e). In panel a, stent struts can still be seen (arrows) from 
1 to 5 0' clock, while at 9 0' dock a dissection flap is noted (asterisk). At the proximal end of the 
dissection a calcified plaque can be seen (head arrows in panels d and e). 
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Tissue prolapse can be identified in OCT as protrusion of tissue between the 
struts (Figure 4e). The clinical relevance of the detection of this feature after 
stenting remains controversiaL Pathological examinations have associated stent 
thrombosis with the prolapse of necrotic core between stent struts and is not able 
to provide tissue characterization21 • However, greyscale IVUS study in diabetic 
patients undergoing PC! did not show higher incidence of stent thrombosis in 
patients with plaque prolapse53 • This might be relat ~d with the resolution of grey-
scale !VUS that is not able to detect small amount of tissue protruding between 
the stent struts. In this scenario a high resolution technique as OCT could provide 
very valuable information for a better understanding of the clinical implications 
of this phenomenon. 
OCT has also demonstrated to be able to visualize the cuts in the atherosclerotic 
plaque made by the blades of a cutting balloon". This can help to identifY if the 
amount of cutting in the plaque has been enough and may help in the selection of 
the better technique to use this device. 
D. Stent apposition at follow-up 
Stent apposition at follow up can be assessed with OCT using the same criteria 
previously exposed for incomplete stent apposition at baseline. IVUS studies in 
patients with late stent thrombosis after DES implantation have shown a high 
prevalence of incomplete stent apposition 55• 56 • The incomplete stent apposition 
at follow-up can be persistent or acquired (not present after stent implantation). 
Several mechanisms have been proposed as cause of late acquired incomplete 
stent apposition: i) Expansive vessel remodelling ii) Chronic stent recoil. iii) 
Dissolution of thrombus jailed between the stent and the vessel wall in patients 
undergoing primary PC! for acute myocardial infarction, and iv) the resolution 
of an intramural haematoma created by vessel dissection during PC! has been also 
postulated as the origin oflate incomplete stent apposition". It has been reported 
that the prevalence of malapposed struts by OCT is higher in sirolimus-eluting 
stent (SES) than in bare metal stents (BMS) 58· 59 • In another study that evaluated 
57 SES at 6 months follow up, 79 out of the 6840 struts visualized by OCT 
showed malapposition and were more often located in areas of SES overlap60 • 
E. Struts coverage following DES implantation 
Endothelial struts coverage has been identified in pathology as the most powerful 
histological predictor of stent thrombosis61 •62• Finn eta!., reported that a stent with 
a ratio of uncovered to total stent struts per section >30% has an odds ratio for stent 
thrombosis of 9 (95o/o Cl, 3.5 to 22) "· Angioscopic studies have shown a correla-
tion between the neointimal grade and the presence of thrombi63 •64 • DES inhibits 
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neointimal proliferation to such extent that it may not be detectable by IVUS65-'7• 
The higher resolution of OCT allows the visualization and measurement of tiny 
layers of tissue covering the stent struts68• 69 (Figure 4f). A study in carotid rabbit 
model evaluated the usefulness of OCT to identifY struts coverage after stenting. 
No differences in the mean neointimal thickness measured by histology and OCT 
were found (the intra and interobserver reproducibility of neointimal thickness 
measurements by OCT was excellent, R2 =0.90 and 0.88 respectively)70 • Recently 
several OCT studies evaluating the struts coverage in DES in humans at different 
time intervals have been published. Xie et al., compared the neointimal coverage at 3 
months follow-up in 16 patients treated with BMS and 24 patients that underwent 
SES implantation. The neointimal thickness per strut and the percentage of neonti-
mal thickness area per cross section were higher in the BMS group than in the SES 
group (351± 248 VS 31± 39 jlm; p < 0.0001; 45.0±14o/o VS 10.0 ±4o/o; p < 0.0001, 
respectively). The frequency of uncovered struts (figure 4h) and malapposed struts 
was higher in theSES group than the BMS group (15% vs 0.1 %; p < 0.0001 and 
15% vs 1.1 o/o p < 0.0001 respectively). There was no significant difference in the 
incidence of stent thrombus between the 2 groups (14% vs 0%; p= 0.23)58 • These 
results were confirmed in another similar study that compared BMS with SES. 
The percentage of uncovered struts in SES was significantly higher than in BMS 
while the neointimal thickness was lower in SES than in BMS59 • Matsumoto et al., 
studied 34 patients (57 SES) with IVUS and OCT at 6 months follow-up. The 
authors reported that 64% of the struts were covered by thin neointima undetect-
able by IVUS (median neointima thickness 52.5 Jlm, 25'h and 75th percentiles 28 
and 147.6 Jlm respectively). Overall 89% of the struts were covered by tissue but 
only in 16% of the stents all the struts were covered60• A study evaluated the strut 
coverage in SES at 6 and 12 months follow-up. Forty-six SES (6561 struts) were 
studied in 36 patients. The authors reported that only 4 SES at 6 months (18.2%) 
and 10 SES at 12 months (41.7%) were fully covered by tissue. The analysis showed 
a significant increase in the average thickness of the tissue covering the struts from 
42±28 Jlm at 6 months to 88±32 Jlm at 12 months71 • Yamamoto et al., evaluated 
the long-term follow up of SES in 21 patients. Overall the frequency of uncovered 
struts was 5% and 81 o/o of the patients presented uncovered struts at 2 years follow-
up. The presence of uncovered struts was more frequent at side branches and at 
overlapping segments. They found 3 patients with thrombi by OCT examination 
but no clinical stent thrombosis was observed". 
Some data suggest that OCT might be able to provide details on the character-
istics of the neointimal tissue such as the presence of neovessels73 • Neovasculariza-
tion adjacent to stent struts is a common finding in experimental animal models 
but the incidence and significance in human is unknown. 
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Some considerations must be taken into account when studying struts cover-
age by OCT. Until now OCT can not distinguish if the tissue covering the struts 
is neointimal tissue or fibrin. Furthermore, different types of neointimal tissue 
can be present and may have different functionality". Thus, the presence of tissue 
covering the strut does not warrant that the normal endothelial function in the 
area is restored. Pathological and functional studies are needed to understand the 
real meaning of the OCT findings in strut coverage. 
F. Assessment of restenosis 
OCT can be very useful in the evaluation of the causes that contribute to resteno-
sis after DES implantation such as incomplete coverage lesion or gaps between 
stents75 . 
Stem fracture (with subsequent defect of local drug delivery) has also been 
related to restenosis in DES and could be visualized with OCT76• Non-uniform 
distribution of stent struts could affect the drug delivery and therefore have an 
influence in restenosis in DES. This has been confirmed in pre-clinical" and !VUS 
studies. The maximum interstrut angle has been identified in IVUS as predictor 
of intimal hyperplasia cross-sectional area78• OCT allows the assessment of strut 
distribution in vivo with high accuracy. A study with phantom models showed 
how the strut distribution of SES and paclitaxel eluting stems (PES) assessed by 
OCT were significantly different, suggesting that SES maintained a more regular 
strut distribution despite expansion79 . 
Another field of clinical use for OCT might be the assessment of the perfor-
mance of DES in complex coronary interventions such as bifurcations. Buellesfeld 
et al., reported the 9-month OCT follow-up in a case of crush-stenting with PES. 
Crush stenting results in three layers of metal in the segment of the main vessel 
proximal to the stented side branch. There has been concern that this could release 
a higher dose of drug locally with the potential adverse effect of delayed endothe-
lization. In this report, OCT imaging showed the overlapping struts layers in the 
crushed segment completely covered by tissue. Furthermore, OCT allowed clear 
visualization of the struts located in the ostium demonstrating a non-uniform 
distribution and different patterns of tissue coverage80• The effect of overlapping 
stenrs eluting different drugs in the development of endothelial coverage might 
also be studied with OCT. 
G. Evaluation of future DES 
Fully biodegradable stems has emerged as one of the most promising future 
stems because they may avoid the potential long-term complications of metal-
lic drug-eluting stems such as late and very late stent thrombosis and the need 
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for prolonged dual anti platelet therapy. The ABSORB trial recently published, 
showed the feasibility of implantation of the bioabsorbable everolimus-eluting 
coronaty stent (BVS: Abbott Laboratories, IL, USA), composed of a poly-L-lactic 
acid backbone, coated with a degradable polymer I everolimus matrix. In a subset 
of 13 patients, OCT was performed after stent implantation and at 6 months 
follow up. In that scenario OCT allowed not only a vety precise characterization 
of the stent apposition and coverage but also demonstrated structural changes in 
the bioabsorbable DES along time. At baseline 738 struts were visualized while 
at follow up only 671 could be identified. The difference in number of struts can 
be explained presumably due to complete stent bioabsorption. Furthermore, the 
optical properties of the remaining struts changed from baseline to follow up 
probably related with the partial absorption process81 • At present OCT appears as 
the best available tool for the assessment of the absorption of the stent struts. 
Assessment of the relationship between coronary devices and vessel wall by 
optical coherence tomography 
OCT offers the possibility to study in great detail incomplete stent apposi-
tion. This has been related in IVUS studies with stent thrombosis 
Coverage of each of the struts can also be examined. 
Dissection, thrombus and tissue prolapse are clearly visible. 
OCT-guided stent implantation is still not in practice, due to lack of infor-
mation that supports it use. 
ii. Plaque characterization 
Acute coronaty syndromes caused by the rupture of a coronaty plaque are com-
mon initial manifestations of coronary atherosclerosis. The detection of the lesions 
with high risk of rupture (the so called "vulnerable plaques") would be of main 
importance for the prevention of future ACS. In the last years there has been a 
growing interest in this field and a lot of different techniques have been developed 
to evaluate diverse aspects involved in plaque vulnerability. Among them, OCT 
has emerged as one of the most promising due to its ability to provide unique 
information about the plaque composition, the presence of macrophages and the 
thickness of the fibrous cap. 
A. Plaque composition 
The propensity of atherosclerotic lesions to destabilize and rupture is highly 
dependent on their composition. In comparison with histology OCT, has dem-
onstrated to be highly sensitive and specific for characterizing different types of 
atherosclerotic plaques. Yabushita et a!., analyzed 357 diseased carotid and coro-
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Figure 6. Optical coherence tomography images of intact atherosclerotic coronary plaques. 
Panel a shows a normal-looking vessel wall. Panel b depicts a red thrombus inside the lumen. Its 
OCT signature is the shadowing behind the mass (asterisk). Panel c illustrates a ruptured plaque. 
The cavity is at 2 O'Clock (arrowhead). Some disrupted tissue is adjacent to it (arrows). From 7 to 9 
O'clock a poor-signal region with low reflectivity is seen, suggesting a thin fibrous cap fibroarheroma. 
nary segments ex vivo and classified them as fibrous, fibrocalcific and lipid-rich 
plaques. Fibrous plaques were characterized as homogeneous, signal-rich regions; 
fibrocalcific plaques as signal-poor regions with sharp borders; and lipid-rich 
plaques as signal-poor regions with diffuse borders. The comparison with his-
tology showed a sensitivity and specificity ranging from 71-79% and 97-98% 
for fibrous plaques, 95-96% and 97% for fibrocalcific plaques, and 90-94% and 
90-92% for lipid-rich plaques82• Ex-vivo validations have also shown that OCT 
is superior to conventional and integrated backscatter IVUS for the characteriza-
tion of coronary arherosclerotic plaque composition83•86• In vivo, OCT is able to 
identifY most of the architectural features identified by IVUS and may be superior 
for the identification of lipid pools". Several authors have evaluated rhe OCT 
appearance of coronary plaques in different groups of patients reporting higher 
prevalence of lipid-rich plaques in ACS rhan in patients with stable angina88 and 
no differences in the culprit plaque imaged by OCT between diabetics and non-
diabetics patients" and men or women with ACS90• According to histological and 
IVUS examinations, the percentage of lipid-rich plaque by OCT has been found 
to be higher in plaques wirh expansive remodelling". 
However, a study comparing OCT to histopathology reported a lower sensitiv-
ity for plaque components. Misclassification occurred in 41 o/o oflesions predomi-
nantly due to a combination of incomplete penetration depth into rhe vessel wall 
and rhe inability to distinguish calcium deposits from lipid pools92 
B. Plaque rupture and intracoronary thrombus identification 
Plaque rupture with subsequent thrombosis is the most frequent cause of ACS. 
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OCT can identifY intracoronary thrombus (figure 6b) and plaque rupture (figure 
6c) with high accuracy93• Recently, Kubo et al evaluated the abiliry of OCT for 
the assessment of the culprit lesion morphology in acute myocardial infarction 
in comparison with IVUS and angioscopy. They found an incidence of plaque 
rupture by OCT of73o/o, significantly higher than that detected by both angios-
copy (47%, p= 0.035) and IVUS (40%, p =0.009). Intracoronary thrombus was 
observed in all cases by OCT and angioscopy bur was identified only in 33% of 
patients by IVUS". Furthermore, Kume et al., demonstrated that OCT might 
be able to distinguish between white and red thrombus. Red thrombus appears 
in OCT as high-backscattering structure with signal-free shadowing (figure 6b) 
while white thrombus appears as a low-backscattering structure". OCT could 
be helpful to identifY the culprit lesion in ACS and might provide additional 
information about the underlying cause that lead to the plaque rupture. 
C. Measurement of the fibrous cap 
Autopsy studies of sudden cardiac death victims have shown that the most 
frequent cause of the coronary occlusion is rupture of a thin-cap fibroatheroma 
(TCFA) plaque. Such lesions are characterized by a large necrotic core with a thin 
fibrous cap usually < 65 microns in thickness. While conventional intracoronary 
imaging techniques such as IVUS-VH do not have enough resolution to evaluate 
in detail the fibrous cap, OCT has demonstrated in correlation with histological 
examinations that it is able to provide accurate measurements of the thickness of 
the fibrous cap96• 97• Therefore, it could be useful for the in vivo detection ofTCFA 
(Figure 3). In the study with IVUS, OCT and angioscopy in acute myocardial 
infarction patients by Kubo et al., the incidence of TCFA was 83% and only 
OCT was able to estimate the fibrous cap thickness (mean 49±2lf1m). Two stud-
ies have reported that the plaque colour by angioscopy is related to the thickness 
of the fibrous cap as measured by OCT with yellow plaques often presenting thin 
caps98• 99 • It has been suggested that the ability of OCT to measure changes in 
the fibrous cap thickness could be useful to assess the effect of statins in plaque 
stabilization 100• 101 • Furthermore, recent data suggest that new OCT technology 
(such as polarization-sensitive OCT) could be able to assess the collagen content 
and smooth muscle cell density in the fibrous cap102• This could provide very 
valuable information about the mechanical stability of the fibrous cap enabling 
the identification of lesions at high risk of rupture. 
C. Macrophages detection 
Intense infiltration by macrophages of the fibrous cap is another of the features 
of the vulnerable plaques. An ex-vivo study by Tearney et al., demonstrated OCT 
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could be able to quantifY macrophage within the fibrous cap103• In vivo, it has been 
demonstrated that unstable patients present a significantly higher macrophage 
density detected by OCT in the culprit lesion than stable patients. Furthermore, 
in the same population) the sites of plaque rupture demonstrated a greater mac-
rophage density than non-ruptured sites104• 
Raffel et a!., reported that macrophage density in the fibrous cap detected by 
OCT correlated with the white blood cell count, and both parameters could be 
useful to predict the presence ofTCFA'05 • 
COMBINED ASSESSMENT USING VIRTUAL HISTOLOGY AND OPTICAL 
COHERENCE TOMOGRAPHY 
i. study of intact plaques 
OCT can provide very valuable information for the detection of high-risk plaques 
in vivo especially measuring the thickness of the fibrous cap. However due to its 
limited penetration OCT can not provide a full analysis oflarge plaques. Further, 
histological examinations have demonstrated that OCT may not be sufficient to 
discriminate lipid pools from calcium deposits92 On the contrary, other techniques 
such as IVUS and IVUS-VH analysis can image the complete plaque thickness 
and can identifY the presence of necrotic core but its limited axial resolution does 
not allow the evaluation of the fibrous cap. Thus, the combination of the IVUS-
VH and OCT appears promising to better characterize such plaques. Indeed, 
Sawada eta!., reported how the combined use of IVUS-VH analysis and OCT 
improved the accuracy forTCFA detection. 56 patients with angina (126 plaques) 
were included. Of the sixty-one plaques diagnosed initially as TCFA by IVUS-VH 
analysis criteria only 28 had a thin fibrous cap as measured by OCT, so they were 
considered as definite TCFAs. In addition, eight OCT-derived TCFA did not have 
necrotic in the IVUS-VH analysis mainly due to the misreading in OCT caused 
by dense calcium106. This data suggests that the combination of the information 
provided by different methods could be essential for better identification of high-
risk coronary lesions. (figure 3). 
We have evaluated the in-vivo frequency and distribution of high-risk plaques 
(i.e necrotic core rich) at bifurcations using a combined plaque assessment with 
IVUS virtual histology and optical coherence tomography (figure 2). A total of 
30 patients (103 bifurcations) were imaged. 27 fibroatheromas (26.2%) and 18 
thin-cap fibroatheromas (17.4%) were found. Overall the o/o of necrotic core 
decreases from proximal to distal rim (16.8% vs. 13.5% respectively p=0.01) 
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ABSTRACT 
Aims: to assess the inter and intra observer reproducibility for strut count, strut 
apposition and strut tissue coverage measurements with optical coherence tomog-
raphy (OCT). 
Methods and results: Ten drug-eluting stents (244 frames, 1712 struts) imaged 
with OCT 9 months after implantation were analyzed by 2 independent analysts. 
One of the analysts repeated the analysis of 5 stents (120 frames, 795 struts) 
one week later. Offline analysis was performed with the proprietary LightLab 
Imaging software. The number of struts was counted and lumen and stent area 
contours were traced. Tissue coverage thickness was measured at 360 degrees of 
vessel circumference and in front of every individual strut. The number of malap-
posed struts was determined. There was good agreement for strut number count 
(Kendall's Tau-b 0.90 for inter and 0.94 for intraobserver variability). The relative 
difference for lumen area, stent area and tissue coverage measurements was around 
1 o/o. There was complete inter and intraobserver agreement for malapposed struts 
classification ( 4 out of 1708 struts, Kappa= I). 
Conclusions: In a corelab setting, the inter and intra observer reproducibility for 
strut count, strut apposition and strut tissue coverage measurements with OCT 
is excellent. This emphasizes the value of OCT as a tool for the clinical long-term 
assessment of stents. 
CONDENSED ABSTRACT 
The present study sought to evaluate the reproducibility of quantitative OCT 
for stent assessment in a detailed analysis on per strut level. Ten drug-eluting 
stents (244 frames, 1712 struts) imaged with OCT 9 months after implantation 
were analyzed by 2 independent analysts using the LightLab Imaging proprietary 
software. One of the analysts repeated the analysis of 5 stents (120 frames, 795 
struts) one week later. There was very good agreement for strut number count and 
malapposition classification and a higher reproducibility of OCT measurements 
emphasizing the value of this technique as a tool for the clinical long-term assess-
ment of stents. 
Key words: optical coherence tomography, stent analysis, reproducibility 
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ABBREVIATIONS 
OCT: optical coherence romography 
DES: drug-eluting stent 
ROI: region of interest 
INTRODUCTION 
Optical Coherence Tomography (OCT) is a light-based imaging modality that can 
provide in vivo high-resolution images of the coronary artery(!). This technique 
offers rhe possibility to identifY coronary stems and individual stent struts(2). 
Further, it is able to provide detailed information about struts apposition and tis-
sue coverage. This is of special interest in drug-eluting stems (DES) in which the 
neointimal proliferation is inhibited to such extent that might not be visualized 
with conventional intracoronary IVUS(3). Animal studies demonstrated good 
correlation between intracoronary OCT and pathology for neointimal thickness 
measurements (4,5). However, no criteria have been established for the quantita-
tive analysis of stems on a per strut level with OCT. The objective of the present 
study was to assess the inter and intra observer reproducibility for strut count, 
strut apposition and strut tissue coverage measurements with OCT. 
METHODS 
Study population 
Ten stems (244 frames, 1712 struts) were analyzed in 8 asymptomatic patients 
undergoing an intracoronary OCT study 9 months after sirolimus (Cypher Select, 
Cordis, Johnson & Johnson, Miami, FL; 40%) or biolimus-eluting (Biomatrix 
III, Biosensors, Merges, Switzerland; 60%) stent implantation. The target vessel 
was the LAD in 50%, the LCX in 20% and the RCA in the 30% of the cases. 
OCT acquisition 
The OCT acquisition was performed using a commercially available system for 
inrracoronary imaging (LightLab Imaging Inc, Westford, Massachusetts, US). 
The Image Wire (LightLab Imaging Inc, Westford, Massachusetts, US) consists 
of an optical fiber core (125 rm) covered by a protective sheath with a maximum 
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outer diameter of 0.019". It was positioned distal to the region of interest using a 
double lumen catheter (Twin Pass catheter, Vascular Solutions Inc) rhat had been 
previously placed in the artery over a conventional guide wire. The automated 
pullback was performed at 3 mm/s while the blood was removed by the con-
tinuous injection ofiso-osmolar contrast (Iodixanol370, Visipaque~, GE Health 
Care, Ireland) at 3r Celsius rhrough rhe guiding catheter. The data was stored on 
CD for offiine analysis. 
OCT quantitative analysis 
The analysis was performed wirh the proprietary LightLab software for off-line 
analysis (LightLab Imaging, Westford, Massachuserts, US). The data was imported 
in the workstation using the LightLab database format. 
Z-Offset correction 
The Z-Offset was adjusted in the carheterization laboratory before image acquisi-
tion while holding the Image Wire between two fingers. The Z-Offset is set prop-
erly when the Image Wire shearh is aligned with the yellow fiducials in the OCT 
image. During image acquisition, the optical fibers can stretch, especially at the 
beginning of rhe pullback. This may produce changes in the size of the Z-Offset 
along the pullback that can affect the accuracy of rhe measurements. Therefore, 
the Z-Offset was checked and modified if necessary in all rhe pullbacks before 
performing any measurement. To correct the Z-offSet in saved pullbacks a frame 
in which the Image Wire shearh was in direct contact wirh the vessel wall was 
selected. In this frame the Z-Offset was corrected aligning the Image Wire sheath 
and the vessel wall with the yellow fiducials. This value of the Z-Offset was applied 
at rhe beginning of the pullback. If needed, the Z-Offset was recalibrated again 
along rhe pullback. The corrected Z-Offset was the same for borh analysists. 
Definition of the region of interest and frame selection 
The region of interest (ROI) comprised rhe stented region and rhe reference seg-
ments. The ROI was systematically analysed in longitudinal intervals rhroughout 
rhe pullback. The stented region was defined as rhe region comprised between 
rhe first and the last frame wirh circumferentially visible struts. The reference 
segments were defined as the 5 mm proximal and distal to rhe stem. Frames were 
excluded when they presented severe artefacts such as incomplete blood clearance 
or non-uniform rotation distortion. When a frame was not analyzable an alterna-
tive frame located wirhin the 2 proximal or distal frames was selected for analysis. 
No overlapping stem segments were included in the analysis. 
402 
Reproducibility of quantitative optical coherence tomography for stent analysis. 
Lumen analysis 
The lumen contour was obtained with an automated detection algorithm avail-
able in the LightLab proprietary software and additional manual corrections were 
performed if necessary. 
Stent analysis 
Strut definitions: stem struts can show different appearances in OCT. In the present 
study structures were considered struts according to the following definitions. 
a) Highly reflective surfaces (metal) with cast dorsal, radial shadows. 
b) Highly reflective surfaces without dorsal shadowing. 
c) Sector shaped shadows with sharp defined borders radial to the lumen. 
Stentarea 
The stent contour was traced using a multiple point detection function. A support 
point for the contour was set in the middle of the endoluminal border of each 
stem strut. A semi-automated contour was then applied linking the points. 
Struts coverage definitions and measurements 
The tissue coverage area was calculated as stent area minus lumen area. Assessment 
of tissue coverage thickness was performed using a new function of the software 
which provides 360 degrees measurements, at I degree incremental, around the 
circumference of a given cross sectional image, developed in collaboration by 
Cardialysis-Cleveland, Cardialysis-Rotterdam and Lighclab (Figure 1). This also 
permits the measurement of the tissue located in front of every strut that was 
defined as strut coverage. The mean, maximum and minimum tissue coverage per 
strut were calculated. 
Mal apposition definitions and measurements 
Malapossition was defined as separation of at least one stem strut from the vessel 
walL To evaluate apposition by OCT, especially with DES, some considerations 
must be taken into account. Most DES are constituted by a metal body covered 
by a polymer. Since OCT can show only the endoluminal surface of the strut due 
to limited penetration through the metal, strut and polymer thickness must be 
considered in assessing apposition for each type of stent design. For the present 
study a strut was considered malapposed if the distance from its endo-luminal 
surface to the vessel wall was higher than the sum of the metal and polymer 
thickness (Figure 2). 
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Figure 1: Tissue coverage measurement. A. Sirolimus eluting stent 9 months after stent 
implantation. B. The figure shows the lumen contour (white) and the stent contour (green). The 
tissue coverage area was calculated as stent area minus lumen area. The tissue coverage thickness was 
measured in 360 points (represented by the white chords). C. Magnification of2 struts showing all 
the measurements (white chords) of the tissue coverage in front of every strut. For every strut the 
minimum, maximum and mean strut coverage was calculated. 
Reproducibility design 
The reproducibility for the struts count and the malapposition and tissue coverage 
thickness measurements were tested independently. 
Strut count reproducibility 
In order to assess the interobserver variability for the struts count, rwo experienced 
observers analyzed independently 100 cross sections and counted the number of 
struts in each one. To test the intraobserver variability one of the two observers 
repeated the analysis of 50 randomly selected cross sections one week later. 
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Figure 2: Malapposition. A Example of a malapposed strut in a sirolimus eluting stem at 9 months 
follow up. B. Magnification of the malapposed strut. The yellow line represents the lumen contour 
and the white line corresponds to the stent contour. The distance from the endoluminal surface of 
the strut to the vessel wall (red arrow) was 440 p.m. (higher than the sum of the metal and polymer 
thickness for this type of stent). 
Strut apposition and tissue coverage reproducibility 
Two experienced observers analyzed independently 10 stems in order assess the 
interobserver variability for the struts apposition and tissue coverage measure-
ments. One of the observers repeated the analysis in 5 of the cases one week later 
to evaluate the intraobserver variability. 
Statistical analysis 
The agreement of the number of struts counted in the same frame was estimated 
by calculating the Kendall's Tau-b rank correlation coefficient with its 95% con-
fidence interval. 
The inter and intraobserver reproducibility for lumen, stent and tissue coverage 
measurements were tested at 3 levels: per stent, per frame and per strut. 
On a per stent level the mean and minimum lumen and stent area and the mean 
lumen and stent diameters were compared. The mean tissue coverage area and the 
mean, minimum and maximum tissue coverage thickness and strut coverage were 
also compared. The lumen, stent and tissue coverage volume were calculated by 
Trapezoidal rule. In the proximal and distal reference, the mean luminal area, 
diameter and volume were compared. 
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On a per frame level the luminal and stem areas and diameters were compared 
as well as the tissue coverage area and the mean, minimum and maximum tissue 
coverage thickness and strut coverage. In the frames corresponding to the proximal 
and distal edge, the mean luminal area and diameter were compared. 
On a per strut level the mean, minimum and maximum tissue coverage in 
front of every strut were compared. 
The reproducibiliry was calculated by estimating tbe residual standard devia-
tion in an ANOVA model. The true value is expected to be within 1.96 times 
the calculated reproducibiliry of the single measurement for 95% of tbe observa-
tions. In addition the agreement between both observations has been expressed in 
Bland-Airman plots. The Bland-Altman plot depicts the differences of each pair of 
observations versus their mean values with reference lines for the mean difference 
of all paired observations and its 95% confidence limits, the so-called limits of 
agreement. 
The Kappa coefficient for the agreement bervveen observers for struts classifica-
tion as incompletely apposed was tested for being not equal to zero. 
RESULTS 
A total of 244 frames and 1712 struts were evaluated for tbe imerobserver re-
producibiliry and 120 frames, 795 struts were evaluated for tbe intraobserver 
variability. 
Strut count reproducibility 
lnterobserver variability 
There was complete agreement in the number of struts bervveen the rvvo observers 
in 55% of the cross sections, difference of 1 strut in 31 o/o, difference of 2 struts 
in 9% and difference of more tban 2 struts in only 5% of tbe cross sections. The 
correlation between botb observers was high, i.e. Kendall's Tau-b was 0.90 (95% 
confidence interval 0.85- 0.94). 
/ntraobserver variability 
There was complete agreement in tbe number of struts in 72% of the cross sec-
tions, difference of one strut in 24% and difference of 2 struts in 4% of the cross 
sections. The correlation between both observations was very high, i.e. Kendall's 
Tau-b was 0.94 (95% confidence interval 0.91- 0.97). 
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Lumen, stent and tissue coverage measurements reproducibility 
Stent level 
The results for the inter and intraobserver reproducibility at the stem level are 
summarized in Tables 1 and 2 respectively. 
Table 1. lnterobserver reproducibility at stent levd. N=lO stents. Min: minimum. Max: 
maximum. Obsl: observer 1 Obs2: observer 2. aa Reproducibility defined as residual standard 
deviation. = Bland-Airman limits of agreement defined as mean ± 1.96 SD of absolute difference. 
Limits of 
Table 1 Difference Agreement-•• 
Relative 
Observa- (Obs1/ Reproduci-
Observation 1 tion2 Absolute Obs2) bility"• Lower Upper 
Stent Mean StentArea (mm1) 5.44±1.6 5.47±1.5 -o.o2 ±02 1.0 0.1043 ·032 0.28 
Mean Luminal Area (mm2) 4.71±1.5 4,70±1.5 0.00±0.0 1.0 0,0173 ·0.05 0.05 
Mean Tissue Coverage 0.60 ± 0.5 0,63 ±0.5 .(),03± 0.1 0.9 0.0780 -0.25 020 
Area (mm2) 
Min StentArea (mm1) 3.89± 1.2 3.84±1.1 0.05 ±0.2 1.0 0.1549 ·0.39 0.49 
Min Luminal Area (mm2) 3.24 ± 1.1 3.26 ± 1.1 ·0.01 ±0.0 1.0 0.0158 -o.o5 0.02 
Mean Tissue Coverage 0.08±0.1 0,08±0.1 0,00±0.0 0.9 0,0100 -Q,03 0.02 
Thickness (mm) 
Min Tissue Coverage 0.00 ±0.0 0.00±0.0 0.00±0.0 0.0000 0.00 0.00 
Thickness (mm) 
Max Tissue Coverage 0.33 ±0.1 0.33±0.1 0.01 ±0.0 1.1 0.0179 ·0.04 0.06 
Thickness (mm) 
Mean Strut Coverage (mm) 0.08±0.1 0.09 ± 0.1 -0,01 ±0.0 0.9 0.0066 -0.02 0,01 
Min Strut Coverage (mm) 0.00±0.0 0.00± 0.0 0.00±0.0 0.0 0.0067 -0.02 0.02 
Max Strut Coverage (mm) 031 ±0.1 032±0.1 0.00±0.0 1.0 0.0158 ·0.05 0.04 
Mean Stent Diameter (mm) 260±0.4 2.61 ±0.4 ·0,01 ±0.0 1.0 0.0253 ·0.08 0.07 
Mean Luminal Diameter 2.41±0.4 2.41±0.4 0.00±0.0 1.0 0,0038 -0,01 O.Dl 
(mm) 
StentVolume (mrrfl 101.58±48.2 102.15± -0.58±2.7 1.0 1,8894 ·5.97 4.81 
48.3 
luminal Volume (mm3) 91.76±48.0 91.67±47.9 0.09 ± 0.5 1.0 03347 -0.87 1.05 
Tissue Coverage Volume 13.49± 11.6 14.13±10.3 -0.65±2.5 0.9 1.7454 ·557 427 
(mm3) 
ln-stent Obstruction 13.73± 10.3 14.46±9.0 ·0.73 ±2.2 0.9 1.5341 -4.95 3.49 
Volume(%) 
Distal Mean Luminal Area (mm2) 4.13±1.5 4.14±1.4 0.00±0.0 1.0 0.0085 ·0.03 0.02 
reference 
Mean Luminal Diameter 2.20 ± 0,3 2.20±03 0.00 ±0.0 1.0 0.0067 ·0.02 0.02 
(mm) 
luminal Volume (mm3) 1839±11.1 18.40±11.1 ·0.02±0.1 1.0 0.0492 -0.16 0.12 
Proximal Mean Luminal Area (mm2) 533±2.4 5.27±23 0.06±0.1 1.0 0.1051 -D23 035 
reference 
Mean Luminal Diameter 2.55±0.6 254±0.6 O.D1 ±0.0 1.0 O.D198 -0.04 0.07 
(mm) 
Lumina1Volume(mm3) 23.05±8.6 22.87 ±8.5 0.17±0.4 1.0 0.3030 ·0.67 1.01 
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Table 2. lntraobserver reproducibility at stent level. N""5 scents. Min: minimum. Max: maximum. 
Obsl: observation 1. Obs2: observation 2. ua Reproducibility defined as residual standard deviation. 
uaa Bland-Aleman limits of agreement defined as mean± 1.96 SD of absolute difference. 
Table2 Limits of 
Difference Agreementua 
Relative Reproduci-
Observation 1 Observation 2 Absolute (Obs1/0bs2) bilityU Lower Upper 
Stent Mean StentArea {mm2) 5.95±1.7 5.90± 1.6 0.05±0.1 1.0 0.0621 -0.11 011 
Mean Luminal Area 4.97±1.6 4.98± 1.6 -O.Q1 ±0.0 1.0 0.0186 -0.06 0.05 
(mm2) 
Mean Tissue Coverage 0.80±0.7 0.76± 0.8 0.04±0.1 1.1 0.0518 -0,09 0.17 
Area (mm2) 
Min Stent Area (mm2) 4.01 ± 1.0 3.88±0.9 0.13±0.2 1.0 0.1487 -014 0.49 
Min Luminal Area 3.14±0.6 3.14±0.6 0.00±0.0 1.0 0.0077 -O.o2 0.02 
(mm2) 
Mean Tissue Coverage 0.10±0.1 0.09±0.1 0.00±0.0 1.1 0.0060 -O.Dl 0.02 
Thickness {mm) 
Min Tissue Coverage 0.00 ± 0.0 0.00±0.0 0.00±0.0 0.0000 0.00 0.00 
Thickness (mm) 
Max Tissue Coverage 0.37±0.1 0.35 ± 01 0.02 ± 0.0 1.1 0.0161 -0.02 0.05 
Thickness (mm) 
Mean Strut Coverage 0.11 ±0.1 0.11 ±0.1 0.00± 0.0 1.1 0.0029 -O.Dl O.Dl 
(mm) 
Min Strut Coverage 0.00± 0.0 0.00±0.0 0,00±0.0 0.0000 0.00 0.00 
(mm) 
Max Strut Coverage 0.35± 0.2 0.34± 0.2 O.Dl ± 0.0 1.1 0.0122 -0.01 0.04 
(mm) 
Mean Stent Diameter 2.72 ± 0.4 2.71 ± 0.4 0.01 ± 0.0 1.0 0.0138 -0.02 0.05 
(mm) 
Mean Luminal 2.48±0.4 2.48± 0.4 0.00 ± 0.0 1.0 0.0043 -0.01 0.01 
Diameter {mm) 
StentVolume (mm3) 112.26±58.0 11137±57.3 0.89±15 1.0 1.1265 -2.00 3.78 
Luminal Volume (mm3) 98.63 ±58.2 98.74±583 -0.11 ±0.5 1.0 03502 -1.17 0.94 
Tissue Coverage 18.05 ± 15.2 17.03±16.0 1.02±1.6 1.1 1.2617 -2.18 413 
volume (mm3) 
ln·stent Obstruction 16.81 ± 13.8 16.07±13.9 0.74±1.1 1.1 0.8790 -1.44 2.93 
Volume(%) 
Distal Mean Luminal Area 393 ± 1.4 393 ± 1.4 0.00± 0.0 1.0 0.0039 -0.01 om 
reference (mm2) 
Mean Luminal 2.19±0.3 2.19±0.3 0.00 ± 0.0 1.0 0.0023 -O.Dl O.Dl 
Diameter (mm) 
Luminal Volume (mm3) 17.14±8.6 17,14±8.6 -Q.Ql ± 0.0 1.0 0.0239 -0.08 0.07 
LuminalVolumea (mm3) 17.63±9.2 17.69±9.2 -om± o.o 1.0 0.0196 -O.Q7 0.04 
Proximal Mean Luminal Area 5.86±4.9 5.79±4.8 0,07±0.1 1.0 0.0628 -O.o? 0.21 
reference (mm2) 
Mean Luminal 2.60± 1.2 258± 1.2 0.02± 0.0 1.0 0.0121 -O.Dl 0.04 
Diameter (mm) 
Luminal Volume (mm3) 18.61 ± 14.4 1838± 14.2 0.23± 0.3 1.0 01035 -017 0.72 
Luminal Volume" (mm3) 18.46 ± 15.3 18.23±15.1 013±01 1.0 0.1977 -0.21 0.67 
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Frame/eve/ 
The results for the inter and intraobserver reproducibility at the frame level are 
summarized in Tables 3 and 4 respectively. Figures 3 and 4 show the results for 
the lumen, stent and tissue coverage area and mean neointimal thickness for inter 
and intraobserver reproducibility respectively. 
Table 3. lnterobserver reproducibility at fi:ame levd. N =>244 frames. Min: minimum. Max: 
ma.ximum. Obsl: observer 1 Obs2: observer 2. a Reproducibility defined as residual standard 
deviation. aa Bland-Aleman limits of agreement defined as mean ± 1.96 SD of absolute difference. 
Limits of 
Table 3 Difference Agreement"" 
Relative 
Observer (Obs1/ Reproduci-
Observer1 2 Absolute Obs2) bility" Lower Upper 
Stent StentArea (mm2) 5.67 ± 1.7 5.71±1.7 ·0.03±0.2 1.0 0.1694 -050 0.44 
Luminal Area (mm~ 4.95± 1.7 4.95±1.7 0.00 ± 0.1 1.0 0.0380 -0.10 0.11 
Tissue Coverage Area 056±0.7 0.59 ±0.6 -0.03 ±01 0.9 0.1400 -0.41 0.36 
(mm2) 
Mean Tissue Coverage 0.07±0.1 0.07±0.1 0.00±0.0 0.9 0.0177 -o.o5 0.05 
Thickness (mm) 
Min Tissue Coverage 0.02::!::0.0 0.02 ± 0,0 0.00±0.0 0.4 0.0132 -0.04 0.03 
Thickness (mm) 
Max Tissue Coverage 0.15±0.1 0.15±0.1 0.00±0.0 1.0 0.0207 -0,06 0.06 
Thickness (mm) 
Mean Strut Coverage 0.08±0.1 0.08±0.1 -0.01 ± 0.0 0.9 0.0099 -0.03 0,02 
(mm) 
Min Strut Coverage (mm) 0.03 ± 0.1 0.04±0.1 -0.01 ±0.0 0.6 0.0125 ·0.04 0.03 
Max Strut Coverage (mm) 0.14±0.1 0.14±0.1 0.00 ± 0.0 1.0 0.0141 -0.04 0.04 
Stent Diameter (mm) 2.66 ±0.4 2.66±0.4 -0.01 ±0.1 1.0 0.0409 -0.12 0,10 
Luminal Diameter (mm) 2.47±0.4 2.47 ±0.4 0.00±0.0 1.0 0.0090 -0.02 0.03 
Distal Luminal Area (mm2) 434±1.6 4.35±1.6 -0.01 ±0.0 1.0 0.0148 -0.05 0.03 
reference 
Luminal Diameter (mm) 2.28±0.4 2.28 ± 0.4 0.00±0.0 1n 0.0077 -0.02 0.02 
Proximal Luminal Area (mm2) 5.25±2.1 510±2.0 0.05 ::!::0.1 1.0 0.0944 -0.21 030 
reference 
Luminal Diameter (mm) 2.54±0.5 253±0.5 0.01 ±0.0 1.0 0.0180 -0.04 0.06 
Strut level 
Tables 5 and 6 show the inter (A) and intraobserver (B) reproducibility for the 
measurements at the strut level. Figure 5 shows the variability for the mean strut 
coverage. 
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Table 4. Intraobserver reproducibility at frame levd. N::: 120 frames. Min: minimum. Max: 
maximum. Obsl: observation 1. Obs2: observation 2. a Reproducibility defined as residual standard 
deviation. aa Bland-Altman limits of agreement defined as mean± 1.96 SD of absolute difference. 
Limits of 
Table4 Difference Agreement"" 
Relative 
Observer Observer (Obs1/ Reproduci-
2 Absolute Obs2) bility• Lower Upper 
Stent Stent Area (mm2) 5.28±1.7 6.23 ± 1.7 0.05 ± 0.2 1.0 0.1224 -017 0.38 
Luminal Area (mm2) 5.33±1.8 5.34± 1.8 -O.Q1 ± 0.1 1.0 0.0596 -0.17 0.16 
Tissue Coverage Area 0.75 ±0.9 0,70±0.9 0.05±0.1 1.6 0.1021 -Q12 0.32 
(mm2) 
Mean Tissue Coverage 0.09±0.1 0.08±0.1 0.00±0.0 11 0.0117 ·0.03 0.04 
Thickness (mm) 
Min Tissue Coverage 0.03±0.1 0.03±0.1 0.00±0.0 1.1 0.0197 ·0.06 0.05 
Thickness (mm) 
Max Tissue Coverage 0.17±0.2 0.17±0.2 0.00±0.0 1.1 0.0168 ·0.04 0.05 
Thickness (mm) 
Mean Strut Coverage 0.10±0.1 0.10±0.1 0.00±0.0 1.1 0.0083 -0.02 0.02 
(mm) 
Min Strut Coverage 0.05±0.1 0.05±0.1 0.00±0.0 1.1 0.0181 -0.05 0.05 
(mm) 
Max Strut Coverage 0.17±0.2 0.16±0.2 0.00±0.0 1.1 0.0125 -0.03 0.04 
(mm) 
Stent Diameter (mm) 2.80 ± 0.4 2.79± 0.4 0.01 ± 0.0 1.0 0.0272 ·0.06 0.08 
Luminal Diameter (mm) 2.57±0.4 2.57 ± 0.4 0.00 ± 0.0 1.0 0.0131 ..0.04 0.04 
Distal Luminal Area (mm2) 3.98±1.6 3.98± 1.6 0.00 ± 0.0 1.0 0.0109 ..0.03 O.G3 
reference 
Luminal Diameter (mm) 2.20±0.4 220±0.4 0.00 ± 0.0 1D 0.0041 -om 0.01 
Proximal Luminal Area (mm~) 5.86±3.8 5.79±3.7 0.07±0.1 1.0 0.0826 -0.12 017 
reference 
Luminal Diameter (mm) 2.60±0.9 258±0.9 O.Q2 ±0.0 1.0 0.0164 ..Q.02 0.05 
Ma/apposition classification reproducibility 
The observers had complete agreement for the classification of malapposed struts 
(4 out of 1712 struts malapposed, Kappa coefficient 1). The intraobserver analysis 
show the same result (4 out of795 struts malapposed, Kappa coefficient I) 
DISCUSSION 
Due to its high resolution OCT can be a very valuable tool for the evaluation 
of the acute and long-term impact of stem implantation. OCT offers the pos-
sibility to assess stent apposition in great detail and allows the visualization and 
measurement of the tissue covering the struts even if this consists on tiny layers 
as it is frequently observed in DES(3). & the use of OCT is increasing rapidly, 
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Figure 3: lnterobserver reproducibility. Bland-Aleman plots for the interobserver variability for 
mean lumen (A), scent (B) and tissue coverage area (C) and mean tissue coverage thickness (D). 
Table 5. lnterobserver reproducibility at strut level. N-=:1712 struts. Min; minimum. Max: 
maximum. a Reproducibility defined as residual standard deviation. 
a;J. Bland-Aleman limits of agreement defined as mean± 1.96 SD of absolute difference. 
TableS Difference Limits of Agreement"a 
Relative 
Observer1 Observer2 Absolute (Obs1/0bs2) Reproducibility" Lower Upper 
Min Coverage Strut 0.09±0.1 0.10±0.1 ..0.01 ±0.0 0.9 0.0179 -o.os 0.04 
(mm) 
Mean Coverage Strut 0.10±0.1 0.11±0.1 -om ±O.O 0.9 O.D174 -o.os 0.04 
(mm) 
Max Coverage Strut 0.11 ±0.1 0.11 ±0.1 -0.01 ± 0.0 0.9 0.0175 -0.05 0.04 
(mm) 
standardization of the methodology to measure and report stent apposition and 
tissue coverage is needed as well as data about the reproducibility of these mea-
surements. Our results show that the methodology described in the present study 
allows analysis of stents by experienced analysts in a highly reproducible way. 
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Figure 4: lntraobserver reproducibility. Bland-Altman plots for intraobserver variabiliry for mean 
lumen (A), stent (B) and tissue coverage area (C) and mean tissue coverage thickness (D). 
Table 6.1ntraobserver reproducibility at strut level. N=795 struts. Min: minimum. Max: 
maximum. a Reproducibility defined as residual standard deviation. 
aa Bland-Altman limits of agreement defined as mean ± 1.96 SD of absolute difference. 
Table 6 Difference Limits of Agreement•a 
Relative 
Observer 1 Observer 2 Absolute (Obs1/0bs2) Reproducibility" Lower Upper 
Min Coverage Strut 0.13 ± 0.1 0.13±0.1 0.00 ± 0.0 1.1 0.0161 -0.04 0.05 
(mm) 
Mean Coverage Strut 0.14±0.1 0.13±0.1 0.00 ± 0.0 1.1 0.0153 -0.04 0.04 
(mm) 
Max Coverage Strut 0.14±0.1 0.14±0.1 0.00± 0.0 1.0 0.0154 -{).04 0.04 
(mm) 
Stent struts can have different appearances by OCT. The reproducibility of 
struts count has not been previously reported. Our data suggests that the inter and 
intraobserver variability for strut count is low when applying strict strut definitions. 
For the intraobserver variability, only in 4% of the cases the difference between 
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Figure 5: Strut coverage measurement reproducibility. Bland-.Altman plots for the inter (A) and 
intraobserver (B) reproducibility for mean strut coverage measurements. 
the 2 observations was more than one single strut while for the interobserver in 
only 5% of the cases the difference was higher than 2 struts. 
High accuracy and precision for diameters measurement in vitro using propri-
etary software from LightLab has been reported(6). Tanimoto eta! reported a low 
interobserver variability for lumen and stent area measurements with OCT using 
dedicated computer-assisted contour analysis(?). However, no specific study to as-
sess the reproducibility of strut apposition and strut tissue coverage measurements 
by OCT has been reported. 
Recently several OCT studies evaluating the struts apposition and tissue 
coverage in DES in humans at different time intervals using proprietary off-line 
software provided by LightLab Imaging have been published(S-11). 
In most of these studies, the operator manually traced the stent and lumen 
area, to derive the tissue coverage area. Stent struts apposition and tissue coverage 
are usually individually measured at 1-mm intervals. However the way of report-
ing the tissue coverage varies between studies. Some authors report just tissue 
coverage thickness without detailed methodology (8,12). Other studies report 
the minimum, maximum or average tissue coverage but the selection method, 
the number of measurements and calculations method was not specified (9,10). 
The methodology used in the present study provides 360 data points for tissue 
coverage thickness for each cross section. Further the mean, the minimum and the 
maximum tissue coverage is reported for each individual strut. The mean tissue 
coverage per strut is derived from all the measurements at equidistal intervals 
along the strut. 
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Prati et al reponed high inter and intraobserver reproducibility for neointima 
thickness measurements with OCT in carotid rabbit model (r2 0.88 and 0.90 
respectively)(4). Another study in humans comparing tissue coverage between 
SES and BMS reported 6 ± 8 )lm and 8 ± 8 )lm intra and interobserver variability 
for the measurement of tissue coverage(8). However the authors did not specify if 
the measurements correspond to mean, minimum or maximum tissue coverage, 
how many measurements were performed per strut or in which part of the strut 
measurements were taken. In the present study we observed absolute differences 
around 10 pm for the maximum and minimum strut coverage in repeated mea-
surements. Those differences are in the limit of resolution of the technique. The 
absolute differences for tissue coverage area were 0.06 ± 0.02 mm2 and 0.04 ± 
0.02 mm2 for the intra and interobserver variability respectively. Similar results 
were found when comparing stent and lumen area. A very good reproducibility 
for lumen measurement was expected as the automatic contour detection was 
used and not modified by the analyst in the majority of cases. The differences 
found in the present study are smaller than the ones reported previously by Xie 
et al for area measurements with OCT (0.3 ± 0.5 mm2 and 0.2 ± 0.4 mm2 for 
the intra and interobserver variability respectively). There are no reports on the 
reproducibility of lumen, stent and tissue coverage volumes derived from OCT. 
We found absolute differences around 1 mm3 for the intra and 0.65 mm3 for 
the interobserver variability for tissue coverage volume. Similar values (0.99 and 
0.55 mm3 for the intra and interobserver respectively) were obtained for the stent 
volume. As expected, the lumen volume variability was even lower (around 0.10 
mm3) as it was derived from automatic contour detection. 
The higher resolution of OCT makes this technique superior to IVUS for the 
detection and measurement of tissue covering the stent struts. An IVUS study 
reported 62% of inter-observer agreement for the presence of neointimal tissue 
with discrepancy between observers in very thin neointimal layers and when 
the neointimal area was <2 mm2 (13). In the present study evaluating DES, a 
very good agreement was found between observers for the measurement of tis-
sue coverage even when the mean tissue coverage area was less than 1 mm2 . An 
increased variability in the classification of individual struts was observed when 
the tissue coverage was below 50 pm. This may be related to the image resolution 
but also to softvvare limitations. Automatic algorithms for detecting stent coverage 
from OCT datasets are under development(l4). This could help eliminating the 
remaining small observer-related variability found in our study. 
Kubo et al reported a good intra and interobserver agreement (Kappa=0.90 
and 0.75 respectively) for malapposed struts classification in sirolimus eluting 
stents(15). Those results are in line with our study in which the agreement between 
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observers for malapposed struts was excellent (kappa=l) even when applying cus-
tomized cur-off points for each srent. However our results are limited by rhe small 
number of malapposed struts found in our population. 
Clinical implications 
The evaluation of strut apposition is essential in the evaluation of new stents de-
signs as IVUS data have suggested a possible relation between apposition and the 
risk of stent thrombosis in DES(l6,17). However interpretation of malapposirion 
as assessed by OCT requires caution. Due to the high image resolution, malap-
posirion of stent struts is a relatively common finding by OCT(S) bur irs clinical 
implications remain poorly understood. Incomplete endothelial struts coverage 
has been identified in pathology as the most powerful histological predictor of 
srent rhrombosis(l8,19). Pathological data in human suggests rbar neointimal 
coverage of srent struts could be used as a surrogate marker of endorbelialization 
due to rbe good correlation between strut coverage and endorhelializarion. Animal 
data suggest good correlation between mean neointimal thickness measured by 
histology and OCT (4). The present study confirms rhar rhe tissue covering rhe 
strut can be measured with high reproducibility. However, rbe clinical relevance 
of uncovered struts as detected by OCT is nor clear as some studies have reported 
presence of uncovered struts at follow-up nor associated ro clinical events (IS). 
Further investigation and srudies with longer follow up are needed in this field. 
Although OCT has proved ro be a highly informative imaging technique in 
assessing stents, standardization of the analysis of such images is not yet in place. 
In addition, OCT is a rapidly evolving imaging technology, and there is lack 
of large srenr trials wirb long-term clinical follow-up linking OCT findings and 
clinical events. Thereby this methodology of analysis is prone ro changes in rbe 
future in order ro adjust to the new clinical needs. 
CONCLUSIONS 
In a corelab setting, the inter and intra observer reproducibility for strut count, 
strut apposition and strut tissue coverage measurements with OCT is excellent. 
This finding emphasizes rbe value of OCT as a roo! for the clinical long-term 
assessment of stents. 
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OBJECTIVES This study sought to evaluate the in vivo frequency and distribution of high-risk 
plaques (i.e., necrotic core rich) at bifurcations using a combined plaque assessment with intravascular 
ultrasound-virtual histology (JVUS-VH) and optical coherence tomography (OCD. 
B A C KG R 0 UN D Pathological examinations have shown that atherosclerotic plaque rich in necrotic 
core is prone to develop at bifurcations. High~risk plaque detection could be improved by the combined 
use of a technique able to detect necrotic core (IVUS-VH) and a high-resolution techn.1que that allows the 
measurement of the fibrous cap thickness cocn. 
METHODS From 30 patients imaged with IVUS-VH and OCT, 103 bifurcations were selected. The 
main branch was analyzed at the proximal rim of the ostium of the side branch, at the in-bifurcation 
segment and at the distal rim of the ostium of the side branch. Plaques with more than 1 O% confluent 
necrotic core by IVUS-VH were selected and classified as fibroatheroma (FA) or thin-cap fibroatheroma 
(TCFA) depending on the thickness of the fibrous cap by OCT (>65 or :S65 .urn for FA and TCFA, 
respectively). 
RESULTS Twenty-seven FA (262%) and 18 TCFA {1 7 .4%) were found out of the 103 Jes·1ons studied. 
Overall the percentage of necrotic core decreases from proximal to distal rim (16.8% vs. 13.5% 
respectively, p = 0.01), whereas the cap thickness showed an inverse tendency (130 ± 1 OS ,um vs. 151 
± 68 ,urn for proximal and distal rim, respectively, p = 0.05). The thin caps were more often located in 
the proximal rim (15 of 34, 44.1%), fo!!owed by the in-bifurcation segment (14 of 34, 41.2%), and were 
less frequent ·m the distal rim (5 of 34, 14.7%). 
C 0 N C L US I 0 l\' S The proximal rim of the ostium of the side branch has been identified as a region 
more likely to contain thin fibrous cap and a greater proportion of necrotic core. (JAm Coli Cardiol lmg 
2009;2:473-82) © 2009 by the American College of Cardiology Foundation 
From the Thoroxcenter, Ern.smu_~ Medk:U Center, Rotterdam, the :\letherlands. 
Mrulllseript rcccived September 30, 2008; revised m;Lnuoeript received Kovembcr 10, 2008, accepted ~ovcmber 16, 2008. 
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ABBREVIATIONS 
AND ACRONYMS 
'" igh-risk atherosclerotic plaques (i.e., rich in 
necrotic core) are prone to develop at bifur-
cations because of the specific shear stress 
_conditions present in these regions (1,2). 
Stented bifurcations lesions represent a comple.x lesion 
subset at high risk of restenosis and thrombosis (3,4). 
These phenomena may reflect certain procedural as-
pects such as incomplete stent apposition, undere."{-
pansion, or gap regions (5,6), but may also be asso-
See page 483 
ciated vvith specific compositional and morpholog-
ical plaque features in these regions. Thin-cap 
fibroatheroma (TCF A) has been described 
as the plaque vvith an increased risk of 
rupture (7). Such lesions are characterized 
ACS = acut~ coronary syndrome 
by a large necrotic core vvith a thin fibrous 
cap, usually <65 JJ..m in thickness (8). 
AJT = adaptatlvelntlmal 
thick~nlng 
C;>FA = c:.ldfi<'d fibroatheroma 
Recently, it has been reported that TCFA 
detection could be improved by the com-
bined use of intravascular ultrasound-
virtual histology (IVUS-VH) and optical 
fibroath~roma 
FA= fibroatheroma 
coherence tomography (OCT) (9). 
IVUS.VH =Intravascular 
ultmsound-vlrtual histology 
lVUS-VH uses spectral analysis of 
IVUS radiofrequency data to identify 4 
tissue types in the atherosclerotic plaque, 
among them necrotic core (10). Optical 
coherence tomography is a high-resolution 
imaging modality that uses reflected near-
LAD = left anterior desc~nd!ng 
1.0: = left clrcumfiexartery 
MMP=matrix 
metalloprotelnas~ 
NC = n~crotlc core 
OCT= optlcal coherence 
tomography 
PIT= p.>thologlc:.llntlmal 
thickening 
infrared light, allovving a very precise vi-
sualization and measurement of vascular 
microstructures such as the fibrous cap 
(11). To our knowledge, in vivo character-
ization of necrotic core rich plaques at 
RCA = right coronary artery 
bifurcation regions has not been e:\:plored. 
The objective of the present study was 
therefore to evaluate in vivo the frequency 
and distribution of high-risk plaques at 
TCFA = thln-c<~pfibroatheroma 
bifurcation lesions using a combined plaque assess-
ment with IVUS-VH and OCT. 
METHODS 
Study population. AJ1 of the patients admitted to 
our hospital between January 2005 and March 2008 
in whom IVUS-'VH and OCT were performed in 
the same vessel were investigated for bifurcations 
adequately visualized by both imaging techniques. 
The indication for the IVUS-VH and OCT was 
the assessment of intermediate, nonflow-limiting 
lesions by angiography or post stent implantation 
assessment. Only regions located more than 5 mm 
422 
beyond the stent were included. AJ1 patients gave 
written informed consent. 
IVU$-VH acquisition. The IVUS was performed us-
ing the Eagle Eye 20 MHz catheter (Volcano 
Corp., Rancho Cordova, California) vvith an auto-
matic continuous pullback at a rate of 0.5 mm/s. 
Grayscale images and radiofrequency data required 
for VH analysis were acquired during the same 
pullback. The VH processing was performed ofE.ine 
with pc'VH 2.1 software (Volcano Corp.) that 
permits semiautomated contour detection and pro-
vides the compositional structure of the vessel. The 
IVUS-'VH uses spectral analysis to classifY the 4 
d.ifferent components of the atherosclerotic plaque 
and gives a color-coded map distinguishing be-
tween fibrous tissue (green), fibrofatty tissue (light 
green), necrotic core (red), and dense calcium (white). 
OCT acquisition. The OCT acquisition was per-
formed using a commercially available system for 
intracoronary imaging and a 0.019-inch Image Wrre 
(LightLab Imaging, Westford, Massachusetts). 
Red blood cells represent a nontransparent tissue 
causing multiple light scattering and substantial 
signal attenuation. Therefore, for adequate OCT 
image acquisition blood must be temporarily re-
moved from the vessel. In 77% of the cases this was 
achieved with the occlusion technique in which a 
proximal, low-pressure (0.4 atm) occlusion balloon 
(Helios, Goodman Inc., Nagoya, Japan) is inflated 
vvith simultaneous distal flush delivery (lactated 
Ringer solution; flow rate 0.8 mlls) to remove blood 
from the vessel lumen. Images were acquired during 
a pullback rate of 1.0 mrn/s. The possibility to 
increase the pullback speed up to 3 mrn/s in the new 
OCT system permitted 23% of the cases to be 
acquired C."{clusively using a nonocclusive technique 
in which the blood was removed by the continuous 
injection of contrast (Iodixanol370, Visipaque, GE 
Health Care, Cork, Ireland) through the guiding 
catheter. The nonocclusive technique reduces the 
procedural time and the incidence of chest pain and 
electrocardiographic changes during image acquisi-
tion vvithout affecting the image quality (12). 
Bifurcation selection and analysis. Simultaneous vi-
sual assessment of IVUS-'VH and OCT pullbacks, 
in 2 contiguous screens, allowed the selection of all 
bifurcations that could be identified vvith both 
techniques (13). To ensure proper matching be-
tween 2 imaging modalities that have d.ifferent 
lateral resolutions (20 JJ..m for OCT and 300 JJ..m for 
IVUS) and depth penetration, a strict selection of 
the frames was followed. Only the main branch was 
analyzed. The lesion analysis included: 1) proximal 
In Vivo Assessment of High-risk Coronary Plaques 
Figure 1. Bifurcation Selection and Analys.i~ 
Blfur<:<~tlons thJt could be '1dentlfied In both lntr<:~v<~scular ultrJsound-vlrtu<:~l histology (IVUSNH) ;;~nd optlc;;~l coherence tomography (Ocr) 
pullbacks were Included. A strict selection of the <~nalyzed cross-sections {CS) was followed to ensure correct mJtchlng between the 2 
techniques. PIJques were analyzed only In the main branch. The lesion <:~nJiysls Included: ll proxlm;;~l rim of the ostium of the side 
br.:mch (58) CS (first fr<:~me proximal to the take-off of the SB); 2) ln-blfur<:<~tlon CS (frame with the IJrger ostial diameter of the SB); and 
3) distal rim of the ostium of the SB CS (first frJme distill to the take off of the SB). 
rim of the ostium of the side branch cross-section 
(first frame proximal to the take-off of the side 
branch); 2) in-bifurcation cross-section (frame with 
the larger ostial diameter of the side branch); and 
3) distal rim of the ostium of the side branch 
cross-section (first frame distal to the take off of 
the side branch) (Fig. 1). In each bifurcation the 
plaque location in relation to the flow divider was 
analyzed (Fig. 2). 
Figure 2. Location of the Plaque in Relation to the Flow Divider 
Plaque type classification. Two o.:perienced observ-
ers joincly analyzed the IVUS-VH data and the 
OCT measurements in the selected frames to char-
acterize the plaque type according to the following 
hierarchical classification (7,14,15) (Figs. 3 to 5): 
1. Adaptive intimal thickening (AIT): intimal 
thickening of <600 /.LID for <20o/o of the 
circumference. 
To describe the piJque loe<~tlon In reiJt'1on to the flow dlv'ider, the vessel cross-section w;;~s divided In 4 quadrants according to the posi-
tion of the side branch. Qu;;~drJnts 1 ;;md 4 correspond to the ostium of the side branch, where<lS quadr<:~nts 2 and 3 correspond to the 
p<Jrt of the vessel wall lo<:<~ted In front of the ostium of the side branch. (A) Gr<:~yscale IVUS. (B) Virtu;;~ I histology. (0 OCT. AbbreviJtlons 
JS In Figure 1. 
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Yes 
l 
Yes__. 
l 
PIT 
--. No 
-----. No Yes 
l l 
FT FC 
Figure 3. Plaque Clil$$ifi(ation Algorithm 
/ 
>651Jm 
/ 
No 
l 
FA 
" Yes 
l 
C~FA 
"-. <65 ~m 
/'-,. 
No Yes 
l l 
·-
AIT "" adaptive lr'ltlmal thlcker'llr'lg; C..FA "" e<~lclficd fibroathcromil; CaTCFA == calcified thlr1-<:ap fibroatheroma; CNC "" cor'lfluer'lt r'lecrotlc 
core; DC"' der'ISC calcium; FA "' fibroatheroma; FC ""fibrocalclc; FF = fibrofatty; FT = fibrotic; OCT== optical coherence tomography; 
PIT = pathologlcallr'ltlmal thkker'llng; TCFA "' thlr'l-<:ap fibroatheroma; VH "" virtual histology. 
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Figure 4. low-Risk Plaques 
Matched Images of grayscale IVUS (A), virtual histology (B), and OCT (Q for the 4 types of plaques considered at low risk. 1: adaptive 
Intimal thlckenlr'lg, 2: pathologle<~l Intimal thlckenlr'lg, 3: fibrOCJiclfic plaque, 4: fibrotic plaque. Abbrevlatlor'ls as ir'l Figure 1. 
In Vivo Assessment of High-risk Coronary Plaques 
MJtched lmJges of gr<~ysc.;~le IVUS (A), virtual histology (B), Jnd ocr (C) for the 4 types of pl<~qucs considered Jt high risk of rupture. 
1: fibro.;~theroma, 2: calcified fibroatheromJ, 3: thin-cap fibroatheromJ, 4: calcified thin-cJP fibro;:,theromJ. AbbrcviJtlons Jsln Figure 1. 
2. Pathological intimal thickening (PIT): intimal 
thickening ==::600 f.LID for more than 20% of the 
circumference with more than 15% of fibrofatty 
tissue, and no confluent necrotic core or dense 
calcium. 
3. Fibrotic plaque: plaque constituted predomi-
nantly by fibrous tissue without confluent ne-
crotic core (NC) or dense calcium. 
4. Fibrocalci:fic plaque: more than 10% of conflu-
ent dense calcium without confluent NC. 
5. Fibroatheroma (FA): plaque characterized by 
the presence of more than 10% confluent NC 
covered by a fibrous cap thicker than 65 JLm. 
6. Calcified fibroatheroma (CaFA): fibroatheroma 
that contains more than 10% of confluent dense 
calcium. 
7. IVUS/OCT -derived thin-capped fibroathe-
roma (TCF A): defined as the presence of more 
than 10% confluent NC at the lumen covered 
by a thin fibrous cap ( <65 Mm). 
8. IVUS/OCT -derived calcified thin-capped fi-
broatheroma (CaTCFA): TCFA that contains 
more than 10% of confluent dense-calcium. 
F As and TCF As are considered high-risk plaques 
in American Heart Association and V rrmani classifi-
cations (7,16). The necrotic core was considered 
confluent when it was forming a major pool This 
definition was used to avoid misclassification as high-
risk plaques oflesions with isolated islets or individual 
pixels of necrotic core, which can be artifacts. The 
presence of confluent NC >10% at the lumen was 
measured using dedicated in house developed software 
(MATLAB Math Works, Natick, Massachusetts) (9). 
A validation with pathology of a similar algorithm was 
reported m the CAPITAL (Carotid Artcry Plaque 
Vll1:Ual Histology Evaluation) study (14). The iliag-
nostic accuracy of NUS-VH compared with histology 
in different carotid plaque types was 99.4% forTCF.A, 
96.1% for CaTCFA, 85.9% m FA, 85.5% for fibro-
calcific, 83.4% in PIT, and 72.4% for CaFA To 
overcome the limitations ofiVUS-VH in the fibrous 
cap evaluation, the classification used in our study 
combines the information about plaque composition 
provided by rvus-"VH and the measurements of 
fibrous cap as assessed by OCT (9). The thinnest part 
of the fibrous cap was measured by OCT in all the 
plaques that contain more than 10% of confluent NC 
to distinguish between FA and TCF A The fibrous 
cap measurement by OCT was guided by the 
NUS-"VH to avoid misclassification between lipid 
pools and calcium. The cap was measured in the area 
where the ::--JC was closer to the lumen. The repro-
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ducibility of fibrous cap measurements has previously 
been reported (12). If different morphologies were 
present along the lesion, the highest degree plaque was 
established as the definite plaque type. 
Statistical analysis. Statistical analyses were per-
formed usmg SPSS 12.0.1 for Windows (SPSS 
Inc., Chicago, Illinois). Continuous variables are 
o..-pressed as mean ± SD. Categorical variables arc 
e;...-pressed as percentages. The bifurcation (lesion) 
was the unit of analysis without corrections for 
correlated observations in the same subjects. To 
compare continuous variables between lesions, t test 
or analysis of variance was used. To compare 
continuous variables between different segments of 
the bifurcation, paired samples t test or Wilcoxon 
signed ranks test for 2 dependent samples was used. 
Comparison among groups for categorical variables 
was made with the chi-square method. 
RESULTS 
Clinical and procedural characteristics. One hundred 
and three bifurcations were selected in 32 pullbacks 
performed in 30 patients. The mean age was 60 :t 
7 years, and 73% were male. Regarding cardiac risk 
factors, 48.3%, 6. 9%, and 72.4% had hypertension, 
diabetes mellitus, and hyperlipidemia, respectively, 
and 27.6% were smokers. Seven percent had prior 
myocardial infarction, and 43.3% had undergone a 
prior percutaneous coronary intervention. The clin-
ical presentation was stable angina in 86.7%, unsta-
ble angina in 10%, and acute myocardial infarction 
in 3.3%. The investigated vessel was the left ante-
rior descending artery (LAD) in 34%, left circum-
flex artery (LCX) in 33% and right coronary artery 
(RCA) in 33% of the cases. The type ofbifurcations 
studied were LAD/diagonal, LAD/septal branch, 
LCX/marginal, and RCA/right ventricular branch 
in 21.4%, 12.6%, 33%, and 33% of the cases, 
respectively. The indication for IVUS-VH and 
OCT was assessment of intermediate, non-flow 
limiting lesions by angiography in 40% of the cases 
and post-stent implantation assessment in the re-
maining 60% of cases. .AJl studied lesions were 
considered nonsignificant by angiographic criteria 
and had a lumen area >4 mm2 by IVUS. Overall 
the mean vessel and lumen area and plaque burden 
were 13.9 ± 3.7 mm2, 7.7 ::t 2.2 mm2, and 43.2::!: 
13%, respectively. Table 1 shows the number of 
quadrants containing plaque and the location of the 
thickest part of the plaque in relation to the side 
branch. 
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Table 1. Number of Quadrants Containing Plaque and 
Location of the Thickest Part of the Plaque in Relation to the I 
Flow Divider 
Number of quadrants containing plaque 
1 25(103 (24.3%) 
2 
3 
4 
Location of the thkke-;t part of the plaque 
Quadrant 1 
Qu<Jdr;;~nt 2 
Quadrant 3 
Quadr<Jnt 4 
33(1 03 (32.0%) 
29/103 (28.2%} 
16/103 (155%} 
28/103 (27.2%) 
18/103 (17.5%) 
26/103 (25.2%) 
31/103 (30.1%) 
Frequency of plaque type. The plaque type was 
analy.t:ed in 103 lesions and 293 cross-sections. 
Eight distal and 8 proximal rims could not be 
analy.t:ed because of artifacts. Overall, the frequency 
of each plaque type per lesion was: AIT 20 (19.4%), 
PIT 16 (15.5%), fibrocalcific 15 (14.6%), fibrotic 7 
(6.8%), FA 8 (7.8%), CaFA 19 (18.4%), TCFA 10 
(9.7%), and CaTCFA 8 (7.8%). In the analy-£ed 
cross-sections the distribution was as follows: AIT 
76 (25.9%), PIT 53 (18.1%), fibrocalcific 42 
(14.3%), fibrotic 28 (9.6%), FA 18 (6.1%), CaFA 
42 (14.3%), TCFA 21 (7.2%), and CaTCFA 13 
(4.4%). 
NC and cap thickness distribution. The NC and cap 
thickness distribution in the proximal rim, in-
bifurcation, and distal rim cross-sections are shown 
in Figure 6. Overall, the mean NC area and mean 
percentage of NC decreased from proximal to 
distal, whereas the mean cap thickness showed an 
inverse tendency. 
High~risk plaque distribution and compositional and 
geometrical analysis. The distribution of the diff'er-
ent plaque types in relation to the location is shown 
in Table 2. Figure 7 shows the number of cross-
sections v.rith high-risk plaque morphology in the 
proximal rim, in-bifurcation, and distal rim. The 
thin caps were more often located in the proximal 
rim (15 of 34, 44.1%), followed by the in-
bifurcation (14 of 34, 41.2%), and were less fre-
quent in the distal rim (5 of 34, 14.7%). The 
location of the thin cap in the 18lesions classified as 
TCF As was as follows: In 4 cases the thinning of 
the cap e.xtended from the proximal rim into the 
distal rim, in 7 cases the thin cap was located in 
the proximal rim and in the in-bifurcation; in 3 
TCF As the thinning of the cap was located only in 
the in-bifurcation and, in 3 cases only in the 
proximal rim; there was 1 TCF A that presented the 
thin cap at both rims whereas the cap at the 
Proximal In-bifurcation Distal 
rim rim 
Proximal In-bifurcation Distal 
rim rim 
c p=O.OS 
-155 
E 150 
a 145 
~ 140 
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Proximal In-bifurcation Distal 
rim rim 
Figure 6. Necrotic Core and Cap Thickness Dirtribution 
Necrotic core (Nq area (A), necrotic core percentage {B). and 
cJp thickness (C) distribution in the proximal rim of the ostium 
of the side bra11ch, in-bifurCJtion, and distal rim cross-sections. 
in-bifurcation frame was thicker. There were no 
cases in which the thin cap was located only in the 
distal rim. The mean cap thickness in proximal rim, 
In Vivo Assessment of High-risk Coronary Plaques 
in-bifurcation, and distal rim in TCFAs is shown in 
Figure 8. 
The vessel area and the plaque burden was 
significancly greater in the subgroup of lesions 
considered high risk (FA, CaF A, TCF A, and 
CaTCFA) than in the rest of lesions (16.5 ± 3 
mm2 vs. 14.1 ± 3 mm2, p = 0.002 and 55± 9% vs. 
42 :::!::: 12%, p < 0.001 for vessel area and plaque 
burden, respectively), whereas the lumen area was 
not significancly different (6.8 :::!::: 2 mm2 vs. 7.1 ± 2 
mm2 , p = 0.39). Table 3 shows the plaque burden, 
NC percentage, and cap thickness in FA, CaFA, 
TCFA, and CaTCFA. 
Plaque type in relation to the clinical presentation. As 
e..ploratory analysis, patients with acute coronary 
syndromes (ACS) had a significant higher propor-
tion of lesions with high-risk morphology plaques 
than stable patients (17 of 23 [73.9%] vs. 28 of 80 
[35%], p = 0.002). Specifically the number of 
lesions with TCF A morphology was 6 of 23 
(26.1 %) vs. 12 of 80 (15%), p = 0.2, for ACS and 
stable patients respectively, and the number of 
lesions with FA morphology was 11 of23 (47.8%) 
vs. 16 of 80 (20%), p = 0.01, for ACS and srable 
patients respectively. 
DISCUSSION 
To our knowledge this is the first in-vivo study 
evaluating the frequency and distribution of high-
risk plaques at bifurcations in coronary arteries 
using a combined plaque assessment -with NUS-VH 
and OCT. The main finding is that the thinning of 
the fibrous cap occurs more often in the proximal 
rim of the ostium of the side branch. The NC 
shows also a differential distribution along the 
bifurcation being higher at the proximal rim. 
Multi~modality plaque assessment. The detection of 
plaques at potentially high risk of rupture could 
prevent future occurrence of acute coronary syn-
dromes. At present, multiple techniques are avail-
able that evaluate different aspects of the athero-
sclerotic plaque, such as its structure, composition, 
or mechanical properties (17). The combined infor-
Table 2. Distribution of the Different Plaque Types in the Proximal Rim of the Ostium of the Side Branch, In-Bifurcation, and Distal Rim Cross Sections 
AIT PIT FC FT FA CaFA TCFA CaTCFA Total 
Proximal rim 21 (22.1%) 19(20%) 13(13.7%) 5 (5.3%) 8 (8.4%) 14(14.7%) 10(10.5%) 5 {5.3%) 95 
in·bifurcJtiol'l 24(23.3%) 18(17.5%) 15(14.6%) 12(11.7%) 5(4.9%) 15(14.6%) 8{7.8%) 6(5.8%) 103 
Distal rim 31 (32.6%) 16(16.8%) 14(14.7%) 11 (11.6%) 5 (5.3%) 13 (13.7%) 3 (3.2%) 2(2.1%) 95 
N - 293 cro~~·~cctlono. 
AIT- JdJpt.:ltlv<: lntlmJI thlckening;C...FA- oiclfied fibroJtheromJ; C...TCFA - c,:,lclfied thin-.cap fibroatheromJ; FA ~ f1brootheroma; FC - iibrocalclc:; FT ~ fibrotl<:; PIT~ pathologlcJIIntimJI 
thickening: TCFA ~ d1ln-<:Jp libroJtheromJ. 
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Figure 7. OistTibution of the High-Risk Plaques in the Proximal Rim of 
the Ostium of the Side Branch, ln-Bifun;ation, and Distal Rim 
Cross-Sections 
I 
Number of cross-sections with high-risk plaque morphology In the proximal 
rim, In-bifurcation, and distal rim. Abbreviations as in Figure 3. 
marion provided by the different methods is essen-
tial for better identification of high-risk coronary 
lesions. In this study, a combined approach with 
IVUS-VH and OCT was used. The IVUS-VH 
allows the detection and quantification ofNC, one 
of the main components of high-risk plaques. 
However, the limited axial resolution of IVUS 
(approximately 200 f.Lm) does not permit an accu-
rate evaluation of the fibrous cap. On the contrary, 
OCT has a very high resolution (10 to 20 f.Lm), 
allowing a very precise measurement of the fibrous 
cap. Savvada et al. (9) recendy reported that the 
combined use of IVUS-VH and OCT improved 
the accuracy for TCF A detection. They studied 126 
plaques in 56 patients with angina. Of the 61 
plaques diagnosed as TCF A by IVUS-VH criteria, 
only 28 had a thin fibrous cap, as measured by 
Proximal rim In-bifurcation Distal rim 
Figure 8. Cap Thi(kness Distribution in Thin.Cap Fibroatheromas 
Mean cap thickness In the proximal rim of the ostium of the side branch, 
in-bifurcation, and dlst:JI rim cross-sections in thin-cap fibroatherom<:~s. 
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OCT. In addition, 8 OCT -detived TCF A did not 
have NC in the VH analysis, mainly because of the 
misinterpretation in the OCT analysis caused by 
dense calcium. This source of error in plaque 
characterization by OCT has previously been de-
scribed and indicates the difficulty in identifYing 
TCFAs using only OCT (18). To avoid this mis-
classification in our study, the measurement of the 
fibrous cap in OCT was guided by !1/US-VH. At 
the present stage neither modality independently is 
sufficient for detecting the highest risk plaques; the 
combined approach seems to be mandatory for the 
accurate diagnosis of TCF A in vivo. 
High-risk plaque frequency, distribution, composition, 
and geometrical analysis. The in vivo frequency of 
TCF As at bifurcations is not known. In our study, in 
which a highly selected population was included, 18 of 
103 bifurcations presented TCFAs (17%). Consider-
ing that the number of bifurcations in the complete 
coronary tree is approximately 15 (19), the frequency 
ofTCF As per heart would be approximately 2.5. This 
is in agreement with reported pathological data (1). 
The bifurcation left main/LAD has been studied with 
IVUS-VH showing that the plaque burden and the 
amount of necrotic core are higher in the LAD than 
in the left main artery. However, plaque morphology 
in the different segments of other bifurcations has not 
been previously evaluated in vivo. The present study, 
which extended the assessment of bifurcation lesions 
beyond the left main artery, showed that the amount 
of necrotic core is higher at the proximal rim of the 
ostium of the side branch with a thin fibrous cap more 
often identified in the proximal rim. The fibrous cap 
thickness is determined by the balance between matrix 
synthesis by the smooth muscle cells and matrix 
degradation by metalloproteinases (MMP) produced 
by macrophages (20). It has been shown that the 
distribution of inflammatory cells in atherosclerotic 
plaques relates to the direction of the flow with higher 
concentration of macrophages and :rviMP activity in 
the upstream or proximal part (21). One of the 
mechanisms that have been proposed for the differ-
ential distribution of the high-risk plaques along the 
artery is the influence of endothelial shear stress. 
Bifurcations are geometrically irregular regions in 
which disturbed laminar flow occurs, generating ab-
normal endothelial shear stress patterns that may play 
a role in plaque destabilization. Previous studies 
showed that atherosclerosis develops preferentially at 
low shear stress locations such as the outer wall of 
bifurcations (2). However, in our data the thickest part 
of the plaque did not show a preferential location for 
this region. 
In Vivo Assessment of High-risk Coronary Plaques 
Table 3. PB and NC Percent and Cap Thickness in FA, CaFA, TCFA, and CaTCFA 
PB (%) 
NC (%) 
CJp thickness (iJ.m) 
FA(n=S) 
51.7::: 11 
20.1:::5.3 
165±59 
CaFA (n = 19) 
53.7::: 10 
27.1 :::6 
174::: B8 
NC ~ nCO" otic core; PS ~ plaque burden; other JbbrC\IIJtlon~ o~ In Tobie 2. 
Different pathological and IVUS studies have 
confirmed that plaque rupture occurs usually at sites 
of significant plaque accumulation associated with 
positive remodeling (2,22). This is in agreement 
with our data showing that the vessel area and the 
plaque burden were higher in high-risk plaques 
compared with stable lesions. In line with patho-
logical series, TCF As in our study were located in 
areas with nonsignificant lumen compromise, with 
a mean luminal area of 6.8 :±: 2 mm2 (8). Similarly, 
NC in TCFAs in this population is concordant 
with previously published pathological findings (8). 
High-risk plaques in relation to dinical presentation. 
Although the comparison benveen ACS and stable 
patients in this study was c,'\:ploratory, patients with 
unstable clinical presentation showed a high-risk 
profile of plaque types at bifurcations with a higher 
proportion ofTCF As and FA. This is in agreement 
with previous data regarding TCF A detection with 
I'VUS-VH showing that ACS patients present a 
significantly higher prevalence of IVUS-derivcd 
TCF A than stable patients (10). 
Study limitations. Currently 'i/H -derived necrotic 
core rich plaques can only be considered as allegedly 
high-risk lesions because it has not been shown 
TCFA (n = 10) 
54.2±6 
33.0 ± 8 
49::: 15 
CaTCFA (n = 8) 
61.8:::5 
31.7:::8 
51 ::: 13 
p Value 
0.13 
0.002 
<0.001 
whether they are associated with a higher incidence 
of clinical events at follow-up. In the present study, 
OCT and 'i/H were restricted to 1 or 2 vessels; 
therefore, and unlike pathological studies, this does 
not allow us to draw conclusions on the incidence of 
TCF A in bifurcations vvithin the complete coronary 
tree. No comparison with nonbi:furcation lesions 
was performed. Still the detailed plaque assessment 
combining 2 imaging modalities has given the first 
insight into the distribution of these allegedly high-
risk lesions at bifurcations. 
CO:-lCLUSIO:-lS 
This study has given unique, in vivo data on the 
localization of plaque occurring at bifurcation le-
sions. Further, the proximal rim of the ostium of 
the side branch has been identified as a region more 
likely to contain thin fibrous cap and a greater 
proportion of necrotic core. 
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Aims 
Methods 
and results 
Keywords 
To evaluate the feasibility of the combined use of virtual histology (YH)-intravascular ultrasound (IVUS) and optical 
coherence tomography (OCT) for detecting in vivo thin-cap fibroatheroma (TCFA). 
In 56 patients with angina. 126 plaques identified by IVUS findings were analysed using both VH-IVUS and OCT. 
IVUS..derived TCFA was defined as an abundant necrotic core (>10% of the cross-sectional area) in contact with 
the lumen (NCCL) and %plaque-volume >40%. OCT -derived TCFA was defined as a fibrous cap thickness of 
<65 p..rn overlying a low-intensity area with an unclear border. Plaque meef1ng both TCFA criteria was defined as 
definite-TCFA Sixty-one plaques were diagnosed as lVUS-derived TCFA and 36 plaques as OCT-derived TCFA 
Twenty-eight plaques were diagnosed as definite-TCFA; the remaining 33 IVUS-derived TCFA had a non-thin-cap 
and eight OCT-derived TCFA had a non-NCCL (in discord with NCCL visualized by VH-IVUS, ma'1nly due to 
misreading caused by dense calcium). Based on IVUS findings, definite-TCFA showed a larger plaque and vessel 
volume, %plaque-volume, higher vessel remodelling index. and greater angle occupied by the NCCL in the lumen 
circumference than non-thin-cap IVUS-derived TCFA 
Neither modality alone is sufficient for detecting TCFA The combined use of OCT and VH-IVUS might be a feasible 
approach for evaluating TCFA 
Thin-cap fibroatheroma • VH-IVUS • OCT • Necrotic core Vessel positive remodelling 
Introduction core, a thin fibrous cap (<65 JJ-m), and macrophage infiltra-
tion into the cap.43 This entity is usually known as thin-cap 
fibroatheroma (TCFA). Acute coronal)' syndrome (ACS) commonly results from plaque 
rupture,1 - 3 and occasionally results from erosion or calcified 
nodules.4.s The pathologic features of plaque prone to rupture 
are a positively remodelled vessel, including a large necrotic 
The accurate detection ofTCFA is vital for the diagnosis of vul-
nerable patients. New imaging modalities. such as virtual histology 
(YH)-intravascular ultrasound (IVUS) and optical coherence 
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tomography (OCT). were developed to precisely evaluate coron~ 
ary plaques. Radiofrequency data analysis by VH-IVUS allows for 
atherosclerotic plaques to be classified as one ofthe four different 
types (fibrous, fibre-fatty, dense calcium, and necrotic core), and is 
especially useful for quantifying the necrotic core.6.7 VH-IVUS 
cannot visualize the thin fibrous cap, however, because of its 
limited resolution (>100 JJ.-ffi). ocr. on the other hand, can 
provide a high resolution image (10-20 p..m), but its penetration 
is limited ( <2 mm).8- 11 OCT can visualize the thin fibrous cap, 
but is not able to dct(!ct a large and deep lipid core. Thus, it is dif-
ficult to diagnose TCFA using each modality alone. The combined 
use of these complementary imaging modalities, VH-IVUS and 
OCT, might result in more effective detection of TCFA 
The aim of this study was to elucidate the feasibility of the com-
bined use of VH-IVUS and OCT to detect in vivo TCFA and to 
clarify the lesion characteristics ofTCFA 
Methods 
Patient and tesion popu~tion 
Between August 2005 and March 2007, 402 patients with de novo 
ischaemic heart disease underwent coronary angiogmphy in our hospi-
tal. Angina pectoris was identified as a significant coronary stenosis 
causing apparent myocardial ischaemia based on symptoms or c!ectro-
C;J.rdiographic ST-T ch;J.nges during ;J.n ;J.ngina ;J.ttack. To ensure safety 
during the OCT procedure, 121 patients were excluded because 
they had ST-segment elevation indicating an acute myocardial infarc-
tion or unstable angina pectoris warmnting emergency percutaneous 
coronary intervention (PCI). Another 160 patients were excluded 
because 39 patients had chronic total occlusion, 20 patients had 
heavily calcified lesions that required rota-ablation, five patients had 
significant left main disease, and 96 p;J.ticnts had tortuous lesions 
expected to cause difficulty in advancing the IYUS and OCT catheters. 
Furthermore. we excluded six patients because they had vessels with ;J. 
diameter >4.0 mm by angiography. which was too large to occlude 
blood flow. In the remaining 115 patients, 59 did not consent to the 
invasive intra-coronary examination, and the remaining 56 allowed us 
to perform the YH-IYUS and OCT examination. We identified 
plaques based on the IVUS findings and ;J.nalyscd each plaque using 
both YH-IYUS and OCT. 
We assessed patient ch;J.racteristics, including age, sex, body mass 
index, presence of coronary risk factors (hypertension, hyperlipidaemia. 
diabetes mellitus. smoking), and medication. Hypertension was defined 
as systolic blood pressure 2::_140 mmHg, diastolic blood pressure 
:,::90 mmHg, or use of anti-hypertensive drugs. Hyper\ipidaemia was 
defined as ;J. present or past history of low-dcnsrty lipoprotcin-choles-
tcrollevcl 2:140 mgld~ or usc of statin. Diabetes mellitus was defined as 
a fasting blood sugar >126 mg/dl and haemoglobin A 1 c 2:6.4%. or use 
of anti-diabetic medications (insulin or oral hypoglycaemics). 
Binary examinations were performed if the patient experienced a 
severe angina attack or consented to a 6 month fo\low-up study 
(21 patients). This study was approved by the Ethics Committee of 
Kobe Univcrsrty. 
Quantitative coronary arteriography 
measurement 
Coronary angiogram was performed ;J.fter intmcoronary injection of 
nitroglycerin (250 f.l.g). and the severity of stenosis was measured with 
a quantitative coronary arteriography cardiovascular measurement 
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system (CMS-Medis Medical imaging Systems. Leiden). We assessed tra-
ditional lesion types using the American Heart Association/American 
College of Cardiology's classification, and mapped the plaque location 
(proximaL mid. or distal vessel) angiographically. Because some 
plaques were completely undetectable by angiography, information 
from the IVUS was used to determine the plaque location. 
~ntravascular ultrasound procedure and 
quantitative coronary ultrasound 
measurement 
A 2.9Fr 20 MHz IVUS catheter (Eagle-Eye™: Yobno Therapeutics. 
Inc .. Rancho Cordova. CA USA) was inserted into the coronary 
artery more than two-thirds distal, and subsequently pulled back 
with the aid of motorized pullback system (0.5 mm/s). The IVUS 
images obtained were digitized for quantitative and qualitative analysis 
;J.ccording to the criteria of the American College of Cardiology's Clini-
cal Expert Consensus Document on IYUS.12 A 3D reconstruction of 
volumetric gray-scale IVUS data was performed using a semi-
automated quantitative coronary ultrasound cardiovascubr measure-
ment system (CMS-Medis Medical Imaging Systems). If the patient 
required PCI, we obtained the IVUS data before the PCI procedure. 
Plaques in the same artery were considered to be separate lesions if 
the reference segment between them was > 5 mm: otherwise, they 
were considered to be part of a single lesion. 
IYUS data recorded on CD-ROM for off-line analysis were used to 
calcul;J.tc the lesion length. lumen volume, vessel volume, and plaque 
volume (vessel volume-lumen volume) based on manual counter-
detection of both the lumen and vessel interfaces in each cross-
sectional frame. We then used these data to calculate %plaque-volume 
(plaque volume/vessel volume x 100) and remodelling index (vessel 
cross-sectional area of minimum lumen sitc!avcragcd reference 
vessel cross-sectional area). 
Virtuai histology ana[ysis and definition of 
intravascu:l.arr ultrasound-derived thin-cap 
fibroatheroma 
Raw radiofrequency data of these lesions were stored on a DVD for 
off-line quantitative analysis, and plaques were classified by version 
2.0 YH software into fibrotic, fibre-fatty. dense calcium, and necrotic 
core components. Plaque components were represented as a ratio 
of plaque volume (%fibrous, %fibre-fatty, %dense-calcium, %necrotic-
core). Using a previously reported definition,13 we defilled lYUS-
derived TCFA as a lesion meeting the following two criteria in at 
least three consecutive frames: (1) focal necrotic core-rich lesions 
(%necrotic-core >10%) without evident overlying fibrous tissue and 
(2) %plaque-volume :;:40%. 
An independent investigator at the Erasmus Medical Center quan-
tified the area of the necrotic core in contact with the lumen 
(NCCL) as well as the major confluent NCCL area and angle occu-
pied by the NCCL in the lumen circumference using a program 
implemented in MATL.A.B™ (MathWorks. Natick. MA USA). The 
angle formed by the connected necrotic core pixels on the border 
of the lumen was measured with respect to the lumen centre of 
gravity (Figure 1).14 
Optica[ coherence tomography examination 
and definition of optical coherence 
tomography-derived thin-cap fibroatheroma 
After the IVUS procedure, OCT examination was performed as pre-
viously dcscribed.8 Briefly. an over-the-wire type occlusion balloon 
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(A) 
'%necrotic-core 
31.1% 
(B) 
Blue area; 
major NCCL. 28.3% 
Purple plus blue area 
Total NCCL, 30.5% 
(C) 
Red line; 
angle of the major NCCL. 9" 
White and red line; 
an-gle of the total NCCL. 35" 
Figur-e I An example of selective quantification of the necrotic core in contact with the lumen (NCCL). (A) The original virtual 
histology-intr.J.vascubr ultrasound cross-sectional arm. (B) The blue area was selectively quantified as the major confluent NCCL areas and 
blue plus purple areas indicate total NCCL areas. (C) Measurement of the angle occupied by the total NCCL (white and red line) and the 
angle occupied by the major confluent NCCL (red line). 
Table I Clinical characteristics 
Patients without definite--TCFA Patients with definite--TCFA P-value 
Number (n) 
Age (yeJ.r) 
Male {11) 
Body mass index (kg/m2) 
Risk factor (11) 
Hypertension 
Hyperlipidemia 
Diabetes mellitus 
Smoke 
Acute coronal)' syndrome (n) 
Diseased vessel (112/3) 
Statin (11) 
(Month) 
ARB/ACEI (n) 
(Mo11th) 
Tot:il cholesterol (mgldl) 
LDL-cholesterol (mgldl) 
HDL-cholestcrol (mg/dl) 
Triglyceride (mg/dl) 
Fasting blood sugar (mgfdl) 
HcmoglobinA1c (%) 
hs-CRP (mgldl) 
32 
68.1 ± 8.7 
18 
23.7 ± 2.8 
25 
24 
18 
10 
2 
9/19/4 
21 
15.0 (6.8, 34.5) 
21 
22.0 (15.0, 96.0) 
177.1::23.9 
993 ::!: 17.4 
54.2 ± 21.6 
132.6 ± 100.0 
115.1 ± 36.0 
6.2 ± 1.2 
0.12 ± 0.11 
24 
70.1::::8.2 
17 
24.6 ± 28 
19 
17 
11 
9 
10/9/5 
16 
9.0 (6.3, 17.0) 
19 
15.0 (12.0, 225) 
193.1 ± 40.2 
112,8±35.1 
52.1 ± 128 
154.0 ± 93.0 
118.4::40.2 
5.9 ± 0.9 
0.15 ± 0.20 
Data >~re e:.:prc:;sed mean v.1iue ± SD or median (2S<~>, 75th j)<!rCentilc), P < 0.05 WJ$ considered :otati~IColll)' slef'llfiColnt. 
ARB. angiotensin receptor blocker; ACEI, angloten~ln converting enzyme Inhibitor: hs-CRP. high-sensitive C-reactlve protein. 
............... 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
0.07 
0,09 
NS 
NS 
0,07 
NS 
NS 
NS 
NS 
NS 
NS 
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catheter (Helios™, Lightlab Imaging Inc., Westford, MA USA) and an 
OCT imaging, probe (lmageWire ™, Lightlab Imaging Inc.) were 
inserted into the coronary artery more than two-thirds distal The 
entire vessel length was imaged with an automatic pullback device at 
1 mm/s, and OCT data were recorded on a CD-ROM for off-line 
analysis. 
An OCT image of a signal-poor lesion with an unclear border was 
diagnosed as a lipid core and a signal-rich homogenous lesion overlying 
lipid content was diagnosed as a fibrous cap.9 - 11 The thinnest part of 
the fibrous cap was measured three times and the average v;:t.luc calcu-
lated. Because the previous histopathology report revealed that 95% of 
the fibrous cap thickness ncar a rupture site was <65 !J.m,15 a lesion 
whose fibrous cap thickness ;rt the thinnest part was < 65 ILm was 
diagnosed as OCT-derived TCFA 
Comparison of virtual histology-intravascular 
ru:[trasm.md and optnca[ coherence 
tomography images and definition of 
definite-thin-cap fibroatheroma 
We compared the VH-IVUS and OCT images of identical lesions using 
the locations of side brnnches, longitudinal plaque distribution, or cal-
cification as landmarks. If the plzi.que met the criteria of both the lVUS-
derived TCFA and OCT-derived TCFA. we diagnosed it as 
dcfinite-TCFA If IVUS-derivc<l TCFA did not have a thin fibrous cap 
(<65~-Lm) by OCT measurement, we diagnosed it as non-thin-cap 
IVUS-derived TCFA If VH-IVUS did not detect an NCCL that was 
detected by OCT-derived TCFA. the plaque was diagnosed as 
non-NCCL OCT -derived TCFA. 
To assess intrn- and intcr-observerv;:t.riability, all VH-IVUS and OCT 
data were read by two independent observers. The first observer 
repeated a blind analysis of all the data ;rt two separnte time points 
(with at least 1 month interval between the two analyses). If there 
was discordance of either the IVUS- or OCT-derived TCFA diagnosis 
between the two observers, a consensus diagnosis was obtained with 
repeated off-line readings. 
Statistica[ ana~ysis 
This is a pilot study that compared the data between VH-IVUS and 
OCT. Because a previous study demonstrated that plaque volume, 
vessel remodelling, necrotic core volume, and circumference were 
associated with an unstable plaque type_2·16 we hypothesized th;rt 
the factors indicative of thin fibrous cap in IVUS-dcrivcd TCFA were 
%plaque-volume, remodelling index, and angle occupied by NCCL in 
the lumen circumference. Thus, the sample size was based on the pre-
liminary data obtained in our laboratory and was determined on the 
basis of the following assumptions: A type-I error of 0.05 (two-sided): 
power of 80%: difference in the%plaquc-volume, remodelling index, 
and the NCCL angle between definite TCFA and non-thin-cap IVUS-
derivcd TCFA of 8.0%, 0.1, and 30°, respectively, and a standard devia-
tion of 8.0, 0.12, and 35, respectively. Therefore, the minimum 
required sample size was 23 lesions in each group. We stopped 
recruitment at 20 months, because the power of these data was 
beyond 99.9%. Because of the limited sample size of non~NCCL OCT-
derived TCFA (eight lesions), the data for this group were considered 
exploratory. 
Statvicw version 5.0 (SAS, Cary, NC. USA) was used for the data 
analysis. Qualitative data are presented with frequencies and quanti-
tative data arc shown as medians (25th and 75th percentiles) or 
mean ± SD when indicated. Comparison of laboratory data 
between the two groups was performed using the unpaired t-test. 
If the data were not normally distributed, as determined by 
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Kolmogorov-Smimov analysis, the data were analysed using a 
Mann-Whitney test. A two-sided P-v;:t.\uc of <0.05 was considered 
statistically significant. 
Angiographical data, gray-scale IVUS and VH-IVUS data were ana-
lysed using random-effects generalized least-squares regression in 
order to account for repeated measurements on individual patients. 
Wald's test was used for assessing differences in means between 
plaque type categories. Fitted models were used in calculating pre-
dicted means and their 95% confidence intervals (Cts). For the 
values in Table 2, a model with two categories of plaque types 
(dcfinite-TCFA and non-TCFA) was fit For the values displayed in 
Tables 3 and 4, a separate model with four categories of plaque 
types (definite-TCFA and the three subcategories of non-TCFA 
plaque types) was fit Predicted means and Cis for 
definite-TCFA in Tables 3 and 4 occasionally differ slightly from 
those in Table 2, because separnte models were used. An adjusted 
P-value of <0.0167 (0.05/3, Bonferroni's correction for multiple 
comparisons) was used as the threshold for significance to avoid 
an inflated typc-1 error because three pair-t~~ise planned comparisons 
were made, 
To assess the inter- and intro-obscrver variability, the results 
were compared using the K-test of concordance for the 
categorical data and Bland-Altman plot was fulfilled for continuous 
variables. 
Results 
Feasibility of virtual 
histology~intravascular ultrasound 
and optical coherence tomography 
examinations 
In 56 patients, 82 diseased vessels were observed with VH-IVUS 
and OCT without any complications. We identified 126 plaques 
in the 82 diseased vessels. The average procedure time of 
VH-IVUS and OCT, including preparation of both devices, was 
18.7 ± 4.4 min. The mean evaluation length by VH-IVUS was 
48.6 ± 16.3 mm and that measured by OCT was 44.5 ± 
12.8 mm. The average balloon occlusion time for one-time OCT 
imaging was 49.8 ± 11.4 s. 
~dentification of intravascular ultrasound-, 
optical coherence tomography~derived 
thin~cap fibroatheroma, and 
definite-thin-cap fibroatheroma 
Of 126 plaques, VH-IVUS observations identified 61 plaques 
(48.4%) as IVUS-derived TCFA. and OCT examination diagnosed 
36 plaques (28.6%) as OCT-derived TCFA. Twenty-eight (22.2%) 
of the plaques met both criteria for TCFA and were diagnosed 
as definite-TCFA, The remaining 33 IVUS-derived TCFA (26.2%) 
were diagnosed as non-thin-cap IVUS-derived TCFA (mean 
fibrous cap thickness by OCT was 99.0 ± 13.3~-Lm) and the 
remaining eight OCT-derived TCFA (6.3%) were diagnosed as 
non-NCCL OCT-derived TCFA. The positive ratio of VH-IVUS 
for detecting definite TCFA was 45.9% and that of OCT was 
77.8%. A summary of the lesion diagnoses is shown in Figure 2 
and representative cases of non-thin-cap IVUS-derived TCFA, 
Feasibility of Combined Use of Intravascular Ultrasound Radiofrequency Data Analysis 
Table 2 Comparison of angiographical data, gray-scale intravascular ultrasound. and virtual histology-intravascular 
ultrasound data between non-thin-cap fibroatheroma and definite-thin-cap fibroatheroma 
Non-TCFA (n = 98) Definite-TCFA (n = 28) P-va(ue (vs. definite-TCFA} 
Left anterior descending artery 40 12 
Left circumflex artery 16 4 
Right coronary artery 42 12 NS 
............... 
Type of lesion 
A/B1 84 22 
B2/C 14 6 NS 
................ 
Locatbn of lesion 
Proximal 21 15 
Mid 56 12 
Distal 21 1 0.002 
Quantitative coronary arteriography data 
Reference vessel diameter (mm) 2.42 (230. 255) 2.53 (230. 276) NS 
M'1nimum lumen diameter (mm) 1.84 {1.62. 205) 1.84 (1.62 205) NS 
~oArea-stenosis (%) 34.3 (30.6, 38.0) 45.1 (38.2 52.1) 0.007 
................ ............... 
Gray-scale IVUS mc~urements 
Plaque volume {mm3/cm) 71.2 (53.2 89.3) 96.1 (J3.7, 118.4) 0.0001 
Vessel volume (mm3/cm) 139,9 (109.0, 176.5) 162.1 (124.7. 200.0) 0.004 
Plaque le11gth (mm) 12.8 (11.1.14.6) 17.5 (14.4. 20.6) NS 
%Plaque-volume (%) 48.6 (46.8, 50.4) 56.5 (53.3. 59.7) <0.0001 
Remodelli11z·it1dcx 1.06 (1.03, 1.08) 1.21 (1.17, 1.25) <0.0001 
................. .............. . .............. , 
VH measurements 
%Fibrous 621 (60.3. 65.1) 56.8 {526. 61.0) 0.01 
%Fibro-fatty 13.4 (11.8. 14.9) 13.5 (10.7, 16.4) NS 
%Dcnse-caldum 8.8 (7.3. 10.4) 9.9 (J.O. 1 0.4) NS 
%Necrotk-corc 15.3 (13.7.16.9) 20.0 (17.0, 23.0) 0.006 
Data ~rc cxpre-..,;ed predicted mean~ and their 95% Cis, For the value:; In thi~ t.1blc, a model ~th two c.:ttcgories of plaque types (dcfinltc-TCFA and non-TCFA) was frt. An 
adju,;ted P-valucy of < 0.0167 (6onferroni's correction for multlpl<'l comp.lrlsons) Wol5 considered signinc.:tnt. 
non-NCCL OCT-derived TCFA. and definite-TCFA are shown in 
Figure 3A-C. respectively. 
Base!ine clharacterist~cs and [aboratory 
data 
At least one definite-TCFA was identified in 24 patients (42.9%) 
but not in the other 32 patients (57.1%). The baseline character-
istics and laboratory data for these two patient groups were sum-
marized in Table 1. There were no differences in age, sex, body 
mass index. or cardiac risk factors between the two groups. In 
the present study, frve (8.9%) patients had ACS that did not 
warrant emergency PCI and most of our study populatio11 
(91.1%) had stable angina. Among the five ACS pati<~11ts, three 
had at least one defi11ite-TCFA 
Although patients without definite-TCFA te11ded to take statins 
for a longer duration and their total cholesterol level tended to be 
lower than that in patients with definite-TCFA (P = 0.07. both), 
there were no sig11ificant differences in the lipid profiles, blood 
sugar profiles. and high-sensitive C-reactive-protein between the 
two groups. 
Comparison of non-tlhDn-cap 
fibroatlheroma and definite-tlhln-cap 
fibroatlheroma 
The summarized angiographical data. gray-scale IVUS, and 
VH-IVUS data for non~TCFA and definite-TCFA are shown 
in Table 2. There were no differences in lesion type, reference 
diameter, a11d minimum lumen diameter between the two 
groups. but definite~TCFA showed significantly higher o/oarea-
stenosis and tended to be located in the proximal part of the 
vessel (P = 0.007 and P = O.OOl respectively). Based on the 
gray-scale IVUS analysis. plaque volume and vessel volume of 
definite-TCFA were significantly higher than those of non-TCFA 
(P = 0.0001 and P = 0.004, respectively). Also, the values for 
%plaque-volume a11d the vessel remodelling index of 
definite-TCFA were significantly higher than those of non-TCFA 
(P < 0.0001, both). VH a11alysis showed that the %necrotic-core 
of defi11ite-TCFA was significantly higher than that of no11~TCFA 
and %fibrous of definite-TCFA was significantly lower than that 
of non-TCFA (P = 0.006 and P = 0.01, respectively). 
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Table 3 Comparison of angiographical data, gray..scale intravascular ultrasound, and virtual histology-intravascular 
ultrasound data between non-thin-cap intravascular ultrasound~derived thin-cap fibroatheroma and definite-thin-cap 
fibroatheroma 
Quantitative coronary arteriography data 
Reference vessel diameter (mm) 
Minimum lumen diameter (mm) 
%Area-~enosis (%) 
Gray-scale IYUS measurcmerrts 
Plaque volume (mm3/cm) 
Vessel volume (mm3/cm) 
Pbque length (mm) 
%Plaque-volume (%) 
Remodelling index 
YH measurements 
%Fibrous 
%Fibro-tltty 
%Dense-calcium 
%Necrotic-core 
Major NCCL area (mm2) 
Total NCCL angle (degree) 
Major NCCL angle (degree) 
Non-thin-cap IVUSwdcrivcd 
TCFA (n = 33) 
2.40 (2.19. 2.61) 
1.92 (1.71. 2.12) 
35.4 (28.6, 48.1) 
65.3 (39.3, 91.4) 
132.6 (89.1, 176.2) 
13.4 (1 0.5, 16.4) 
48.1 (45.0, 51.1) 
1.10 (1.06, 1.13) 
58.9 (55.1, 627) 
12.3 (9.5,15.1) 
10.5 (7.9, 13.1) 
18.6 (15.7, 21.4) 
0.62 (0.46, 0.94) 
54.6 (35.6, 73.5) 
19.0 (15.1. 21.2) 
Definite-TCFA 
(n = 28) 
....................... 
252 (2.31, 2.74) 
1.84 (1.62, 205) 
45.1 (38.2. 521) 
96.3 (75.6, 117.0) 
1620 (127.4,196.4) 
17.4 (14.4. 20.5) 
56.5 (53.4, 59.7) 
1.21 (1.17. 1.25) 
57.0 (53.1. 60.9) 
13.5 (10.7.16.4) 
9.9 (7.3, 12.6) 
20.0 (17.0, 229) 
1.15 (0.77. 1.39) 
89.4 (63.6. 1124) 
29.0 (20.2. 28.1) 
P·valuc (vs. 
definite·TCFA) 
NS 
NS 
NS 
0.001 
O.D1 
NS 
0.0001 
0.0005 
NS 
NS 
NS 
NS 
0.003 
0.0003 
0.005 
Datt~ Jrc cxpi'C'..scd predicted mean~ and their 95% Cl>. For the value:; In thl> tt~ble, J model with four otegorle~ of pl.lque type:; (dcflnlte-TCFA Jnd three ~ubcrt:cgoric:; of 
non-TCFA plaque type~) was fit. An adju:oted P-V<!\uc of <0.0167 (Bonfcrronl'~ correction for multiple compari~on~) W<tS con~idcred ~lgnlfic~nt. 
NCCL. necrotic core cont.1ct with lumen. 
Table 4 Comparison of angiographical data, gray..scale intravascular ultrasound, and virtual histology-intravascular 
ultrasound data between non-necrotic core in contact with the lumen optical coherence tomography-derived thin-cap 
fibroatheroma and definite-thin-cap fibroatheroma 
Qu;tntitative coromry arteriogmphy data 
Reference vessel diameter (mm) 
Minimum lumen diameter (mm) 
%Area-stenosis (%) 
Gray-scale IYUS measurements 
PIJ.que volume (mm3/cm) 
Vessel volume (mm3/cm) 
Plaque length (mm) 
%PIJ.que-volume (%) 
Remodelling index 
VH measurements 
%Fibrous 
%Fibro-tltty 
%Densc-c<lldum 
%Necrotic-core 
Non-NCCL OCT -derived 
TCFA (n = 8) 
3.26 {285, 3.60) 
2.50 (2.10, 2.90) 
38.8 (25.7, 47.8) 
1225 (87.8, 157.2) 
2325 (171.9. 285.7) 
19.3 {13.6, 24.9.4) 
52.9 {47.0, 58.8) 
1.04 (0.97, 1.12) 
49.8 (42.6, 56.9) 
128 (7.4, 18.1) 
19.3 (14.3, 24.3) 
17.3 (11.8, 227) 
Definite-TCFA (n = 28) P-vatuc (vs. definite-TCFA) 
252 (2.31. 274) 0.002 
1.84 (1.62. 205) 0.004 
45.1 {38.2, 52.1) NS 
96.3 (75.6, 117.0) NS 
1620 (127.4. 196.4) 0.01 
17.4 (14.4, 20.5) NS 
56.5 {53.4, 59.7) NS 
1.21 (1.17. 1.25) 0.003 
............... 
57.0 (53.1, 60.9) NS 
13.5 (10.7, 16.4) NS 
9.9 (7.3, 126) 0.01 
20.0 (17.0, 229) NS 
D~'ttl ~rc cxpi'C'..scd predicted me~ns ~nd their 95%0s. F<lr the V<~lucs in thl5 t.1ble, a model with four c~tcgorlcs of pl.lquc type:; (definite-TCFA Jnd three subcategories of 
non-TCFA plaque types} was fit. An ~dju:otcd P-V<llue of <0.0167 (Bonferronl's correction for multiple comp~ri~ons) W<tS con~idercd ~lznlfiont. 
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Summary of lesion diagnosis 
Figure 2 Among 126 lesions in 56 cases, virtual histology-intravascu!J.r ultrasound (VH-!VUS) di;:tgnosed 61 lesions (48.4%) as IVUS-derived 
thin-cap-fiberatheroma (TCFA) and optical coherence tomography (OCT) revealed 36 lesions (28.6%) as OCT-derived TCFA Twenty-eight 
lesions (22.2%) met the criteria of both IVUS-dcrivcd TCFA ;md OCT -derived TCFA and were diagnosed as definite-TCFA: 33 lesions were 
diagnosed as non-thin-cap IVUS-derived TCFA and eight lesions as non-NCCL OCT-derived TCFA 
Compa~ison of non~th~n~cap intravascular 
uit~rasound-derived thin-cap 
fibroatheroma and definite~thin-cap 
fibroatheroma 
The summarized angiographical data. gray-scale IVUS, and 
VH-IVUS data for non-thin-cap IVUS-derived TCFA and definite 
TCFA are shown in Table 3. There were no differences in angiogra-
phical data betvveen the tvvo groups. Definite-TCFA however, had 
a significantly larger plaque volume. vessel volume, %plaque-
volume, and vessel remodelling index than non-thin-cap IVUS-
derivcd TCFA (P = 0.001. P = 0.01, P = 0.0001 and P = 0.0005, 
respectively). Although there were no significant differences in 
the ratio of plaque components in the VH-IVUS analysis, 
definite-TCFA had a significantly larger major confluent NCCL 
area and a larger total angle occupied by NCCL in the lumen 
circumference compared with non-thin-cap IVUS-derived TCFA 
(P = 0.003 and P = 0.0003, respectively). 
Comparison of non~necrotk core in 
contact with the lumen optical coherence 
tomography-derived thin~cap 
fibroatheroma and definite-thin-cap 
fibroatheroma 
The summarized angiographical data, gray-scale IVUS, and 
VH-IVUS data for non-NCCL OCT-derived TCFA and definite 
TCFA arc shown in Table 4. The sample size of non-NCCL OCT-
derived TCFA was small, thus we considered these data explora-
tory, but non-NCCL OCT-derived TCFA had a s'1gn'1ficantly 
larger %dense-calcium and vessel volume, and smaller vessel remo-
delling index than dcfinite-TCFA (P= 0.01, P= 0.01 and 
P = 0.003, respectively). Furthermore, non-NCCL OCT-derived 
TCFA had a larger reference diameter and minimum lumen dia-
meter than definite~TCFA (P = 0.002 and P = 0.004, respectively). 
intra- and inter~observer variability 
The estimated limit of agreement for the intra- and inter-observer 
variability in the VH-IVUS and OCT measurements was reasonable 
based on the Bland-Altman plot (%necrotic-core by VH-IVUS: 
intra-observer: mean difference: 0.03"/o, upper two-standard devi-
ation (2$0): 1.63% and lower 2SD: -1.68%, inter-observer: 
mean difference: 0.10%, upper 2SD: 2.00% and lower 
250: -1.90%, fibrous cap thickness by OCT: intra-observer: 
mean difference: 0.6 j.l.m, upper 250: 12.2 j.l.m and lower 250: 
-13.4~J,.m, inter-observer: mean difference: 1.9 j.l.m, upper 2SD: 
13.8 j.l.m and lower 2SD: -17.7 j.l.m). 
There was little intra- or inter-observer disagreement in the 
diagnosis of IVUS-derived TCFA (intra-observer: K = 0,87, 95% 
Cl, 0.79-0.96, inter-observer: K = 0,81, 95% Cl 0.71-0.91) and 
in the diagnosis of OCT-derived TCFA (intra-observer: K = 0.87 
O.n-0.96, inter-observer, K = O.n, 0.65-0.90). 
Patient follow-up 
In 21 patients with binary angiography (11 patients with 
definite-TCFA and 10 patients without definite-TCFA; 13 lesions 
were definite-TCFA and 32 lesions were non-TCFA: average 
span 205.0 ± 68.0 days), four lesions required PC! because of 
increasing plaque size and a constricting lumen, and three of 
these were definite-TCFA A representative case of definitc-TCFA 
progression is shown in Figure 4. 
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(A) Non-thin-cap IVUS-deriYed TCF A 
':>foplaqut>-Yolum('; 47.6'% 
0/one<:rotic-corc; 15°/o 
An~<' of the major NCCL 15 .. 3'" 
Anglc of the total NCCL 35.8" 
0/oplaquc-Yolumc; 57.6°/o.. 
0/on&I'Otic-core; 22.0/o, 
0/odense-calcium; -14%• 
%plaquc-Yolumc; 55.8% 
0/on«rotic-core; 22%• 
Angle of the major NCCL 24.8• 
.-\nglc of the total NCCL 100.3° 
Cap tbicknc:-~s; 90 IJ.m 
Cap thicknt:'S. . ?; 5() IJ.m 
Cap tbicknel'$; .W urn 
Figure 3 (A) A rcprcscnt<l.tivc C;l!;C of non-thin-cap IYUS-dcrived thin-cap fibroatheroma (TCFA). Virtual histo!ogy-IVUS shows 47.6% 
of%p!aque-volume, 15% of%necrotic-corc. The angle ofthc major NCCL was 15.3°, and that ofthc totJ.l NCCL was 35.8°. OCT shows signal-
poor lesions with an overlying signal-rich band in the upper right quadrant. A signal-poor lesion indicates a lipid pool and signal-rich band indi-
cates a fibrous cap. The fibrous cap thickness was 90 IJ.m. (8) A representative case of non-NCCL OCT-derived TCFA OCT identified a 
fibrous cap thickness of 50 f).m which covers the low intensity area. but VH-IVUS did not identify the NCCL (C) A representative c<lSe of 
definitc-TCFA Virtual histology-IVUS shows%p!aque-volume of 55.8% and%necrotic-core of 22%. The angle of the major NCCL was 
24.8", and that of the total NCCL was 1 OO.r. Its minimum fibrous cap thickness was 40 IJ.m. 
Discussion 
Pathology studies have demonstrated that acute coronary events 
most commonly arise from the disruption of TCFA Several 
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imaging modalities, including IVUS,17 VH-IVUS,13·14 angioscopy.~8 
elastography.19 and thermography.2° have been used to detect 
TCFA The sensitivity or specificity of these modalities for the 
detection of TCFA in vivo, however, has not been satisfactory. 
Feasibility of Combined Use of Intravascular Ultrasound Radiofrequency Data Analysis 
(A) 
(B) 
Ft\>1'<:>11» cnp !lu~l:II~AA40 lUlL 
PL1q11e vchuu~ -9.- uuu' CI\L Ye""d vchune 1:5.0 !lun> an. 
0 oj>l:~qne-\..,hl.Uie 6~.8"~. •oll«l'OUc....:Ne :t3 eo, ..... 1)::1e dU1e l<"lt:Ll NCCL D?i-
Figure 4 (A) Coronary angiography (CAG) revealed 50% stenosis in the mid-left anterior descending artery in July 2006. VH-IVUS revealed a 
68.8 mm3/cm plaque volume, 117.8 mm3/cm vessel volume. 58.4% %plaque-volume, and 28".!6 %necrotic-core, The fibrous cap thickness of this 
lesion was 60 iJ..m by OCT measurement and this lesion was diagnosed as definite-TCFA (B) After 6 months, because the patlent experienced 
chest pain at rest with increased frequency. we performed CAG. The CAG revealed 90% stenosis at the site of the previous definite-TCFA 
lesion. VH-IVUS revelled an increase in plaque volume (68.8- 79.7 mm3/cm), vessel volume (117.8-125.0 mm3/cm), %plaque-volume 
(58.4%-63.8%), and%necrotic-core (28%-->-33%). OCT rcveJ.led ulcer<~.tion of the fibrous cap. 
VH-IVUS for spectral analysis of radio-frequency data has the 
potential to detect TCFA. VH-IVUS is highly accurate for identify-
ing plaque components both in vitro and in vivo.6•7 Rodrigucz-
Gran'tllo et a/.13 were the first to focus on the distribution of 
plaque components using VH-IVUS studies. They defined IVUS-
derived TCFA based on pathologic data. and demonstrated that 
the mean plaque volume and mean %necrotic-core of IVUS-
derived TCFA were similar to previously reported histopathologic 
TCFA data. Thus, the ability of VH-IVUS to produce real-time 
assessment of plaque morphology has been established and 
m'1ght be useful for identifying TCFA Because the maximum resol-
utlon of VH-IVUS is 100 JJ.m. however, it is difficult to assess the 
thin fibrous cap (<65 IJ..m). 
Optlcal coherence tomography is a new imaging modality for 
detecting vulnerable plaque. OCT provides a high·reso!ution 
image and is able to evaluate detailed plaque morphology in 
vivo.8 - 11 OCT, therefore, seems to have the potential to visualize 
the thin fibrous cap and detailed structures. The penetration of 
OCT is limited ( <2 mm), so that it is frequently difficult to delin-
eate large Upid plaques. Manfrini et a!. 21 reported that OCT could 
be unreliable to differentiate areas with heterogenous composition 
because of its low signa! penetratlon. In our study, eight OCT-
derived TCFA lesions were not ident'1fied as an NCCL by 
VH-JVUS analysis. This discrepancy might be because of the pen-
etration limitation of OCT. These lesions had a larger reference 
diameter, minimum lumen diameter, and minimum vessel volume 
than definite-TCFA (P = 0.002, P = 0.004, P = 0.01, respectively), 
and had severely calcified components compared with 
definite·TCFA (P=0.01). When a target vessel or plaque is 
large, the optical signal might be attenuated by the plaque and 
failed to identify plaque morphology. It might also be sometimes 
difficult to discriminate between lipid and calcified lesions 
because both these appear as low·intensity images, usually differ· 
entiated in OCT by an unclear border (lipid) or a dear border 
(calcium). In this regard, large calcified lesions are likely to be mis-
diagnosed as TCFA by OCT examination. Therefore, it is difficult 
to detect TCFA using only one modality. Using a combination of 
complementrt.ry tools such as VH·IYUS and OCT might be a feasi-
ble approach for more accurate detection ofTCFA 
Although the positive ratio of VH-IVUS for detecting 
definite-TCFA was 45.9% and that for OCT was higher than 
VH-IVUS (77.8%). OCT has several procedural limitations and is 
only used in selected hospitals. IVUS is now routinely used for 
PCI procedures. Thus, it is important to determine the criteria 
for TCFA by VH-IVUS. Previous IVUS and pathological studies 
showed that positive vessel remodelling is associated with an 
unstable clinical presentation and characteristic pathologic lesion 
types.16•22.23 Kolodgie et a/.2 reported that whether the necrotic 
core is circumferential might be critical for determining the instabil-
ity of a plaque, and they demonstrated that proximal coronary 
lesions with greater than 500/o diameter stenosis with an necrotic 
core circumference > 120" strongly suggests the presence of 
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plaque with a vulnerable morphology. In the present study, 
definite-TCFA identified by both modalities tended to locate in 
the proximal part of the vessels, areas with a higher %area-
stenosis, %plaque-volume and more positively remodelled lesions 
in comparison to non-TCFA These data arc compatible with pre-
viously reported histopathologic data. 2.23 Furthermore, the major 
confluent NCCL area of definite-TCFA was larger and its NCCL 
occupied a larger circumference of the lumen than non-thin-cap 
IVUS-derived TCFA Thus, %plaque-volume, vessel remodelling 
index. confluent major NCCL area, and degree of NCCL circum-
ference were the identifying factors for definite-TCFA by VH-IVUS. 
One ofthc clinical implications ofthc present study was to identify 
the VH-IVUS indices useful for diagnosing definite-TCFA 
lUm[tat~ons 
Because patients excluded from the study were those with high 
risk-ACS, we could not reach any conclusions about the general 
prevalence of definite-TCFA Further, we could observe only 
limited vessel areas, as the VH-IVUS and OCT procedures have 
several limitations for imaging certain lesions, such as severely cal-
cified tortuous lesions or other complex lesions. Thus, our study 
results do not represent an unbiased sampling of all coronary 
arteries, and the detection rate of TCFA in our study patients 
might be underestimated. 
There were three cases of definite-TCFA with progression 
requiring PCI: it is unclear whether the detected definite-TCFA 
wi!l cause acute coronary events and was a true vulnerable 
plaque. Although the frequency of the progression was too low 
to reach any statistical significance, definite-TCFA tended to pro-
gress more compared with non-TCFA Our findings. therefore, 
should be confirmed with a larger study population and the sub-
sequent course of the lesions observed as well. 
In the present study. 61 plaques were identified as IVUS-derived 
TCFA by VH-IVUS examination. This identification was based on 
the criteria of a previous published report. 13 This high prevalence 
of high-risk plaque, however, was at variance with previously pub-
lished in vivo and in vitro studies,5·~ 3 which might be because of inac-
curate VH determination by in vitro testing. Further, we selected 
cut-off values of IVUS-derived TCFA criteria as %plaque-volume 
>40% and%necrotic-core >10% because pathologic TCFA is 
very unlikely to be present in segments with <40% occlusive 
lesion, and nearly 90% of ruptured plaque comprised > 10% necrotic 
core in the plaque area? We did consider that the necrotic core size 
of 10% was too low, because the average %necrotic-core of 
definite-TCFA was 20.0 ± 6.8% and that of non-TCFA vvas 15.3 ± 
8.6%. This data is in line with the previous pathologic findings in 
this subset of lesions and also in previous VH-IVUS studies?·3·14 
Thus, TCFA might be over-diagnosed if based on the current defi-
nition of IVUS-derived TCFA Our study population WJS too small, 
however, to establish new criteria for defining IVUS-derived TCFA 
Although we could perform the VH-IVUS and OCT procedures 
within 20 min and without complications, the combined use of 
VH-IVUS and OCT is laborious and costly. A new device with 
both IVUS and OCT functions to enable the simultaneous usc of 
both modalities should be developed. 
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Conclusions 
This is the first study to evaluate TCFA using a combination of two 
new imaging modalities, VH-IVUS and OCT. Neither modality 
alone is sufficient for detecting TCFA The combined usc of 
these complementary imaging modalities, VH-IVUS and OCT, 
however, should be considered a feasible approach for more 
precise detection of TCFA 
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Summary and Conclusions 
Undoubtedly, intravascular ultrasound (IVUS) is a highly accurate tool for the 
serial assessment of the natural history of coronary atherosclerosis, and for the 
evaluation of the effect of established and emerging drug therapies on the progres-
sion of atherosclerosis. 
The existing and future application of IVUS is connected to the study of the 
different applications of the analysis of radiofrequency data, both for the im-
provement of plaque characterization, and for the assessment of the mechanical 
properties of plaque. 
This thesis provides important data regarding the internal and external valida-
tion of both the spectral analysis of radiofrequency data and optical coherence 
tomography for the assessment of the intact plaque composition and the perfor-
mance of stents. 
INTERNAL VALIDATION 
We compared the ability of OCT and IVUS-RF to classify plaque and assessed the 
performance of a combination of the two modalities to identify different plaque 
types. In this work we present the first comparison between IVUS-RF and OCT, 
using histology as a benchmark (chapter 2.1). 
The reproducibility study ofiVUS-RF demonstrated that the geometrical and 
compositional output ofiVUS-RF has acceptable reproducibility, and that non-
uniform pullbacks, which can occur when using phased array catheters devoid of a 
covering sheath, remain an issue of concern, and this should be taken into account 
during the conductance oflongitudinal studies (chapter 2.2). 
DISTRIBUTION OF PLAQUE COMPOSITION ALONG CORONARY ARTERIES 
In pathological studies and in clinical studies (using angiography and IVUS), it has 
been demonstrated that local factors play a role in determining the progression and 
stability of plaque throughout the coronary tree. This thesis extensively addressed 
the non-uniformity of plaque composition along the coronary tree (chapters 3.1-
3.5). We established that plaque composition is unevenly distributed along the 
left coronary artery. There is a progressive increase in necrotic core starting from 
the proximal segment of the left anterior descending, followed by a steady decline 
towards those segments which are more distally located along the vesseL 
In chapter 3.4, we found that atherosclerotic plaque located at the ostium 
of the left anterior descending artery had a larger plaque burden, eccentricity 
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and maximum plaque thickness than distal left main plaques. In addition, latger 
calcified necrotic core content was found distal to the circumflex take-off. Lesions 
were predominantly located in the outer wall of the carina, and such locations 
were associated with larger necrotic core content. Overall, these results confirm 
the key role of flow dynamics in the genesis and progression of atherosclerosis. In 
chapter 3.5, we replicated these observations and extended the analysis to other 
bifurcations. The bifurcation sites of LM-LAD had greater necrotic core at just 
and distal segments of the bifurcation, while non-LM bifurcations showed greater 
necrotic core in proximal segment of bifurcation. 
RELATIONSHIP OF CARDIOVASCULAR RISK FACTORS AND CORONARY 
PLAQUE COMPOSITION 
In chapter 4, we found after multivariate adjustment that in non-culprit vessels, 
patient demographics (age, male gender), anthropometric measurements (waist 
circumference), and clinical risk factors (systolic blood pressure) ate all related 
to plaque composition (larger necrotic core area). Accordingly, necrotic core, as 
assessed by IVUS-RF, could be viewed as a novel in situ/in vivo biomarker, poten-
tially reflecting the long-term impact of cardiovasculat risk on plaque phenotype. 
HIGH-RISK PLAQUES 
The so-called IVUS-derived TCFA (IDTCFA) is common in non-culprit lesions 
of patients undergoing percutaneous intervention in another vessel; frequency 
is higher in patients with ACS compated to stable patients, and the distribution 
of IDTCFA lesions along the coronary vessels is clearly clustered. These findings 
were further confirmed in a 3-vessel population. 
We explored in vivo the relationship between plaque composition and coronaty 
remodelling. Necrotic core size was significantly larger in coronary lesions that 
demonstrated positive remodelling, than in those who experienced vessel shrink-
age. In addition, the fibrotic burden of the plaque was significantly and inversely 
correlated to the remodelling index. 
In a prospective 3-vessel IVUS study, patients with a least one plaque rupture 
in the coronary tree had a larger body mass index, and overall worse IVUS-derived 
characteristics, when compared to patients without evidence of plaque rupture. 
In addition, plaque ruptures sited had a worse phenotype than the most diseased 
sites of the same vessels. 
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FOCAL TREATMENT OF CORONARY HIGH-RISK ATHEROSCLEROTIC PLAQUES 
Treatment of asymptomatic, non-obstructive coronary lesions may be a desirable 
pursuit, but the pre-emptive strike may be a risk-y, time-consuming and an expen-
sive undertaking. Importantly, at present there is no evidence to support this focal 
treatment. We described in chapter 6 the current available options. 
SYSTEMIC TREATMENT OF CORONARY HIGH-RISK ATHEROSCLEROTIC 
PLAQUES 
In chapter 7, we described the results ofiBIS 2, which to me is the most important 
piece of this thesis. This study demonstrated that necrotic core expansion occurs 
despite contemporary cardiovascular therapies, even in the absence of an increase 
in overall plaque size. This unabated necrotic core expansion could be responsible, 
in part, for the recurrent cardiovascular events in high-risk patients. Lp-PLA, 
inhibition with darapladib halted this process, and therefore may represent a new 
approach for the treatment of atherosclerosis. Firstly, however the benefit of this 
intervention needs to be confirmed by the results of future event-driven outcomes 
trials. 
NOVEL INVASIVE IMAGING OF CORONARY STENTS 
We investigated the IVUS-RF usefulness for the study of edge restenosis in metal 
stems. Serial expansive vascular remodelling was observed at proximal and distal 
stent edges. Remodeling occurred in response to tissue growth, which was mainly 
due to increased fibrofatty tissue. We used also IVUS-RF to assess the serial changes 
of lesions treated with bioabsorbable stents. IVUS-RF changes at 6 months sug-
gest alteration of the BVS with reduction of RF backscattering by polymeric 
struts. Strained plaques on the palpograrns were almost abolished following stent 
implantation. However, strain values reappeared within 6 months suggesting an 
increase in en do luminal deformabiliry of the stented vessel. Chapter 8. 
PLAQUE PROGRESSION/ REGRESSION 
In chapter 9, we described the use ofiVUS to assess in vivo, the effect of established 
and novel medical therapies on plaque size and composition. In a meta-analysis 
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of clinical studies that assessed IVUS-based progression/ regression of coronary 
atherosclerosis to evaluate whether treatment with statins can promote coronary 
plaque regression over time, we found that statin therapy, in particular when 
achieving the target LDL-C <IOOmg/dllevel, appears to promote a significant 
regression of plaque volume in coronary artery segments as measured by NUS. 
Additionally, we evaluated the effect of ACE-inhibitors on coronary athero-
sclerosis. Our results suggests that in patients with established CAD, and stable 
angina without overt heart failure, the clinical benefit obtained with perindopril 
treatment during a period of 3 years cannot be attributed to an effect on coronary 
plaque size. 
Thiazolidinediones (TZDs) have effects on cardiovascular risk factors, including 
insulin sensitivity, inflammatory biomarkers, endothelial function, coa,oulability, 
plaque instability, and blood pressure, that may slow the progression of coronary 
atherosclerosis. Active-controlled trials of both thiazolidinediones (rosiglitazone 
and pioglitazone) in patients with type 2 diabetes have suggested a favourable 
effect of these agents on carotid atherosclerosis and in-stent restenosis, however, 
the applicability of these data to native vessel coronary disease is uncertain. The 
APPROACH study supports, bur does not prove the hypothesis that rosiglitazone 
has a greater anti-atherosclerotic effect than glipizide in patients with type 2 
diabetes. 
COMBINING DIFFERENT IVUS-RF AND OPTICAL COHERENCE TOMOGRAPHY 
In chapter 10, the combined use ofiVUS-RF and optical coherence tomography 
is described. Greyscale intravascular ultrasound allows evaluation of coronary ath-
erosclerosis bur its limited resolution (axial 150-200 p.m) precludes the visualiza-
tion of certain microstructures (such as the thin fibrous cap or fine strut coverage). 
Optical coherence tomography (OCT) is a light-based imaging modality can be 
used to study tissues in vivo with near-histologic, ultrahigh resolution. This has 
also provided new insights into the interaction between the stent and the vessel 
wall, and has allowed a more precise characterization of atherosclerotic plaques. 
OCT can provide very valuable information for the detection of high-risk 
plaques in vivo, especially by measuring the thickness of the fibrous cap. How-
ever due to its limited penetration OCT can not provide a full analysis of large 
plaques. Further, histological examinations have demonstrated that OCT may not 
be sufficient to discriminate lipid pools from calcium deposits. On the contrary, 
other techniques such as IVUS and IVUS-VH analysis can image the complete 
thickness of the plaque and can identifY the presence of necrotic core, bur their 
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limited axial resolution does nor allow rhe evaluation of the fibrous cap. Thus, we 
showed rhar the combination of rhe IVUS-VH and OCT appears promising ro 
better characterize such plaques. 
CONCLUSION 
I believe that this thesis is of value to better understand the extent, distribution, 
morphology and composition of coronary atherosclerosis in our patients. 
We have provided important data regarding the accuracy of an in vivo tissue 
characterization technique (IVUS-RF and optical coherence tomography). The 
combination of the IVUS-RF and OCT appears promising ro better characterize 
high-risk plaques. Nevertheless, these findings must be interpreted cautiously 
until conclusive data by prospective natural history studies is supplied. 
Several systemic treatments have proved to be effective in reducing plaque size, 
however, perindopril and rosiglitazone, which were tested in this thesis, did not 
meet the primary endpoint. 
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Ongetwijfeld is inrravasculaire echografie (intravascular ultrasound - IVUS) een 
zeer nauwkeurig hulpmiddel voor de seriele beoordeling van her natuurlijke be-
loop van coronaire atherosderose en voor de evaluatie van het effect van verschil-
lende conventionele en moderne medicinale behandelingen op de progressie van 
atherosclerose. 
De huidige en toekomstige toepassing van IVUS is gekoppeld aan her onder-
zoek naar de verschillende toepassingen van de analyse van radiofrequentiedata, 
zowel voor een betere plaque typering als voor de beoordeling van de mechanische 
eigenschappen van plaques. In her algemeen kan een dergelijke inzichrelijke 
analyse van de radiofrequentiedata potentieel zinnig zijn voor de opsporing van 
hoogrisico plaques en voor her vervolgen van de natuurlijke ontwikkeling van 
deze plaques in prospectieve naruurlijk beloop studies. 
Dit proefschrift bevat belangrijke data over de interne en externe validarie van 
spectrumanalyse van radiofrequentiedata ter beoordeling van de plaquesamenstel-
ling in vivo. 
INTERNE VALIDATIE 
Wij vergeleken OCT en VH-IVUS war betreft classificatie van plaque en beoor-
deelden de prestatie van een combinatie van de twee modaliteiten ter identificatie 
van de verschillende plaquetypes. In dit werk presenreren wij de eerste vergelijking 
russen VH-IVUS en OCT, met histologie als maatstaf (Hoofdsruk 2.1). 
De reproduceerbaarheid van IVUS-VH roonde aan dar de geometrische en 
compositionele output van IVUS-VH acceptabel reproduceerbaar is, en dar non-
uniforme uitzonderingen) in her bijzonder aanwezig bij her gebruik van gefaseerde 
array katheters zonder omhullende mantel, een punt van zorg blijven waarmee 
rekening gehouden moet worden bij longitudinale studies (Hoofdsruk 2.2). 
DISTRIBUTIE VAN PLAQUESAMENSTELLING IN DE CORONAIRE ARTERIEN 
Bij plaqueprogressie en -stabiliteit in de coronaire vaatboom lijken plaatselijke 
factoren een rol te spelen. Dit werd zowel in parhologische als in klinische studies 
aangetoond met behulp van angiografie en IVUS (het laatste ter detectie van 
plaqueruptuur). De non-uniformiteit van de plaquesamenstelling in de coronaire 
vaatboom wordt in dit proefschrift uirgebreid behandeld (Hoofdsruk 3.1 - 3.6). 
Wij hebben met name vastgesteld dar de plaquesamenstelling niet gelijk is 
verdeeld over de linker coronaire arterie. Er is sprake van een progressieve toename 
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van necrotische kern die begim vanaf de proximale helft van de linker hoofd-
coronaire arterie naar het meest proximale segment van de linker arteria anterior 
descendens of circumflexa, gevolgd door een gestage afname langs die segmenten 
die meer distaal in het vat zijn gelokaliseerd. 
In Hoofdstuk 3.6 zagen wij dat atherosclerotische plaques die gelokaliseerd 
zijn in het ostium van de linker arteria anterior descendens presenteerden met 
een grotere plaquelast, excemriciteit en maximale plaquedikte dan plaques in de 
distale linker hoofdvaten. Bovendien werd distaal van de circumflexa oorsprong 
een grotere gecalcificeerde en necrotische kerninhoud gezien. De laesies waren 
voornamelijk in de buitenste wand van de carina gelokaliseerd. Een dergelijke 
locatie ging gepaard met een grotere necrotische kerninhoud. De sleutelrol van 
flow dynamica in de genese en progressie van atherosclerose wordt door deze 
resultaten nog eens bevestigd. 
VERBANDTUSSEN CARDIOVASCULAIRE RISICOFACTOREN EN CORONAIRE 
PLAQUESAMENSTELLING 
In hoofdstuk 4 zagen wij dar de demografische gegevens van de patient (leeftijd, 
mannelijk geslacht), antropometrische maten (tailleomvang), klinische risicofac-
toren (sysrolische bloeddruk) in nier-culpritvaten na multivariate correctie gerela-
teerd zijn aan de plaquesamenstelling (grotere necrotische kerninhoud). Hiermee 
in overeenstemming kan de necrotische kern, vastgesteld met IVUS-RF, gezien 
worden als een nieuwe in situ/in vivo biomarker, die mogelijk de lange-termijn 
gevolgen van het cardiovasculaire risico op het plaquefenotype weerspiegelt. 
KWETSBAAR PLAQUE 
In hoofdstuk 5 werd een prospectieve 3-taks IVUS- studie besproken waarin 
patienten met ten minste een plaqueruptuur in de coronaire vaatboom een hogere 
body mass index en in her algemeen ernstiger IVUS-afgeleide kenmerken hadden, 
vergeleken met patienten zonder bewezen plaqueruptuur. Bovendien hadden deze 
plaquerupturen een ongunstiger fenotype dan de meeste aangedane locaties in 
dezelfde vaten. 
Aangetoond is dar de thin-cap fibroarheroom (TCFA) laesies met grote 
avasculaire, hypocellulaire, lipide kernen, her meest prevalente substraat van pla-
queruptuur zijn. Onderzoek bij een groot aantal slachtoffers van plotse harrdood 
lijkt erop te wijzen dat geruptureerde TCFA de aanleiding was voor 60% van 
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acute coronaire trombi. Dezelfde studie toonde dat plaqueruptuur in TCFAs 
ook zonder klinische consequenties kan optreden. De mogelijkheid om TCFA te 
identificeren zou de naruurlijke ontwikkeling van deze laesies kunnen ophelderen 
en middelen aanreiken om de effecten van farmacologische of andere interventies 
te beoordelen. 
Wij hebben tevens gevonden dat de IVUS-VH bevindingen, vergelijkbaar 
met IVUS-afgeleide TCFA (IDTCFA), vaak voorkwamen in niet-culpritlaesies 
van patienren die in een ander vat percutane interventie ondergingen. Bovendien 
was de prevalentie van IDTFCA significant hoger bij patienten die presenteerden 
met ACS vergeleken met stabiele patienten. De distributie van IDTCFA laesies 
in de coronaire vaten was duidelijk geclusterd. Deze bevindingen werden verder 
bevestigd in een populatie met 3-taks lijden. 
Wij verifieerden in vivo her verband tussen plaquesarnenstelling en coronaire 
remodellering. De necrotische kerngrootte was significant groter in coronaire 
laesies met positieve remodellering dan in die met negatieve remodellering ('shrin-
kage'). 
Verder was de fibrotische last van de plaque significant en omgekeerd evenredig 
gecorreleerd aan de remodelleringsindex. 
FOCALE BEHANDELING VAN CORONAIRE HOOGRISICO 
ATHEROSCLEROTISCHE PLAQUES 
De behandeling van asymptomatische, nier-obsrructieve coronaire laesies mag 
dan een wenselijk srreven zijn, maar her aanpakken van deze laesies is een mogelijk 
riskante, langdurige en dure kwestie. Een focale behandeling wordt echter op dit 
moment niet door bewijs ondersteund. In hoofdstuk 6 worden de op dit moment 
beschikbare opties beschreven. 
SYSTEM!SCHE BEHANDELING VAN CORONAIRE HOOGRISICO 
ATHEROSCLEROTISCHE PLAQUES 
In hoofdstuk 8 worden de resultaten van IBIS 2 beschreven, volgens mij het 
belangrijkste onderdeel van dit proefschrift. Deze srudie toonde aan dat ondanks 
de moderne cardiovasculaire therapieen necrotische kernexpansie optreedt, zelfs 
als er in her algemeen geen roenarne van plaquegrootte is. Deze onverminderde 
necrotische kernexpansie kan, voor een dee!, verantwoordelijk zijn voor de recidi-
verende cardiovasculaire events bij hoogrisico patienten. Lp-PL\, remming met 
457 
Samenvatting en Conclusies 
Darapladib stopte dit proces en is daarmee mogelijk een nieuwe benadering voor 
de behandeling van atherosclerose, indien de gunstige effecten van deze interventie 
bevestigd worden door resultaten van toekomstige event-driven resultatentrials. 
PLAQUE PROGRESSIE I REGRESSIE 
In hoofdstuk 9 wordt het gebruik van IVUS beschreven om in vivo bet effect van 
conventionele en nieuwe medische rherapieen op plaquegrootte en samensrelling 
te beoordelen. In een meta-analyse van klinische studies die IVUS-gebaseerde 
progressie/regressie van coronaire atherosclerose bepaalden om te zien of een 
behandeling met statines de regressie van coronaire plaque in de tijd bevordert, 
vonden wij dar statinetherapie, met name bij her bereiken van het doelniveau 
LDL-C<IOO mg/dl, een significante regressie van plaquevolume in coronaire 
arteriesegmenten (gemeten door IVUS) bevordert. 
Daarnaast evalueerden wij het effect van ACE remmers op coronaire athe-
rosclerose. De resulraren lijken erop te wijzen dat bij patienten met vastgestelde 
CAD, stabiele angina zonder manifest harrfalen, her klinisch gunstige effect van 
Perindropril behandeling tijdens een periode van 3 jaar niet kan worden toege-
schreven aan een effect op de coronaire plaquegrootte. 
Thiazolidinediones (TZDs) hebben effect op cardiovasculaire risicofactoren, 
zoals insulinegevoeligheid, inflammatoire biomarkers, endorheliale functie, co-
agulabiliteit, plaque instabiliteit en bloeddruk, die de progressie van coronaire 
atherosclerose kunnen vertragen. Actief-gecontroleerde trials van zowel thiazoli-
dinediones (rosiglitazone en pioglitazone) bij patiemen met T2DM suggereerden 
een gunstig effect van deze middelen op carotis atherosclerose en in-srent restenose. 
De toepasbaarheid van deze gegevens op natieve vat coronarialijden is niet zeker. 
De APPROACH srudie ondersteum de hypothese dat rosiglitazone een groter 
anti-atherosclerotisch effect heeft dan glipizide bij patiemen met type 2 diabetes, 
en suggereen dar rosiglirazone meer anti-atherosclerotisch is bij patH~nten met 
gevorderde diabetes of met een boger risico voor cardiovasculair lijden. In lopende 
analyses worden de factoren in verband met veranderingen in atherosclerose, ge-
meten door middel van IVUS, geevalueerd en zullen de effecten van risoglirazone 
op atherosclerose en plaque nader worden onderzocht. 
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COMBINEREN VAN VERSCHILLENDE INVASIEVE BEELOVORMENDE 
TECHNIEKEN 
In hoofdsruk 10 wordt her gecombineerde gebruik van meerdere beeldvormende 
technieken besproken. Met greyscale intravasculaire echografie is evaluatie van 
coronaire atherosclerose mogelijk, maar de beperkte resolutie (axiaal 150-200 
p.m) sluit visualisatie van bepaalde microstructuren (zoals de thin fibrous cap of 
de fine strut coverage) uit. Optical Coherence Tomography (OCT) is een beeld-
vormingsmethode op basis van licht, die gebruikt kan worden om weefsels in vivo 
te bestuderen met bijna-histologische, ultrahoge resolutie. Dit heeft tevens nieuwe 
inzichten opgeleverd over de wisselwerking tussen de scent en de vaarwand en heeft 
een nauwkeuriger typering van atherosclerotische plaques mogelijk gemaakt. 
OCT kan zeer waardevolle informatie leveren voor in vivo detectie van hoog-
risico plaques, met name bij her meten van de dikte van de fibreuze cap. Vanwege 
de beperkte penetratie van OCT kan geen volledige analyse verricht worden van 
grote plaques. Verder hebben histologische onderzoeken aangeroond dar OCT 
mogelijk niet voldoende kan differentieren tussen lipide pools en kalkafZettingen. 
Daarentegen kunnen andere technieken zoals IVUS en IVUS-VH analyse de 
complete plaquedikte afbeelden en de aanwezigheid van necrotische kern iden-
tificeren. De beperkte axiale resolurie maakt een beoordeling van de fibreuze cap 
onmogelijk. Wij hebben hiermee aangeroond dar de combinatie van de IVUS-VH 
en ACT veelbelovend lijkt om dergelijke plaques te typeren. 
CONCLUSIE 
Wij zijn van mening dat het in dit proefschrift gepresenteerde werk van waarde is 
voor een beter begrip van de omvang, distributie, morfologie en samenstelling van 
atherosclerose in levende patienten. 
Wij hebben belangrijke gegevens gepresenteerd met betrekking tot de nauw-
keurigheid van een in vivo weefselryperingtechniek (IVUS-VH). Een van onze 
bevindingen was dat wij een potentieel in vivo surrogaat van thin cap fibroa-
theroom hebben geidentificeerd, de meest prevalente voorloper van plaquerup-
tuur. Desondanks moeten onze bevindingen voorzichtig worden geYnterpreteerd 
totdat definitieve data uit natuurlijk beloop studies vrij worden gegeven. 
Verscheidene systemische behandelingen hebben bewezen effectief te zijn ter 
verkleining van de plaque. Perindopril en rosiglirazone, die in dit proefschrift 
werden getest, bereikten het primaire eindpunt echter niet. 
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De combinatie van IVUS-VH en OCT lijkt veelbelovend te zijn voor een 
betere typering van hoogrisico plaques. 
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The details of this story will remain there for the future, as something that has 
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marked our lives. After a while, I visited Japan and then I had the opportunity 
to see you again. You and your family went to Hiroshima to meet me. You never 
told me, but I think you and your family went specifically to see me; you travelled 
- 6 hours on Nov 22, 2006, we had dinner in a typical Japanese restaurant; a 
restaurant where you have to be shoeless and seat on the floor. The next day, you 
were going back to your home town. I truly appreciated this. 
Andrew Ong, unfortunately we did not have much time together. I still have the 
barbecue you gave us. 
Joost Daemen, initially we worked quite a lot together and there are some 
manuscripts as a result of that. We spent also very much time together abroad. 
One time together with my family, we were in New York. We went together to the 
Central Park and also to get every day our meals. I still remember when at the cash 
desk the employee of the CVS pharmacy asked you where you bought your colour-
ful scarf. It became clear to me that these colourful clothes can only be bought in 
Holland. Actually, this is the same sort of comment, Filippo Cademartiri wrote in 
his thesis about Nico Mollet's colourful trousers. Thanks for all. 
Sophia Vaina, my neighbour during some years in Teilingerstraat. I really appreci-
ated you a lot. I liked your determination to get a proper clinical training and the 
ways you used to achieve it. 
Neville Kukreja, "big guy", I really enjoyed the time we worked together. I was 
a fan of your unique black sense of humour. The most unbelievable story we 
had together was at Harvard Square in Boston. There we rook a cab in order to 
go back to our hotel. As expected, I let you speak to the taxi driver. So in your 
British accent, you gave him indications how to get our hoteL After a rather long 
drive, we asked the taxi driver where we were going to. He told us that he was 
heading to the place indicated by Neville. Then, we realized that he was taking 
us t6 a complete different place, in other words, there was a misunderstanding 
in the avenue name, and I dare to say today that that was due to the differences 
in pronunciation between Neville and the taxi driver. \X'hen we discovered that, 
you started discussing and arguing with him. At certain point, we were just going 
rounds, the taxi driver would not let us go our of the taxi, if we did not pay the 
quite expensive fee. You were determined not to pay, because he made the mistake 
of not making sure ro get the correct address. Eventually, I suggested you to call 
911, so you called them, we were getting instructions what to do from the 911 
operator, because nothing worked out, the police was sent to chase the taxi that 
we were in. They came close to us and asked the taxi driver to pull over. Finally, 
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the deal was that the taxi would take us back to Harvard square and we did not 
pay anything. What an odd situation! Although what I just mentioned is not a 
good background to say thanks for helping me to improve my English in every 
way, you really did. 
Anne-Louise was a Danish colleague. You have had always an excellent taste to 
pick your houses. The one in Denmark was extremely beautiful and the one now 
in Bergen is even more beautifuL I have been always envious about that. I was 
always puzzled as to why you did and said things in a contradictory manner. Let 
me clarifY what I mean. On one hand, you saw life so simply, but on the other 
hand your emotional life was so complex. I would like to thank you for your 
friendship and I wish you all the best. Finally, if you ever decide to move to a 
Spanish speaking country, I could help you to improve your Spanish. 
Steve Ramcharitar, the way I will always remember you is asking: "Hector, how are 
you?" and before letting me answer you say: ~~Good, eh, I am also good". In other 
words, you greeted and answered yourself without letting the other people talk. 
We have had a sort of bumpy relationship, sometimes we argued, sometimes we 
laughed. From my perspective, the end result is positive, our friendship prevails. 
I wish you all the best. 
Shuzo-san, only after few days in Holland, your wife had ro be admitted ro the 
hospital due to some pregnancy complications. Eventually, everything was OK 
and your first daughter was born. You were above of all a fair man. Because of this, 
I saw you struggling many times when you saw injustice, either inside or outside 
the hospital. We have had the opportunity to work together in the BETAX study 
where you were very supportive. 
Carlos van Mieghem, my current neighbour in the Ommord wijk It does not 
seem like it, but I think you are one of the fellows with whom I have spent the 
most hours working shoulder to shoulder. I say: it doesn't seem like it, because 
we only produced one manuscript together. I was happy to learn that your dream 
came true; you were asked to go to work to Aalst! I wish you all the success you 
deserve. 
Emanuele Meliga, the most snob Italian colleague I have ever had. I really got 
to like you very much, although I never understood why you wore long knee-
high, striped colourful toe socks. Through you I learnt a lot about Italian cuisine, 
especially in the last months when you were always cooking for all of us (Nieves, 
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Koen, Yoshi and Nick). We were also roommates at the Zl20, when I moved to 
Cardialysis, you moved your office to Cardialysis as well. You could not cope with 
boredom, so you needed to be teasing Nieves and myself. Most of the memories 
I have about you is laughing for usually simple things, making fun of everybody. 
Professor Serruys should ask you how you mimic him (of course you did that 
always in a positive manner, "you know ... "). 
Scientifically, we did together the entire DELFT saga, which became the core 
of your PhD thesis. I have to say that we got a lot support from the Italian mafia, 
they agreed on pooling their patients. 
Last bur not least, I met your beautiful wife, Sylvia, and as I write, you are 
becoming the parents of a beautiful boy (Aprill5'h, 2009). 
Lele, I really would like ro thank you for your friendship, for being a good 
partner in work, but mainly for being a good partner in crime. I wish you all the 
best in your personal life and scientific career. 
Yoshi-sama, as a researcher, you are really a master, almost a genius. But I think 
that what makes you special is that above of all, you are a very good friend. You are 
patient and listen carefully to everybody. This may have to do with your Japanese 
culture. If I have to move again, I will not hesitate to ask for your help. You 
proved yourself to be a skilled builder of IKEA furniture. However, I will only 
do it in combination with your other half, I mean together with Nick. You are a 
box full of surprises. Nobody doubts of your dancing skills (all sort of music, even 
salsa), your cooking skills Qapanese curry with steam rice) and you even resulted 
to be a good "pusher" (do not get it wrong!), I mean when you needed to push 
aside your one-day acquired car from the Erasmus bridge, you did it successfully. 
Thus, having all these good qualities, I do not understand why you have not got 
a beautiful Dutch woman. 
Yoshi-san, you know what, we really enjoy your presence, your talking, and 
your uninterested help. Thanks for being my friend. 
Nieves Gonzalo (la ria!), since you came was clear to me that we could work 
together. You are not only such a hard worker, bur also an intelligent woman. The 
language undoubtedly played a role in our close research relationship, but we have 
also the same scientific curiosity. Fortunately, our friendship went beyond the hos-
pital environment and I was next to you in important moments of your life (e.g. 
when you met Koen), bur also in sad occasions. This strengthens our friendship 
considerably. One example of this last, it is that your friends became my friends 
and my friends were also your friends (Ceci, Poncho, Vera- in two words ... -, Paul 
Vazquez and his family) and got to know through you all the nice people of the 
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Clinic Hospital in Madrid Qavier, Fernando, Roxana, Pilar, Camino, Mane! and 
Carlos Macaya). I am sure you will be a corner stone at your new hospital. Thanks 
for being always there. Before finishing, ii may give you some advice, just make 
sure you learn how to cook Spanish food other than tortilla de patata, in other 
words, take advantage of this time at your mother's house, so next time we visit 
you in Madrid, we can enjoy your cooking. 
Nicolo, Nico, Nick, Guey, etc ... Guy, you know you are a special friend. It has 
been precious your friendship. Thanks to you, I realized I was unintentionally 
acting like the Godfather towards the entire community of fellows. You have 
confronted me many times with myself, in other words, you made me conscious 
of my acts. This has helped me to become a better person, because sometimes you 
do unconsciously good or bad things. Thanks to your generous presents, my son 
is now playing guitar (now I wonder who is really the Godfather). A word about 
your beautiful woman, whose name is Lisa. Together guys, you form a wonderful 
couple. I will never forget the day I tried ice in your house (actually it was snow 
brought by Lisa from Montreal) and maple syrup. 
The new Fellows at Thoraxcenter, Joanna W, Giovanna, Carl, Scot, Shin, Tak-
ayuki, Juan Luis. Joanna, I still have to learn how to reply to the vast number 
of emails you are able to send in a short period of time, all marked "in red". 
Giovanna, thanks for being such a good person. I hope you have a successful stay 
in Rotterdam. I cannot wait to see all of what we have started consolidated in 
many manuscripts. But, more urgently, I cannot wait much longer to try some of 
your delicious Italian dishes. Carl, I started enjoying playing squash with you. I 
also wish you a wonderful career here in Rotterdam. I hope in the near future we 
can collaborate on some research projects. Scot, it has been nice to work with you 
on the InfraReDx project. I am pretty sure this is only the beginning of a fruitful 
research relationship between us. I am already looking forward to working with 
you on more projects. Eun-Seok Shin, I could not like you more, you are not only 
a wonderful person, bur also an extremely hard worker and intelligent woman. We 
share the same scientific curiosity; therefore I think we will be working for a lot 
time together. Takayuki-sama, (Taka-nieves) you are extremely kind to everybody. 
We worked closely on the Terumo trial and it has been always a pleasure. We have 
some other lines of connection. Your daughter is my son's classmate. Thanks for 
the nice pictures you gave me after the school performance where my son was 
disguised as a small dog. Shen, I have been learning how to treat you. You are in a 
positive way, different to all my other colleagues It may be the age difference, or 
your large clinical experience in the field ofinterventional Cardiology. Your short 
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stay has been extremely successful in the sense that you came here to get some 
experience in research, and in a short period of time, you have learnt to use many 
different imaging softwares and I can even say that you have mastered them by 
now. You have got involved in many interesting projects with many fellows. This 
emphasizes your capability to work in a team. I really hope this experience gives 
you enough background to boost research in your hospital in Beijing. Juan Luis, it 
has been short time that I know you. I can see already that you are not the typical 
Spanish sort of person. You have not told me, but I discovered that you are able 
to speak English, Italian, German and I think you also speak some Portuguese, I 
have heard that in less than a month you started to speak you first Dutch words. 
Being polyglot is of course not the main quality of your Spanish countrymen. We 
(Apostolos, Carl and myself) will remember always the circumstance in which 
you got the corneal erosion. Chris, after Sophia Vaina you were the second Greek 
colleague that I had. I empathized quite a lot with you. I share the way you see life 
in general, but in particular the way you face working situations. We have pro-
voked already many situations to create the opportunity to work in some research 
projects with you. I hope at some point we can do it. Here I have to mention that 
I also feel lot of sympathy for your Eline. Apostolos, after only this short period 
of time, I can see you are also determined to be successful here at Thoraxcenter. 
Hope you find your way to get your echocardiography projects done. 
Professor Patrick W. Serruys always reads this section in order to get ideas to write 
the speech that he gives at the end of the PhD ceremony, or at least this is what he 
has been doing for the last 5 years. As I am aware of that, I have to pick the right 
words and describe only the things that I want him to mention. While reading 
this text, I think that he will feel a challenge and try to write something from 
scratch, which of course will be a surprise for me during the ceremony. But if I do 
not write some hints here, it can be also risky; he can consider mentioning things 
that will make me uncomfortable at that moment. However, I am going to be fair 
and sincere, and write here a message that conveys above of all my immeasurable 
gratitude to him. 
I would like to thank you for your patience bur also for your impatience, for 
your thoughtfulness, bur also for your thoughtlessness, for your unconditional 
support, bur also for your conditional support, for teaching me how to work hard, 
but also for teaching me how to enjoy life. This dualism is what ultimately has 
given to our relationship a great balance. I sincerely hope our working relationship 
last for many years. 
I would like also to take the opportunity and write some words of gratitude 
to Danielle Serruys. You have always been extremely kind and sensitive towards 
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me and my family. Your encouragement has helped me overcome many difficult 
situations I have encountered during my stay in Rotterdam. You have graciously 
offered me dinner many times ar your house. For all of this, I would like to thank 
you sincerely. 
Paul Cummins, the most Irish of my coworkers and the most catholic as well 
(Marie-angele, do not take me wrong). You are such a great chap; I do really enjoy 
working next to you. You know that, since you loaded the video in You Tube from 
the Buddy Guy's Blues Bar, Chicago, I am more famous now than before. I think 
I have not told you that my son enjoyed the video as well. 
Nico Bruining, I would like to thank you for all you have taught me, mostly 
indirectly, I mean through Gaston. The other opportunity was in the meetings we 
have had to discuss the guidelines for progression/regression studies. I have always 
enjoyed the time I have spent with you outside of work. One nice memory was 
when we went to see the red bulls in Chicago. Thanks for being a good friend to 
me. 
ACKNOWLEDGEMENTS TO THE PEOPLE FROM CARDIALYSIS 
Marie-angele, of all the people I have met in a professional capacity, I can say that 
you are the person who stands out because of your ever-present willingness to 
help. You have been, all this time, somebody I could always count on. You have 
listened many times when I have had problems. You know that listening helps 
already a lot; being listened to is the beginning of the cure, the beginning of the 
solution of a problem. I remember the day of my birthday, 27"' January 2008, 
when we (Pro£ Serruys, Gerrit-Anne, you and me) were at the revolving roof 
top restaurant in NY city, the View Restaurant at the New York Marriot Marquis 
Hotel at Times Square. From that day on, you keep a picture of all of us in your 
office. Thanks for being such a great colleague and team partner. 
Gerrit-Anne, I got to know you a lot during 2-week trip to US in the months of 
Octuber and November 2008. We visited many cities together and had all our 
dinners together. Then we talked about everything bur work. I could see the way 
you see life and how you got through all the same sort of situations I am currently 
going through. You told me that you were also working, while trying to sort out 
your PhD. In my case, I have currently 2 chiefs, I am finishing up a PhD, getting 
the BIG registration and working at Cardialysis. This may sound simple, when 
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you do not consider that one of my chiefs is Prof. Serruys at Thoraxcenter and he 
is also part of the board of Directors at Cardialysis. Gerrit-Anne, a great deal of 
the credit for my success in this multi-task sort of position is you. You have made 
this time smoother, I can say a bit less traumatic. Thanks for being always there. 
Peter-Paul, since day one, you have been always supponive and kind to me. I like 
from you especially your optimism. Thanks for all your help. 
Yvonne and Marjorie, thank you for making my stay in Cardialysis easier. Some-
times you even talk to me in Spanish, so I can feel like working at Home. Yvonne, 
you specially understand quite well my background, because you know Mexico 
and the Mexicans very well. I was surprised to see all you have visited in Mexico. 
I am pretty sure that you have been to many more places in Mexico that I have 
been to. Thanks both of you for your help and assistance. 
The other 3 people that are very imponant for me at Cardialysis are the 3 senior 
IVUS analysts, Ali, Jamal and Ravindra. You have taught me so much, bur more 
importantly you have been so patient in so doing. Today I know, figuurlijk gespro-
ken, that I do not have one right hand, bur four. I enjoy very much working with 
you. I hope we can continue to be such a good team. 
Koen Commisaris, gracias Koen for being a good collaborator and friend. Thanks 
also for being so helpful during our last verhuizen. More importantly, I would like 
to thank you for teaching me some interesting concepts about brewing. 
Dick Goedhart, thanks for all your patience and help. I do really admire your en-
ergy to finish up statistical analysis during late evenings and even on weekends. 
I wish I could have the opportunity to thank many other colleagues from Cardi-
alysis such as Bianca Backx, Monique Schuijer, Janette Symons, Marco Bressers, 
Jessica, Tessa, Anouk, Barbara, Frits, Richard, Angelien, Claudia, Eline, Ana, 
Witteke, Rene, and Ad. 
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Todo empez6 en 2003, cuando siendo residente del 2o aiio de Cardiologia In-
tervencionista, escribi a Rotterdam, preguntando por los requisites que se nece-
sitaban para venir al Thoraxcenter. Cuando recibi contestaci6n de mi e-mail de 
Anja, me fi.je como meta, venir a este centro. Me platicaban que era un sirio de 
excelencia, donde se trabajaba bastante, aunque no me lo podia ni imaginar en 
ese entonces. A trav6; de Mauricio L6pez, me entere un poco de la experiencia 
de Manuel Sabate. Mauricio mismo me deda que me vendria a las grandes Iigas 
de la invesrigaci6n en Cardiologia Intervencionista, otra vez no comprendia del 
rodo lo que eso significaba. La decision principal de venir, Ia tome, basado en dos 
hecbos fundamentales: primero, que yo queria estar en el mejor Iugar para hacer 
investigaci6n clinica en Cardiologia Intervencionista; y segundo, queria estar en 
Europa (nunca antes habia estado en este continente). El primer paso que di, 
fue convencer al Intituto Nacional de Cardiologia "Ignacio Chavez" (INC) que 
necesitaba exponerme a este ambiente, que si me quedaba en Mexico, me quedaria 
incomplete, que era una necesidad personal. Afortunadamente, el Doctor Pause 
Attie acept6. 
Se lleg6 el dia de Ia entrevisra con el Profesor Patrick W. Serruys, durante el 
AHA en Ia Ciudad de Orlando Florida en 2003. Me cit6 en un hotel relativamente 
pequeiio y modesto, me acompaiiaban mi esposa Lourdes, mi hijo Andres, Ernes-
to Luna y Sylvia Siu; cuando llegamos al hotel IBIS (sed. que desde ese entonces 
me seguia el nombre? - este es el nombre de uno de los estudios en los que mas 
activamente he participado) a preguntar por lobby del mismo, nos dijeron que ese 
hotel no tenia lobby, de hecbo no tenia ninguna otra area, mas que los cuarros del 
hotel. De cualquier forma, el Profesor no se encontraba en el hotel. Asi es que el 
viaje que habia hecho espedficamente para eso, no estaba siendo exitoso, le envie 
un mensaje a Anja, que afortunadamente contesto rapidamente, dando una cita 
para mas tarde. Finalmente me reuni con el, fue una conversaci6n acerca de los 
planes que tenia de investigaci6n. Luego el Profesor escribi6 en una hoja que tenia 
que hablar con Wil Warrhelemy para enviar mis papeles. Empece a enviar todos 
los documentos a Wil Warthelemy para que arreglara el permiso de estancia y el 
de trabajo. Y finalmente rode estaba listo para que me viniera al Thoraxcenter. 
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Esta decisiOn de venir a Rotterdam afect6 primordialmente a mi esposa Lourdes 
(Lulu), que cursaba el segundo aiio de Cardiologia Pediatrica y cuando yo me ruve 
que venir, 4 de agosto de 2004, ella se qued6 a rerminar su formaci6n. 
LulU, alglln dfa me dijiste: "este ha sido tu suefi.o desde hace mucho tiempo, 
ve por el, y haz que se haga realidad" - Esto te lo voy agradecer infinitamente roda 
mi vida-. 
Asf que, mi esposa e hijo se quedaron en Mexico. En aquellos mementos, 
experimente sentimientos encontrados, por un lado me sentia feliz de venir a 
Europa, y por el otro, triste de dejar a mi esposa, hijo, padres, amigos y a mi 
Mexico. 
Sin duda alguna quien mis ha contribuido a que todo este tiempo en Rotter-
dam haya sido un exito en muchos senridos, ha sido mi esposa Lulu. - Tu has sido 
un gran soporte en mi carrera, no s6lo demostrin.dome tu amor todos los dias 
tambien por escucharme, por haber abandonado un poco rus ideales y unirre a los 
mios. Por todo esto, eres tU ala persona a quien mis tengo que agradecer, te doy 
las gracias otra vez infinitamente. Le doy tambien gracias a Dios porque nos ha 
permitido compartir juntos esta experiencia, que sin duda ya ha marcado nuestras 
vidas para siempre. Te amo inmensamente. 
Quien ha estado todo este tiempo ahi, como testigo silencioso, es mi hijo 
Andres Alejandro. Cuando recien llegasre a Rotterdam (10 mayo 2005), tu tenias 
7 aiios de edad. Aun recuerdo Ia celebraci6n de tu cumpleaiios, fue en Ia casa de 
Teilingestraat 5 lL, est<ibamos solamente nosotros tres, partimos un pastel que 
habiamos preparado previamente con nutela. Fue un dia muy especial, porque 
cuando las celebraciones son mis grandes, se pierde ese acercamiento que puedes 
tener con el festejado. 
Tus primeros dias en la escuela fueron relativamente f<iciles, conociste a tu 
amigo Josue y eso ayudo a que re acosrumbraras mis rapido. Todos los dias re 
llevaba a la escuela en el asiento de atris de mi bicicleta. En ese entonces, en la 
escuela, te pedian que escribieras un diario describiendo las actividades que hacias 
y rambien tenias que dibujar los hechos mas relevanres. Aun conservamos esos 
dibujos, que para ti, era lo mas imporranre que ocurria a tu alrededor. En uno de 
ellos ilusrras como te llevo en el asiento de arras a Ia escuela. 
Hijo Andres, a ti tambi6n te quiero dar las gracias por tu inmensa paciencia y 
porIa comprensi6n que muestras hacia las profesiones de tus padres. Ahora que ya 
eres casi un adolescente y te enfrentaras a esos cambios fisicos y psicol6gicos, yo te 
tendre toda Ia paciencia y comprensi6n que ru me haz tenido. Te amo hijo. 
Mis padres, Hector y Enedina. A usredes les rengo que agradecer Ia vida, esos 
aiios de lucha para enviarme a Ia escuela. Creo que siguiendo su ejemplo, me he 
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enfrentado yo tambien a muchas situaciones dificiles. Nunca me he dejado ven-
eer, siempre he luchado hasta lo Ultimo; esto ha heche que afronte los resultados 
serenamente, sabiendo que he dado lo mejor de mi. Gracias por estar siempre ahi 
cuando los necesito. 
A mis hermanos, Sandra, Juan, Adrian y Eduardo, tambien les quiero agradecer 
por compartir conmigo los buenos y males mementos; y sobre todo por simpa-
tizar, y a veces tambien por estar en desacuerdo con lo que hago. Les deseo con 
todo mi coraz6n que ustedes tambien sean muy felices con lo que decidan hacer 
con sus vidas. 
Gracias a mis suegros, Manuel y Consuela, por ser un gran apoyo para LulU y 
Andres cuando se quedaron en Mexico. No tengo con que agadecer su amor y 
paciencia a mi hijo. A mis cuiiados, Birbara, Manuel y Margarita, igualmente 
mi agradecimiento por estar ahl cerca de ellos, alent:indolos y haci6ndoles sentir 
su apoyo. Especialmente quiero agradecer a Susana por su incondicional ayuda y 
sabre todo por dejarme ver su gran corazon y valentia. 
A mis amigos, Arturo y MOnica, que ademis son mis compadres, gracias por todo 
este tiempo de amistad. Especialmente por que han sido un gran apoyo moral. 
Gracias por ser parte de mi historia y por dejarme ser parte de !a suya. Paul y 
Karla, gracias tambien por su amistad incondicional. 
A mi paisa Samuel Varela, gracias por tu amistad, tu paciencia y sobrerodo por 
com partir conmigo ese gran ser humane que llevas por dentro. 
A Tere Resendiz, durante mis ai\os en el INC, no solo demostraste ser !a mas efi-
ciente, leal y servicial de mis compafi.eros de trabajo, sino que adem:is me dejaste 
conocer tu lado humane. Muchas veces me escuchaste, me diste consejos, pero 
sabre todo siempre me ayudaste en todo, alln estando en Rotterdam, siempre 
fuiste tu !a persona a !a que recurri cuando alga necesitabamos. Gracias tambien 
por que nos dejaste conocer a tu familia. Tere, sigue siempre igual, eres una gran 
persona, gracias otra vez por tu inmensa ayuda. 
A! Dr. Jose F. Guadalajara Boo tambien le quiero dar las gracias por su valioso 
ejemplo. Le tengo una gran admiraci6n y respeto. No he conocido mejor Cardi6-
logo, en toda !a extension de !a palabra, que Usted. Los tres ai\os que trabaje junto 
a Usted fueron de gran aprendizaje y en general una gran experiencia. Gracias por 
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haber alimemado mis aspiraciones, cuando platicibamos de Ia posibilidad de 
venir a Holanda. 
AI Dr. Martin Rosas tambien tengo mucho que agradecerle. La semilla que habia 
en mi, de hacer investigaci6n, fue sin duda promovida por su ensefi.anza y ejemplo. 
En los mementos en que mas dude acerca de mi futuro profesional, su consejo fue 
muy importante, sino es que casi determinante. Espero que pronto encontremos 
la forma de trabajar juntos, en la investigaci6n, que es algo que nos satisface a los 
dos. 
En general, quiero agradecer a los Cardiologos del INC, sobre todo a aquellos que 
me ensefi.aron Cardiolog.fa. 
Agradezco tambien a Ia Sociedad Mexicana de Cardiologia, por su apoyo econ6-
mico durante los primeros afi.os de mi estancia en Rotterdam. 
Podria seguir agradeciendo a miles de personas m:is, que quiero y que admiro, 
pero creo que a las que aqui agradezco son las que forman pane de alguna manera 
de este capitulo en mi vida. 
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CHAPTER 1.1 
Figure 1. IVUS-Virtual histology proposed lesion types. AIT, adaprative inrimal thickening; PIT. 
pathological intimal thickening; FT, fibrotic plaque; FC, fibrocalcific; FA, fibroatheroma;CaFA, 
calcified fibroatheroma; TCFA, thi n-capped fibroatheroma. 
Figure 2. IVUS-palpography. In the upper left side the palpography srrain map is opened up. The 
local strain is calculated from the gated radiofrequency traces using cross-correlation analysis and 
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displayed, color-coded, from blue (for Oo/o main) ro red ro yellow (for 2o/o main). Plaque strain 
values are assigned a Rorrerdam C lassificarion (ROC) score ranging from I ro 4 (ROC 1= 0-<0.6 
o/o; ROC ll= 0.6- <0.9 o/o; ROC lll= 0.9-<1.2 o/o; ROC IV= >1.2 o/o). Ar rhe borrom, in rhe same 
cross-sectional area a high-srrain spar (ROC III) is shown (lefr); in the virrual hisrology (VH) image 
(righr) a confluent necrotic core area in conracr with rhe lumen is seen, suggesting an !VUS-derived 
thin capped fibroatheroma. The IVUS-VH color-code is fibrous tissue (green), fibro-fatry tissue (light 
green), necrotic core (red) and dense calcium (whire). 
Figure 3. The optical coherence tomography image shows thin cap fibrous atheroma (TCFA). 
The cross-section demonstrates a region of low reflectivity with diffuse borders between the 3 and 5 
o'clock position consistent wirh a lipid-rich plaque. This is covered by a rhi n, highly reflective fibrous 
cap (TCFA) which measured berween I 0-30 microns in thickness 
488 
Color section 
• soft plaque , echogenicity < the surrounding adventitia. 
fibrous plaque , intennediate echogenicity between so ft and calcified 
calcified plaque. echogenicity > the adventitia with shadowing. 
mixed plaques, when they contain more than one acoustical subtype. 
necrotic core , remnants of foam cells and lymphocytes, cholesterol clefts and ca~ 
fibrous tissue , densely packed bundles of collagen fibers with no lipid 
fibrofatty tissue, loosely packed collagen fibers and cells with high lipid content. 
dense calcium. identifi es focal areas of calcification in pathology 
fibrous plaque . high reflectivity, homogenous and finely textured 
calcified plaque , low reflectivity. inhomogeneous and sharp margins 
lipid plaque 
no substantial lipid deposition 
intermediate lipid deposition 
artefact, usually seen in calcified plaques 
Figure 4. Multi-imaging in the coronary arteries. The same coronary segmenr (represenred by one 
frame) has been imaged by 4 differenr imaging techniques. In the greyscale IVUS (panel A), NUS-
virtual h istology (panel B), op tical coherence tomography (panel C) and inrravascular magnetic 
resonance spectrosco py (IVMR) the resul ts of the same fra me across different techniques are shown. 
Of note, in the uppe r left quadranr of the plaque a calcified area is seen in three imaging modalities, 
bur in IVMR where an artifact is observed. O n the right hand side, rhe different plaque and tissues 
types across the coronary imaging techniques is shown. 
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Figure 5 . vPredict'" optical catheter system (OCS). This catheter has 8 optical fibers that deliver 
infrared light to the vessel wall and captures a portion of rhe reflected light for spectral analysis. 
Image courtesy of Prescient Medical, Inc 
Figure 6. IVUS-virtual histology in stented segments. In the left hand side, a coronary angiogram 
of rhe left coronary system shows on the distal segment of rhe left circumflex artery an eccentric 
lesion. A pre-scenting virtual histology (VH) frame showed a fibrotic type of plaque (location ofVH 
frame is indicated by a black line). On the right hand side, the post-stenting VH frame is depicted. 
Of note, at the lumen and surrounding areas an increase in the amount of"dense calcium" and 
"necrotic core" is observed. This is due ro the presence of stent struts that are misclassified by VH. 
PCI, percutaneous coronary intervention. 
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Figure 7. OCT and stent. Panel A: Demonstrates the optical coherence tomography (OCT) 
imaging of a bare metal stem 4 months following implantation. The circumferential tissue struts are 
visible with shadowing induced by the metal. The neointimal tissue measured berween 140 and 220 
microns in thickness. Panel B: OCf imaging of a drug-eluting stem (DES) at 4 months follow-up 
showing the circumferential struts with a very thin neoinrimal layer (1 0-40 microns thick). The 
arrow indicates a strut with no visible tissue coverage 
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CHAPTER 1 .2 
Catheter I 
E 
E 
Catheter 2 
~ 
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Figure 1. This patient was imaged in the same region with two 
different catheters during the same procedure. The graphs show all the 
frames acquired (x axis) and in they axis the distance between them 
is given. Small variations in the intervals were observed. 
Mean distance = 
0.51±0.02 
Mean distance = 
0.52±0.02 
Figure 2. This figure shows the heart beats recorded during VH-IVUS 
acquisition (in this case palpography was also recorded simultaneously). 
In black, the EGG signal; in purple the "R'' top marker; in green and red 
the acquired VH-IVUS frames. The blue line indicates the segmentation 
per heart beats based on the blood pressure signal (blood pressure curve 
not shown). In panel A, a quasi-normal EGG-gating acquisition is seen, 
the VH-IVUS frames (green markers) were constantly acquired 
throughout the pullback. Only few extra VH-IVUS non-"R"-top related 
were acquired (red markers). In panel 8, due to a bad EGG signal the 
EGG gating was poor. This graph has been created by Frits Mastik at 
Erasmus Medical Center. 
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Figure 3. Panels A and A' show that the lumen border was drawn hallway into the flare Iring down artefact! of the catheter (yellow circle!. in the 
VH frame this was misclassified as dense calcium. Panels 8 and 8' show the recommended approach to draw the lumen border. away from the 
flare of the catheter. Panels C and 0 show the proposed method to draw the contours at Side-branches. Luminal contour (yellow line} should be 
drawn just beyond the vessel contour. so that in the VH-IVUS th1s appears as an empty space. SB, Side-branch. 
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Figure 4. Two consecutive frames showing a ruptured plaque in 
a patient wi th an acute coronary syndrome. The luminal contour (not 
shown to allow visualisation of the discontinuity area of plaque surface) 
should be drawn including the cavity (white arrow) in the analysis. 
Figure 5. Coronary plaque rupture with overlying luminal thrombus. 
A shows the area of the thrombus and rupture site (arrow) and 8 shows 
the site of rupture (arrow) with the overlying thrombus at higher 
magnification. 
....... 
\' 
D 
Figure 6. Ulcerated plaque, carotid artery. A. Haematoxylin eosin stain. 
B. Movat pentachrome stain showing the ulcerated plaque (arrow) and 
the various plaque components. C. Macrophage staining (CD68! 
showing macrophages (brown) close to the area of the ulceration and 
the underlying core. D. There is abundant fibrin within the ulcerated 
necrotic core. 
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Figure 7. Stable plaque, coronary artery. A shows focal calcification 
(dark purple areas). 8 shows an area of sheet calcification (double 
arrow) of a collagen rich plaque where as the single arrow points to an 
area of necrotic core calcit;cation. C illustrates as area of speckled 
calcification along a necrotic core. Dis the area from C underneath the 
arrow at higher magnification showing single cell calcification. 
·li· ·:. 
Figure 8. Coronary arteries showing patterns of calcification. Left: 
A. Pathologic intimal thickening. B. Calcium stain demonstrating 
microscopic calcifications (von Kassa). Middle: A. Fibrocalcific plaque, 
non-occlusive. 8. Speckled calcification within an early necroNc core 
(Movat stain). C. Shows fibrous plaque calcification. Right, A. 
"Pipestem'' calcification circumferentially around the vessel, with 
apparent stabilisation of the plaque. 
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Figure 9. Unstable calcification. A. Macrophage marker (CD 68) 
demonstrating macrophage infiltraNon of an early necrotic core. B. 
Higher magnification of spicule of calcification (arrow) within an area 
of necrotic core. 
Figure 10. Coronary plaque showing healing plaque rupture. A and 8 
at higher magnification show the site of previous plaque rupture where 
the fibrous cap is disturbeo (arrow) and overlying healing thrombus. 
The rupture is almost fully healed towards the lumen. 
Figure 11. Nodular calcification in a coronary plaque. Note the calcification 
(A) some of which 1s nodular in nature in the area close to lumen. 8 is 
area underneath arrow in A at higher power showing nodular 
calcification with fibrin {dull red) in between nodules (bright red). 
Figure 12. AHA plaque classification. (Stary HC. The histological 
classification of atherosclerotic lesions in human coronary arteries. In: 
Fuster V. Ross R, Topol £, eds. Atherosclerosis and Coronary Artery 
Disease.). fc: fibrous cap; nc: necrotic core 
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F1gure 13. Modified AHA classification, Virmani eta/, ATVB 2000; 20:1262·75. EL; extracellular lipid; nc: necrotic COI'e; fc: fibrous cap; th: thrombus 
Figure 14. Examples of VH·tVUS 1mages classified by a two·dimens1ona/ lesion analysiS. lfMTI mtimaf medial thickening; (PIT) pathological intimal 
thickening; (FT) fibrotic plaque; (FC) fibroca/cific plaque; (FA) fibroatheroma and (caFAJ calcified fibroatheroma; IVH· TCFAJ Virtual Histology· thin 
cap f1broatheroma and (VH·caTCFA) Virtual Histofogy·cafcified thin cap fibroatheroma. 
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Figure 1. Chart of misclassifications. Only misclassificarions occurring ~2 are included in rhe 
figure. Misclassificarions are derived from 36 cross-sections in VH-IVUS and OCT and VH-IVUS 
combined, misclassificarions in OCT are derived from 50 cross-sections. Yellow = histology, green = 
VH-IVUS, orange= OCT, OCT!VH-lVUS = red. IT= intimal th ickening, FC = fibrocalcific, FA 
= fibro-arheroma, CaFA = calcified fibroatheroma, TCFA = thin-cap fibro-arheroma. For example: 
of the lesions rhat were identified as IT in histology, 7 were classified as FA in OCT, 3 as FA in VH-
IVUS, and 2 as FA in OCT and VH-IVUS combined. 
Figure 2. (A) Histology of a calcified fibroarheroma (hematoxylin-eosin stain). (B) Corresponding 
VH-IVUS classified as calcified fib roacheroma. (C) Corresponding OCT classified as calcified 
fibroarheroma. The needle used to mark the site can be seen in the bright feature at G o'clock in 
OCT, as well as in the appearance of dense calcium in that location in VH-IVUS. 
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Figure 3 (A) CD68 stained cross-secrion. The intima consisting of a collagen/glycoprotei n marrix 
is densely inlilrrared by macrophages. (B) Magnification of selected region in A. (C) Corresponding 
OCT image. The region inlilrrared by macrophages appears as a thin-cap fib ro-arheroma. The bar 
indicates 1 mm. 
Figure 4. (A) H&E stained cross-section. (B) Intimal th ickening is misinrerprered as thin-cap 
fibro-arheroma (TCFA) in optical coherence romrography (OCT). The large arrow points ar the 
spot interpreted as a chin-cap. The four small arrows indicate the OCT beams and are all of rhe same 
length. The loss of signal due co tissue penetration is similar for each arrow. Because of eccentric 
carherer position chis cross-section, classified as intimal thickening in histology, appears as a chin-cap 
libra-atheroma (TCFA) in OCT. The bar indicates 1 mm. 
Figure 5 . (A) H&E stained cross-section with (B) rhe corresponding optical coherence tomography 
(OCT). The arrow ind icates a collagenous region in histology mistaken for a lipid region in OCT. 
Reduced optical efficiency of rhe carherer in chis image section creates a dark sector, making mild 
intimal thickening appear as a fib ro-arheroma. The bar indicates 1 mm. 
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Figure 5. Sequential plotting of a matched ROI interrogated with t\\O catheters. The mean CSA (r axis) of each plaque component is 
colour-coded (calcium: white. fibrous: green. fibrol1pidic: grccnish·yellow and necrotic core: red). This figure shows an example of the 
impact or non· uniform pullbacks on geomctricil l and compositional measurements. 
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Figure I. Bar graph shows plaque CSA (PCSA) categorized into 3 groups 
according to plaque size (x axis) and relative amount of the NC (y axis) in 
the left anterior descending coronary anery (blue bars), left circumflex 
coronary artery (gree11 bars). and right coronary artery (yellow bars). 
A NOVA = analysis of variance. 
CHAPTER 3.3 
Figure 3 IVUS·VH CSA along a coronary vessel. IVUS·VH cross-sectional areas 
in a representative patient showing the change in plaque composition 
(calcium: white; fibrous: green; fibrolipidic: greenish-yellow; and lipid 
core: red) along the longitudinal axis of the vessel. LM, left main coronary 
artery; CFX, circumflex artery; lAD, left anterior descending artery. The dis· 
tance between the cross-sectional area and the ostium of the vessel is 
reported in millimetres (mm). 
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f"liUre 1. lntraV"J.Scular ultrasound cross-section images from the carina of the left anterior descending coronary :lftery and of the left main coronary artery. 
The left side shows the reconstructed grayscale, and the right side shows the color-coded data (green = fibrous; yellow-green = fibrolipidic; n:d = necrotic 
core; white= calcium) provided by the IVUS-VH unit (Volcano Therapeutics, Rancho CordoV<t, California). LCx = left circumflex arttf}'i MPT = 
maximal plaque thickness. 
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5mn 5mn k= 5mn 
Proximal Just bifurcation Distal 
segment 
segment segment 
Fig. 1. The schematic definicion of proximal, jusr bifurcation and distal segments of bifurcations 
(upper panel) . Gray fVUS (middle panel) and VH-IVUS (lower panel) of each frame were analyzed. 
The proximal segment and distal segment of rhe bifurcation sires were analyzed in rhe 5 mm 
proximal and distal ro bifurcation sires. The jusr bifurcation segment were analyzed in each segment 
length. The proximal and distal reference sires were analyzed in rhe frame which showed rhe least 
P+M % wirhin I 0 mm of rhe bifurcation sire. 
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~/)J \Y CRF 
F 
• Fibrous 
0 Fibrofatty 
0 Calcium 
• Necrotic core 
Figure 1. Top: C ross-sectional areas o f the same coronary atherosclerotic plaque, on the left 
hand side a greyscale image and on the right hand side the corresponding IVUS rad iofrequency 
data image. Bottom: Cardiovascular risk fac tors (CRF) act alone or in combination (biological 
interaction) to assert their effect on overall plaque composition. Note that the impact of these CRFs 
varies (thickness of the arrow). Their effect could exclusively be on overall plaque composition or 
simultaneously affect necrotic core, once again, individually or collectively. 
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Figure 2. The population has been divided by age, gender and diabetes, resulting in eighr categories. 
The same cardiovascular risk facror (CRF) "A" is assessed in each of them in terms of change in 
necrocic core. This CRF "A" can have nor effect (horizontal arrow), increase (upward arrow) or 
decrease (downward arrow) rhe amount of necrotic core. When a population based analysis is 
conducted, eirher by age, gender or cl inical presentation no effecr can be found, alrhough rhere is a 
significant change in some of the categories. 
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Figure 1. Stratification o f mean plaque area and necrotic core area according to both age and waist 
circumference rerriles. 
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Figure 1. An eJCample of select1ve quantification of the necrotic core m contact with the lumen. (a) The origmai/VUS-VH cross-sectional area; 
(b) Modification using the VH tool to select ively quantify the major confluent necrotic core that is in direct contact with the lumen. 
(c) Measurement of the angle occupied by the entlfe necrotiC core in contact w1th the lumen (white and red lines) and spectficafly the angle 
occupied by the major confluent necrotic core m contact with the lumen (red lmes). 
proximai-~IJJ~ distal 
Referen~e segment --- Distance is 5 mm --- M~A 
MLA, 5.77 mm2 
PB, 44.6% 
VCSA 10.39 mm2 
MLA, 3. 94 mm2 
PB, 66.4% 
Remodelling index 
1.13 --vcsA 11.75 mm2 
MLA, 3.81 mm2 
PB, 49.3% 
VCSA 7.51 mm2 
Figure 2. The figure shows the /VUS grey scale and the corresponding IVUS-VH frames of an JVUS derived thin cap fibre-atheroma (four central 
frames) and the proJCimal and d1stal reference segment in which the remodelling index was calculated. MLA, minimum Juminaf area,· PB, plaque 
burden; VCSA, vessel cross sectional area. 
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Figure 3. Bar graph shows the number of IVUS-derived thin cap fibro-
atheroma according to the largest confluent necrotic core in contact 
with the lumen (NCCL) and the remodelling index. It seems that 
among the IOTCFAs there are different degrees of disease, possibly 
with different likelihoods of rupture. 
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f"'!pre 1. Left :anterior descending artery dcpieted by lntt:l\'2.SCU.I:u Ula-asound·V'lttU:al Histology, where alcifit:d, fibrous, fibrolipid.ic, and necrotic oore 
regions a.tt labeled wh.ite, green, grcenish-yc.Uow, and red, respectively. Panel A shows an inmwascular ulrrasound cross-section:U are2 rcconscruc:ted from 
backsc:mcrcd signals . . Panel 8 shows t he corresponding tissue map depicting :a necrotic core-rich plaque with necrotic core tissue in contact with the lumen. 
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Figure 2. Bar graphs illustrating the frequency of intravascular ultrasound-
derived thin-cap fibroatheroma {IDTFCA) starting from the ostium. 
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Figure 1 Three-vessel imaging using IVUS-VH (where calcified tissue is 
labelled as white, fibrous as green, fibrolipidic tissue as greenish-yellow, 
and necrotic core as red) in a 57-year-old male presenting with unstable 
angina. PR in the ostial LAD (LAD a) . The underlying substrate of the cavity 
is rich in necrotic-core (red) and calcium (white), whereas the thrombus 
has migrated distally (LAD c, asterisk). 
CHAPTER 5.4 
Figure 1 Minimum lumen areo (MLA) 
sites depicting the progression of 
atherosclerotic disease. The plaque 
components were assigned colour 
codes. Calcified, fibrous, fibrolipidic, 
and lipid core regions were labelled 
white, g reen, greenish yellow, and red, 
respectively. MLA sites feature 
(A) pathological intimal thickening and 
(B) fibrocolc ific, (C) fibroatheromotous, 
and (D) thin cop fibroatheromotous 
lesio ns. 
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Figure 1. (A, B & C) show three consecutive intravascular ultrasound images of the 
proximal left anterior descending (D), which is disease-free angiographically. Note that 
the intravascular ultrasound images show a plaque burden of 50%. 
Figure 2. IVUS plaque types. These IVUS images, taken from distal to proximal in the same vessel (A- F), represent different IVUS gray 
scale plaque !ypes. (A) shows a soft plaque, large plaque burden and positive remodeling. On the contrary, (B) shows a fibrotic plaque 
(Similar echogenicity to adventitia}. (C) Depicts a superficial calcified plaque (see shadowing). (0- F), a plaque rupture is illustrated; a 
large empty cavity (red oval, [D)) with the remnant of fibrous cap 1S overhanging the lumen (arrow, [E)). 
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Figure 3. Intravascular ultrasound (IVUS) gray-scale frames and their corresponding virtual histology frames of an 
IVUS·derived thin-cap fibroatheroma (four central frames) and the proximal and d istal reference segment in which the 
remodeling index was calculated. 
MLA: Minimum luminal area; PB: Plaque burden; VCSA: Vessel cross-sectional area. 
Virtual histology color code: green is fibrous, greenish is f•brofatty, red is necrotic core and white is dense calcium. 
ROtterdam Classification (ROC) 
Grades (ROC) 
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Figure 4. IV US palpography. The local strain is calculated from the gated 
radiofrequency traces using cross-correlation analysis and displayed, color-coded, from 
blue (for 0% strain) to red to yellow (for 2% strain). 
Plaque strain values are assigned a Rotterdam Classification (ROC) score ranging from 
1 to 4 (ROC I= 0 to <0.6%; ROC II= 0.6 to <0.9%; ROC Ill= 0.9 to <1.2%; ROC IV 
> 1.2%). 
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Figure 5. OCT and standard coronary angiography correlation. Angiography 
shows a complex lesion in the mid left anterior descending. The optical coherence 
tomography image shows a ruptured plaque with thrombus at that site (white arrow). 
Proximally and distally to the culprit lesion. thin-capped fibroatheroma lesions are 
present ([B] and (A] respedively). 
Figure 6. Intravascular magnetic resonance. The magnetic fields generated by the 
probe located at the tip of the catheter, create a FOV with a sector shape, looking 
sideways into the artery wall. The FOV has a lateral resolution of 60°, a longitudinal 
length of 2 mm and a depth of 200 ~m. It makes the analysis for the area comprised 
between 50 and 200 ~m from the lumen. 
Acquired data is displayed as color-code sectors based of the lipid fraction index for each 
zone of the FOV Blue indicates no lipid, gray correspond to intermediate lipid content 
and yellow indicates high lipid content. 
FOV: Field of view. 
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Figure 7. Near infra-red spectroscopy. Demonstration of spectral findings in t he left 
anterior descending coronary artery of an autopsy specimen (unpublished data, on file 
lnfraReDx, Inc., Burlington, Massachusetts). The panel shows the results of the scan, 
w ith distance along the lumen on the x-axis and arc of rotation on they-axis. As 
indicated by the yellow signal, the scan successfully detected lipid necrotic core rich areas. 
Image courtesy of James E M uller. 
In vivo 
TCFA recognition 
l 
Mechanical vessel wall reconstruction 
(increasing resistance to rupture) 
I Reshape lumen to restore hemodynamics! 
I Reinforce fibrous cap I 
I Retract and retain necrotic core! 
I Recover endothelium functionality I 
I Remodelling of the vesselJ 
Reassessment beyondi----~1Vulnerable vascular bed, myocardium, 
the coronary ostia c:b:.:.lo:.:.o:.:.d:.a:::nccd=pa:::tc.:ie:.:.n:.:.t ------ --' 
Figure 8. Treatment of co ronary vulnerable plaques. 
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Figure 1. A, The ultrasound signal Is generated in a piezoelectric crystal (') that transmits and receives sound waves. B. Ultrasound 
reflected by the tissue deforms crystal, generating RF signal. C, Gray-scale IVUS is derived from the amplitude of RF signal, discarding 
information beneath the peaks of the signal. D, Changes In the electric field of the piezoelectric crystal caused by ultrasound reflection 
are used to generate a gray-tone image. E, IVUS RF analysis uses several additional spectral parameters to identify 4 plaque compo-
nents. F. Plaque components that are identified are dense calcium (white), fibrous (green), fibrofatty (greenish-yellow), and necrotic core 
(red). G, IVUS palpography takes advantage of RF signals generated by the artery being deformed by blood pressure (BP). Using analy-
sis of RF signals at "low· and .. high'" BP, the strain (deformation) in the inner layer of atheroma is determined. H. This strain is quanti· 
fied and superimposed on the IVUS image at the lumen/vessel wall boundary. Note that high strain (yellow) is found at the shoulders of 
the eccentric plaque. 
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Figure 4. Top, Representative examples of plaque composition in the darapladib- and placebo-treated groups. The gray-scale frames 
and corresponding IVUS RF frames are shown. The pie charts provide quantitative display of individual plaque components in the 
cross sections. Values are in millimeters squared (and percent of RF-derived atheroma area). In the darapladib-treated patient, a 
decrease In necrotic core is seen. In the placebo-treated patient. an increase in necrotic core is demonstrated. Bottom, Differential 
changes in plaque components from IVUS RF analysis in the overall placebo and darapladib groups. Results are expressed as mean 
change from baseline (BL). with individual components expressed as percent of RF-derived atheroma volume. FUP indicates follow-up. 
"Within.group change from baseline. 
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Figure 1. Temporal changes in necrotic core in a patient treated with placebo in the IBIS 2 study 
Top: graph displayed the necrotic core (NC) areas in all consecutive cross-sections in this patient, the 
increase of necrotic core in placebo treated patient is apparent at several locations of the pullback, as 
highJighted by the arrows. In the entire analyzed region, there was increase in necrotic core volume 
of 25.1 mm3 after one year, whUe in the worst I 0 mm segment, an increase of 11 mm3 in NC was 
observed. 
Bottom: In these rwo sequential cross-sections from the same anatomical location, there is evidence of 
progression of necrotic core area (depicted in red) at the expense of fibrous tissue (depicted in green). 
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Figure 2. Temporal changes in necrotic core in a patient treated with an Lp-PLA2 inhibitor 
(darapladib) in the IBIS 2 study 
Top: graph displayed the necrotic core (NC) areas in all consecutive cross-sections in rhis patienr, a 
decrease of necrotic core in darapladib treated parienr is apparem ar several locations of rhe pullback, 
as highlighted by rhe arrows. In the enrire analyzed region , rhere was increase in necrotic core volume 
of 19.1 mm3 after one year, while in the worse I 0 mm segmenr, a decrease of 8.7 mm3 in NC was 
observed. 
Borrom: In conrrasr co placebo, rwo cross-sections from rhe darapladib-rreared parienr demonstrate 
reduction in necrotic core area depicted in red. Of note, concomiranr increase in fibrous tissue (in 
green) is consisrenr with plaque srabiliz.arion effect. 
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Findings on greyscale IVUS during stent implantation 
associated with stent thrombosis 
Findings on IVUS·RFD during stent implantation potentially 
associated with stent thrombosis I 
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Figure 1. This illustration displays the potential use of greyscale IVU$ and IVU$-radiofrequency data IRFD) analysis across the different stages of 
the interventionaf procedure and imaging follow-up of the patients. Greyscafe IVUS can categorise plaque types and the acute result of the 
intervention. as well as provide useful information on some characteristics that have been related to stent thrombosis such as incomplete stent 
apposition (ISA}, edge dissection, residual stenosis, under-expansion and thrombus. IVUS-RFD could provide valuable information on the intact 
plaque, especially on necrotic core (NC} amount and location. 
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Figure 2 . Panel A shows a longitudinal view of an /VUS pullback. The 
arrow points to a proximal segment that is not apposed to the vessel 
wall. Panel 8 is the corresponding cross-sectional area (GSA). The 
arrow shows multiple stent struts that are not apposed. Panel G is a 
diagrammatic representation of the longitudinal view. Notice the lack 
of stent apposition signalled by the arrow. Panel D indicates the stent 
GSA throughout the segment. An important decrease in stent area is 
seen at the proximal part. 
Figure 3. Greyscale IVUS frame and its corresponding IVUS-
radiofrequency data frames of an IVUS derived thin cap fibro-atheroma 
(two upper frames). At the bottom, a stented necrotic core-rich plaque 
is shown. Notice the presence of stent struts at the lumen in the color 
picture as "dense calcium" on top of a confluent area of necrotic core. 
Virtual histology color code: green is fibrous, greenish is fibro-fatty, red 
is necrotic core and white is dense calcium. 
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Figure 1. Serial changes in the stent struts as assessed by IVUS Virtual 
HistologyrM (VH). On the left hand side, greyscale IVUS images are 
shown at pre-, post-stenting and follow-up. In the central part, their 
corresponding colour code VH images are depicted. On the right hand 
side, per-cross section quantification in absolute and relative terms is 
shown. Of note, increases in "dense calcium" (white) and "necrotic 
core" (red) are noted after stenting. At follow-up, a change in the stent 
strut appearance in greyscale JVUS is noted and decreases in the 
"dense calcium" and "necrotic core" contents in JVUS- VH are 
detected. Fibrous -green; and fibro-fatty - light green. 
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Figure 2. Temporal changes in virtual histology tissue types. From top to 
bottom, the mean percentage of "dense calcium", "necrotic core", fibrous 
tissue and fibro-fatty tissue is reported. Thirteen patients were imaged at 
pre-, post-stenting and follow-up (red solid lines). A further 14 patients 
were only imaged at post-stenting and follow-up (black dotted lines). 
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Figure 3. Sequential changes in high-strain values as assessed by IVUS-palpography. Panel A shows an intact plaque with a ROC Ill spot at 4 
o'clock (white arrow). Panel 8 depicts abolition of this high strain spot following stenting (ROC 1}, In panel C a slight increase in plaque 
deformabllity was documented !ROC II). 
Mean of the 
cumulative strain 
values including 
ROC I, II, Ill and IV 
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Figure 4. Temporal changes in strain values. The mean cumulative strain 
values in all frames with ROC I-IV scores are shown. Twelve patients were 
imaged at pre-, post-stenting and follow-up (red solid lines). Another 13 
patients were only imaged at post-stenting and follow-up (black dotted 
lines). After stenting, abolition of the strain values was noted; however a 
higher level of plaque deformability was present at follow-up. 
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CHAPTER 8.4 
Figure 1. IVUS pullbdck. The top panel shows the IOfl(litudinal recon-
struction. The double-headed arrqw indicates the location of the stent. 
The characters Na" through "d" indicate the posttion of the cross sec-
tional panels "A" through "D". Panel A: proximal part of the stent, 
arrows indicatestent malapposition. Panel 8 : minimal luminal area 
within the stent (MLA 4.6 mm2J. Panel C: eccentric plaque rupture 
(arrowed). Panel 0: directly distal, intact eccentric neo-intimal plaque. 
Panel c·· (magmfied frame): IVUS VH of ruptured plaque within the 
nec>-intima. Panel D" (magmfied frame): Immediately alter the rup-
ture. Panels C" and D" sh<1W a majority of fibrous t1ssue. Of note IVUS-
VH analysis included the stents' struts that were seen as spots of cal-
cium and necrotic core. Fl, fibrotic tissue; FF. fibrofatty; DC, dense 
calcium; NC, necrotic core. 
Color section 
Figure 2. H1stoi0JIY of the case IMovat Pentachromel. A, 8 : Long1tudinal section of the stent. The distal part of the stent shows site of plaque 
rupture and a superimposed platelet-rich adherent thrombus. C: X-ray of stented artery JUSt above the bifurcation of LAD and left d1agonal branch. 
D: High magmfication image of the rupture site ( "')and overlying platelet-rich thrombus is identified by the black arrow. E: The cross sect ton of 
the prox1mal portion of the LAD stent. !corresponds to the black lines in panel A and 8). Note the presence of a thin-cap fibroatheroma (vulner-
able plaque/ Within the stent s1te (•). F. G: The fibrous cap is extremely thin and mfiltrated by foamy macrophages With an underlying necrotiC 
core INC). 
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CHAPTER 10.1 
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Figure 1: Schematic diagram of virtual histology (IVUS-VH) and optical coherence tomography 
(OCT). Left: The ultrasound signal is generated in a piezoelectric crystal that transmits and receives 
sound waves. Ultrasound reAected by the tissue deforms crystal generating radiofrequency (RF) 
signal (a) . Greyscale IVUS is derived from the amplimde (b) of RF signal, discarding information 
beneath the peaks of the signal. IVUS-VH analysis uses several additional spectral parameters to 
identify four plaque components (c) . Plaque components that are identified are dense calcium 
(white), fibrous (green), fibro-fatty (greenish-yellow) and necrotic core (red) (d) . 
Right: the electromagnetic spectrum encompasses the following regions: x-rays, microwaves and light 
(e). The visible part of the spectrum ranges from 0.4 to 0.77 )Jm. The wavelengths used fo r OCT are 
indicated. Since the speed of light is much faster than that of sound, it is needed to use correlation or 
an in terferomete r to measure the backscattered light. The interferometer splits the light source into 
two arms - a reference arm and a measurement arm- (/J. The measurement arm is directed into the 
tissue through the image wire and collects the backscattered light (g). The light coming back from 
both arms is recombined at a detector (h) in which the interferogram- the sum of the two signals 
- is generated. The optical properties of the tissue can be deduced by comparing the back-reAected 
optical inrensiry of the two arms (i). Panel d and i correspond to the san1e anaromical region. Please 
note that the shape of the calcified regions is similar. 
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Plaque thickness >600 ~m. >3 frames 
Figure 2: Plaque classification using OCT and IVUS-VH. OCT: optical coherence tomography; 
VH: virtual histology; NC: necrotic core; AIT: adaptive intimal thickening; PIT: pathological 
intimal thickening; FC: fibrocalcic; FT: fibrotic; CaFA: calcified fibroatheroma; FA: fibroatheroma; 
CaTCFA: calcified thin cap fibroatheroma; TCFA: thin cap fibroatheroma. 
Figure 3. IVUS-derived thin cap fibroatheroma by and virtual histology and its corresponding 
optical coherence tomography image (OCT). Right: Virrual histology image is color coded: red-
necrotic core, white - dense calcium, green - fibrous and greenish - fibro-farty. There is an area of 
conAuem necrotic core (NC) that is in direct contact with the lumen (CL). Left: OCT image shows 
an area with low reAectiviry behind a thin cap. These characteristics have been correlated with a 
fib rous cap overlying a necrotic core rich area (arrow). 
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Figure 4 . O p tical coherence tomography images of common stent findings. Panel a shows 
a newly placed stenr. Stene struts are recognized as bright structures that span 360 degrees wim 
shadowing. Panel b depicts a frame with insufficient blood clearance. Panel c illustrates an incomplete 
stenr apposition sire. Of note, stent struts are nor apposed to me vessel wall (arrows). Panel d shows 
the relationshi p of a stent and the ostium of a sidebranch (arrowhead). Panel e depicts a frame wim 
tissue prolapse. D otted line denotes the space berween rwo stru ts. A mass of tissue is protruding inro 
me lumen (asterisk). Panel/illustrates a Stene with neoinrimal hyperplasia which is the signal-rich 
area between me stem stru ts and the lumen (arrows) . Panel g shows an overlapped segmen t. Two 
layers of stenr can be seen along the circum fe rence (arrowheads). Panel h illustrates an uncovered 
strut (no tissue is at the endolumi nal side of the stru t - arrow). In contrast, some other struts are 
covered by neoinrimal tissue (arrowheads). 
Figure 5 . Edge dissection. In th is patient a drug eluting stent was placed p roximally in the left 
anterior descending. At the proximal edge of the stenr a 4-mm dissection was noted in the optical 
coherence tomography images (a th rough e). In panel a, stem struts can still be seen (arrows) from 
1 to 5 O'clock, while at 9 O'clock a dissection Aap is noted (asterisk). At the p roximal end of rhe 
dissection a calcified plaque can be seen (head arrows in panels d and e) . 
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Figure 6 . Optical coherence tomography images of intact atherosclerotic coronary plaques. 
Panel a shows a normal-looking vessel wall . Panel b depicrs a red rhro mbus inside rhe lumen. Irs 
OCT signarure is rhe shadowing beh ind rhe mass (asrerisk). Panel c illusrrares a ruprured plaque. 
The caviry is ar 2 O 'Clock (arrowhead) . Some disrupred rissue is adjacenr ro ir (arrows) . From 7 ro 9 
O 'clock a poor-signal region wirh low reAecriviry is seen, suggesring a rhin fibrous cap fibroarheroma. 
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CHAPTER 10.2 
Figure 1: Tissue coverage measurement. A. Sirolimus eluting Stene 9 months after stent 
implantation. B. The figure shows the lumen contour (white) and the stent contour (green). The 
tissue coverage area was calculated as stent area minus lumen area. The tissue coverage thickness was 
measured in 360 points (rep resented by the white chords). C. Magnification of2 struts showing all 
the measurements (white chords) of the tissue coverage in front of every strut. For every strm the 
minimum, maxi mum and mean strut coverage was calculated. 
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Figure 2: Malapposition. A. Example of a malapposed strut in a sirolimus during srent at 9 months 
follow up. B. Magnification of the malapposed strut. The yellow line represents the lumen contour 
and the white line corresponds to the stent contour. The distance from the endoluminal surface of 
the strut to the vessel wall (red arrow) was 440 fJffi (higher than the sum of the metal and polymer 
thickness for this type of stent). 
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CHAPTER 10.3 
Figure 1. Bifurcation Selection and Analysis 
Bifurcations that could be Identified In both intravascular ultrasound-virtual histology (IVUS·VH) and optical coherence tomography (ocn 
pullbacks were included. A strict selection of the analyzed cross· sections (CS) was followed to ensure correct matching between the 2 
techniques. Plaques were analyzed only In the main branch. The lesion analysis included: 1) proximal rim of the ostium of the side 
branch (SB) CS (first frame proximal to the take-off of the SB); 2) In-bifurcation CS {f rame with the larger ost ial d iameter of the SB); and 
3) distal rim of the ostium of the 58 CS (first frame distal to the take off of the 58). 
Figure 2. loca tion of the Plaque in Relation to the Flow Divider 
To describe the plaque location in relation to the flow divider, the vessel cross~section was divided in 4 quadrants according to the posi· 
tion of the side branch. Quadrants 1 and 4 correspond to the ostium of the side branch, whereas quadrants 2 and 3 correspond to the 
part of the vessel wall located in front o f the ost ium of the side branch. (A) Grayscale IVUS. (B) Virtual histology. (C) OCT. Abbrevia tions 
as in Figure 1. 
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All = adaptive intimal thickening; CaFA = calcified fibroatheroma; CaTCFA = calcified thin-cap fibroatheroma; CNC = confluent necrotic 
core; DC = dense calcium; FA • fibroatheroma; FC = fibrocalcic; FF • fibroratty; FT = fi brotic; Ocr = optical coherence tomography; 
PIT = pathological intimal thickening; TCFA = thin-cap fibroatheroma; VH = virtual histology. 
figure 4 . Low-Risk Plaques 
Matched images or grayscale IVUS (AI. vinual histology (B), and OCT (C) For the 4 types or plaques considered at low risk. 1: adaptive 
intimal thickening, 2: pathological intimal thickening, 3: fibrocalcifk plaque. 4: fibrotic plaque. Abbreviations as in Figure 1. 
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Figure 5. High-Risk Plaques 
Matched images of grayscale IVUS (A), vlnual histology (8), and OCT (C) for the 4 types of plaques considered at high risk of rupture. 
1: fibroatheroma, 2: calcified fibroatheroma, 3: thin-<ap fibroatheroma, 4: calcified thin-cap fibroatheroma. Abbreviations as in Figure 1. 
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Overall NC 
31. 1% 
Blue area; 
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Figure I An example of selective quantification of the necrotic core in contact with the lumen (NCCL). (A} The o riginal virtual 
histology-intravascular ultrasound cross-sectional area. (8) The blue area was selectively quantified as the major confluent NCCL areas and 
blue plus purple areas indicate total NCCL areas. (C) Measurement of the angle occupied by the total NCCL (white and red line) and the 
angle occupied by the major confluent NCCL (red line). 
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%PV; 47.6% %NC; 15% 
Angle of the major NCCL 15.3° 
Angle of the total NCCL 35.8° 
Cap thickness; 90!Jm 
non-NCCL OCT-derived-TCFA 
%PV; 7.6%, %NC; 22%, Cap thickness? ; SO!Jm 
%DC;44% 
definite-TCFA 
%PV; 55.8% %NC; 22% Cap thickness;40!Jm 
Angle of the major NCCL 24.8° 
Angle of the total NCCL 100.3° 
F igure 3 (A) A representative case of non-thin-cap IVUS-de<ived thin-cap fobroatheroma (TCFA). Virtual histology-IVUS shows 47.6% 
of%pta.que-volume, 15% of %necrotic-core. The angle of the major NCCL was 15.3", and that of the total NCCL was 35.8". ocr shows signal-
poor lesions with an overtying signal-rich band in the upper right quadrant. A signal-poor lesion indicates a lipid pool and signat-rich band Indi-
cates a fibrous cap. The fibrous cap thickness was 90 ~- (8) A re presentative case of non-NCCL OCT ..derived TCFA. OCT identified a 
fibrous tap thickness of 50 IJ.m which covers the low lntensity area. but VH-!VUS did not Identify the NCCL. (C) A representative case of 
definite-TCFA Virtual histology-IVU5 shows %plaque-volume of 55.8% and %necrotic-core of 22%. The angle of the major NCCL was 
2-4.8 "', and that of the total NCCL was 100.3' . Its minimum fibrous cap thickness was 40 ttm. 
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Figure 4 (A) Coronary angiography (CAG) revealed 50% stenosis In the mid-left anterior descending artery In July 2006. VH-IVUS revealed a 
68.8 mm3/cm plaque volume. 117.8 mm3/cm vessel volume, 58.4% %plaque.volume, and 28% %necrotic-core. The fibrous cap thickness of this 
lesion was 60 v.m by ocr measurement and this lesion was diagnosed as definite-TCFA (B) After 6 months, because the patient experienced 
chest pain at rest with increased frequency. we performed CAG. The CAG revealed 90% stenosis at the site of the previous definite-TCFA 
lesion. VH-IVUS revealed an increase in plaque volume (68.8-t- 79.7 mm3/cm). vessel volume (117.8~ 125.0 mm1/cm). %plaque-volume 
(58.4%~ 63.8%). and %necrotic-core (28%~ 33%). OCT revealed ulceration of the fibrous cap. 
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